{"meta":{"query_hash":"6ac4a1fc57b1","filters":{"venue":"PharmacoEconomics"},"cohort_total":375,"direct_labels_cover":0,"predictions_cover":375,"exported":375,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/6ac4a1fc57b1","api":"https://metacan.xera.ac/api/v1/cohort?venue=PharmacoEconomics"},"results":[{"id":"W10179705","doi":"10.2165/00019053-199813060-00006","title":"Who should benefit and why?: Discourses on REDD+ benefit sharing","year":2012,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Housing, Finance, and Neoliberalism","field":"Economics, Econometrics and Finance","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"CLARITY; Legitimacy; Business; Affect (linguistics); Public economics; Public relations; Political science; Economics; Psychology","score_opus":0.0637720317163588,"score_gpt":0.2940960229464842,"score_spread":0.23032399123012537,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W10179705","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90796083,0.004163098,0.0001344616,0.0012250606,0.0016310847,0.00022441361,0.00026729028,0.000085075095,0.084308684],"genre_scores_gemma":[0.98560995,0.0034148633,0.0002914527,0.004770945,0.0011598105,0.00003615662,0.000024145123,0.00009342018,0.0045992383],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979113,0.0000042511215,0.00067317346,0.00062727585,0.000034563673,0.0007494369],"domain_scores_gemma":[0.9988331,0.000059944698,0.00036512344,0.00042153613,0.000015963884,0.00030428727],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004406857,0.00034620325,0.0006105163,0.00025595597,0.00023466678,0.00017553795,0.00033848447,0.00014102859,0.00059652934],"category_scores_gemma":[0.0000064646665,0.00042125923,0.00014415286,0.000105031955,0.00008729055,0.00091319694,0.00016868256,0.0002970984,0.00063694286],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000737814,0.0002039669,0.11241826,0.00005329096,0.00013135899,0.0000038118528,0.0015651777,0.000612611,0.00008679672,0.8708639,0.0058604577,0.0081265895],"study_design_scores_gemma":[0.0016469745,0.00007773582,0.026046231,0.000050387283,0.000039542196,0.000023152379,0.000077352495,0.0055684745,0.0020229723,0.017200455,0.94614923,0.0010975141],"about_ca_topic_score_codex":0.0003091037,"about_ca_topic_score_gemma":0.00003824804,"teacher_disagreement_score":0.9402887,"about_ca_system_score_codex":0.0001695473,"about_ca_system_score_gemma":0.000007429236,"threshold_uncertainty_score":0.9998239},"labels":[],"label_agreement":null},{"id":"W1479842140","doi":"10.2165/00019053-200927010-00004","title":"Statin Therapy in Rheumatoid Arthritis","year":2009,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Arthritis Research Centre of Canada; University of British Columbia; Centre for Advancing Health Outcomes; St. Paul's Hospital","funders":"","keywords":"Medicine; Rheumatoid arthritis; Statin; Quality-adjusted life year; Physical therapy; Randomized controlled trial; Internal medicine; Cost-effectiveness analysis; Combination therapy; Intensive care medicine; Cost effectiveness; Risk analysis (engineering)","score_opus":0.020837138331397227,"score_gpt":0.32319156734117654,"score_spread":0.3023544290097793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1479842140","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9769489,0.013503051,0.000025420532,0.0034957714,0.00009765919,0.00036606143,0.000011259652,0.00006924126,0.00548262],"genre_scores_gemma":[0.71494675,0.28254282,0.0003501765,0.0020115022,0.000043144315,0.000016697917,0.000014556482,0.000013910199,0.00006045163],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989243,0.000039255025,0.00033144874,0.00022666075,0.00009901205,0.00037929352],"domain_scores_gemma":[0.9995101,0.000046259152,0.000048458445,0.0001709729,0.000031384738,0.0001928195],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002478222,0.0001414902,0.0003016434,0.00016970062,0.000047859918,0.000044330358,0.000097696655,0.000038905106,0.0009933761],"category_scores_gemma":[0.00002212993,0.00014212869,0.00007564263,0.000095216885,0.000049172744,0.00019518116,0.000011632631,0.00023539031,0.00023380131],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00066574774,0.0003402023,0.012258638,0.000004358696,0.00004193516,0.00009049921,0.000550777,0.000024694922,0.01635443,0.0013908212,0.00464696,0.9636309],"study_design_scores_gemma":[0.0588009,0.0027617316,0.11403183,0.00049314933,0.0000017349079,0.0006898812,0.0005795621,0.0064314622,0.123935,0.014834654,0.6762641,0.0011759673],"about_ca_topic_score_codex":0.00004736129,"about_ca_topic_score_gemma":0.000022988965,"teacher_disagreement_score":0.962455,"about_ca_system_score_codex":0.00006873775,"about_ca_system_score_gemma":0.00010689601,"threshold_uncertainty_score":0.99991983},"labels":[],"label_agreement":null},{"id":"W1520835857","doi":"10.2165/11597660-000000000-00000","title":"Cost Effectiveness of Hepatitis C-Related Interventions Targeting Substance Users and Other High-Risk Groups","year":2012,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Hepatitis C virus research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto; Institute for Work & Health; Toronto Baptist Seminary and Bible College","funders":"Canadian Institutes of Health Research","keywords":"Health economics; Quality of Life Research; Public health; Psychological intervention; Health administration; Medicine; Environmental health; Psychiatry; Nursing","score_opus":0.1327897595535637,"score_gpt":0.4346726858988664,"score_spread":0.30188292634530267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1520835857","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.030112172,0.9652749,0.00013759574,0.000007198783,0.00056761986,0.0023417792,0.0010405867,0.000050058065,0.00046811838],"genre_scores_gemma":[0.016487781,0.9822406,0.00026797527,0.000021664871,0.00016023425,0.00030310525,0.00027877293,0.00015662004,0.000083228566],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969423,0.0008471402,0.0011393769,0.00046318225,0.00014062603,0.00046740755],"domain_scores_gemma":[0.9976282,0.0008738259,0.00075969513,0.00033468002,0.00009172448,0.0003118531],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019351651,0.00041437964,0.0020137941,0.0003383824,0.000084872365,0.00002765716,0.00021084283,0.0002692357,0.0008874256],"category_scores_gemma":[0.00012728386,0.00039940022,0.0006019284,0.00022045606,0.00020121236,0.00018126426,0.00011319628,0.00086843903,0.00019545939],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007109798,0.00019978372,0.03726953,0.06172582,0.0018153673,0.00001525184,0.00013024875,0.0000060509433,0.00001507318,0.0002802864,0.00019221292,0.89827925],"study_design_scores_gemma":[0.0023571837,0.000118447686,0.0010591174,0.01903911,0.00408532,0.00003239558,0.000010724317,0.000196813,0.00014044637,0.000049432525,0.9723663,0.0005447442],"about_ca_topic_score_codex":0.0010428866,"about_ca_topic_score_gemma":0.00011915135,"teacher_disagreement_score":0.97217405,"about_ca_system_score_codex":0.00049550785,"about_ca_system_score_gemma":0.00015868987,"threshold_uncertainty_score":0.9998458},"labels":[],"label_agreement":null},{"id":"W1545016258","doi":"10.1007/s40273-012-0007-4","title":"The Humanistic and Economic Burden of Systemic Lupus Erythematosus","year":2012,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Systemic Lupus Erythematosus Research","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre","funders":"U.S. National Library of Medicine","keywords":"Medicine; Quality of life (healthcare); Health economics; Psychological intervention; MEDLINE; Intensive care medicine; Lupus nephritis; Public health; Disease; Gerontology; Family medicine; Pathology; Nursing","score_opus":0.06936924900146456,"score_gpt":0.3824387648429726,"score_spread":0.31306951584150805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1545016258","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0020573176,0.99147564,0.0000045262523,0.000050819745,0.0018569953,0.0024447232,0.00012225583,0.000053232925,0.0019344714],"genre_scores_gemma":[0.0027458323,0.9927157,0.000032759366,0.0000118923135,0.0013770777,0.000298223,0.00004358858,0.00018705025,0.0025878563],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99657696,0.0002393285,0.0017536032,0.00054537,0.00018132525,0.00070338626],"domain_scores_gemma":[0.99613196,0.0013447802,0.0010997173,0.0009699203,0.00006797333,0.00038563734],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014211435,0.0006120317,0.0029750657,0.00027612544,0.00018512481,0.00008477367,0.0005680656,0.00030639794,0.00016278504],"category_scores_gemma":[0.000050855084,0.00042025826,0.00057989266,0.000076370525,0.0003377073,0.000097964876,0.00034599143,0.0006059672,0.00075267494],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001549148,0.000079811725,0.00087698165,0.27573583,0.0037927656,0.00004441591,0.0012359932,0.000005234256,0.00002214759,0.004458507,0.0064850054,0.7071084],"study_design_scores_gemma":[0.0010138568,0.000042049185,2.1361902e-7,0.010512604,0.0027458777,0.06975446,0.00030341707,0.00017828122,0.000005236408,0.000031011026,0.91506827,0.00034473237],"about_ca_topic_score_codex":0.00005987176,"about_ca_topic_score_gemma":0.0000053888675,"teacher_disagreement_score":0.9085833,"about_ca_system_score_codex":0.0008932868,"about_ca_system_score_gemma":0.00082533923,"threshold_uncertainty_score":0.99982494},"labels":[],"label_agreement":null},{"id":"W1547731140","doi":"10.2165/00019053-200624002-00006","title":"Disease Management Programmes in Germany","year":2006,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Primary Care and Health Outcomes","field":"Health Professions","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Economics","funders":"","keywords":"Reimbursement; German; Medicine; Quality of Life Research; Incentive; Sick leave; Disease; Health economics; Public health; Family medicine; Physical therapy; Nursing; Economic growth; Economics; Health care; Internal medicine","score_opus":0.03409108430248398,"score_gpt":0.4351410120294341,"score_spread":0.40104992772695014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1547731140","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6834297,0.0010715321,0.00006961142,0.018635908,0.0017967547,0.0020753257,0.00005773118,0.00025733229,0.29260606],"genre_scores_gemma":[0.9375903,0.00084034726,0.0007892159,0.04623882,0.00086587935,0.0008121865,0.000083054074,0.000050011367,0.01273021],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.998438,0.00010237114,0.0005552775,0.00025049536,0.00006282504,0.00059101527],"domain_scores_gemma":[0.99939007,0.000103802384,0.00012128385,0.00020698323,0.000018440218,0.00015939701],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003492739,0.0001351949,0.00020584626,0.00014459643,0.00020170723,0.000009441676,0.00017517351,0.00004811916,0.0008007223],"category_scores_gemma":[0.0000033366414,0.00013910583,0.000060602855,0.000084726686,0.000022795375,0.00015190536,0.00012257014,0.00029370416,0.0010394739],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030698656,0.00031203777,0.5582543,0.0012471593,0.000038067265,0.00014365972,0.00029422482,0.00014406725,0.000036018548,0.05200712,0.34888926,0.038327105],"study_design_scores_gemma":[0.0014000854,0.0000046679766,0.26402977,0.00001604677,0.000019442488,2.0996156e-7,0.00007083573,0.00022865704,0.000005857378,0.0032034446,0.7308704,0.00015055895],"about_ca_topic_score_codex":0.0003056569,"about_ca_topic_score_gemma":0.000307086,"teacher_disagreement_score":0.38198116,"about_ca_system_score_codex":0.00066547666,"about_ca_system_score_gemma":0.0002757474,"threshold_uncertainty_score":0.99973834},"labels":[],"label_agreement":null},{"id":"W1550647847","doi":"10.2165/11537550-000000000-00000","title":"Cost Effectiveness of Leukotriene Receptor Antagonists versus Inhaled Corticosteroids for Initial Asthma Controller Therapy","year":2010,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Asthma and respiratory diseases","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Quality of Life Research; Asthma; Health economics; Medicine; Inhaled corticosteroids; Pharmacoeconomics; Public health; Intensive care medicine; Pharmacology; Internal medicine; Nursing","score_opus":0.05073648609986783,"score_gpt":0.3876800217527853,"score_spread":0.3369435356529175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1550647847","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950678,0.000222689,0.00028718903,0.00006711549,0.0020838997,0.001753201,0.00021614514,0.000037346963,0.00026462684],"genre_scores_gemma":[0.9982961,0.00012339477,0.000210054,0.00039742095,0.0005750175,0.00024868222,0.00008593034,0.00004656622,0.000016833908],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99890804,0.00005480143,0.0003987032,0.00028318327,0.00008329129,0.00027196313],"domain_scores_gemma":[0.99863666,0.00056323083,0.00019517301,0.00019535075,0.00016192997,0.0002476612],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003078666,0.00020693312,0.0005353765,0.00008764534,0.00007330417,0.000020469199,0.000120560944,0.00009210145,0.00035552154],"category_scores_gemma":[0.00008686351,0.00018443621,0.00023564744,0.000053430686,0.00014730587,0.00013979759,0.000026732714,0.00020180125,0.00004265761],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06540565,0.0005070704,0.0070049935,0.00020975439,0.00038182276,0.000013059996,0.000071316514,0.000038473805,0.7903918,0.00016054789,0.00044165997,0.13537385],"study_design_scores_gemma":[0.075480826,0.0014442622,0.009797277,0.000041514366,0.00014967531,0.000025498151,0.000088865534,0.0013681547,0.8527135,0.000030768926,0.058524106,0.00033551996],"about_ca_topic_score_codex":0.000028743128,"about_ca_topic_score_gemma":0.000010546771,"teacher_disagreement_score":0.13503833,"about_ca_system_score_codex":0.000111140915,"about_ca_system_score_gemma":0.00044799116,"threshold_uncertainty_score":0.75210905},"labels":[],"label_agreement":null},{"id":"W1592571893","doi":"10.2165/00019053-200927020-00004","title":"Effectiveness and Cost Effectiveness of Human Papillomavirus Vaccine","year":2009,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":96,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Centre for Disease Control; Centre for Advancing Health Outcomes; Université Laval; University of British Columbia","funders":"","keywords":"Medicine; Vaccination; Cost effectiveness; Cervical cancer; Human papillomavirus; Cost-effectiveness analysis; Health economics; Economic evaluation; Clinical trial; Quality of Life Research; Gynecology; Medical physics; Public health; Cancer; Immunology; Risk analysis (engineering); Pathology; Internal medicine","score_opus":0.08947033810605287,"score_gpt":0.48156241707605435,"score_spread":0.3920920789700015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1592571893","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015422503,0.990362,0.000009104159,0.000007727361,0.00014628306,0.0029549473,0.00010223438,0.000035061985,0.0048403996],"genre_scores_gemma":[0.0050549065,0.99412876,0.000010091137,0.00004173599,0.0002527783,0.00023504866,0.00015611794,0.00007633436,0.00004424877],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978503,0.00047652744,0.0006118303,0.00056950236,0.00013480919,0.00035705513],"domain_scores_gemma":[0.9980481,0.00093474594,0.00022876251,0.00035898018,0.00011706245,0.00031232391],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012168944,0.00044458275,0.003104816,0.0002772496,0.00007316187,0.000025685229,0.0001997457,0.00023725706,0.00065977796],"category_scores_gemma":[0.00004100319,0.00037942777,0.00045308293,0.00017959575,0.00007990923,0.00007084563,0.0001372881,0.000645096,0.000041123636],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004468467,0.00014232656,0.00009589768,0.09948484,0.0004053785,0.000021500873,0.000004825226,6.0432797e-7,0.00011398417,0.00017548633,0.00007874413,0.89902955],"study_design_scores_gemma":[0.0075603034,0.00078224007,0.008405034,0.009090851,0.0030378483,0.00013079064,0.0000024807898,0.000015209247,0.0015038204,0.00022804443,0.968638,0.0006053555],"about_ca_topic_score_codex":0.00006845188,"about_ca_topic_score_gemma":0.0000034648665,"teacher_disagreement_score":0.96855927,"about_ca_system_score_codex":0.00043025706,"about_ca_system_score_gemma":0.00028015336,"threshold_uncertainty_score":0.9998658},"labels":[],"label_agreement":null},{"id":"W1592767674","doi":"10.2165/0019053-200826120-00005","title":"Management and Prevention of Diabetic Foot Ulcers and Infections","year":2008,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Diabetic Foot Ulcer Assessment and Management","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Health economics; Medicine; Diabetic foot; Quality of Life Research; Public health; Intensive care medicine; Diabetes mellitus; Health administration; Foot (prosody); Nursing","score_opus":0.037480069368571234,"score_gpt":0.36612063785218824,"score_spread":0.328640568483617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1592767674","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00078322936,0.98204666,0.00006698482,0.00004698589,0.00027955018,0.0016209051,0.000013797003,0.00003380263,0.01510809],"genre_scores_gemma":[0.00033882586,0.996773,0.0005705865,0.000052242885,0.0000710932,0.00016669414,0.00006512206,0.00003998091,0.0019224402],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988862,0.000037611153,0.000495546,0.0003293899,0.00007089564,0.00018030283],"domain_scores_gemma":[0.9993555,0.000049346323,0.00026302147,0.00019729607,0.000016343753,0.000118468466],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00011898554,0.0002673764,0.0009871883,0.00032553528,0.00004690626,0.000018767643,0.00006180057,0.00007568006,0.00009332863],"category_scores_gemma":[0.0000033419506,0.0002586768,0.0001997565,0.00009173122,0.00009908726,0.00006973957,0.0001614135,0.00015120152,0.000014633554],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000005312141,0.00012196298,0.00009290884,0.01871333,0.0011407498,0.000007387611,0.0000199586,6.2738775e-7,2.3085167e-7,0.00056124176,0.002073274,0.97726303],"study_design_scores_gemma":[0.0009177955,0.0001511156,0.00014210652,0.0020036455,0.003831906,0.000039684553,0.000016442127,0.0000341244,0.0000033228762,0.00012696441,0.99252826,0.00020462874],"about_ca_topic_score_codex":0.000005136478,"about_ca_topic_score_gemma":0.0000011343142,"teacher_disagreement_score":0.990455,"about_ca_system_score_codex":0.00010046911,"about_ca_system_score_gemma":0.00005733058,"threshold_uncertainty_score":0.9999865},"labels":[],"label_agreement":null},{"id":"W1593327399","doi":"10.2165/00019053-200725120-00003","title":"NICE Cost-Effectiveness Appraisal of Cholinesterase Inhibitors","year":2007,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Nova Scotia Health Authority","funders":"National Institutes of Health","keywords":"Health economics; Quality of Life Research; Nice; Health administration; Public health; Medicine; Cholinesterase; Pharmacoeconomics; Cost effectiveness; Intensive care medicine; Pharmacology; Risk analysis (engineering); Nursing; Computer science","score_opus":0.6032728442129532,"score_gpt":0.5930197540342943,"score_spread":0.010253090178658941,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1593327399","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004590473,0.98258483,0.0011373512,0.0003009637,0.005249879,0.003670446,0.0023183597,0.000100393416,0.0041787075],"genre_scores_gemma":[0.00015846419,0.9938015,0.0008438483,0.0015671955,0.0020466284,0.00068426057,0.0004574858,0.00025003316,0.00019059125],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9848726,0.00091955345,0.011811254,0.0014004302,0.00011014022,0.00088605104],"domain_scores_gemma":[0.98120236,0.007303161,0.009827032,0.0010665589,0.00011345115,0.00048742318],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.026799414,0.0009144374,0.00700207,0.0013175412,0.00015108,0.00010747572,0.0010116578,0.00070930074,0.0005899542],"category_scores_gemma":[0.001993046,0.001182217,0.001236494,0.00043864516,0.00019361108,0.0007266474,0.0002297849,0.00085298414,0.0042893332],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012375685,0.0009779087,0.0017563188,0.1591455,0.0024249272,0.00001832089,0.00073017995,0.00042715814,0.0000011802466,0.04209649,0.03902735,0.7532709],"study_design_scores_gemma":[0.0011049191,0.000038906564,0.000034602468,0.0027197558,0.00018336988,0.00003114577,0.00003810004,0.00029167463,0.0000076058172,0.00029580435,0.99428433,0.0009698078],"about_ca_topic_score_codex":0.0003007753,"about_ca_topic_score_gemma":0.000021186888,"teacher_disagreement_score":0.95525694,"about_ca_system_score_codex":0.0016734552,"about_ca_system_score_gemma":0.0007064086,"threshold_uncertainty_score":0.9990628},"labels":[],"label_agreement":null},{"id":"W1751576414","doi":"10.2165/11536150-000000000-00000","title":"International Comparison of Comparative Effectiveness Research in Five Jurisdictions","year":2010,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"International Arbitration and Investment Law","field":"Business, Management and Accounting","cited_by":43,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Dalhousie University","funders":"National Pharmaceutical Council; NHS Health Scotland","keywords":"Quality of Life Research; Health economics; Health administration; Comparative effectiveness research; Public health; Health services research; Health care management; Medicine; Political science; Environmental health; Health care; Nursing; Law","score_opus":0.19668410348605272,"score_gpt":0.48433326515327785,"score_spread":0.2876491616672251,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1751576414","genre_codex":"other","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013228074,0.42047158,0.00002626023,0.00018191556,0.004580237,0.0016881581,0.0001048353,0.000055719982,0.5715685],"genre_scores_gemma":[0.0147161,0.9806102,0.00011775941,0.000512518,0.0024839905,0.0004350967,0.00084171415,0.000060526014,0.00022209917],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983378,0.000086121734,0.00080154743,0.00034767034,0.00021567402,0.00021118988],"domain_scores_gemma":[0.9985583,0.0004258318,0.00055145635,0.00015938748,0.00029009604,0.000014940843],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009390361,0.0002435809,0.0009471173,0.001115929,0.00009318581,0.00015678332,0.0006019447,0.00015509613,0.0005169892],"category_scores_gemma":[0.000024242854,0.00023960363,0.00022960792,0.00034111095,0.00015468184,0.0007110791,0.0002130996,0.00096186146,0.0007385513],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012672787,0.0013863831,0.00055983994,0.0086580105,0.00058398786,0.0000067972633,0.0002845933,0.00031931532,0.00004675638,0.7472002,0.008495431,0.23233195],"study_design_scores_gemma":[0.00038595794,0.0000059963654,0.000024520536,0.0009994982,0.000077689074,0.0000010981759,0.00003361991,0.004924206,0.000030932995,0.0009457209,0.9923759,0.00019483441],"about_ca_topic_score_codex":0.00020272999,"about_ca_topic_score_gemma":0.0000913641,"teacher_disagreement_score":0.9838805,"about_ca_system_score_codex":0.00022133157,"about_ca_system_score_gemma":0.00011898751,"threshold_uncertainty_score":0.9770752},"labels":[],"label_agreement":null},{"id":"W1761940517","doi":"10.2165/11531870-000000000-00000","title":"Cost Effectiveness of Donepezil in the Treatment of Mild to Moderate Alzheimerʼs Disease","year":2010,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":77,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Eisai Canada","keywords":"Donepezil; Medicine; Health economics; Disease; Clinical trial; Placebo; Economic evaluation; Randomized controlled trial; Cognition; Psychiatry; Gerontology; Public health; Dementia; Internal medicine; Alternative medicine","score_opus":0.42221274920245633,"score_gpt":0.5004944244712676,"score_spread":0.07828167526881125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1761940517","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890969,0.00087013026,0.00043264913,0.005138684,0.0007636569,0.0019388993,0.0008120106,0.0000128092315,0.0009342533],"genre_scores_gemma":[0.99585015,0.00031103275,0.00065813796,0.0024405327,0.00017775052,0.0004706931,0.00003488615,0.000030414663,0.000026408614],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962949,0.00035438713,0.0025300195,0.00045226223,0.0000486866,0.00031970663],"domain_scores_gemma":[0.99646616,0.001644301,0.00103584,0.0005926187,0.00004515442,0.00021595214],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0080100745,0.00021631594,0.0009603161,0.0003101259,0.00006894377,0.000033079643,0.00040061283,0.00007260509,0.00019573487],"category_scores_gemma":[0.0002979217,0.00022485173,0.0001763181,0.00015456164,0.000083023006,0.00024952888,0.00002818953,0.00013638128,0.0003287137],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004684698,0.0074831946,0.56325746,0.002691032,0.0013820578,0.000012352531,0.027889522,0.0706408,0.0029058354,0.30258992,0.008876663,0.007586458],"study_design_scores_gemma":[0.024295168,0.0011832707,0.5559968,0.0003013428,0.00027269806,0.000010516719,0.0018357126,0.12049694,0.02086914,0.044019457,0.22819689,0.0025221056],"about_ca_topic_score_codex":0.0010099463,"about_ca_topic_score_gemma":0.0002469921,"teacher_disagreement_score":0.25857046,"about_ca_system_score_codex":0.000248146,"about_ca_system_score_gemma":0.00014787112,"threshold_uncertainty_score":0.9169187},"labels":[],"label_agreement":null},{"id":"W185692532","doi":"10.2165/00019053-200018010-00006","title":"Using Economic Evaluations to Make Formulary Coverage Decisions","year":2000,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":55,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Advancing Health Outcomes; St. Paul's Hospital; University of British Columbia","funders":"","keywords":"Formulary; Checklist; Time horizon; Medicine; Health economics; Actuarial science; Discounting; Health administration; Economic evaluation; Cost–benefit analysis; Operations management; Public health; Family medicine; Business; Economics; Psychology; Political science; Finance; Nursing","score_opus":0.45840472527537623,"score_gpt":0.5295531540210864,"score_spread":0.07114842874571015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W185692532","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92263395,0.0008618479,0.01629371,0.015313366,0.0017644888,0.0017448512,0.0019308588,0.00017172236,0.03928522],"genre_scores_gemma":[0.89948016,0.0011044088,0.023320504,0.068848595,0.0019306877,0.00036687168,0.0002016863,0.00022913741,0.0045179394],"study_design_codex":"simulation_or_modeling","study_design_gemma":"not_applicable","domain_scores_codex":[0.9929987,0.0002381514,0.004749532,0.0010757485,0.000090030866,0.00084781455],"domain_scores_gemma":[0.9961906,0.0010377984,0.0011084791,0.0009334688,0.000048525726,0.0006811389],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.008456263,0.00041919356,0.0012008602,0.00059532374,0.0005360419,0.00025590195,0.0006910415,0.00017933111,0.018857464],"category_scores_gemma":[0.0006198656,0.000616113,0.0003189329,0.0001943344,0.00006258804,0.0009968255,0.00011580076,0.000279157,0.04283352],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030789681,0.00057452044,0.021319296,0.00016509464,0.0007912115,0.0000112909875,0.0041327756,0.6056674,0.00026472096,0.13967717,0.17757504,0.04951358],"study_design_scores_gemma":[0.002696138,0.000089394285,0.0038283218,0.00006592203,0.000053318538,0.000043608772,0.00019270724,0.26594463,0.00014078422,0.039504834,0.6861113,0.0013291097],"about_ca_topic_score_codex":0.0010581017,"about_ca_topic_score_gemma":0.00025125474,"teacher_disagreement_score":0.5085362,"about_ca_system_score_codex":0.002256435,"about_ca_system_score_gemma":0.0004039861,"threshold_uncertainty_score":0.999629},"labels":[],"label_agreement":null},{"id":"W1880829571","doi":"10.1007/s40273-015-0292-9","title":"A Checklist for Reporting Valuation Studies of Multi-Attribute Utility-Based Instruments (CREATE)","year":2015,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":71,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Canadian Institutes of Health Research; EuroQol Research Foundation; McMaster University","keywords":"Checklist; Reimbursement; Delphi method; Valuation (finance); Health care; Health administration; Health economics; Actuarial science; Psychological intervention; Delphi; EconLit; Benchmarking; Business; Medicine; Public health; MEDLINE; Computer science; Accounting; Psychology; Nursing; Marketing; Economics; Political science","score_opus":0.7950611671991774,"score_gpt":0.5695950477640246,"score_spread":0.22546611943515282,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1880829571","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95554256,0.0031374355,0.025059551,0.009930033,0.002084536,0.0021935578,0.0012487763,0.000105497435,0.0006980634],"genre_scores_gemma":[0.9758227,0.00013278512,0.018493151,0.004184774,0.00031499,0.00041077335,0.0001687178,0.000059232807,0.000412864],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99004006,0.00021070996,0.0085226605,0.00068148534,0.00008592454,0.00045913158],"domain_scores_gemma":[0.9876169,0.00074274646,0.010489093,0.0004984783,0.00037891886,0.00027383893],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.028515879,0.00027982978,0.0015007822,0.0003191566,0.00016560547,0.000054903205,0.00029786566,0.00012496779,0.00009564348],"category_scores_gemma":[0.012341328,0.00037440093,0.00026179256,0.0001373021,0.0001244591,0.0005752471,0.00007380092,0.00013929234,0.00025510116],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003044059,0.0012046559,0.86699617,0.0034784242,0.0016689057,0.0000021310068,0.009980518,0.010462752,0.00016213706,0.016753804,0.08578668,0.0031994183],"study_design_scores_gemma":[0.012773712,0.00025687163,0.007063894,0.00015134412,0.00012284506,0.0000066620505,0.0037388676,0.88690275,0.0030562251,0.011635192,0.07326201,0.0010296092],"about_ca_topic_score_codex":0.000261313,"about_ca_topic_score_gemma":0.000038264814,"teacher_disagreement_score":0.87644,"about_ca_system_score_codex":0.0009943832,"about_ca_system_score_gemma":0.0003029234,"threshold_uncertainty_score":0.9998708},"labels":[],"label_agreement":null},{"id":"W1891390685","doi":"10.1007/s40273-015-0330-7","title":"Transforming Healthcare Delivery: Integrating Dynamic Simulation Modelling and Big Data in Health Economics and Outcomes Research","year":2015,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Primary Care and Health Outcomes","field":"Health Professions","cited_by":48,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saskatchewan Health Authority; University of Saskatchewan; University of Calgary","funders":"Agency for Healthcare Research and Quality","keywords":"Health economics; Health administration; Quality of Life Research; Big data; Health care; Healthcare delivery; Health informatics; Public health; Health services research; Data science; Business; Computer science; Medicine; Economics; Nursing; Economic growth; Data mining","score_opus":0.4067404254781069,"score_gpt":0.5568233110544322,"score_spread":0.15008288557632526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1891390685","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95381826,0.004010351,0.0028277258,0.03552775,0.0010910683,0.001621025,0.00032777945,0.00007069453,0.0007053147],"genre_scores_gemma":[0.97092295,0.015908897,0.002039101,0.0105183115,0.00021829657,0.000049506274,0.00019355494,0.00005139507,0.000097997305],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9964506,0.0007009755,0.0012162175,0.0006296544,0.00011470654,0.0008878618],"domain_scores_gemma":[0.9970043,0.001611028,0.00027177497,0.0004466989,0.00013732302,0.0005289215],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006390778,0.0002260329,0.00061202655,0.00041993603,0.0006877951,0.00004126564,0.00031747425,0.00016436803,0.000007774911],"category_scores_gemma":[0.000113233895,0.00023200811,0.000025146592,0.00013371836,0.00007528567,0.00073684467,0.00042809316,0.0012130152,0.000014455701],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00056090904,0.00009612856,0.20140812,0.002801761,0.00008589881,0.000007629485,0.033291366,0.056006804,0.000009805131,0.0035359506,0.0013316903,0.70086396],"study_design_scores_gemma":[0.0024696186,0.00006976948,0.0011464221,0.0001063147,0.000008677343,0.0000021101632,0.0070311334,0.92762035,0.000001740494,0.0024802207,0.058811422,0.00025221522],"about_ca_topic_score_codex":0.009172461,"about_ca_topic_score_gemma":0.015274105,"teacher_disagreement_score":0.87161356,"about_ca_system_score_codex":0.0018780592,"about_ca_system_score_gemma":0.0031686667,"threshold_uncertainty_score":0.99742556},"labels":[],"label_agreement":null},{"id":"W192050759","doi":"10.2165/00019053-200220001-00001","title":"New Solutions for Type 2 Diabetes Mellitus","year":2002,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Peroxisome Proliferator-Activated Receptors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Eli Lilly (Canada)","funders":"Eli Lilly and Company","keywords":"Insulin resistance; Pioglitazone; Internal medicine; Endocrinology; Diabetes mellitus; Type 2 diabetes; Medicine; Insulin; Type 2 Diabetes Mellitus; Adipose tissue","score_opus":0.07626349876678085,"score_gpt":0.357591888788485,"score_spread":0.2813283900217042,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W192050759","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000064229134,0.99675304,0.0002161248,0.000034369485,0.0015031897,0.0007767798,0.00028006127,0.000032116208,0.00034010503],"genre_scores_gemma":[0.00001578664,0.99432015,0.00082637963,0.00018379086,0.0019590838,0.00017151539,0.0010187994,0.00013108422,0.0013734258],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982964,0.00005585533,0.00045882844,0.00057200715,0.000039489365,0.00057744596],"domain_scores_gemma":[0.9990454,0.00004147593,0.0002609747,0.00036682075,0.000052377716,0.00023298647],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014808598,0.00043926525,0.000798753,0.000093379334,0.00012162427,0.000051782208,0.00041746203,0.00042560959,0.00030391745],"category_scores_gemma":[0.00004432151,0.00044392582,0.00050654594,0.00008607648,0.00003729818,0.00000652408,0.00016511294,0.00021971176,0.00025609875],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008893338,0.000034503733,0.0000012571817,0.001185853,0.0005836052,1.7356942e-7,0.000004428204,0.000011848722,0.0012664169,0.000030691444,0.11872402,0.8781483],"study_design_scores_gemma":[0.00029763964,0.000080503916,2.013479e-8,0.00016420873,0.0004306731,0.0000044739786,0.0000010406152,0.000051484138,0.006750834,0.0000175662,0.9917266,0.00047498968],"about_ca_topic_score_codex":0.0000020664002,"about_ca_topic_score_gemma":0.0000011289078,"teacher_disagreement_score":0.8776733,"about_ca_system_score_codex":0.000102750804,"about_ca_system_score_gemma":0.00039464713,"threshold_uncertainty_score":0.9998013},"labels":[],"label_agreement":null},{"id":"W194666946","doi":"10.2165/11593030-000000000-00000","title":"Common Drug Review Recommendations","year":2012,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":46,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Programs for Assessment of Technology in Health Research Institute; McMaster University; Environment and Climate Change Canada","funders":"","keywords":"Formulary; Medicine; Univariate; Family medicine; Multivariate statistics; Statistics","score_opus":0.43995788830095434,"score_gpt":0.5232746190447435,"score_spread":0.08331673074378915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W194666946","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.09346522,0.21211155,0.0020010679,0.56013143,0.010234104,0.003203179,0.0017057864,0.0004885713,0.1166591],"genre_scores_gemma":[0.5005317,0.060520392,0.007778179,0.42122766,0.0034375829,0.0006946306,0.00056092546,0.00019469898,0.00505424],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99427897,0.000339192,0.004189163,0.00044414768,0.000047807138,0.0007007067],"domain_scores_gemma":[0.9960121,0.00077370624,0.0021024824,0.0006089718,0.00003593495,0.00046679057],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.01623373,0.0002692097,0.0011241331,0.00021980052,0.00025781928,0.00006202996,0.0004327095,0.00007593997,0.0068871193],"category_scores_gemma":[0.0006121569,0.000374779,0.00021886185,0.00015599818,0.000055026594,0.001475301,0.000104340186,0.00029031467,0.021231296],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000045337765,0.00015740588,0.02505231,0.0007148024,0.00009086463,1.8449629e-7,0.00064954517,0.00001886015,0.0000038228122,0.06744486,0.9049294,0.00093339296],"study_design_scores_gemma":[0.0005245947,0.000008336841,0.0015991146,0.00018233406,0.000024939902,0.000010740531,0.00015796199,0.00083348004,0.000045110177,0.0034793634,0.9926805,0.00045355418],"about_ca_topic_score_codex":0.0002656447,"about_ca_topic_score_gemma":0.000030124444,"teacher_disagreement_score":0.40706646,"about_ca_system_score_codex":0.00070179766,"about_ca_system_score_gemma":0.00007102765,"threshold_uncertainty_score":0.9998704},"labels":[],"label_agreement":null},{"id":"W1947519512","doi":"10.1007/s40273-015-0332-5","title":"Cost Effectiveness of Ofatumumab Plus Chlorambucil in First-Line Chronic Lymphocytic Leukaemia in Canada","year":2015,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"Health Canada; Novartis Pharmaceuticals Canada; GlaxoSmithKline","keywords":"Chlorambucil; Ofatumumab; Medicine; Fludarabine; Quality-adjusted life year; Cost effectiveness; Life expectancy; Actuarial science; Internal medicine; Chronic lymphocytic leukemia; Population; Chemotherapy; Leukemia; Environmental health; Economics","score_opus":0.07660397386840974,"score_gpt":0.35768279047389434,"score_spread":0.2810788166054846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1947519512","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948959,0.0015110568,0.00003402618,0.00012240038,0.0004522189,0.0012802281,0.000036392124,0.000018081608,0.0016496998],"genre_scores_gemma":[0.9988041,0.00049313105,0.000035732413,0.00018245968,0.00014563387,0.00014280816,0.000052543037,0.00005425288,0.000089361856],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99764997,0.00013489832,0.000729125,0.0004693598,0.00032221767,0.00069443445],"domain_scores_gemma":[0.99830836,0.0005494795,0.00015000302,0.00045340083,0.00012015862,0.0004185778],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011725837,0.0002744395,0.0008564625,0.0002850768,0.000020433852,0.000012833649,0.00031480286,0.0001038001,0.00012379338],"category_scores_gemma":[0.00021731516,0.00029149093,0.000076653065,0.00038960975,0.000112780406,0.0001588348,0.00017801243,0.000383284,0.000055462948],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.014013388,0.00033202858,0.04214622,0.005215346,0.00032598103,0.002044307,0.0009288828,0.9175071,0.0021782278,0.00021004623,0.002649167,0.012449294],"study_design_scores_gemma":[0.1410857,0.00023395475,0.0038482326,0.00059336616,0.00005920761,0.00020858164,0.00018693245,0.80671954,0.042624928,0.000092496935,0.00394812,0.00039892824],"about_ca_topic_score_codex":0.8963996,"about_ca_topic_score_gemma":0.84821,"teacher_disagreement_score":0.25970244,"about_ca_system_score_codex":0.46395162,"about_ca_system_score_gemma":0.20424917,"threshold_uncertainty_score":0.99995375},"labels":[],"label_agreement":null},{"id":"W1965598649","doi":"10.2165/11314010-000000000-00000","title":"Cost Effectiveness of Herpes Zoster Vaccine in Canada","year":2009,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Herpesvirus Infections and Treatments","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Centre for Disease Control; Centre for Advancing Health Outcomes; University of British Columbia","funders":"","keywords":"Medicine; Shingles; Vaccination; Postherpetic neuralgia; Health economics; Incidence (geometry); Varicella zoster virus; Pharmacoeconomics; Vaccine efficacy; Health care; Cost effectiveness; Public health; Pediatrics; Demography; Emergency medicine; Intensive care medicine; Immunology; Virus; Alternative medicine","score_opus":0.026473600106542705,"score_gpt":0.3349733757912241,"score_spread":0.3084997756846814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1965598649","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99577135,0.000112184454,0.000018527104,0.00020525085,0.00016740392,0.0003489256,0.00001738104,0.0000082295255,0.0033507235],"genre_scores_gemma":[0.9991753,0.00008418613,0.000052693988,0.0005883099,0.000030843916,0.000014706705,0.000011938927,0.000008025069,0.000034008364],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9994674,0.000031333107,0.0002021852,0.00012544676,0.000034035787,0.00013964818],"domain_scores_gemma":[0.99967533,0.0000725726,0.00004596141,0.00010863122,0.00002194035,0.000075560274],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011320123,0.00009115047,0.00025457641,0.00006410496,0.000014359157,0.0000030699623,0.00003330834,0.000021292632,0.00017591978],"category_scores_gemma":[0.000006522198,0.000085631895,0.000036730456,0.0000690997,0.000005052887,0.000053742213,0.000007765437,0.00006400374,0.000013733663],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011504049,0.0007632851,0.48116127,0.00013418923,0.00022619919,0.00011493868,0.000058022677,0.0009243846,0.0028872436,0.00012610269,0.0007756837,0.5116783],"study_design_scores_gemma":[0.010174491,0.00013306788,0.8356022,0.00010463812,0.000103035534,0.000035588775,0.000026169153,0.0011828153,0.112998426,0.00010545013,0.039361615,0.00017248267],"about_ca_topic_score_codex":0.30314243,"about_ca_topic_score_gemma":0.19354762,"teacher_disagreement_score":0.5115058,"about_ca_system_score_codex":0.0006412588,"about_ca_system_score_gemma":0.00038285463,"threshold_uncertainty_score":0.821168},"labels":[],"label_agreement":null},{"id":"W1966422135","doi":"10.2165/00019053-200220002-00003","title":"The Development and Use of Quality-of-Life Measures to Evaluate Health Outcomes in Japan","year":2002,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BioPhage Pharma (Canada); McMaster University","funders":"","keywords":"Health economics; Quality of life (healthcare); Quality-adjusted life year; EQ-5D; Quality of Life Research; Valuation (finance); Cost–utility analysis; Health administration; Measure (data warehouse); Health Utilities Index; Medicine; Health care; Actuarial science; Index (typography); Economic evaluation; Data collection; Quality (philosophy); Public health; Health related quality of life; Cost effectiveness; Business; Risk analysis (engineering); Economics; Economic growth; Computer science; Nursing; Statistics; Disease; Data mining; Finance","score_opus":0.7722328633379373,"score_gpt":0.5690684352575697,"score_spread":0.2031644280803676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1966422135","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009395252,0.9799715,0.00009949202,0.0061197774,0.00077779836,0.0027156607,0.0007229968,0.000021567768,0.00017595402],"genre_scores_gemma":[0.00047262223,0.99179244,0.002403683,0.004351825,0.00010083829,0.00039088906,0.000036799724,0.00009256995,0.00035835357],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.981452,0.0013690508,0.0154973455,0.0008635194,0.00014497113,0.00067312765],"domain_scores_gemma":[0.9842592,0.005394568,0.009022905,0.0007906219,0.00007826901,0.00045446676],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.034637634,0.0005610257,0.0063129305,0.0008228932,0.00020547559,0.00010713228,0.0006739625,0.00021676843,0.000086634755],"category_scores_gemma":[0.0044606016,0.0005572262,0.0004004671,0.00025355013,0.00012506181,0.00032745904,0.0002201703,0.00039829226,0.0004178638],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000054597684,0.0004195248,0.03039093,0.039620478,0.0017752658,3.3321476e-7,0.0072335294,0.00041507912,1.1231734e-7,0.042004522,0.013911769,0.8641739],"study_design_scores_gemma":[0.0006607835,0.00003498961,0.0019048335,0.0010705515,0.000027978447,0.0000010960323,0.0001707031,0.00022703121,4.211028e-7,0.00025900113,0.99513054,0.00051204744],"about_ca_topic_score_codex":0.0011461248,"about_ca_topic_score_gemma":0.0009934315,"teacher_disagreement_score":0.9812188,"about_ca_system_score_codex":0.0012756751,"about_ca_system_score_gemma":0.0011571499,"threshold_uncertainty_score":0.9996879},"labels":[],"label_agreement":null},{"id":"W1967055941","doi":"10.2165/11535400-000000000-00000","title":"Comparative Effectiveness Research","year":2010,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Government of Ontario; H2020 European Research Council; Eli Lilly and Company","keywords":"Comparative effectiveness research; Health technology; Context (archaeology); Pharmaceutical industry; Drug development; Business; Health care; Risk analysis (engineering); Management science; Medicine; Engineering; Economic growth; Economics; Drug; Pharmacology","score_opus":0.6774839488949597,"score_gpt":0.6109221430259052,"score_spread":0.06656180586905447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1967055941","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9370887,0.00050948875,0.0007210089,0.009241561,0.0029190117,0.001093011,0.00025788802,0.00011006102,0.04805925],"genre_scores_gemma":[0.99210984,0.000066017856,0.0018377817,0.0040591187,0.0010508837,0.0002965901,0.000033822427,0.000050621915,0.00049532263],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99501014,0.00071940426,0.0026186446,0.00083004823,0.000088294415,0.0007334435],"domain_scores_gemma":[0.99415094,0.0037368475,0.00093761424,0.0006598083,0.00014827197,0.00036654645],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.037714623,0.0002455161,0.0011467987,0.0005291608,0.00044211638,0.00018006534,0.00062705984,0.00018009152,0.0023844638],"category_scores_gemma":[0.0013335822,0.000335902,0.0001523746,0.00024443955,0.00027490527,0.000761257,0.00013974868,0.0010355432,0.019366626],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012823229,0.00041115945,0.050193213,0.00039708888,0.00029139657,0.0000037978136,0.0035715848,0.0004764439,0.0035483672,0.83272207,0.107860446,0.00039619883],"study_design_scores_gemma":[0.003156403,0.00012794421,0.038959693,0.000044318433,0.000012764566,0.00002486209,0.0010026343,0.019910559,0.004943316,0.107083805,0.8236226,0.00111114],"about_ca_topic_score_codex":0.0005192465,"about_ca_topic_score_gemma":0.00017015255,"teacher_disagreement_score":0.7256383,"about_ca_system_score_codex":0.000489518,"about_ca_system_score_gemma":0.00021936285,"threshold_uncertainty_score":0.9999093},"labels":[],"label_agreement":null},{"id":"W1967313838","doi":"10.2165/00019053-200119100-00005","title":"Incremental Cost-Effectiveness Analysis Comparing Rofecoxib with Nonselective NSAIDs in Osteoarthritis","year":2001,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Inflammatory mediators and NSAID effects","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Merck Canada Inc. (Canada); TransCanada (Canada); McMaster University","funders":"Merck Canada","keywords":"Rofecoxib; Medicine; Prostaglandin-Endoperoxide Synthase; Pharmacoeconomics; Osteoarthritis; Medical prescription; Internal medicine; Clinical trial; Cost effectiveness; Surgery; Intensive care medicine; Pharmacology; Cyclooxygenase; Alternative medicine","score_opus":0.02325721789784359,"score_gpt":0.3218060208392704,"score_spread":0.2985488029414268,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1967313838","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942694,0.00016431547,0.0005295349,0.000050217688,0.00017546068,0.0011799345,0.000010586616,0.0000600783,0.003560485],"genre_scores_gemma":[0.9989096,0.000105605206,0.00013676177,0.00031062603,0.00016083397,0.00024276556,0.00006041963,0.000036037414,0.000037358008],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99857205,0.00015577671,0.0003254478,0.0003988229,0.00012078603,0.00042712566],"domain_scores_gemma":[0.99917054,0.00024184425,0.00011070721,0.00019905547,0.00005739883,0.00022042867],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006105912,0.0002482009,0.0007105787,0.00051457394,0.0000807013,0.00002857495,0.000089193265,0.000069823385,0.00025695295],"category_scores_gemma":[0.000024270394,0.00024175581,0.00012038304,0.00064112095,0.00007073522,0.00021261346,0.00003978031,0.0003237139,0.000076478085],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026556686,0.00018867948,0.97639436,0.000049756723,0.0007116473,0.00033921355,0.00023343036,0.0023151531,0.006977364,0.000037521862,0.00003734901,0.010059885],"study_design_scores_gemma":[0.021109631,0.0009181115,0.85769016,0.0001891179,0.0016431072,0.00027109263,0.00018492619,0.031428672,0.08302915,0.000018487586,0.0028468927,0.0006706378],"about_ca_topic_score_codex":0.00031517912,"about_ca_topic_score_gemma":0.0010016949,"teacher_disagreement_score":0.11870416,"about_ca_system_score_codex":0.0005647051,"about_ca_system_score_gemma":0.00011407607,"threshold_uncertainty_score":0.9858516},"labels":[],"label_agreement":null},{"id":"W1967566969","doi":"10.2165/11531480-000000000-00000","title":"Cost Effectiveness of High-Dose Intravenous Esomeprazole for Peptic Ulcer Bleeding","year":2010,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Gastrointestinal Bleeding Diagnosis and Treatment","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Montreal General Hospital","funders":"AstraZeneca","keywords":"Esomeprazole; Medicine; Proton-pump inhibitor; Clinical trial; Intensive care medicine; Internal medicine; Emergency medicine","score_opus":0.03462260142695433,"score_gpt":0.3408558796709964,"score_spread":0.30623327824404206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1967566969","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969189,0.000038160557,0.00034710846,0.00029176267,0.00075361034,0.0011534387,0.00006096967,0.00003970289,0.00039631868],"genre_scores_gemma":[0.9941513,0.000038555547,0.0050164075,0.00013106532,0.0002995403,0.00024309027,0.00004641262,0.0000397983,0.000033860917],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99910426,0.000013622038,0.00027943047,0.00026696248,0.000060611274,0.00027510518],"domain_scores_gemma":[0.99885595,0.00054862985,0.00013416051,0.00016837838,0.00011862717,0.00017424252],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039021578,0.00017475005,0.00041183655,0.00009715207,0.000058523732,0.00001853019,0.00008953214,0.00004920884,0.00014399916],"category_scores_gemma":[0.0000875218,0.00016429315,0.0001391442,0.000050011775,0.00006764257,0.00007937808,0.000033894656,0.00019559864,0.000039874474],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028482722,0.0023978902,0.16010226,0.0013586023,0.00083127036,0.000036184752,0.0002438254,0.00060129084,0.79657215,0.0061199865,0.0011117607,0.027776478],"study_design_scores_gemma":[0.017253632,0.0015589972,0.16935518,0.00030107115,0.0011541102,0.00028687387,0.00007240172,0.0040363106,0.8016701,0.00097423553,0.0029765524,0.00036054268],"about_ca_topic_score_codex":0.000074303105,"about_ca_topic_score_gemma":0.000005014275,"teacher_disagreement_score":0.027415935,"about_ca_system_score_codex":0.00010458912,"about_ca_system_score_gemma":0.00007849065,"threshold_uncertainty_score":0.669968},"labels":[],"label_agreement":null},{"id":"W1969013485","doi":"10.2165/00019053-200826080-00001","title":"Waiting for Reimbursement of New Medicines in Canada","year":2008,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Fraser Institute","funders":"","keywords":"Reimbursement; Public health; Health economics; Public health insurance; Certification; Medicine; Family medicine; Quality of Life Research; Environmental health; Health insurance; Health administration; Business; Health care; Economic growth; Nursing; Political science","score_opus":0.11448916653243718,"score_gpt":0.31835818760973206,"score_spread":0.20386902107729488,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1969013485","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98063654,0.0013453155,0.000222443,0.004704014,0.0008113638,0.00036063025,0.00031390143,0.000009752073,0.011596063],"genre_scores_gemma":[0.9932519,0.0011269279,0.0004550928,0.0044869008,0.0003233112,0.000028048884,0.000016302132,0.00002764105,0.00028385167],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982724,0.000005414091,0.0010298156,0.00030122086,0.000017013965,0.00037413771],"domain_scores_gemma":[0.9991093,0.00012749546,0.00038232034,0.00016924315,0.00001553175,0.00019609332],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030363936,0.00015338346,0.00051933544,0.00015474141,0.00004653509,0.000006574064,0.0002554548,0.000036612983,0.00047524108],"category_scores_gemma":[0.000053617863,0.00019987761,0.000093698465,0.00008252069,0.00003769744,0.00012786877,0.000044389937,0.0001167443,0.00003371706],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033258655,0.00023309384,0.48262694,0.0003069064,0.0003776843,0.00002119813,0.0016899729,0.012916117,0.00057965,0.22403584,0.26271424,0.014165773],"study_design_scores_gemma":[0.0072939787,0.00006623928,0.013963995,0.00002709854,0.000019984363,0.000018577097,0.00015552444,0.18829371,0.008974875,0.02694179,0.7534628,0.0007814596],"about_ca_topic_score_codex":0.46897626,"about_ca_topic_score_gemma":0.17135203,"teacher_disagreement_score":0.49074855,"about_ca_system_score_codex":0.00045314367,"about_ca_system_score_gemma":0.00066174095,"threshold_uncertainty_score":0.84376866},"labels":[],"label_agreement":null},{"id":"W1970656907","doi":"10.2165/00019053-200220010-00006","title":"Economic Comparison of Leflunomide and Methotrexate in Patients with Rheumatoid Arthritis","year":2002,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Arthritis Research Centre of Canada; University of Ottawa; University Health Network","funders":"","keywords":"Medicine; Leflunomide; Rheumatoid arthritis; Placebo; Discontinuation; Physical therapy; Demography; Internal medicine; Alternative medicine","score_opus":0.019293109582837552,"score_gpt":0.3016139661087729,"score_spread":0.28232085652593536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1970656907","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914172,0.006414341,0.000008276555,0.0002391531,0.000057068093,0.00033641828,0.00003137667,0.000018021037,0.0014781321],"genre_scores_gemma":[0.96498424,0.03425905,0.0005826241,0.000079823236,0.000013833909,0.00001533003,0.000012811108,0.00002483189,0.00002745064],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99896926,0.000040853698,0.00043233868,0.00023047968,0.00006865905,0.00025842007],"domain_scores_gemma":[0.9994573,0.00007750405,0.00012722964,0.00015204406,0.000027608534,0.00015830333],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014936733,0.00014325928,0.00050317065,0.00017340858,0.000035809888,0.000022694661,0.000070240145,0.000035684592,0.0006719612],"category_scores_gemma":[0.000012292758,0.00013767893,0.000040159328,0.000039470233,0.00014131328,0.00020353794,0.00003532375,0.0001659125,0.000064453125],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004881296,0.00025907747,0.8987594,0.000026744588,0.00010502616,0.0000033777953,0.0005541139,0.00008672359,0.00023668844,0.00017901692,0.0006636676,0.09863799],"study_design_scores_gemma":[0.07241614,0.0021554176,0.81411475,0.000736845,0.000016808115,0.00006533194,0.0004607839,0.039047085,0.027913544,0.00034436994,0.041746717,0.0009822074],"about_ca_topic_score_codex":0.00008979379,"about_ca_topic_score_gemma":0.000105205385,"teacher_disagreement_score":0.09765578,"about_ca_system_score_codex":0.0000704059,"about_ca_system_score_gemma":0.000027552662,"threshold_uncertainty_score":0.7357504},"labels":[],"label_agreement":null},{"id":"W1970936993","doi":"10.2165/00019053-200321090-00004","title":"Economic Evaluation of Norethisterone Acetate/Ethinylestradiol (FemHRT??) for Women with Menopausal Symptoms","year":2003,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Menopause: Health Impacts and Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"Ottawa Hospital Research Institute","keywords":"Norethisterone; Medicine; Medroxyprogesterone acetate; Hormone replacement therapy (female-to-male); Norethisterone acetate; Cost effectiveness; Gynecology; Hormone therapy; Quality-adjusted life year; Obstetrics; Menopause; Internal medicine; Estrogen; Population; Breast cancer; Health services","score_opus":0.05937105870043457,"score_gpt":0.3790195173445483,"score_spread":0.31964845864411373,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1970936993","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991144,0.0002970676,0.00009074984,0.00036816913,0.0003402118,0.0019149556,0.0001106679,0.000029684932,0.005704505],"genre_scores_gemma":[0.9968348,0.000104594874,0.0014246788,0.00062556006,0.00010439286,0.00039158307,0.00005014918,0.000056656885,0.00040758206],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9984159,0.00009360918,0.00052661594,0.000347651,0.0001508038,0.00046541376],"domain_scores_gemma":[0.9987563,0.000107070795,0.00033082615,0.00029415276,0.00012374252,0.0003879106],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013509018,0.00024172872,0.0005197027,0.000111808025,0.00007969351,0.00001793111,0.00007914482,0.00007778765,0.0005949958],"category_scores_gemma":[0.00003471777,0.00020717864,0.000013910703,0.000038157574,0.00007934798,0.00017578356,0.00000934939,0.00012811244,0.0000394589],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06177905,0.0073853,0.08280728,0.011266993,0.024815619,0.000107582135,0.02209864,0.03883487,0.4533249,0.012417584,0.021697067,0.2634651],"study_design_scores_gemma":[0.3794079,0.07819843,0.030561808,0.00065444456,0.013405844,0.0012231894,0.0017078848,0.0669643,0.3071769,0.007653276,0.10957166,0.0034743792],"about_ca_topic_score_codex":0.00003216037,"about_ca_topic_score_gemma":0.000012866018,"teacher_disagreement_score":0.31762886,"about_ca_system_score_codex":0.0013345473,"about_ca_system_score_gemma":0.0009955651,"threshold_uncertainty_score":0.84485},"labels":[],"label_agreement":null},{"id":"W1971246182","doi":"10.2165/00019053-200321060-00005","title":"A Pharmacy-Based Health Promotion Programme in Hypertension","year":2003,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Pharmaceutical Practices and Patient Outcomes","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Merck Canada Inc. (Canada); Hôpital du Saint-Sacrement; Université Laval","funders":"","keywords":"Pharmacy; Medicine; Pharmacist; Health economics; Psychological intervention; Health care; Family medicine; Health administration; Health promotion; Public health; Nursing; Environmental health","score_opus":0.26896895992880454,"score_gpt":0.4459164199547492,"score_spread":0.17694746002594464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1971246182","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9770914,0.00050134084,0.00020957665,0.016494881,0.0005682705,0.0014458828,0.000007723785,0.000100553516,0.0035804077],"genre_scores_gemma":[0.98338693,0.00028112586,0.0020618872,0.01398728,0.00006425533,0.000054942684,0.000041538962,0.000029731287,0.00009232002],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985448,0.0001473481,0.00043809507,0.00030103326,0.00010792125,0.00046077924],"domain_scores_gemma":[0.9991919,0.000105410734,0.00015232194,0.00015271931,0.00003408846,0.00036355839],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006678857,0.00016985527,0.00033248734,0.0001444678,0.00005729264,0.000022445933,0.000059286136,0.000033495347,0.00039684738],"category_scores_gemma":[0.000075704855,0.00015928023,0.000097671815,0.00015421346,0.00003237963,0.00019539017,0.0000129558,0.0003439508,0.00013347412],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021806883,0.008628068,0.80194604,0.001297336,0.00018478594,0.00022826658,0.00029572088,0.00080980675,0.0124417385,0.0018643714,0.0037200616,0.16640313],"study_design_scores_gemma":[0.027832748,0.00077167846,0.003853331,0.00015342423,0.00015785688,0.00022251885,0.00007746851,0.18274133,0.03191299,0.00026519463,0.75147444,0.0005370467],"about_ca_topic_score_codex":0.0000619437,"about_ca_topic_score_gemma":0.000010419974,"teacher_disagreement_score":0.7980927,"about_ca_system_score_codex":0.00026358722,"about_ca_system_score_gemma":0.00037105905,"threshold_uncertainty_score":0.64952594},"labels":[],"label_agreement":null},{"id":"W1971890855","doi":"10.2165/00019053-200119090-00004","title":"Cost-Utility Analysis of Tissue Plasminogen Activator Therapy for Acute Ischaemic Stroke","year":2001,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Acute Ischemic Stroke Management","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Hospital and Health Sciences Centre; University of British Columbia","funders":"National Institute of Neurological Disorders and Stroke; Heart and Stroke Foundation of Canada","keywords":"Medicine; Ischaemic stroke; Stroke (engine); Cohort; Tissue plasminogen activator; Thrombolysis; Quality-adjusted life year; Clinical trial; Internal medicine; Cost effectiveness; Emergency medicine; Physical therapy; Pediatrics; Ischemia; Myocardial infarction","score_opus":0.048404564636495694,"score_gpt":0.37625090538830464,"score_spread":0.32784634075180896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1971890855","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98549086,0.00018854208,0.0060883528,0.0009036255,0.0002177749,0.0015602957,0.0006701376,0.000056341156,0.004824081],"genre_scores_gemma":[0.9913238,0.0014984789,0.0023671938,0.0016279428,0.00020007679,0.00019165411,0.00026808892,0.0000404671,0.002482278],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99863213,0.000018010198,0.00048546723,0.000410551,0.000115127346,0.00033869527],"domain_scores_gemma":[0.9989007,0.00013443556,0.000263763,0.00044442143,0.000086871034,0.00016981483],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00024199806,0.00022828949,0.00071621983,0.00031898252,0.000047405338,0.000012218677,0.00022878106,0.00008022725,0.0012708061],"category_scores_gemma":[0.0000174671,0.00022612119,0.0003473993,0.00024401295,0.00007070533,0.00012776803,0.000074918644,0.00013493138,0.000023273737],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008321021,0.00086167746,0.12587334,0.000110645866,0.052386165,0.000033877037,0.00073795934,0.00046045837,0.55832773,0.000074623655,0.0927459,0.1600666],"study_design_scores_gemma":[0.0048148404,0.00016562351,0.0063048108,0.0000052393357,0.0064235805,0.000010573596,0.0001287918,0.02316491,0.5261941,0.00000695136,0.43255445,0.00022615233],"about_ca_topic_score_codex":0.000036538455,"about_ca_topic_score_gemma":0.0000043552413,"teacher_disagreement_score":0.33980855,"about_ca_system_score_codex":0.00016601868,"about_ca_system_score_gemma":0.00007032671,"threshold_uncertainty_score":0.9996422},"labels":[],"label_agreement":null},{"id":"W1972323838","doi":"10.2165/11584330-000000000-00000","title":"The Direct Medical Costs Associated with Suspected Heparin-Induced Thrombocytopenia","year":2011,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Heparin-Induced Thrombocytopenia and Thrombosis","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto","funders":"Bayer Fund; Sanofi","keywords":"Medicine; Emergency medicine; Indirect costs; Health economics; Health care; Adverse effect; Thrombosis; Public health; Surgery; Internal medicine; Pathology","score_opus":0.05595436473697466,"score_gpt":0.3136412365119274,"score_spread":0.2576868717749527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1972323838","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8518797,0.00008131204,0.0000073608553,0.0012666958,0.00059121125,0.0007694717,0.000014474089,0.000285025,0.14510472],"genre_scores_gemma":[0.9966237,0.0004600668,0.00010974104,0.0016827312,0.00024418405,0.000098528944,0.000045426797,0.00011307436,0.00062252925],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997168,0.00019561111,0.000688596,0.0006531135,0.00041057373,0.00088411925],"domain_scores_gemma":[0.9975444,0.00046937494,0.00028909836,0.0006990585,0.00020702716,0.0007910402],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009683565,0.0004626257,0.0009598651,0.00010736622,0.00050417363,0.00009345265,0.0006063043,0.00026588442,0.002191717],"category_scores_gemma":[0.00038482546,0.00031769057,0.0001999423,0.00032993604,0.00029462256,0.0002594118,0.00020758,0.00081384537,0.0005170767],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010723291,0.008400152,0.6231396,0.0002162086,0.023524519,0.0026728965,0.0074309004,0.000006763702,0.15225254,0.029510206,0.033781826,0.10834107],"study_design_scores_gemma":[0.019969689,0.001899174,0.6403829,0.00040763707,0.002059574,0.00059011957,0.0005664978,0.002945857,0.30229187,0.00041139612,0.026462143,0.002013184],"about_ca_topic_score_codex":0.000606572,"about_ca_topic_score_gemma":0.001426858,"teacher_disagreement_score":0.15003932,"about_ca_system_score_codex":0.00069328543,"about_ca_system_score_gemma":0.0008120531,"threshold_uncertainty_score":0.9999275},"labels":[],"label_agreement":null},{"id":"W1972649100","doi":"10.2165/00019053-200119010-00003","title":"Glycoprotein IIb/IIIa Receptor Therapy in Percutaneous Coronary Intervention and Non???ST-Segment Elevation Acute Coronary Syndromes","year":2001,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Acute Myocardial Infarction Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Abciximab; Medicine; Eptifibatide; Conventional PCI; Percutaneous coronary intervention; Tirofiban; Myocardial infarction; Internal medicine; Acute coronary syndrome; Cost effectiveness; Cardiology","score_opus":0.05854457222835281,"score_gpt":0.39484833766169447,"score_spread":0.3363037654333417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1972649100","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02424839,0.9676047,0.00006531913,0.0008935934,0.0008028853,0.005573719,0.0003738061,0.00010040968,0.00033720225],"genre_scores_gemma":[0.0006649833,0.99346364,0.00044406948,0.0010125724,0.00035872508,0.000660701,0.0016386998,0.00016118724,0.0015954556],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99676394,0.00028148276,0.0012614427,0.0008688901,0.00026169553,0.00056251895],"domain_scores_gemma":[0.9984948,0.00016677495,0.00048253493,0.00045284512,0.000097878576,0.00030518352],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00071138755,0.0006589607,0.0019442987,0.00065427925,0.00010516119,0.00008036472,0.00028183084,0.0004270621,0.0022397626],"category_scores_gemma":[0.000023199114,0.0006330357,0.00056872424,0.00029860437,0.00014057416,0.0002645934,0.00022209596,0.0011107519,0.0004097938],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00069044164,0.00026647723,0.00024924122,0.002428054,0.0015985153,0.00065560365,0.000058664435,0.0000035520554,0.00014832744,0.000005980609,0.0065212715,0.9873739],"study_design_scores_gemma":[0.0029563962,0.00079153944,0.00016476856,0.0025603329,0.00069114566,0.0078012114,0.0000418728,0.00030401134,0.000024928773,0.000016832071,0.98409873,0.00054820464],"about_ca_topic_score_codex":0.0001585225,"about_ca_topic_score_gemma":0.0000047615626,"teacher_disagreement_score":0.98682564,"about_ca_system_score_codex":0.0015612675,"about_ca_system_score_gemma":0.00037057474,"threshold_uncertainty_score":0.9996121},"labels":[],"label_agreement":null},{"id":"W1973112266","doi":"10.2165/00019053-200220090-00004","title":"Direct Medical Cost of Managing Deep Vein Thrombosis According to the Occurrence of Complications","year":2002,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Royal Victoria Hospital","funders":"","keywords":"Medicine; Deep vein; Ambulatory; Emergency medicine; Health economics; Intensive care unit; Ambulatory care; Intensive care medicine; Thrombosis; Public health; Indirect costs; Health administration; Inpatient care; Health care; Low molecular weight heparin; Surgery; Business; Nursing","score_opus":0.059229731182579216,"score_gpt":0.3531829625436581,"score_spread":0.29395323136107887,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1973112266","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83082825,0.0014685495,0.0062323245,0.05382359,0.001126675,0.0026939572,0.00017404006,0.00011198081,0.10354061],"genre_scores_gemma":[0.99356556,0.002135736,0.00029438332,0.0037954664,0.00008312325,0.0000821184,0.000010686423,0.000011992444,0.000020961983],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990313,0.000028157356,0.00039250194,0.0002014356,0.00015317125,0.0001934394],"domain_scores_gemma":[0.9991573,0.00016604702,0.00014811411,0.00032615307,0.000053441334,0.00014890677],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00032225775,0.000108294385,0.00039138933,0.000099338315,0.00007263333,0.000010756947,0.00030557835,0.000026775475,0.0009222667],"category_scores_gemma":[0.00006552594,0.00008989493,0.00009748396,0.00015476096,0.000075300246,0.00005964485,0.00015084325,0.000107028245,0.00010650624],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008087009,0.004303555,0.060093503,0.001107809,0.0020447408,0.000011363468,0.0064341743,0.008173838,0.0068563777,0.012327493,0.28940994,0.6091563],"study_design_scores_gemma":[0.0060325344,0.00058438233,0.12161616,0.001015779,0.0023515825,0.00003573839,0.003700446,0.26501024,0.05251226,0.0002522863,0.5457618,0.0011267471],"about_ca_topic_score_codex":0.00008300254,"about_ca_topic_score_gemma":0.00002148166,"teacher_disagreement_score":0.6080296,"about_ca_system_score_codex":0.00005816599,"about_ca_system_score_gemma":0.000019906418,"threshold_uncertainty_score":0.999991},"labels":[],"label_agreement":null},{"id":"W1974629898","doi":"10.1007/s40273-014-0204-4","title":"Some Inconsistencies in NICE’s Consideration of Social Values","year":2014,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":68,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of Alberta","funders":"Canadian Institutes of Health Research; Genome Canada","keywords":"Nice; Excellence; Quality-adjusted life year; Health economics; Actuarial science; Medicine; Health technology; Cost effectiveness; Economic evaluation; Health care; Economics; Public health; Economic growth; Risk analysis (engineering); Political science; Nursing; Computer science; Law","score_opus":0.29187287307462745,"score_gpt":0.4549529332373815,"score_spread":0.16308006016275406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1974629898","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9645316,0.0010561078,0.00056473474,0.022559782,0.0011037418,0.0005101684,0.00018711034,0.000055594417,0.009431165],"genre_scores_gemma":[0.98519415,0.00014805577,0.00132446,0.012223588,0.0007465198,0.000060884446,0.000029714038,0.0000346825,0.00023797505],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9947581,0.0003444126,0.004011483,0.000469092,0.000052241878,0.00036464905],"domain_scores_gemma":[0.99647355,0.0010218724,0.0020729515,0.00027548906,0.000051654977,0.00010449099],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.010746286,0.00020212588,0.0010836255,0.00043574063,0.00014119069,0.000057508907,0.00025317963,0.0001360038,0.0003976834],"category_scores_gemma":[0.0012623783,0.00029287324,0.00014912379,0.00010369727,0.00014469249,0.00082697667,0.000065275904,0.0001868975,0.000841278],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000041153125,0.00018047476,0.05622715,0.00040482674,0.00010318443,5.1735714e-7,0.005049335,0.0012716275,0.00022424142,0.91147274,0.02459943,0.0004253023],"study_design_scores_gemma":[0.008651649,0.00020870718,0.10027448,0.00011242995,0.00004954364,0.000013935475,0.0037212246,0.14028159,0.0022532986,0.58970475,0.15282014,0.0019082623],"about_ca_topic_score_codex":0.0004248624,"about_ca_topic_score_gemma":0.00014239541,"teacher_disagreement_score":0.32176802,"about_ca_system_score_codex":0.0004481148,"about_ca_system_score_gemma":0.00013763813,"threshold_uncertainty_score":0.9999523},"labels":[],"label_agreement":null},{"id":"W1974907410","doi":"10.2165/00019053-200624100-00002","title":"QALYs","year":2006,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":62,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Quality-adjusted life year; Health economics; Life expectancy; Actuarial science; Health technology; Cost–utility analysis; Economic evaluation; Cost–benefit analysis; Value (mathematics); Health administration; Cost effectiveness; Quality (philosophy); Medicine; Economics; Operations research; Public economics; Health care; Risk analysis (engineering); Computer science; Microeconomics; Population; Environmental health; Engineering","score_opus":0.32534079039432967,"score_gpt":0.4713800522101522,"score_spread":0.14603926181582255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1974907410","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6694002,0.0050838822,0.010314471,0.06477322,0.0036219559,0.0011663425,0.00079455273,0.00045643916,0.24438895],"genre_scores_gemma":[0.9586068,0.00015841651,0.004334263,0.02923167,0.0021920246,0.0001335399,0.00011792039,0.0000903188,0.0051350463],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9947834,0.000121700985,0.00384646,0.0006483208,0.000046717294,0.00055342616],"domain_scores_gemma":[0.9972146,0.00043884467,0.0016408977,0.0004843589,0.000035185065,0.00018608314],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0066551412,0.0002507348,0.0008525562,0.00030747495,0.00020218344,0.00013090063,0.0003935403,0.00011780538,0.0028964155],"category_scores_gemma":[0.00027039065,0.00036248862,0.00020076716,0.00012935058,0.000073902076,0.0006882626,0.00006655909,0.00019535054,0.018442893],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000017348653,0.00016355331,0.047344863,0.00011451799,0.00009021876,0.000002673713,0.00023644853,0.0020249656,0.000086923465,0.553017,0.39663586,0.0002656037],"study_design_scores_gemma":[0.001577613,0.000026646296,0.009580125,0.00001263236,0.000013559615,0.000012597922,0.00013142734,0.016938094,0.0003042763,0.0879086,0.88279366,0.0007007361],"about_ca_topic_score_codex":0.0013551946,"about_ca_topic_score_gemma":0.00009421774,"teacher_disagreement_score":0.48615783,"about_ca_system_score_codex":0.000619371,"about_ca_system_score_gemma":0.000088549685,"threshold_uncertainty_score":0.9998827},"labels":[],"label_agreement":null},{"id":"W1975774094","doi":"10.2165/00019053-200321130-00002","title":"Quality of Life in Patients with Rheumatoid Arthritis","year":2003,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Etanercept; Rheumatoid arthritis; Leflunomide; Quality of life (healthcare); Minimal clinically important difference; Internal medicine; Refractory (planetary science); Infliximab; Physical therapy; Polyarthritis; Rheumatology; Arthritis; Methotrexate; Disease; Randomized controlled trial","score_opus":0.04599196494103063,"score_gpt":0.36185948515112076,"score_spread":0.3158675202100901,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1975774094","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.018800275,0.9783802,0.000003220587,0.000014588077,0.00012980378,0.0012384674,0.00018687877,0.000019932091,0.001226605],"genre_scores_gemma":[0.001524522,0.99777794,0.00015771245,0.00009707889,0.000024501725,0.00010087331,0.00020527882,0.00007840055,0.000033679604],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973813,0.00024719865,0.0013668874,0.00038869435,0.00021677815,0.00039911497],"domain_scores_gemma":[0.9984891,0.00017029486,0.0005573552,0.00037790582,0.00009663156,0.0003087518],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005218845,0.00037066473,0.002860822,0.00032115626,0.000031009688,0.000022374668,0.00017437758,0.00014289905,0.00059006695],"category_scores_gemma":[0.00008930298,0.00031098843,0.0003194507,0.00017567848,0.00014475908,0.00012763086,0.00004487137,0.0005007034,0.00010316406],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027179674,0.00044417207,0.01834946,0.0054970733,0.00045257056,0.0000050303697,0.00003487691,8.2891296e-7,1.415557e-7,0.00020823439,0.00060840865,0.9741274],"study_design_scores_gemma":[0.007574023,0.00016043193,0.00070049556,0.007474295,0.000009972495,0.000009366101,0.000009566826,0.0000018615042,0.0000019203708,0.000021546623,0.9837087,0.00032786047],"about_ca_topic_score_codex":0.00006857008,"about_ca_topic_score_gemma":0.00003458434,"teacher_disagreement_score":0.98310024,"about_ca_system_score_codex":0.00015089744,"about_ca_system_score_gemma":0.0008321003,"threshold_uncertainty_score":0.9999342},"labels":[],"label_agreement":null},{"id":"W1975962137","doi":"10.2165/11537370-000000000-00000","title":"The Value of Value of Information","year":2010,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":104,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"Value of information; Computer science; Simplicity; Risk analysis (engineering); Management science; Value (mathematics); Operations research; Economics; Mathematics","score_opus":0.15159650207376027,"score_gpt":0.4322360465584539,"score_spread":0.28063954448469364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1975962137","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96241546,0.0005073358,0.0021244953,0.01393318,0.0030053225,0.00068752986,0.00051065994,0.000035388744,0.016780604],"genre_scores_gemma":[0.9916034,0.00036082044,0.0032731167,0.0042081806,0.00030732458,0.000051203817,0.000028997167,0.000024219295,0.0001427676],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9947957,0.00011358417,0.0045050886,0.00021566765,0.000061833816,0.00030814158],"domain_scores_gemma":[0.99424857,0.0012293544,0.0037378666,0.0005579072,0.000097175696,0.00012910509],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.011853117,0.00016049045,0.00066736527,0.00021866824,0.00016961276,0.000056743786,0.00056445564,0.00011787863,0.0003126876],"category_scores_gemma":[0.0015395529,0.00017551181,0.00017370378,0.00011296126,0.000182702,0.00095109036,0.00008169046,0.00027748424,0.00088055996],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003076037,0.000050479564,0.013504828,0.00020240681,0.000104089675,4.8126523e-8,0.0011413492,0.001317806,0.00027261974,0.96997976,0.0121330805,0.0012627504],"study_design_scores_gemma":[0.0024204913,0.00009593498,0.025174597,0.000034186698,0.000032769305,0.000009082478,0.00097233045,0.11406796,0.005348559,0.07931904,0.7719182,0.00060689857],"about_ca_topic_score_codex":0.00057547586,"about_ca_topic_score_gemma":0.00004394315,"teacher_disagreement_score":0.89066076,"about_ca_system_score_codex":0.00012847276,"about_ca_system_score_gemma":0.00019009698,"threshold_uncertainty_score":0.99989736},"labels":[],"label_agreement":null},{"id":"W1976080636","doi":"10.2165/00019053-200523020-00006","title":"Providing Systematic Guidance in Pharmacoeconomic Guidelines for Analysing Costs","year":2005,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Economics","funders":"","keywords":"Activity-based costing; Health economics; Valuation (finance); Pharmacoeconomics; Identification (biology); Resource (disambiguation); Risk analysis (engineering); Cost driver; Process costing; Actuarial science; Computer science; Management science; Operations management; Business; Medicine; Health care; Economics; Accounting","score_opus":0.5371022765154605,"score_gpt":0.5497056761301654,"score_spread":0.012603399614704913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1976080636","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6927681,0.04049423,0.03855448,0.1985473,0.004820739,0.0130739,0.001554686,0.0005538214,0.009632755],"genre_scores_gemma":[0.8904047,0.00084193144,0.0374255,0.064619526,0.003009485,0.002114627,0.00009822047,0.00021334081,0.0012726696],"study_design_codex":"not_applicable","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.98784846,0.00029845597,0.0097068325,0.0011412741,0.00007085856,0.00093412335],"domain_scores_gemma":[0.99324363,0.001639441,0.0039553945,0.00065177365,0.0001906646,0.00031909725],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.022897657,0.0004890621,0.0022550793,0.0008892204,0.00025195145,0.00024708477,0.0007487901,0.00016940225,0.00039725515],"category_scores_gemma":[0.0035438647,0.0006662069,0.00039184382,0.00020603248,0.000064493695,0.0016731689,0.000097808756,0.00025411084,0.002279271],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000510331,0.0011838797,0.064137414,0.050275095,0.0021359145,0.000009193118,0.0064992527,0.16919614,0.0016270743,0.30477154,0.39353752,0.0061166617],"study_design_scores_gemma":[0.0055120024,0.00005208847,0.00054240343,0.001383769,0.00009060344,0.000018656785,0.0007456044,0.8759725,0.0009079867,0.0038379764,0.10949701,0.0014394026],"about_ca_topic_score_codex":0.00035093966,"about_ca_topic_score_gemma":0.00031133826,"teacher_disagreement_score":0.7067764,"about_ca_system_score_codex":0.0036501815,"about_ca_system_score_gemma":0.00020796077,"threshold_uncertainty_score":0.9995789},"labels":[],"label_agreement":null},{"id":"W1977585061","doi":"10.1007/s40273-014-0146-x","title":"Achieving Allocative Efficiency in Healthcare: Nice in Theory, not so NICE in Practice?","year":2014,"lang":"en","type":"letter","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Institute for Health and Care Research","keywords":"Allocative efficiency; Nice; Health economics; Health administration; Quality of Life Research; Health care; Public health; Quality-adjusted life year; Public economics; Business; Medicine; Economics; Cost effectiveness; Nursing; Operations management; Microeconomics; Economic growth; Computer science","score_opus":0.24596408068605594,"score_gpt":0.4786617127778069,"score_spread":0.23269763209175096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1977585061","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.026440019,0.0044401716,0.0006657773,0.9570606,0.0022752916,0.002466902,0.00043307026,0.000074767915,0.0061434363],"genre_scores_gemma":[0.103171505,0.002130332,0.00087739254,0.88988775,0.0023902259,0.00059827825,0.00024914913,0.00021776264,0.00047762788],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.982013,0.003548977,0.010199291,0.0022798027,0.00017791346,0.0017810105],"domain_scores_gemma":[0.98141766,0.010505798,0.006502921,0.0012176774,0.00009587311,0.00026007442],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.05048744,0.0008970178,0.0033053078,0.0023017933,0.00018795457,0.00029521508,0.0015019618,0.001223361,0.00031236024],"category_scores_gemma":[0.0061286613,0.0013291389,0.00029298427,0.00056759344,0.00021909356,0.0014239656,0.0002685264,0.004613555,0.0036635092],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000638634,0.0012012523,0.05898969,0.0055342047,0.00048498332,0.0002526528,0.017834209,0.011690872,0.000011188092,0.13810451,0.7631334,0.002124365],"study_design_scores_gemma":[0.0036573184,0.00010718623,0.0031061356,0.00047112512,0.000028362121,0.000032118896,0.0006385219,0.016333047,0.000008471307,0.00602427,0.967893,0.0017004414],"about_ca_topic_score_codex":0.013160602,"about_ca_topic_score_gemma":0.0024993618,"teacher_disagreement_score":0.20475957,"about_ca_system_score_codex":0.005787525,"about_ca_system_score_gemma":0.0011028679,"threshold_uncertainty_score":0.9989158},"labels":[],"label_agreement":null},{"id":"W1977937211","doi":"10.1007/s40273-014-0185-3","title":"Hospital-Based Health Technology Assessment: Developments to Date","year":2014,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":73,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Saint-François d'Assise","funders":"Canada Research Chairs","keywords":"Health technology; Multidisciplinary approach; Health economics; Health administration; Medicine; Technology assessment; Psychological intervention; Public health; Discontinuation; Pharmacoeconomics; Management science; Health care; Nursing; Intensive care medicine; Engineering; Political science","score_opus":0.24823222275365942,"score_gpt":0.49499207490877034,"score_spread":0.24675985215511093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1977937211","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.39486036,0.0006940605,0.12093637,0.45468268,0.004344347,0.002739232,0.00059431855,0.00057312264,0.020575494],"genre_scores_gemma":[0.8146263,0.00008491168,0.056315932,0.12761548,0.00039943354,0.0003536711,0.00013627991,0.00009690084,0.0003710936],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99386936,0.00022321203,0.0039999527,0.0009835534,0.00007114044,0.0008527922],"domain_scores_gemma":[0.9961526,0.00038315923,0.002128092,0.0007285313,0.00006191956,0.0005456953],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.011913242,0.00033984656,0.0012358563,0.000892211,0.00033835354,0.00012746929,0.0007273206,0.0001481271,0.0005088164],"category_scores_gemma":[0.00061905134,0.00049146666,0.00011567034,0.00032717513,0.00006708179,0.00041270125,0.00015281074,0.0002973848,0.008045492],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000041324227,0.0007280675,0.22947197,0.00082880387,0.0003681743,0.0000020275384,0.0019645945,0.006973024,0.00004545673,0.54940474,0.19281939,0.017352462],"study_design_scores_gemma":[0.0020647976,0.00021445507,0.009640795,0.000063661,0.000006055489,0.0000022437944,0.00033772053,0.028300185,0.00014343338,0.007359866,0.95105505,0.0008117217],"about_ca_topic_score_codex":0.00018860324,"about_ca_topic_score_gemma":0.000038271584,"teacher_disagreement_score":0.7582357,"about_ca_system_score_codex":0.0011682069,"about_ca_system_score_gemma":0.0005219089,"threshold_uncertainty_score":0.9997537},"labels":[],"label_agreement":null},{"id":"W1979215948","doi":"10.2165/00019053-200119002-00003","title":"Using Humanistic Health Outcomes Data in Asthma","year":2001,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Quality of life (healthcare); Asthma; Disease; Clinical trial; Quality of Life Research; Physical therapy; Intensive care medicine; Family medicine; Public health; Internal medicine; Nursing","score_opus":0.7421242204092596,"score_gpt":0.5783843211896595,"score_spread":0.16373989921960008,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1979215948","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8671646,0.0065631815,0.015100902,0.09500564,0.0034064557,0.0018987324,0.0020563568,0.000205762,0.00859834],"genre_scores_gemma":[0.9245099,0.0012064711,0.010581009,0.061791994,0.0007824816,0.000053986365,0.00032899677,0.00012173627,0.00062346103],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99293905,0.00027924232,0.004939095,0.0010078226,0.000063583255,0.000771229],"domain_scores_gemma":[0.99562615,0.0005982178,0.0021943732,0.0012504798,0.000022574832,0.00030820398],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.014983583,0.00030267652,0.0013983692,0.00052924623,0.00023044048,0.00013675509,0.0009860826,0.000101956386,0.0012784563],"category_scores_gemma":[0.00082211714,0.00043176365,0.00010067744,0.00019485831,0.0000677291,0.0011910296,0.00028383496,0.00030090276,0.0025037301],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004526758,0.0004503281,0.8590777,0.0003771707,0.00019643288,0.000015099499,0.0016108757,0.0050497567,0.000008749703,0.093740545,0.03814615,0.0012819428],"study_design_scores_gemma":[0.004118372,0.000067973415,0.08433978,0.00008744589,0.000011533146,0.0000556511,0.0008306215,0.3735482,0.0000039877586,0.017017292,0.5186801,0.0012390489],"about_ca_topic_score_codex":0.003932961,"about_ca_topic_score_gemma":0.0011594697,"teacher_disagreement_score":0.7747379,"about_ca_system_score_codex":0.0015401182,"about_ca_system_score_gemma":0.00033084245,"threshold_uncertainty_score":0.99981344},"labels":[],"label_agreement":null},{"id":"W1982028492","doi":"10.2165/00019053-200018030-00007","title":"The Economic Value of a New Insulin Preparation, Humalog?? Mix 25???","year":2000,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada); Princess Margaret Cancer Centre; University Health Network","funders":"Eli Lilly Canada","keywords":"Willingness to pay; Insulin lispro; Medicine; Confidence interval; Insulin; Human insulin; Economics; Internal medicine; Microeconomics","score_opus":0.01617676700983851,"score_gpt":0.31315808945981577,"score_spread":0.29698132244997727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1982028492","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9336195,0.00081596576,0.000009878627,0.0018790794,0.00023859754,0.00049366313,0.000011561151,0.0000418698,0.0628899],"genre_scores_gemma":[0.9682375,0.0032220578,0.00045369568,0.0014055663,0.00035565544,0.000029484083,0.000046916586,0.000027167218,0.026221946],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99925375,0.000015776457,0.00032772936,0.0001816899,0.00003832919,0.00018270334],"domain_scores_gemma":[0.99948645,0.000046475896,0.000095466436,0.00025597663,0.000010712138,0.00010493937],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00014186658,0.000120292345,0.00020312371,0.000037778897,0.00007610454,0.000028718843,0.0001276222,0.000027763506,0.0018124565],"category_scores_gemma":[0.0000040977734,0.000096801385,0.000101445505,0.000026130505,0.000047064572,0.00010754044,0.000026415382,0.000055979992,0.00085660274],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013347534,0.00034741833,0.0041610547,0.00008010153,0.0016949712,0.0000068409895,0.00092970894,0.0073159067,0.0009765653,0.016320975,0.34778342,0.6190483],"study_design_scores_gemma":[0.0031215162,0.00018892769,0.0026067665,0.000010458324,0.00027355066,0.000003448208,0.000026861533,0.008839464,0.007879651,0.0008480839,0.97608185,0.000119403296],"about_ca_topic_score_codex":0.00008331564,"about_ca_topic_score_gemma":0.000015940414,"teacher_disagreement_score":0.62829846,"about_ca_system_score_codex":0.00017045895,"about_ca_system_score_gemma":0.00012717838,"threshold_uncertainty_score":0.9999213},"labels":[],"label_agreement":null},{"id":"W1982131526","doi":"10.2165/00019053-200321060-00001","title":"Health-Related Quality of Life and Regulatory Issues in the US and Canada","year":2003,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Credibility; Transparency (behavior); Clinical trial; Quality (philosophy); Regulatory affairs; Medicine; Product (mathematics); Process (computing); Business; Risk analysis (engineering); Process management; Operations management; Computer science; Political science; Economics; Pathology","score_opus":0.41544806704401827,"score_gpt":0.49887460194409283,"score_spread":0.08342653490007457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1982131526","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013994591,0.9734161,0.0000031370407,0.008896672,0.0006265641,0.001414909,0.00093095185,0.000011754245,0.00070530566],"genre_scores_gemma":[0.0012841929,0.98727864,0.00013176903,0.010754404,0.00013177616,0.00011436709,0.00007288985,0.000058635433,0.00017329607],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98710954,0.0018493603,0.0096934885,0.00078343734,0.000081004844,0.0004831578],"domain_scores_gemma":[0.99014294,0.0020517185,0.0068578664,0.0006320094,0.000026341113,0.00028909527],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.02557105,0.0004505354,0.005010625,0.00032842078,0.00014647542,0.00006688361,0.0004298242,0.00025341767,0.00013658179],"category_scores_gemma":[0.0009512888,0.00048287358,0.00018218423,0.00015001165,0.00015981388,0.00023629182,0.000079152975,0.0005237847,0.00004681271],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000062264335,0.0004781837,0.048819087,0.1957038,0.0022308673,0.0000087928365,0.0062115723,0.00018861769,8.801181e-8,0.28781605,0.32731843,0.13116224],"study_design_scores_gemma":[0.00063095964,0.000018016119,0.0016506468,0.0005372059,0.000024891542,0.00001528649,0.0002210552,0.000105245264,3.0876144e-8,0.001075339,0.99528164,0.00043970408],"about_ca_topic_score_codex":0.50039953,"about_ca_topic_score_gemma":0.20212115,"teacher_disagreement_score":0.6679632,"about_ca_system_score_codex":0.0010253938,"about_ca_system_score_gemma":0.0020802252,"threshold_uncertainty_score":0.9997623},"labels":[],"label_agreement":null},{"id":"W1982493386","doi":"10.2165/00019053-200422090-00005","title":"A Cost-Effectiveness Analysis of Fondaparinux Sodium Compared with Enoxaparin Sodium as Prophylaxis Against Venous Thromboembolism","year":2004,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"U.S. Food and Drug Administration","keywords":"Fondaparinux; Medicine; Enoxaparin sodium; Low molecular weight heparin; Venous thrombosis; Regimen; Emergency medicine; Anesthesia; Surgery; Venous thromboembolism; Intensive care medicine; Heparin; Thrombosis","score_opus":0.03669305115081794,"score_gpt":0.3306948623787169,"score_spread":0.294001811227899,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1982493386","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871953,0.00023115042,0.00061558775,0.000337157,0.00031049826,0.0024671175,0.000055992085,0.00012324745,0.008663963],"genre_scores_gemma":[0.9967388,0.00044245573,0.00065738225,0.0013336919,0.0001404885,0.00037038844,0.00018872145,0.00007851681,0.000049549628],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.9976352,0.000082217324,0.0006687793,0.00071725465,0.0002899581,0.000606584],"domain_scores_gemma":[0.99828184,0.00010592933,0.00040238304,0.00066206016,0.0002078077,0.0003399992],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00044241874,0.00045237236,0.0021226357,0.00064882793,0.00015346512,0.00005886234,0.00031124603,0.00011831862,0.00021156522],"category_scores_gemma":[0.000022632597,0.00041679834,0.00041206146,0.00073331816,0.00023305147,0.0001975835,0.00015949756,0.00032535428,0.00011885251],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01266734,0.04882394,0.07518168,0.005329285,0.118636906,0.001090804,0.01951293,0.5110965,0.08946552,0.028363064,0.0021138603,0.08771818],"study_design_scores_gemma":[0.037985764,0.0059118597,0.61263436,0.0005850333,0.03202815,0.00008454739,0.0017107258,0.008535769,0.27535254,0.0011370892,0.021595431,0.0024387436],"about_ca_topic_score_codex":0.0013293459,"about_ca_topic_score_gemma":0.00019990544,"teacher_disagreement_score":0.53745264,"about_ca_system_score_codex":0.00059609243,"about_ca_system_score_gemma":0.00043120832,"threshold_uncertainty_score":0.9998284},"labels":[],"label_agreement":null},{"id":"W1983479493","doi":"10.2165/11589240-000000000-00000","title":"Health Economic and Infectious Disease Modelling","year":2011,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Public Health; University of Toronto","funders":"GlaxoSmithKline","keywords":"Health economics; Public health; Quality of Life Research; Health administration; Infectious disease (medical specialty); Disease; Medicine; Environmental health; Nursing; Pathology","score_opus":0.412451901260778,"score_gpt":0.4483275977605574,"score_spread":0.0358756964997794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1983479493","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86400366,0.0132959755,0.042852394,0.0339083,0.0037946445,0.0021510608,0.0013269192,0.00048875116,0.03817832],"genre_scores_gemma":[0.96955067,0.0024774263,0.003946284,0.02290726,0.0005399525,0.00012322143,0.00003709635,0.00008827118,0.00032980373],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9950993,0.00017067391,0.0032697706,0.0008239773,0.000031217325,0.0006050526],"domain_scores_gemma":[0.99667317,0.00025321136,0.0017995648,0.00047452914,0.000018959867,0.00078054285],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0060538817,0.00030519828,0.0010200146,0.0003475865,0.0003002827,0.00009649697,0.00027202407,0.00008294578,0.0010438889],"category_scores_gemma":[0.00011798028,0.00044461843,0.00014078217,0.000053849948,0.00010703017,0.000904293,0.0001034198,0.00022120342,0.002882912],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012545822,0.00027045683,0.14989346,0.0006638738,0.0003227242,0.0000045500115,0.0065663783,0.013145083,0.0000014297569,0.7945085,0.032572314,0.0019257806],"study_design_scores_gemma":[0.0038076935,0.00017907185,0.016447447,0.00008326755,0.000039557748,0.000035102577,0.00055809494,0.58193105,0.000024756815,0.19962397,0.19546239,0.0018075851],"about_ca_topic_score_codex":0.0025485228,"about_ca_topic_score_gemma":0.00011213518,"teacher_disagreement_score":0.5948845,"about_ca_system_score_codex":0.000909239,"about_ca_system_score_gemma":0.0002859463,"threshold_uncertainty_score":0.9998693},"labels":[],"label_agreement":null},{"id":"W1983800857","doi":"10.2165/11585910-000000000-00000","title":"Consistently Estimating Absolute Risk Difference when Translating Evidence to Jurisdictions of Interest","year":2010,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; University of Toronto","funders":"","keywords":"Absolute risk reduction; Relative risk; Jurisdiction; Odds; Medicine; Framing effect; Odds ratio; Actuarial science; Econometrics; Demography; Psychology; Economics; Confidence interval; Internal medicine; Logistic regression; Social psychology; Law; Political science","score_opus":0.49827847882706383,"score_gpt":0.48029319655707564,"score_spread":0.01798528226998819,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1983800857","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9438,0.00047401714,0.031592704,0.017328203,0.0028835214,0.0008352653,0.0007680372,0.000101339094,0.0022169366],"genre_scores_gemma":[0.9245918,0.000079595244,0.07053477,0.0038519492,0.0005597367,0.00011693742,0.000012101182,0.000053631684,0.00019947304],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9940245,0.00018844545,0.00448158,0.0007381702,0.00005553582,0.0005117473],"domain_scores_gemma":[0.9940331,0.0019763508,0.0028120917,0.0006674985,0.000101635844,0.00040930766],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.008804161,0.00029338239,0.0010481592,0.0003996434,0.0002927428,0.0001196839,0.000612673,0.00014116534,0.0009815415],"category_scores_gemma":[0.0038307172,0.0004011467,0.00022446021,0.00014105314,0.00013602938,0.00065594225,0.00011552462,0.00060733303,0.0012867831],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035677047,0.0010808934,0.5156974,0.003028962,0.0015400307,0.000006832829,0.06418553,0.02004471,0.020954706,0.29835084,0.045949433,0.028803848],"study_design_scores_gemma":[0.0047152275,0.00048254745,0.10255189,0.0011257594,0.00026629385,0.00006291032,0.0018049709,0.7219557,0.002572745,0.0939763,0.0672011,0.0032845351],"about_ca_topic_score_codex":0.0013813209,"about_ca_topic_score_gemma":0.0011396832,"teacher_disagreement_score":0.70191103,"about_ca_system_score_codex":0.00024489968,"about_ca_system_score_gemma":0.0001910047,"threshold_uncertainty_score":0.9999317},"labels":[],"label_agreement":null},{"id":"W1983841278","doi":"10.1007/s40273-014-0167-5","title":"A Review of the Psychometric Properties of Generic Utility Measures in Multiple Sclerosis","year":2014,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Health Utilities Index; Quality of Life Research; Statistic; EQ-5D; Discriminative model; Ceiling effect; Statistics; Psychometrics; Reliability (semiconductor); Quality of life (healthcare); Quality-adjusted life year; Convergent validity; Index (typography); Psychology; Medicine; Health related quality of life; Cost effectiveness; Mathematics; Public health; Computer science; Artificial intelligence; Alternative medicine; Nursing","score_opus":0.43205942516604046,"score_gpt":0.4150444235009553,"score_spread":0.017015001665085183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1983841278","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000712054,0.9951591,0.000003138834,0.00014315483,0.0002663427,0.0032901259,0.00011510206,0.000014636501,0.0002963599],"genre_scores_gemma":[0.0061898944,0.9927338,0.0000877813,0.0003293525,0.00012245924,0.00043454661,0.000011686928,0.00005909023,0.00003141897],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962533,0.0005950597,0.0019196281,0.0005045285,0.00034436042,0.00038309733],"domain_scores_gemma":[0.997249,0.0003487791,0.001065674,0.0009525628,0.00025938742,0.0001246166],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0020393871,0.00044871186,0.0038675985,0.0005197086,0.000050404633,0.000008169336,0.0006929527,0.00014094311,0.00009137397],"category_scores_gemma":[0.0024086025,0.00026978384,0.0011323153,0.0011303021,0.00036583818,0.000055822544,0.0003691259,0.00059948035,0.000020227959],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002821206,0.00017163009,0.0007185067,0.31369734,0.00031359578,8.98851e-8,0.000021379452,7.3417243e-7,0.00012784344,7.188779e-7,0.0023758223,0.6825441],"study_design_scores_gemma":[0.0009153093,0.000032748176,0.0010881402,0.19479175,0.0008142977,0.0000037891712,0.000005541274,0.00012906823,0.00045406396,6.948743e-7,0.8015533,0.00021127435],"about_ca_topic_score_codex":0.00013879464,"about_ca_topic_score_gemma":0.000027344147,"teacher_disagreement_score":0.7991775,"about_ca_system_score_codex":0.00027127203,"about_ca_system_score_gemma":0.00049982074,"threshold_uncertainty_score":0.99997544},"labels":[],"label_agreement":null},{"id":"W1984160769","doi":"10.1007/s40273-013-0079-9","title":"Impacts of Health Insurance Benefit Design on Percutaneous Coronary Intervention Use and Inpatient Costs among Patients with Acute Myocardial Infarction in Shanghai, China","year":2013,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Healthcare Systems and Reforms","field":"Economics, Econometrics and Finance","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Health economics; Percutaneous coronary intervention; Myocardial infarction; Health administration; China; Emergency medicine; Public health; Intensive care medicine; Medical emergency; Environmental health; Internal medicine; Nursing","score_opus":0.021425713652811474,"score_gpt":0.251050596510918,"score_spread":0.2296248828581065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1984160769","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972242,0.00027149977,0.0001607097,0.0001953756,0.00044451293,0.0013201621,0.00030197532,0.00001761793,0.000063949956],"genre_scores_gemma":[0.99835443,0.00095132785,0.00017034858,0.00031204394,0.000031255313,0.00006145775,0.000062422856,0.000034513687,0.000022190889],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99817973,0.000054057742,0.0010111816,0.00037192827,0.000042651092,0.00034046968],"domain_scores_gemma":[0.99879783,0.000029668246,0.00077250635,0.00018501253,0.000047709444,0.00016725562],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000438957,0.00020995023,0.00054206897,0.00030579526,0.000077462966,0.000064587104,0.00010094336,0.00009156022,0.00004330171],"category_scores_gemma":[0.000016541464,0.00019249365,0.000082973726,0.00011000152,0.000046618225,0.00082070363,0.00004214821,0.00020178813,0.0000339101],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018307575,0.00018695908,0.9683711,0.000077107135,0.000116840834,0.0000019125553,0.00065311196,0.000805756,0.000008051376,0.00016198102,0.00004429571,0.029389825],"study_design_scores_gemma":[0.0016916702,0.00080242415,0.994701,0.00012187564,0.0000025692448,0.000010712935,0.000031612515,0.0021025455,0.000019604857,0.00024640173,0.000060034345,0.00020953655],"about_ca_topic_score_codex":0.02889764,"about_ca_topic_score_gemma":0.0004329864,"teacher_disagreement_score":0.029180288,"about_ca_system_score_codex":0.00079407747,"about_ca_system_score_gemma":0.000031757645,"threshold_uncertainty_score":0.97756904},"labels":[],"label_agreement":null},{"id":"W1984717160","doi":"10.2165/00019053-200018040-00007","title":"The Cost Effectiveness of Antiretroviral Regimens for the Treatment of HIV/AIDS","year":2000,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; HIV Legal Network; St. Paul's Hospital","funders":"Centers for Disease Control and Prevention","keywords":"Didanosine; Zalcitabine; Stavudine; Lamivudine; Zidovudine; Medicine; Indinavir; Cost effectiveness; Reverse-transcriptase inhibitor; Internal medicine; Viral load; Virology; Human immunodeficiency virus (HIV); Antiretroviral therapy; Viral disease; Virus","score_opus":0.02345318179831839,"score_gpt":0.3238373498151319,"score_spread":0.3003841680168135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1984717160","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932957,0.0011589704,0.000089548295,0.0008953179,0.00018834986,0.0020215942,0.00011793187,0.000017404911,0.002215124],"genre_scores_gemma":[0.98188627,0.004367214,0.00037092462,0.000047517806,0.00010216447,0.0003067193,0.000054714837,0.000025080562,0.012839424],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992147,0.000050312003,0.0002999383,0.0001662482,0.000064648695,0.0002041687],"domain_scores_gemma":[0.9985903,0.0009502757,0.00010491411,0.00025423302,0.000044237684,0.000056023866],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029608974,0.00015739059,0.00034094317,0.000033801218,0.0001324256,0.000009454433,0.000105094245,0.000030626394,0.00012779966],"category_scores_gemma":[0.0000076702145,0.000084783154,0.00021226998,0.000059674763,0.00013427771,0.000038817627,0.000008162517,0.000038301117,0.00003247881],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012791453,0.002527243,0.10238016,0.00035200507,0.0052843,0.000012151352,0.0023314627,0.00058967416,0.008137915,0.0035909275,0.007970689,0.85403204],"study_design_scores_gemma":[0.018497445,0.0018221851,0.007973489,0.000077350116,0.0014282777,0.000018166782,0.00027122675,0.0043686535,0.3659869,0.00016936343,0.59915096,0.00023597316],"about_ca_topic_score_codex":0.000015616793,"about_ca_topic_score_gemma":0.0000029341613,"teacher_disagreement_score":0.85379606,"about_ca_system_score_codex":0.0001810925,"about_ca_system_score_gemma":0.00010015732,"threshold_uncertainty_score":0.34573567},"labels":[],"label_agreement":null},{"id":"W1984921391","doi":"10.2165/00019053-200826020-00005","title":"The Burden of Schizophrenia on Caregivers","year":2008,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Family Caregiving in Mental Illness","field":"Psychology","cited_by":808,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Humber River Regional Hospital; McMaster University; University of Toronto","funders":"","keywords":"Caregiver burden; Psychosocial; Embarrassment; Shame; Feeling; Economic cost; Blame; Psychology; Psychiatry; Indirect costs; Medicine; Clinical psychology; Dementia; Psychotherapist; Social psychology","score_opus":0.05579451945753411,"score_gpt":0.386098591713241,"score_spread":0.3303040722557069,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1984921391","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016496901,0.96043694,9.926794e-7,0.00004631967,0.0068337987,0.0006749756,0.00021153167,0.00005204588,0.0315784],"genre_scores_gemma":[0.00009983753,0.9959584,0.000017907747,0.000063722655,0.0009858488,0.00017118234,0.000050370658,0.00012107192,0.0025316738],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979044,0.0002867221,0.00074449583,0.0005297672,0.00012586315,0.00040874688],"domain_scores_gemma":[0.99721503,0.0010121951,0.0007362883,0.0008976842,0.000032889013,0.00010588328],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00020096883,0.0004870739,0.0012258857,0.00016300322,0.00020718595,0.000030251504,0.0012441913,0.00025232273,0.0003431768],"category_scores_gemma":[0.000019785792,0.0003733363,0.0007054612,0.00012934467,0.00033087487,0.000042336796,0.00015823517,0.00065640255,0.0017536063],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005569582,0.00002965485,3.4554105e-7,0.00070763484,0.00061375846,0.000021871361,0.00062581635,0.000025812607,2.8651266e-7,0.0014076678,0.100835666,0.8956758],"study_design_scores_gemma":[0.0005284992,0.000042295647,4.3545373e-7,0.00086510106,0.00027551243,0.000070536335,0.0002828882,0.0000055269966,0.00000463935,0.000017390446,0.9975642,0.00034300616],"about_ca_topic_score_codex":0.00018897545,"about_ca_topic_score_gemma":0.0000021123753,"teacher_disagreement_score":0.8967285,"about_ca_system_score_codex":0.00037822349,"about_ca_system_score_gemma":0.00019031821,"threshold_uncertainty_score":0.99987185},"labels":[],"label_agreement":null},{"id":"W1985149660","doi":"10.2165/11591570-000000000-00000","title":"Challenges in Health State Valuation in Paediatric Economic Evaluation","year":2011,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":155,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; SickKids Foundation; Institute for Clinical Evaluative Sciences; University of Toronto","funders":"Hospital for Sick Children","keywords":"Health economics; Preference; Valuation (finance); Health Utilities Index; Economic evaluation; Proxy (statistics); Medicine; Health administration; Quality-adjusted life year; Cost–utility analysis; Health care; EQ-5D; Actuarial science; Public economics; Public health; Cost effectiveness; Economics; Risk analysis (engineering); Computer science; Economic growth; Nursing; Microeconomics; Disease","score_opus":0.6867786026475992,"score_gpt":0.5036153730572293,"score_spread":0.1831632295903699,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1985149660","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8892989,0.03360703,0.0009002623,0.034917526,0.0033557408,0.0043583596,0.00033997867,0.00014577915,0.033076435],"genre_scores_gemma":[0.9790181,0.012819095,0.0021852802,0.004842706,0.00035997113,0.000545678,0.000068262474,0.00008094249,0.000079946294],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99046284,0.0010927978,0.006436345,0.0011013817,0.000097713564,0.00080892484],"domain_scores_gemma":[0.99568784,0.00051974435,0.0029211456,0.00056306866,0.000042115906,0.0002660931],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.05062336,0.00033907927,0.0012238047,0.00141294,0.00009072421,0.000051654013,0.0004313685,0.00014328415,0.0013870945],"category_scores_gemma":[0.0006294304,0.0005118805,0.00013328677,0.00020343551,0.000050336395,0.0012461076,0.000082242455,0.00035232163,0.0038413676],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003267415,0.0014144392,0.51980907,0.0015136307,0.00025943064,0.000007864382,0.06221127,0.060765542,0.000008344245,0.22980951,0.010241743,0.11363238],"study_design_scores_gemma":[0.00972571,0.00024974035,0.3214761,0.00014603451,0.000018137605,0.00001295647,0.002944157,0.38307777,0.00005842135,0.2459805,0.034681592,0.0016288832],"about_ca_topic_score_codex":0.0038738307,"about_ca_topic_score_gemma":0.0054742927,"teacher_disagreement_score":0.32231224,"about_ca_system_score_codex":0.0046784794,"about_ca_system_score_gemma":0.0007091609,"threshold_uncertainty_score":0.99973327},"labels":[],"label_agreement":null},{"id":"W1985428484","doi":"10.2165/00019053-200422100-00005","title":"Warfarin in the Secondary Prevention of Thromboembolism in Atrial Fibrillation","year":2004,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"United States Pharmacopeia","keywords":"Warfarin; Atrial fibrillation; Medicine; Stroke (engine); Rivaroxaban; Internal medicine; Cardiology; Intensive care medicine","score_opus":0.06516114370617322,"score_gpt":0.3804681444717699,"score_spread":0.3153070007655967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1985428484","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927516,0.00018823649,0.000067880515,0.00280321,0.00027023908,0.0005830147,0.000002867257,0.000011568182,0.0033213669],"genre_scores_gemma":[0.99846464,0.00025149787,0.00027878958,0.00020298111,0.0006935617,9.820209e-7,0.000028547598,0.000008508032,0.000070508526],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99924606,0.000040698396,0.0004045034,0.00012526449,0.00007165455,0.00011179611],"domain_scores_gemma":[0.9996662,0.0000659025,0.0001229867,0.00011407004,0.000011640349,0.00001920503],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043495814,0.00007912721,0.00023822117,0.00015652257,0.000016701719,0.0000098606415,0.00006399522,0.000041796382,0.0001337206],"category_scores_gemma":[0.000024074903,0.00006710997,0.00013937989,0.00013554642,0.000021901275,0.00016745308,0.000024431853,0.000103349135,0.000021653934],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016201701,0.00005132236,0.7312895,0.00032704652,0.00023287704,0.000017921737,0.004533873,0.072744586,0.005284784,0.026384585,0.00040669335,0.15710662],"study_design_scores_gemma":[0.016385509,0.0001357364,0.9403538,0.00006307975,0.00014693759,0.000009976585,0.00042916104,0.0023126972,0.0030206137,0.013297891,0.023646867,0.00019769259],"about_ca_topic_score_codex":0.000099205834,"about_ca_topic_score_gemma":0.00006445033,"teacher_disagreement_score":0.20906432,"about_ca_system_score_codex":0.00009601094,"about_ca_system_score_gemma":0.00008118331,"threshold_uncertainty_score":0.2736665},"labels":[],"label_agreement":null},{"id":"W1986793930","doi":"10.2165/00019053-200523070-00003","title":"Evaluating Health-Related Quality-of-Life Studies in Paediatric Populations","year":2005,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":255,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; Centre for Advancing Health Outcomes; Vancouver General Hospital; University of British Columbia; McGill University","funders":"","keywords":"Normative; Context (archaeology); Quality of life (healthcare); Consistency (knowledge bases); Medicine; Focus group; Health related quality of life; Quality of Life Research; Quality (philosophy); Psychology; Gerontology; Public health; Applied psychology; Nursing; Disease; Sociology; Computer science; Pathology","score_opus":0.6052144855470185,"score_gpt":0.6085773217654783,"score_spread":0.003362836218459786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1986793930","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004091538,0.9902159,0.000003903091,0.0016390119,0.0015343139,0.0020478235,0.00017378316,0.00008662179,0.0002070929],"genre_scores_gemma":[0.00038081547,0.99449104,0.0017642837,0.001469474,0.0011524289,0.00015755578,0.000330738,0.000118579206,0.00013510579],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99134547,0.0013720425,0.0057221283,0.00070786517,0.00033713272,0.00051539426],"domain_scores_gemma":[0.9942147,0.0014256646,0.00330584,0.00058110163,0.00012256268,0.00035010558],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.006111107,0.0005844053,0.005677543,0.00078679406,0.0000951854,0.00001374359,0.00028506826,0.00025871085,0.00021510222],"category_scores_gemma":[0.0014280705,0.0006014248,0.00086126325,0.00061290216,0.00011851469,0.00014358896,0.0001764784,0.0010253782,0.00013482348],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000048753576,0.0002644651,0.0005624234,0.048432812,0.00097236334,0.0000025412792,0.0017874809,0.00029090434,1.5361076e-7,0.00029756597,0.0024826177,0.9448579],"study_design_scores_gemma":[0.006887968,0.00025738482,0.00045198618,0.019337738,0.002807061,0.00005965131,0.00083946047,0.00067354314,5.6734376e-7,0.000345427,0.96692467,0.0014145214],"about_ca_topic_score_codex":0.00067515974,"about_ca_topic_score_gemma":0.00040152526,"teacher_disagreement_score":0.9644421,"about_ca_system_score_codex":0.0014504561,"about_ca_system_score_gemma":0.0025560483,"threshold_uncertainty_score":0.9996437},"labels":[],"label_agreement":null},{"id":"W1987205549","doi":"10.2165/00019053-200119050-00009","title":"Economic Evaluation of a New Acellular Vaccine for Pertussis in Canada","year":2001,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Bacterial Infections and Vaccines","field":"Immunology and Microbiology","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Golder Associates (Canada); Institut National de Santé Publique du Québec; University of Toronto; SickKids Foundation; Kingston Health Sciences Centre; Hospital for Sick Children; McMaster University; PharmIdeas (Canada)","funders":"Health Canada","keywords":"Medicine; Whooping cough; Pertussis vaccine; Vaccination; Health economics; Cohort; Public health; Pediatrics; Health care; Incidence (geometry); Environmental health; Immunology; Immunization; Nursing; Internal medicine","score_opus":0.03546658025033926,"score_gpt":0.307517927745233,"score_spread":0.27205134749489374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1987205549","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99668986,0.00072881224,0.000037232287,0.00050025235,0.0014227483,0.0003145376,0.000047772875,0.000006339527,0.00025242817],"genre_scores_gemma":[0.99915355,0.00024581052,0.000026084892,0.000078121164,0.00009109417,0.000035581128,0.00007067686,0.000010116339,0.000288971],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993461,0.000039873652,0.0003031465,0.0001471784,0.0000048562338,0.00015889037],"domain_scores_gemma":[0.9996706,0.00006057415,0.00011208287,0.00010490282,0.000033483248,0.00001831199],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002689741,0.00008867581,0.00020090817,0.00006889709,0.00003166352,0.0000044425024,0.000086340784,0.000047159596,0.0030154388],"category_scores_gemma":[0.0000143463585,0.00009320851,0.000045573943,0.000027889375,0.0000048626757,0.00008199222,0.000017749573,0.000054880897,0.000032449283],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010832786,0.00014153449,0.14315194,0.000031039544,0.00047709764,4.2414484e-7,0.0002710907,0.011455556,0.6463786,0.00048104936,0.058569726,0.13795869],"study_design_scores_gemma":[0.017638236,0.000101592865,0.03471591,0.000016676875,0.0003132931,0.000043409753,0.0002398944,0.014281742,0.30791888,0.00056246296,0.62372583,0.0004421011],"about_ca_topic_score_codex":0.63196343,"about_ca_topic_score_gemma":0.8033709,"teacher_disagreement_score":0.5651561,"about_ca_system_score_codex":0.0005112822,"about_ca_system_score_gemma":0.0010866475,"threshold_uncertainty_score":0.99789596},"labels":[],"label_agreement":null},{"id":"W1987378502","doi":"10.2165/11587130-000000000-00000","title":"Sample Size Determination for Cost-Effectiveness Trials","year":2011,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; University of Toronto","funders":"","keywords":"Sample size determination; Bayesian probability; Cost effectiveness; Computer science; Sample (material); Value of information; Health administration; Decision theory; Statistics; Econometrics; Mathematics; Medicine; Public health; Artificial intelligence","score_opus":0.830530749302641,"score_gpt":0.6175450279615677,"score_spread":0.2129857213410733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1987378502","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000013853802,0.94186974,0.02817064,0.00038779297,0.0041952096,0.012192161,0.01175997,0.00013049344,0.001280154],"genre_scores_gemma":[0.00001755394,0.9773286,0.008643915,0.0021660877,0.0018760491,0.008756256,0.0006139462,0.00026776228,0.00032980673],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98332864,0.0021413257,0.012140239,0.0014963667,0.00005210213,0.0008413132],"domain_scores_gemma":[0.9323741,0.054379966,0.011888286,0.00086802966,0.000114999784,0.0003745771],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":["metaresearch","insufficient_payload"],"category_scores_codex":[0.06286071,0.00087024,0.009493123,0.0006508834,0.00029659207,0.00021574512,0.0009261249,0.0006713125,0.0018650946],"category_scores_gemma":[0.030713761,0.0010781299,0.0019503987,0.0001788065,0.00009113688,0.00072804047,0.00012819663,0.00043960018,0.0032094535],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000929539,0.0002569338,0.000075993215,0.05629457,0.0012465395,9.310601e-7,0.0003665801,0.00001992535,1.7464347e-7,0.08199894,0.022560174,0.83708626],"study_design_scores_gemma":[0.00154506,0.00006459742,0.000009255021,0.0012914909,0.00043099478,0.0000089122095,0.000021989823,0.0010611878,0.0000026179337,0.017418418,0.9771377,0.0010077943],"about_ca_topic_score_codex":0.0002886604,"about_ca_topic_score_gemma":0.000021086194,"teacher_disagreement_score":0.9545775,"about_ca_system_score_codex":0.0024032483,"about_ca_system_score_gemma":0.0006812317,"threshold_uncertainty_score":0.9991669},"labels":[],"label_agreement":null},{"id":"W1987719831","doi":"10.2165/00019053-200725110-00007","title":"The Economic Impact of Introducing Serotonin-Noradrenaline Reuptake Inhibitors into the Brazilian National Drug Formulary","year":2007,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Treatment of Major Depression","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; PharmIdeas (Canada)","funders":"","keywords":"Formulary; Health economics; Quality of Life Research; Pharmacoeconomics; Drug; Public health; Reuptake inhibitor; Serotonin; Medicine; Psychiatry; Pharmacology; Intensive care medicine; Internal medicine","score_opus":0.037351443414151496,"score_gpt":0.4217582958759115,"score_spread":0.38440685246176004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1987719831","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009689464,0.9849872,0.0000045015568,0.0006176012,0.0011107116,0.002326493,0.00014016757,0.000059011745,0.0010648522],"genre_scores_gemma":[0.0016238311,0.994232,0.00025200244,0.00015246707,0.002401382,0.00014284087,0.0004235244,0.00013952496,0.00063243095],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99685967,0.00016416372,0.0016187063,0.0006187825,0.00026171663,0.00047693407],"domain_scores_gemma":[0.9965002,0.0010751715,0.0012748704,0.00081511715,0.00011046087,0.00022416575],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019295188,0.0006626915,0.0015486275,0.0003113159,0.00031908014,0.00007833759,0.000640134,0.00021459884,0.00020427385],"category_scores_gemma":[0.00010408569,0.00035859444,0.0014073247,0.00014551067,0.00021493965,0.00020979784,0.00025907837,0.0008626322,0.0002025448],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000193101,0.00007599785,0.00017733792,0.0017061906,0.0018638098,0.0000089342275,0.00020818235,0.0004519266,0.000016174885,0.000097382515,0.025956722,0.96924424],"study_design_scores_gemma":[0.0013023956,0.00008765365,0.000062819025,0.0016340775,0.0012719224,0.00014157814,0.00002232631,0.0006322261,0.00033618632,0.00010242072,0.9940861,0.00032033303],"about_ca_topic_score_codex":0.0003631897,"about_ca_topic_score_gemma":0.00010768332,"teacher_disagreement_score":0.9689239,"about_ca_system_score_codex":0.004237043,"about_ca_system_score_gemma":0.0024418645,"threshold_uncertainty_score":0.99988663},"labels":[],"label_agreement":null},{"id":"W1988339481","doi":"10.1007/s40273-013-0096-8","title":"Systematic Literature Review of the Costs of Pregnancy in the US","year":2013,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Reproductive Health and Contraception","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Pregnancy; Systematic review; Medicine; Unintended pregnancy; Health economics; Pharmacoeconomics; Family medicine; Cost effectiveness; Public health; MEDLINE; Obstetrics; Environmental health; Intensive care medicine; Family planning; Population; Nursing; Risk analysis (engineering); Political science","score_opus":0.043577986719561944,"score_gpt":0.39209591380124914,"score_spread":0.3485179270816872,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988339481","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000032775733,0.9894383,7.401527e-7,0.00038876862,0.00035608673,0.009025005,0.000036305173,0.0000040543946,0.0007179776],"genre_scores_gemma":[0.000026766129,0.99784064,0.000012761717,0.00093019725,0.00019169584,0.0007939607,0.000029900646,0.000021853866,0.00015222095],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9974585,0.0006093805,0.0014125223,0.00024432782,0.000119503835,0.00015571827],"domain_scores_gemma":[0.9974787,0.00019896531,0.0013660947,0.00078536465,0.00012865085,0.00004222251],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00095657347,0.0002292649,0.0020449867,0.00007659748,0.000018774772,0.00000846338,0.0003491096,0.00010948561,0.000050342933],"category_scores_gemma":[0.00022701127,0.00010614892,0.00050041464,0.00025757638,0.000045156685,0.00006357809,0.000034344168,0.00049515825,0.000028060402],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000028175293,0.000045199984,0.000007057064,0.82232124,0.00007220059,0.0000012985624,0.000059564576,9.184295e-8,9.553403e-7,0.00009423594,0.00087021943,0.1765251],"study_design_scores_gemma":[0.0001899609,0.000019926067,0.000009074139,0.82945555,0.0011598439,0.000096724114,0.00000595435,0.0000055141672,0.000003344117,0.0000057457064,0.1689812,0.00006716489],"about_ca_topic_score_codex":0.000009554548,"about_ca_topic_score_gemma":0.0000011740091,"teacher_disagreement_score":0.17645794,"about_ca_system_score_codex":0.00016957647,"about_ca_system_score_gemma":0.0003077278,"threshold_uncertainty_score":0.43286273},"labels":[],"label_agreement":null},{"id":"W1988459290","doi":"10.2165/00019053-200220002-00002","title":"Information Barriers to the Implementation of Economic Evaluations in Japan","year":2002,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BioPhage Pharma (Canada); McMaster University","funders":"","keywords":"Health economics; Health administration; Guideline; Health care; Economic evaluation; Business; Data collection; Quality of Life Research; Health technology; Public health; Risk analysis (engineering); Public economics; Economic growth; Medicine; Economics; Nursing","score_opus":0.3551933142264207,"score_gpt":0.5475350555330352,"score_spread":0.19234174130661447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988459290","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011487826,0.9736004,0.00029831514,0.008567095,0.0024533018,0.005926598,0.0050522946,0.00005062615,0.0029025902],"genre_scores_gemma":[0.001060464,0.9905893,0.0003099255,0.0054530925,0.0004898763,0.0014225877,0.00047005908,0.000080677906,0.00012399592],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9883488,0.0005360882,0.009935831,0.0005269971,0.000086897955,0.00056542986],"domain_scores_gemma":[0.9918807,0.0009277801,0.0059440047,0.0008256266,0.00004960062,0.00037227775],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0131263845,0.00049260084,0.0027970942,0.0014011987,0.00019184068,0.00015108951,0.0009346882,0.00024861927,0.005205835],"category_scores_gemma":[0.00077133824,0.0005564835,0.0004978607,0.000332769,0.00006234601,0.0012825631,0.00015002405,0.00040414033,0.011978868],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000014122851,0.00007509794,0.0021584355,0.011512913,0.0008006358,3.2405464e-7,0.01568661,0.005363898,7.398103e-8,0.06889134,0.18265295,0.7128436],"study_design_scores_gemma":[0.0006210875,0.000034791385,0.00010056945,0.00041380923,0.00009383259,0.000004454223,0.0017507849,0.0018627794,6.762228e-7,0.00055081747,0.99407065,0.0004957575],"about_ca_topic_score_codex":0.0014315046,"about_ca_topic_score_gemma":0.0007555993,"teacher_disagreement_score":0.8114177,"about_ca_system_score_codex":0.0029657371,"about_ca_system_score_gemma":0.0010003716,"threshold_uncertainty_score":0.9996887},"labels":[],"label_agreement":null},{"id":"W1990285876","doi":"10.2165/00019053-200220120-00004","title":"UK Department of Health Guidance on Prescribing for Impotence Following the Introduction of Sildenafil","year":2002,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Pharmaceutical Quality and Counterfeiting","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St Mary's Hospital Centre","funders":"National Institutes of Health","keywords":"Medicine; Health economics; Sildenafil; Health care; Pound (networking); Health administration; Primary care; Family medicine; Public health; Medical emergency; Nursing; Economic growth","score_opus":0.10781810422991114,"score_gpt":0.39035931512567534,"score_spread":0.2825412108957642,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1990285876","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9756426,0.0018825504,0.0017593759,0.018714905,0.00051168515,0.0008483064,0.000047431906,0.000021528254,0.00057161326],"genre_scores_gemma":[0.99559027,0.00027418692,0.00051936234,0.003119599,0.00036420213,0.000038106653,0.000009474505,0.0000122101565,0.00007260751],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988861,0.0000613371,0.0005521451,0.0001911798,0.00009743455,0.00021176793],"domain_scores_gemma":[0.99924415,0.00019524092,0.00026985645,0.00018621594,0.000041723244,0.00006281166],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009593852,0.0000976848,0.00028635262,0.00003361631,0.00008935117,0.0000066710686,0.00010641139,0.000022103844,0.000084174455],"category_scores_gemma":[0.000109511326,0.00007991239,0.00015323126,0.000051355022,0.000048332065,0.000066289685,0.000024802015,0.00012214525,0.000005515545],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034089708,0.0026052487,0.012805855,0.0041136523,0.002077381,0.000007778876,0.0071380604,0.008898931,0.36020446,0.017540118,0.11984778,0.46135178],"study_design_scores_gemma":[0.0064834137,0.0010334085,0.0010409964,0.0003433044,0.00039796712,0.000025482348,0.0006518112,0.10514951,0.8018282,0.00072629866,0.08197361,0.00034597152],"about_ca_topic_score_codex":0.00001522821,"about_ca_topic_score_gemma":0.0000012063895,"teacher_disagreement_score":0.4610058,"about_ca_system_score_codex":0.00010929669,"about_ca_system_score_gemma":0.000032396296,"threshold_uncertainty_score":0.32587326},"labels":[],"label_agreement":null},{"id":"W1991319128","doi":"10.2165/00019053-200523060-00008","title":"Development of an Economic Model to Assess the Cost Effectiveness of Treatment Interventions for Chronic Obstructive Pulmonary Disease","year":2005,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":134,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada); University of Toronto","funders":"GlaxoSmithKline","keywords":"Salmeterol; Fluticasone propionate; Medicine; COPD; Quality-adjusted life year; Exacerbation; Cost effectiveness; Fluticasone; Life expectancy; Placebo; Intensive care medicine; Internal medicine; Corticosteroid; Population; Environmental health","score_opus":0.09286242364850257,"score_gpt":0.4167017950636132,"score_spread":0.32383937141511066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1991319128","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902217,0.0005194913,0.0037471321,0.00021504484,0.00014507325,0.0037788432,0.0009816079,0.000023510276,0.00036764366],"genre_scores_gemma":[0.99272454,0.00006301239,0.005016855,0.00003852582,0.00020737447,0.0015104295,0.00023744704,0.000054552645,0.00014724534],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99834037,0.00009914243,0.0006272509,0.0004724527,0.0000969487,0.0003638389],"domain_scores_gemma":[0.9985057,0.00025358214,0.00020317329,0.00046277445,0.00012791992,0.00044684493],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045652397,0.00026010073,0.00051025796,0.00018552174,0.00012558681,0.00001532978,0.00029039226,0.000042114418,0.0001407083],"category_scores_gemma":[0.000021146685,0.00022351497,0.00038546955,0.000065979366,0.00014877392,0.0002539288,0.00012625518,0.000101697944,0.000024876777],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009942108,0.00339707,0.007086233,0.005651168,0.0016926622,0.0000102303475,0.00089721347,0.43771666,0.04988852,0.0036257652,0.00007016794,0.4800222],"study_design_scores_gemma":[0.005885044,0.00035111757,0.13299027,0.00036588576,0.0007590543,0.000015333948,0.0003075583,0.72892976,0.12392372,0.00044701959,0.005572229,0.00045303002],"about_ca_topic_score_codex":0.000023502178,"about_ca_topic_score_gemma":0.000059111662,"teacher_disagreement_score":0.47956917,"about_ca_system_score_codex":0.005215247,"about_ca_system_score_gemma":0.0026004722,"threshold_uncertainty_score":0.9986036},"labels":[],"label_agreement":null},{"id":"W1991474680","doi":"10.2165/00019053-200725030-00004","title":"Do Drugs Reduce Utilisation of Other Healthcare Resources?","year":2007,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Global Health Care Issues","field":"Health Professions","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis; Université du Québec à Montréal","funders":"","keywords":"Life expectancy; Per capita; Health care; Consumption (sociology); Health economics; Population; Panel data; Environmental health; Medicine; Economics; Economic growth","score_opus":0.09060899737625107,"score_gpt":0.5068280098437068,"score_spread":0.41621901246745574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1991474680","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95653254,0.0011011865,0.00006549356,0.0034525401,0.002027064,0.00086045597,0.000105834195,0.000119110664,0.035735782],"genre_scores_gemma":[0.99059093,0.00014857207,0.00065863086,0.0068622255,0.00091310474,0.000025403735,0.0000144914875,0.000048351827,0.00073831045],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974186,0.0002847193,0.0011017122,0.00033108413,0.00015929267,0.0007045902],"domain_scores_gemma":[0.99787575,0.0005659931,0.000644943,0.00036720844,0.00023056597,0.0003155579],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0024938432,0.00017440792,0.0003467975,0.00016039149,0.00029918578,0.0000054650486,0.00026503336,0.00020017252,0.0010066062],"category_scores_gemma":[0.00007605537,0.00018736043,0.000077475095,0.00015808622,0.0000705955,0.0001452441,0.00009162064,0.0005165598,0.00089547905],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004118462,0.00051372184,0.34210232,0.0054749968,0.00025588105,0.000015876214,0.20206814,0.00018163456,0.008832925,0.05498787,0.2672851,0.11416308],"study_design_scores_gemma":[0.0022568703,0.000095523894,0.023660861,0.00026653367,0.00003610669,0.0000023286013,0.01609115,0.00026107143,0.0065299543,0.001667914,0.94877034,0.0003613432],"about_ca_topic_score_codex":0.0021130126,"about_ca_topic_score_gemma":0.00022092352,"teacher_disagreement_score":0.68148524,"about_ca_system_score_codex":0.00057986146,"about_ca_system_score_gemma":0.0002578058,"threshold_uncertainty_score":0.9999066},"labels":[],"label_agreement":null},{"id":"W1992312698","doi":"10.1007/s40273-013-0053-6","title":"Transferability of Indirect Cost of Chronic Disease: A Systematic Review and Meta-Analysis","year":2013,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; St. Joseph’s Healthcare Hamilton; Programs for Assessment of Technology in Health Research Institute","funders":"","keywords":"Health economics; Quality of Life Research; Transferability; Public health; Health administration; Pharmacoeconomics; Meta-analysis; Medicine; Intensive care medicine; Economics; Econometrics; Internal medicine; Pathology","score_opus":0.6010832373460577,"score_gpt":0.5294009854553547,"score_spread":0.07168225189070299,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1992312698","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000008530544,0.9789754,0.00031791136,0.0012522595,0.00013111452,0.010080407,0.009020516,0.000026776981,0.00018706544],"genre_scores_gemma":[0.000121623634,0.9942262,0.00017313434,0.0014931477,0.00006443304,0.0032840145,0.00027598738,0.00008496275,0.00027645452],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9814559,0.0015645201,0.015295483,0.0011295336,0.0001021979,0.00045235627],"domain_scores_gemma":[0.9837887,0.002488043,0.011660103,0.0015037089,0.00012443298,0.00043500774],"candidate_categories":["metaepi_narrow","metaepi_broad","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.01783442,0.00076499063,0.028481402,0.0009327376,0.00007569249,0.00005316356,0.00079919846,0.000250455,0.003941284],"category_scores_gemma":[0.0012138812,0.00076137495,0.004564655,0.0005755108,0.00020505462,0.0004291168,0.00010876457,0.0003660057,0.0004635141],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000014481207,0.00009465325,0.000015009034,0.89605,0.10098613,2.3445656e-7,0.00006213487,0.000022131304,1.05845475e-8,0.0016205115,0.0008077917,0.00033995535],"study_design_scores_gemma":[0.000323442,0.00003922179,0.000007349793,0.016279329,0.8437527,0.0000046242817,0.000016824335,0.0006768193,6.145489e-7,0.00039960357,0.1375626,0.00093691197],"about_ca_topic_score_codex":0.00023639793,"about_ca_topic_score_gemma":0.000041412688,"teacher_disagreement_score":0.87977064,"about_ca_system_score_codex":0.0008809891,"about_ca_system_score_gemma":0.0006013443,"threshold_uncertainty_score":0.9994837},"labels":[],"label_agreement":null},{"id":"W1992882473","doi":"10.2165/11537760-000000000-00000","title":"The Analysis of Multinational Cost-Effectiveness Data for Reimbursement Decisions","year":2010,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Programs for Assessment of Technology in Health Research Institute","funders":"Wellcome Trust","keywords":"Multinational corporation; Generalizability theory; Reimbursement; Health administration; Cost effectiveness; Health care; Jurisdiction; Actuarial science; Benchmarking; Business; Economics; Risk analysis (engineering); Marketing; Psychology; Finance; Political science; Economic growth","score_opus":0.576343542811226,"score_gpt":0.5646879305875006,"score_spread":0.011655612223725464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1992882473","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86631423,0.0011669698,0.0741314,0.0260703,0.0052448665,0.0048798868,0.02003119,0.0000691119,0.002092015],"genre_scores_gemma":[0.98496175,0.00034385122,0.009067099,0.0028632414,0.0004806317,0.0007464421,0.0012785649,0.00004626695,0.00021217421],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.995718,0.0001687951,0.0030637586,0.0006392313,0.000065988665,0.0003442531],"domain_scores_gemma":[0.9853543,0.010995476,0.0020607118,0.0012847226,0.00015315393,0.00015162773],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.026314627,0.00017116072,0.000843734,0.00039216023,0.00039830102,0.00009418697,0.0011401164,0.00009170243,0.00033985393],"category_scores_gemma":[0.0059578926,0.00018405987,0.00024069895,0.00026498034,0.00012901606,0.0004596297,0.00020657244,0.00019799896,0.00016753712],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030945963,0.00060604076,0.08424035,0.00020493446,0.006334348,3.6660398e-7,0.00064527884,0.016559118,0.0005491395,0.8018474,0.0704801,0.018223472],"study_design_scores_gemma":[0.0015063278,0.000021075117,0.048388418,0.000008991984,0.00023114048,8.240068e-7,0.00015896677,0.45805675,0.0001544739,0.00915968,0.48203018,0.00028317102],"about_ca_topic_score_codex":0.00020354931,"about_ca_topic_score_gemma":0.00061251764,"teacher_disagreement_score":0.7926877,"about_ca_system_score_codex":0.00022410277,"about_ca_system_score_gemma":0.00017609121,"threshold_uncertainty_score":0.9120177},"labels":[],"label_agreement":null},{"id":"W1993997366","doi":"10.2165/00019053-200220001-00002","title":"The Role of Models Within Economic Analysis","year":2002,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Ottawa Hospital; University of Ottawa","funders":"Eli Lilly Canada","keywords":"Health economics; Psychological intervention; Transparency (behavior); Risk analysis (engineering); Economic model; Health administration; Relevance (law); Cost–benefit analysis; Disease; Public economics; Economic analysis; Medicine; Actuarial science; Health care; Management science; Computer science; Economics; Microeconomics; Economic growth; Political science","score_opus":0.4714536748754177,"score_gpt":0.5009097687648176,"score_spread":0.029456093889399904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1993997366","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000050812596,0.9797586,0.00027199247,0.000635667,0.001381931,0.0013995192,0.002601259,0.00006631623,0.01383391],"genre_scores_gemma":[0.00029471546,0.99602497,0.0004950843,0.00065198017,0.00069356675,0.0004134399,0.00018667233,0.00016209226,0.0010774741],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.984126,0.00064802245,0.013087334,0.0012662144,0.00008519527,0.0007872888],"domain_scores_gemma":[0.9816003,0.0028764617,0.013487707,0.0016360435,0.000051829476,0.0003476867],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.014791776,0.0007916083,0.00675993,0.0011741461,0.0003922601,0.00024420855,0.0017396137,0.00047718515,0.0011241931],"category_scores_gemma":[0.00033542718,0.0008246675,0.002249579,0.00044096546,0.0002340707,0.0006957715,0.00023955549,0.00065076404,0.005626739],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000024215475,0.0002413415,0.0003275581,0.009225851,0.019586688,0.00000184419,0.0017399999,0.033067387,6.701618e-8,0.69236404,0.022653677,0.2207673],"study_design_scores_gemma":[0.0002473018,0.000016980424,0.000001208077,0.00023159196,0.0011347692,0.000005391591,0.00014107829,0.118753836,6.6736396e-7,0.015927536,0.8628831,0.00065655494],"about_ca_topic_score_codex":0.00079266075,"about_ca_topic_score_gemma":0.00018734054,"teacher_disagreement_score":0.8402294,"about_ca_system_score_codex":0.0019059238,"about_ca_system_score_gemma":0.0004957685,"threshold_uncertainty_score":0.99978894},"labels":[],"label_agreement":null},{"id":"W1996028644","doi":"10.2165/00019053-200422040-00006","title":"The NICE Reference Case Requirement","year":2004,"lang":"en","type":"letter","venue":"PharmacoEconomics","topic":"Nuclear and radioactivity studies","field":"Engineering","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Quality of Life Research; Nice; Health economics; Health administration; Public health; Medicine; Computer science; Nursing","score_opus":0.034961927505383315,"score_gpt":0.27705090510886454,"score_spread":0.24208897760348122,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1996028644","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0102317,0.009106883,0.00015392303,0.87976336,0.013284286,0.0010430905,0.00046298408,0.0012947882,0.08465895],"genre_scores_gemma":[0.08880896,0.03141143,0.0003884683,0.8552974,0.017005045,0.0002274875,0.00012449997,0.00059954566,0.006137203],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990578,0.000020255862,0.0002477738,0.00021767545,0.00006746204,0.00038899545],"domain_scores_gemma":[0.9994289,0.00014425362,0.000057430094,0.0003115852,0.000017113563,0.0000406864],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000119443386,0.0002802898,0.00024127275,0.000039746876,0.0002701757,0.000101007594,0.00027345505,0.00018170572,0.00006290225],"category_scores_gemma":[0.000004407445,0.00023007358,0.00009508501,0.000029392231,0.00007148269,0.000100121586,0.000070753966,0.0012892358,0.0003786896],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000027469675,0.0000030783685,9.639973e-7,0.00008594791,0.00027867837,0.0008126607,0.00007343126,0.0016371603,0.000043186323,0.00003627577,0.9938383,0.0031875474],"study_design_scores_gemma":[0.00019950725,0.0000071589175,0.0000012757521,0.000011830744,0.000074810814,0.00041835086,0.00002584813,0.001093566,0.00027350988,0.000118749376,0.997486,0.00028939964],"about_ca_topic_score_codex":0.00006103253,"about_ca_topic_score_gemma":0.00005033333,"teacher_disagreement_score":0.07857726,"about_ca_system_score_codex":0.00048646823,"about_ca_system_score_gemma":0.000031034608,"threshold_uncertainty_score":0.9382128},"labels":[],"label_agreement":null},{"id":"W1998739853","doi":"10.2165/11586420-000000000-00000","title":"Health Technology Funding Decision-Making Processes Around the World","year":2011,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":91,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research","keywords":"Health economics; Quality of Life Research; Health administration; Public health; Health informatics; Health services research; Business; Medicine; Nursing","score_opus":0.555836418940262,"score_gpt":0.5556271042711015,"score_spread":0.00020931466916052077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1998739853","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00002078915,0.9774899,0.001739369,0.008574132,0.0029002102,0.0025918134,0.00072867953,0.00022840968,0.005726719],"genre_scores_gemma":[0.00015935813,0.98261493,0.0029481049,0.0105712935,0.0016075948,0.0008338416,0.000067284294,0.00024456173,0.0009530224],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.986396,0.00045928292,0.010188683,0.0015817243,0.00008126331,0.0012930579],"domain_scores_gemma":[0.9814231,0.005362676,0.011354363,0.0014431177,0.000088342786,0.00032844106],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.017467387,0.00090551114,0.005665724,0.0022090056,0.0008526784,0.00034477544,0.002164385,0.00043066882,0.0011815701],"category_scores_gemma":[0.0027234503,0.000909917,0.00063157105,0.0012438075,0.00025162182,0.00071622856,0.00044287991,0.0012404373,0.009186934],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000014173174,0.00014905239,0.00039837713,0.029807772,0.0007989066,0.0000031846048,0.0007109463,0.000047508573,3.3287137e-9,0.14171015,0.09619662,0.7301633],"study_design_scores_gemma":[0.0002589885,0.00002860944,0.000003566135,0.0055069784,0.00008898096,0.000055861143,0.0002148898,0.00019890419,7.067836e-8,0.020783324,0.97206604,0.0007937566],"about_ca_topic_score_codex":0.00015922208,"about_ca_topic_score_gemma":0.0005856499,"teacher_disagreement_score":0.87586945,"about_ca_system_score_codex":0.0029038154,"about_ca_system_score_gemma":0.0020507665,"threshold_uncertainty_score":0.9997315},"labels":[],"label_agreement":null},{"id":"W1998954570","doi":"10.2165/00019053-200220040-00003","title":"Putting Your Money Where Your Mouth Is","year":2002,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Dental Anxiety and Anesthesia Techniques","field":"Dentistry","cited_by":60,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Dalhousie University","funders":"AstraZeneca","keywords":"Medicine; Population; Recall; Willingness to pay; Beneficiary; Dentistry; General anaesthetic; Surgery; Environmental health; Psychology; General anaesthesia; Business; Finance; Economics","score_opus":0.04991906757695675,"score_gpt":0.31053717336119824,"score_spread":0.2606181057842415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1998954570","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9766696,0.0013061208,0.00010465194,0.0015844555,0.0004960051,0.00020280771,0.00007256785,0.0005118077,0.019051975],"genre_scores_gemma":[0.97911185,0.0011250083,0.0014415145,0.0033552398,0.00050139683,0.000025309793,0.000009946813,0.00006129395,0.014368452],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988069,0.000026559852,0.0003516336,0.00036369386,0.000097054595,0.0003541415],"domain_scores_gemma":[0.99939746,0.000021546542,0.00015580961,0.0002531107,0.000024410421,0.00014769334],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00013613855,0.00022526793,0.000236908,0.000056945213,0.00014837309,0.00014676165,0.00037138417,0.000102778395,0.005325552],"category_scores_gemma":[0.0000060344805,0.000248066,0.00019543151,0.0000695788,0.000042601965,0.00039897038,0.00010066761,0.00025526228,0.0055834283],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006495251,0.0006144938,0.08087742,0.0001932225,0.00029546762,0.0004746935,0.0024054945,0.00007400086,0.02221877,0.001281458,0.59920233,0.29229772],"study_design_scores_gemma":[0.0017655153,0.000043525582,0.002651655,0.00006087665,0.00010053142,0.0006948952,0.00046958748,0.02194575,0.13386294,0.0017058249,0.83572716,0.00097174227],"about_ca_topic_score_codex":0.000098480166,"about_ca_topic_score_gemma":0.0000070135857,"teacher_disagreement_score":0.29132596,"about_ca_system_score_codex":0.00007718674,"about_ca_system_score_gemma":0.000007021365,"threshold_uncertainty_score":0.99999714},"labels":[],"label_agreement":null},{"id":"W1999044673","doi":"10.2165/00019053-200422100-00001","title":"An Economic Model of 2-Hour Post-Dose Ciclosporin Monitoring in Renal Transplantation","year":2004,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Renal Transplantation Outcomes and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; Dalhousie University; University of British Columbia","funders":"Novartis Pharma","keywords":"Ciclosporin; Medicine; Transplantation; Therapeutic drug monitoring; Kidney transplantation; Azathioprine; Intensive care medicine; Surgery; Urology; Internal medicine; Pharmacokinetics; Disease","score_opus":0.03410034828414198,"score_gpt":0.3522375280277698,"score_spread":0.3181371797436278,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1999044673","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99835217,0.00003992989,0.00050235266,0.00016387658,0.00014515083,0.0002396491,0.00012813865,0.000025273794,0.00040346687],"genre_scores_gemma":[0.9948804,0.0010287691,0.0037379854,0.000101102894,0.00008226835,0.0000149128355,0.00010562548,0.000023547957,0.000025438669],"study_design_codex":"simulation_or_modeling","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99916595,0.000010790897,0.000396631,0.00020826272,0.000052868967,0.00016549144],"domain_scores_gemma":[0.9996179,0.000017369424,0.00009762858,0.00012545014,0.000020189953,0.000121502104],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000916407,0.0001360562,0.0002531644,0.00015167732,0.000021608166,0.000009258498,0.00007188743,0.000046309822,0.000034058092],"category_scores_gemma":[8.688805e-7,0.00014001632,0.00008423113,0.00003188923,0.000019097832,0.00028451113,0.000003182383,0.00010098976,0.000025840258],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020400782,0.00048582838,0.15357423,0.00027605557,0.00015729156,0.0000907622,0.0017680642,0.6715565,0.16568579,0.00079835707,8.657056e-7,0.00356622],"study_design_scores_gemma":[0.028168336,0.0004532701,0.17558865,0.00032596072,0.00038160235,0.0001208213,0.00017506622,0.04782129,0.745712,0.0008516583,0.000013717116,0.00038763072],"about_ca_topic_score_codex":0.00031150115,"about_ca_topic_score_gemma":0.000044734767,"teacher_disagreement_score":0.6237352,"about_ca_system_score_codex":0.00023756835,"about_ca_system_score_gemma":0.00015189953,"threshold_uncertainty_score":0.57097},"labels":[],"label_agreement":null},{"id":"W1999652777","doi":"10.1007/s40273-015-0277-8","title":"Reply to Roberts et al.: CHEERS is Sufficient for Reporting Cost-Benefit Analysis, but May Require Further Elaboration","year":2015,"lang":"en","type":"letter","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Institute of Health Economics","funders":"","keywords":"Elaboration; Quality of Life Research; Health economics; Health administration; Public health; Pharmacoeconomics; Actuarial science; Public economics; Medicine; Business; Economics; Nursing; Intensive care medicine; Philosophy","score_opus":0.3777948078585878,"score_gpt":0.49237525681750066,"score_spread":0.11458044895891284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1999652777","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010915105,0.0013725725,0.00826912,0.9602407,0.0030994543,0.0039316607,0.009438466,0.00014564369,0.0025872304],"genre_scores_gemma":[0.0020357256,0.0003113137,0.0038507534,0.97777945,0.0028102277,0.0013587677,0.004382892,0.00026880813,0.007202064],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9822116,0.00030413928,0.013512846,0.0024816094,0.00022817824,0.0012616328],"domain_scores_gemma":[0.9780054,0.0010600144,0.018100092,0.0017271368,0.0005664315,0.00054092595],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.034363788,0.000866343,0.0033907066,0.001611133,0.00028525083,0.00054607715,0.00085407234,0.0006618945,0.0014447592],"category_scores_gemma":[0.0038156332,0.00121273,0.000906823,0.0006147935,0.000072032024,0.0010693875,0.00018813272,0.0010899154,0.001983919],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000038564674,0.000055519387,0.0015660812,0.0002918194,0.0012267719,0.000008385088,0.0019651556,0.0091667995,0.00000430332,0.0010757771,0.9844472,0.00015362905],"study_design_scores_gemma":[0.00096172607,0.00007490983,0.00012290923,0.000054752316,0.0002694075,0.000008514881,0.00036746738,0.022033548,0.00004251278,0.0013044596,0.97354853,0.0012112865],"about_ca_topic_score_codex":0.002045166,"about_ca_topic_score_gemma":0.00020954272,"teacher_disagreement_score":0.030548155,"about_ca_system_score_codex":0.003478821,"about_ca_system_score_gemma":0.0008087119,"threshold_uncertainty_score":0.999468},"labels":[],"label_agreement":null},{"id":"W2002448686","doi":"10.2165/11537420-000000000-00000","title":"No Head-to-Head Trial? Simulate the Missing Arms","year":2010,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":95,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Replicate; Missing data; Head (geology); Psychological intervention; Clinical trial; Index (typography); Placebo; Computer science; Econometrics; Medicine; Operations research; Statistics; Mathematics; Machine learning; Alternative medicine","score_opus":0.3929399017357939,"score_gpt":0.5105554715258175,"score_spread":0.11761556979002358,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2002448686","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.84097636,0.00039985916,0.0013725589,0.12660743,0.009883093,0.0023143718,0.00031388164,0.00016710584,0.01796535],"genre_scores_gemma":[0.8610842,0.00013203292,0.005570532,0.12395263,0.005320218,0.00033004995,0.000044512733,0.00016422354,0.0034015886],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99361396,0.00024113657,0.004326396,0.00091594283,0.000082012804,0.00082056393],"domain_scores_gemma":[0.99470097,0.0017194281,0.0018223558,0.0011009652,0.0000907559,0.0005655429],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0152392695,0.0003895243,0.0011348866,0.00031844128,0.00050632615,0.0003648978,0.00093530485,0.00020320492,0.0026852342],"category_scores_gemma":[0.0024640437,0.00041867085,0.00029806476,0.00019001671,0.00012726584,0.00064380036,0.00015043105,0.00075093866,0.02716667],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01080163,0.0020957368,0.03733915,0.0011441538,0.001685808,0.000018596415,0.017498221,0.025755445,0.004757535,0.2746059,0.6016847,0.022613134],"study_design_scores_gemma":[0.0117081655,0.00010681081,0.0011411961,0.000019953703,0.000019257302,0.000008079048,0.0001171242,0.044694826,0.00014269113,0.00986532,0.9315164,0.00066015346],"about_ca_topic_score_codex":0.000713856,"about_ca_topic_score_gemma":0.00027559468,"teacher_disagreement_score":0.32983172,"about_ca_system_score_codex":0.00039142178,"about_ca_system_score_gemma":0.00023715336,"threshold_uncertainty_score":0.9998265},"labels":[],"label_agreement":null},{"id":"W2003190574","doi":"10.2165/11537560-000000000-00000","title":"Cost Effectiveness of Leukotriene Receptor Antagonists versus Long-Acting Beta-2 Agonists as Add-On Therapy to Inhaled Corticosteroids for Asthma","year":2010,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Asthma and respiratory diseases","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Asthma; Quality-adjusted life year; Quality of life (healthcare); Cost effectiveness; Clinical endpoint; Randomized controlled trial; B2 receptor; Pediatrics; Cost-effectiveness analysis; Economic evaluation; Health economics; Internal medicine; Intensive care medicine; Physical therapy; Public health","score_opus":0.05528417132397774,"score_gpt":0.39068709915799066,"score_spread":0.33540292783401293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2003190574","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943374,0.00011657656,0.00020369985,0.00019018917,0.0022988657,0.0021007808,0.00016428558,0.000063325046,0.0005248985],"genre_scores_gemma":[0.99760425,0.00006201519,0.00031508823,0.00089983863,0.0005895997,0.00027327996,0.00011386719,0.00007650912,0.000065565146],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985186,0.00006178933,0.00044784512,0.00045986462,0.0001314626,0.0003804242],"domain_scores_gemma":[0.99814296,0.0006508456,0.00023324398,0.00035355115,0.0001714858,0.00044790708],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004150599,0.00029570673,0.00057380623,0.00014325007,0.00013860266,0.000043739703,0.00018230443,0.00011946906,0.0003770248],"category_scores_gemma":[0.000168529,0.00027596453,0.0002515802,0.00010438984,0.00010794581,0.0001421594,0.00004724452,0.00026969513,0.00013753129],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05086032,0.0007713949,0.0072096125,0.0003466157,0.0003916656,0.000036461555,0.00020255559,0.00014654364,0.6991775,0.00014818122,0.00083607156,0.2398731],"study_design_scores_gemma":[0.01653162,0.0023438693,0.008171469,0.00008528897,0.00009092202,0.000021375958,0.0000729884,0.00013898338,0.8954708,0.0000073830856,0.07673484,0.0003304644],"about_ca_topic_score_codex":0.000014496581,"about_ca_topic_score_gemma":0.000009304437,"teacher_disagreement_score":0.23954263,"about_ca_system_score_codex":0.00014894913,"about_ca_system_score_gemma":0.00031023074,"threshold_uncertainty_score":0.99996924},"labels":[],"label_agreement":null},{"id":"W2003344015","doi":"10.1007/s40273-014-0238-7","title":"Is There an Economic Rationale for Cancer Drugs to Have a Separate Reimbursement Review Process for Resource Allocation Purposes?","year":2014,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Bayer Canada","keywords":"Reimbursement; Health economics; Health administration; Quality of Life Research; Process (computing); Resource allocation; Public health; Public economics; Business; Medicine; Actuarial science; Economics; Health care; Computer science; Economic growth; Nursing; Management","score_opus":0.5122120980658947,"score_gpt":0.5829441577757695,"score_spread":0.07073205970987473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2003344015","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009311691,0.94394195,0.0027029237,0.02238049,0.0012401524,0.01839658,0.010227195,0.00008796733,0.0009295994],"genre_scores_gemma":[0.000018628996,0.91406405,0.0012754878,0.048356317,0.0026075293,0.02850903,0.0023238761,0.00030650353,0.002538598],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9881577,0.00040553955,0.008311088,0.0021299985,0.00009285506,0.0009028342],"domain_scores_gemma":[0.9890758,0.0014121239,0.0075105983,0.0011923529,0.00020674044,0.0006024247],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.015778555,0.00093917886,0.0052724555,0.00052657805,0.00040809627,0.0002599974,0.0012154406,0.0003982284,0.00097031274],"category_scores_gemma":[0.00055098237,0.0011866678,0.0010336338,0.00012363867,0.00005727553,0.0007504989,0.00009228261,0.0003149025,0.0021248627],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010061754,0.00023086226,0.00003983664,0.2254135,0.0015113921,2.0712588e-7,0.002094474,0.0027107282,1.7384694e-7,0.020647973,0.5835981,0.16365215],"study_design_scores_gemma":[0.0009760193,0.00012328269,9.649402e-7,0.0071015693,0.0004669918,0.0000031076527,0.00016921997,0.0100946,0.0000043134355,0.0018479333,0.97799927,0.0012127509],"about_ca_topic_score_codex":0.00018842654,"about_ca_topic_score_gemma":0.00015813818,"teacher_disagreement_score":0.39440116,"about_ca_system_score_codex":0.0032628914,"about_ca_system_score_gemma":0.0014052304,"threshold_uncertainty_score":0.99994296},"labels":[],"label_agreement":null},{"id":"W2003446384","doi":"10.2165/00019053-200321030-00001","title":"NICE Methodological Guidelines and Decision Making in the National Health Service in England and Wales","year":2003,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":63,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Nice; Excellence; Health economics; Equity (law); Health care rationing; Health technology; Economic evaluation; Service (business); Actuarial science; Public economics; Health care; Medicine; Operations research; Economics; Business; Computer science; Marketing; Political science; Economic growth; Microeconomics","score_opus":0.7631365332457298,"score_gpt":0.5923564086783528,"score_spread":0.170780124567377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2003446384","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9379126,0.006769641,0.001994802,0.051350884,0.0002696241,0.0005575912,0.00008647132,0.000014402573,0.001043978],"genre_scores_gemma":[0.8432151,0.0025839207,0.040663157,0.1132177,0.00020202794,0.00007851427,0.000008829385,0.000020410575,0.000010329252],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99542594,0.0007943054,0.0028714945,0.00051900744,0.000059756705,0.000329499],"domain_scores_gemma":[0.9941007,0.004751699,0.0008614802,0.00014804755,0.000048552043,0.00008954944],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.04491131,0.00016954822,0.00066536106,0.00030162343,0.00013085698,0.00009774801,0.0001985149,0.00009083641,0.00009364674],"category_scores_gemma":[0.0040670177,0.00017453091,0.000033708144,0.0001694645,0.000041871157,0.0003596089,0.000051736497,0.00023402656,0.00006866321],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018174437,0.00030598624,0.60977846,0.0007936392,0.00008665972,0.000005309312,0.022324529,0.008156698,0.0000135824785,0.31664005,0.01817622,0.023537109],"study_design_scores_gemma":[0.005975071,0.00008384299,0.20047112,0.00020157748,0.0000060912603,0.00012955304,0.002727056,0.09442671,0.00000573444,0.32107562,0.3741107,0.0007869282],"about_ca_topic_score_codex":0.00039783068,"about_ca_topic_score_gemma":0.0015779078,"teacher_disagreement_score":0.40930736,"about_ca_system_score_codex":0.00032756812,"about_ca_system_score_gemma":0.00013305437,"threshold_uncertainty_score":0.9834648},"labels":[],"label_agreement":null},{"id":"W2004704164","doi":"10.2165/00019053-200826100-00004","title":"Quality-of-Life Assessment in Rheumatoid Arthritis","year":2008,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Quality of Life Research; Health economics; Rheumatoid arthritis; Public health; Quality of life (healthcare); Health administration; Medicine; Pharmacoeconomics; Quality (philosophy); Quality-adjusted life year; Intensive care medicine; Internal medicine; Nursing; Risk analysis (engineering); Cost effectiveness","score_opus":0.09301655368558759,"score_gpt":0.43957224455821947,"score_spread":0.3465556908726319,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2004704164","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016271126,0.99304426,0.000013193329,0.00009368862,0.00029958715,0.0011554087,0.000151814,0.000043430067,0.0035715245],"genre_scores_gemma":[0.0005559107,0.9981418,0.0004632756,0.00012950852,0.00010810973,0.00022613835,0.00021679384,0.000096097916,0.000062336374],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963547,0.00033500366,0.0020590906,0.00048307492,0.00025791212,0.0005102442],"domain_scores_gemma":[0.99801713,0.00044115816,0.00062378723,0.00045881758,0.000064580294,0.0003944985],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006161824,0.00045268828,0.0037066923,0.000549253,0.000058353548,0.000027248696,0.00028530654,0.000209446,0.0007656735],"category_scores_gemma":[0.00012206544,0.00043998298,0.0007675973,0.00020608823,0.00019454524,0.00014522846,0.0001180637,0.0009771942,0.00021418012],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000049339542,0.0002579133,0.0005436197,0.0044355122,0.00040906775,0.00004955116,0.00006101282,0.0000014978427,0.000002962239,0.00068815623,0.002251226,0.99125016],"study_design_scores_gemma":[0.0031589642,0.000064965934,0.0000697874,0.007705248,0.000005325862,0.00022946607,0.000024729348,0.000030873893,0.000004647719,0.0000522713,0.9883081,0.0003456272],"about_ca_topic_score_codex":0.00016543467,"about_ca_topic_score_gemma":0.000041370902,"teacher_disagreement_score":0.9909045,"about_ca_system_score_codex":0.00030388727,"about_ca_system_score_gemma":0.0024127536,"threshold_uncertainty_score":0.9998052},"labels":[],"label_agreement":null},{"id":"W2005305338","doi":"10.2165/00019053-200422110-00001","title":"The Measurement of Contingent Valuation for Health Economics","year":2004,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":119,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"","keywords":"Contingent valuation; Valuation (finance); Actuarial science; Health economics; Willingness to pay; Payment card; Willingness to accept; Economics; Public economics; Payment; Business; Health care; Microeconomics; Accounting; Finance","score_opus":0.5143036724427065,"score_gpt":0.4939732345693773,"score_spread":0.020330437873329166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005305338","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.43587866,0.020782217,0.11974942,0.39759704,0.00827999,0.009434168,0.0019784507,0.00020964177,0.006090387],"genre_scores_gemma":[0.95924425,0.0038126884,0.01081513,0.024193967,0.0009114571,0.000715552,0.00006458148,0.00010644541,0.00013594584],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9935298,0.0001255108,0.005153212,0.0005426873,0.00007692009,0.0005718864],"domain_scores_gemma":[0.994074,0.0006813494,0.004333299,0.0005156693,0.00017982716,0.00021586767],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.030193891,0.00023783433,0.00095034146,0.00016985062,0.0005324158,0.00009702385,0.00045754778,0.00008156405,0.00004122136],"category_scores_gemma":[0.0011613079,0.00027310764,0.00027466036,0.00007489474,0.0001063427,0.0003715153,0.000053993073,0.00013170237,0.0002800231],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018014031,0.00024056382,0.0017490044,0.00050757464,0.0004641633,7.3007264e-8,0.0025025276,0.023280874,0.00006326592,0.9480012,0.019179123,0.003831495],"study_design_scores_gemma":[0.008078854,0.0003592958,0.002706031,0.00010322526,0.000037904047,0.0000042941097,0.0010167519,0.03877224,0.0013586398,0.3176924,0.6290602,0.00081012875],"about_ca_topic_score_codex":0.00041879635,"about_ca_topic_score_gemma":0.00035889074,"teacher_disagreement_score":0.6303088,"about_ca_system_score_codex":0.0024316953,"about_ca_system_score_gemma":0.0008033609,"threshold_uncertainty_score":0.9999721},"labels":[],"label_agreement":null},{"id":"W2005333158","doi":"10.1007/s40273-013-0048-3","title":"Lopinavir/Ritonavir Versus Darunavir Plus Ritonavir for HIV Infection: A Cost-Effectiveness Analysis for the United States","year":2013,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Darunavir; Lopinavir; Emtricitabine; Medicine; Ritonavir; Regimen; Lopinavir/ritonavir; Cost effectiveness; Clinical trial; Viral load; Cost-effectiveness analysis; Intensive care medicine; Internal medicine; Human immunodeficiency virus (HIV); Immunology; Antiretroviral therapy; Risk analysis (engineering)","score_opus":0.06119449999214679,"score_gpt":0.3712327756547588,"score_spread":0.31003827566261205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005333158","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94620156,0.00042557082,0.028417926,0.012175271,0.001414122,0.01020662,0.00054091326,0.0002228172,0.0003951828],"genre_scores_gemma":[0.9674586,0.0015993955,0.0026527697,0.0015104383,0.00080207374,0.014690384,0.006225166,0.00013782337,0.004923339],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99840283,0.000065961256,0.0004393614,0.00049445,0.00011400631,0.0004834167],"domain_scores_gemma":[0.99722236,0.0017610858,0.00017424344,0.00035027124,0.00027680027,0.00021525075],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00041442065,0.00036123357,0.00060014875,0.0003396933,0.0003782293,0.000112867376,0.00016523252,0.00009729399,0.00027762118],"category_scores_gemma":[0.000050850074,0.0002800364,0.00046805284,0.00049599155,0.0001036667,0.00024540446,0.00006248547,0.00017975674,0.00018667348],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03720695,0.0041095996,0.3379635,0.0024514976,0.105117716,0.00005108831,0.005484933,0.15476625,0.0022673642,0.005021802,0.13973829,0.20582104],"study_design_scores_gemma":[0.028043903,0.00030472598,0.01956046,0.000045784152,0.007099338,0.00001043025,0.00030831966,0.24063854,0.006703539,0.00037148327,0.69629854,0.00061494624],"about_ca_topic_score_codex":0.0005352341,"about_ca_topic_score_gemma":0.00007019162,"teacher_disagreement_score":0.5565603,"about_ca_system_score_codex":0.0007824395,"about_ca_system_score_gemma":0.00020104168,"threshold_uncertainty_score":0.9999652},"labels":[],"label_agreement":null},{"id":"W2006447179","doi":"10.1007/s40273-012-0022-5","title":"The Evaluation and Use of Economic Evidence to Inform Cancer Drug Reimbursement Decisions in Canada","year":2013,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Cancer Care Ontario; Canadian Centre for Applied Research in Cancer Control; St. Michael's Hospital","funders":"","keywords":"Reimbursement; Health economics; Medicine; Pharmacoeconomics; Economic evaluation; Advisory committee; Cancer drugs; Cost effectiveness; MEDLINE; Family medicine; Actuarial science; Public health; Health care; Drug; Business; Intensive care medicine; Political science; Risk analysis (engineering); Economics; Nursing; Pharmacology; Economic growth; Public administration; Pathology","score_opus":0.47535048308160655,"score_gpt":0.5047315089868688,"score_spread":0.02938102590526226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2006447179","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94267017,0.0030067973,0.000054307788,0.05085683,0.0010299231,0.0018900188,0.00018828432,0.000007970336,0.00029572178],"genre_scores_gemma":[0.9850031,0.004100095,0.0005885595,0.008993578,0.00012068479,0.0009063704,0.000007788637,0.000026699181,0.0002531353],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952158,0.00018209337,0.0036016647,0.000468226,0.000097843666,0.0004344046],"domain_scores_gemma":[0.9942115,0.0034884594,0.0014415443,0.00047998808,0.000107676926,0.00027084444],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008863853,0.00019849175,0.00063341245,0.00023052566,0.00020090754,0.00015930101,0.00037101653,0.00004254509,0.00081596023],"category_scores_gemma":[0.0019500972,0.0002179622,0.000055254437,0.00012146924,0.0000530635,0.001285688,0.00013863335,0.00015272213,0.0004707807],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000083895895,0.00004985611,0.5510134,0.00012491617,0.00021065671,4.3906735e-7,0.0028151646,0.09322628,0.000043513908,0.021838812,0.28163895,0.048954092],"study_design_scores_gemma":[0.001767251,0.000042173804,0.39722726,0.00026381566,0.000032155716,0.0000027962444,0.00209604,0.37570298,0.00022537018,0.007845701,0.21398956,0.0008048988],"about_ca_topic_score_codex":0.8760935,"about_ca_topic_score_gemma":0.8652464,"teacher_disagreement_score":0.2824767,"about_ca_system_score_codex":0.004849309,"about_ca_system_score_gemma":0.0017870243,"threshold_uncertainty_score":0.9989709},"labels":[],"label_agreement":null},{"id":"W2007015456","doi":"10.2165/00019053-200725060-00002","title":"Estimation, Power and Sample Size Calculations for Stochastic Cost and Effectiveness Analysis","year":2007,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Confidence interval; Sample size determination; Statistics; Rectangle; Null hypothesis; Value (mathematics); Mathematics; Sample (material); Null (SQL); Econometrics; Statistical power; Computer science; Data mining","score_opus":0.3875913884959831,"score_gpt":0.5439592198493887,"score_spread":0.15636783135340554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2007015456","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004233936,0.7944165,0.19448377,0.00043630143,0.0005365837,0.0038706067,0.0056608827,0.0000541789,0.000117801515],"genre_scores_gemma":[0.0020361445,0.9771238,0.01593851,0.0018990438,0.00038317466,0.0016784415,0.0006543618,0.00017361242,0.00011291739],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99360937,0.00029548502,0.0044232015,0.001091012,0.000046890953,0.0005340468],"domain_scores_gemma":[0.9705579,0.025598366,0.0029426136,0.0004594978,0.000071822935,0.00036979638],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.012819972,0.00053830165,0.003981059,0.00096578355,0.00035158865,0.00021318623,0.00023324745,0.0003439485,0.0002598639],"category_scores_gemma":[0.005932843,0.0006964656,0.0005520232,0.00037757575,0.0001321028,0.00040630405,0.00009419618,0.00027155192,0.00016721386],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001734533,0.00057673606,0.0047804313,0.09719501,0.022772968,0.0000030818417,0.0022706692,0.029141525,2.0554666e-7,0.229716,0.008088259,0.60528165],"study_design_scores_gemma":[0.0012209563,0.00004334067,0.0007073683,0.0006072587,0.0020744025,0.000012163161,0.00004999597,0.07402481,1.322448e-7,0.0075467695,0.91268355,0.0010292684],"about_ca_topic_score_codex":0.00028812684,"about_ca_topic_score_gemma":0.000063686544,"teacher_disagreement_score":0.90459526,"about_ca_system_score_codex":0.0008981972,"about_ca_system_score_gemma":0.00022935381,"threshold_uncertainty_score":0.9995487},"labels":[],"label_agreement":null},{"id":"W2007217751","doi":"10.2165/00019053-200321140-00004","title":"A Cost Comparison of Oral Tegafur Plus Uracil/Folinic Acid and Parenteral Fluorouracil for Colorectal Cancer in Canada","year":2003,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Bristol-Myers Squibb (Canada); Simon Fraser University; Princess Margaret Cancer Centre; Ottawa Regional Cancer Foundation","funders":"","keywords":"Folinic acid; Medicine; Regimen; Fluorouracil; Concomitant; Internal medicine; Tegafur; Surgery; Chemotherapy","score_opus":0.06386310239425377,"score_gpt":0.38521957971072845,"score_spread":0.32135647731647465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2007217751","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99429244,0.0032883661,0.0000104318215,0.00034070993,0.00034995377,0.0008056977,0.00033417722,0.000006994058,0.00057121366],"genre_scores_gemma":[0.99845725,0.0006380134,0.0002085306,0.00026772058,0.0000321577,0.00030588236,0.000018429884,0.000015251332,0.000056758676],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99905777,0.000020968113,0.00037864206,0.00022261297,0.000060655417,0.00025934528],"domain_scores_gemma":[0.99956465,0.00008469996,0.00012585262,0.00006307985,0.000051095314,0.00011064683],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008487202,0.00016254713,0.00057732937,0.00004584931,0.000049242157,0.000008104024,0.00004312562,0.000027873033,0.00012959239],"category_scores_gemma":[0.00002490888,0.00015004964,0.000056079556,0.000051165447,0.000042051946,0.00005730069,0.000023035573,0.0001030086,7.3024665e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002952157,0.00018847328,0.9405106,0.0001619319,0.0004648161,0.000011710676,0.0014685559,0.0006261846,0.0011832705,0.000069554066,0.0032130769,0.049149726],"study_design_scores_gemma":[0.08528152,0.0030356487,0.44427058,0.00032957623,0.0018445089,0.00011658363,0.011720268,0.10670303,0.19770837,0.00019092213,0.14705996,0.001739028],"about_ca_topic_score_codex":0.25707614,"about_ca_topic_score_gemma":0.82779276,"teacher_disagreement_score":0.5707166,"about_ca_system_score_codex":0.0013819041,"about_ca_system_score_gemma":0.001221967,"threshold_uncertainty_score":0.74787104},"labels":[],"label_agreement":null},{"id":"W2007373992","doi":"10.2165/00019053-200018050-00004","title":"Cost Analysis of an Adult Outpatient Parenteral Antibiotic Therapy (OPAT) Programme","year":2000,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Antibiotics Pharmacokinetics and Efficacy","field":"Medicine","cited_by":98,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Vancouver Hospital and Health Sciences Centre","funders":"","keywords":"Medicine; Cloxacillin; Emergency medicine; Discontinuation; Intensive care medicine; Antibiotics; Surgery","score_opus":0.048288349272671734,"score_gpt":0.35609680249651904,"score_spread":0.3078084532238473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2007373992","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970449,0.00013886804,0.00004116211,0.0003008635,0.0001708698,0.0006556294,0.00010572034,0.000057698788,0.0014842876],"genre_scores_gemma":[0.99486214,0.0019696455,0.00069900847,0.0017131828,0.00015086621,0.0000049870173,0.00037169317,0.000039203132,0.00018926854],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9984537,0.000045189503,0.00057392096,0.00038152846,0.0001377373,0.00040793355],"domain_scores_gemma":[0.9989678,0.0000310949,0.00016523867,0.00035786687,0.00012790642,0.00035006486],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00017151162,0.00023523335,0.0005920421,0.00026142484,0.00005252369,0.000034074426,0.00018156937,0.00006677902,0.001973253],"category_scores_gemma":[0.0000073226947,0.00021787094,0.00031978078,0.00033712442,0.00009952658,0.00010780247,0.000021767084,0.00018976638,0.00007087083],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026877585,0.005185935,0.1690493,0.00010307587,0.004822506,0.00004316298,0.0014827668,0.008234427,0.011271435,0.00014057294,0.0008031764,0.7961759],"study_design_scores_gemma":[0.016280677,0.002061026,0.14616561,0.00006758764,0.005833789,0.000031886393,0.0002675687,0.66430646,0.12714224,0.000022000551,0.03689736,0.0009238267],"about_ca_topic_score_codex":0.00009941723,"about_ca_topic_score_gemma":0.0000113003925,"teacher_disagreement_score":0.7952521,"about_ca_system_score_codex":0.00006743008,"about_ca_system_score_gemma":0.000057706762,"threshold_uncertainty_score":0.9989391},"labels":[],"label_agreement":null},{"id":"W2007393518","doi":"10.2165/00019053-200523120-00005","title":"Cost-Effectiveness Acceptability Curves and a Reluctance to Lose","year":2005,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":61,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Willingness to pay; Willingness to accept; Health economics; Contingent valuation; Incremental cost-effectiveness ratio; Cost effectiveness; Econometrics; Economics; Valuation (finance); Cost-effectiveness analysis; Actuarial science; Medicine; Statistics; Health care; Mathematics; Microeconomics","score_opus":0.6243452194347576,"score_gpt":0.5808348646582401,"score_spread":0.043510354776517546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2007393518","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001982347,0.9819886,0.0005449951,0.004380452,0.0013364971,0.0066901445,0.0026182174,0.00012779547,0.0021150748],"genre_scores_gemma":[0.00005474179,0.9807236,0.0015565633,0.013555101,0.001098107,0.002360501,0.00016643187,0.00017902751,0.0003059161],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98928523,0.0010323918,0.006833016,0.0019200419,0.00007840171,0.0008509217],"domain_scores_gemma":[0.9914177,0.0029711546,0.003667126,0.0011312251,0.00007040725,0.00074240624],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0194318,0.0008680854,0.005904046,0.0005984583,0.00023187228,0.00019553573,0.0008697278,0.00040625382,0.0017523388],"category_scores_gemma":[0.002221895,0.0011265142,0.0005891621,0.00031498887,0.00013818522,0.00085056835,0.0003479436,0.000693883,0.0072005014],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000036176134,0.00024555594,0.0006324788,0.08905436,0.0006226598,0.0000033543483,0.00043439915,0.00007107536,7.728426e-8,0.009805227,0.056539886,0.84255475],"study_design_scores_gemma":[0.0005388919,0.000034359557,0.00019851082,0.0036252341,0.00013780479,0.000025287123,0.000026393063,0.00019654533,4.381938e-7,0.0007151701,0.9934508,0.0010505378],"about_ca_topic_score_codex":0.00017692128,"about_ca_topic_score_gemma":0.00006022911,"teacher_disagreement_score":0.9369109,"about_ca_system_score_codex":0.0026333446,"about_ca_system_score_gemma":0.00048689055,"threshold_uncertainty_score":0.9991602},"labels":[],"label_agreement":null},{"id":"W2007661673","doi":"10.2165/00019053-200119020-00001","title":"Direct-to-Consumer Promotion of Prescription Drugs","year":2001,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Pharmaceutical industry and healthcare","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":129,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Care Foundation","funders":"","keywords":"Medical prescription; Promotion (chess); Revenue; Direct-to-consumer advertising; Advertising; Newspaper; Prescription drug; Business; Government (linguistics); Marketing; Public health; Pharmacy; Food and drug administration; Medicine; Environmental health; Family medicine; Pharmacology; Political science","score_opus":0.5404877927635222,"score_gpt":0.5898891784635181,"score_spread":0.04940138569999586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2007661673","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000533013,0.97140735,0.00001909489,0.00038983073,0.004274195,0.0030358888,0.001211094,0.00019831519,0.018931238],"genre_scores_gemma":[0.0004638203,0.9926673,0.000110091,0.0013979153,0.0012979532,0.00058404723,0.00034704703,0.0001501048,0.002981705],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9944909,0.0013501811,0.0019367556,0.000988572,0.00018789813,0.0010456936],"domain_scores_gemma":[0.99648565,0.0006541485,0.00095557387,0.00052141206,0.00017575383,0.001207444],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.001651958,0.0008890464,0.0024920804,0.0005401715,0.00025300457,0.000039926035,0.0009013187,0.0017043167,0.004363644],"category_scores_gemma":[0.00010521559,0.0009004464,0.00075082824,0.0006124748,0.00022499988,0.0002768743,0.00028562258,0.0031656018,0.001706227],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015571139,0.0005445159,0.000047993082,0.011231566,0.0007466387,0.00002033494,0.00022810584,0.000065725224,0.00010940472,0.00031878418,0.01919771,0.9673335],"study_design_scores_gemma":[0.0008112232,0.00010192528,0.0000017424028,0.0013149963,0.0024473784,0.00004931949,0.000021434675,0.00023407722,0.0015328677,0.000055615033,0.99266297,0.00076643395],"about_ca_topic_score_codex":0.000034149478,"about_ca_topic_score_gemma":0.000004861315,"teacher_disagreement_score":0.97346526,"about_ca_system_score_codex":0.00056526164,"about_ca_system_score_gemma":0.0005807157,"threshold_uncertainty_score":0.9995917},"labels":[],"label_agreement":null},{"id":"W2007798395","doi":"10.1007/s40273-013-0071-4","title":"Constructing Indirect Utility Models: Some Observations on the Principles and Practice of Mapping to Obtain Health State Utilities","year":2013,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Institute for Health and Care Research","keywords":"Sophistication; Quality-adjusted life year; Health economics; Valuation (finance); Health administration; Computer science; Health care; Actuarial science; Reimbursement; Conflation; Risk analysis (engineering); Econometrics; Management science; Data mining; Economics; Medicine; Cost effectiveness; Accounting","score_opus":0.665575177705313,"score_gpt":0.45862933502476355,"score_spread":0.2069458426805495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2007798395","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.82310975,0.0011246514,0.0028488517,0.16332583,0.00042539075,0.0018977169,0.0007493562,0.000061857805,0.006456609],"genre_scores_gemma":[0.91708374,0.00076345843,0.017461069,0.06377692,0.00019276004,0.00034302258,0.000026802816,0.000050145685,0.0003021027],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9946598,0.00064025883,0.0035729476,0.00056888064,0.00007157471,0.00048653796],"domain_scores_gemma":[0.99088097,0.0055418676,0.0026865704,0.00050180353,0.00011771088,0.00027106196],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.016889917,0.00023864068,0.0008975071,0.00028362358,0.00037144386,0.00015523827,0.00032917043,0.00006116523,0.00021208037],"category_scores_gemma":[0.0039040032,0.00026532286,0.000086544904,0.00015024452,0.00015541456,0.0015121805,0.00014525605,0.000263691,0.000292875],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000050026447,0.00015208425,0.021211341,0.00059748744,0.0002949887,2.505326e-7,0.01765358,0.0038295025,0.000015834685,0.9375395,0.013409885,0.0052454784],"study_design_scores_gemma":[0.0020232175,0.00024266473,0.028812546,0.00032492843,0.000026226595,0.000024460387,0.06378547,0.4545915,0.0002598972,0.25920787,0.18934506,0.0013561348],"about_ca_topic_score_codex":0.0025494657,"about_ca_topic_score_gemma":0.000084246014,"teacher_disagreement_score":0.6783317,"about_ca_system_score_codex":0.00058612233,"about_ca_system_score_gemma":0.0002629167,"threshold_uncertainty_score":0.9999799},"labels":[],"label_agreement":null},{"id":"W2009528141","doi":"10.2165/00019053-200321070-00003","title":"Measuring the Outcomes and Pharmacoeconomic Consequences of Venous Thromboembolism Prophylaxis in Major Orthopaedic Surgery","year":2003,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":71,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Antithrombotic; Intensive care medicine; Health economics; Venous thromboembolism; Pharmacoeconomics; Orthopedic surgery; Vascular surgery; Quality of Life Research; Public health; Surgery; Thrombosis; Cardiac surgery; Internal medicine","score_opus":0.08033706881388836,"score_gpt":0.3475524195523622,"score_spread":0.26721535073847386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2009528141","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04821347,0.9465909,0.0000011886266,0.00028211155,0.0011562218,0.0026576559,0.000079458,0.000038196184,0.000980799],"genre_scores_gemma":[0.015551286,0.98270905,0.000049711074,0.00083732954,0.00017594258,0.00044299095,0.00002884905,0.00011890459,0.000085917265],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963196,0.00033184775,0.0018220702,0.00074351224,0.00017762704,0.0006053695],"domain_scores_gemma":[0.9972882,0.0008864638,0.0010198656,0.00054540863,0.000049657327,0.00021035431],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016149224,0.00072193675,0.0052391505,0.000634266,0.00011897274,0.00006222098,0.00034993372,0.00022816504,0.00029272848],"category_scores_gemma":[0.000076100056,0.0005244498,0.00093528617,0.00023848117,0.00045152436,0.00015710398,0.00018105104,0.0007131048,0.00006607706],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000035556594,0.0009280689,0.0025500632,0.029502058,0.0035942583,0.00011094499,0.00033261775,0.000014268141,0.00001550589,0.0005512815,0.002264073,0.9601013],"study_design_scores_gemma":[0.0016185164,0.00012296047,0.0014320259,0.0040427027,0.005530733,0.00023411888,0.00011937967,0.000014964967,0.000097756456,0.00014603994,0.9857904,0.00085044134],"about_ca_topic_score_codex":0.00025089105,"about_ca_topic_score_gemma":0.000033031818,"teacher_disagreement_score":0.9835263,"about_ca_system_score_codex":0.00033317946,"about_ca_system_score_gemma":0.0008669271,"threshold_uncertainty_score":0.9997207},"labels":[],"label_agreement":null},{"id":"W2010913334","doi":"10.2165/00019053-200826090-00004","title":"The NICE Cost-Effectiveness Threshold","year":2008,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":846,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Nice; Reimbursement; Excellence; Equity (law); Actuarial science; Cost effectiveness; Medicine; Health economics; Psychological intervention; Health care; Economics; Public economics; Risk analysis (engineering); Computer science; Economic growth; Political science; Nursing","score_opus":0.6331953834987152,"score_gpt":0.5585722418347147,"score_spread":0.07462314166400053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2010913334","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000025029167,0.9776002,0.00023346157,0.0018092913,0.004235297,0.004504046,0.0011086523,0.00014259666,0.010341413],"genre_scores_gemma":[0.000022096447,0.99050176,0.00012289318,0.0036751793,0.0016801871,0.0023983796,0.00020345059,0.00024597842,0.0011500554],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9879269,0.0010700367,0.008346378,0.0014436616,0.00010179829,0.0011112252],"domain_scores_gemma":[0.98379457,0.007724196,0.006476317,0.0014987609,0.00007306913,0.0004331011],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.016720785,0.00092371943,0.005122991,0.00043308001,0.0010532896,0.00034365657,0.0017640056,0.00053714844,0.0003817194],"category_scores_gemma":[0.0012524578,0.0009303567,0.001291533,0.00029699667,0.00028899199,0.0006226699,0.00029651102,0.0010851868,0.018892627],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005258461,0.0002835032,0.00031286437,0.023628362,0.0025838404,0.000018261215,0.00046088904,0.00027847977,5.7684144e-8,0.16789503,0.3889784,0.41550773],"study_design_scores_gemma":[0.00062175374,0.000023047094,0.000013835009,0.00097341393,0.00009200713,0.00008732459,0.000032792323,0.00069575605,3.713245e-7,0.0021476457,0.9943883,0.0009237776],"about_ca_topic_score_codex":0.00016341191,"about_ca_topic_score_gemma":0.00003466543,"teacher_disagreement_score":0.6054099,"about_ca_system_score_codex":0.0028262446,"about_ca_system_score_gemma":0.0009114861,"threshold_uncertainty_score":0.9993147},"labels":[],"label_agreement":null},{"id":"W2011129617","doi":"10.1007/s40273-015-0271-1","title":"Simulation and Matching-Based Approaches for Indirect Comparison of Treatments","year":2015,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":107,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"TransCanada (Canada)","funders":"","keywords":"Matching (statistics); Reliability (semiconductor); Confounding; Econometrics; Complement (music); Medicine; Treatment effect; Population; Statistics; Computer science; Mathematics; Environmental health","score_opus":0.7091266408074673,"score_gpt":0.5280108896812138,"score_spread":0.18111575112625355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2011129617","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.948142,0.0017204253,0.04316437,0.0034313924,0.00049861835,0.0012043859,0.0005778183,0.000048400412,0.0012126216],"genre_scores_gemma":[0.98996943,0.000009668747,0.008122283,0.0014037215,0.00015531798,0.00012452637,0.00010011865,0.000034308487,0.000080605074],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99692106,0.000102874226,0.002310497,0.00039121526,0.0000365122,0.00023785437],"domain_scores_gemma":[0.99656993,0.0012177944,0.0017559213,0.00021773475,0.000043188018,0.0001954361],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004822954,0.00017412951,0.00092539866,0.00022702765,0.00008461402,0.00004420657,0.00014075948,0.00009073995,0.000036635953],"category_scores_gemma":[0.0005316209,0.00023094084,0.0000928786,0.00005603337,0.000054168413,0.00033768432,0.000026687592,0.00007252203,0.00009772554],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021136319,0.0004374778,0.17425059,0.00055066095,0.00030845584,1.2313221e-7,0.005568161,0.79291874,0.0000075524404,0.019197712,0.0042923978,0.0022567848],"study_design_scores_gemma":[0.0029548318,0.000118550604,0.0021705995,0.000014883118,0.000030248993,3.2891063e-7,0.0006708933,0.97026855,0.00020402513,0.0121751325,0.01113786,0.00025412135],"about_ca_topic_score_codex":0.0001394079,"about_ca_topic_score_gemma":0.00002219163,"teacher_disagreement_score":0.17734979,"about_ca_system_score_codex":0.00036560305,"about_ca_system_score_gemma":0.000116942756,"threshold_uncertainty_score":0.94174945},"labels":[],"label_agreement":null},{"id":"W2011259658","doi":"10.2165/11539960-000000000-00000","title":"Modelling the Epidemiology of Infectious Diseases for Decision Analysis","year":2011,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"COVID-19 epidemiological studies","field":"Mathematics","cited_by":124,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec","funders":"Canada Research Chairs","keywords":"Infectious disease (medical specialty); Psychological intervention; Health economics; Epidemiology; Disease; Public health; Natural history; Medicine; Intensive care medicine; Risk analysis (engineering); Pathology","score_opus":0.563839307484957,"score_gpt":0.5446055309012252,"score_spread":0.01923377658373182,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2011259658","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000346922,0.7677248,0.23045477,0.000032442495,0.00024312545,0.0010054907,0.00037262007,0.0000507253,0.000081325954],"genre_scores_gemma":[0.00014302302,0.99249256,0.00614672,0.00027551898,0.00025456524,0.00056543946,0.000039023336,0.00005179936,0.000031368207],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99615604,0.0006141914,0.002148769,0.000618275,0.00004200365,0.00042069756],"domain_scores_gemma":[0.9166216,0.08068895,0.0018980796,0.0006027326,0.00008550662,0.00010307629],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0028234478,0.0004940859,0.004977247,0.00025618344,0.00016894781,0.0000055566256,0.0006928449,0.00025445622,0.00012983901],"category_scores_gemma":[0.0076344763,0.00029174052,0.002955858,0.00028513416,0.00018541349,0.00004825848,0.00032930638,0.00031151855,0.000021492242],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006763458,0.00024357082,0.001336259,0.015266541,0.0137913795,7.460694e-7,0.00010285138,0.041984826,8.836965e-9,0.060318895,0.0070321998,0.8598551],"study_design_scores_gemma":[0.00015120144,0.00003010327,0.0000025927916,0.00040374164,0.021329962,0.000001290164,0.0000037942582,0.043599084,7.929676e-8,0.22412534,0.71005607,0.0002967564],"about_ca_topic_score_codex":0.00011958906,"about_ca_topic_score_gemma":0.000016578027,"teacher_disagreement_score":0.85955834,"about_ca_system_score_codex":0.00022467598,"about_ca_system_score_gemma":0.000098170734,"threshold_uncertainty_score":0.99995345},"labels":[],"label_agreement":null},{"id":"W2011961341","doi":"10.2165/11591170-000000000-00000","title":"Economic and Humanistic Burden of External Genital Warts","year":2011,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Female Genital Mutilation/Cutting Issues","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Providence Health Care Research Institute; Providence Health Care; BC Centre for Disease Control; Centre for Advancing Health Outcomes; University of British Columbia","funders":"Canadian Institutes of Health Research; Canada Research Chairs","keywords":"Health economics; Quality of Life Research; Genital warts; Genital herpes; Health administration; Public health; Humanism; Medicine; Quality-adjusted life year; Cost effectiveness; Political science; Family medicine; Nursing; Virology; Risk analysis (engineering)","score_opus":0.078036945444984,"score_gpt":0.3824648000097444,"score_spread":0.3044278545647604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2011961341","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0051787253,0.9898324,0.000012630259,0.000012799688,0.00055137824,0.000743587,0.00014470186,0.00004684799,0.003476932],"genre_scores_gemma":[0.0047900467,0.9918692,0.0008811874,0.000028608327,0.001025623,0.000038215505,0.000079642436,0.00011004772,0.0011774324],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99824333,0.000042398195,0.0009433906,0.00045916202,0.000049598813,0.00026212723],"domain_scores_gemma":[0.99870646,0.00012857934,0.0005963122,0.0003388599,0.000031592503,0.0001981763],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00019260973,0.00041635244,0.0017152636,0.00024112726,0.000045788605,0.000027795972,0.00019435583,0.00018018624,0.0009570165],"category_scores_gemma":[0.000020325366,0.00041601728,0.00034875915,0.000027106486,0.00014981013,0.000107843,0.00015366307,0.00030383398,0.0005316131],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000071940805,0.00007216502,0.0001432748,0.024456415,0.0007384962,0.00004738673,0.00067897665,0.0000063330267,0.00004073113,0.0009423418,0.0009128954,0.971889],"study_design_scores_gemma":[0.00061270554,0.00010916254,0.000021020209,0.00227978,0.0028990454,0.0005400498,0.000018714965,0.00021800378,0.000086219996,0.0001280915,0.9926828,0.00040441303],"about_ca_topic_score_codex":0.00006989563,"about_ca_topic_score_gemma":0.0000025249471,"teacher_disagreement_score":0.9917699,"about_ca_system_score_codex":0.00022542922,"about_ca_system_score_gemma":0.00026585162,"threshold_uncertainty_score":0.99995625},"labels":[],"label_agreement":null},{"id":"W2012983297","doi":"10.2165/00019053-200220020-00004","title":"Health-Related Quality of Life in a UK-Based Population of Men with Erectile Dysfunction","year":2002,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Sexual function and dysfunction studies","field":"Medicine","cited_by":84,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Northwood","funders":"","keywords":"Medicine; Quality of life (healthcare); Erectile dysfunction; Marital status; Population; Gerontology; Demography; Public health; Physical therapy; Internal medicine; Environmental health","score_opus":0.08000241966388037,"score_gpt":0.3445059483275316,"score_spread":0.26450352866365123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2012983297","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99213266,0.00043618685,0.00022806993,0.0015531249,0.00024769356,0.00035329626,0.00001155424,0.000041563635,0.004995874],"genre_scores_gemma":[0.99825877,0.00009482564,0.0001428977,0.00094809645,0.0000419112,0.000017765307,0.000035559005,0.000013883175,0.00044628858],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986788,0.000078627665,0.0008117558,0.00019019426,0.00010993328,0.00013070836],"domain_scores_gemma":[0.99912363,0.000110517256,0.00046248446,0.000141009,0.000065428125,0.000096917734],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003754309,0.00011265653,0.00053526816,0.00020852819,0.000035426237,0.0000028958484,0.000026121812,0.00004695126,0.0010469826],"category_scores_gemma":[0.00007073466,0.00010247061,0.00005852143,0.00022124166,0.000040261726,0.00006849913,0.0000086114915,0.00012428784,0.000021272268],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029484702,0.0004933794,0.97762525,0.00025519327,0.00018717404,6.559096e-7,0.00046256994,0.0030968876,0.0010815134,0.00014589597,0.0069408366,0.006762195],"study_design_scores_gemma":[0.018230561,0.0009243952,0.9360779,0.000085390275,0.000089927096,0.000008061493,0.0006658715,0.03993989,0.0017576247,0.000040638977,0.0019333158,0.00024640423],"about_ca_topic_score_codex":0.0025515961,"about_ca_topic_score_gemma":0.0001724599,"teacher_disagreement_score":0.041547313,"about_ca_system_score_codex":0.00015111492,"about_ca_system_score_gemma":0.000055178985,"threshold_uncertainty_score":0.9998662},"labels":[],"label_agreement":null},{"id":"W2013022047","doi":"10.2165/11539840-000000000-00000","title":"To Fund or Not to Fund","year":2011,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Health economics; Quality of Life Research; Investment fund; Health administration; Business; Economics; Public health; Finance; Medicine; Nursing","score_opus":0.7491966194607523,"score_gpt":0.530442776108682,"score_spread":0.21875384335207038,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2013022047","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8829429,0.00030656817,0.008071296,0.037029568,0.0043071634,0.0024716903,0.0013106867,0.00026347788,0.06329665],"genre_scores_gemma":[0.80556977,0.00012220025,0.017879156,0.16688237,0.0012905807,0.00036063552,0.00002624192,0.00014684381,0.007722201],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99384737,0.0001473128,0.003991927,0.0010635308,0.00006848193,0.00088137825],"domain_scores_gemma":[0.99641263,0.00053235295,0.0011220236,0.0008289897,0.00006724621,0.0010367599],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.008151045,0.0003831491,0.0011932321,0.0006465439,0.00023334088,0.00013765447,0.00080216996,0.00014826779,0.010147826],"category_scores_gemma":[0.00083832565,0.0004928743,0.00018270111,0.00027454976,0.000047299927,0.00069646415,0.00022862393,0.0002362774,0.0578495],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001719799,0.00071194145,0.03446978,0.00059264386,0.00065575016,0.000021582433,0.02907951,0.001824774,0.00026642103,0.18312229,0.7431024,0.0044331616],"study_design_scores_gemma":[0.0016935181,0.00029863446,0.016705282,0.000039615985,0.000023534652,0.000015996045,0.0010229518,0.002797368,0.00094539643,0.0027379112,0.97247744,0.0012423706],"about_ca_topic_score_codex":0.0010354914,"about_ca_topic_score_gemma":0.00033935905,"teacher_disagreement_score":0.22937508,"about_ca_system_score_codex":0.0008885842,"about_ca_system_score_gemma":0.00020311389,"threshold_uncertainty_score":0.9997523},"labels":[],"label_agreement":null},{"id":"W2013340278","doi":"10.1007/s40273-014-0215-1","title":"Are We Lacking Economic Evaluations in Gastric Cancer Treatment?","year":2014,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto; Sunnybrook Hospital; Queen's University","funders":"","keywords":"Medicine; Cancer; MEDLINE; Health economics; Intensive care medicine; Nursing research; Health care; Breast cancer; Cost–benefit analysis; Quality of Life Research; Quality-adjusted life year; Cost effectiveness; Public health; Risk analysis (engineering); Pathology; Internal medicine","score_opus":0.07026263137955564,"score_gpt":0.39791730637204265,"score_spread":0.327654674992487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2013340278","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9825927,0.0005032724,0.000090157955,0.008483559,0.00069647364,0.00044168765,0.000021227039,0.000055696233,0.007115203],"genre_scores_gemma":[0.9921368,0.0036310775,0.00016301211,0.0015360566,0.00058107794,0.00012234626,0.000015405443,0.000025748304,0.0017884985],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991566,0.000026252563,0.00027194977,0.00025472703,0.000042386135,0.0002481073],"domain_scores_gemma":[0.9994743,0.00007825132,0.00017013034,0.00017061995,0.000012232399,0.00009447629],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00015562697,0.00015112216,0.00030154217,0.0002388859,0.00004152921,0.000027437438,0.00007666074,0.000029159144,0.0011632626],"category_scores_gemma":[0.0000119140295,0.00015066401,0.000094113646,0.000076527926,0.000019964846,0.00011734464,0.000028216296,0.00007864175,0.0001971343],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000090465845,0.0000881125,0.879512,0.00005179796,0.00014622835,0.0000053924696,0.00013910607,0.009481004,0.0001750872,0.00024969399,0.006685333,0.103375785],"study_design_scores_gemma":[0.01548647,0.00018296625,0.52904713,0.000120101286,0.0006993355,0.000014264002,0.0002635345,0.10392722,0.0017669196,0.00040981933,0.347611,0.00047126246],"about_ca_topic_score_codex":0.0002703383,"about_ca_topic_score_gemma":0.0008148909,"teacher_disagreement_score":0.35046488,"about_ca_system_score_codex":0.0010541098,"about_ca_system_score_gemma":0.00010751023,"threshold_uncertainty_score":0.9997498},"labels":[],"label_agreement":null},{"id":"W2013468959","doi":"10.1007/s40273-014-0209-z","title":"Estimating Productivity Costs in Health Economic Evaluations: A Review of Instruments and Psychometric Evidence","year":2014,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":57,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"Canadian Institutes of Health Research","keywords":"Health economics; Quality of Life Research; Public health; Health administration; Productivity; Public economics; Economics; Quality-adjusted life year; Environmental health; Actuarial science; Medicine; Cost effectiveness; Economic growth; Nursing; Operations management","score_opus":0.5176089015945724,"score_gpt":0.5871666219186712,"score_spread":0.06955772032409879,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2013468959","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00028157656,0.98652804,0.00034481817,0.00513845,0.0017143841,0.0049201455,0.0006178996,0.00004074784,0.0004139112],"genre_scores_gemma":[0.00014872341,0.9892824,0.004687853,0.004186976,0.00054030935,0.0008458549,0.00012403775,0.00011776245,0.0000660428],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9811008,0.001935399,0.014399928,0.0017112826,0.0001242404,0.0007283355],"domain_scores_gemma":[0.9800784,0.0029569343,0.0154029075,0.0011236368,0.000067731984,0.00037036306],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.05593401,0.00073051034,0.0077432413,0.001889499,0.00015238606,0.0000960784,0.0007806925,0.0002596149,0.00039501744],"category_scores_gemma":[0.008123342,0.0009438287,0.0004676229,0.00061215245,0.00014853595,0.0010530116,0.00022754542,0.00065202557,0.0010354045],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000062179956,0.00011126879,0.0011451215,0.38621274,0.00020687305,1.8829137e-7,0.00013087533,0.000090049274,1.8941961e-8,0.0035478945,0.0068374383,0.60171133],"study_design_scores_gemma":[0.0008091628,0.00010455175,0.00014155768,0.17101555,0.00012402315,0.000030189869,0.000016349206,0.008827693,1.933856e-7,0.0011514435,0.81686544,0.00091386965],"about_ca_topic_score_codex":0.0010368305,"about_ca_topic_score_gemma":0.000087756656,"teacher_disagreement_score":0.81002796,"about_ca_system_score_codex":0.0049755583,"about_ca_system_score_gemma":0.00159927,"threshold_uncertainty_score":0.9997424},"labels":[],"label_agreement":null},{"id":"W2014890077","doi":"10.2165/00019053-200725060-00008","title":"Being Led Down the Wrong Garden PATH: the Importance of Knowledge and Facts for the Crossroads","year":2007,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Healthcare Policy and Management","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Programs for Assessment of Technology in Health Research Institute","funders":"","keywords":"Health economics; Quality of Life Research; Health administration; Public health; Path (computing); Gerontology; Medicine; Nursing; Computer science","score_opus":0.056419758293608756,"score_gpt":0.3405667232654615,"score_spread":0.28414696497185277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2014890077","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8685713,0.016807191,0.009630636,0.04209824,0.0023099435,0.0028799819,0.00042224515,0.00005583277,0.057224646],"genre_scores_gemma":[0.993512,0.0019743973,0.00010028456,0.0032001196,0.0003923455,0.00007369007,0.000004486194,0.00002386986,0.0007188299],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99858284,0.000017965122,0.00070479227,0.0002715884,0.000018849123,0.00040399222],"domain_scores_gemma":[0.9983594,0.000772855,0.00039189574,0.00037451112,0.000029701623,0.00007164085],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030572165,0.00015215253,0.00026511843,0.000058587808,0.00042968927,0.00007735989,0.000446982,0.000050716608,0.000069388494],"category_scores_gemma":[0.000076888304,0.000100187055,0.00012497531,0.00007835271,0.00016689619,0.00011852663,0.00015035486,0.00017761835,0.000039704293],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014166706,0.00009370802,0.058059905,0.00024517308,0.0005046113,0.0000013335489,0.009008918,0.00025561528,0.00005626321,0.874048,0.014536103,0.043048736],"study_design_scores_gemma":[0.00094049633,0.00003647331,0.03541953,0.000008513022,0.0000422692,0.000002982182,0.00048245754,0.007788549,0.00058023294,0.016563445,0.93791795,0.00021713004],"about_ca_topic_score_codex":0.0003485158,"about_ca_topic_score_gemma":0.0004602034,"teacher_disagreement_score":0.9233818,"about_ca_system_score_codex":0.000088658446,"about_ca_system_score_gemma":0.000032125285,"threshold_uncertainty_score":0.40855095},"labels":[],"label_agreement":null},{"id":"W2015092746","doi":"10.2165/00019053-200119070-00001","title":"Highly Active Antiretroviral Therapy","year":2001,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"HIV/AIDS Research and Interventions","field":"Medicine","cited_by":144,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung","keywords":"Antiretroviral therapy; Medicine; Intensive care medicine; Indinavir; Health economics; Quality of Life Research; Human immunodeficiency virus (HIV); Public health; Immunology; Viral load; Nursing","score_opus":0.04197461033679368,"score_gpt":0.3861028409825094,"score_spread":0.34412823064571574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2015092746","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93219787,0.00028238102,0.00014667619,0.0014319267,0.00010280898,0.00024108784,0.00002832687,0.00004996633,0.065518945],"genre_scores_gemma":[0.9812594,0.0038140782,0.000121229714,0.0009817361,0.0003270013,0.000024376459,0.00003216133,0.000021849013,0.013418151],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992489,0.000027328935,0.0001853121,0.00017949696,0.000071608985,0.00028730722],"domain_scores_gemma":[0.9995089,0.000029643079,0.000042651274,0.00015842341,0.000045242563,0.00021509759],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00009270224,0.00010113607,0.00017801828,0.00011532797,0.00006089798,0.000023023045,0.00010482954,0.000026996984,0.0043399353],"category_scores_gemma":[0.000015165746,0.000092422146,0.00017107952,0.00008141651,0.000045779132,0.00020678618,0.00002771355,0.00020697227,0.0012916813],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014138079,0.00037392596,0.054520596,0.000018762923,0.00033608478,0.00007847858,0.00018370898,0.0000057771945,0.055388056,0.0004051397,0.080035366,0.8072403],"study_design_scores_gemma":[0.009275193,0.0039764126,0.019065248,0.00004344756,0.000064686974,0.00019183726,0.000345367,0.017207365,0.15004034,0.00032668983,0.7990903,0.00037308745],"about_ca_topic_score_codex":0.00054883317,"about_ca_topic_score_gemma":0.000031000778,"teacher_disagreement_score":0.8068672,"about_ca_system_score_codex":0.0002064922,"about_ca_system_score_gemma":0.00013708729,"threshold_uncertainty_score":0.9994859},"labels":[],"label_agreement":null},{"id":"W2015570846","doi":"10.2165/11594180-000000000-00000","title":"The General Publicʼs Willingness to Pay for Tax Increases to Support Unrestricted Access to an Alzheimerʼs Disease Medication","year":2012,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Joseph’s Healthcare Hamilton; Programs for Assessment of Technology in Health Research Institute; McMaster University","funders":"Canadian Institutes of Health Research","keywords":"Willingness to pay; Public health; Health economics; Medicine; Disease; Adverse effect; Telephone interview; Actuarial science; Environmental health; Economics; Internal medicine","score_opus":0.431547687135586,"score_gpt":0.5252481835544757,"score_spread":0.09370049641888967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2015570846","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.81283176,0.00048007473,0.019773306,0.15463246,0.003832205,0.0046776505,0.0031997452,0.00015765341,0.00041511885],"genre_scores_gemma":[0.8886718,0.00018716778,0.0048145093,0.09743041,0.0041240803,0.0031951428,0.0005638941,0.00014067408,0.0008723323],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99458086,0.00025584738,0.0031368833,0.0008279385,0.0001096302,0.0010888438],"domain_scores_gemma":[0.99384135,0.0011734559,0.0011783155,0.00090474647,0.00015666825,0.0027454707],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.011894699,0.0003493805,0.0007509799,0.0004233701,0.0006200177,0.0005822774,0.0012897378,0.00010144983,0.0005087489],"category_scores_gemma":[0.0034247136,0.0003532283,0.00015473657,0.00034009118,0.00004067099,0.0021285883,0.00025624808,0.00015819685,0.0025516432],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004470817,0.00054692227,0.17493314,0.00018333786,0.00031235212,7.0536817e-7,0.0017242375,0.004375762,0.000047023463,0.034215875,0.77576935,0.007444195],"study_design_scores_gemma":[0.00089887803,0.00012619712,0.08029599,0.000014868207,0.000049902756,0.00000250645,0.00017094686,0.008711717,0.00014471261,0.0016235741,0.90727633,0.00068436965],"about_ca_topic_score_codex":0.0008669349,"about_ca_topic_score_gemma":0.00022211022,"teacher_disagreement_score":0.13150696,"about_ca_system_score_codex":0.0007551374,"about_ca_system_score_gemma":0.00042584832,"threshold_uncertainty_score":0.999892},"labels":[],"label_agreement":null},{"id":"W2015874148","doi":"10.2165/00019053-200220120-00002","title":"Long Term Cost-of-Illness in Stroke","year":2002,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Acute Ischemic Stroke Management","field":"Medicine","cited_by":84,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Association of Radiation Oncology","funders":"","keywords":"Health economics; Stroke (engine); Medicine; Indirect costs; Total cost; Public health; Incidence (geometry); Cost estimate; Health care; Quality of Life Research; Cost–benefit analysis; Demography; Economics; Accounting","score_opus":0.0667940689031264,"score_gpt":0.3815905539314578,"score_spread":0.3147964850283314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2015874148","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00033770993,0.97534555,0.000039081857,0.000046212754,0.00066202774,0.0021626311,0.00016197625,0.0000387375,0.021206073],"genre_scores_gemma":[0.00016883784,0.99468094,0.00016579925,0.00020260189,0.0003613525,0.00025224153,0.00018693402,0.00010384199,0.00387744],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977902,0.000047012694,0.001138496,0.00050323317,0.000121260295,0.0003997601],"domain_scores_gemma":[0.9985892,0.00012510153,0.0005806173,0.0005211808,0.000025655541,0.00015820358],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00024495946,0.0004726679,0.0023082343,0.0004927792,0.000017854962,0.000015450576,0.0003782453,0.00021524391,0.0011116904],"category_scores_gemma":[0.000021348305,0.0004588981,0.000528185,0.00014864864,0.00007033963,0.00008003817,0.00023422002,0.00060661946,0.00031673413],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000015637608,0.0001269347,0.0003745456,0.016499843,0.00047222644,0.000101809106,0.000041446827,0.0000023885812,0.0000024583182,0.000011031614,0.008963588,0.9733881],"study_design_scores_gemma":[0.0013293318,0.000021824975,0.000024740657,0.0039782478,0.0017422208,0.00007087548,0.000011306389,0.00008821814,0.00006447771,3.6536255e-7,0.992308,0.00036037638],"about_ca_topic_score_codex":0.000011424545,"about_ca_topic_score_gemma":0.0000023659757,"teacher_disagreement_score":0.98334444,"about_ca_system_score_codex":0.00064183364,"about_ca_system_score_gemma":0.00014215185,"threshold_uncertainty_score":0.99980146},"labels":[],"label_agreement":null},{"id":"W2016319444","doi":"10.1007/s40273-013-0112-z","title":"Treating Idiopathic Pulmonary Fibrosis with the Addition of Co-Trimoxazole: An Economic Evaluation Alongside a Randomised Controlled Trial","year":2013,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"National Institute for Health and Care Research","keywords":"Medicine; Quality-adjusted life year; Pirfenidone; Placebo; Cost effectiveness; Clinical endpoint; Health economics; Idiopathic pulmonary fibrosis; Economic evaluation; Quality of life (healthcare); Randomized controlled trial; Incremental cost-effectiveness ratio; Internal medicine; Physical therapy; Public health; Intensive care medicine; Lung; Nursing; Alternative medicine; Pathology","score_opus":0.01546096084820266,"score_gpt":0.3043373580715766,"score_spread":0.28887639722337394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2016319444","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9858253,0.0004256022,0.000054172455,0.0007596282,0.00027652478,0.0076157846,0.00011668145,0.000053123877,0.004873187],"genre_scores_gemma":[0.9956185,0.00009031573,0.00008748546,0.00041449218,0.0010325075,0.0022985833,0.00031981993,0.00004913203,0.000089153036],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99794286,0.00034067724,0.0008009758,0.00039444852,0.00021646863,0.0003045661],"domain_scores_gemma":[0.9983191,0.00026660686,0.00062346127,0.0003695036,0.00020003617,0.00022128827],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010787586,0.00029318826,0.000815996,0.00012796812,0.00017928207,0.00007131939,0.0001775755,0.00009644629,0.0018700365],"category_scores_gemma":[0.00005186533,0.00020191731,0.0003667845,0.000057660385,0.0001538528,0.0005794605,0.000023611965,0.00021355234,0.00009911139],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9651297,0.0005057545,0.00017355329,0.00011798447,0.00048897805,0.000010663397,0.00024440596,0.0012047596,0.01921393,0.00008390114,0.0017642917,0.011062104],"study_design_scores_gemma":[0.7196308,0.004201433,0.00072887284,0.00017700372,0.0022436972,0.000110563196,0.00056168635,0.2655914,0.0059633413,0.0001178181,0.00029666585,0.00037672237],"about_ca_topic_score_codex":0.00031908034,"about_ca_topic_score_gemma":0.000009316363,"teacher_disagreement_score":0.26438665,"about_ca_system_score_codex":0.0002984899,"about_ca_system_score_gemma":0.0005044187,"threshold_uncertainty_score":0.9990424},"labels":[],"label_agreement":null},{"id":"W2016354863","doi":"10.2165/00019053-200321070-00005","title":"Economic Evaluation of Orlistat in Overweight and Obese Patients with Type 2 Diabetes Mellitus","year":2003,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Pharmacology and Obesity Treatment","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Orlistat; Medicine; Overweight; Diabetes mellitus; Population; Internal medicine; Type 2 diabetes; Metformin; Placebo; Obesity; Type 2 Diabetes Mellitus; Weight loss; Pharmacoeconomics; Intensive care medicine; Endocrinology; Environmental health","score_opus":0.01564541919626944,"score_gpt":0.3081739561632776,"score_spread":0.29252853696700815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2016354863","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99603903,0.0014423662,5.1025074e-7,0.000055478256,0.00017288413,0.00044141823,0.000015275828,0.000007148116,0.0018259133],"genre_scores_gemma":[0.9988745,0.0006180332,0.00014733612,0.0002561845,0.00001663467,0.000018653564,0.000032355463,0.000011648929,0.000024679885],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993255,0.00007376593,0.00020271726,0.00018635878,0.00005896027,0.00015268807],"domain_scores_gemma":[0.99961734,0.00005702916,0.00008820404,0.0000949442,0.000060344348,0.00008212205],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033423127,0.000111263944,0.00023463975,0.00009034549,0.000021804792,0.0000046682126,0.000029475252,0.000038659346,0.00053960603],"category_scores_gemma":[0.000015455435,0.00009851083,0.000020817468,0.000037268383,0.000056223926,0.0001150347,0.00001108276,0.000079664904,0.000027003714],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003069658,0.00044667293,0.99328417,0.000047821417,0.00017694564,0.000001808945,0.0001477638,0.0003747092,0.0005245284,0.00018805996,0.00021679628,0.0042837574],"study_design_scores_gemma":[0.028068842,0.0006731688,0.87809414,0.000058830985,0.0011869873,0.000004579492,0.00004719305,0.0075071002,0.077862166,0.0010474196,0.0051288414,0.00032075864],"about_ca_topic_score_codex":0.000011282824,"about_ca_topic_score_gemma":0.000030232395,"teacher_disagreement_score":0.11519006,"about_ca_system_score_codex":0.0002766551,"about_ca_system_score_gemma":0.00017532206,"threshold_uncertainty_score":0.5908308},"labels":[],"label_agreement":null},{"id":"W2017172077","doi":"10.2165/11589260-000000000-00000","title":"Cost Effectiveness of Tenofovir Disoproxil Fumarate for the Treatment of Chronic Hepatitis B from a Canadian Public Payer Perspective","year":2011,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Hepatitis B Virus Studies","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; University Health Network","funders":"Gilead Sciences","keywords":"Lamivudine; Medicine; Tenofovir; Chronic hepatitis; Public health; Hepatitis B virus; Entecavir; Hepatitis B; Cirrhosis; Internal medicine; Family medicine; Virology; Human immunodeficiency virus (HIV); Virus; Nursing","score_opus":0.08835373679432976,"score_gpt":0.3395906074555045,"score_spread":0.2512368706611747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2017172077","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891307,0.0037655989,0.00026748903,0.0005717969,0.0004065022,0.0026148255,0.0015874754,0.000018264334,0.0016373993],"genre_scores_gemma":[0.99309033,0.005648036,0.00013593824,0.00011553303,0.00016331233,0.0007174926,0.000041218056,0.00003535208,0.00005275706],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99900186,0.00006733362,0.00029582734,0.0002656486,0.00005486863,0.00031447655],"domain_scores_gemma":[0.99872667,0.0004430616,0.00015674144,0.0002751132,0.00022648888,0.00017191702],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018977934,0.00019185971,0.00050653715,0.00010546572,0.00011684033,0.000007907833,0.00012324638,0.000049620146,0.0003552412],"category_scores_gemma":[0.000047614114,0.00014098563,0.00018561466,0.00007209109,0.00019034704,0.00009329185,0.000020571237,0.00006287805,0.000023040518],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013071416,0.0012503429,0.920269,0.00026826773,0.0050446168,0.000017925373,0.01019793,0.000027422877,0.0052784025,0.0038299568,0.0005817349,0.05192727],"study_design_scores_gemma":[0.011511556,0.0030624024,0.76300704,0.00012385554,0.0016051898,0.000007796466,0.00058780896,0.0065088477,0.17083237,0.0012402155,0.041034613,0.00047828475],"about_ca_topic_score_codex":0.6266933,"about_ca_topic_score_gemma":0.5339726,"teacher_disagreement_score":0.16555396,"about_ca_system_score_codex":0.0019262478,"about_ca_system_score_gemma":0.00071756804,"threshold_uncertainty_score":0.5749227},"labels":[],"label_agreement":null},{"id":"W2017564455","doi":"10.2165/00019053-200119080-00006","title":"Incremental Cost Analysis of Ambulatory Clinic and Home-Based Intravenous Therapy for Patients with Multiple Myeloma","year":2001,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Regional Laboratory Medicine Program; University of Toronto","funders":"","keywords":"Medicine; Ambulatory; Multiple myeloma; Cancer; Physical therapy; Emergency medicine; Surgery; Internal medicine","score_opus":0.030471698388158434,"score_gpt":0.33638224249804316,"score_spread":0.3059105441098847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2017564455","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99767464,0.00015006741,0.00016363256,0.00007213474,0.00003973284,0.0014750719,0.00032733192,0.000019032183,0.00007833735],"genre_scores_gemma":[0.9975414,0.0004017022,0.00097526464,0.00037260947,0.000035900222,0.00012032113,0.00049596187,0.000027606824,0.000029176625],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989963,0.000028138656,0.00030832703,0.00028013837,0.00011724532,0.0002698486],"domain_scores_gemma":[0.9990896,0.00024018495,0.00014568759,0.00018972831,0.000108949454,0.0002258808],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015231685,0.00016294322,0.00045256322,0.00028998914,0.00006737346,0.0000141442415,0.00006809978,0.0000360819,0.00027772528],"category_scores_gemma":[0.000019905958,0.0001334966,0.00013004406,0.00016533799,0.00009790274,0.000073294934,0.000018237888,0.000079679354,0.0000069650587],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008698903,0.0010652988,0.93457955,0.000031426112,0.0026747044,0.000007543965,0.000050856714,0.00006018979,0.0005468923,0.000001430283,0.0000637857,0.052219402],"study_design_scores_gemma":[0.031451177,0.0012393423,0.9386516,0.000010952621,0.0007665842,0.0000015879527,0.000030370396,0.022330008,0.004012627,0.0000029993787,0.0013593654,0.00014335169],"about_ca_topic_score_codex":0.00007824816,"about_ca_topic_score_gemma":0.000050626986,"teacher_disagreement_score":0.05207605,"about_ca_system_score_codex":0.00012309913,"about_ca_system_score_gemma":0.000096242424,"threshold_uncertainty_score":0.54438335},"labels":[],"label_agreement":null},{"id":"W2018229747","doi":"10.1007/s40273-013-0046-5","title":"The Authors’ Reply to van Baal et al.: “Pharmacoeconomic Guidelines Should Prescribe Inclusion of Indirect Medical Costs! A Response to Grima et al.”","year":2013,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Humber River Regional Hospital; St. Michael's Hospital","funders":"","keywords":"Health economics; Quality of Life Research; Medical costs; Medicine; Pharmacoeconomics; Health administration; Inclusion (mineral); Indirect costs; Intensive care medicine; Public health; Economics; Psychology; Health care; Accounting; Nursing","score_opus":0.3467508769534195,"score_gpt":0.5215144405189353,"score_spread":0.17476356356551576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018229747","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.38600853,0.00089520443,0.001112914,0.60556215,0.001875743,0.0021319033,0.0005170316,0.00010921214,0.00178735],"genre_scores_gemma":[0.18635671,0.001384447,0.004128524,0.8055794,0.00033603745,0.0008779039,0.000056036784,0.00015919335,0.0011217418],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98685855,0.001820384,0.008349994,0.0015203381,0.00032501656,0.0011256929],"domain_scores_gemma":[0.9889452,0.005129724,0.0027532524,0.0013560388,0.00034818612,0.001467611],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":["metaresearch","insufficient_payload"],"category_scores_codex":[0.06616918,0.00062496954,0.0017517502,0.0008122725,0.00071585615,0.000342404,0.0019077614,0.0002131024,0.0030358185],"category_scores_gemma":[0.012161804,0.000674758,0.00037619605,0.0003418558,0.00016651159,0.0011757805,0.0018121415,0.00079028314,0.006895536],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00055142376,0.0001329621,0.0019972327,0.000044486893,0.00020120606,0.000002935317,0.0022352224,0.0015388677,0.00078069046,0.0046158456,0.98445493,0.0034441839],"study_design_scores_gemma":[0.0017469823,0.00017917782,0.0024410905,0.00010280215,0.000016793727,0.000021929727,0.00038566263,0.0207137,0.0006973883,0.002124244,0.97084814,0.00072206085],"about_ca_topic_score_codex":0.003412117,"about_ca_topic_score_gemma":0.00037557035,"teacher_disagreement_score":0.20001727,"about_ca_system_score_codex":0.0016268314,"about_ca_system_score_gemma":0.0010021747,"threshold_uncertainty_score":0.99957037},"labels":[],"label_agreement":null},{"id":"W2018803491","doi":"10.1007/s40273-014-0179-1","title":"Network vs. Pairwise Meta-Analyses: A Case Study of the Impact of an Evidence-Synthesis Paradigm on Value of Information Outcomes","year":2014,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Meta-analysis and systematic reviews","field":"Decision Sciences","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Coastal Health Research Institute; Vancouver Coastal Health; Centre for Advancing Health Outcomes; St. Paul's Hospital; McMaster University; University of British Columbia","funders":"","keywords":"Placebo; Pharmacotherapy; Medicine; Meta-analysis; Randomized controlled trial; Pairwise comparison; Quality-adjusted life year; Random effects model; Bayesian probability; Internal medicine; Statistics; Cost effectiveness; Mathematics","score_opus":0.7468746274918396,"score_gpt":0.5769829321063179,"score_spread":0.16989169538552173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018803491","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972745,0.00012236771,0.00086482597,0.0001656164,0.0001427925,0.0010345771,0.000044145636,0.0000026791456,0.00034846514],"genre_scores_gemma":[0.999148,0.0000125854385,0.00046700367,0.00022410964,0.000035186447,0.00005991016,9.2318396e-7,0.000008781746,0.000043480213],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.97704124,0.011276468,0.009579042,0.0004290602,0.0014678184,0.00020636902],"domain_scores_gemma":[0.9725242,0.012034104,0.011361438,0.0035034795,0.0004406327,0.00013612205],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.06974418,0.00033608673,0.005129386,0.000336798,0.00009820554,0.00017408982,0.0018757184,0.00004973069,0.0022977188],"category_scores_gemma":[0.012574887,0.00013206307,0.004221613,0.00070808537,0.00006960397,0.00090206333,0.0001427703,0.00011948491,0.000094761446],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013093014,0.00069251884,0.15328452,0.000101277525,0.015881382,0.0000030472265,0.00402665,0.8040938,0.000040217732,0.0006333254,0.0069763553,0.014136002],"study_design_scores_gemma":[0.0014619578,0.0011937106,0.0758592,0.000059653798,0.046988104,0.00006226484,0.0047305687,0.86153466,0.0014261707,0.0047423956,0.0013245824,0.0006167166],"about_ca_topic_score_codex":0.0011053944,"about_ca_topic_score_gemma":0.00008523342,"teacher_disagreement_score":0.07742532,"about_ca_system_score_codex":0.000052446427,"about_ca_system_score_gemma":0.0000928428,"threshold_uncertainty_score":0.9986143},"labels":[],"label_agreement":null},{"id":"W2018866297","doi":"10.2165/00019053-200422050-00002","title":"Longitudinal versus Cross-Sectional Methodology for Estimating the Economic Burden of Breast Cancer","year":2004,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Breast cancer; Cross-sectional study; Longitudinal study; Cross-sectional data; Reimbursement; Medicine; Health economics; Health administration; Health care; Quarter (Canadian coin); Medical Expenditure Panel Survey; Public health; Gerontology; Actuarial science; Cancer; Econometrics; Economics; Economic growth; Health insurance; Geography; Nursing","score_opus":0.1505092119136746,"score_gpt":0.39837215346886634,"score_spread":0.24786294155519173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018866297","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9549972,0.0012427913,0.026829457,0.0021381697,0.007904089,0.0005397902,0.0031720435,0.000042224157,0.0031342432],"genre_scores_gemma":[0.98389137,0.0002792281,0.012607317,0.00030413552,0.0025033616,0.00018279169,0.000022916138,0.000056694505,0.0001521874],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.997814,0.0000142045465,0.0011267184,0.0005517238,0.000019464487,0.00047391118],"domain_scores_gemma":[0.99818325,0.0003676682,0.00095965515,0.000314042,0.00006165467,0.00011371361],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001129268,0.00025336928,0.0006052981,0.00014258182,0.0002430471,0.00010505324,0.0005376955,0.0001389255,0.00089190516],"category_scores_gemma":[0.00008819244,0.00027066702,0.0003309609,0.000056810073,0.00027737365,0.0005204519,0.000094480034,0.00020515612,0.00020781759],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011372733,0.00004284663,0.08355078,0.00007544778,0.0005324806,6.8501305e-7,0.00042046176,0.6397876,0.00013526969,0.2699617,0.0006773306,0.0036781086],"study_design_scores_gemma":[0.03238786,0.0005508419,0.3891708,0.000059234782,0.00022276152,0.00012490612,0.00020073012,0.1939857,0.004532717,0.3205051,0.055661447,0.0025978894],"about_ca_topic_score_codex":0.0034575383,"about_ca_topic_score_gemma":0.00014870446,"teacher_disagreement_score":0.44580188,"about_ca_system_score_codex":0.0010724082,"about_ca_system_score_gemma":0.00028541178,"threshold_uncertainty_score":0.99997455},"labels":[],"label_agreement":null},{"id":"W2019655913","doi":"10.2165/00019053-200624060-00006","title":"Dalteparin versus Warfarin for the Prevention of Recurrent Venous Thromboembolic Events in Cancer Patients","year":2006,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Joseph's Hospital; Ottawa Regional Cancer Foundation; Augmentium Pharma Consulting (Canada)","funders":"","keywords":"Medicine; Warfarin; Low molecular weight heparin; Population; Anticoagulant; Emergency medicine; Internal medicine; Intensive care medicine; Heparin; Surgery; Environmental health","score_opus":0.04274829190689254,"score_gpt":0.3629977748597806,"score_spread":0.320249482952888,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2019655913","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945199,0.0007609446,0.000058544792,0.00045711384,0.0013968943,0.0018339821,0.000043846067,0.000016715614,0.00091209426],"genre_scores_gemma":[0.9973005,0.001510148,0.00009991922,0.00017372901,0.00023372255,0.00048782237,0.00008154173,0.000027356786,0.00008527674],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99890393,0.000024045043,0.0004590841,0.00024015906,0.00010187195,0.0002709016],"domain_scores_gemma":[0.9994027,0.00008291121,0.00022182417,0.00019199474,0.00005780174,0.00004277548],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023195923,0.00014803308,0.00041000184,0.0000922909,0.00006445613,0.0000063547395,0.00014582237,0.000041559186,0.000096955664],"category_scores_gemma":[0.000014928141,0.00012606427,0.00014303147,0.000085322485,0.000030382635,0.0000786129,0.00006549578,0.000101257814,0.000010530215],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0072236634,0.047603272,0.34767428,0.002434787,0.0025108184,0.0000046136665,0.0019328342,0.02248356,0.0033148138,0.012646333,0.06544437,0.48672664],"study_design_scores_gemma":[0.017432934,0.0012526423,0.9290043,0.00015632673,0.000943517,5.0805716e-7,0.000079694764,0.005902569,0.0058454974,0.0011311776,0.03794364,0.00030717836],"about_ca_topic_score_codex":0.0013050968,"about_ca_topic_score_gemma":0.00076612015,"teacher_disagreement_score":0.58133,"about_ca_system_score_codex":0.00028075778,"about_ca_system_score_gemma":0.00008005135,"threshold_uncertainty_score":0.5140752},"labels":[],"label_agreement":null},{"id":"W2019716535","doi":"10.1007/s40273-014-0235-x","title":"Value-Based Reimbursement Decisions for Orphan Drugs: A Scoping Review and Decision Framework","year":2014,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":98,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research; National Institute for Health and Care Research; Genome Canada","keywords":"Reimbursement; Orphan drug; Health economics; Transparency (behavior); Value (mathematics); Health care; Actuarial science; Medicine; Management science; Business; Economics; Computer science","score_opus":0.45359984577742674,"score_gpt":0.5688167359387032,"score_spread":0.11521689016127645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2019716535","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000007094019,0.90547764,0.07878783,0.003569537,0.0017035694,0.008718697,0.001305719,0.00009611787,0.00033377254],"genre_scores_gemma":[0.000002605815,0.91100776,0.051819645,0.032835975,0.0009437084,0.0027719275,0.00031327855,0.00023337489,0.00007169805],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9853832,0.0005196336,0.011120499,0.0019458291,0.000118077995,0.0009127553],"domain_scores_gemma":[0.9731846,0.017046629,0.007601336,0.001426009,0.00010512897,0.0006362992],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.025968192,0.0009669598,0.008273277,0.00078681036,0.00047115312,0.0002836534,0.0009799171,0.0005980604,0.00071340386],"category_scores_gemma":[0.0075561623,0.001157403,0.0011751177,0.00027226834,0.00011741877,0.00039628163,0.00022986505,0.0006350193,0.0020935868],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000025516443,0.00015797208,0.000018510776,0.33105585,0.00059701985,9.592982e-7,0.00012801513,0.00015677813,1.2592426e-8,0.046610437,0.07023799,0.5510109],"study_design_scores_gemma":[0.0008068774,0.000058205304,6.2013055e-7,0.18809432,0.00065685075,0.0000063194598,0.000012249024,0.002115772,1.456046e-7,0.012962479,0.79436135,0.0009247818],"about_ca_topic_score_codex":0.00004322643,"about_ca_topic_score_gemma":0.0000117713935,"teacher_disagreement_score":0.7241234,"about_ca_system_score_codex":0.0013333767,"about_ca_system_score_gemma":0.0009808372,"threshold_uncertainty_score":0.9990876},"labels":[],"label_agreement":null},{"id":"W2021642387","doi":"10.2165/00019053-200624110-00004","title":"Utility Measurement in Healthcare","year":2006,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":55,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Health economics; Expected utility hypothesis; Certainty; Axiom; Health care; Health administration; Property (philosophy); Economics; Field (mathematics); Scale (ratio); Decision theory; Management science; Actuarial science; Positive economics; Public economics; Microeconomics; Mathematical economics; Mathematics","score_opus":0.7363133382407497,"score_gpt":0.5558515791593466,"score_spread":0.18046175908140316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2021642387","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000024184992,0.98157686,0.0001886146,0.0060057826,0.0020434922,0.0026447906,0.0016944705,0.00010777863,0.0057140244],"genre_scores_gemma":[0.00020429121,0.9913618,0.0004317265,0.0055201887,0.00097584305,0.0006129757,0.00033597188,0.00017806194,0.00037915277],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98322976,0.0010167081,0.0128561845,0.0016673037,0.00014771213,0.0010823562],"domain_scores_gemma":[0.99154,0.00075038936,0.006131128,0.0011077011,0.00008349527,0.0003872738],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.026309188,0.0008514975,0.006356411,0.0010821684,0.00016398141,0.00015237388,0.00093006913,0.0006103476,0.00064281304],"category_scores_gemma":[0.00084956334,0.0011524918,0.000860151,0.00035347967,0.000089588924,0.0005062242,0.00016812226,0.0010140466,0.007396141],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000031211956,0.00096755585,0.006034401,0.1346538,0.0008474036,0.0000237654,0.00042971416,0.000113090486,4.1455834e-8,0.099593446,0.3197761,0.43752944],"study_design_scores_gemma":[0.00064037665,0.000017103224,0.00012194156,0.0017320168,0.000054906795,0.000009416557,0.000017907274,0.00056451734,1.34444e-7,0.0038715482,0.9920723,0.000897861],"about_ca_topic_score_codex":0.0044785007,"about_ca_topic_score_gemma":0.0016191632,"teacher_disagreement_score":0.67229617,"about_ca_system_score_codex":0.0048142276,"about_ca_system_score_gemma":0.0012604429,"threshold_uncertainty_score":0.9990925},"labels":[],"label_agreement":null},{"id":"W2021743374","doi":"10.2165/00019053-200321120-00003","title":"Defining Monetary Values for Quality of Life Improvements","year":2003,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Willingness to pay; Respondent; Health economics; Quality of life (healthcare); Psychological intervention; Quality of Life Research; Medicine; Intervention (counseling); Variance (accounting); Sample (material); Health administration; Actuarial science; Public health; Environmental health; Demography; Economics; Nursing","score_opus":0.37360829233665666,"score_gpt":0.48650149270084375,"score_spread":0.1128932003641871,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2021743374","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9565212,0.0069475374,0.01362572,0.0042208997,0.0022858696,0.001796608,0.0019194671,0.000090578935,0.012592099],"genre_scores_gemma":[0.96717465,0.00032038463,0.015650382,0.0156994,0.0002542813,0.00027542855,0.00009481995,0.000078034296,0.00045260097],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99275446,0.00034846755,0.0056716925,0.0006473267,0.000058849422,0.0005191779],"domain_scores_gemma":[0.99374074,0.001866692,0.0035210254,0.0005008688,0.00008254097,0.00028811605],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.021665052,0.000264366,0.0013423483,0.00025242884,0.00017815149,0.000049398826,0.00033948437,0.0001287939,0.00062803685],"category_scores_gemma":[0.004287193,0.00037780352,0.0003034803,0.00009333542,0.00008103984,0.0005491957,0.000044213146,0.00014605008,0.00064315397],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017812617,0.00037948703,0.11251673,0.0016139492,0.0006049776,1.7242107e-7,0.0013441389,0.0022922868,0.00024270728,0.84182274,0.037938852,0.0010657994],"study_design_scores_gemma":[0.028001381,0.00089406595,0.027028982,0.0001568599,0.0001713158,0.0000066461994,0.0043882616,0.078459725,0.00933701,0.400795,0.44639048,0.0043702642],"about_ca_topic_score_codex":0.00043625053,"about_ca_topic_score_gemma":0.000020727022,"teacher_disagreement_score":0.44102776,"about_ca_system_score_codex":0.00038241874,"about_ca_system_score_gemma":0.00027448748,"threshold_uncertainty_score":0.9998674},"labels":[],"label_agreement":null},{"id":"W2022259512","doi":"10.2165/00019053-200422050-00001","title":"Economic Impact of Respiratory Syncytial Virus-Related Illness in the US","year":2004,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Respiratory viral infections research","field":"Medicine","cited_by":210,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"","keywords":"Health economics; Quality of Life Research; Public health; Virus; Health administration; Respiratory system; Medicine; Virology; Environmental health; Internal medicine; Nursing","score_opus":0.03891501728550519,"score_gpt":0.4134410688946323,"score_spread":0.3745260516091271,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2022259512","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99275565,0.00021769664,0.000009157576,0.00017369856,0.00023192714,0.00059366674,0.000038785416,0.00002813742,0.0059512863],"genre_scores_gemma":[0.998943,0.00011060356,0.000014169152,0.0006487233,0.00017397487,0.000047523507,0.0000074842874,0.000031740696,0.000022817032],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.998578,0.00012381213,0.00060957513,0.00026466028,0.00009772302,0.00032621622],"domain_scores_gemma":[0.9992024,0.00008801364,0.00014718159,0.00040393064,0.0000386682,0.000119810196],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007900611,0.00017951486,0.00036008866,0.0003541573,0.00007350923,0.000028894805,0.00026461604,0.00010218245,0.00047504512],"category_scores_gemma":[0.000043293712,0.00013859732,0.00024231187,0.00019186026,0.00018505356,0.00024369672,0.00005286719,0.00047747826,0.00033762373],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027266277,0.001495985,0.32074133,0.00021567597,0.0011907008,0.00030032772,0.002472832,0.34646344,0.29776573,0.004660664,0.0043226555,0.017644033],"study_design_scores_gemma":[0.036851563,0.0035610604,0.56848663,0.00016209399,0.00034768382,0.0004117474,0.0003537321,0.007236941,0.3447518,0.0025162227,0.033983134,0.0013373785],"about_ca_topic_score_codex":0.0017330121,"about_ca_topic_score_gemma":0.00024887116,"teacher_disagreement_score":0.3392265,"about_ca_system_score_codex":0.0015712711,"about_ca_system_score_gemma":0.0010385027,"threshold_uncertainty_score":0.56518346},"labels":[],"label_agreement":null},{"id":"W2023872131","doi":"10.2165/00019053-200220050-00005","title":"The Practice of Splitting Tablets","year":2002,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Pharmaceutical studies and practices","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Pharmacy; Medical prescription; Medicine; Product (mathematics); Business; Risk analysis (engineering); Operations management; Family medicine; Pharmacology; Mathematics; Engineering","score_opus":0.06657594678489463,"score_gpt":0.3978907093335888,"score_spread":0.33131476254869413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2023872131","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.20366368,0.026868565,0.000072561634,0.10786602,0.0011268011,0.0006225754,0.000015419766,0.000075004195,0.65968937],"genre_scores_gemma":[0.9685289,0.02211095,0.0007851487,0.007021994,0.00034239888,0.000011669337,9.2294624e-7,0.000015366584,0.0011826329],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992691,0.0000440294,0.00027698578,0.00012275,0.00007770251,0.00020942761],"domain_scores_gemma":[0.9980623,0.0014347245,0.0001961941,0.00014083134,0.00006946189,0.000096496646],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005361016,0.0000819327,0.00015947717,0.000014281818,0.00017990489,0.000023272692,0.000094508294,0.00002176995,0.0005990291],"category_scores_gemma":[0.00048078317,0.000057610185,0.00006391323,0.00005987062,0.00007910038,0.00020195192,0.00006304125,0.00021416994,0.00017587392],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017217428,0.0010537283,0.0062052696,0.00030752187,0.0020768049,0.000076046585,0.0013912388,0.00013174253,0.023228887,0.009386859,0.15923564,0.7951845],"study_design_scores_gemma":[0.00080342474,0.00004285502,0.00010237192,0.00000690037,0.00020846576,0.00005507629,0.00021270577,0.0094826855,0.0062081227,0.000042612523,0.9827723,0.000062509134],"about_ca_topic_score_codex":0.000018261015,"about_ca_topic_score_gemma":6.425747e-7,"teacher_disagreement_score":0.82353663,"about_ca_system_score_codex":0.000037057576,"about_ca_system_score_gemma":0.000010625909,"threshold_uncertainty_score":0.6558949},"labels":[],"label_agreement":null},{"id":"W2024683988","doi":"10.2165/00019053-200017030-00005","title":"Assessing Health Utilities in Schizophrenia","year":2000,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Western University","funders":"Ministère de l’Éducation, Gouvernement de l’Ontario; Bộ Giáo dục và Ðào tạo","keywords":"Health economics; Schizophrenia (object-oriented programming); Quality of life (healthcare); Quality-adjusted life year; Preference; Health care; Health administration; Rating scale; Medicine; Willingness to pay; Psychiatry; Mental illness; Health Utilities Index; Quality of Life Research; Time-trade-off; Public health; Economic evaluation; Scale (ratio); Psychology; Mental health; Cost effectiveness; Nursing; Health related quality of life; Economics; Risk analysis (engineering); Developmental psychology; Disease","score_opus":0.4158554268910543,"score_gpt":0.5122417427117003,"score_spread":0.096386315820646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2024683988","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.919738,0.0047586113,0.0003109391,0.041734647,0.00084470067,0.000677388,0.00023201267,0.00013320657,0.03157049],"genre_scores_gemma":[0.9480642,0.0013882227,0.0037781657,0.044420633,0.0006163136,0.00011226224,0.00005894063,0.000073101815,0.0014881751],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99344367,0.00034298052,0.0046800543,0.0007379268,0.00005287339,0.0007424843],"domain_scores_gemma":[0.99742764,0.0005397072,0.0012501786,0.00046274584,0.000017255914,0.0003024616],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.011741199,0.00027792205,0.0011799341,0.00043448913,0.00022395547,0.00027402627,0.00038823558,0.00011078411,0.007970719],"category_scores_gemma":[0.0002748826,0.0004117039,0.00014245829,0.000187487,0.000085032196,0.0017750465,0.000040012055,0.00034247828,0.0072412],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046919764,0.0014285303,0.17928298,0.0021750873,0.00047368716,0.00002012742,0.019960692,0.017098961,0.00003202292,0.37338534,0.24291883,0.16275454],"study_design_scores_gemma":[0.007441017,0.00010881084,0.06404973,0.00022038362,0.000008949591,0.000031941436,0.0028435036,0.08051063,0.00005100523,0.054648023,0.7883858,0.0017001893],"about_ca_topic_score_codex":0.0018526464,"about_ca_topic_score_gemma":0.00023363618,"teacher_disagreement_score":0.54546696,"about_ca_system_score_codex":0.00124246,"about_ca_system_score_gemma":0.00034690867,"threshold_uncertainty_score":0.99983346},"labels":[],"label_agreement":null},{"id":"W2024733263","doi":"10.2165/00019053-200624110-00005","title":"Pharmacoeconomics and Pharmacoepidemiology","year":2006,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Pharmacoeconomics; Pharmacoepidemiology; Health economics; Medicine; Quality of Life Research; Health administration; Economic evaluation; Public health; Management science; Risk analysis (engineering); Economics; Intensive care medicine; Pharmacology; Nursing","score_opus":0.5675004273166744,"score_gpt":0.5703214458833197,"score_spread":0.0028210185666452947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2024733263","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000085660875,0.97638917,0.00052020344,0.0039664013,0.0036244101,0.0024623962,0.0034125939,0.00027664137,0.0092624985],"genre_scores_gemma":[0.000020280188,0.9746559,0.0016879332,0.016604433,0.0031920553,0.000778373,0.0007934133,0.00039416403,0.0018733944],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98056626,0.0012882941,0.014004529,0.0025420876,0.00007471196,0.0015241408],"domain_scores_gemma":[0.9837501,0.0043783835,0.009967051,0.001062804,0.000055445602,0.0007862324],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.018449571,0.0015305253,0.00959626,0.0012881602,0.0004170251,0.00029110047,0.0012311784,0.00092586246,0.0018270909],"category_scores_gemma":[0.00089025556,0.0019890917,0.0011948134,0.00026494893,0.00035910483,0.0010299076,0.00046402682,0.0013918802,0.010779584],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000025625437,0.00027609707,0.00039045748,0.031034568,0.0018563125,0.000018874189,0.00022917814,0.00013690263,3.9785226e-7,0.07014968,0.62466,0.2712219],"study_design_scores_gemma":[0.0012231722,0.000033447857,0.000008128094,0.0006678167,0.00043077054,0.00012113432,0.000026345313,0.002240089,7.699825e-7,0.004272587,0.9892545,0.0017212711],"about_ca_topic_score_codex":0.00067767955,"about_ca_topic_score_gemma":0.0000429062,"teacher_disagreement_score":0.36459446,"about_ca_system_score_codex":0.0019853916,"about_ca_system_score_gemma":0.00057436293,"threshold_uncertainty_score":0.99974436},"labels":[],"label_agreement":null},{"id":"W2024882643","doi":"10.2165/00019053-200624040-00007","title":"Post-Exposure Influenza Prophylaxis with Oseltamivir","year":2006,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Influenza Virus Research Studies","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Oseltamivir; Medicine; Neuraminidase inhibitor; Life expectancy; Emergency medicine; Health economics; Neuraminidase; Zanamivir; Internal medicine; Intensive care medicine; Public health; Pediatrics; Environmental health; Virology; Coronavirus disease 2019 (COVID-19); Virus; Infectious disease (medical specialty); Disease","score_opus":0.03437580619583032,"score_gpt":0.35248804743410134,"score_spread":0.31811224123827103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2024882643","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9793949,0.0010809699,0.000022368979,0.0006830739,0.00009091336,0.0007366131,0.00006952544,0.0001490427,0.01777256],"genre_scores_gemma":[0.9913575,0.00009673972,0.0011308305,0.0050887843,0.0005465655,0.00010481305,0.000025178751,0.000061463434,0.0015881235],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985457,0.000033262193,0.0003499395,0.00035984445,0.00020471525,0.0005065056],"domain_scores_gemma":[0.99908966,0.00007481712,0.000099893354,0.00030842924,0.00026914486,0.0001580845],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002175359,0.0002507492,0.00036161207,0.0001737319,0.00015114437,0.00004854714,0.00014351598,0.000070623275,0.00029450434],"category_scores_gemma":[0.00004145608,0.00019925705,0.000092892704,0.0001409345,0.00019123488,0.00022420086,0.00008793342,0.00037989242,0.00054628355],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008126143,0.0013101355,0.7443662,0.00087404985,0.0013898925,0.00047399863,0.0008908512,0.00207271,0.17364766,0.0020018131,0.020200644,0.044645853],"study_design_scores_gemma":[0.017557997,0.0033592968,0.23132336,0.0000906672,0.00033063957,0.00021221736,0.00026766115,0.0008331411,0.12463419,0.00024685758,0.620045,0.0010989483],"about_ca_topic_score_codex":0.0003109161,"about_ca_topic_score_gemma":0.000056394558,"teacher_disagreement_score":0.5998444,"about_ca_system_score_codex":0.00021507681,"about_ca_system_score_gemma":0.00022363327,"threshold_uncertainty_score":0.8125467},"labels":[],"label_agreement":null},{"id":"W2026751503","doi":"10.2165/00019053-200119001-00004","title":"An Economic Model for Determining the Costs and Consequences of Using Various Treatment Alternatives for the Management of Arthritis in Canada","year":2001,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Inflammatory mediators and NSAID effects","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Pfizer (Canada); University of Alberta","funders":"","keywords":"Health economics; Quality of Life Research; Health administration; Public health; Arthritis; Pharmacoeconomics; Health care management; Medicine; Intensive care medicine; Nursing; Internal medicine","score_opus":0.03857266971576977,"score_gpt":0.3372385351255037,"score_spread":0.29866586540973394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2026751503","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976418,0.0003368788,0.0006460015,0.00011093927,0.00014011536,0.0010134593,0.00008000708,0.0000019596284,0.00002881673],"genre_scores_gemma":[0.99721473,0.0016761799,0.0008175056,0.00012415802,0.000045430883,0.00010195896,0.0000037121813,0.00001048092,0.0000058518563],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99947107,0.000013617618,0.00024654498,0.00011626301,0.000024059846,0.0001284532],"domain_scores_gemma":[0.9994851,0.00022459019,0.00013643818,0.00009836942,0.000016035698,0.000039464627],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018898887,0.000086967935,0.00021191324,0.000026868118,0.000047536414,0.000005909709,0.000065153596,0.000012080047,0.0000039137967],"category_scores_gemma":[0.0000025416311,0.000059024696,0.000033321674,0.000009833202,0.00006722111,0.000051672745,0.000010160482,0.000024021727,5.5015782e-8],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002721447,0.00024227751,0.27413443,0.0006542387,0.0014605143,0.00004477905,0.0033510912,0.24438117,0.008824977,0.0022033304,0.000099786244,0.46188197],"study_design_scores_gemma":[0.0038228366,0.00011529806,0.0028614756,0.000048464604,0.00013262215,0.000008696864,0.0003480737,0.9792397,0.013104538,0.000077063254,0.00017259362,0.00006862559],"about_ca_topic_score_codex":0.055446893,"about_ca_topic_score_gemma":0.1175272,"teacher_disagreement_score":0.7348585,"about_ca_system_score_codex":0.00039579303,"about_ca_system_score_gemma":0.00033177994,"threshold_uncertainty_score":0.950843},"labels":[],"label_agreement":null},{"id":"W2027483687","doi":"10.1007/s40273-013-0115-9","title":"Cost Effectiveness of a 21-Gene Recurrence Score Assay Versus Canadian Clinical Practice in Post-Menopausal Women with Early-Stage Estrogen or Progesterone-Receptor-Positive, Axillary Lymph-Node Positive Breast Cancer","year":2013,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Western University","funders":"Canadian Institutes of Health Research; Canada Research Chairs","keywords":"Medicine; Breast cancer; Gynecology; Oncology; Progesterone receptor; Internal medicine; Cost effectiveness; Population; Stage (stratigraphy); Public health; Estrogen receptor; Cancer; Pathology; Biology","score_opus":0.022698309579264612,"score_gpt":0.33830955152828124,"score_spread":0.31561124194901663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2027483687","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937522,0.0005701395,0.000012939923,0.00046482118,0.00037776207,0.0012120082,0.003307121,0.000010834291,0.00029220793],"genre_scores_gemma":[0.9963645,0.0009735079,0.00048047793,0.00061806163,0.000168732,0.0009603493,0.0003528621,0.000059234146,0.000022326562],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977604,0.00039402716,0.00042362514,0.0006909433,0.00010967294,0.00062132406],"domain_scores_gemma":[0.99834657,0.0003237731,0.0002972915,0.00028758644,0.0003759019,0.00036887202],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004669076,0.00037269833,0.00046482272,0.00008542944,0.00009451951,0.00004677962,0.0002644157,0.0001546591,0.00009912143],"category_scores_gemma":[0.000079064775,0.00033513227,0.000045286724,0.0001291228,0.0002470444,0.00007477621,0.00013910425,0.00018673924,0.000026732043],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07007083,0.0014217517,0.7451061,0.00023819186,0.0066069323,0.00014304266,0.0014264405,0.00091460015,0.11357179,0.000033510583,0.0003015475,0.060165238],"study_design_scores_gemma":[0.011471884,0.0015963049,0.9011873,0.0001948585,0.000267029,0.000113123286,0.0005796815,0.00004639663,0.08258022,0.000001922541,0.0011753326,0.00078596774],"about_ca_topic_score_codex":0.06665397,"about_ca_topic_score_gemma":0.010265845,"teacher_disagreement_score":0.15608115,"about_ca_system_score_codex":0.00088001555,"about_ca_system_score_gemma":0.001450215,"threshold_uncertainty_score":0.99991006},"labels":[],"label_agreement":null},{"id":"W2028342787","doi":"10.2165/00019053-200422050-00005","title":"Cost Effectiveness of Representatives of Three Classes of Antidepressants Used in Major Depression in the UK","year":2004,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Treatment of Major Depression","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"","keywords":"Venlafaxine; Fluoxetine; Venlafaxine Hydrochloride; Fluvoxamine; Pharmacoeconomics; Amitriptyline; Medicine; Psychiatry; Paroxetine; Depression (economics); Cost effectiveness; Antidepressant; Internal medicine; Psychology; Intensive care medicine; Serotonin","score_opus":0.06534176464295775,"score_gpt":0.3946588932483937,"score_spread":0.32931712860543594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2028342787","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971494,0.00064170297,0.00012794217,0.00008046727,0.000088465764,0.0012508768,0.000041118754,0.000008593982,0.0006114517],"genre_scores_gemma":[0.99920946,0.00023586483,0.0004059446,0.000024513209,0.000018117467,0.000064305925,0.000019051125,0.000019767282,0.0000029978398],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985659,0.00020569869,0.00059348485,0.0002831998,0.00017096434,0.00018074017],"domain_scores_gemma":[0.99837464,0.0007993293,0.00035326704,0.00038405386,0.000045899953,0.00004278162],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063678937,0.00016588377,0.0005985113,0.0002391046,0.000014977661,0.00000407644,0.0002250003,0.000072535644,0.000036757836],"category_scores_gemma":[0.00009807399,0.00012185798,0.000108329186,0.00018509624,0.0001539063,0.00015106173,0.000083645995,0.0001756998,0.000002204112],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016632775,0.00075203116,0.77987343,0.00034353044,0.000070735,0.000022246626,0.0005098267,0.0020660427,0.21359865,0.000056752066,0.000010113898,0.0010333452],"study_design_scores_gemma":[0.008488891,0.000072363546,0.5213264,0.0004561426,0.000055683224,0.0000066171965,0.00014067994,0.000090834736,0.46897855,0.000329541,0.000003413657,0.00005089436],"about_ca_topic_score_codex":0.0007232463,"about_ca_topic_score_gemma":0.00017597794,"teacher_disagreement_score":0.25854704,"about_ca_system_score_codex":0.00009228171,"about_ca_system_score_gemma":0.00009357636,"threshold_uncertainty_score":0.49692243},"labels":[],"label_agreement":null},{"id":"W2029403036","doi":"10.2165/00019053-200119050-00010","title":"Cost Effectiveness of Nasal Calcitonin in Postmenopausal Women","year":2001,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Bone health and osteoporosis research","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital","funders":"","keywords":"Medicine; Cost effectiveness; Cost-effectiveness analysis; Randomized controlled trial; Calcitonin; Internal medicine; Physical therapy","score_opus":0.12189264107641917,"score_gpt":0.48413106340409684,"score_spread":0.36223842232767767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2029403036","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013322917,0.98091114,0.0000021833914,0.000026544549,0.000383028,0.0034112837,0.00017183907,0.000024882187,0.0017462138],"genre_scores_gemma":[0.0007406436,0.9974681,0.00003880251,0.0001485973,0.00022353533,0.0008503526,0.00023570875,0.00009764706,0.00019659687],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99699676,0.0004597182,0.0010773961,0.0005004905,0.00016215297,0.00080350984],"domain_scores_gemma":[0.9979812,0.000750418,0.00031810816,0.00035339736,0.00006912442,0.00052778557],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017365594,0.00040362965,0.0028888278,0.00056356756,0.000031719097,0.000014079739,0.00023605296,0.00032636127,0.0004295858],"category_scores_gemma":[0.000075309705,0.00037085486,0.00023343683,0.00040148656,0.00010206523,0.00007399488,0.00011695953,0.0009866746,0.00020421941],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00071791775,0.00038527738,0.0004752401,0.07180642,0.0001897599,0.00012131499,0.000057289253,0.0000027857952,0.000026457545,0.000033412074,0.000239651,0.92594445],"study_design_scores_gemma":[0.0032118962,0.0004024559,0.00028621752,0.0066380557,0.00020269354,0.00016183477,0.000022199867,0.000032289183,0.000069250156,0.0000123290265,0.98866856,0.00029223147],"about_ca_topic_score_codex":0.00018239312,"about_ca_topic_score_gemma":0.000009349359,"teacher_disagreement_score":0.9884289,"about_ca_system_score_codex":0.001906234,"about_ca_system_score_gemma":0.0019465063,"threshold_uncertainty_score":0.99987435},"labels":[],"label_agreement":null},{"id":"W2031350791","doi":"10.2165/00019053-200119060-00005","title":"International Validation of the CLAU-S Quality-of-Life Questionnaire for Use in Patients with Intermittent Claudication","year":2001,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Peripheral Artery Disease Management","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Public Health Association","funders":"","keywords":"Quality of Life Research; Health economics; Quality of life (healthcare); Health administration; Intermittent claudication; Medicine; Health care management; Public health; Claudication; Physical therapy; Nursing; Surgery; Arterial disease; Vascular disease","score_opus":0.0374428898214138,"score_gpt":0.3335150779606571,"score_spread":0.2960721881392433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031350791","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963899,0.00000653738,0.0011683486,0.0013662612,0.00020028371,0.00065191835,0.00003040779,0.000008645604,0.00017769496],"genre_scores_gemma":[0.9985382,0.000021213953,0.0004036424,0.00079293764,0.000043014796,0.00005137962,0.0000865435,0.0000095377345,0.00005350908],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99927455,0.00003472306,0.0003878295,0.00012977356,0.00009930715,0.00007383482],"domain_scores_gemma":[0.99939007,0.000028074428,0.00027132343,0.00015320588,0.00011643608,0.000040912608],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015142013,0.00006992595,0.00014139056,0.000071190356,0.000015190979,0.000008305262,0.00010400704,0.000017812014,0.000053182837],"category_scores_gemma":[0.000060513263,0.000054291173,0.00005874433,0.000054319647,0.000037637084,0.00018454263,0.000035920162,0.000045405257,0.000002174437],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011943292,0.0003540659,0.9901797,0.00006613487,0.0000787858,8.328673e-8,0.00007066931,0.0005875369,0.00025275792,0.00024779022,0.00031574658,0.0066523594],"study_design_scores_gemma":[0.0038898347,0.00005347116,0.98924154,0.0000706902,0.000045454613,1.893555e-7,0.00001954265,0.0032750678,0.0008232064,0.000052424235,0.0024696572,0.000058947822],"about_ca_topic_score_codex":0.000041080253,"about_ca_topic_score_gemma":0.00001629534,"teacher_disagreement_score":0.006593412,"about_ca_system_score_codex":0.00014845615,"about_ca_system_score_gemma":0.000041826155,"threshold_uncertainty_score":0.22139297},"labels":[],"label_agreement":null},{"id":"W2032207957","doi":"10.2165/00019053-200119050-00011","title":"Gastrointestinal-Related Healthcare Resource Usage Associated with a Fixed Combination of Diclofenac and Misoprostol versus Other NSAIDs","year":2001,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Inflammatory mediators and NSAID effects","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôtel-Dieu de Montréal; Centre Hospitalier de l’Université de Montréal; McGill University","funders":"Merck Canada","keywords":"Misoprostol; Diclofenac; Medicine; Medical prescription; Logistic regression; Health care; Health administration; Internal medicine; Emergency medicine; Anesthesia; Public health; Pharmacology; Abortion; Pregnancy","score_opus":0.018451037199828827,"score_gpt":0.28520704669899216,"score_spread":0.26675600949916334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2032207957","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99694747,0.00021370174,0.000019468791,0.0007237573,0.0001144805,0.00050395046,0.000020596604,0.00006467217,0.0013919282],"genre_scores_gemma":[0.9988595,0.000043062588,0.00013741516,0.00043181764,0.00005386164,0.000018765413,0.00004740233,0.000041329582,0.00036684755],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989668,0.000087465756,0.00033226665,0.00023233065,0.00011474612,0.0002663775],"domain_scores_gemma":[0.9990693,0.00023018074,0.0002600425,0.00015011455,0.00008762528,0.00020278702],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036290215,0.00017558598,0.00035629308,0.000114807975,0.00006668568,0.0000103144075,0.00005642501,0.000055214972,0.00010114179],"category_scores_gemma":[0.000116066585,0.00015968109,0.00005112513,0.00013333594,0.00011304983,0.00008408656,0.000022460874,0.00023309901,0.000011197972],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00959887,0.00060641475,0.9555357,0.0004209654,0.000498578,0.0002369652,0.001037687,0.00008903436,0.020889707,0.00038666392,0.0019119788,0.008787415],"study_design_scores_gemma":[0.21297413,0.018109823,0.56535316,0.0039602094,0.0025014183,0.002162518,0.0016509031,0.068315096,0.081081115,0.00030753994,0.041063517,0.002520581],"about_ca_topic_score_codex":0.00007201076,"about_ca_topic_score_gemma":0.000033762884,"teacher_disagreement_score":0.39018255,"about_ca_system_score_codex":0.00014877022,"about_ca_system_score_gemma":0.00008468196,"threshold_uncertainty_score":0.6511606},"labels":[],"label_agreement":null},{"id":"W2032287810","doi":"10.2165/00019053-200624110-00007","title":"???Lost in Translation???","year":2006,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":77,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto; Population Health Research Institute","funders":"Wellcome Trust","keywords":"Health administration; Health economics; Health care; Multinational corporation; Medicine; Cost effectiveness; Actuarial science; Computer science; Risk analysis (engineering); Public health; Business; Economics; Finance; Nursing","score_opus":0.6193967510465721,"score_gpt":0.5494153435115084,"score_spread":0.06998140753506366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2032287810","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000023026572,0.9638292,0.0002620774,0.0020832315,0.0015291624,0.0019163326,0.0017696902,0.000076354045,0.02851092],"genre_scores_gemma":[0.000017466671,0.99197406,0.0011972848,0.003021577,0.0011821707,0.00039153072,0.0006246754,0.00019355066,0.0013976824],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98631734,0.0005062803,0.011021982,0.001280527,0.00006489848,0.0008090034],"domain_scores_gemma":[0.9924937,0.0016636063,0.0048254263,0.000751033,0.000023819897,0.00024243881],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.010643072,0.00073612767,0.0053008045,0.0013384364,0.00011160097,0.00016496822,0.00078576565,0.0005667912,0.0017692238],"category_scores_gemma":[0.0002910211,0.0010162649,0.00080443505,0.00037693832,0.00008252889,0.00068455463,0.00007390636,0.0007649663,0.022026377],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002249192,0.00071734114,0.0011754167,0.06411019,0.0008270795,0.000027574359,0.0008917481,0.00078738027,8.364854e-8,0.089837305,0.24562562,0.5959778],"study_design_scores_gemma":[0.00074990105,0.000012435629,0.000015926953,0.0011126696,0.00006712838,0.000012918312,0.00001947665,0.0011309476,9.9348476e-8,0.0029430243,0.99303776,0.0008976992],"about_ca_topic_score_codex":0.0007075685,"about_ca_topic_score_gemma":0.00027875468,"teacher_disagreement_score":0.74741215,"about_ca_system_score_codex":0.0020932164,"about_ca_system_score_gemma":0.00050647475,"threshold_uncertainty_score":0.9992288},"labels":[],"label_agreement":null},{"id":"W2034014431","doi":"10.2165/11588350-000000000-00000","title":"Adjuvant Trastuzumab for Breast Cancer","year":2011,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nova Scotia Cancer Centre; Atlantic School of Theology; Cancer Care Nova Scotia; Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"","keywords":"Trastuzumab; Breast cancer; Adjuvant; Quality of Life Research; Medicine; Oncology; Health economics; Internal medicine; Public health; Cancer; Pathology","score_opus":0.1428086307434459,"score_gpt":0.43489554137371356,"score_spread":0.29208691063026765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2034014431","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.951658,0.0017343957,0.0008799535,0.006279948,0.0022135747,0.0026282738,0.0019186416,0.00022609967,0.03246112],"genre_scores_gemma":[0.9922938,0.0010182732,0.0013873744,0.00243714,0.00088316284,0.0004650306,0.000015524483,0.000071887975,0.00142786],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99892545,0.000014585044,0.00025725728,0.00030069047,0.000084034946,0.00041800295],"domain_scores_gemma":[0.9992984,0.00004085813,0.0000594669,0.00021783728,0.0000995288,0.0002839088],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00023639014,0.00014392928,0.00028049893,0.0000845444,0.000058182024,0.0000131965435,0.00016497803,0.000054200184,0.0068373973],"category_scores_gemma":[0.000009946561,0.00013873636,0.00012488758,0.000055587952,0.00006933795,0.00009509296,0.00004020196,0.00018832462,0.0001893531],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00455405,0.0007020192,0.047004297,0.00081320724,0.0007242264,0.000049673406,0.0022260298,0.00003212882,0.022400416,0.0011436775,0.13672706,0.7836232],"study_design_scores_gemma":[0.01998586,0.0008736315,0.10507319,0.00023165795,0.0007824557,0.00054921815,0.0004912229,0.018281337,0.22615868,0.0012301117,0.6251389,0.0012037414],"about_ca_topic_score_codex":0.0003014517,"about_ca_topic_score_gemma":0.0000358531,"teacher_disagreement_score":0.78241944,"about_ca_system_score_codex":0.00041308277,"about_ca_system_score_gemma":0.00042350913,"threshold_uncertainty_score":0.9940705},"labels":[],"label_agreement":null},{"id":"W2035696027","doi":"10.2165/00019053-200220060-00005","title":"Reporting Heterogeneity in the Measurement of Health and Health-Related Quality of Life","year":2002,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health disparities and outcomes","field":"Social Sciences","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"McMaster University","keywords":"Categorical variable; Quality of life (healthcare); Socioeconomic status; Population; Public health; Sample (material); Psychology; Econometrics; Medicine; Gerontology; Environmental health; Statistics; Mathematics","score_opus":0.3980112718076854,"score_gpt":0.4694687805807528,"score_spread":0.07145750877306739,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2035696027","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9545769,0.005725143,0.0000050148697,0.037671484,0.00017180205,0.00031889387,0.000006529352,0.000008464032,0.0015157663],"genre_scores_gemma":[0.98906106,0.0028976102,0.000049390288,0.007944701,0.000029569515,0.0000062871727,7.646099e-7,0.0000040193577,0.0000066107036],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99652433,0.00063583144,0.0022164483,0.0001362032,0.00019045422,0.00029671588],"domain_scores_gemma":[0.9974536,0.0001445215,0.0020857637,0.00011475257,0.000040019288,0.0001613563],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01787041,0.00006258833,0.0004266397,0.00003587931,0.00019720153,0.000011745198,0.00012860181,0.000030440731,0.000055057386],"category_scores_gemma":[0.00056182174,0.000055024157,0.00005568069,0.00008361006,0.00010021179,0.00007684858,0.000020900447,0.000108460255,0.0000012125342],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000023075547,0.00019016063,0.9043837,0.00086583075,0.00004018122,4.499486e-7,0.054628946,0.00008721422,0.000009192875,0.009256543,0.002823029,0.027691685],"study_design_scores_gemma":[0.0024960733,0.00011997192,0.9336343,0.00017241045,0.000011192586,0.0000018349343,0.03213362,0.0016165279,0.00015006702,0.0014202865,0.027894527,0.00034919052],"about_ca_topic_score_codex":0.046110597,"about_ca_topic_score_gemma":0.009794275,"teacher_disagreement_score":0.03631632,"about_ca_system_score_codex":0.00019515202,"about_ca_system_score_gemma":0.0004000912,"threshold_uncertainty_score":0.96024144},"labels":[],"label_agreement":null},{"id":"W2039074033","doi":"10.2165/11539450-000000000-00000","title":"A Systematic Review to Assess the Policy-Making Relevance of Dementia Cost-of-Illness Studies in the US and Canada","year":2010,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ontario Stroke Network; McMaster University","funders":"","keywords":"Dementia; CINAHL; Relevance (law); EconLit; Cochrane Library; MEDLINE; Medicaid; Medicine; Health administration; Public health; Psychology; Gerontology; Psychiatry; Health care; Nursing; Alternative medicine; Psychological intervention; Political science; Pathology","score_opus":0.49726007890058127,"score_gpt":0.5555469059657333,"score_spread":0.058286827065152036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2039074033","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00031914163,0.985772,0.000037125537,0.0053536086,0.0008969616,0.0065827277,0.0007477481,0.0000066909715,0.00028395836],"genre_scores_gemma":[0.0009061564,0.98241353,0.00014707411,0.014480091,0.00022555224,0.0017255335,0.000016436365,0.000054161206,0.000031482225],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9887497,0.0012444276,0.008846123,0.0005911026,0.00011740664,0.00045125856],"domain_scores_gemma":[0.9823231,0.008071908,0.008348578,0.001044509,0.00010697178,0.000104929466],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.024845274,0.0004629796,0.0058826245,0.00035343756,0.00015838463,0.000052828433,0.001280937,0.00013868297,0.000025369469],"category_scores_gemma":[0.009033706,0.0003624914,0.00029020855,0.000353014,0.00015174379,0.00019281037,0.00022005389,0.00054269773,0.00004215737],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000023856992,0.000029398743,0.00010415417,0.97388035,0.0007435254,0.000001467973,0.0011368529,0.000039693517,3.784075e-8,0.01375973,0.0066053346,0.003697066],"study_design_scores_gemma":[0.00020094123,0.000014209506,0.000012245469,0.15176727,0.0006736603,0.000031379383,0.0006912571,0.00011913733,3.9526452e-7,0.00035009655,0.84568304,0.00045639894],"about_ca_topic_score_codex":0.047109153,"about_ca_topic_score_gemma":0.09413566,"teacher_disagreement_score":0.83907765,"about_ca_system_score_codex":0.0009731001,"about_ca_system_score_gemma":0.0014322955,"threshold_uncertainty_score":0.9998827},"labels":[],"label_agreement":null},{"id":"W2040131196","doi":"10.1007/s40273-013-0077-y","title":"Navigating Time and Uncertainty in Health Technology Appraisal: Would a Map Help?","year":2013,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Capital District Health Authority","funders":"National Institute for Health and Care Research","keywords":"Quality of Life Research; Health economics; Health administration; Public health; Health informatics; Health services research; Medicine; Data science; Management science; Computer science; Nursing; Economics","score_opus":0.18154876757317873,"score_gpt":0.47075395266461867,"score_spread":0.28920518509143994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2040131196","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7846101,0.004063429,0.00020095005,0.20822035,0.00060553855,0.0012232505,0.00016820514,0.00015728128,0.00075091],"genre_scores_gemma":[0.9411721,0.00090401457,0.0064797974,0.049568225,0.0005277101,0.0006176667,0.00009590358,0.00013106293,0.0005035272],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9941216,0.00020030326,0.0040777023,0.00079849997,0.000042198248,0.00075969903],"domain_scores_gemma":[0.99654275,0.00073893374,0.0019495874,0.00041753933,0.000037011392,0.00031416825],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0076699294,0.00029454433,0.0011962873,0.0003359254,0.00017704764,0.00013345249,0.00034953127,0.00029322229,0.0012221904],"category_scores_gemma":[0.0007513071,0.00041076413,0.00007788647,0.00022113202,0.0001429007,0.000727536,0.0001497247,0.0008698552,0.006997239],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000100826284,0.0009822969,0.47478685,0.0038147091,0.0006037874,0.000010873615,0.014847297,0.019397397,0.00048643583,0.19569507,0.22073978,0.06853468],"study_design_scores_gemma":[0.0059800986,0.00025319576,0.01263087,0.0004654211,0.000010124645,0.000052537613,0.004154386,0.53980297,0.000081510596,0.06169924,0.372903,0.0019666806],"about_ca_topic_score_codex":0.0043206913,"about_ca_topic_score_gemma":0.0001302531,"teacher_disagreement_score":0.52040553,"about_ca_system_score_codex":0.00081958703,"about_ca_system_score_gemma":0.00015215627,"threshold_uncertainty_score":0.9998344},"labels":[],"label_agreement":null},{"id":"W2040573992","doi":"10.2165/00019053-200321080-00004","title":"The Cost Effectiveness of ACE Inhibitors as First-Line Antihypertensive Therapy","year":2003,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Blood Pressure and Hypertension Studies","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Medicine; Observational study; Left ventricular hypertrophy; Combination therapy; Internal medicine; Cost effectiveness; Pharmacotherapy; Fenoldopam; ACE inhibitor; Antihypertensive drug; Pharmacoeconomics; Cardiology; Intensive care medicine; Physical therapy; Blood pressure; Angiotensin-converting enzyme","score_opus":0.044894476780071635,"score_gpt":0.33491569550029837,"score_spread":0.29002121872022674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2040573992","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97039,0.021611644,0.000017227934,0.0023966178,0.00086181855,0.00090968807,0.000010869665,0.000030519088,0.0037715882],"genre_scores_gemma":[0.9784902,0.018301092,0.00005221876,0.0028457467,0.0001182767,0.000044203705,0.000003273592,0.000026233422,0.00011878835],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99909216,0.00011004699,0.00027949704,0.00021218845,0.000085968924,0.00022013982],"domain_scores_gemma":[0.99847275,0.0008594914,0.000118059754,0.00024435553,0.00021636295,0.00008896723],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046312425,0.0001654508,0.0005052592,0.000041393465,0.00018414804,0.000012236817,0.000085101456,0.00004516631,0.00006230856],"category_scores_gemma":[0.00008922045,0.00010824522,0.00013751,0.000078675395,0.00012421914,0.000059600312,0.000034020577,0.00016473397,0.000072629206],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017325701,0.0026301336,0.23327705,0.0012355623,0.017222596,0.00034470606,0.0025348184,0.0013504898,0.3766625,0.010117108,0.16631158,0.17098776],"study_design_scores_gemma":[0.0047804713,0.00018366596,0.0028314216,0.000056994268,0.00036013903,0.00009718172,0.00022952263,0.00013339549,0.479649,0.0002454826,0.51127666,0.00015606602],"about_ca_topic_score_codex":0.00019072865,"about_ca_topic_score_gemma":0.000023406908,"teacher_disagreement_score":0.34496507,"about_ca_system_score_codex":0.000029614012,"about_ca_system_score_gemma":0.0001368548,"threshold_uncertainty_score":0.4414112},"labels":[],"label_agreement":null},{"id":"W2042919218","doi":"10.1007/s40273-014-0183-5","title":"Decision-Analytic Models: Current Methodological Challenges","year":2014,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Computer science; Health care; Probabilistic logic; Management science; Risk analysis (engineering); Operations research; Set (abstract data type); Actuarial science; Economics; Medicine; Artificial intelligence; Engineering","score_opus":0.8275456816076244,"score_gpt":0.5732696120548255,"score_spread":0.2542760695527989,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2042919218","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.15874213,0.087390356,0.55694896,0.0946101,0.011358053,0.002155096,0.00053582306,0.00063782436,0.08762164],"genre_scores_gemma":[0.8887276,0.024128864,0.053763594,0.029173475,0.0031738416,0.00034714825,0.000060849055,0.00017587302,0.0004487314],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99298394,0.0007411991,0.0044023897,0.0011077609,0.0000902627,0.00067444483],"domain_scores_gemma":[0.9919877,0.004787532,0.0019030189,0.000803616,0.00006519847,0.00045291855],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.03008974,0.00036766048,0.0016305598,0.00041185168,0.00021316114,0.00011634346,0.00070814765,0.00017356762,0.0011588612],"category_scores_gemma":[0.003465359,0.00044881707,0.00034375535,0.00011253293,0.00009897452,0.00080694986,0.00016721529,0.00039566905,0.0068934313],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000050548537,0.00021291409,0.0012345231,0.00026782905,0.00017382871,6.9307293e-7,0.000877739,0.010597946,0.0000029578619,0.8994928,0.035566855,0.05152139],"study_design_scores_gemma":[0.0008847787,0.000040313127,0.0006672151,0.000026524294,0.000018511006,0.0000055450555,0.000115102695,0.28160608,0.000009461696,0.33827877,0.37790698,0.0004407071],"about_ca_topic_score_codex":0.000067864254,"about_ca_topic_score_gemma":0.000030343099,"teacher_disagreement_score":0.7299855,"about_ca_system_score_codex":0.0005721742,"about_ca_system_score_gemma":0.00008758472,"threshold_uncertainty_score":0.99979633},"labels":[],"label_agreement":null},{"id":"W2043000760","doi":"10.2165/11584810-000000000-00000","title":"Resource Utilization and Cost of Treatment with Anidulafungin or Fluconazole for Candidaemia and Other Forms of Invasive Candidiasis","year":2011,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Antifungal resistance and susceptibility","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Astellas Pharma; Pfizer","keywords":"Anidulafungin; Fluconazole; Invasive candidiasis; Health economics; Pharmacoeconomics; Quality of Life Research; Public health; Resource (disambiguation); Health administration; Medicine; Business; Intensive care medicine; Antifungal; Computer science; Nursing; Caspofungin","score_opus":0.0969956000448805,"score_gpt":0.33484317685723564,"score_spread":0.23784757681235513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2043000760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975039,0.0003418395,0.000183242,0.000025452237,0.000009958545,0.00071844703,0.00015214675,0.0000060973407,0.0010589138],"genre_scores_gemma":[0.99852765,0.00060567085,0.00047564073,0.00015207012,0.000014715747,0.00003415073,0.000015879015,0.000014980829,0.00015926574],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99949795,0.000008356028,0.00019845416,0.00015785969,0.00002737529,0.00011001365],"domain_scores_gemma":[0.99957085,0.000082647486,0.00011834203,0.00010345792,0.000043335574,0.00008135158],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008781932,0.0000984881,0.0002696442,0.00004231902,0.000027947342,0.0000035782423,0.000023493656,0.000034301887,0.00007416175],"category_scores_gemma":[0.000014809257,0.0000666728,0.000028775858,0.000030830142,0.000102035454,0.00006440851,0.000009820306,0.000024352385,2.7677618e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011274803,0.000210431,0.9396892,0.0006875787,0.0003704909,0.0000036266688,0.004196097,0.000005313327,0.017669229,0.0005761083,0.00014456757,0.025172522],"study_design_scores_gemma":[0.014754568,0.0039312956,0.090507224,0.00020219937,0.0008611541,0.000035817367,0.004229876,0.0023681142,0.87170774,0.00019981722,0.0108778775,0.0003243449],"about_ca_topic_score_codex":0.00033320326,"about_ca_topic_score_gemma":0.0011910897,"teacher_disagreement_score":0.8540385,"about_ca_system_score_codex":0.0000754086,"about_ca_system_score_gemma":0.00014722274,"threshold_uncertainty_score":0.2718838},"labels":[],"label_agreement":null},{"id":"W2043132614","doi":"10.2165/00019053-200018050-00003","title":"Health-Related Quality-of-Life Measurement in Hypertension","year":2000,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Blood Pressure and Hypertension Studies","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Saint-Sacrement; Université Laval","funders":"","keywords":"Medicine; Quality of life (healthcare); Tolerability; Adverse effect; MEDLINE; Health economics; Alternative medicine; Disease; Gerontology; Public health; Intensive care medicine; Physical therapy; Internal medicine; Pathology; Nursing","score_opus":0.3210045973917947,"score_gpt":0.4249187854935109,"score_spread":0.10391418810171621,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2043132614","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013488076,0.9952667,4.7355124e-7,0.0011455315,0.00043230763,0.0011134179,0.000044457403,0.000045333654,0.0018169425],"genre_scores_gemma":[0.0004394992,0.9952991,0.00007189021,0.0037075374,0.00015409946,0.00005432015,0.00006495137,0.00006999074,0.0001386086],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.995958,0.00032917797,0.0025897296,0.00050220446,0.00025546187,0.00036545552],"domain_scores_gemma":[0.9981987,0.0001939898,0.0008255284,0.00041286647,0.000113555885,0.00025534985],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014662378,0.0004403862,0.0061709904,0.0003693162,0.00005445306,0.000007832331,0.00015218918,0.00024504904,0.000290697],"category_scores_gemma":[0.00007605372,0.00036800173,0.0006233925,0.00019244838,0.000063294916,0.000049883387,0.000076899996,0.0006430935,0.0002097689],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000117437805,0.00031471995,0.000031950454,0.018419696,0.0014528243,0.000020703656,0.000071614486,0.0000028878183,0.0000028907953,0.000027837441,0.02284392,0.95669353],"study_design_scores_gemma":[0.0019462861,0.000053153515,0.000036516427,0.0066171098,0.0018047321,0.00006970621,0.000014019573,0.00001484809,0.000002347849,0.000012468723,0.9891397,0.00028914431],"about_ca_topic_score_codex":0.0004405017,"about_ca_topic_score_gemma":0.000040635132,"teacher_disagreement_score":0.9662957,"about_ca_system_score_codex":0.00014958071,"about_ca_system_score_gemma":0.0010324895,"threshold_uncertainty_score":0.9998772},"labels":[],"label_agreement":null},{"id":"W2043943400","doi":"10.1007/s40273-013-0035-8","title":"A Comparative Analysis of Models Used to Evaluate the Cost-Effectiveness of Dabigatran Versus Warfarin for the Prevention of Stroke in Atrial Fibrillation","year":2013,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Dabigatran; Medicine; Warfarin; Quality-adjusted life year; Stroke (engine); Cost effectiveness; Atrial fibrillation; Health economics; Markov model; Actuarial science; Statistics; Public health; Markov chain; Risk analysis (engineering); Internal medicine; Mathematics","score_opus":0.2647009948908782,"score_gpt":0.46447964092576055,"score_spread":0.19977864603488232,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2043943400","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885568,0.0000777426,0.006593832,0.00040942762,0.00018569698,0.003983515,0.00004478256,0.0000046143323,0.00014357202],"genre_scores_gemma":[0.9995413,0.000037805883,0.0001925946,0.000008867023,0.00010909384,0.000027740725,0.000040281753,0.0000060095094,0.000036297723],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9990293,0.00014971399,0.00048715336,0.00013099742,0.00010823102,0.000094602634],"domain_scores_gemma":[0.99780834,0.0016114837,0.00024475987,0.0001693921,0.00013963245,0.00002637878],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00096525054,0.000090503,0.0005221106,0.00020355546,0.000026180865,0.0000074100585,0.00009017597,0.000027952829,0.000056078934],"category_scores_gemma":[0.00005063999,0.000060918515,0.0004043244,0.0002845379,0.000041335566,0.00013152188,0.000032159965,0.000039036295,0.0000017671604],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0058497824,0.000008462962,0.026117139,0.0000850925,0.002795569,1.8353138e-8,0.00083155266,0.9426197,0.015864301,0.0010795715,0.00001899115,0.0047298213],"study_design_scores_gemma":[0.008488842,0.00022455833,0.09541177,0.000021879774,0.0037974096,5.2856066e-8,0.00034966238,0.86104876,0.030065827,0.0003312064,0.00018531168,0.00007470802],"about_ca_topic_score_codex":0.00021604926,"about_ca_topic_score_gemma":0.000090585185,"teacher_disagreement_score":0.08157092,"about_ca_system_score_codex":0.00006895598,"about_ca_system_score_gemma":0.0000453135,"threshold_uncertainty_score":0.2484185},"labels":[],"label_agreement":null},{"id":"W2044932116","doi":"10.1007/s40273-013-0123-9","title":"Survival Modeling for the Estimation of Transition Probabilities in Model-Based Economic Evaluations in the Absence of Individual Patient Data: A Tutorial","year":2013,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":143,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; St. Joseph’s Healthcare Hamilton; Programs for Assessment of Technology in Health Research Institute","funders":"","keywords":"Computer science; Parametric statistics; Statistics; Statistical model; Parametric model; Logistic regression; Data mining; Econometrics; Machine learning; Mathematics","score_opus":0.585087396856932,"score_gpt":0.5634263158170457,"score_spread":0.021661081039886287,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2044932116","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.48233354,0.000011007854,0.5141474,0.0004641229,0.00037273337,0.0018827897,0.00076004624,0.000005690539,0.000022668099],"genre_scores_gemma":[0.7570214,0.000009071254,0.24237993,0.00006676463,0.0000832228,0.0004045395,0.000023718381,0.000011001593,3.3645642e-7],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9977695,0.0004591647,0.0012510305,0.0002280915,0.00014226788,0.00014998073],"domain_scores_gemma":[0.97086364,0.028275004,0.00033577788,0.00043187066,0.00007221266,0.000021499682],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0063431077,0.00011180025,0.00034852803,0.00006467512,0.00003682551,0.000030860992,0.0005256536,0.000059197933,0.00003828258],"category_scores_gemma":[0.0049678604,0.00008171819,0.00006996073,0.000051958785,0.00011073223,0.00022974449,0.000048158065,0.00014151716,0.0000016117739],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010829421,0.00014543705,0.000017839615,0.00011188764,0.000024841911,2.2131486e-8,0.0016039567,0.9674618,0.000042344072,0.020707846,0.00008602287,0.00968969],"study_design_scores_gemma":[0.00084263703,0.00002892581,0.000016809592,0.000016979815,0.00004579289,6.820541e-8,0.0002432789,0.60495543,0.00018889812,0.39361078,0.0000011739551,0.00004921243],"about_ca_topic_score_codex":0.00012868042,"about_ca_topic_score_gemma":0.00006257739,"teacher_disagreement_score":0.37290293,"about_ca_system_score_codex":0.00008490276,"about_ca_system_score_gemma":0.00022499125,"threshold_uncertainty_score":0.5947352},"labels":[],"label_agreement":null},{"id":"W2045226478","doi":"10.2165/00019053-200523120-00002","title":"Comment on ???The Economics of Follow-On Drug Research and Development: Trends in Entry Rates and the Timing of Development???","year":2005,"lang":"en","type":"letter","venue":"PharmacoEconomics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":104,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Institute of Health Economics","funders":"","keywords":"Drug development; Drug; Pharmaceutical industry; Competition (biology); Drug class; Medicine; Marketing; Pharmacology; Business; Actuarial science","score_opus":0.17386903855911948,"score_gpt":0.36626858022991754,"score_spread":0.19239954167079806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2045226478","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.30284533,0.0021530846,0.0000031684242,0.66745406,0.00045643083,0.0007538246,0.00038263848,0.000011826156,0.02593963],"genre_scores_gemma":[0.39112824,0.011201588,0.00045612326,0.5935367,0.0011462971,0.00029434063,0.00019959321,0.00018109851,0.0018560202],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99642813,0.00013848575,0.0019458369,0.00073435216,0.00005736765,0.0006958169],"domain_scores_gemma":[0.99641544,0.0019935677,0.00096657936,0.00047638261,0.00003473847,0.000113301045],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0035384097,0.0004730193,0.0011875338,0.0010368249,0.00023918953,0.00012665002,0.00076226855,0.0002879849,0.00046115],"category_scores_gemma":[0.00005377648,0.000412589,0.00013282712,0.0001691405,0.00064278004,0.00014019283,0.00039802215,0.0017316799,0.000113092174],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00082493835,0.00034722823,0.0033070864,0.00039480894,0.0009802178,0.000007226528,0.0060030334,0.00035285958,0.00000480708,0.1211744,0.8376201,0.028983342],"study_design_scores_gemma":[0.00327224,0.000036809153,0.000305818,0.00006951567,0.000012380837,0.000002519693,0.000070211296,0.0030909202,0.0015946514,0.0046613575,0.9864572,0.00042636957],"about_ca_topic_score_codex":0.00011354283,"about_ca_topic_score_gemma":0.000047002104,"teacher_disagreement_score":0.14883715,"about_ca_system_score_codex":0.0004484579,"about_ca_system_score_gemma":0.00014372668,"threshold_uncertainty_score":0.9998326},"labels":[],"label_agreement":null},{"id":"W2046221591","doi":"10.2165/00019053-200523110-00003","title":"Antiviral Agents for Influenza","year":2005,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Influenza Virus Research Studies","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Programs for Assessment of Technology in Health Research Institute; University of British Columbia","funders":"","keywords":"Medicine; Zanamivir; Rimantadine; Intensive care medicine; Oseltamivir; Economic evaluation; MEDLINE; Population; Cost effectiveness; Health economics; Vaccination; Amantadine; Public health; Influenza A virus; Disease; Environmental health; Internal medicine; Immunology; Virology; Virus; Infectious disease (medical specialty)","score_opus":0.3813457548146653,"score_gpt":0.5646355491973175,"score_spread":0.1832897943826522,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2046221591","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000015428268,0.98903143,0.000018619567,0.00006751651,0.0004377553,0.0031979047,0.00048959086,0.000090721835,0.0066510444],"genre_scores_gemma":[0.0000014840899,0.9909212,0.00091335695,0.0026911672,0.0021027813,0.0007880359,0.0001498492,0.00015813032,0.002273982],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99761784,0.00005617002,0.00091272884,0.00057088974,0.00014302056,0.00069934694],"domain_scores_gemma":[0.99861455,0.00029422945,0.00034688914,0.0004126801,0.000111263136,0.00022039036],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004317437,0.0005656117,0.0023297144,0.00034776205,0.000135371,0.000052642004,0.0003170604,0.000239412,0.0002284376],"category_scores_gemma":[0.00014717314,0.0004970437,0.001047051,0.00011276347,0.00011210872,0.00015303082,0.0002155223,0.0005821036,0.0014308218],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007998557,0.000075051605,0.00001039751,0.013564147,0.0010685159,0.000008546755,0.00002721256,0.0000013075838,9.565033e-7,0.00009299113,0.03724348,0.9478274],"study_design_scores_gemma":[0.001770943,0.00006886445,0.0000017435015,0.0016533547,0.0017858709,0.000019190846,0.000003990663,0.00009454874,0.00001274243,0.000011660413,0.994175,0.00040207166],"about_ca_topic_score_codex":0.0000043918935,"about_ca_topic_score_gemma":0.0000016367463,"teacher_disagreement_score":0.95693153,"about_ca_system_score_codex":0.0006636731,"about_ca_system_score_gemma":0.0006186827,"threshold_uncertainty_score":0.9997481},"labels":[],"label_agreement":null},{"id":"W2047003881","doi":"10.2165/00019053-200119070-00002","title":"A Clinical and Economic Review of Disease-Modifying Antirheumatic Drugs","year":2001,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"Fogarty International Center","keywords":"Health economics; Quality of Life Research; Antirheumatic drugs; Medicine; Public health; Health administration; Antirheumatic Agents; Disease; Pharmacoeconomics; Intensive care medicine; Internal medicine; Pathology","score_opus":0.08164672349616478,"score_gpt":0.45443617150456594,"score_spread":0.3727894480084012,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2047003881","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000513795,0.9961182,0.000003363297,0.00020703897,0.0002952823,0.0015331869,0.0001632423,0.00003507016,0.0011308112],"genre_scores_gemma":[0.0000313633,0.9987003,0.00018538868,0.00040356646,0.00021956157,0.00009987536,0.0001415913,0.00008461904,0.00013371119],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99685794,0.00024444176,0.0019034409,0.0005238995,0.00010982404,0.00036042897],"domain_scores_gemma":[0.9977309,0.0004521344,0.00066837843,0.00049372687,0.00004004136,0.00061481685],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011621731,0.00041186702,0.0035385857,0.00020248152,0.00005473002,0.00003251134,0.0002350469,0.00011554467,0.00083410507],"category_scores_gemma":[0.00011495282,0.00036008394,0.00091353105,0.0000752822,0.00031565852,0.00013445829,0.00015047115,0.0005148619,0.00028048723],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003897729,0.00005901779,0.00018278768,0.17902747,0.0004939113,0.000013028572,0.000009383876,6.534674e-8,3.927612e-8,0.000100882346,0.0023677966,0.81770664],"study_design_scores_gemma":[0.0011003359,0.00005229407,0.000007890764,0.1668162,0.00037523947,0.00009944182,0.000004434624,0.00009573455,2.3056218e-7,0.000051690673,0.831158,0.00023849412],"about_ca_topic_score_codex":0.000016110229,"about_ca_topic_score_gemma":7.7746074e-7,"teacher_disagreement_score":0.8287902,"about_ca_system_score_codex":0.00010088385,"about_ca_system_score_gemma":0.0008962076,"threshold_uncertainty_score":0.99988514},"labels":[],"label_agreement":null},{"id":"W2047186977","doi":"10.1007/s40273-014-0145-y","title":"Methods for Adjusting for Bias Due to Crossover in Oncology Trials","year":2014,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":56,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"TransCanada (Canada)","funders":"Pfizer","keywords":"Crossover; Crossover study; Censoring (clinical trials); Medicine; Randomized controlled trial; Treatment effect; Computer science; Statistics; Intensive care medicine; Mathematics; Internal medicine; Machine learning","score_opus":0.8723868667747371,"score_gpt":0.7400603947834757,"score_spread":0.13232647199126135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2047186977","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008907406,0.000027545319,0.98192674,0.0015618628,0.0029480795,0.0029735344,0.00025911536,0.00006425558,0.001331464],"genre_scores_gemma":[0.002153224,0.00001044397,0.9910405,0.0036506897,0.0016460696,0.0012380366,0.0000034334043,0.00007956144,0.00017800619],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99347955,0.0028490783,0.0024735983,0.0005741427,0.000056108547,0.0005674998],"domain_scores_gemma":[0.56905276,0.42960656,0.0006969459,0.00029877535,0.000116875366,0.00022810501],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.057752516,0.00024852256,0.002025834,0.00014514108,0.00008112354,0.000060092843,0.000382957,0.00022856027,0.00021825898],"category_scores_gemma":[0.47692102,0.00023824016,0.00038198588,0.00009956257,0.000060017635,0.0000739989,0.00012468302,0.00021848794,0.000029027537],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016590983,0.00016789917,0.000022538794,0.00024572024,0.00010417968,7.230942e-7,0.00017905075,0.00010098658,0.0020343345,0.16033998,0.011108625,0.82403684],"study_design_scores_gemma":[0.0062789256,0.0002602714,0.000011707856,0.000022636317,0.00017830865,0.000002137614,0.000024271616,0.028944321,0.01775009,0.7844038,0.16186595,0.00025757193],"about_ca_topic_score_codex":0.000009016582,"about_ca_topic_score_gemma":0.0000126780715,"teacher_disagreement_score":0.8237793,"about_ca_system_score_codex":0.00024248565,"about_ca_system_score_gemma":0.00011588633,"threshold_uncertainty_score":0.9715152},"labels":[],"label_agreement":null},{"id":"W2047422349","doi":"10.2165/00019053-200523100-00003","title":"Pharmacological Management of Overactive Bladder","year":2005,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Urinary Bladder and Prostate Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal General Hospital; McGill University; Canadian Association of Radiation Oncology","funders":"","keywords":"Overactive bladder; Oxybutynin; Tolterodine; Medicine; Discontinuation; Pharmacoeconomics; Cost effectiveness; Intensive care medicine; Urinary incontinence; Health economics; Economic evaluation; Pharmacotherapy; Urology; Internal medicine; Public health; Alternative medicine; Nursing","score_opus":0.14290427449321239,"score_gpt":0.4967414699887055,"score_spread":0.3538371954954931,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2047422349","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000047489684,0.95395255,0.000007295779,0.000095636846,0.00024919576,0.001798101,0.00017456105,0.000042068503,0.04363309],"genre_scores_gemma":[0.000052682673,0.99472755,0.00057913153,0.0001808002,0.000536027,0.00019544037,0.00018602847,0.000077309654,0.003465002],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99793553,0.00011426157,0.000798145,0.00051633705,0.0001879816,0.00044772457],"domain_scores_gemma":[0.9988679,0.00017945847,0.00032532256,0.0002903996,0.00005781908,0.0002790912],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00032139246,0.00043247108,0.0017478394,0.00024750066,0.00004535448,0.000017448316,0.00027944328,0.00019020664,0.005476746],"category_scores_gemma":[0.000003371791,0.00035935696,0.0006953383,0.00016577185,0.000104568026,0.00010983519,0.00025509516,0.0007810178,0.0007096714],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017101853,0.00046048797,0.0000019641466,0.012852809,0.004095319,0.00020972274,0.000021866566,0.0000026296448,0.000003478615,0.00009772374,0.006966492,0.9751165],"study_design_scores_gemma":[0.0013144619,0.00014981657,0.000003892601,0.0013387571,0.0053791935,0.0001899891,0.00001727468,0.00005258333,0.000058336154,0.000013533982,0.9911934,0.0002887699],"about_ca_topic_score_codex":0.0000031546574,"about_ca_topic_score_gemma":9.828682e-8,"teacher_disagreement_score":0.9842269,"about_ca_system_score_codex":0.0003366949,"about_ca_system_score_gemma":0.0002961462,"threshold_uncertainty_score":0.99988586},"labels":[],"label_agreement":null},{"id":"W2052610701","doi":"10.2165/00019053-200624110-00010","title":"Building Bridges Between Academic Research and Policy Formulation","year":2006,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health and Medical Research Impacts","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ministry of Health and Long Term Care; University of Toronto; McMaster University","funders":"","keywords":"Quality of Life Research; Health economics; Health administration; Public health; Health services research; Health care management; Management science; Public economics; Economics; Political science; Engineering ethics; Medicine; Engineering; Nursing","score_opus":0.5756712662218212,"score_gpt":0.6532551146880488,"score_spread":0.07758384846622757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2052610701","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011273269,0.9913284,0.000055979923,0.004069938,0.000095804855,0.001706457,0.000121696015,0.000050909253,0.0014434549],"genre_scores_gemma":[0.0003553498,0.99213237,0.0002196686,0.0008438079,0.0053535993,0.000081094295,0.00024208281,0.00008315355,0.00068887917],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99648815,0.00020201576,0.00087447243,0.00048637617,0.00042027238,0.0015286956],"domain_scores_gemma":[0.99362826,0.0015471398,0.00019415753,0.00025394655,0.0001141739,0.0042623165],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0039433404,0.0003048877,0.0014570095,0.0011271288,0.00017376433,0.00004921569,0.00021861863,0.0005312127,0.00003468086],"category_scores_gemma":[0.0051240865,0.00026116188,0.00015633908,0.00037664123,0.00016446346,0.0001613703,0.00019917873,0.002908832,0.0001376147],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000014772027,0.000016346175,0.000112838134,0.01588127,0.00005555312,0.0000100708985,0.000009691628,1.3322503e-7,0.0000025177637,0.0005851949,0.016102893,0.96720874],"study_design_scores_gemma":[0.0006691417,0.000118874996,0.000083740975,0.0039683436,0.0001949566,0.000058790043,0.0000019947738,0.000067647416,0.000016980082,0.0004537778,0.9941951,0.00017067735],"about_ca_topic_score_codex":0.0003474031,"about_ca_topic_score_gemma":0.0000017315498,"teacher_disagreement_score":0.9780922,"about_ca_system_score_codex":0.001570466,"about_ca_system_score_gemma":0.009301772,"threshold_uncertainty_score":0.9999841},"labels":[],"label_agreement":null},{"id":"W2053187674","doi":"10.2165/00019053-200220110-00002","title":"Cost Effectiveness of Implantable Cardioverter Defibrillator Therapy versus Drug Therapy for Patients at High Risk of Sudden Cardiac Death","year":2002,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Cardiac pacing and defibrillation studies","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"National Health and Medical Research Council","keywords":"Medicine; Ventricular fibrillation; Ventricular tachycardia; Implantable cardioverter-defibrillator; Sudden cardiac death; Amiodarone; Cost effectiveness; Intensive care medicine; Clinical trial; Pharmacotherapy; Internal medicine; Emergency medicine; Atrial fibrillation; Risk analysis (engineering)","score_opus":0.08632814917779946,"score_gpt":0.3784360256998538,"score_spread":0.29210787652205433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2053187674","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.076773405,0.901037,0.0000067237806,6.3548066e-7,0.0022160583,0.0038594317,0.0061833602,0.000037024794,0.009886405],"genre_scores_gemma":[0.024964347,0.9734932,0.00006062403,0.000010994426,0.00043297373,0.00027258016,0.00055334304,0.00012922155,0.00008270394],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975799,0.0003606966,0.00090790994,0.00056658365,0.00020683395,0.00037811015],"domain_scores_gemma":[0.99563736,0.0024707713,0.0009554983,0.00052348024,0.00027094386,0.00014195168],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00057592546,0.00059732975,0.005697178,0.0002155,0.0001152124,0.000014491583,0.000068635694,0.000201011,0.000009894319],"category_scores_gemma":[0.00004695526,0.0004952344,0.002447833,0.00012597656,0.0000664935,0.00007368067,0.00008577223,0.00016737096,0.000030174042],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009386245,0.00022827386,0.023800483,0.016327271,0.032182448,3.6724308e-7,0.00029061062,0.00013078129,0.000019610923,0.000030389005,0.040822554,0.876781],"study_design_scores_gemma":[0.009547631,0.00028670303,0.0005163277,0.0010501668,0.003470948,0.00001181401,0.000008895278,0.0000053505755,0.0005329136,0.0000047047206,0.98414636,0.0004181742],"about_ca_topic_score_codex":0.00020165062,"about_ca_topic_score_gemma":0.0000011264675,"teacher_disagreement_score":0.9433238,"about_ca_system_score_codex":0.00048296934,"about_ca_system_score_gemma":0.00014630795,"threshold_uncertainty_score":0.99974996},"labels":[],"label_agreement":null},{"id":"W2054744500","doi":"10.2165/00019053-200119090-00006","title":"The Cost of Palliative Care for Hepatocellular Carcinoma in Hong Kong","year":2001,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Hepatocellular carcinoma; Palliative care; Health economics; Liver cancer; Health care; Health administration; Cost effectiveness; Observational study; Total cost; Emergency medicine; Public health; Demography; Internal medicine; Nursing; Business","score_opus":0.1413662426449138,"score_gpt":0.43021783059366614,"score_spread":0.2888515879487523,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2054744500","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897238,0.0069319317,0.00024011247,0.00039936294,0.00019245454,0.0007369907,0.00006722893,0.000008687089,0.0016994457],"genre_scores_gemma":[0.99400926,0.0050827255,0.00037038114,0.0001825463,0.0001338162,0.00006419304,0.000038595448,0.00001954556,0.00009894897],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99917823,0.000022952556,0.00036825758,0.00016000417,0.000058448724,0.00021211186],"domain_scores_gemma":[0.9991163,0.00034895996,0.00016392133,0.00015952838,0.00014468114,0.00006662417],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015484194,0.00011906835,0.0003364806,0.000064511114,0.000044748525,0.0000057344273,0.00012111747,0.000044539942,0.000025008763],"category_scores_gemma":[0.000068522844,0.00009803514,0.0001254417,0.000081092054,0.00008335539,0.00005028647,0.00002827415,0.00010397946,0.0000048118427],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044558998,0.00003916654,0.98623526,0.00016890268,0.00007241169,0.000010598453,0.0028029955,0.00012356184,0.0023473743,0.00026252074,0.0003492469,0.0071423743],"study_design_scores_gemma":[0.011373115,0.00035806015,0.1234519,0.00050206465,0.00030830427,0.0000041189733,0.0138948625,0.043450225,0.43847552,0.00033570075,0.36741966,0.00042645988],"about_ca_topic_score_codex":0.00016320885,"about_ca_topic_score_gemma":0.00009812784,"teacher_disagreement_score":0.8627834,"about_ca_system_score_codex":0.00015060275,"about_ca_system_score_gemma":0.000097535274,"threshold_uncertainty_score":0.39977568},"labels":[],"label_agreement":null},{"id":"W2054892688","doi":"10.2165/00019053-200826020-00002","title":"Management of Anaemia","year":2008,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Erythropoietin and Anemia Treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Darbepoetin alfa; Epoetin alfa; Intensive care medicine; Health economics; Disease; Kidney disease; Pharmacoeconomics; Cost effectiveness; Erythropoietin; Anemia; Clinical trial; Public health; Internal medicine; Risk analysis (engineering); Pathology","score_opus":0.06135507168500458,"score_gpt":0.3980985499857165,"score_spread":0.3367434783007119,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2054892688","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000032243228,0.97210604,0.0000023692494,0.000046846675,0.00026935982,0.0006987447,0.000043934506,0.00003444003,0.026766015],"genre_scores_gemma":[0.0000069619687,0.99514985,0.0016763658,0.000070968155,0.00017532955,0.000060668008,0.00017018834,0.000057737863,0.0026319195],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988362,0.00001949124,0.0005870151,0.00029617915,0.00007028203,0.00019081094],"domain_scores_gemma":[0.9992036,0.000031332536,0.00029750142,0.00032351233,0.000017048476,0.00012697848],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000044983808,0.000310267,0.0014953866,0.00011362448,0.000027026817,0.0000036737972,0.00012340446,0.000116051255,0.0004395233],"category_scores_gemma":[9.546844e-7,0.0002583822,0.0006339572,0.00007818976,0.000067281835,0.00002106572,0.00007011236,0.00019842376,0.00035480998],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000009184914,0.00014807166,0.0000058770866,0.02381902,0.0011368337,0.0002866816,0.00001147797,3.5936483e-7,1.3462974e-7,0.00014089579,0.010064603,0.96437687],"study_design_scores_gemma":[0.0008112114,0.00004415278,0.000001660022,0.0052604964,0.0021922113,0.0003522421,0.00000999971,0.0000038263865,0.000020599256,0.0000038263775,0.99112374,0.00017604571],"about_ca_topic_score_codex":0.000004876401,"about_ca_topic_score_gemma":8.691931e-8,"teacher_disagreement_score":0.98105913,"about_ca_system_score_codex":0.00025597133,"about_ca_system_score_gemma":0.00014084484,"threshold_uncertainty_score":0.9999868},"labels":[],"label_agreement":null},{"id":"W2055026645","doi":"10.1007/s40273-014-0239-6","title":"Objectivity and Equity: Clarity Required. A Response to Hill and Olson","year":2014,"lang":"en","type":"letter","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of Alberta","funders":"Canadian Institutes of Health Research; Health Research Board","keywords":"CLARITY; Quality of Life Research; Equity (law); Health economics; Objectivity (philosophy); Positive economics; Public health; Economics; Political science; Sociology; Epistemology; Philosophy; Medicine; Law; Nursing; Chemistry","score_opus":0.39183422357754366,"score_gpt":0.4890259197931236,"score_spread":0.09719169621557994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2055026645","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.101259455,0.001988801,0.0009633963,0.88815737,0.0015046948,0.0016229196,0.0016321881,0.0001409144,0.0027302734],"genre_scores_gemma":[0.033168886,0.00064703537,0.001429079,0.9582358,0.0042425306,0.00027019807,0.00013524905,0.00018661882,0.0016845987],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99069285,0.0016179294,0.004491692,0.0019907772,0.00011837313,0.0010883926],"domain_scores_gemma":[0.99133587,0.004059056,0.0028653685,0.0010383546,0.00007424512,0.0006271002],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.03777442,0.0007371108,0.0026055465,0.0008411361,0.00037357304,0.0005005065,0.000610384,0.0010879115,0.00032522698],"category_scores_gemma":[0.0038837825,0.0010636168,0.00021875536,0.00013948246,0.00021330189,0.0007266692,0.00069685356,0.0017606212,0.0020659305],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019199283,0.00003313587,0.0028413385,0.0008626538,0.00018032604,0.000013163498,0.0007928124,0.000022261966,0.000022647062,0.0020671198,0.99206185,0.00091069925],"study_design_scores_gemma":[0.0011867448,0.00014040114,0.0018550855,0.00009438758,0.00004395515,0.000056883666,0.000052467738,0.0036128329,0.000011146224,0.009403321,0.98245037,0.0010923848],"about_ca_topic_score_codex":0.0011837534,"about_ca_topic_score_gemma":0.00010214743,"teacher_disagreement_score":0.07007845,"about_ca_system_score_codex":0.0015465613,"about_ca_system_score_gemma":0.00028561216,"threshold_uncertainty_score":0.9991814},"labels":[],"label_agreement":null},{"id":"W2055508765","doi":"10.2165/00019053-200725030-00007","title":"Modelling Cost Effectiveness of Insulin Glargine for the Treatment of Type 1 and 2 Diabetes in Canada","year":2007,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Diabetes Management and Research","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sanofi (Canada)","funders":"Institute for Clinical Evaluative Sciences","keywords":"Medicine; Insulin glargine; Diabetes mellitus; Insulin; Type 2 diabetes; NPH insulin; Internal medicine; United Kingdom Prospective Diabetes Study; Type 1 diabetes; Type 2 Diabetes Mellitus; Quality of Life Research; Intensive care medicine; Endocrinology; Pediatrics; Public health","score_opus":0.04198260012634948,"score_gpt":0.33509967947392305,"score_spread":0.2931170793475736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2055508765","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969132,0.0017214038,0.00017138624,0.00007634407,0.00009910187,0.0008247509,0.000014646989,0.0000016974444,0.00017745468],"genre_scores_gemma":[0.9985404,0.0012334324,0.00009161879,0.000028117878,0.00003035024,0.000020786665,0.000011300467,0.0000081295075,0.000035856076],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9995594,0.000012656355,0.0001577256,0.00008369379,0.00003862803,0.00014791261],"domain_scores_gemma":[0.9991638,0.000640247,0.00004115555,0.00007171482,0.000045495573,0.000037601843],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045470515,0.0000582822,0.00019201708,0.00005744503,0.0000134532265,0.0000022971103,0.000039371953,0.000012031496,0.00000827607],"category_scores_gemma":[0.000009849679,0.00004102482,0.000020750389,0.00007019526,0.000029115821,0.000020121977,0.000011539535,0.000030363339,2.6082802e-7],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028128698,0.0004664336,0.74127716,0.001367208,0.000628301,0.000004283966,0.00013473544,0.08943213,0.0073747495,0.00024604486,0.00009834773,0.15615775],"study_design_scores_gemma":[0.0065048942,0.00039280113,0.03134808,0.00007020712,0.00013661751,1.1599076e-7,0.00008519383,0.8425165,0.110279255,0.00006354528,0.008520972,0.00008186219],"about_ca_topic_score_codex":0.046429098,"about_ca_topic_score_gemma":0.022105917,"teacher_disagreement_score":0.7530843,"about_ca_system_score_codex":0.00019183209,"about_ca_system_score_gemma":0.00013764566,"threshold_uncertainty_score":0.9957381},"labels":[],"label_agreement":null},{"id":"W2058547566","doi":"10.2165/11531590-000000000-00000","title":"A Review of Methods Used in Long-Term Cost-Effectiveness Models of Diabetes Mellitus Treatment","year":2010,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Diabetes Management and Research","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; St. Joseph’s Healthcare Hamilton; Programs for Assessment of Technology in Health Research Institute","funders":"","keywords":"Quality of Life Research; Health economics; Health administration; Term (time); Medicine; Diabetes mellitus; Public health; Pharmacoeconomics; Cost effectiveness; Intensive care medicine; Quality-adjusted life year; Type 2 Diabetes Mellitus; Risk analysis (engineering); Nursing; Endocrinology","score_opus":0.20669767070550096,"score_gpt":0.5208117208390047,"score_spread":0.3141140501335038,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2058547566","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000634618,0.9912905,0.0000764021,0.000023738421,0.0002845213,0.0067483857,0.00008925844,0.0000162493,0.0008363175],"genre_scores_gemma":[0.00003333964,0.9976141,0.00064916705,0.00006811274,0.00008784447,0.001058373,0.000281694,0.000082796614,0.00012456474],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99698335,0.0007079491,0.0012626682,0.00049725734,0.000115573384,0.00043322594],"domain_scores_gemma":[0.99742126,0.0009923526,0.00068717694,0.0006319231,0.00009523744,0.00017201834],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0024771788,0.0004882439,0.004417694,0.0005478687,0.000015348287,0.000011256727,0.00035746658,0.00022225252,0.00023181573],"category_scores_gemma":[0.000059884034,0.00037340733,0.0009596816,0.00030196382,0.0001385725,0.000114222996,0.00015940827,0.0004846825,0.000020109032],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001418131,0.00035376538,0.00033574627,0.31252334,0.00063827494,0.0000029793387,0.0000074918357,0.0000035696485,0.000021923915,0.000033309283,0.000028535931,0.6860369],"study_design_scores_gemma":[0.0029530872,0.00031089527,0.00007815186,0.19792204,0.005808384,0.0000017072203,0.0000012854534,0.00065725506,0.0012711989,0.00006181349,0.79047185,0.00046231563],"about_ca_topic_score_codex":0.000008776565,"about_ca_topic_score_gemma":0.0000023706273,"teacher_disagreement_score":0.7904433,"about_ca_system_score_codex":0.0003961072,"about_ca_system_score_gemma":0.0003981411,"threshold_uncertainty_score":0.9998718},"labels":[],"label_agreement":null},{"id":"W2060265964","doi":"10.2165/11530860-000000000-00000","title":"Principles of Design of Access with Evidence Development Approaches","year":2010,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Assistive Technology in Communication and Mobility","field":"Health Professions","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Quality of Life Research; Health economics; Public health; Health administration; Business; Medicine; Management science; Economics; Nursing","score_opus":0.5435838607676401,"score_gpt":0.5010077940784446,"score_spread":0.042576066689195446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2060265964","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97537965,0.000067230125,0.018236293,0.0005687316,0.00013782544,0.0007541671,0.000005837722,0.0000540413,0.004796207],"genre_scores_gemma":[0.9512715,0.00008148137,0.048176114,0.00011366816,0.000013976213,0.00018765529,0.0000024470385,0.000009521399,0.00014364076],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990056,0.00014850755,0.00050237897,0.00015253978,0.00004639392,0.00014454173],"domain_scores_gemma":[0.99804074,0.00083703006,0.0005109261,0.0004506316,0.00011632699,0.0000443256],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011726724,0.00008536202,0.00020500635,0.000062427614,0.00014761522,0.0000020268483,0.0006362873,0.000093926654,0.00026527746],"category_scores_gemma":[0.00014545696,0.00007112744,0.00001801427,0.00006358798,0.0002549884,0.00014391262,0.00031008062,0.00046518457,0.000015451453],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000443854,0.0002912796,0.94689536,0.0004513905,0.00013695857,2.5290942e-7,0.0017310109,0.00055127445,0.018654412,0.012420635,0.00030035587,0.018123224],"study_design_scores_gemma":[0.0024700456,0.00012152103,0.4851738,0.00038158792,0.0001113204,0.0000028166312,0.0015173289,0.00954566,0.43788567,0.00037631637,0.061877683,0.00053624663],"about_ca_topic_score_codex":0.00002659802,"about_ca_topic_score_gemma":0.000096447075,"teacher_disagreement_score":0.46172157,"about_ca_system_score_codex":0.00005058816,"about_ca_system_score_gemma":0.0005853809,"threshold_uncertainty_score":0.29046023},"labels":[],"label_agreement":null},{"id":"W2060836363","doi":"10.1007/s40273-014-0244-9","title":"Systematic Review of Cost-Effectiveness Analyses of Treatments for Psoriasis","year":2014,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Advancing Health Outcomes; St. Paul's Hospital; University of British Columbia","funders":"Canadian Institutes of Health Research; AbbVie Canada; Michael Smith Health Research BC; Pfizer","keywords":"Medicine; MEDLINE; Time horizon; Health economics; Health care; Health administration; Cost effectiveness; Economic evaluation; Public health; Risk analysis (engineering); Nursing; Business; Pathology","score_opus":0.12097548477240598,"score_gpt":0.43272456523198516,"score_spread":0.31174908045957916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2060836363","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00003277156,0.9898436,0.00008604174,0.0000024127735,0.0009697349,0.007050013,0.0018560365,0.00002179022,0.00013756726],"genre_scores_gemma":[0.00003868416,0.99460894,0.000056917863,0.000031010713,0.00004726951,0.0033298158,0.0015815814,0.00006276084,0.00024303135],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9963164,0.0011127219,0.0018107368,0.0004474397,0.00002643977,0.00028631042],"domain_scores_gemma":[0.9947269,0.0021888183,0.0023552228,0.0005675726,0.00012870945,0.000032769316],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00093435036,0.0005851115,0.006847958,0.00024885437,0.00005661238,0.0000050534495,0.00045135067,0.00032336437,0.00016025502],"category_scores_gemma":[0.00016076952,0.00043817208,0.0020370735,0.00014174126,0.0000823037,0.00005366059,0.000056859488,0.00010243534,0.0001416332],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000047346057,0.00016159347,0.0000014726659,0.82443595,0.014368326,3.9297387e-7,0.000007540954,6.241539e-7,0.00009245956,0.000047381054,0.00026046933,0.16057646],"study_design_scores_gemma":[0.0026217573,0.00020910785,0.0000011978169,0.6415924,0.12718548,0.000030066476,0.000004901109,0.0000018044416,0.007368973,0.000016261227,0.22046375,0.00050434313],"about_ca_topic_score_codex":0.000018105547,"about_ca_topic_score_gemma":7.768233e-7,"teacher_disagreement_score":0.22020328,"about_ca_system_score_codex":0.0001858392,"about_ca_system_score_gemma":0.00018212409,"threshold_uncertainty_score":0.999807},"labels":[],"label_agreement":null},{"id":"W2060853834","doi":"10.2165/00019053-200725050-00003","title":"The Work Productivity and Activity Impairment Questionnaire for Patients with Gastroesophageal Reflux Disease (WPAI-GERD)","year":2007,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Gastroesophageal reflux and treatments","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; AstraZeneca (Canada); McGill University; McMaster University","funders":"","keywords":"GERD; Reflux; Medicine; Work productivity; Productivity; Esomeprazole; Physical therapy; Internal medicine; Disease","score_opus":0.008155376778851982,"score_gpt":0.28626728982741695,"score_spread":0.278111913048565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2060853834","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966515,0.00010592665,0.00065934705,0.00055676023,0.00024769473,0.0016217406,0.000050272083,0.00005809568,0.000048713802],"genre_scores_gemma":[0.9981973,0.000020303723,0.0008427986,0.00016535667,0.00026895545,0.00012875529,0.000038837,0.000038007325,0.00029969256],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99872154,0.000030248737,0.00021153926,0.0004206102,0.00013420945,0.00048183426],"domain_scores_gemma":[0.9988907,0.00011435733,0.00014181962,0.00028039337,0.000100648576,0.0004720613],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004281448,0.00024431557,0.00023444887,0.00004877796,0.00034557385,0.000048381156,0.0000727619,0.000032152682,0.000006997821],"category_scores_gemma":[0.000053751846,0.000161229,0.0000810344,0.000067456764,0.00013789008,0.00019386518,0.000047288973,0.0001560351,0.000008804281],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0057871854,0.00083550304,0.9384302,0.000064256805,0.00018624074,0.000047159538,0.00004759968,0.0000114883,0.000018963912,0.00002459366,0.0002476274,0.054299176],"study_design_scores_gemma":[0.005082209,0.0006406934,0.99254483,0.000024024177,0.0002447979,0.0000070877336,0.0000040974637,0.0000904958,0.00082472863,0.00006451546,0.0003874103,0.00008511966],"about_ca_topic_score_codex":0.0000035392334,"about_ca_topic_score_gemma":0.0000053499366,"teacher_disagreement_score":0.054214057,"about_ca_system_score_codex":0.00025661013,"about_ca_system_score_gemma":0.00009588755,"threshold_uncertainty_score":0.65747285},"labels":[],"label_agreement":null},{"id":"W2062898140","doi":"10.2165/00019053-200220090-00003","title":"Cost Effectiveness of Tinzaparin Sodium Versus Unfractionated Heparin in the Treatment of Proximal Deep Vein Thrombosis","year":2002,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Association of Radiation Oncology","funders":"","keywords":"Medicine; Deep vein; Heparin; Enoxaparin sodium; Low molecular weight heparin; Thrombosis; Pharmacoeconomics; Quality-adjusted life year; Cost effectiveness; Clinical trial; Intensive care medicine; Economic evaluation; Internal medicine","score_opus":0.09383213385810416,"score_gpt":0.36446008411330133,"score_spread":0.27062795025519715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2062898140","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894823,0.00032896432,0.000019884501,0.00036596385,0.00032527858,0.001485392,0.000017745764,0.000016454054,0.007958007],"genre_scores_gemma":[0.9966457,0.0027365054,0.00009460718,0.000116774085,0.0000670327,0.00026389438,0.000031498286,0.000019000387,0.00002498866],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9989697,0.00012100816,0.0003687061,0.00022511838,0.00010435171,0.00021113364],"domain_scores_gemma":[0.99912995,0.00036253678,0.00016677537,0.00024787668,0.000042178115,0.00005065758],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003088019,0.00016423094,0.0005412948,0.00012345763,0.00003529855,0.00000960091,0.00012364167,0.00004855628,0.00040769126],"category_scores_gemma":[0.000016056394,0.00012989625,0.00013198878,0.0001409286,0.00007218119,0.00008119474,0.00002325108,0.00008592656,0.00004783547],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017561706,0.12756477,0.31543106,0.004684152,0.010991698,0.00015752696,0.02666736,0.019007482,0.07277959,0.011985247,0.011914207,0.3812552],"study_design_scores_gemma":[0.04156262,0.0049030213,0.6757929,0.00017327176,0.0017913072,0.000012201187,0.0011997382,0.032443445,0.19158511,0.000113876726,0.049877033,0.00054552173],"about_ca_topic_score_codex":0.00043161612,"about_ca_topic_score_gemma":0.000070067,"teacher_disagreement_score":0.38070968,"about_ca_system_score_codex":0.0003071003,"about_ca_system_score_gemma":0.000023675071,"threshold_uncertainty_score":0.52970153},"labels":[],"label_agreement":null},{"id":"W2063141697","doi":"10.2165/11587430-000000000-00000","title":"The Impact of Disease Stage on Direct Medical Costs of HIV Management","year":2010,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"HIV/AIDS Research and Interventions","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Centre for Advancing Health Outcomes; St. Paul's Hospital; Dalhousie University","funders":"Johnson and Johnson","keywords":"Health economics; Health administration; Public health; Quality of Life Research; Medicine; Pharmacoeconomics; Health care management; Disease; Disease management; Human immunodeficiency virus (HIV); Stage (stratigraphy); Environmental health; Intensive care medicine; Virology; Internal medicine; Nursing","score_opus":0.05005736980866225,"score_gpt":0.47091810087675184,"score_spread":0.4208607310680896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2063141697","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00026547193,0.94833416,0.000015534031,0.0001863245,0.00015813278,0.0014416794,0.0015307165,0.000017357219,0.048050627],"genre_scores_gemma":[0.0002950261,0.98442066,0.000012051801,0.00002397072,0.00017302815,0.00010809299,0.0002183272,0.000043735643,0.014705095],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981908,0.00015484948,0.000803838,0.00025552875,0.00028874585,0.00030621397],"domain_scores_gemma":[0.99793553,0.00041711182,0.00037520682,0.00057336135,0.000059223763,0.000639542],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00079113967,0.0002596847,0.0010663192,0.00021963898,0.000054565295,0.000017152859,0.00047744744,0.00010286833,0.00275736],"category_scores_gemma":[0.00022712219,0.00015251977,0.0014947063,0.00009924928,0.00020734224,0.000036942976,0.00015737543,0.0006929699,0.00020273679],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019840406,0.00036577677,0.000023396868,0.00629173,0.0011906784,0.000028174205,0.0000048566685,0.0000013455464,0.0000011763123,0.0005242771,0.05875355,0.93261665],"study_design_scores_gemma":[0.00072016753,0.00040277737,0.000017475013,0.0056041977,0.00066791894,0.000003405424,0.0000051260636,0.0005488367,0.0000131235065,0.000007018972,0.9918959,0.0001140292],"about_ca_topic_score_codex":0.00003830282,"about_ca_topic_score_gemma":0.000005613636,"teacher_disagreement_score":0.93314236,"about_ca_system_score_codex":0.00028796942,"about_ca_system_score_gemma":0.0006413506,"threshold_uncertainty_score":0.9981543},"labels":[],"label_agreement":null},{"id":"W2063252993","doi":"10.2165/00019053-200220001-00004","title":"Economic Evaluation of Pioglitazone Hydrochloride in the Management of Type 2 Diabetes Mellitus in Canada","year":2002,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Eli Lilly (Canada); Ottawa Hospital; University of Ottawa","funders":"Eli Lilly Canada","keywords":"Pioglitazone; Medicine; Type 2 diabetes; Metformin; Rosiglitazone; Diabetes mellitus; Type 2 Diabetes Mellitus; Internal medicine; Repaglinide; Intensive care medicine; Endocrinology","score_opus":0.030143520336680916,"score_gpt":0.2844244656490735,"score_spread":0.25428094531239254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2063252993","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9822269,0.0018919214,2.8422113e-7,0.00044930287,0.00020432741,0.0006207691,0.000008930207,0.0000030715153,0.014594512],"genre_scores_gemma":[0.9978522,0.0017035448,0.00006039244,0.00023302087,0.00002248256,0.00004238063,0.00001870391,0.000009570913,0.000057688212],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99913955,0.000036918373,0.0003791335,0.0001484182,0.0001230835,0.00017288182],"domain_scores_gemma":[0.99959075,0.000042534542,0.0001149671,0.00020402815,0.000018819059,0.000028867846],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005259121,0.00009869696,0.00024366958,0.00011008767,0.000008292965,0.0000037862148,0.00012230554,0.000013879209,0.0004842522],"category_scores_gemma":[0.0000028567265,0.00008595318,0.000036542355,0.0000883804,0.000018503673,0.000063726206,0.000030531428,0.000052966294,0.000020180014],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034423152,0.0017818508,0.4226767,0.001595135,0.002647832,0.000053514013,0.0019412395,0.05403394,0.000849761,0.003586488,0.012358562,0.49813074],"study_design_scores_gemma":[0.024346163,0.00041992858,0.27075696,0.00040645472,0.0030549723,0.0000023240207,0.0027313689,0.6442032,0.02958829,0.0013396872,0.0224974,0.0006532483],"about_ca_topic_score_codex":0.041361585,"about_ca_topic_score_gemma":0.06366743,"teacher_disagreement_score":0.59016925,"about_ca_system_score_codex":0.00085409224,"about_ca_system_score_gemma":0.000076541386,"threshold_uncertainty_score":0.9650221},"labels":[],"label_agreement":null},{"id":"W2063999798","doi":"10.2165/00019053-200523120-00008","title":"A Willingness-To-Pay Assessment of Parents?? Preference for Shorter Duration Treatment of Acute Otitis Media in Children","year":2005,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Ear Surgery and Otitis Media","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôtel-Dieu de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Health economics; Quality of Life Research; Willingness to pay; Acute otitis media; Medicine; Public health; Health administration; Duration (music); Otitis; Preference; Environmental health; Economics; Nursing; Surgery","score_opus":0.03556059862634995,"score_gpt":0.35106162035920363,"score_spread":0.31550102173285366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2063999798","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99733543,0.00005754295,0.00054992526,0.00044532566,0.00029058265,0.00081529625,0.00027943825,0.000011308034,0.00021514876],"genre_scores_gemma":[0.9941393,0.0009151539,0.004033648,0.00020094514,0.0002530255,0.00011793951,0.00024467948,0.000017222423,0.00007808876],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990153,0.00001904471,0.0005145998,0.00020527247,0.00007395064,0.00017184748],"domain_scores_gemma":[0.9994432,0.00009191366,0.00015397185,0.00014632483,0.000051542,0.00011308669],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013689227,0.00012781617,0.0003959161,0.000113223214,0.000013635522,0.000005112522,0.000060931514,0.000046292673,0.00014918197],"category_scores_gemma":[0.000011795897,0.00010783316,0.00009842415,0.00006095196,0.000026325657,0.00011450838,0.000012194587,0.000052655767,0.0000065851236],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015924421,0.00045902192,0.95589703,0.00002899161,0.00022499006,0.0000015052593,0.00057293125,0.00022208464,0.004314559,0.00006941061,0.00018359,0.037866637],"study_design_scores_gemma":[0.0034353577,0.00035395855,0.91641766,0.000062141626,0.0002828886,0.000010841766,0.00002409545,0.004851041,0.073010415,0.000028619597,0.0013838761,0.00013910934],"about_ca_topic_score_codex":0.000027949469,"about_ca_topic_score_gemma":0.00008929101,"teacher_disagreement_score":0.06869586,"about_ca_system_score_codex":0.00015089341,"about_ca_system_score_gemma":0.0001315495,"threshold_uncertainty_score":0.43973088},"labels":[],"label_agreement":null},{"id":"W2064406802","doi":"10.2165/00019053-200220002-00001","title":"Why Has the Use of Health Economic Evaluation in Japan Lagged Behind that in Other Developed Countries?","year":2002,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BioPhage Pharma (Canada); McMaster University","funders":"","keywords":"Formulary; Reimbursement; Health care; Health economics; Economic evaluation; Business; Health technology; Population health; Health administration; Population; Public economics; Economic growth; Medicine; Economics; Environmental health","score_opus":0.8097905546259976,"score_gpt":0.5352025390544429,"score_spread":0.27458801557155466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2064406802","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0022529252,0.97320765,0.000089882466,0.014517745,0.0017039673,0.00570502,0.0019934122,0.00003502238,0.00049434317],"genre_scores_gemma":[0.00057765085,0.97927773,0.00042135082,0.017718635,0.00034485004,0.00096933416,0.00026342497,0.00019844445,0.00022856618],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98234564,0.0026417645,0.012528325,0.0013484077,0.0001547677,0.0009811238],"domain_scores_gemma":[0.9844018,0.0031959186,0.010991275,0.0011509553,0.00005827808,0.0002017785],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.03764494,0.000804736,0.005666798,0.0015164139,0.00022609957,0.00032317423,0.0010585455,0.0004978971,0.0028254262],"category_scores_gemma":[0.0008748315,0.0008925991,0.00052194536,0.00026101182,0.0002373907,0.0011745628,0.00016625738,0.0008451119,0.002210448],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009596748,0.00095097657,0.030322472,0.037031416,0.0018299677,0.000003969818,0.01704643,0.014532951,6.311665e-8,0.02005742,0.42180666,0.4563217],"study_design_scores_gemma":[0.0014558629,0.000027496833,0.0003381542,0.0018120612,0.000068588495,0.000007877375,0.00014186386,0.01329462,2.7158833e-7,0.00045156176,0.9816765,0.0007251409],"about_ca_topic_score_codex":0.0100965705,"about_ca_topic_score_gemma":0.008893315,"teacher_disagreement_score":0.5598698,"about_ca_system_score_codex":0.0072937813,"about_ca_system_score_gemma":0.0023044057,"threshold_uncertainty_score":0.99935246},"labels":[],"label_agreement":null},{"id":"W2064604288","doi":"10.2165/00019053-200119010-00002","title":"The Cost of HIV Treatment and Care","year":2001,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"HIV/AIDS Research and Interventions","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"University of Nottingham","keywords":"Purchasing power parity; Health economics; Context (archaeology); Medicine; Indirect costs; Health care; Total cost; Population; Public health; Purchasing power; Health administration; Economic cost; Formulary; Productivity; Pharmacoeconomics; Environmental health; Gross domestic product; Cost driver; Economics; Economic growth; Intensive care medicine; Family medicine; Geography; Accounting; Nursing","score_opus":0.09981778601993617,"score_gpt":0.46138635784955967,"score_spread":0.3615685718296235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2064604288","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000025300746,0.9827907,0.000006960057,0.00011674471,0.00005663073,0.0010596986,0.00034855385,0.000009464905,0.015585918],"genre_scores_gemma":[0.000011901071,0.98090947,0.00001887674,0.000012664419,0.00017972916,0.00017708888,0.0002019542,0.000027458094,0.01846085],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991145,0.000058845897,0.00040400162,0.00017879672,0.00004147862,0.00020235323],"domain_scores_gemma":[0.9992468,0.00015628256,0.00014518028,0.00023546857,0.000046424804,0.0001698843],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000098893775,0.00018287146,0.00076437194,0.000086100306,0.00008338901,0.000024382858,0.00010917667,0.00006102222,0.0002950051],"category_scores_gemma":[0.00002050062,0.000109792316,0.0004472977,0.00005504669,0.000102531194,0.000028336572,0.000047529786,0.00017241934,0.00012566315],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000151086615,0.00004246544,0.00001348568,0.003138759,0.0003930056,0.000005383542,0.00004853099,9.942472e-8,4.650784e-7,0.000052228123,0.014524364,0.9817661],"study_design_scores_gemma":[0.0006205717,0.00035025852,6.726382e-7,0.0013902938,0.0008326703,0.000060621758,0.00009718846,0.00005123543,0.000013016373,0.0000027303927,0.996503,0.000077739474],"about_ca_topic_score_codex":0.00003116527,"about_ca_topic_score_gemma":0.000023469971,"teacher_disagreement_score":0.98197865,"about_ca_system_score_codex":0.00029333704,"about_ca_system_score_gemma":0.0002563985,"threshold_uncertainty_score":0.44772008},"labels":[],"label_agreement":null},{"id":"W2066651696","doi":"10.2165/00019053-200523100-00005","title":"Using Policy Simulation to Predict Drug Plan Expenditure when Planning Reimbursement Changes","year":2005,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ministry of Health","funders":"National Institute on Aging","keywords":"Reimbursement; Pharmacy; Medical prescription; Health policy; Prescription drug; Actuarial science; Finance; Public health; Medicine; Database; Business; Computer science; Economics; Health care; Family medicine; Economic growth; Nursing","score_opus":0.4817690817088586,"score_gpt":0.5174527065581008,"score_spread":0.0356836248492422,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2066651696","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8472966,0.0024276662,0.018662175,0.11709708,0.002044171,0.0022000037,0.0011539937,0.00028884597,0.008829445],"genre_scores_gemma":[0.924745,0.00008368401,0.01160931,0.05593809,0.0063736667,0.00013638553,0.00011424792,0.00010430613,0.000895298],"study_design_codex":"simulation_or_modeling","study_design_gemma":"not_applicable","domain_scores_codex":[0.9955504,0.00016291057,0.002696842,0.0007911006,0.000090863476,0.0007078838],"domain_scores_gemma":[0.99700516,0.0004520783,0.0015306548,0.00050206075,0.00004230435,0.00046772754],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.005372833,0.0003478427,0.0008641838,0.00079388585,0.000308904,0.00017285754,0.00044946308,0.00013146657,0.0010173615],"category_scores_gemma":[0.00034059398,0.0004946014,0.000119620505,0.00013818388,0.00003486151,0.0008056643,0.00013571669,0.00024648692,0.0020553775],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006779579,0.00011388479,0.0161887,0.00015121704,0.00018005645,0.0000018187557,0.012972639,0.8774981,0.00009471235,0.01224514,0.07874475,0.0017412059],"study_design_scores_gemma":[0.0012280239,0.00003943537,0.0011433465,0.00007103589,0.000017751116,0.00000568732,0.0008172185,0.38130656,0.000307191,0.001765834,0.6126597,0.0006382212],"about_ca_topic_score_codex":0.0007234296,"about_ca_topic_score_gemma":0.00013328294,"teacher_disagreement_score":0.533915,"about_ca_system_score_codex":0.0020856145,"about_ca_system_score_gemma":0.00018270848,"threshold_uncertainty_score":0.9998959},"labels":[],"label_agreement":null},{"id":"W2066712604","doi":"10.2165/00019053-200523020-00004","title":"The Case for Stratified Cost-Effectiveness Analysis by Baseline Health-Related QOL","year":2005,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria","funders":"","keywords":"Medicine; Pharmacotherapy; Health economics; Quality of life (healthcare); Quality-adjusted life year; Cost-effectiveness analysis; Pharmacoeconomics; Quality of Life Research; Cost effectiveness; Public health; Physical therapy; Intensive care medicine; Internal medicine; Pathology","score_opus":0.2908016787876391,"score_gpt":0.4913464064672718,"score_spread":0.20054472767963272,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2066712604","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5180245,0.021532077,0.17050658,0.2616387,0.002869376,0.011061203,0.011967813,0.00034988715,0.00204987],"genre_scores_gemma":[0.9751016,0.0007897252,0.0018895532,0.018122675,0.0006189085,0.0014679878,0.0005478249,0.00008925537,0.0013725059],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9923833,0.000760556,0.005203419,0.00083923957,0.000046200304,0.0007673128],"domain_scores_gemma":[0.9907823,0.005182988,0.0028992335,0.00064372976,0.00009148315,0.00040024676],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.034275834,0.00033243594,0.0013926058,0.00031845065,0.0009436451,0.00023826103,0.0004118847,0.00014509771,0.0005118961],"category_scores_gemma":[0.001013979,0.00037672883,0.0004361274,0.00033413156,0.00010375816,0.0005785323,0.000048996404,0.00026942242,0.0008400247],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00055264565,0.0008888746,0.008969186,0.0008593284,0.0076169698,0.000015356452,0.0026378706,0.08573627,0.000063628046,0.18624009,0.6465525,0.059867263],"study_design_scores_gemma":[0.0026637106,0.00006427552,0.0002762498,0.000009621068,0.00011424796,0.0000393233,0.00042371318,0.43475553,0.000117792806,0.0021584658,0.5588765,0.00050057296],"about_ca_topic_score_codex":0.0014157321,"about_ca_topic_score_gemma":0.0013368966,"teacher_disagreement_score":0.45707706,"about_ca_system_score_codex":0.0014636742,"about_ca_system_score_gemma":0.00023714188,"threshold_uncertainty_score":0.99993795},"labels":[],"label_agreement":null},{"id":"W2067068357","doi":"10.2165/00019053-200826060-00003","title":"Guidelines for Conducting Pharmaceutical Budget Impact Analyses for Submission to Public Drug Plans in Canada","year":2008,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":81,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Child and Family Research Institute; McMaster University; St. Joseph's Hospital","funders":"","keywords":"Reimbursement; Guideline; Agency (philosophy); Advisory committee; Medicine; Process management; Business; Health care; Political science; Public administration","score_opus":0.8838236794225288,"score_gpt":0.6563261702826145,"score_spread":0.2274975091399143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2067068357","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012237704,0.95621383,0.0014723572,0.016068617,0.0026645737,0.00631756,0.015729124,0.00005750353,0.00025266196],"genre_scores_gemma":[0.00023095144,0.9745617,0.0047716023,0.014145207,0.0020249577,0.0022898912,0.0013053858,0.00024614876,0.0004241793],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9858431,0.0003716339,0.01074424,0.001542573,0.000102620994,0.0013958253],"domain_scores_gemma":[0.988804,0.0049537015,0.0042957207,0.00067229493,0.00028414823,0.000990166],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00983042,0.00091608544,0.0057286643,0.001205833,0.00032156386,0.00017569837,0.0010270422,0.00028327567,0.00040336713],"category_scores_gemma":[0.0066361655,0.0010576388,0.0010861354,0.00038235742,0.00004413556,0.0005877936,0.00014347906,0.00050523883,0.00026750652],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00006346972,0.000116658186,0.0009553955,0.012970734,0.0009301648,0.0000042323118,0.0003005338,0.0019648361,8.666674e-7,0.001333078,0.90142727,0.07993278],"study_design_scores_gemma":[0.0013483209,0.000029516848,0.000007871306,0.00074590114,0.00010248239,0.000027815247,0.00018936682,0.013894708,0.000005071776,0.00021931082,0.9823916,0.0010380112],"about_ca_topic_score_codex":0.22673276,"about_ca_topic_score_gemma":0.19074365,"teacher_disagreement_score":0.08096437,"about_ca_system_score_codex":0.00914277,"about_ca_system_score_gemma":0.007763544,"threshold_uncertainty_score":0.9991874},"labels":[],"label_agreement":null},{"id":"W2068218519","doi":"10.2165/00019053-200523070-00007","title":"Costs and Medical Care Consequences Associated with the Diagnosis of Peripheral Arterial Disease","year":2005,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Peripheral Artery Disease Management","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Association of Radiation Oncology; McGill University","funders":"","keywords":"Medicine; Myocardial infarction; Emergency medicine; Population; Arterial disease; Disease; Health economics; Medical care; Public health; Internal medicine; Pediatrics; Vascular disease","score_opus":0.01408995194429847,"score_gpt":0.2922336100092169,"score_spread":0.2781436580649184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2068218519","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97897947,0.0007080932,0.0000054485736,0.018911075,0.00008317933,0.0003750749,0.00008432885,0.00003111558,0.00082222087],"genre_scores_gemma":[0.99313873,0.0003319189,0.000035114128,0.0060423426,0.00023296963,0.00009946669,0.00004229523,0.000014713951,0.00006245314],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992103,0.000051313014,0.00019704718,0.00019664572,0.00016940151,0.00017530176],"domain_scores_gemma":[0.9993361,0.000070473616,0.000089243396,0.00013526878,0.00004718659,0.00032170795],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00011353617,0.0001315154,0.00021601564,0.00002613968,0.00006778404,0.000026554235,0.00010732064,0.00002679604,0.0011008901],"category_scores_gemma":[0.000038774695,0.00008856986,0.000051969713,0.000038130747,0.00036098753,0.0001000385,0.000052610707,0.000093886294,0.000007259658],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045212354,0.0011253714,0.80485046,0.00036819922,0.0016888101,0.00031671594,0.003785439,0.0004478486,0.0011857272,0.00072587724,0.03392344,0.14706089],"study_design_scores_gemma":[0.028699687,0.00084433286,0.7575699,0.00068397913,0.0029950552,0.00006127631,0.003262655,0.022801692,0.004628845,0.00006861901,0.17720042,0.0011835155],"about_ca_topic_score_codex":0.00002444334,"about_ca_topic_score_gemma":0.00012190119,"teacher_disagreement_score":0.14587736,"about_ca_system_score_codex":0.0001847969,"about_ca_system_score_gemma":0.00016735417,"threshold_uncertainty_score":0.99981225},"labels":[],"label_agreement":null},{"id":"W2070111960","doi":"10.2165/11531510-000000000-00000","title":"We Know Accurately Only When We Know Little","year":2010,"lang":"en","type":"editorial","venue":"PharmacoEconomics","topic":"Meta-analysis and systematic reviews","field":"Decision Sciences","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Coastal Health; Provincial Health Services Authority; Vancouver Coastal Health Research Institute; University of British Columbia","funders":"","keywords":"Need to know; Quality of Life Research; Health economics; Public health; Health administration; Medicine; Actuarial science; Business; Computer science; Nursing","score_opus":0.5312092419018025,"score_gpt":0.5345524901447978,"score_spread":0.003343248242995256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2070111960","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00034080484,0.025975594,0.00054693903,0.004257908,0.9473569,0.0012871482,0.0013401933,0.000035926023,0.018858602],"genre_scores_gemma":[0.00008930884,0.034673635,0.0026393076,0.00041970363,0.74172455,0.000121465084,0.00024717048,0.00014107881,0.2199438],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9725447,0.0049725557,0.014369369,0.0028952358,0.0044006184,0.0008174834],"domain_scores_gemma":[0.9593631,0.01904106,0.01329449,0.005621289,0.0019519153,0.0007281288],"candidate_categories":["metaresearch","metaepi_narrow","scholarly_communication","open_science","research_integrity","insufficient_payload"],"consensus_categories":["metaresearch","insufficient_payload"],"category_scores_codex":[0.07118274,0.0012527548,0.008236649,0.00083499815,0.00028887266,0.0039955243,0.008228522,0.0012918479,0.08997855],"category_scores_gemma":[0.026588833,0.00077040825,0.00445556,0.00050036435,0.00015243591,0.00077710353,0.00075662363,0.00252678,0.07963752],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000017718461,0.000056237976,0.00003515015,0.00012112219,0.00050615665,0.0000064607507,0.0002919023,0.000020283558,0.000036691796,0.00014101464,0.8515151,0.14725213],"study_design_scores_gemma":[0.00049545354,0.000026158365,0.000002749103,0.00010469496,0.00081709767,0.0000068249924,0.000095113675,0.0024051364,0.000070240625,0.0045726993,0.9906379,0.00076595123],"about_ca_topic_score_codex":0.000043731092,"about_ca_topic_score_gemma":0.00033721403,"teacher_disagreement_score":0.20563236,"about_ca_system_score_codex":0.00022512145,"about_ca_system_score_gemma":0.0015200725,"threshold_uncertainty_score":0.99977446},"labels":[],"label_agreement":null},{"id":"W2070320826","doi":"10.1007/s40273-013-0032-y","title":"Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement","year":2013,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":214,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Institute of Health Economics; University of Ottawa","funders":"","keywords":"Checklist; Health economics; Government (linguistics); Delphi method; Consolidated Standards of Reporting Trials; Statement (logic); Systematic review; Economic evaluation; Medicine; Public relations; Psychological intervention; Public health; Delphi; MEDLINE; Medical education; Political science; Psychology; Nursing; Computer science; Law","score_opus":0.45454325920949434,"score_gpt":0.5560167446385411,"score_spread":0.10147348542904677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2070320826","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8582546,0.003871155,0.0039257775,0.099439934,0.004078018,0.0057350337,0.0023198542,0.00036110944,0.022014502],"genre_scores_gemma":[0.96068954,0.00070864905,0.0036016647,0.031850353,0.0008439225,0.0010397377,0.0004599906,0.00013885339,0.00066727574],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98282295,0.0006135031,0.014149238,0.001183235,0.00020588437,0.0010251575],"domain_scores_gemma":[0.9823103,0.0004757476,0.0154795535,0.0008289665,0.00028013083,0.0006253338],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.058679562,0.00045050491,0.0017408319,0.00047751164,0.00042957405,0.00039587208,0.00045880073,0.00014914003,0.016142275],"category_scores_gemma":[0.0025387777,0.0006236369,0.00025559208,0.00012278698,0.000109436274,0.0017152145,0.0001282886,0.00034178185,0.01124239],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000045528875,0.00022275242,0.027731812,0.0005086816,0.0006422669,0.0000018050912,0.0035895982,0.010242479,0.00007619731,0.034923777,0.9141366,0.007878515],"study_design_scores_gemma":[0.006152546,0.00022533823,0.010439649,0.00012198386,0.000053992953,0.0000350828,0.0033685598,0.36174163,0.00037714047,0.032183506,0.5834387,0.0018618801],"about_ca_topic_score_codex":0.004652416,"about_ca_topic_score_gemma":0.00022386371,"teacher_disagreement_score":0.35149917,"about_ca_system_score_codex":0.008428506,"about_ca_system_score_gemma":0.0019442921,"threshold_uncertainty_score":0.9996215},"labels":[],"label_agreement":null},{"id":"W2070353359","doi":"10.2165/11530820-000000000-00000","title":"Funding the Unfundable","year":2010,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":132,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research; New York Academy of Medicine","keywords":"Health care; Stakeholder; Health technology; Scarcity; Health administration; Health economics; Grey literature; Knowledge management; Business; Public relations; Management science; Computer science; Medicine; MEDLINE; Political science; Economics","score_opus":0.6552266900290561,"score_gpt":0.5597536411938446,"score_spread":0.09547304883521146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2070353359","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000017554861,0.9662272,0.00029336428,0.005697231,0.0056058886,0.0019575944,0.0010949497,0.0001359122,0.01897036],"genre_scores_gemma":[0.000010510968,0.9817323,0.00066841254,0.009461722,0.003054415,0.00063934695,0.00019232697,0.00022714895,0.0040138345],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98894304,0.0005311262,0.008195297,0.0012317799,0.00007757458,0.0010212096],"domain_scores_gemma":[0.98800874,0.003155323,0.006935346,0.0014602023,0.000042466574,0.00039793926],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.021839892,0.00077989564,0.0044785407,0.0005534498,0.0006419724,0.0004772138,0.0017509941,0.00064755953,0.0032864376],"category_scores_gemma":[0.0012872487,0.0007674985,0.0010494739,0.00028766406,0.00019398172,0.0006425143,0.00027963106,0.0017438066,0.03278387],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008113837,0.00017036307,0.00013569124,0.020679235,0.0011215385,0.0000050680014,0.0007802538,0.00005581345,1.8952294e-7,0.28627512,0.29334202,0.39742658],"study_design_scores_gemma":[0.00029208363,0.0000125645,0.000002116266,0.0006199215,0.00014895941,0.000037401354,0.00005876233,0.0005250395,2.7037987e-7,0.0035652323,0.99394953,0.0007881408],"about_ca_topic_score_codex":0.00023995075,"about_ca_topic_score_gemma":0.0000586627,"teacher_disagreement_score":0.7006075,"about_ca_system_score_codex":0.0013000641,"about_ca_system_score_gemma":0.0006962198,"threshold_uncertainty_score":0.9994776},"labels":[],"label_agreement":null},{"id":"W2070921516","doi":"10.1007/s40273-013-0117-7","title":"Review of Models Used in Economic Analyses of New Oral Treatments for Type 2 Diabetes Mellitus","year":2013,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Quality of Life Research; Health economics; Diabetes mellitus; Type 2 Diabetes Mellitus; Health administration; Medicine; Public health; Pharmacoeconomics; Intensive care medicine; Endocrinology; Nursing","score_opus":0.28139725041198266,"score_gpt":0.47458829889532744,"score_spread":0.19319104848334478,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2070921516","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005756632,0.99436367,0.0000062500367,0.00004014704,0.00025510677,0.0038996367,0.00018449368,0.00001609977,0.0006589142],"genre_scores_gemma":[0.000022895996,0.9965545,0.0011061867,0.00018920684,0.00008386715,0.00028279438,0.00091766764,0.00007769227,0.0007651872],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978364,0.000047183552,0.0013399571,0.00040945408,0.000053853903,0.0003131457],"domain_scores_gemma":[0.9983559,0.00014309604,0.00088031305,0.000427863,0.000042552296,0.00015026586],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021914035,0.0004640698,0.0037388594,0.0003505615,0.000010458004,0.000010312243,0.0002239661,0.000113633556,0.00044202924],"category_scores_gemma":[0.000012238284,0.00038157386,0.0008547601,0.00011664103,0.000036156085,0.00016522403,0.00007140291,0.000090667556,0.00008379626],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000018573779,0.000231222,0.000037985465,0.1076136,0.0042955135,7.0483884e-7,0.000011591502,0.000040795137,0.000003828594,0.0000812251,0.012292061,0.8753729],"study_design_scores_gemma":[0.0025814483,0.00029063094,0.0000018489831,0.03577493,0.020147644,5.865258e-7,0.0000030972938,0.0010216943,0.00028387626,0.00019569557,0.93937945,0.00031911908],"about_ca_topic_score_codex":0.000119630546,"about_ca_topic_score_gemma":0.0000047965564,"teacher_disagreement_score":0.92708737,"about_ca_system_score_codex":0.00044117187,"about_ca_system_score_gemma":0.0003789127,"threshold_uncertainty_score":0.9998636},"labels":[],"label_agreement":null},{"id":"W2072395026","doi":"10.2165/11597890-000000000-00000","title":"A Parent-Child Dyad Approach to the Assessment of Health Status and Health-Related Quality of Life in Children with Asthma","year":2012,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Asthma and respiratory diseases","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; SickKids Foundation; Hospital for Sick Children","funders":"Canadian Institutes of Health Research","keywords":"Dyad; Quality of life (healthcare); Medicine; Asthma; Convergent validity; Health Utilities Index; Clinical psychology; Pediatrics; Psychometrics; Psychology; Health related quality of life; Developmental psychology; Disease; Nursing","score_opus":0.0550603518973729,"score_gpt":0.38134509092638647,"score_spread":0.32628473902901356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2072395026","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99193716,0.0046554613,0.00013690528,0.001744784,0.00004851312,0.0009917908,0.00008038885,0.000011760621,0.00039324275],"genre_scores_gemma":[0.9962138,0.00032312528,0.00039492437,0.0029107162,0.000058770427,0.000030198931,0.000045748082,0.000017699947,0.0000050285657],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983943,0.00017768177,0.0007753147,0.0001892878,0.000115376024,0.0003480003],"domain_scores_gemma":[0.9987963,0.000031750915,0.00046125782,0.00020692142,0.000024843985,0.00047893557],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011808497,0.00013640602,0.00058085436,0.00009088722,0.00005913516,0.000005560642,0.00007240438,0.000028407632,0.0000202617],"category_scores_gemma":[0.000013829484,0.000092709255,0.00004914533,0.00011124775,0.00007548952,0.00008690838,0.000048406677,0.00017804181,0.0000015474685],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013192493,0.00066584727,0.9891278,0.00019120882,0.000120235985,3.7537013e-8,0.0007153167,0.00041622945,0.00000842332,0.00036625264,0.00027656578,0.007980141],"study_design_scores_gemma":[0.0025243468,0.0002257805,0.9954796,0.00004326112,0.000017509497,0.0000047193425,0.00058921677,0.00030573615,0.000018252742,0.0000030701235,0.0007016245,0.0000868754],"about_ca_topic_score_codex":0.0011140667,"about_ca_topic_score_gemma":0.0000410145,"teacher_disagreement_score":0.007893266,"about_ca_system_score_codex":0.00012478155,"about_ca_system_score_gemma":0.0005478936,"threshold_uncertainty_score":0.37805736},"labels":[],"label_agreement":null},{"id":"W2072493460","doi":"10.1007/s40273-014-0176-4","title":"Transparency in Reimbursement Decisions: In Whose Best Interest?","year":2014,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Law, Economics, and Judicial Systems","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Transparency (behavior); Reimbursement; Health economics; Quality of Life Research; Health administration; Business; Accounting; Public health; Public interest; Actuarial science; Medicine; Economics; Health care; Nursing; Political science","score_opus":0.0801949536739273,"score_gpt":0.29556486691926864,"score_spread":0.21536991324534133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2072493460","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91857046,0.0014355904,0.0011397062,0.0009757092,0.0022680303,0.0005120399,0.00011038667,0.000036851932,0.07495121],"genre_scores_gemma":[0.9949698,0.0030707386,0.0002260162,0.00096197653,0.00038629328,0.000102432925,0.000022500824,0.000053205993,0.0002070701],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966005,0.000049288738,0.0019912696,0.00075711694,0.000022378867,0.000579416],"domain_scores_gemma":[0.9987274,0.0001736096,0.00045346998,0.0004491154,0.00001402544,0.00018240724],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016166827,0.0002487227,0.0008460887,0.000589555,0.000062069776,0.00010655539,0.0005488942,0.00014858067,0.00054744165],"category_scores_gemma":[0.000110953195,0.00038844047,0.0001621507,0.00018272964,0.000090526635,0.0004906465,0.0000785326,0.00030290152,0.0022301388],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015984173,0.00079874246,0.44076785,0.00006060016,0.00009005498,0.000016396474,0.0018963864,0.0036404817,0.000107733475,0.5217064,0.0022311562,0.028524373],"study_design_scores_gemma":[0.01105098,0.00031687325,0.032532696,0.0002920341,0.000026075373,0.000011972117,0.00057714665,0.05943765,0.00080738124,0.44532833,0.44743842,0.00218045],"about_ca_topic_score_codex":0.0018980732,"about_ca_topic_score_gemma":0.00379689,"teacher_disagreement_score":0.44520727,"about_ca_system_score_codex":0.00053922855,"about_ca_system_score_gemma":0.000032685268,"threshold_uncertainty_score":0.99985677},"labels":[],"label_agreement":null},{"id":"W2073038050","doi":"10.2165/00019053-200725100-00001","title":"Lessons from Trial-Based Cost-Effectiveness Analyses of Mental Health Interventions","year":2007,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Addiction and Mental Health; University of Toronto; St. Michael's Hospital","funders":"","keywords":"Health economics; Willingness to pay; Psychological intervention; Actuarial science; Economic evaluation; Cost effectiveness; Health administration; Outcome (game theory); Relevance (law); Medicine; Cost–benefit analysis; Public health; Public economics; Economics; Risk analysis (engineering); Nursing; Microeconomics","score_opus":0.6989318515623156,"score_gpt":0.6222232909191193,"score_spread":0.07670856064319631,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2073038050","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8493221,0.006215494,0.09939127,0.029170748,0.003561472,0.0041617393,0.0058943485,0.0001248386,0.0021580262],"genre_scores_gemma":[0.9882203,0.00025617436,0.003312972,0.0070605366,0.00038658385,0.00016585688,0.00046389567,0.000056927533,0.00007676943],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9924627,0.0005288795,0.0057191043,0.00067542813,0.00007345555,0.00054044666],"domain_scores_gemma":[0.99290764,0.0021066188,0.004060077,0.0005242656,0.000060122693,0.00034125376],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.022028232,0.000275299,0.0016405443,0.0005932259,0.00022731324,0.000057905592,0.000421091,0.00011602352,0.0011515946],"category_scores_gemma":[0.0006232531,0.00038006908,0.00058193627,0.00020922135,0.00011707998,0.00042458187,0.000068412366,0.00022244155,0.00061943743],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.048192598,0.017135106,0.23271467,0.012062816,0.010742874,0.000016379796,0.013478926,0.038425002,0.004309835,0.36916125,0.20801474,0.045745794],"study_design_scores_gemma":[0.32851273,0.0027007668,0.14565854,0.0026957022,0.00042418676,0.000012568513,0.005770396,0.09968173,0.03094115,0.043759145,0.33437255,0.0054705394],"about_ca_topic_score_codex":0.0037296498,"about_ca_topic_score_gemma":0.0005078572,"teacher_disagreement_score":0.3254021,"about_ca_system_score_codex":0.0013923474,"about_ca_system_score_gemma":0.00032321928,"threshold_uncertainty_score":0.9998651},"labels":[],"label_agreement":null},{"id":"W2074041399","doi":"10.1007/s40273-014-0149-7","title":"Health-Related Productivity Loss: NICE to Recognize Soon, Good to Discuss Now","year":2014,"lang":"en","type":"editorial","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Advancing Health Outcomes; St. Paul's Hospital; University of British Columbia","funders":"","keywords":"Nice; Health economics; Quality of Life Research; Health administration; Public health; Productivity; Quality-adjusted life year; Medicine; Public economics; Economics; Business; Cost effectiveness; Operations management; Economic growth; Computer science; Nursing","score_opus":0.15961372067196816,"score_gpt":0.4497081695783074,"score_spread":0.29009444890633923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2074041399","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007171153,0.0018725428,0.0018393755,0.18346034,0.78663766,0.0048842197,0.009154391,0.00037962952,0.004600671],"genre_scores_gemma":[0.0056751687,0.0012233759,0.0048134476,0.0434574,0.9169896,0.0018200801,0.0020472768,0.0008451626,0.02312849],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9813736,0.0011510251,0.011552687,0.003615253,0.0003154803,0.001991931],"domain_scores_gemma":[0.98418975,0.0036260334,0.0076058935,0.0022274824,0.0003513097,0.0019995382],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":["metaresearch","insufficient_payload"],"category_scores_codex":[0.038529657,0.0012690254,0.0053049587,0.0013379358,0.0005792712,0.00046806235,0.0019327153,0.0011324438,0.0011550323],"category_scores_gemma":[0.011314242,0.0017397387,0.000615457,0.0005387134,0.00011979738,0.00092351146,0.0005907741,0.0018910051,0.05495688],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011588118,0.00021970888,0.00063063065,0.0010725941,0.00038542663,0.0000019849754,0.0013143608,0.0009175683,0.0000033448894,0.0011978894,0.99286896,0.0012716574],"study_design_scores_gemma":[0.001712017,0.00026730617,0.00019121749,0.00025871056,0.000044681525,0.0000066197726,0.00008026271,0.0007123519,0.00002184217,0.0030372313,0.9918462,0.001821578],"about_ca_topic_score_codex":0.0024923973,"about_ca_topic_score_gemma":0.0019117907,"teacher_disagreement_score":0.14000295,"about_ca_system_score_codex":0.005196548,"about_ca_system_score_gemma":0.0017205836,"threshold_uncertainty_score":0.99975806},"labels":[],"label_agreement":null},{"id":"W2074344385","doi":"10.2165/00019053-200624110-00008","title":"Information Created to Evade Reality (ICER)","year":2006,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":96,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Quality of Life Research; Health economics; Public health; Health administration; Medicine; Health informatics; Nursing","score_opus":0.5486522672038072,"score_gpt":0.543804526969932,"score_spread":0.004847740233875242,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2074344385","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000046985522,0.95144343,0.0016527579,0.005475973,0.0023973763,0.0037291779,0.006584352,0.00027575108,0.0283942],"genre_scores_gemma":[0.000024438017,0.97797185,0.0009963971,0.01461013,0.0015408676,0.0009329163,0.0025380673,0.00015731172,0.0012280095],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9851557,0.0005440775,0.012322464,0.00092331244,0.00010913908,0.0009452877],"domain_scores_gemma":[0.989701,0.0010840448,0.0073102396,0.00118531,0.00010562857,0.00061379245],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.013406329,0.0008797658,0.0051678065,0.0013507965,0.00028068805,0.00042837282,0.0010679257,0.00062653964,0.001318868],"category_scores_gemma":[0.001220773,0.001161365,0.00083770574,0.00047069986,0.00006620055,0.00172013,0.00023572914,0.0006714945,0.0489428],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002103009,0.00014662417,0.00009916188,0.023306426,0.0005898014,0.0000018127355,0.0006821796,0.0005718984,4.3574637e-8,0.026803447,0.78924453,0.15853305],"study_design_scores_gemma":[0.0005265066,0.000031043866,0.000029030612,0.00086231885,0.00014445666,0.00001371857,0.00004962787,0.00065288076,3.9955407e-7,0.0010911301,0.99551874,0.0010801211],"about_ca_topic_score_codex":0.0020857686,"about_ca_topic_score_gemma":0.00007932051,"teacher_disagreement_score":0.20627424,"about_ca_system_score_codex":0.0035091012,"about_ca_system_score_gemma":0.0006668501,"threshold_uncertainty_score":0.99959403},"labels":[],"label_agreement":null},{"id":"W2074907399","doi":"10.1007/s40273-013-0025-x","title":"What Evidence Is There for the Reimbursement of Personalised Medicine?","year":2013,"lang":"en","type":"letter","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Capital District Health Authority","funders":"National Institute for Health and Care Research","keywords":"Health economics; Reimbursement; Quality of Life Research; Health administration; Public health; Medicine; Alternative medicine; Pharmacoeconomics; MEDLINE; Family medicine; Business; Health care; Intensive care medicine; Nursing; Economics; Political science; Economic growth","score_opus":0.5874732654311046,"score_gpt":0.5081335896968592,"score_spread":0.07933967573424539,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2074907399","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015548007,0.063704744,0.000863971,0.9225168,0.0062773162,0.003303052,0.0010258916,0.000038589435,0.0007148268],"genre_scores_gemma":[0.0020569772,0.024475532,0.00051335146,0.95365566,0.009367273,0.0013516531,0.00017504048,0.00016374249,0.0082407445],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99153775,0.00030774527,0.006101393,0.0011276962,0.00016244102,0.00076297385],"domain_scores_gemma":[0.9829454,0.008613978,0.0067582442,0.0012999473,0.000227282,0.00015517346],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.013031891,0.0006048044,0.002230112,0.00034904067,0.00027703078,0.0002512255,0.0015389564,0.0005782742,0.009345923],"category_scores_gemma":[0.0013298526,0.00058074144,0.0005758578,0.00011324493,0.000358181,0.0013817988,0.00013022945,0.00096214656,0.0020211171],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000018662464,0.000018907376,0.0002755274,0.0014873607,0.0005324978,7.3884235e-7,0.002028346,0.00004107073,0.0000031845289,0.002717077,0.99250287,0.0003737715],"study_design_scores_gemma":[0.0010189214,0.00009125304,0.000110333815,0.000669239,0.00013424805,0.0000039033193,0.0013808877,0.009509688,0.00003179748,0.0060931738,0.9803914,0.0005651928],"about_ca_topic_score_codex":0.0011185074,"about_ca_topic_score_gemma":0.000021757134,"teacher_disagreement_score":0.03922921,"about_ca_system_score_codex":0.00088836264,"about_ca_system_score_gemma":0.00029920213,"threshold_uncertainty_score":0.9996644},"labels":[],"label_agreement":null},{"id":"W2075355967","doi":"10.2165/11314780-000000000-00000","title":"Case-Control Studies in Pharmacoeconomic Research","year":2009,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Historical and modern epidemiology studies","field":"Social Sciences","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Medicine; Confounding; Health economics; Pharmacoeconomics; Cohort study; Cohort; Epidemiology; Quality of life (healthcare); Public health; Intensive care medicine; Health administration; Pathology; Nursing","score_opus":0.6567926222189158,"score_gpt":0.6275752726192679,"score_spread":0.029217349599647835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2075355967","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004478101,0.9797451,0.000003739619,0.0007710638,0.0020594292,0.0013984751,0.00007587555,0.00008990745,0.015811633],"genre_scores_gemma":[0.00024970708,0.99400496,0.000057838675,0.00074884365,0.0021235626,0.0004344397,0.0000057743937,0.00005202614,0.0023228398],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9925897,0.003597463,0.0014002931,0.00093684613,0.00014289447,0.0013327792],"domain_scores_gemma":[0.9930206,0.005825526,0.00042172402,0.00029951977,0.00013014696,0.0003024664],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.009487976,0.00051935215,0.0032184534,0.0007357713,0.0010510612,0.000045425833,0.0007507893,0.00043474426,0.00017595277],"category_scores_gemma":[0.00085797365,0.00049367704,0.0005690465,0.00036398272,0.0011960198,0.00024761827,0.0001562623,0.0016698233,0.0008907858],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000011867597,0.00007276977,0.000007714992,0.0011271681,0.00054643233,0.0009705395,0.00322955,0.000015174466,4.287111e-8,0.0020381957,0.04127896,0.9507016],"study_design_scores_gemma":[0.00046842283,0.000021020443,1.5941738e-7,0.00052396074,0.00046167368,0.0001205511,0.0006909699,0.000025644917,6.679059e-8,0.001369847,0.9958638,0.00045389915],"about_ca_topic_score_codex":0.00088586536,"about_ca_topic_score_gemma":0.0019267971,"teacher_disagreement_score":0.95458484,"about_ca_system_score_codex":0.004069591,"about_ca_system_score_gemma":0.0008514966,"threshold_uncertainty_score":0.9998871},"labels":[],"label_agreement":null},{"id":"W2076869933","doi":"10.1007/s40273-014-0241-z","title":"Cost Effectiveness of Dabrafenib as a First-Line Treatment in Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma in Canada","year":2014,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"GlaxoSmithKline; Eli Lilly and Company","keywords":"Dabrafenib; Dacarbazine; Vemurafenib; Medicine; Oncology; Progression-free survival; Internal medicine; Hazard ratio; Metastatic melanoma; Melanoma; Cancer research; Overall survival; Confidence interval","score_opus":0.013149909881605824,"score_gpt":0.26533107913349996,"score_spread":0.25218116925189416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2076869933","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983977,0.000042784257,0.00019804917,0.000016728303,0.00009024542,0.00074476673,0.0001715477,0.0000022210318,0.0003359725],"genre_scores_gemma":[0.9991285,0.000030330992,0.00010601298,0.00008779281,0.00002196094,0.00013498022,0.00043126763,0.000020693455,0.000038431204],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990448,0.00014486517,0.00025342725,0.00028319366,0.00005729895,0.00021644999],"domain_scores_gemma":[0.99946016,0.00014685391,0.00011620841,0.0001559353,0.000043757344,0.00007708512],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015052472,0.00017191957,0.00028513774,0.00006078335,0.000024981937,0.000007749091,0.00010433903,0.000030801777,0.000038792354],"category_scores_gemma":[0.000030331457,0.00014140473,0.000028501992,0.00007033153,0.000023226137,0.000009845975,0.000030727482,0.000047880196,0.000003410025],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010847455,0.0012585095,0.9268394,0.0003097542,0.0004907878,0.00007300181,0.00028797376,0.031865355,0.015161846,0.00014378567,0.000057513516,0.0126646],"study_design_scores_gemma":[0.023856942,0.0031506517,0.2757384,0.00008657194,0.00008742387,0.000010112439,0.00007840418,0.002462333,0.69260895,0.000053214,0.0013961581,0.00047082288],"about_ca_topic_score_codex":0.20100187,"about_ca_topic_score_gemma":0.6659194,"teacher_disagreement_score":0.67744714,"about_ca_system_score_codex":0.00031022375,"about_ca_system_score_gemma":0.0006677825,"threshold_uncertainty_score":0.8043187},"labels":[],"label_agreement":null},{"id":"W2077033962","doi":"10.2165/11586120-000000000-00000","title":"Unit Costs for Delivery of Antiretroviral Treatment and Prevention of Mother-to-Child Transmission of HIV","year":2011,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"HIV/AIDS Research and Interventions","field":"Medicine","cited_by":74,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Fogarty International Center; Association of Canadian Universities for Northern Studies","keywords":"Activity-based costing; Medicine; Health economics; Psychological intervention; Unit cost; Environmental health; Total cost; Public health; Indirect costs; Service delivery framework; Nursing; Business; Service (business); Economics","score_opus":0.09002927836267538,"score_gpt":0.42066742773724575,"score_spread":0.33063814937457037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2077033962","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0046105403,0.9881525,0.0014196567,0.000027836275,0.00003799328,0.0025591021,0.0011735789,0.000008024634,0.0020107718],"genre_scores_gemma":[0.0010656656,0.99423736,0.00095883955,0.0000062556564,0.00004665557,0.00008563415,0.00022529444,0.000038836857,0.0033354778],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987269,0.0000774553,0.0007687201,0.00021564549,0.000049036506,0.00016222446],"domain_scores_gemma":[0.9991028,0.00008179679,0.00037083257,0.0001839314,0.00009072656,0.00016994975],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020776723,0.00020446647,0.0012415905,0.00033403197,0.000022597294,0.0000031824763,0.00010801448,0.0000977964,0.00025774183],"category_scores_gemma":[0.000014063122,0.00016739943,0.00071343547,0.00006168942,0.00006655335,0.00006348417,0.00002589547,0.00009915402,0.0000066501525],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028217863,0.00037815107,0.000034110097,0.015589978,0.0006153567,4.9112333e-7,0.00007961451,2.9990713e-7,0.0001875109,0.00007627509,0.00063558103,0.98212045],"study_design_scores_gemma":[0.0023688015,0.006447082,0.00000792733,0.0114897825,0.0019485313,0.000011223689,0.000024173281,0.00022619296,0.004419719,0.000021501657,0.9728946,0.000140464],"about_ca_topic_score_codex":0.000085106025,"about_ca_topic_score_gemma":0.000005506644,"teacher_disagreement_score":0.98197997,"about_ca_system_score_codex":0.00009750021,"about_ca_system_score_gemma":0.00019857896,"threshold_uncertainty_score":0.68263507},"labels":[],"label_agreement":null},{"id":"W2077085544","doi":"10.2165/00019053-200119010-00001","title":"Enteroviral Meningitis","year":2001,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Viral Infections and Immunology Research","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"","keywords":"Medicine; Meningitis; Aseptic meningitis; Lumbar puncture; Viral meningitis; Psychological intervention; Intensive care medicine; Emergency medicine; Public health; Population; Pediatrics; Bacterial meningitis; Environmental health; Internal medicine; Psychiatry; Nursing","score_opus":0.1309644883297103,"score_gpt":0.4774486924316285,"score_spread":0.3464842041019182,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2077085544","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006672846,0.97991467,0.00001575813,0.00009330018,0.0005922058,0.00059449935,0.000038224927,0.000075614036,0.018608995],"genre_scores_gemma":[0.000008616407,0.99076456,0.00005583491,0.00020994073,0.00042389752,0.00012680303,0.00020391273,0.0000697796,0.008136672],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987213,0.00006373893,0.00047567085,0.0003317003,0.000049272756,0.0003582929],"domain_scores_gemma":[0.9993161,0.0000758667,0.00014438141,0.0002983915,0.00003120512,0.00013405358],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00015449635,0.00029037156,0.0012871178,0.0003168503,0.00008376735,0.00004088218,0.00015674027,0.00021792247,0.0021121665],"category_scores_gemma":[0.000021013138,0.0002550612,0.000585459,0.00015522995,0.000085087784,0.00009407022,0.00011450788,0.00078722724,0.0026849092],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000012719537,0.000071086106,0.000042959404,0.0020453185,0.00053872255,0.000055591077,0.000004695752,1.1504371e-7,0.0000015126147,0.000026248406,0.010423167,0.98677784],"study_design_scores_gemma":[0.000500825,0.000131749,0.0000017365583,0.001041311,0.0008296123,0.00062049413,0.0000027986896,0.000017055001,0.0000066727894,0.0000062157205,0.99665296,0.00018853955],"about_ca_topic_score_codex":0.000020825666,"about_ca_topic_score_gemma":8.589588e-7,"teacher_disagreement_score":0.9865893,"about_ca_system_score_codex":0.00031045725,"about_ca_system_score_gemma":0.00025556356,"threshold_uncertainty_score":0.99999017},"labels":[],"label_agreement":null},{"id":"W2077682525","doi":"10.2165/11535270-000000000-00000","title":"Perspective and Desire in Comparative Effectiveness Research","year":2010,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Perspective (graphical); Health economics; Value (mathematics); Foundation (evidence); Quality of Life Research; Context (archaeology); Positive economics; Health administration; Outcome (game theory); Sociology; Psychology; Management science; Public health; Epistemology; Actuarial science; Medicine; Economics; Political science; Computer science; Law; Nursing; Microeconomics","score_opus":0.6765631596578086,"score_gpt":0.6128368200944262,"score_spread":0.06372633956338236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2077682525","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96907026,0.00108465,0.00014855567,0.0065887244,0.00074093346,0.0010028984,0.000114528564,0.000037021648,0.02121245],"genre_scores_gemma":[0.9965099,0.00015020755,0.0010294674,0.0015962167,0.00032847893,0.00021660246,0.000008194294,0.000032389653,0.00012853516],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99612343,0.0006820309,0.001788784,0.00079483073,0.000057323075,0.0005536166],"domain_scores_gemma":[0.99556226,0.0031684164,0.000553419,0.00035322117,0.00012004811,0.00024263885],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.025701815,0.00020741968,0.00093079236,0.0006568172,0.00023669432,0.00012758092,0.00030601537,0.00015083869,0.0003757307],"category_scores_gemma":[0.001290636,0.0002858447,0.000066152046,0.00022849248,0.00029298585,0.0006742594,0.0001174581,0.0008961099,0.0014444601],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000990925,0.00018524127,0.09519474,0.00017027311,0.000077237724,0.0000033467177,0.0066981693,0.00016921935,0.00041812958,0.8941854,0.0026298335,0.00016927031],"study_design_scores_gemma":[0.0072899335,0.00022290814,0.38108498,0.00011936726,0.000013888892,0.000045056586,0.013333907,0.04161273,0.001830857,0.49294734,0.05995323,0.0015457991],"about_ca_topic_score_codex":0.0017128047,"about_ca_topic_score_gemma":0.0007252761,"teacher_disagreement_score":0.4012381,"about_ca_system_score_codex":0.0009105821,"about_ca_system_score_gemma":0.00017610613,"threshold_uncertainty_score":0.99995935},"labels":[],"label_agreement":null},{"id":"W2078342884","doi":"10.2165/00019053-200523080-00008","title":"An Economic Evaluation of Rizatriptan in the Treatment of Migraine","year":2005,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Migraine and Headache Studies","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Merck Canada Inc. (Canada); Nexus Clinical Research (Canada); Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Rizatriptan; Quality of Life Research; Health economics; Migraine; Medicine; Pharmacoeconomics; Public health; Intensive care medicine; Sumatriptan; Internal medicine","score_opus":0.07230910605407972,"score_gpt":0.4273265135412343,"score_spread":0.3550174074871546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2078342884","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99240667,0.0014226801,0.0000027550268,0.0016501419,0.00002092715,0.0004514007,0.000023977227,0.0000050079593,0.0040164217],"genre_scores_gemma":[0.9974549,0.001665845,0.00019900201,0.00025405575,0.0002740893,0.000032699783,0.000024230696,0.0000078494295,0.00008736619],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99931604,0.000057800433,0.00033984115,0.000119853816,0.000064523134,0.00010192203],"domain_scores_gemma":[0.999584,0.00004731161,0.000110016714,0.00018975904,0.000037777514,0.0000310995],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005446217,0.00008765635,0.0002585479,0.000088843924,0.00001671833,0.0000025243787,0.000065348635,0.000022740498,0.00029139454],"category_scores_gemma":[0.0000069584935,0.000064203006,0.000093674535,0.00003392808,0.00003985766,0.0000635514,0.0000039787697,0.0000347914,0.000013175169],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001986109,0.010391716,0.31708145,0.0002985859,0.0015918991,0.0000063603975,0.08435493,0.02291126,0.06915777,0.0033649234,0.034294903,0.45456007],"study_design_scores_gemma":[0.031826098,0.0038684292,0.15213415,0.00004861934,0.0026490334,0.000037900696,0.0059830886,0.36603683,0.1367401,0.00058055785,0.29960376,0.0004914159],"about_ca_topic_score_codex":0.00020092759,"about_ca_topic_score_gemma":0.0007015081,"teacher_disagreement_score":0.45406866,"about_ca_system_score_codex":0.00020579356,"about_ca_system_score_gemma":0.00010857896,"threshold_uncertainty_score":0.31905657},"labels":[],"label_agreement":null},{"id":"W2078517534","doi":"10.2165/00019053-200523120-00006","title":"Willingness to Pay for Inhaled Insulin","year":2005,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Inhalation and Respiratory Drug Delivery","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; University of Toronto","funders":"","keywords":"Insulin; Medicine; Diabetes mellitus; Willingness to pay; Insulin analog; Type 1 diabetes; Contingent valuation; Internal medicine; Endocrinology; Human insulin; Economics","score_opus":0.026291284379856828,"score_gpt":0.3449360948945748,"score_spread":0.31864481051471794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2078517534","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98514926,0.00012601186,0.0024250909,0.008101197,0.0005518023,0.0007694564,0.000029239794,0.00008743767,0.0027605179],"genre_scores_gemma":[0.9655261,0.00004614959,0.0034954592,0.027120315,0.0012976999,0.00006779002,0.0000208969,0.000030127296,0.0023954639],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993137,0.000009900101,0.00026094835,0.00018943088,0.000042756914,0.00018327047],"domain_scores_gemma":[0.9995081,0.000043279688,0.000051257044,0.00012469287,0.00007839292,0.00019430957],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017295724,0.00010479076,0.00018400238,0.00007733495,0.000063291816,0.000015657022,0.00006513529,0.000047638758,0.00037205237],"category_scores_gemma":[0.000025104746,0.000086204345,0.00008824404,0.00005152518,0.000012791263,0.00009048261,0.000019911424,0.000095864845,0.0007081761],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030252251,0.0008845981,0.009374543,0.00035204284,0.00039317255,0.00003627502,0.0018222275,0.012091739,0.086194076,0.0012958596,0.1281406,0.7563896],"study_design_scores_gemma":[0.0029945325,0.000058274352,0.00033277035,0.000011288505,0.000049637965,0.000019496809,0.000023495048,0.016816081,0.08404105,0.000010160463,0.8954868,0.00015644298],"about_ca_topic_score_codex":0.0000020636091,"about_ca_topic_score_gemma":0.000003632075,"teacher_disagreement_score":0.76734614,"about_ca_system_score_codex":0.000105382926,"about_ca_system_score_gemma":0.000086999906,"threshold_uncertainty_score":0.91024077},"labels":[],"label_agreement":null},{"id":"W2078569420","doi":"10.2165/00019053-200725030-00003","title":"Enzyme Replacement Therapy in Orphan and Ultra-Orphan Diseases","year":2007,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Lysosomal Storage Disorders Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Shire Human Genetic Therapies; University of Manitoba","keywords":"Orphan drug; Enzyme replacement therapy; Quality-adjusted life year; Medicine; Health economics; EQ-5D; Cost effectiveness; Quality of life (healthcare); Fabry disease; Public health; Disease; Internal medicine; Bioinformatics; Pathology","score_opus":0.026851018753520705,"score_gpt":0.3524826568531943,"score_spread":0.3256316380996736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2078569420","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99154866,0.0030410269,0.00006593034,0.0011171625,0.0001264603,0.00062758307,0.000015002341,0.000043403506,0.003414763],"genre_scores_gemma":[0.9940335,0.0031583908,0.0000945665,0.002038744,0.00017233855,0.000027182914,0.000026021506,0.00003247129,0.00041678277],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99877304,0.00003055305,0.00030941397,0.00033989712,0.0001269302,0.00042013943],"domain_scores_gemma":[0.9992851,0.00011164371,0.00005520954,0.00019715737,0.000032543183,0.00031836852],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004478515,0.00015824115,0.00025434827,0.00019929434,0.000051037376,0.000028685008,0.00009834077,0.000048813992,0.0007088537],"category_scores_gemma":[0.000038511356,0.00015281174,0.000055360142,0.000115884046,0.00008220489,0.00013047595,0.00003365768,0.00018696768,0.000059652433],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006340542,0.001010663,0.7925372,0.00012893946,0.00020787305,0.000281744,0.0009500953,0.000027270476,0.05235446,0.0002421062,0.0043505826,0.1415685],"study_design_scores_gemma":[0.053222146,0.0019163246,0.39477503,0.00010995169,0.0001393116,0.00020589921,0.001322866,0.0030832652,0.34763348,0.000761864,0.1955415,0.0012883766],"about_ca_topic_score_codex":0.00013460864,"about_ca_topic_score_gemma":0.000053735803,"teacher_disagreement_score":0.3977622,"about_ca_system_score_codex":0.00021771782,"about_ca_system_score_gemma":0.0000831906,"threshold_uncertainty_score":0.7761451},"labels":[],"label_agreement":null},{"id":"W2081398893","doi":"10.1007/s40273-014-0135-0","title":"Assessing the Value of Healthcare Interventions Using Multi-Criteria Decision Analysis: A Review of the Literature","year":2014,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":288,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Multiple-criteria decision analysis; Psychological intervention; Reimbursement; Health care; Medicine; Decision analysis; Prior authorization; Medical prescription; Health economics; Health administration; Decision aids; Management science; Public health; Nursing; Alternative medicine; Operations research; Political science; Engineering","score_opus":0.6197602703662343,"score_gpt":0.6302883873459656,"score_spread":0.010528116979731328,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2081398893","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00023196569,0.9852248,0.0058753667,0.0029753193,0.0017104121,0.0021361636,0.001753874,0.000017131091,0.000074981835],"genre_scores_gemma":[0.00051112036,0.98968315,0.004292201,0.004701281,0.00036333618,0.0001369621,0.00017715702,0.00008313627,0.000051653205],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9835944,0.0024834643,0.012547879,0.0008268689,0.0001226973,0.00042465836],"domain_scores_gemma":[0.9790061,0.0022899562,0.016630497,0.0016954069,0.00022208606,0.00015594962],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.025913706,0.0005502664,0.0062767584,0.00076953316,0.00029678285,0.00019551595,0.0015608239,0.00033072554,0.00028442263],"category_scores_gemma":[0.0024965145,0.0004356547,0.0039351867,0.0012496308,0.00016486064,0.0005364914,0.00035728447,0.00073185726,0.0000851566],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000006396075,0.00031470388,0.0008806473,0.91190886,0.005037357,7.423739e-7,0.00097042765,0.00052085996,4.076332e-7,0.015419447,0.0061694216,0.058770742],"study_design_scores_gemma":[0.00042797407,0.000019517569,0.00015018633,0.23415439,0.0033377537,0.000018778,0.00010179674,0.013525535,8.051154e-7,0.0007191805,0.7469756,0.0005684956],"about_ca_topic_score_codex":0.00039905185,"about_ca_topic_score_gemma":0.000051285435,"teacher_disagreement_score":0.74080616,"about_ca_system_score_codex":0.00083229074,"about_ca_system_score_gemma":0.0005849796,"threshold_uncertainty_score":0.9998095},"labels":[],"label_agreement":null},{"id":"W2082074737","doi":"10.1007/s40273-014-0134-1","title":"Methods for Identifying the Cost-effective Case Definition Cut-Off for Sequential Monitoring Tests: An Extension of Phelps and Mushlin","year":2014,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Capital District Health Authority","funders":"Biotechnology and Biological Sciences Research Council; Medical Research Council; National Institute for Health and Care Research","keywords":"Health administration; Health economics; Test (biology); Quality of Life Research; Cost effectiveness; Medicine; Health care; Population health; Actuarial science; Population; Risk analysis (engineering); Public health; Business; Economics; Environmental health; Nursing","score_opus":0.7227974291532423,"score_gpt":0.6577397002386661,"score_spread":0.06505772891457617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2082074737","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.21444374,0.00007803806,0.7807957,0.00006898225,0.0014460514,0.002925973,0.00016647777,0.000037376238,0.000037697897],"genre_scores_gemma":[0.124272995,0.0000766287,0.8736138,0.000109967055,0.00085423863,0.0010123189,0.000004208467,0.000051393898,0.000004469224],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9973418,0.0011219257,0.0008139708,0.00040747056,0.000057606874,0.00025724107],"domain_scores_gemma":[0.9078244,0.09112558,0.00046412696,0.00028703938,0.0001850761,0.000113769216],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.009489249,0.00019321578,0.0005551658,0.00005781102,0.00021622809,0.00006723711,0.00016009735,0.000109178814,0.000015369402],"category_scores_gemma":[0.028025934,0.00016262755,0.00016020813,0.000047251568,0.00014112073,0.00017257794,0.000087331486,0.00017711226,0.0000013623514],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006246579,0.00016538141,0.00008236458,0.0005780031,0.00018469592,0.0000030471404,0.0004519829,0.00003650644,0.03557752,0.0641409,0.00014247526,0.89801246],"study_design_scores_gemma":[0.0026601655,0.00022490384,0.000050059214,0.000058073576,0.00056772726,0.000052491567,0.00022453103,0.05759742,0.11365018,0.823725,0.0009786988,0.00021075935],"about_ca_topic_score_codex":0.000012265023,"about_ca_topic_score_gemma":0.000004591561,"teacher_disagreement_score":0.8978017,"about_ca_system_score_codex":0.0000688379,"about_ca_system_score_gemma":0.000022255374,"threshold_uncertainty_score":0.9801614},"labels":[],"label_agreement":null},{"id":"W2082957553","doi":"10.2165/11530850-000000000-00000","title":"Access with Evidence Development Schemes","year":2010,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":87,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Institutes of Health; National Institute for Health and Care Research","keywords":"Reimbursement; Health economics; Health administration; Risk analysis (engineering); Health informatics; Public health; Health technology; Scheme (mathematics); Quality of Life Research; Health care; Key (lock); Business; Actuarial science; Management science; Process management; Computer science; Medicine; Economics; Nursing; Computer security","score_opus":0.5279640526757208,"score_gpt":0.5269170405202137,"score_spread":0.0010470121555070655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2082957553","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9676742,0.0008139445,0.003856056,0.018273238,0.0014729057,0.000722162,0.000061002112,0.00014742232,0.0069790836],"genre_scores_gemma":[0.95465994,0.00019446842,0.021665957,0.021370515,0.0007927298,0.00028563288,0.00002496175,0.00008272607,0.0009230946],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9956947,0.000071552764,0.0028446196,0.0007687564,0.00007062349,0.0005497354],"domain_scores_gemma":[0.99660426,0.00072377623,0.0016646624,0.0005850033,0.00007384891,0.00034846715],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0077523757,0.00029211075,0.0007745842,0.00029236183,0.0002849159,0.00031477967,0.00084820535,0.00012366832,0.0027529194],"category_scores_gemma":[0.000809767,0.00035033934,0.000081812235,0.00014652648,0.00011552166,0.00205841,0.00015849924,0.0004419265,0.0052386564],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020879121,0.00041627407,0.7363362,0.000893852,0.00059783336,0.000009273673,0.003437575,0.00073545956,0.000744938,0.17973141,0.07122882,0.005659637],"study_design_scores_gemma":[0.0015703528,0.000042358846,0.023861637,0.00009572393,0.000016423104,0.000028101418,0.00016089727,0.0053798915,0.003515506,0.0031465297,0.961096,0.0010866019],"about_ca_topic_score_codex":0.0002253339,"about_ca_topic_score_gemma":0.0003247749,"teacher_disagreement_score":0.8898672,"about_ca_system_score_codex":0.0003558721,"about_ca_system_score_gemma":0.0004481892,"threshold_uncertainty_score":0.99989486},"labels":[],"label_agreement":null},{"id":"W2082962434","doi":"10.2165/00019053-200523050-00005","title":"Valuing Patient and Caregiver Time","year":2005,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":121,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences; Canadian Foundation for Healthcare Improvement; Hospital for Sick Children; Institute of Population and Public Health; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Valuation (finance); Health economics; Public economics; Economics; Health care; Activity-based costing; Unpaid work; Actuarial science; Productivity; Work (physics); Business; Accounting; Economic growth","score_opus":0.42404659701883957,"score_gpt":0.503347239421462,"score_spread":0.07930064240262241,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2082962434","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000104380255,0.98664033,0.00007301652,0.0016779192,0.0010627892,0.0014950815,0.0013206253,0.000108274166,0.007517588],"genre_scores_gemma":[0.000024105659,0.99007446,0.0009180485,0.005594536,0.0014054636,0.0002667378,0.0001926761,0.00018262467,0.0013413724],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9908865,0.00040492386,0.006641987,0.0012938638,0.00006586232,0.0007068728],"domain_scores_gemma":[0.9928138,0.0011700767,0.004837263,0.0006968761,0.000037816742,0.00044415673],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.006085359,0.0007229795,0.0044433917,0.00063955673,0.0002331035,0.00022102383,0.0005084903,0.00042424616,0.0021767153],"category_scores_gemma":[0.00040559706,0.0009379254,0.00056747854,0.00013397838,0.0001081684,0.0006555763,0.0002527925,0.0005600252,0.01973048],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000006138039,0.00009973535,0.000028781062,0.010442587,0.00071228284,0.0000050942626,0.0015948153,0.000072648756,6.4396495e-8,0.009352519,0.10671723,0.8709681],"study_design_scores_gemma":[0.00039449756,0.000027465501,0.0000020191276,0.00095150643,0.0001480205,0.000039594473,0.00006089663,0.0016982662,1.4799768e-7,0.0004655059,0.99533165,0.0008804242],"about_ca_topic_score_codex":0.00011711261,"about_ca_topic_score_gemma":0.000007830941,"teacher_disagreement_score":0.8886144,"about_ca_system_score_codex":0.0016553493,"about_ca_system_score_gemma":0.00032327737,"threshold_uncertainty_score":0.99930716},"labels":[],"label_agreement":null},{"id":"W2083791045","doi":"10.2165/00019053-200624080-00007","title":"Cost Effectiveness of Adding Ezetimibe to Atorvastatin Therapy in Patients Not at Cholesterol Treatment Goal in Canada","year":2006,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; Merck Canada Inc. (Canada)","funders":"","keywords":"Ezetimibe; Atorvastatin; Quality of Life Research; Health economics; Medicine; Public health; Ldl cholesterol; Pharmacotherapy; Cholesterol; Cost effectiveness; Intensive care medicine; Internal medicine; Risk analysis (engineering)","score_opus":0.021071013579764025,"score_gpt":0.29399228974178526,"score_spread":0.2729212761620212,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2083791045","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99772125,0.00007761513,0.000007598323,0.00007562025,0.00015533785,0.0016831098,0.00009566193,0.0000053901986,0.00017839114],"genre_scores_gemma":[0.999007,0.00009467942,0.00006873551,0.00047966128,0.00006199424,0.00018727685,0.00006174472,0.000024011484,0.000014888189],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989182,0.000108108536,0.0003513254,0.00024211816,0.00012003121,0.00026023385],"domain_scores_gemma":[0.9995363,0.000065607004,0.00007212131,0.00018495039,0.00002844363,0.000112581656],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030030304,0.0001489942,0.00045322668,0.00009624192,0.000019621199,0.000004566583,0.000053172545,0.00002755349,0.000032718377],"category_scores_gemma":[0.000004923239,0.00014043528,0.000078361496,0.000084956024,0.000009417297,0.000041932934,0.000022813892,0.000072865456,0.0000064927513],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016443356,0.00028940543,0.9231113,0.00009533914,0.00007253715,0.000014214158,0.000111025045,0.004497523,0.0019710762,0.0000047645904,0.0000776362,0.06811083],"study_design_scores_gemma":[0.01310254,0.00023768951,0.91365546,0.000066168184,0.000015567924,0.0000019787024,0.00001734574,0.0002650176,0.06980085,0.0000012914845,0.0027196677,0.00011643193],"about_ca_topic_score_codex":0.7440121,"about_ca_topic_score_gemma":0.49300653,"teacher_disagreement_score":0.25100556,"about_ca_system_score_codex":0.0042310087,"about_ca_system_score_gemma":0.0004886613,"threshold_uncertainty_score":0.9995916},"labels":[],"label_agreement":null},{"id":"W2084273456","doi":"10.2165/00019053-200624010-00008","title":"Economic Evaluation of Rivastigmine in Patients with Parkinson??s Disease Dementia","year":2006,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Programs for Assessment of Technology in Health Research Institute; Public Health Ontario; McMaster University; University of Toronto; Toronto Public Health","funders":"","keywords":"Rivastigmine; Medicine; Dementia; Quality of life (healthcare); Quality-adjusted life year; Clinical trial; Health economics; Physical therapy; Cost effectiveness; Pediatrics; Disease; Public health; Internal medicine; Donepezil","score_opus":0.014660395367932658,"score_gpt":0.2837625494827499,"score_spread":0.26910215411481725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2084273456","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975162,0.00035208865,0.000022966735,0.0000701928,0.00012368383,0.0007034834,0.00014451315,0.000015649974,0.001051202],"genre_scores_gemma":[0.99904674,0.000024872055,0.00031085126,0.00008687799,0.000069149995,0.0000743166,0.00033607654,0.0000251127,0.000026003308],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99900985,0.000034867113,0.00031954594,0.00028499434,0.00015581174,0.00019495431],"domain_scores_gemma":[0.9994217,0.000014190612,0.00016397536,0.00019192784,0.00006465523,0.00014352275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019858847,0.0001586949,0.00024435503,0.00014721343,0.000024904028,0.000009479234,0.00005745984,0.000024378816,0.0004801933],"category_scores_gemma":[0.0000050144854,0.00014875692,0.00006402852,0.00004421825,0.0000293453,0.0001328058,0.00002112837,0.000048995047,0.00004907675],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010172197,0.00085980253,0.98994523,0.00003011613,0.00016854193,0.0000052046676,0.000008133068,0.0031408218,0.00005709126,0.000117596726,0.00027622381,0.0043740333],"study_design_scores_gemma":[0.014364314,0.00008426119,0.96718764,0.000027626305,0.00097016495,4.2602522e-7,0.0000033563958,0.012107961,0.0014623561,0.00031956422,0.0033365611,0.00013577602],"about_ca_topic_score_codex":0.00010839003,"about_ca_topic_score_gemma":0.000050339266,"teacher_disagreement_score":0.022757582,"about_ca_system_score_codex":0.00033235198,"about_ca_system_score_gemma":0.00023379795,"threshold_uncertainty_score":0.60661316},"labels":[],"label_agreement":null},{"id":"W2084655166","doi":"10.2165/00019053-200624110-00011","title":"Economic Evaluations in the Canadian Common Drug Review","year":2006,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":46,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Michael's Hospital; University of Toronto; Institute for Clinical Evaluative Sciences","funders":"","keywords":"Health economics; Quality of Life Research; Public health; Health administration; Drug; Medicine; Pharmacoeconomics; Intensive care medicine; Pharmacology; Nursing","score_opus":0.47903852172689615,"score_gpt":0.5609020028368904,"score_spread":0.08186348110999425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2084655166","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000015768095,0.9378731,0.0000071318827,0.023090623,0.0016313081,0.004689639,0.0031121108,0.000048665217,0.029531611],"genre_scores_gemma":[0.0000498056,0.95937455,0.00013866821,0.035000045,0.0011177982,0.0018046123,0.0015591725,0.00016015834,0.000795185],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9843944,0.0019371369,0.011125372,0.0013126638,0.0001114558,0.0011190161],"domain_scores_gemma":[0.98996675,0.002444686,0.0055573364,0.0015832926,0.00003820306,0.00040970932],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.03722888,0.00087013707,0.005519429,0.0012703583,0.00053064834,0.00036849207,0.0020973734,0.0004060159,0.0019663335],"category_scores_gemma":[0.0005436283,0.0009504452,0.0009918173,0.00037457133,0.0001410688,0.00062990776,0.00010700552,0.0012170855,0.023479292],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000011151114,0.00007168482,0.0002297206,0.023279062,0.00017794648,0.000006355178,0.00025444705,0.00017020306,8.039712e-10,0.034059837,0.9119675,0.029782124],"study_design_scores_gemma":[0.00036688655,0.000008954435,0.000046695397,0.0052467654,0.00023513245,0.000036542348,0.00003539312,0.0005745818,1.4615224e-8,0.0029450024,0.989622,0.00088201376],"about_ca_topic_score_codex":0.20704523,"about_ca_topic_score_gemma":0.45927697,"teacher_disagreement_score":0.25223175,"about_ca_system_score_codex":0.008797378,"about_ca_system_score_gemma":0.003387386,"threshold_uncertainty_score":0.9992946},"labels":[],"label_agreement":null},{"id":"W2085650878","doi":"10.2165/00019053-200321010-00001","title":"Generic Clozapine","year":2003,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Riverview Hospital","funders":"","keywords":"Clozapine; Quality of Life Research; Public health; Health economics; Health administration; Medicine; Psychiatry; Schizophrenia (object-oriented programming); Nursing","score_opus":0.13296359262517082,"score_gpt":0.43932258642080163,"score_spread":0.3063589937956308,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2085650878","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000018761302,0.9950191,0.0000060182824,0.0000768809,0.00045093396,0.0010592706,0.00008064946,0.000057406505,0.0032310109],"genre_scores_gemma":[9.685733e-7,0.99419296,0.001609424,0.00035806827,0.00058242964,0.00025704887,0.000348537,0.000102405094,0.0025481707],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984655,0.00007641865,0.0004910697,0.0004539436,0.00010255022,0.00041054375],"domain_scores_gemma":[0.99885285,0.00007037066,0.00016813278,0.0004251837,0.000030089011,0.00045337804],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00015451892,0.00041967034,0.0016060801,0.00022962232,0.000051476934,0.00003131547,0.00015198783,0.0001538058,0.0018075602],"category_scores_gemma":[0.000014205055,0.00033110258,0.0006826672,0.00014562004,0.00004257462,0.0000414499,0.000055919136,0.000439341,0.0032457174],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000121905774,0.00011604122,0.0000023029243,0.0045380094,0.00078527484,0.00013428212,0.0000017892492,2.4815398e-7,2.6956826e-7,0.00019232083,0.009565757,0.9845418],"study_design_scores_gemma":[0.0018396325,0.00007218965,7.912027e-7,0.00067170727,0.0018879898,0.000512139,7.554461e-7,0.000016491986,0.0000084768735,0.000030410034,0.99471587,0.00024356446],"about_ca_topic_score_codex":0.000005243489,"about_ca_topic_score_gemma":0.0000016250942,"teacher_disagreement_score":0.9851501,"about_ca_system_score_codex":0.0005320894,"about_ca_system_score_gemma":0.001115036,"threshold_uncertainty_score":0.9999141},"labels":[],"label_agreement":null},{"id":"W2087332353","doi":"10.1007/s40273-014-0229-8","title":"Costs of Health Resource Utilization Among HIV-Positive Individuals in British Columbia, Canada: Results From a Population-Level Study","year":2014,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"HIV/AIDS Research and Interventions","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; AIDS Vancouver; St. Paul's Hospital; Simon Fraser University; Providence Health Care","funders":"National Institute on Drug Abuse; Canadian Institutes of Health Research","keywords":"Medicine; Health economics; Confidence interval; Demography; Population; Public health; Health care; Generalized estimating equation; Health administration; Logistic regression; Indirect costs; Gerontology; Environmental health; Internal medicine","score_opus":0.04665521805837613,"score_gpt":0.34610844860172074,"score_spread":0.2994532305433446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2087332353","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939941,0.00007189983,0.00014901097,0.0006164747,0.00004541718,0.00094211235,0.0028811616,0.000013793124,0.0012859869],"genre_scores_gemma":[0.9959453,0.000027809085,0.00009970656,0.0003147081,0.000083432395,0.00003043342,0.0019423537,0.000019987052,0.0015362939],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99801904,0.00036442585,0.00085450005,0.0003063161,0.00019385775,0.00026183683],"domain_scores_gemma":[0.999,0.00022185467,0.00029600988,0.00019316575,0.0000868334,0.00020209575],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00094979303,0.00008257775,0.00039232126,0.00009716184,0.0000941535,0.000060169616,0.0001225447,0.000037387414,0.00018818931],"category_scores_gemma":[0.0003837035,0.0001374448,0.000053352782,0.0001447448,0.000038287,0.00012759416,0.000058237172,0.00020213431,0.000005145285],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000061940395,0.00043984322,0.88425475,0.000022142505,0.000098093675,0.0000059346967,0.00059345126,0.00010688933,0.00001369555,0.0000039730016,0.07456683,0.03983246],"study_design_scores_gemma":[0.0049700905,0.00041823022,0.9803236,0.00026187254,0.000027656117,0.000002235928,0.0011008339,0.01070317,0.000054077704,0.00002050925,0.0020144703,0.00010323663],"about_ca_topic_score_codex":0.9863548,"about_ca_topic_score_gemma":0.9908123,"teacher_disagreement_score":0.096068874,"about_ca_system_score_codex":0.0006779711,"about_ca_system_score_gemma":0.00041370717,"threshold_uncertainty_score":0.56048363},"labels":[],"label_agreement":null},{"id":"W2088147052","doi":"10.2165/11313640-000000000-00000","title":"The Cost Effectiveness of Rufinamide in the Treatment of Lennox-Gastaut Syndrome in the UK","year":2010,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Epilepsy research and treatment","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Eisai Canada","keywords":"Lamotrigine; Topiramate; Medicine; Lennox–Gastaut syndrome; Pharmacoeconomics; Placebo; Adjunctive treatment; Epilepsy; Randomized controlled trial; Pediatrics; Clinical trial; Seizure types; Psychiatry; Intensive care medicine; Surgery; Internal medicine","score_opus":0.02984183530600453,"score_gpt":0.3677046797415109,"score_spread":0.33786284443550635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2088147052","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99508715,0.00039501174,0.000002349437,0.0009899571,0.00012026954,0.0015854186,0.000035267403,0.0000034647517,0.0017811187],"genre_scores_gemma":[0.9979535,0.0015074019,0.00001686483,0.000080505524,0.00003286131,0.0003472149,0.000015837051,0.000010468919,0.000035371133],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989256,0.00026347028,0.00028719244,0.00015051257,0.000117273805,0.00025592154],"domain_scores_gemma":[0.9977746,0.0016725585,0.00008548691,0.0003938112,0.000027547512,0.000046003326],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012665736,0.00012883825,0.00028252142,0.00007449151,0.000054791173,0.000014544715,0.0002515421,0.00003527987,0.000037005535],"category_scores_gemma":[0.000033351265,0.000058827067,0.00010736328,0.0001163003,0.00017536928,0.000035492696,0.000017968512,0.00020272266,0.000012195481],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029835782,0.004190384,0.92589486,0.00022184024,0.0004629081,0.00034263224,0.002771544,0.00015638831,0.014447469,0.0045622066,0.0001474089,0.04381877],"study_design_scores_gemma":[0.00877933,0.0016055458,0.9574974,0.000056087905,0.0001167427,0.00017069934,0.0006279643,0.00060121855,0.024112746,0.000583568,0.0057499055,0.00009878507],"about_ca_topic_score_codex":0.0004714646,"about_ca_topic_score_gemma":0.000868153,"teacher_disagreement_score":0.04371999,"about_ca_system_score_codex":0.0001283641,"about_ca_system_score_gemma":0.00011088793,"threshold_uncertainty_score":0.23988982},"labels":[],"label_agreement":null},{"id":"W2088407458","doi":"10.2165/00019053-200826070-00003","title":"Does Direct-to-Consumer Advertising of Antidepressants Lead to a Net Social Benefit?","year":2008,"lang":"en","type":"letter","venue":"PharmacoEconomics","topic":"Treatment of Major Depression","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Quality of Life Research; Health economics; Public health; Direct-to-consumer advertising; Direct marketing; Advertising; Business; Health administration; Lead (geology); Social marketing; Marketing; Medicine; Pharmacology; Medical prescription","score_opus":0.025043897883231622,"score_gpt":0.31852818495342883,"score_spread":0.2934842870701972,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2088407458","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.63716215,0.0009411171,0.000026194468,0.34809512,0.0030044492,0.0021496587,0.0011801252,0.00025752606,0.0071836775],"genre_scores_gemma":[0.18794706,0.0018319201,0.0026526183,0.78401506,0.010014779,0.0002154616,0.0007531343,0.00048026646,0.01208971],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973221,0.000055613353,0.0007685576,0.0008853,0.00031411857,0.0006543359],"domain_scores_gemma":[0.99859476,0.00016676036,0.00036401747,0.00053279253,0.00010690126,0.00023476893],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00010450049,0.0005919108,0.0013340628,0.00046553795,0.00013591742,0.000029683602,0.00034604978,0.000498639,0.00034633084],"category_scores_gemma":[0.000040211627,0.0004613885,0.00036944426,0.0001252476,0.00008542251,0.00013964558,0.00024172578,0.00086160284,0.0004130771],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047233936,0.0001399365,0.008886156,0.00029219006,0.0006190301,0.00038588909,0.00038987788,0.000041408628,0.007050023,5.3690565e-7,0.9596003,0.022122262],"study_design_scores_gemma":[0.0028944963,0.00010862772,0.006247488,0.0003969606,0.00073704816,0.000053124837,0.000009806264,0.00006376504,0.053563032,0.00001207186,0.9352992,0.0006143696],"about_ca_topic_score_codex":0.00018728901,"about_ca_topic_score_gemma":0.000012132558,"teacher_disagreement_score":0.44921508,"about_ca_system_score_codex":0.00031268876,"about_ca_system_score_gemma":0.00013679569,"threshold_uncertainty_score":0.99978375},"labels":[],"label_agreement":null},{"id":"W2090658196","doi":"10.2165/00019053-200826010-00006","title":"Economic Burden of Bilateral Neovascular Age-Related Macular Degeneration","year":2008,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Retinal Diseases and Treatments","field":"Medicine","cited_by":115,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Macular degeneration; Socioeconomic status; Health care; Observational study; Public health; Medical record; Indirect costs; Environmental health; Gerontology; Surgery; Business; Ophthalmology; Population; Nursing; Economic growth","score_opus":0.019435737878942472,"score_gpt":0.29488377750688727,"score_spread":0.2754480396279448,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2090658196","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99596256,0.00070849323,0.000013235825,0.00022955507,0.0002145045,0.0002998402,0.00002880851,0.000033479006,0.0025094985],"genre_scores_gemma":[0.9969638,0.001223089,0.00050108565,0.00014540426,0.00016715475,0.000014666405,0.00018750757,0.000027032975,0.0007702559],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991746,0.000020273043,0.00035944107,0.00022521341,0.00005497412,0.00016549579],"domain_scores_gemma":[0.9995,0.000010947604,0.00011139112,0.00020249441,0.000023642955,0.00015156594],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005475759,0.00014536937,0.0003035334,0.0000809529,0.000056271296,0.000008030769,0.00006540033,0.00005188843,0.00082044053],"category_scores_gemma":[0.0000032001733,0.00013978108,0.00025687471,0.000030853585,0.00007021303,0.00010305313,0.00002461384,0.00006937262,0.00023710015],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044411197,0.002287348,0.43295628,0.0007408876,0.01282308,0.0058036163,0.0035826594,0.12870502,0.32517385,0.0032113215,0.020789338,0.05948548],"study_design_scores_gemma":[0.04797778,0.0012167468,0.18456931,0.00019850093,0.005075367,0.0028431995,0.00014296737,0.20843028,0.46204177,0.001574738,0.08396835,0.0019609898],"about_ca_topic_score_codex":0.00019285087,"about_ca_topic_score_gemma":0.0000016141068,"teacher_disagreement_score":0.24838696,"about_ca_system_score_codex":0.00013920921,"about_ca_system_score_gemma":0.000097446326,"threshold_uncertainty_score":0.89832485},"labels":[],"label_agreement":null},{"id":"W2090799253","doi":"10.2165/00019053-200523050-00008","title":"Economic Evaluation of Levetiracetam as an Add-On Therapy in Patients with Refractory Epilepsy","year":2005,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Epilepsy research and treatment","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Montreal General Hospital","funders":"Université Laval","keywords":"Levetiracetam; Medicine; Epilepsy; Epilepsy surgery; Placebo; Psychiatry","score_opus":0.046598821197151204,"score_gpt":0.38577601919394366,"score_spread":0.33917719799679247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2090799253","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99295014,0.00012810314,4.968426e-7,0.00027210408,0.00006489918,0.0009660395,0.000033863253,0.000015293383,0.005569046],"genre_scores_gemma":[0.99859595,0.000329612,0.00015562416,0.00047540266,0.00014171847,0.00007477355,0.00012688605,0.000029270523,0.00007075555],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988697,0.000106679974,0.00030516175,0.0002909208,0.00019926442,0.0002282799],"domain_scores_gemma":[0.99925375,0.000053991924,0.00013267995,0.00029036085,0.00009408346,0.00017512958],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005526196,0.00015299414,0.00027002126,0.000178795,0.000025369718,0.000010499143,0.000086563196,0.00004670938,0.0018722862],"category_scores_gemma":[0.000013636645,0.00012728525,0.000050042905,0.000035779958,0.000044866763,0.0002549723,0.00001167945,0.00016216651,0.00028771957],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0057173646,0.0024118,0.69624,0.000011329216,0.00019424439,0.0000021774524,0.00024151675,0.0022226113,0.00026502967,0.00008822529,0.00037831906,0.29222736],"study_design_scores_gemma":[0.036787715,0.0057732393,0.9270171,0.000040105366,0.00009835664,0.0000024106407,0.0000479596,0.0074513354,0.017577088,0.00009943386,0.004882087,0.00022315313],"about_ca_topic_score_codex":0.00007777847,"about_ca_topic_score_gemma":0.000107816275,"teacher_disagreement_score":0.2920042,"about_ca_system_score_codex":0.0007344361,"about_ca_system_score_gemma":0.00034640724,"threshold_uncertainty_score":0.9990401},"labels":[],"label_agreement":null},{"id":"W2091281082","doi":"10.2165/00019053-200321020-00004","title":"Cost Analysis of Ropinirole versus Levodopa in the Treatment of Parkinson??s Disease","year":2003,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; PharmIdeas (Canada)","funders":"GlaxoSmithKline","keywords":"Ropinirole; Levodopa; Benserazide; Dyskinesia; Entacapone; Medicine; Pharmacoeconomics; Health economics; Selegiline; Parkinson's disease; Disease; Intensive care medicine; Public health; Internal medicine","score_opus":0.06608418641027519,"score_gpt":0.358011154427996,"score_spread":0.29192696801772083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2091281082","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99608296,0.0012873266,0.00003061081,0.00011672111,0.0001518055,0.00047091045,0.0002394255,0.0000069167945,0.0016133481],"genre_scores_gemma":[0.9975567,0.0019118813,0.0001428975,0.00013639465,0.000023135623,0.00008462529,0.000088553585,0.000012154331,0.000043666216],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991212,0.00007435248,0.00031005967,0.0002205047,0.000095649535,0.0001782587],"domain_scores_gemma":[0.9992594,0.00011033963,0.00014235287,0.00031567476,0.000024698498,0.00014751167],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011230275,0.00015122653,0.00043362632,0.00022794347,0.000025589316,0.0000059862095,0.00007799468,0.000023617387,0.0003335256],"category_scores_gemma":[0.000014333109,0.000111334826,0.00030798095,0.0002811917,0.000040305094,0.00004159857,0.0000056790877,0.00003569842,0.000010912951],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00833874,0.01256207,0.93190753,0.00011611577,0.010837984,0.00025639342,0.0018509873,0.0035876113,0.0008413903,0.0038866694,0.00027667172,0.025537817],"study_design_scores_gemma":[0.03529554,0.0012994463,0.52869314,0.000029350282,0.021520775,0.0000039526994,0.00078842783,0.020628698,0.02514862,0.00023984129,0.36594903,0.00040315665],"about_ca_topic_score_codex":0.00007549859,"about_ca_topic_score_gemma":0.000036615802,"teacher_disagreement_score":0.4032144,"about_ca_system_score_codex":0.0001695078,"about_ca_system_score_gemma":0.000113501796,"threshold_uncertainty_score":0.45401025},"labels":[],"label_agreement":null},{"id":"W2092033713","doi":"10.2165/00019053-200018020-00006","title":"Cost Effectiveness of Epoetin-?? to Augment Preoperative Autologous Blood Donation in Elective Cardiac Surgery","year":2000,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Blood transfusion and management","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"University of Ottawa","keywords":"Medicine; Epoetin alfa; Perioperative; Donation; Erythropoietin; Blood transfusion; Augment; Cardiac surgery; Intensive care medicine; Surgery; Emergency medicine; Internal medicine","score_opus":0.025010670921858963,"score_gpt":0.3191836249523692,"score_spread":0.29417295403051025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2092033713","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909552,0.0001301615,0.00009994707,0.00049373007,0.00020177972,0.0021502401,0.000030017347,0.000033448367,0.005905502],"genre_scores_gemma":[0.9978284,0.0007635145,0.00019867715,0.0005924476,0.000047922844,0.00032904153,0.000035833666,0.000019584724,0.0001845421],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99885356,0.0001941105,0.00034595618,0.00030102747,0.00009075305,0.00021460014],"domain_scores_gemma":[0.9993812,0.00025922546,0.000048712274,0.00013980686,0.000057120607,0.0001139723],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071266695,0.00014367953,0.00050804304,0.0002059897,0.000028643772,0.000008918866,0.000057077348,0.000046542325,0.00046514918],"category_scores_gemma":[0.000019791894,0.00015349593,0.00011710804,0.00017701635,0.000027641756,0.00007648339,0.000019589654,0.00012874941,0.00006191413],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0126198735,0.0076701376,0.2911102,0.0019227881,0.0039167497,0.00012268721,0.005344357,0.012892895,0.12959637,0.001716844,0.0028098118,0.5302773],"study_design_scores_gemma":[0.004759455,0.00035504487,0.37204832,0.00024979978,0.00060674996,0.000009997012,0.00015007298,0.00063508877,0.61293936,0.000073794785,0.00781292,0.0003593812],"about_ca_topic_score_codex":0.00016973057,"about_ca_topic_score_gemma":0.000021786356,"teacher_disagreement_score":0.52991796,"about_ca_system_score_codex":0.0001728749,"about_ca_system_score_gemma":0.000106698055,"threshold_uncertainty_score":0.62593824},"labels":[],"label_agreement":null},{"id":"W2093002176","doi":"10.2165/00019053-200119010-00007","title":"Economic Analysis of Initial HIV Treatment","year":2001,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Royal Victoria Hospital","funders":"","keywords":"Efavirenz; Indinavir; Lamivudine; Zidovudine; Regimen; Medicine; Internal medicine; Reverse-transcriptase inhibitor; Clinical trial; Viral load; Pediatrics; Virology; Human immunodeficiency virus (HIV); Antiretroviral therapy; Virus; Viral disease","score_opus":0.028594484494454984,"score_gpt":0.36910868197365654,"score_spread":0.34051419747920153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2093002176","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9786141,0.000112830494,0.000049644867,0.0016157205,0.00013878022,0.00023286098,0.00008069724,0.000037161437,0.019118186],"genre_scores_gemma":[0.98891634,0.0010289943,0.0005388671,0.0002260444,0.00014576472,0.000033827273,0.0002949134,0.00001934582,0.008795923],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990965,0.000015424686,0.00039414046,0.00024750552,0.000043371056,0.000203034],"domain_scores_gemma":[0.9994514,0.000051075425,0.000121996825,0.00020538879,0.00001894274,0.00015117587],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000073651936,0.00017657099,0.00055192766,0.00039390873,0.000035810197,0.000010120464,0.00006152107,0.00003985539,0.0030219716],"category_scores_gemma":[0.0000023120956,0.00015960228,0.00030769123,0.00014016447,0.00003824642,0.00007688167,0.000020345868,0.000042097443,0.0004820737],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001009718,0.0011120058,0.9300222,0.000021524882,0.021266667,0.00015370002,0.0011839118,0.003054369,0.0010007975,0.0005638844,0.0051225196,0.03548873],"study_design_scores_gemma":[0.026040485,0.00050399743,0.07693861,0.000032439923,0.03290964,0.0001366233,0.00046523532,0.093721025,0.10312232,0.00013131017,0.6649164,0.0010819416],"about_ca_topic_score_codex":0.000051911305,"about_ca_topic_score_gemma":0.000051270585,"teacher_disagreement_score":0.85308355,"about_ca_system_score_codex":0.0005175736,"about_ca_system_score_gemma":0.00015978086,"threshold_uncertainty_score":0.9978894},"labels":[],"label_agreement":null},{"id":"W2094040162","doi":"10.2165/00019053-200220090-00006","title":"Assessment of Health Economics in Alzheimer??s Disease (AHEAD)","year":2002,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Dementia and Cognitive Impairment Research","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Royal Victoria Hospital; Canadian Association of Radiation Oncology","funders":"","keywords":"Galantamine; Health economics; Medicine; Disease; Public health; Euros; Clinical trial; Gerontology; Pharmacoeconomics; Health care; Quality-adjusted life year; Dementia; Psychiatry; Cost effectiveness; Intensive care medicine; Donepezil; Internal medicine; Economics","score_opus":0.06987314835702371,"score_gpt":0.41614317746098606,"score_spread":0.3462700291039623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2094040162","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9781539,0.0018764294,0.00006839851,0.004489987,0.00013840402,0.000667166,0.00003996617,0.000019099913,0.014546642],"genre_scores_gemma":[0.9935479,0.0037659956,0.00036178247,0.0019512532,0.000063443375,0.000047352423,0.000030402694,0.000020900745,0.00021097781],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987221,0.00007116876,0.0005276008,0.00026006612,0.00007947576,0.00033963006],"domain_scores_gemma":[0.9992845,0.000049361766,0.00014317942,0.00018922403,0.000035645564,0.00029806944],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004960747,0.00012723154,0.00035531595,0.000206097,0.000034410736,0.000013997235,0.000098869794,0.00002236757,0.0020681866],"category_scores_gemma":[0.000009737287,0.00013716624,0.000101180245,0.00007864228,0.000061010433,0.00013029858,0.000055052285,0.00016795179,0.00007421081],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000094448296,0.0012154729,0.8856963,0.00013240345,0.00019089086,0.00001894179,0.000098214216,0.00017127035,0.00020268807,0.0009723605,0.0019306563,0.10927639],"study_design_scores_gemma":[0.005442829,0.0002952782,0.9019255,0.000057169018,0.00012223833,0.000007779148,0.00009737644,0.074270085,0.0011583203,0.00023528562,0.016177416,0.00021071474],"about_ca_topic_score_codex":0.000044240147,"about_ca_topic_score_gemma":0.0000068055915,"teacher_disagreement_score":0.109065674,"about_ca_system_score_codex":0.00019653511,"about_ca_system_score_gemma":0.0002395155,"threshold_uncertainty_score":0.9988441},"labels":[],"label_agreement":null},{"id":"W2095469208","doi":"10.2165/00019053-200826050-00004","title":"Economic Evaluations in Rheumatoid Arthritis","year":2008,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Centre for Advancing Health Outcomes; St. Paul's Hospital","funders":"","keywords":"Medicine; Rheumatoid arthritis; Rheumatology; MEDLINE; Physical therapy; Quality of life (healthcare); Pharmacoeconomics; Health administration; Clinical trial; Health economics; Randomized controlled trial; Internal medicine; Intensive care medicine; Public health; Pathology","score_opus":0.05338483011950388,"score_gpt":0.40762281049880084,"score_spread":0.35423798037929694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2095469208","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005493594,0.99306214,0.0000034679176,0.00011633782,0.0004794002,0.0014833384,0.00018196648,0.000075473836,0.004048533],"genre_scores_gemma":[0.00008475326,0.9982407,0.00014684924,0.000106405205,0.00023325368,0.0005056372,0.00037583054,0.00012747924,0.00017910475],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973126,0.00016942594,0.0012208591,0.00058373506,0.00013163692,0.0005817656],"domain_scores_gemma":[0.9986475,0.00024341393,0.0002825359,0.0004587199,0.000032277378,0.0003355221],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00032244567,0.00048351413,0.0023034858,0.0006884187,0.00010915202,0.00006113818,0.0002698883,0.00021962707,0.0020700279],"category_scores_gemma":[0.000049162743,0.0004992902,0.00066326093,0.00012416014,0.00015665578,0.00021626442,0.00009568647,0.0007562472,0.004138949],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002026848,0.00008741926,0.00005056952,0.00069117045,0.0002497825,0.000080552985,0.00006141025,0.000008482718,4.2768255e-7,0.00019773103,0.007889307,0.9906629],"study_design_scores_gemma":[0.0022457128,0.000049706414,0.000008481996,0.0060598315,0.0000125639035,0.0016514041,0.000010260786,0.00021452675,0.0000047170547,0.000080150654,0.9892759,0.0003867481],"about_ca_topic_score_codex":0.000091048976,"about_ca_topic_score_gemma":0.00012681178,"teacher_disagreement_score":0.99027616,"about_ca_system_score_codex":0.0008203363,"about_ca_system_score_gemma":0.0020064008,"threshold_uncertainty_score":0.99974585},"labels":[],"label_agreement":null},{"id":"W2096214040","doi":"10.2165/00019053-200523001-00006","title":"Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada","year":2005,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta","funders":"","keywords":"Quality of Life Research; Health economics; Health administration; Risperidone; Compliance (psychology); Public health; Medicine; Pharmacoeconomics; Business; Intensive care medicine; Environmental health; Public economics; Psychiatry; Economics; Psychology; Nursing; Schizophrenia (object-oriented programming)","score_opus":0.04487550771609063,"score_gpt":0.34798799861995816,"score_spread":0.30311249090386755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2096214040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976245,0.00070298096,0.000026294967,0.0010399735,0.00002486376,0.00035319492,0.000011186648,0.000001934118,0.0002150304],"genre_scores_gemma":[0.99920183,0.00049252715,0.00009650833,0.00013936966,0.000041252795,0.000012160261,0.0000016665314,0.000007783759,0.0000069093503],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.999511,0.00003241032,0.00015307471,0.00009205014,0.00006410603,0.00014736067],"domain_scores_gemma":[0.9991693,0.00054501946,0.000071650844,0.00012888017,0.000018547367,0.000066633605],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012963111,0.00007854605,0.00017279906,0.000025554495,0.000029405328,0.000004658477,0.0000658227,0.000009552431,0.000028691396],"category_scores_gemma":[0.000019217652,0.00004330183,0.000037986625,0.000041274736,0.000036952224,0.000028890967,0.000020411913,0.00014271923,0.0000020420366],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012458992,0.000557429,0.21001992,0.0004231145,0.0011046,0.000096766424,0.00092946726,0.58883244,0.006352759,0.00035683688,0.0009151676,0.1779525],"study_design_scores_gemma":[0.0042256694,0.00015410059,0.03404692,0.0001795793,0.00003652315,0.000014462786,0.00006989152,0.88172776,0.07942379,0.000025281734,0.000025139967,0.00007088568],"about_ca_topic_score_codex":0.41175276,"about_ca_topic_score_gemma":0.10655145,"teacher_disagreement_score":0.3052013,"about_ca_system_score_codex":0.0005531292,"about_ca_system_score_gemma":0.00034707732,"threshold_uncertainty_score":0.90975165},"labels":[],"label_agreement":null},{"id":"W2100804302","doi":"10.2165/00019053-200725060-00007","title":"Building Bridges Between Academic Research and Policy Formulation: When Costing Less Means Costing More","year":2007,"lang":"en","type":"letter","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Activity-based costing; Health economics; Quality of Life Research; Health administration; Pharmacoeconomics; Public health; Business; Management science; Accounting; Economics; Medicine; Nursing","score_opus":0.6833153033704409,"score_gpt":0.5764666633956288,"score_spread":0.10684863997481209,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2100804302","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.11282385,0.003902274,0.0059157056,0.868168,0.0011266127,0.0019947065,0.0021206366,0.00020752494,0.0037406983],"genre_scores_gemma":[0.052258827,0.001533311,0.008788507,0.8842549,0.04907113,0.00025884298,0.0010718692,0.0005215632,0.002241049],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9878417,0.00057757227,0.0073030447,0.0018989801,0.0003055533,0.0020731085],"domain_scores_gemma":[0.9851713,0.008738123,0.0044407505,0.00085258525,0.00027794766,0.00051927543],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0359199,0.00078546576,0.0024460685,0.0026858286,0.0010350065,0.00050505786,0.0012341777,0.0016172156,0.00016591734],"category_scores_gemma":[0.0040885876,0.0011636033,0.00024466822,0.00039599926,0.00036449928,0.0013406705,0.00056915573,0.005630488,0.0007705175],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000024206505,0.000022103872,0.056409832,0.0017303146,0.00036407035,0.000017903758,0.0023705987,0.00032177204,0.000007658701,0.015005253,0.91959953,0.0041267294],"study_design_scores_gemma":[0.00142861,0.000054034335,0.0030565592,0.00043588754,0.000045971985,0.00003725873,0.00052153465,0.009396652,0.000067288864,0.027859287,0.95578843,0.001308493],"about_ca_topic_score_codex":0.0033608887,"about_ca_topic_score_gemma":0.000043705568,"teacher_disagreement_score":0.06056503,"about_ca_system_score_codex":0.0041239364,"about_ca_system_score_gemma":0.0006183406,"threshold_uncertainty_score":0.99969906},"labels":[],"label_agreement":null},{"id":"W2101393165","doi":"10.2165/00019053-200826010-00003","title":"Cost-Effectiveness Analyses of Hepatitis A Vaccine","year":2008,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Hepatitis Viruses Studies and Epidemiology","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut National de Santé Publique du Québec; Centre hospitalier universitaire de Québec; Toronto Public Health; University of Guelph; Children's Hospital of Eastern Ontario; University of Ottawa; GlaxoSmithKline (Canada); University Health Network; Institute of Population and Public Health; University of Toronto","funders":"","keywords":"Quality of Life Research; Health economics; Public health; Health administration; Medicine; Pharmacoeconomics; Hepatitis A; Cost effectiveness; Virology; Environmental health; Intensive care medicine; Hepatitis; Risk analysis (engineering); Nursing","score_opus":0.38128493480989,"score_gpt":0.5332267126210455,"score_spread":0.15194177781115548,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2101393165","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006585119,0.99556446,0.00011900032,0.000029796069,0.0005471203,0.0015609857,0.00029228017,0.000041848845,0.0011860126],"genre_scores_gemma":[0.00005873809,0.99819016,0.0002551343,0.00035458227,0.00042536866,0.00034493115,0.00023425111,0.00008051715,0.000056339508],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99749017,0.00032892762,0.0012561136,0.00048134034,0.00006772034,0.00037572897],"domain_scores_gemma":[0.99756515,0.0010315956,0.0007199943,0.00039498383,0.000100217214,0.00018806619],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00029031132,0.00048272216,0.0050360193,0.00027319966,0.000067457244,0.0000039646407,0.000180247,0.00024681696,0.00035427077],"category_scores_gemma":[0.00019828165,0.00040036597,0.0011178246,0.00019101244,0.00008580914,0.000052349682,0.00014018743,0.00040657367,0.00017873713],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007409201,0.00014626856,0.0054916767,0.018972278,0.0030631635,0.00008842317,0.000021965696,0.000016806842,0.0000047065537,0.000033784465,0.012978355,0.9591085],"study_design_scores_gemma":[0.0009456416,0.00013541835,0.00033818863,0.0028203034,0.002609901,0.00032989806,0.0000017367124,0.00011596538,0.00003549608,0.000007714963,0.9923666,0.00029309842],"about_ca_topic_score_codex":0.001990381,"about_ca_topic_score_gemma":0.00008137846,"teacher_disagreement_score":0.9793883,"about_ca_system_score_codex":0.0003937465,"about_ca_system_score_gemma":0.00036271618,"threshold_uncertainty_score":0.99984485},"labels":[],"label_agreement":null},{"id":"W2107450864","doi":"10.2165/00019053-200321060-00002","title":"Health-Related Quality of Life and Regulatory Issues in the US and Canada","year":2003,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Quality of Life Research; Health economics; Public health; Health administration; Quality (philosophy); Business; Environmental health; Medicine; Nursing","score_opus":0.2480104449355913,"score_gpt":0.438640479605491,"score_spread":0.19063003466989972,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2107450864","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9410709,0.015722755,0.000013758772,0.040618353,0.00033329733,0.00046444545,0.00016905066,0.000009504117,0.0015979011],"genre_scores_gemma":[0.976581,0.0013329467,0.00027171453,0.021603048,0.000051476527,0.000028054903,0.000009179688,0.000018880333,0.000103744955],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9944602,0.0007796171,0.003977043,0.00040630117,0.00005408033,0.00032271922],"domain_scores_gemma":[0.99655515,0.0009778636,0.0019151805,0.00033425045,0.00002131488,0.00019626625],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.018742908,0.00016749148,0.0010441158,0.0001374771,0.0001245493,0.00003733877,0.00018107044,0.00007274363,0.00013560828],"category_scores_gemma":[0.001212165,0.00019279507,0.000042266256,0.000080986516,0.00011178731,0.0002460616,0.00002936148,0.0001928273,0.000021148086],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000026875756,0.00007581299,0.6971565,0.00059789227,0.00009508174,7.137209e-7,0.0031001754,0.00036848595,0.0000054084185,0.26572278,0.03262839,0.00022188714],"study_design_scores_gemma":[0.0040922533,0.000069819944,0.7713768,0.00005043638,0.000008542111,0.000020908521,0.003707745,0.003315257,0.00003223142,0.022252979,0.19433083,0.00074223906],"about_ca_topic_score_codex":0.54366887,"about_ca_topic_score_gemma":0.2835696,"teacher_disagreement_score":0.26009926,"about_ca_system_score_codex":0.00037746903,"about_ca_system_score_gemma":0.00060096773,"threshold_uncertainty_score":0.78619546},"labels":[],"label_agreement":null},{"id":"W2110633362","doi":"10.2165/00019053-200119080-00005","title":"Cost Effectiveness in Canada of a Multidrug Prepackaged Regimen (Hp-PAC??)* for Helicobacter pylori Eradication","year":2001,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Helicobacter pylori-related gastroenterology studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; St. Joseph's Hospital","funders":"","keywords":"Lansoprazole; Clarithromycin; Copayment; Medicine; Metronidazole; Helicobacter pylori; Regimen; Amoxicillin; Pharmacoeconomics; Internal medicine; Cost effectiveness; Proton-pump inhibitor; Health economics; Health care; Intensive care medicine; Public health; Antibiotics","score_opus":0.03413564782754916,"score_gpt":0.32139746956526566,"score_spread":0.2872618217377165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2110633362","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951036,0.0001262439,0.00031026854,0.001861177,0.00044828322,0.0017860623,0.00009484941,0.000027558664,0.00024193537],"genre_scores_gemma":[0.9975267,0.0003631139,0.00038085604,0.0009915591,0.00012463218,0.00041095703,0.00008684701,0.00003964143,0.000075676886],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99849373,0.000103663086,0.0005354486,0.00037177923,0.00007859053,0.0004167999],"domain_scores_gemma":[0.9988994,0.00031787594,0.0002298974,0.00027328718,0.0001288903,0.00015062108],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040707682,0.00022075199,0.0005607567,0.00014956642,0.000049448437,0.0000059724885,0.00013011061,0.00006900356,0.000032377822],"category_scores_gemma":[0.00010452748,0.00023128034,0.00008342176,0.00012584876,0.00006699284,0.00013753425,0.00004700359,0.00023903565,0.000009312354],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030341318,0.00020350119,0.97127444,0.00018601808,0.000610882,0.000021017764,0.0005701815,0.00036179114,0.017085379,0.00001073847,0.0016155642,0.005026363],"study_design_scores_gemma":[0.021599079,0.00035255429,0.8773839,0.00020263354,0.00042415704,0.00009563143,0.00034312913,0.0110022845,0.06635029,0.000036093184,0.021818643,0.0003916042],"about_ca_topic_score_codex":0.12365471,"about_ca_topic_score_gemma":0.19658154,"teacher_disagreement_score":0.09389053,"about_ca_system_score_codex":0.0013720501,"about_ca_system_score_gemma":0.000512503,"threshold_uncertainty_score":0.9431339},"labels":[],"label_agreement":null},{"id":"W2115224809","doi":"10.2165/00019053-200523060-00001","title":"Incorporation of uncertainty in health economic modelling studies","year":2005,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":59,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Health economics; Quality of Life Research; Health administration; Public health; Health services research; Economics; Environmental health; Public economics; Medicine; Nursing","score_opus":0.5165894629374198,"score_gpt":0.5174184369747727,"score_spread":0.0008289740373529364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2115224809","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9078743,0.013357994,0.00614212,0.06681135,0.0013148779,0.0012659025,0.000488351,0.00008393801,0.0026612016],"genre_scores_gemma":[0.97935927,0.003636992,0.0065605706,0.00946585,0.00059087947,0.00009307977,0.000045832297,0.000047077632,0.00020042116],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.992037,0.00024543382,0.006587121,0.00061421446,0.00004389683,0.0004723409],"domain_scores_gemma":[0.994878,0.00062209566,0.003889409,0.00039434072,0.000042500586,0.00017366766],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.013937983,0.0002534176,0.0014591292,0.00057060405,0.00010855288,0.000034037974,0.00031206873,0.00009609473,0.0002908338],"category_scores_gemma":[0.00023481384,0.00036073354,0.00014303773,0.00011290523,0.00009658146,0.00094240333,0.00007222461,0.00021321051,0.0011686371],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000028562006,0.00008032296,0.005879922,0.00030314425,0.00008600845,1.9095053e-7,0.0025123751,0.8942514,0.0000043623254,0.08973788,0.006336707,0.0007791015],"study_design_scores_gemma":[0.0016676261,0.000056855377,0.00031636693,0.000082119346,0.0000047144144,0.000002720638,0.0011297528,0.910926,0.00006253835,0.02360243,0.06174594,0.00040297577],"about_ca_topic_score_codex":0.0019036974,"about_ca_topic_score_gemma":0.0010524449,"teacher_disagreement_score":0.071485035,"about_ca_system_score_codex":0.003061221,"about_ca_system_score_gemma":0.00036445653,"threshold_uncertainty_score":0.9998845},"labels":[],"label_agreement":null},{"id":"W2117460722","doi":"10.1007/s40273-013-0076-z","title":"Cost–Utility Analysis of Deferiprone for the Treatment of β-Thalassaemia Patients with Chronic Iron Overload: A UK Perspective","year":2013,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Hemoglobinopathies and Related Disorders","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Deferiprone; Medicine; Deferasirox; Cost–utility analysis; Quality-adjusted life year; Cost effectiveness; Pharmacoeconomics; Quality of life (healthcare); Intensive care medicine; Cost-effectiveness analysis; Thalassemia; Internal medicine; Risk analysis (engineering)","score_opus":0.015783703217200924,"score_gpt":0.29338491819478413,"score_spread":0.2776012149775832,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2117460722","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952711,0.0013534715,0.00017430344,0.00034158066,0.000068351226,0.0020929137,0.00015457458,0.000009525233,0.00053421047],"genre_scores_gemma":[0.9981503,0.0012710479,0.000117881464,0.00007681116,0.000026008222,0.0001854715,0.00006488682,0.000015101288,0.000092494694],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99920523,0.000016141994,0.00029485245,0.00021799811,0.00007302883,0.00019273085],"domain_scores_gemma":[0.99913675,0.00011503252,0.00020819015,0.00026008402,0.00020024778,0.000079708894],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006299786,0.00015075266,0.00045384443,0.00009462476,0.00004937849,0.000006164954,0.000069561414,0.000057135836,0.0006307036],"category_scores_gemma":[0.000009340401,0.00009038953,0.00024830713,0.0001832136,0.00013620514,0.000048650538,0.000011450085,0.00006301164,0.000005905976],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003761657,0.004567767,0.871261,0.00028173125,0.021436503,0.0000011699096,0.005892884,0.008623375,0.002198483,0.00029078414,0.0015065174,0.080178104],"study_design_scores_gemma":[0.030907575,0.005387544,0.77297926,0.000047000052,0.022954285,0.0000018916683,0.003864661,0.14075327,0.013699054,0.00009277916,0.008851791,0.00046089728],"about_ca_topic_score_codex":0.0010655076,"about_ca_topic_score_gemma":0.000098138895,"teacher_disagreement_score":0.1321299,"about_ca_system_score_codex":0.00050357153,"about_ca_system_score_gemma":0.00012210324,"threshold_uncertainty_score":0.6905762},"labels":[],"label_agreement":null},{"id":"W2118851499","doi":"10.2165/00019053-200422060-00004","title":"Measuring Treatment Preferences and Willingness to Pay for Docetaxel in Advanced Ovarian Cancer","year":2004,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; Sunnybrook Health Science Centre; Augmentium Pharma Consulting (Canada)","funders":"","keywords":"Docetaxel; Health economics; Willingness to pay; Quality of Life Research; Ovarian cancer; Health administration; Medicine; Public health; Oncology; Internal medicine; Economics; Intensive care medicine; Cancer; Nursing; Microeconomics","score_opus":0.06984964040290455,"score_gpt":0.3547769810316263,"score_spread":0.28492734062872177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118851499","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896937,0.0011555593,0.00018204702,0.0069858283,0.0003209156,0.0012946394,0.00007936936,0.000025580968,0.00026233136],"genre_scores_gemma":[0.9908097,0.0032794422,0.0034365081,0.0008388234,0.00018635967,0.0013436599,0.000011016723,0.00002391183,0.00007058134],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9991128,0.000006817466,0.0002275447,0.00036280474,0.00004263413,0.00024744164],"domain_scores_gemma":[0.99957216,0.000040583993,0.000054306776,0.0001196515,0.000028945773,0.0001843585],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007642539,0.00017479766,0.00032080268,0.000071183356,0.000050289804,0.000026180309,0.000044293985,0.000033258515,0.000040215953],"category_scores_gemma":[0.000007005705,0.00013217243,0.000053898013,0.000058015456,0.000013231492,0.00009878772,0.000015892294,0.0000493576,0.0000070117653],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017977873,0.0011974251,0.28413,0.0002193589,0.0007278583,0.00003118478,0.002449334,0.019654917,0.0034876966,0.0011405098,0.0000874892,0.6850764],"study_design_scores_gemma":[0.09949784,0.002770293,0.50284266,0.00087999075,0.0012811072,0.00004047439,0.00042924713,0.0015388129,0.2748681,0.0039883526,0.110576816,0.0012862863],"about_ca_topic_score_codex":0.000729042,"about_ca_topic_score_gemma":0.000868506,"teacher_disagreement_score":0.68379015,"about_ca_system_score_codex":0.0007872037,"about_ca_system_score_gemma":0.00020289632,"threshold_uncertainty_score":0.53898346},"labels":[],"label_agreement":null},{"id":"W2119939498","doi":"10.2165/00019053-200119110-00004","title":"Cost-Effectiveness Analysis and the Consistency of Decision Making","year":2001,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":439,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Government of Canada","keywords":"Reimbursement; Listing (finance); Health economics; Actuarial science; League table; Cost effectiveness; Medicine; Quality-adjusted life year; Pharmacoeconomics; Public health; Economics; Health care; Risk analysis (engineering); Finance; Intensive care medicine; Nursing","score_opus":0.3606329120648894,"score_gpt":0.5047786977032513,"score_spread":0.14414578563836195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2119939498","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92836297,0.003974016,0.055024985,0.004679956,0.0005823083,0.0013034166,0.00020463983,0.000034501947,0.005833197],"genre_scores_gemma":[0.9919303,0.00125318,0.0021233435,0.0043518017,0.0001252503,0.00012991375,0.000010250127,0.000023102783,0.000052846764],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99578434,0.00042886139,0.0029518895,0.00048772604,0.000050311,0.00029688166],"domain_scores_gemma":[0.99205965,0.0053903707,0.0019183664,0.00046077796,0.000062751,0.00010807642],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.017203376,0.0001895539,0.0013414763,0.00046852377,0.00020703555,0.0000750169,0.00029097006,0.00008326294,0.00055448775],"category_scores_gemma":[0.0012971007,0.00019391174,0.0002811548,0.00037568837,0.00027427753,0.0003525092,0.0000991748,0.0001506908,0.00023294351],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010874891,0.00018677789,0.64258826,0.000367398,0.0028016823,0.000004669791,0.0029817026,0.010732345,0.000016872851,0.32364544,0.0021846204,0.0134027265],"study_design_scores_gemma":[0.019347278,0.000112326496,0.34669697,0.00022884982,0.0011007785,0.000089473324,0.0022997002,0.3892511,0.00016665425,0.16335288,0.07577722,0.0015767708],"about_ca_topic_score_codex":0.00041673394,"about_ca_topic_score_gemma":0.00010804168,"teacher_disagreement_score":0.37851876,"about_ca_system_score_codex":0.00025892066,"about_ca_system_score_gemma":0.00006423074,"threshold_uncertainty_score":0.79074913},"labels":[],"label_agreement":null},{"id":"W2120799817","doi":"10.1007/s40273-013-0057-2","title":"The Cost and Public Health Burden of Invasive Meningococcal Disease Outbreaks: A Systematic Review","year":2013,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Bacterial Infections and Vaccines","field":"Immunology and Microbiology","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital; Toronto Public Health","funders":"Canadian Institutes of Health Research; GlaxoSmithKline","keywords":"Public health; Health economics; Outbreak; Quality of Life Research; Health administration; Meningococcal disease; Medicine; Disease burden; Burden of disease; Disease; Environmental health; Quality-adjusted life year; Neisseria meningitidis; Cost effectiveness; Virology; Risk analysis (engineering); Nursing","score_opus":0.06974240109637254,"score_gpt":0.3583605125611188,"score_spread":0.28861811146474625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2120799817","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000043190383,0.99353206,0.0000027056155,0.0007694068,0.00080854254,0.0045021074,0.00027474275,0.000026078684,0.000041193598],"genre_scores_gemma":[0.00004312107,0.9976108,0.0000030714837,0.00021742842,0.000089583344,0.0013899937,0.00024943048,0.000034503657,0.00036207636],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972253,0.0007949071,0.0013136704,0.0002971251,0.000009576468,0.00035941077],"domain_scores_gemma":[0.9972753,0.00073635095,0.001383184,0.00041972776,0.00007060719,0.0001148202],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00077377545,0.00035113323,0.0023479844,0.00008906353,0.00025466815,0.00007002163,0.0003589261,0.0001262408,0.0002449292],"category_scores_gemma":[0.00025459033,0.00021519794,0.00033938282,0.00007950411,0.00013361701,0.000114757626,0.00019225632,0.00030497703,0.0003474033],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00000436497,0.000037264566,0.000001843813,0.82137626,0.001147132,2.1772077e-7,0.00004889211,5.710991e-8,0.0000116366855,0.00038849682,0.008738589,0.16824523],"study_design_scores_gemma":[0.00022449777,0.00002270742,3.648331e-7,0.0871716,0.0013152899,0.000058400612,0.000031576204,0.0000010222797,0.0000015643692,0.0000070872893,0.9109829,0.00018299364],"about_ca_topic_score_codex":0.00014894777,"about_ca_topic_score_gemma":0.000011795728,"teacher_disagreement_score":0.9022443,"about_ca_system_score_codex":0.00011783468,"about_ca_system_score_gemma":0.0005250818,"threshold_uncertainty_score":0.87755173},"labels":[],"label_agreement":null},{"id":"W2123469744","doi":"10.2165/00019053-200119090-00007","title":"A Multinational Study to Measure the Value that Patients with Cancer Place on Improved Emesis Control Following Cisplatin Chemotherapy","year":2001,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Nausea and vomiting management","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Ontario Institute for Cancer Research","funders":"H2020 European Research Council","keywords":"Medicine; Willingness to pay; Chemotherapy; Cisplatin; Cancer; Internal medicine; Anesthesia","score_opus":0.02062754250818304,"score_gpt":0.315755038182846,"score_spread":0.29512749567466295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2123469744","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99080694,0.000027048893,0.00027407813,0.0052090115,0.00026576762,0.002609215,0.000017911809,0.000045174493,0.0007448801],"genre_scores_gemma":[0.9866719,0.000015030092,0.00014870104,0.012121712,0.00019456571,0.0002380101,0.000007334537,0.000039952552,0.00056275754],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99897754,0.000053055286,0.000200322,0.00030668016,0.00021614924,0.00024626858],"domain_scores_gemma":[0.99936235,0.0001440183,0.00011015108,0.00020885715,0.000062158004,0.00011245088],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040013262,0.00018953357,0.00024701294,0.00007660845,0.00014598585,0.00003203906,0.00013861856,0.000020204732,0.00014727512],"category_scores_gemma":[0.000026456859,0.00012913135,0.00008155143,0.00008839282,0.000011980839,0.00007342518,0.000025391324,0.00014746304,0.000023176372],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0054860087,0.0014899387,0.9592684,0.000016046726,0.0014307684,0.000011236549,0.001429631,0.0028654712,0.00052770507,0.000021426265,0.0037184786,0.023734918],"study_design_scores_gemma":[0.081369214,0.0015449255,0.859462,0.000116250645,0.0010956008,0.0000021902647,0.0010687123,0.029932424,0.0015699799,0.000010467747,0.02321699,0.00061121216],"about_ca_topic_score_codex":0.00013349806,"about_ca_topic_score_gemma":0.000052160914,"teacher_disagreement_score":0.099806346,"about_ca_system_score_codex":0.00024204825,"about_ca_system_score_gemma":0.000056620112,"threshold_uncertainty_score":0.52658236},"labels":[],"label_agreement":null},{"id":"W2124777219","doi":"10.1007/s40273-014-0173-7","title":"Cost Effectiveness of Darunavir/ritonavir Combination Antiretroviral Therapy for Treatment-Naive Adults with HIV-1 Infection in Canada","year":2014,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Darunavir; Ritonavir; Quality of Life Research; Medicine; Human immunodeficiency virus (HIV); Antiretroviral therapy; Health economics; Public health; Health administration; Cost effectiveness; Pharmacoeconomics; Intensive care medicine; Virology; Viral load; Nursing","score_opus":0.017243557705987324,"score_gpt":0.2933875668528628,"score_spread":0.2761440091468755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2124777219","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99723285,0.00004161777,0.00021724383,0.00015961104,0.00016191977,0.001743555,0.000059082227,0.000015752254,0.00036838607],"genre_scores_gemma":[0.99853164,0.0002645057,0.00018362424,0.00006582791,0.000040189432,0.00034450344,0.00041877484,0.000025477535,0.00012544474],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992043,0.000065278924,0.00023620132,0.00023667369,0.00006852923,0.00018906017],"domain_scores_gemma":[0.99941194,0.00021827774,0.00012332799,0.000109287364,0.0000647492,0.00007239],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016061433,0.00018317917,0.00038631467,0.00010638937,0.000040785686,0.00000713372,0.000036757556,0.000032663593,0.00001562965],"category_scores_gemma":[0.000008003391,0.00015106046,0.000051329193,0.00008038481,0.000026048392,0.00010991945,0.0000066041202,0.00004570837,0.00000441208],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043738266,0.00049170543,0.94476265,0.00014390127,0.00022314631,0.000004511149,0.00021411607,0.0002073126,0.0005533395,0.000098916054,0.000091161724,0.048835397],"study_design_scores_gemma":[0.0922183,0.0026272028,0.6606702,0.00033953955,0.00022175636,0.000012464799,0.00012765305,0.014224467,0.22046722,0.00006663914,0.008590134,0.00043437455],"about_ca_topic_score_codex":0.1402458,"about_ca_topic_score_gemma":0.114663765,"teacher_disagreement_score":0.28409243,"about_ca_system_score_codex":0.0014694049,"about_ca_system_score_gemma":0.0005912403,"threshold_uncertainty_score":0.9014913},"labels":[],"label_agreement":null},{"id":"W2126509908","doi":"10.2165/00019053-200321050-00005","title":"Peginterferon ??-2a (40kD) [Pegasys??] Improves HR-QOL Outcomes Compared with Unmodified Interferon ??-2a [Roferon??-A]","year":2003,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Hepatitis C virus research","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Toronto Western Hospital; University of British Columbia; University Health Network; Mount Sinai Hospital","funders":"","keywords":"Medicine; Regimen; Alpha interferon; Internal medicine; Gastroenterology; Chronic hepatitis; Interferon; Quality of life (healthcare); Surgery; Virology; Virus","score_opus":0.0481153764406794,"score_gpt":0.3616311150536178,"score_spread":0.31351573861293835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2126509908","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9585957,0.00021086867,0.0005984071,0.0016643942,0.0007282059,0.0014405684,0.000058258964,0.00025294538,0.036450688],"genre_scores_gemma":[0.9911165,0.00022382809,0.0011841676,0.002287516,0.00019658156,0.0001806795,0.0000651453,0.0001741903,0.0045713717],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965354,0.00022946762,0.0008531238,0.00090718025,0.00036263475,0.0011121721],"domain_scores_gemma":[0.99770194,0.00024527512,0.0002458735,0.0008683151,0.00020488251,0.0007337024],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0005968946,0.0006322806,0.0011203446,0.00039408487,0.0001827303,0.00016046446,0.00046198277,0.00017106664,0.0015103751],"category_scores_gemma":[0.00011857045,0.00054931676,0.0002517523,0.00019995405,0.00022630805,0.00043918687,0.00014825129,0.0009003615,0.0011247556],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016178712,0.0037785857,0.62385267,0.0017587091,0.005782373,0.00072843244,0.0051481044,0.00104555,0.19904244,0.004011146,0.051575474,0.0870978],"study_design_scores_gemma":[0.061665114,0.0064491956,0.048676837,0.00065557985,0.0015378275,0.0005518339,0.0029288284,0.03457989,0.36951065,0.00042053068,0.46841517,0.0046085576],"about_ca_topic_score_codex":0.00018261433,"about_ca_topic_score_gemma":0.00021900599,"teacher_disagreement_score":0.5751758,"about_ca_system_score_codex":0.00078640616,"about_ca_system_score_gemma":0.0004799752,"threshold_uncertainty_score":0.99969584},"labels":[],"label_agreement":null},{"id":"W2128419295","doi":"10.2165/00019053-200523080-00001","title":"Real-World Trials to Answer Real-World Questions","year":2005,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"South Health Campus","funders":"","keywords":"Reimbursement; Health economics; Clinical trial; Health administration; Value (mathematics); Medicine; Health care; Relevance (law); Actuarial science; Management science; Public economics; Intensive care medicine; Risk analysis (engineering); Public health; Economics; Political science; Nursing; Computer science; Economic growth","score_opus":0.4318036598781997,"score_gpt":0.5269865391437449,"score_spread":0.09518287926554525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2128419295","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.29066348,0.0019211245,0.003042017,0.23746425,0.008373686,0.0051038046,0.0029362445,0.0008438661,0.44965154],"genre_scores_gemma":[0.6149631,0.005534478,0.05513183,0.20783125,0.01699348,0.00198989,0.00037862375,0.00049072545,0.09668663],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9885345,0.00072177534,0.008509046,0.0012051648,0.000100281744,0.0009292368],"domain_scores_gemma":[0.9928853,0.001960003,0.0031062579,0.0010274248,0.000113891045,0.0009071556],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.027235802,0.0005078103,0.0024243426,0.001602147,0.0003687145,0.00027907023,0.00075190666,0.00015204266,0.0060580466],"category_scores_gemma":[0.0017965958,0.0006931737,0.00045343433,0.00053349714,0.000082104714,0.0011850905,0.00015547799,0.0004012556,0.025522828],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000088106,0.00033226737,0.02099831,0.00013090952,0.00025715228,0.000001409188,0.0009117496,0.004482102,0.00006762433,0.38365832,0.58428466,0.0047873855],"study_design_scores_gemma":[0.0013623518,0.000039834507,0.0068315472,0.00005618529,0.000041141393,0.00000292216,0.00012965583,0.0058459886,0.00018700342,0.0074253366,0.97726077,0.0008172551],"about_ca_topic_score_codex":0.007024107,"about_ca_topic_score_gemma":0.009148397,"teacher_disagreement_score":0.39297614,"about_ca_system_score_codex":0.0026235012,"about_ca_system_score_gemma":0.0005755351,"threshold_uncertainty_score":0.9995882},"labels":[],"label_agreement":null},{"id":"W2132649890","doi":"10.2165/00019053-200321080-00003","title":"Labour Force Participation Among Individuals with Hepatitis C in the US","year":2003,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Hepatitis C virus research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Yukon Health and Social Services; Institute of Health Economics; University of Alberta","funders":"","keywords":"Medicine; Confounding; Hepatitis C virus; Hepatitis C; Workforce; Public health; Hepatology; Demography; Internal medicine; Immunology; Virus; Pathology","score_opus":0.03471233796987222,"score_gpt":0.3608428828755597,"score_spread":0.3261305449056875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132649890","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98098177,0.000062370054,0.0000708499,0.0006337386,0.000056046076,0.00068161654,0.000022853072,0.000021894657,0.017468888],"genre_scores_gemma":[0.9960456,0.0003285954,0.00034818446,0.0025183358,0.0000636796,0.0002092976,0.00001892063,0.000025771027,0.00044160514],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988048,0.00018530675,0.00026493182,0.00020780909,0.00018067633,0.00035647678],"domain_scores_gemma":[0.9993987,0.00013117462,0.00006950865,0.00023221894,0.000046023724,0.00012238644],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00077596755,0.00012003999,0.00019328385,0.00011560537,0.00006564113,0.00005390326,0.00012591445,0.000046133384,0.000598988],"category_scores_gemma":[0.000112919326,0.00008953692,0.000034554054,0.00019594007,0.00007848114,0.00020811836,0.00001650472,0.000284871,0.00013990348],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000030093886,0.00008866718,0.99446625,0.00002295816,0.000043490498,0.000036694502,0.0005933275,0.00023112337,0.00012281568,0.0013871698,0.00064634945,0.0023310657],"study_design_scores_gemma":[0.0030371097,0.00017344691,0.9085891,0.000027829577,0.000057891248,0.000019688792,0.000090774214,0.0027911488,0.0072326637,0.00023935914,0.07755482,0.00018615313],"about_ca_topic_score_codex":0.00069985964,"about_ca_topic_score_gemma":0.0012879877,"teacher_disagreement_score":0.085877135,"about_ca_system_score_codex":0.00012968051,"about_ca_system_score_gemma":0.0001424263,"threshold_uncertainty_score":0.6558498},"labels":[],"label_agreement":null},{"id":"W2136793894","doi":"10.1007/s40273-015-0340-5","title":"Can the EVIDEM Framework Tackle Issues Raised by Evaluating Treatments for Rare Diseases: Analysis of Issues and Policies, and Context-Specific Adaptation","year":2015,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; TransCanada (Canada); SNC-Lavalin (Canada)","funders":"","keywords":"Management science; Context (archaeology); Multiple-criteria decision analysis; Psychological intervention; Prioritization; Risk analysis (engineering); Adaptation (eye); Disease; Process management; Medicine; Psychology; Business; Economics; Operations research","score_opus":0.45654649083546067,"score_gpt":0.5157299019594791,"score_spread":0.059183411124018426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136793894","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8384853,0.10271451,0.0021130976,0.049395964,0.00038327553,0.0016910082,0.005062703,0.000040899202,0.00011321605],"genre_scores_gemma":[0.9816302,0.007066351,0.0029865913,0.006750786,0.0003555677,0.00035174005,0.0003769391,0.000052243602,0.00042959675],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.996512,0.00027660752,0.0022552004,0.00055935164,0.000074833006,0.0003220076],"domain_scores_gemma":[0.9956759,0.0018078053,0.0017292836,0.0003775026,0.00013463788,0.00027487043],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00503413,0.00024954331,0.0011587355,0.00024878475,0.00024652117,0.00016185816,0.00022323686,0.000101239624,0.00011522774],"category_scores_gemma":[0.0014351041,0.000264525,0.00015038796,0.00021139624,0.00015712692,0.0004086814,0.000059816233,0.00010110938,0.000021911967],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007768659,0.00057769584,0.39094445,0.0007778172,0.010562268,7.9616086e-7,0.08653771,0.010899027,0.000077535886,0.1585897,0.31557593,0.024680192],"study_design_scores_gemma":[0.0074309283,0.000508319,0.024901671,0.00012702515,0.0016730648,0.0000027313565,0.027364861,0.59433204,0.00014394008,0.05649524,0.28580904,0.001211097],"about_ca_topic_score_codex":0.0024635964,"about_ca_topic_score_gemma":0.00015463885,"teacher_disagreement_score":0.58343303,"about_ca_system_score_codex":0.00035730898,"about_ca_system_score_gemma":0.00013246595,"threshold_uncertainty_score":0.9999807},"labels":[],"label_agreement":null},{"id":"W2138874398","doi":"10.2165/00019053-200624100-00004","title":"Therapeutic Options for the Prevention and Treatment of Postoperative Nausea and Vomiting","year":2006,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Nausea and vomiting management","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Nausea; Quality of Life Research; Medicine; Vomiting; Health economics; Health administration; Intensive care medicine; Public health; Abdominal surgery; Pharmacoeconomics; Anesthesia; Internal medicine; Nursing","score_opus":0.12778055701150198,"score_gpt":0.4377567835196323,"score_spread":0.30997622650813034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138874398","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009248058,0.99543375,0.00019380306,0.00033541312,0.00009886733,0.0026766034,0.00007889913,0.000013812843,0.00024407715],"genre_scores_gemma":[0.00048644756,0.9973722,0.0003788816,0.00008963301,0.00017863268,0.0003365193,0.000089630135,0.00003149736,0.0010365762],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992088,0.00004290345,0.0003708359,0.00022215272,0.0000290943,0.00012621844],"domain_scores_gemma":[0.999193,0.00036790274,0.00024287688,0.0001302229,0.000027040121,0.000038960192],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017483151,0.00020611977,0.00070013624,0.00007797587,0.00010622426,0.000028817924,0.0000410261,0.000055716002,0.000010210642],"category_scores_gemma":[0.000005872216,0.0001325822,0.00020256115,0.000032563974,0.000059093836,0.000037224487,0.000025116185,0.00006469035,0.0000014647071],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002571405,0.00009229019,0.000029882121,0.0022714785,0.00080517353,6.509032e-7,0.000051492596,0.0000026004493,0.000005278513,0.0009241952,0.00023087618,0.99556035],"study_design_scores_gemma":[0.0014852076,0.00028360522,0.00003255588,0.0006377402,0.0048295828,0.000021180056,0.000030334106,0.0004938741,0.000027476814,0.000060444214,0.9919814,0.00011658825],"about_ca_topic_score_codex":0.000015910318,"about_ca_topic_score_gemma":0.0000067366427,"teacher_disagreement_score":0.99544376,"about_ca_system_score_codex":0.000110803616,"about_ca_system_score_gemma":0.00007429354,"threshold_uncertainty_score":0.5406545},"labels":[],"label_agreement":null},{"id":"W2140200413","doi":"10.1007/s40273-013-0038-5","title":"Optimal Global Value of Information Trials: Better Aligning Manufacturer and Decision Maker Interests and Enabling Feasible Risk Sharing","year":2013,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences; Public Health Ontario; University of Toronto","funders":"","keywords":"Jurisdiction; Value of information; Payment; Actuarial science; Business; Information sharing; Health administration; Value (mathematics); Risk analysis (engineering); Cost–benefit analysis; Clinical trial; Public health; Economics; Medicine; Computer science; Finance; Nursing","score_opus":0.40964457186727316,"score_gpt":0.5135418632303225,"score_spread":0.10389729136304932,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140200413","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03570497,0.95126206,0.006690318,0.00037046862,0.0012223951,0.0022978797,0.0018759142,0.000048393937,0.00052759517],"genre_scores_gemma":[0.00063293177,0.9788997,0.01792079,0.0016099714,0.0004918361,0.0001867169,0.00016899177,0.00006517941,0.000023865477],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98874676,0.00044802445,0.009357668,0.0008484506,0.00008321476,0.00051585614],"domain_scores_gemma":[0.9870338,0.002375604,0.00967732,0.0005357042,0.000061117986,0.0003164617],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.019999085,0.00062754995,0.0047570136,0.00066205714,0.00019332247,0.00050847116,0.00047046054,0.00040930926,0.00036312488],"category_scores_gemma":[0.0020988523,0.0006938822,0.00045887867,0.00013101948,0.000094707386,0.0019707307,0.00043533117,0.0004987227,0.00070774363],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000048247526,0.00005000869,0.003777485,0.017174661,0.0011479259,0.000001171259,0.0008669021,0.0007819066,1.5458224e-7,0.007708435,0.009032526,0.95941055],"study_design_scores_gemma":[0.0018074845,0.000050489976,0.00021377778,0.0030342343,0.00045846307,0.000052000003,0.00022407851,0.015125222,0.000003496446,0.009062332,0.9689881,0.000980312],"about_ca_topic_score_codex":0.00060986384,"about_ca_topic_score_gemma":0.000012034677,"teacher_disagreement_score":0.9599556,"about_ca_system_score_codex":0.00079607946,"about_ca_system_score_gemma":0.00016720215,"threshold_uncertainty_score":0.99955124},"labels":[],"label_agreement":null},{"id":"W2141213392","doi":"10.2165/00019053-200927020-00005","title":"Willingness to Pay for a Treatment for Pain in Multiple Sclerosis","year":2009,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Bayer (Canada); PharmIdeas (Canada)","funders":"Bayer Canada","keywords":"Medicine; Willingness to pay; Pill; Population; Family medicine; Environmental health; Nursing","score_opus":0.17550560153952882,"score_gpt":0.3951472963703454,"score_spread":0.21964169483081658,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2141213392","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96718615,0.00021236278,0.008459637,0.016977169,0.0002159821,0.0064517814,0.0002944896,0.00008119422,0.00012122836],"genre_scores_gemma":[0.9805765,0.00070341956,0.012930313,0.003182851,0.00039991975,0.0018657492,0.000052608193,0.000033649903,0.00025494708],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986218,0.000032330845,0.0003574561,0.00040108306,0.00006645645,0.0005208598],"domain_scores_gemma":[0.99873155,0.00068233657,0.00005383133,0.00019675,0.00008687246,0.00024863545],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006778298,0.00020617896,0.00047230793,0.00014307507,0.00010674123,0.000027943423,0.00010597168,0.000046650373,0.00002188913],"category_scores_gemma":[0.0004918992,0.00016352488,0.0001840056,0.000093792936,0.000019747631,0.000075377146,0.000021449465,0.000054798908,0.000016167574],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032484257,0.00088767335,0.02153271,0.00012171034,0.00016480032,0.0000018297254,0.0008337696,0.0010961819,0.08426975,0.000046870256,0.0095457025,0.8782506],"study_design_scores_gemma":[0.05298288,0.006721224,0.14177656,0.0002921357,0.00019074128,0.0000025036275,0.0004540822,0.23684253,0.1377255,0.0003323932,0.42178446,0.0008950002],"about_ca_topic_score_codex":0.000059739818,"about_ca_topic_score_gemma":0.00011679884,"teacher_disagreement_score":0.8773556,"about_ca_system_score_codex":0.0005618998,"about_ca_system_score_gemma":0.00008393884,"threshold_uncertainty_score":0.6668351},"labels":[],"label_agreement":null},{"id":"W2147206176","doi":"10.2165/00019053-200624040-00008","title":"A Cost-Utility Analysis of Losartan versus Atenolol in the Treatment of??Hypertension with Left Ventricular Hypertrophy","year":2006,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Merck Canada Inc. (Canada); BC Centre for Disease Control; University of British Columbia; Peace Arch Hospital; Centre for Advancing Health Outcomes","funders":"","keywords":"Atenolol; Losartan; Medicine; Left ventricular hypertrophy; Cardiology; Myocardial infarction; Internal medicine; Cost effectiveness; Stroke (engine); Angiotensin II; Blood pressure","score_opus":0.3554939530175164,"score_gpt":0.42136845188425487,"score_spread":0.06587449886673846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2147206176","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99255043,0.0018015152,0.0003326628,0.0027494463,0.00022109514,0.0008790495,0.00043416314,0.000013964518,0.0010176601],"genre_scores_gemma":[0.9981462,0.00039027692,0.00045145853,0.0006774438,0.00009879559,0.00006551526,0.00012396488,0.000020099871,0.000026282903],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99610776,0.00023431644,0.0027813413,0.00047383472,0.00007284922,0.00032988735],"domain_scores_gemma":[0.99671966,0.0009244795,0.0016569515,0.00057098054,0.000060954415,0.00006698844],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002786889,0.00022487821,0.0013648267,0.0006094541,0.00007475644,0.000025268679,0.0002787776,0.00008638008,0.00027020104],"category_scores_gemma":[0.000090724985,0.0002021342,0.0002964422,0.0004526612,0.00011686177,0.00020434384,0.000016417818,0.00008856259,0.000080913596],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022272086,0.003988062,0.90683,0.00025856795,0.0034861797,0.00003495198,0.0039087716,0.057604346,0.000082815954,0.018015748,0.002516842,0.0010464771],"study_design_scores_gemma":[0.020625923,0.002435764,0.53430015,0.000054624827,0.001953963,0.000021405114,0.002979091,0.33205774,0.0012411915,0.0022427824,0.100787506,0.0012998617],"about_ca_topic_score_codex":0.0045838347,"about_ca_topic_score_gemma":0.0011939269,"teacher_disagreement_score":0.3725299,"about_ca_system_score_codex":0.00050881703,"about_ca_system_score_gemma":0.00008809434,"threshold_uncertainty_score":0.82427937},"labels":[],"label_agreement":null},{"id":"W2147993182","doi":"10.2165/11599390-000000000-00000","title":"Cost-Effectiveness Analysis of Therapies for Chronic Kidney Disease Patients on Dialysis","year":2012,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":49,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Humber River Regional Hospital; St. Michael's Hospital","funders":"Amgen","keywords":"Medicine; Dialysis; Intensive care medicine; Reimbursement; Kidney disease; Peritoneal dialysis; Internal medicine; Health care","score_opus":0.3292884502491599,"score_gpt":0.4821966201663837,"score_spread":0.15290816991722378,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2147993182","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9767499,0.0019672038,0.006682028,0.0032607007,0.0015955778,0.0024389043,0.006568263,0.00004978359,0.0006876523],"genre_scores_gemma":[0.9910009,0.0002555427,0.00033314485,0.006309845,0.000510137,0.00082880177,0.0006300303,0.00005268261,0.00007894647],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99600405,0.0002996918,0.0025613953,0.00051530893,0.000062411316,0.0005571541],"domain_scores_gemma":[0.99494904,0.0018183675,0.0020327063,0.00053246896,0.0000877927,0.00057962345],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0077675832,0.00027188778,0.0014052816,0.0008233984,0.00015669687,0.00004248564,0.0003034937,0.00008679686,0.0007883437],"category_scores_gemma":[0.0013074734,0.0003436531,0.0006009744,0.0003301149,0.000072208946,0.0006199806,0.000045756933,0.000104734936,0.0004215063],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002677133,0.00069200277,0.9459717,0.0005330547,0.0035233821,5.1252112e-8,0.0011604475,0.0068053463,0.000010028189,0.033420667,0.0063097053,0.0013058643],"study_design_scores_gemma":[0.005813302,0.00018542662,0.7249874,0.000060574654,0.0013504972,9.28079e-8,0.00014995388,0.07969249,0.00029788355,0.0027826002,0.18366256,0.0010172537],"about_ca_topic_score_codex":0.00013492625,"about_ca_topic_score_gemma":0.000013645962,"teacher_disagreement_score":0.22098437,"about_ca_system_score_codex":0.0012342134,"about_ca_system_score_gemma":0.00015436533,"threshold_uncertainty_score":0.99990153},"labels":[],"label_agreement":null},{"id":"W2151010917","doi":"10.2165/11584210-000000000-00000","title":"Advances in Cancer Therapeutics and Patient Access to New Drugs","year":2010,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cancer; Health economics; Cancer drugs; Pharmacoeconomics; Intensive care medicine; Health care; Disease; Public health; Quality of Life Research; Population; Healthcare system; Cancer incidence; Environmental health; Economic growth; Internal medicine; Pathology","score_opus":0.09089073921970828,"score_gpt":0.39374633602052017,"score_spread":0.30285559680081187,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151010917","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00045710435,0.9841384,0.000073944604,0.00060594716,0.002551132,0.0011066,0.0006651559,0.000034358614,0.010367349],"genre_scores_gemma":[0.00007328146,0.9943624,0.00033799952,0.0037804067,0.00065166614,0.000283226,0.000018946075,0.00013616063,0.0003558868],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966997,0.000017490831,0.0016294906,0.0009795926,0.00002545317,0.0006482952],"domain_scores_gemma":[0.9979743,0.00011467774,0.0010510879,0.00042543054,0.00001955036,0.00041499245],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002692053,0.00063280517,0.002334698,0.0006325577,0.000072830364,0.00032218936,0.00078776944,0.0003963644,0.00054360175],"category_scores_gemma":[0.000025512438,0.00072879414,0.00028853948,0.00024669105,0.000068621935,0.0011413529,0.000322559,0.0008022078,0.0004913818],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000014497212,0.000034911252,0.00025162045,0.00068239105,0.00005069505,0.0000015818778,0.00037182643,0.000036684633,1.08716236e-7,0.0030200428,0.0013521669,0.9941835],"study_design_scores_gemma":[0.00043738665,0.000034313376,0.000022720065,0.0005824754,0.00006284333,0.0000038448243,0.000009722457,0.00004449942,0.0000041976527,0.0042406796,0.993718,0.0008392978],"about_ca_topic_score_codex":0.00065445265,"about_ca_topic_score_gemma":0.00039321076,"teacher_disagreement_score":0.9933442,"about_ca_system_score_codex":0.0005512623,"about_ca_system_score_gemma":0.00035499127,"threshold_uncertainty_score":0.9995163},"labels":[],"label_agreement":null},{"id":"W2153235272","doi":"10.2165/00019053-200017020-00007","title":"Impact of Zanamivir Treatment on Productivity, Health Status and Healthcare Resource Use in Patients with Influenza","year":2000,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Mosquito-borne diseases and control","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Zanamivir; Medicine; Placebo; Absenteeism; Work productivity; Psychological intervention; Health care; Internal medicine; Physical therapy; Productivity; Alternative medicine; Coronavirus disease 2019 (COVID-19); Psychiatry; Disease","score_opus":0.022060285284727,"score_gpt":0.34250113768582274,"score_spread":0.32044085240109577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2153235272","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99768215,0.00043729012,1.8764986e-7,0.0005351938,0.00001460016,0.0009791097,0.0002554478,0.0000149886555,0.000081002996],"genre_scores_gemma":[0.99814343,0.00030128355,0.0000135329465,0.001327314,0.00004438569,0.0000252509,0.000061102604,0.000024567637,0.000059130776],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989556,0.00006022498,0.00027708232,0.0003125255,0.000076303586,0.00031826747],"domain_scores_gemma":[0.999249,0.00003664106,0.0001182594,0.00024922064,0.000027223781,0.00031967572],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007286457,0.00017305088,0.00039910155,0.00009541647,0.00003322519,0.0000141301825,0.000031272488,0.000024486335,0.000088707966],"category_scores_gemma":[0.000006887069,0.0001312645,0.00006294795,0.00006437353,0.000035367313,0.00011317973,0.000009274831,0.00009288309,0.00000440858],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0063399444,0.00093129696,0.8574773,0.00005307685,0.00010956024,0.0000018813798,0.00030138073,0.0005830311,0.0000041384733,0.0000073161727,0.0001012979,0.1340898],"study_design_scores_gemma":[0.010605528,0.003985411,0.9818633,0.00005043403,0.000037126665,8.1937264e-7,0.000017212253,0.00027254588,0.000032517957,0.0000043186174,0.0030269017,0.00010384308],"about_ca_topic_score_codex":0.0035017547,"about_ca_topic_score_gemma":0.00022475338,"teacher_disagreement_score":0.13398595,"about_ca_system_score_codex":0.0005232535,"about_ca_system_score_gemma":0.00029439194,"threshold_uncertainty_score":0.53528106},"labels":[],"label_agreement":null},{"id":"W2153993125","doi":"10.2165/11592250-000000000-00000","title":"Value of Information and Pricing New Healthcare Interventions","year":2012,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; University of Toronto","funders":"","keywords":"Health economics; Health administration; Psychological intervention; Health care; Quality of Life Research; Public health; Value of information; Value (mathematics); Health informatics; Actuarial science; Business; Medicine; Economics; Statistics; Nursing; Mathematics; Economic growth","score_opus":0.3765059328836996,"score_gpt":0.49256008756122993,"score_spread":0.11605415467753033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2153993125","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88922524,0.017934496,0.03643348,0.046039816,0.0026555303,0.0012529213,0.0005412811,0.00010566557,0.00581155],"genre_scores_gemma":[0.98052627,0.0008086202,0.008211298,0.009706815,0.00047491593,0.00003089871,0.000050014252,0.00002289408,0.00016829326],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958475,0.000108877306,0.003467186,0.00018222272,0.00003549118,0.00035871385],"domain_scores_gemma":[0.996907,0.00030660856,0.0021708177,0.00023608132,0.000033847988,0.0003456293],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0065236753,0.00014671439,0.00061423815,0.00034128124,0.000104905484,0.00004785274,0.00016269425,0.000083221814,0.00032033728],"category_scores_gemma":[0.0005294684,0.00020473823,0.00013556692,0.0001073632,0.000041453302,0.0021899953,0.00007730483,0.00014385849,0.0007761245],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002490031,0.00010721672,0.21294439,0.0018170072,0.00015424684,5.694972e-8,0.0074554174,0.00040223,0.000015415037,0.7437327,0.0276196,0.0057268227],"study_design_scores_gemma":[0.0065506436,0.000273391,0.20673177,0.00059903704,0.00011306403,0.00005032916,0.0050547738,0.03372085,0.0007445162,0.057389934,0.68694973,0.0018219787],"about_ca_topic_score_codex":0.0014663689,"about_ca_topic_score_gemma":0.000023739687,"teacher_disagreement_score":0.6863428,"about_ca_system_score_codex":0.00031978972,"about_ca_system_score_gemma":0.00010851506,"threshold_uncertainty_score":0.9975769},"labels":[],"label_agreement":null},{"id":"W2156582040","doi":"10.2165/11587100-000000000-00000","title":"Presenting Evidence and Summary Measures to Best Inform Societal Decisions When Comparing Multiple Strategies","year":2011,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; SickKids Foundation","funders":"University of Oxford","keywords":"Reimbursement; Cost effectiveness; Inference; Risk analysis (engineering); Health economics; Health administration; Actuarial science; Computer science; Management science; Health care; Economics; Medicine; Artificial intelligence","score_opus":0.7197568518310095,"score_gpt":0.4915481136755557,"score_spread":0.22820873815545378,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2156582040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97124696,0.0023702907,0.004550283,0.0032672163,0.00082893466,0.0009639453,0.00011630646,0.00010106906,0.01655502],"genre_scores_gemma":[0.984031,0.00073500787,0.0099606505,0.004480127,0.0003256848,0.000128431,0.000010502924,0.000047638336,0.00028094335],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99558514,0.000112124144,0.0029609718,0.000676139,0.000080681624,0.000584923],"domain_scores_gemma":[0.9964335,0.0014677942,0.001124459,0.0004493355,0.00007992685,0.00044497952],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.007145077,0.0002909173,0.0008859233,0.00030783244,0.00037566735,0.00031395556,0.00052127213,0.00011371519,0.000308659],"category_scores_gemma":[0.0020592604,0.0003910239,0.00013929897,0.000095367235,0.00008799108,0.002432503,0.000318036,0.0002617066,0.0016114636],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018870902,0.00031448685,0.84991354,0.00045903842,0.00047402686,0.0000046096534,0.044252593,0.0015706125,0.00017850919,0.05364835,0.045082618,0.003912886],"study_design_scores_gemma":[0.00889921,0.00061840285,0.2638885,0.001446594,0.0002299787,0.00008412335,0.045149133,0.29244912,0.0013868655,0.11236426,0.26766324,0.0058205714],"about_ca_topic_score_codex":0.0027134947,"about_ca_topic_score_gemma":0.0008873163,"teacher_disagreement_score":0.58602506,"about_ca_system_score_codex":0.00035594165,"about_ca_system_score_gemma":0.00018050917,"threshold_uncertainty_score":0.99985415},"labels":[],"label_agreement":null},{"id":"W2161334757","doi":"10.2165/00019053-200321040-00006","title":"Ontario??s Formulary Committee","year":2003,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":58,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Mount Sinai Hospital; De Veber; University Health Network; University of Toronto; University of Saskatchewan","funders":"Government of Ontario","keywords":"Formulary; Quality of Life Research; Health economics; Health administration; Public health; Medicine; Business; Family medicine; Nursing","score_opus":0.3558578487915637,"score_gpt":0.45099031287817704,"score_spread":0.09513246408661336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2161334757","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6272169,0.0027941936,0.0076645976,0.0182439,0.0039571305,0.0013066642,0.00031068112,0.0001999585,0.338306],"genre_scores_gemma":[0.9193397,0.00020241116,0.008752992,0.059637282,0.0004897918,0.00020444544,0.00006657095,0.0001078335,0.011198983],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99470806,0.00022482465,0.003667248,0.0006836033,0.000054461918,0.0006618166],"domain_scores_gemma":[0.99689054,0.0005480376,0.0015266762,0.00064216525,0.000039627892,0.00035294116],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.009919788,0.00030754626,0.0010005668,0.00028083805,0.00027923056,0.00012599464,0.0004149355,0.00015191964,0.009799441],"category_scores_gemma":[0.00062481937,0.00044450874,0.00023458562,0.00010640369,0.00007062302,0.00089175784,0.000055373515,0.0003703211,0.014567348],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000022717055,0.00020046442,0.13828157,0.0001331227,0.00022308347,0.000003862393,0.0023903286,0.00043984363,0.000018166367,0.66564906,0.19238412,0.00025368627],"study_design_scores_gemma":[0.0014686678,0.00003328454,0.0030830689,0.000011551951,0.000011455472,0.0000189733,0.00023902912,0.0014321211,0.00015772282,0.049049795,0.9439536,0.0005407828],"about_ca_topic_score_codex":0.005293699,"about_ca_topic_score_gemma":0.0037688243,"teacher_disagreement_score":0.75156945,"about_ca_system_score_codex":0.001647378,"about_ca_system_score_gemma":0.00033809527,"threshold_uncertainty_score":0.9998007},"labels":[],"label_agreement":null},{"id":"W216758753","doi":"10.1007/s40273-015-0287-6","title":"Adjusting for Baseline Covariates in Net Benefit Regression: How You Adjust Matters","year":2015,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Toronto","funders":"","keywords":"Baseline (sea); Cost effectiveness; Covariate; Medicine; Health economics; Randomized controlled trial; Quality of life (healthcare); Regression analysis; Health administration; Variable (mathematics); Regression; Variable cost; Public health; Statistics; Econometrics; Economics; Surgery; Mathematics; Risk analysis (engineering)","score_opus":0.41059188024159354,"score_gpt":0.459752640167694,"score_spread":0.04916075992610047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W216758753","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4472666,0.010054307,0.03309389,0.4870448,0.009079159,0.0045785108,0.0039982786,0.0003773766,0.0045070727],"genre_scores_gemma":[0.78705615,0.00090603647,0.04768899,0.15132682,0.0052702148,0.0013641887,0.000983847,0.0003733339,0.005030435],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99476963,0.00017880631,0.0033504255,0.00088081165,0.000066714485,0.00075362035],"domain_scores_gemma":[0.9955212,0.0012656283,0.0021276164,0.0005081815,0.00010797779,0.00046939735],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.017444525,0.00036929888,0.001259349,0.00048912637,0.00014849965,0.00018633941,0.0004959141,0.00018796336,0.0003538396],"category_scores_gemma":[0.0021166732,0.00048293645,0.00017678924,0.00017768171,0.00006106032,0.0009937915,0.000112920025,0.0002702607,0.00090809347],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038600716,0.00035225786,0.07067693,0.0010465711,0.00023437808,0.000007688867,0.0043813614,0.022592086,0.000055067914,0.09407516,0.802726,0.0034664983],"study_design_scores_gemma":[0.008515416,0.000122031626,0.002098469,0.00017957199,0.00003663981,0.00001804425,0.0031747052,0.33983707,0.00015776663,0.02254489,0.6220856,0.0012298196],"about_ca_topic_score_codex":0.00063837087,"about_ca_topic_score_gemma":0.00019473479,"teacher_disagreement_score":0.33978954,"about_ca_system_score_codex":0.0011204156,"about_ca_system_score_gemma":0.00021811058,"threshold_uncertainty_score":0.9998698},"labels":[],"label_agreement":null},{"id":"W2174595477","doi":"10.1007/s40273-015-0331-6","title":"National Database for Autism Research (NDAR): Big Data Opportunities for Health Services Research and Health Technology Assessment","year":2015,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Autism Spectrum Disorder Research","field":"Neuroscience","cited_by":90,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences; SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"National Institutes of Health; National Institute of Mental Health; Simons Foundation Autism Research Initiative","keywords":"Autism; Data collection; Public health; Data sharing; Medicine; Identifier; Data science; Psychological intervention; Knowledge management; Computer science; Psychiatry; Nursing; Alternative medicine","score_opus":0.7495710935510302,"score_gpt":0.6006506699953719,"score_spread":0.14892042355565838,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2174595477","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04637103,0.0025827328,0.0057836547,0.9160405,0.0011569845,0.008315394,0.01704988,0.00030119187,0.0023986339],"genre_scores_gemma":[0.9745402,0.006760927,0.007403045,0.0064855707,0.0005474684,0.0016067661,0.0013225569,0.00013743075,0.0011960595],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99517155,0.0005360301,0.0005988752,0.0012915251,0.000880278,0.0015217318],"domain_scores_gemma":[0.9966586,0.0013387803,0.00019709663,0.0009067031,0.0002315378,0.0006672796],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.017876295,0.000205229,0.00037439217,0.0012870581,0.0013311529,0.00033260032,0.0019124357,0.00008656184,0.000021723368],"category_scores_gemma":[0.000254993,0.0002264192,0.000026434007,0.0005183232,0.0007690589,0.0007755007,0.0023166041,0.0008273191,0.000022649772],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043150774,0.0006938976,0.00034723117,0.0011769155,0.000045817575,0.00000948478,0.0009391106,0.000029108605,0.0017659857,0.77172506,0.15061694,0.07221893],"study_design_scores_gemma":[0.0045586545,0.001426789,0.00012008767,0.00008178788,0.0000043590994,0.000045856894,0.004341139,0.10264506,0.004125429,0.17333815,0.7089355,0.00037721693],"about_ca_topic_score_codex":0.00046883323,"about_ca_topic_score_gemma":0.00057383504,"teacher_disagreement_score":0.92816913,"about_ca_system_score_codex":0.001037082,"about_ca_system_score_gemma":0.008071798,"threshold_uncertainty_score":0.999969},"labels":[],"label_agreement":null},{"id":"W2190338955","doi":"10.2165/00019053-200321060-00006","title":"Cost-Benefit Model Comparing Two Alternative Immunisation Programmes Against Serogroup C Meningococcal Disease","year":2003,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Bacterial Infections and Vaccines","field":"Immunology and Microbiology","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Merck Canada Inc. (Canada)","funders":"Health Canada","keywords":"Medicine; Outbreak; Meningococcal disease; Epidemiology; Vaccination; Public health; Disease burden; Health economics; Environmental health; Incidence (geometry); Pediatrics; Demography; Emergency medicine; Neisseria meningitidis; Immunology; Population; Internal medicine; Virology","score_opus":0.055683705863028024,"score_gpt":0.33345267494193453,"score_spread":0.2777689690789065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2190338955","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99425685,0.00039727084,0.0013726145,0.00010106024,0.0011592546,0.00046642055,0.00004380759,0.000113341244,0.0020893505],"genre_scores_gemma":[0.99850476,0.0001958549,0.00028012277,0.0001960038,0.000071271395,0.00015661972,0.00023451082,0.000026340567,0.00033452144],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99899703,0.000079521196,0.00030909554,0.00027740136,0.000008212583,0.00032873702],"domain_scores_gemma":[0.9995055,0.000044097695,0.00014589589,0.00018855443,0.00005275597,0.00006316997],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017885175,0.00020311293,0.0002385878,0.00008089429,0.00026091325,0.0000655288,0.00014971141,0.000058571914,0.0002284374],"category_scores_gemma":[0.00001358427,0.0002112144,0.00010136743,0.000049495688,0.000060749022,0.000274317,0.000059475413,0.00020904063,0.00021897911],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010587217,0.001173438,0.059570644,0.000053554628,0.0012565588,0.000003056637,0.0016028221,0.16105808,0.6479832,0.07411025,0.001702668,0.050427042],"study_design_scores_gemma":[0.022203673,0.00016757667,0.005362235,0.00006941415,0.000508041,0.000055265104,0.0005567307,0.34170225,0.36240378,0.006952923,0.25795165,0.0020664698],"about_ca_topic_score_codex":0.00008628576,"about_ca_topic_score_gemma":0.000022748587,"teacher_disagreement_score":0.28557938,"about_ca_system_score_codex":0.00011234484,"about_ca_system_score_gemma":0.000050972405,"threshold_uncertainty_score":0.8613073},"labels":[],"label_agreement":null},{"id":"W2210591412","doi":"10.1007/s40273-015-0356-x","title":"Cost-Effectiveness Modelling of Sofosbuvir-Containing Regimens for Chronic Genotype 5 Hepatitis C Virus Infection in South Africa","year":2015,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Hepatitis C virus research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Augmentium Pharma Consulting (Canada)","funders":"North-West University; Gilead Sciences","keywords":"Sofosbuvir; Quality of Life Research; Health economics; Genotype; Virology; Public health; Chronic hepatitis; Medicine; Hepatitis C virus; Health administration; Pharmacoeconomics; Virus; Internal medicine; Biology; Intensive care medicine; Genetics","score_opus":0.23151698398883594,"score_gpt":0.40388306249204514,"score_spread":0.1723660785032092,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2210591412","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94897735,0.00058328465,0.046783775,0.00004123102,0.00026923677,0.001869113,0.00010202402,0.000045497327,0.0013285087],"genre_scores_gemma":[0.99716854,0.0009264947,0.0010542329,0.000054976652,0.00022610046,0.0004086042,0.000050725786,0.00005829798,0.00005201297],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9985181,0.00012387466,0.00044295593,0.00033536306,0.00013796076,0.00044173098],"domain_scores_gemma":[0.99893904,0.0002349865,0.0001571106,0.00021966903,0.00021505253,0.00023413706],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011776407,0.00017618861,0.00047474942,0.0003053457,0.00004702135,0.000019265648,0.000097302385,0.000106016705,0.000045620545],"category_scores_gemma":[0.00013718844,0.00020112674,0.000107542706,0.00016761135,0.000062013714,0.00020743892,0.000059854978,0.0002725917,0.0000507643],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006059794,0.00050456857,0.4768996,0.0011156653,0.00051368214,0.00004453713,0.010723399,0.43113235,0.02400983,0.00047252222,0.0005975257,0.04792654],"study_design_scores_gemma":[0.010520175,0.001081666,0.002936318,0.00015643203,0.00012408674,0.0000061078017,0.000065868655,0.8989676,0.0687745,0.00047069206,0.016547315,0.00034922647],"about_ca_topic_score_codex":0.0031495471,"about_ca_topic_score_gemma":0.0008038148,"teacher_disagreement_score":0.4739633,"about_ca_system_score_codex":0.001429964,"about_ca_system_score_gemma":0.00069013383,"threshold_uncertainty_score":0.820171},"labels":[],"label_agreement":null},{"id":"W2225256005","doi":"10.1007/s40273-015-0370-z","title":"Value-Based Assessment of New Medical Technologies: Towards a Robust Methodological Framework for the Application of Multiple Criteria Decision Analysis in the Context of Health Technology Assessment","year":2016,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":99,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Seventh Framework Programme; Health Technology Assessment international; European Commission","keywords":"Multiple-criteria decision analysis; Preference elicitation; Context (archaeology); Health technology; Management science; Decision analysis; Stakeholder; Computer science; Set (abstract data type); Process (computing); Relevance (law); Health care; Risk analysis (engineering); Knowledge management; Process management; Operations research; Preference; Medicine; Business; Engineering; Economics","score_opus":0.5383525656910848,"score_gpt":0.5885053368938988,"score_spread":0.05015277120281403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2225256005","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.05717604,0.0010270374,0.8235974,0.116115555,0.00019644378,0.0014598821,0.00037125987,0.000028942628,0.0000274563],"genre_scores_gemma":[0.78196263,0.0005521313,0.2142984,0.0027203464,0.00004453361,0.00039028662,0.000014552486,0.00001505492,0.0000020428063],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9929286,0.000654946,0.0053215437,0.0005699499,0.000163295,0.00036167103],"domain_scores_gemma":[0.97764385,0.016782295,0.0044685816,0.0009225822,0.00010862043,0.000074050986],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.03943962,0.00020857238,0.0017656527,0.0007557424,0.000097935175,0.000016447835,0.001209132,0.00033244662,0.00016842071],"category_scores_gemma":[0.008256324,0.00014518804,0.0003387822,0.00066900183,0.00032239602,0.00012776032,0.00012375365,0.00027729693,0.000005521714],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014482516,0.00062941987,0.18472993,0.0004352438,0.0007750799,2.0443996e-7,0.00069167593,0.007154858,0.000103597195,0.6509063,0.0019717205,0.15245709],"study_design_scores_gemma":[0.0052501955,0.00048092182,0.0665729,0.00024533493,0.00017536292,0.0000021274075,0.006508457,0.74265236,0.0007598223,0.16542242,0.011499616,0.00043045587],"about_ca_topic_score_codex":0.00097387354,"about_ca_topic_score_gemma":0.00020902946,"teacher_disagreement_score":0.73549753,"about_ca_system_score_codex":0.0005899902,"about_ca_system_score_gemma":0.00088320306,"threshold_uncertainty_score":0.989099},"labels":[],"label_agreement":null},{"id":"W2225838069","doi":"10.1007/s40273-015-0366-8","title":"Cost Effectiveness of First-Line Oral Therapies for Pulmonary Arterial Hypertension: A Modelling Study","year":2016,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Pulmonary Hypertension Research and Treatments","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; Canadian Agency for Drugs and Technologies in Health; University of Ottawa","funders":"","keywords":"Tadalafil; Medicine; Sildenafil; Ambrisentan; Bosentan; Riociguat; Intensive care medicine; Quality-adjusted life year; Placebo; Cost effectiveness; Internal medicine; Pulmonary hypertension; Chronic thromboembolic pulmonary hypertension; Alternative medicine","score_opus":0.12560509669977174,"score_gpt":0.3724066025839423,"score_spread":0.24680150588417057,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2225838069","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932144,0.000275659,0.0029443698,0.0005941566,0.00029316082,0.0024344777,0.00013786924,0.000035619385,0.00007023582],"genre_scores_gemma":[0.9982719,0.00044361173,0.00046819425,0.00011102862,0.0001681509,0.00033963492,0.00003231631,0.000038703576,0.00012645741],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99884945,0.000086023305,0.0003064296,0.00034608413,0.00011359036,0.00029843822],"domain_scores_gemma":[0.9987475,0.00055424304,0.0000816802,0.0002518095,0.0001805748,0.00018418649],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000404854,0.00019334487,0.00053189916,0.00010821543,0.00009179304,0.000009112781,0.00010108946,0.00004801317,0.00010065731],"category_scores_gemma":[0.000029947434,0.00012322464,0.00015372438,0.000052766714,0.00007019207,0.00014452786,0.000051858096,0.00006202728,0.000025074038],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.120792694,0.028427364,0.2429969,0.0012108259,0.0059051556,0.0025049653,0.00028687893,0.0022725305,0.45515025,0.00013408832,0.001045991,0.13927235],"study_design_scores_gemma":[0.21086438,0.01538922,0.088007525,0.0014976561,0.0031811711,0.0016442518,0.00088562537,0.40827656,0.22986229,0.004630209,0.03363714,0.0021239656],"about_ca_topic_score_codex":0.000054038966,"about_ca_topic_score_gemma":0.0000046733267,"teacher_disagreement_score":0.40600404,"about_ca_system_score_codex":0.00008836317,"about_ca_system_score_gemma":0.000070609975,"threshold_uncertainty_score":0.5024955},"labels":[],"label_agreement":null},{"id":"W2281399600","doi":"10.1007/s40273-016-0388-x","title":"Cost Implications of Value-Based Pricing for Companion Diagnostic Tests in Precision Medicine","year":2016,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Precision medicine; Companion diagnostic; Cost–benefit analysis; Medicine; Cost effectiveness; Health economics; Diagnostic test; Quality of Life Research; Personalized medicine; Medical physics; Actuarial science; Risk analysis (engineering); Public health; Pathology; Economics; Bioinformatics; Pediatrics","score_opus":0.6000055285187244,"score_gpt":0.6131922322189319,"score_spread":0.01318670370020758,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2281399600","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.11411137,0.000035037534,0.8775294,0.0049787727,0.0005714803,0.0020056502,0.0003174257,0.000045556808,0.0004053265],"genre_scores_gemma":[0.5755826,0.00008381898,0.4233715,0.00040666977,0.00022400758,0.0002759063,0.0000036224324,0.00003463654,0.000017240262],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9979672,0.00024207668,0.0011904174,0.00029390748,0.00008056378,0.0002258305],"domain_scores_gemma":[0.79530686,0.20387723,0.00037430497,0.00026215424,0.00009086315,0.00008858364],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0027981068,0.0001413597,0.00057462335,0.00011791631,0.000032796637,0.0000054739944,0.0002575713,0.00007163508,0.00020271224],"category_scores_gemma":[0.092545316,0.000101539394,0.00008043552,0.000102907215,0.00013967503,0.000060029022,0.000045647786,0.00008482776,0.000011515693],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006780546,0.0011348261,0.044954184,0.0007016244,0.00011584419,0.0000016005401,0.00022075132,0.00040877893,0.05388307,0.3514375,0.014609975,0.5318538],"study_design_scores_gemma":[0.006017196,0.0001398144,0.012573472,0.000423103,0.00010889835,8.321329e-7,0.000008980564,0.0045880587,0.019737711,0.9552463,0.0009856302,0.00016997915],"about_ca_topic_score_codex":0.000011992913,"about_ca_topic_score_gemma":0.000007216022,"teacher_disagreement_score":0.6038088,"about_ca_system_score_codex":0.00016052523,"about_ca_system_score_gemma":0.00006523103,"threshold_uncertainty_score":0.91509855},"labels":[],"label_agreement":null},{"id":"W2301554896","doi":"10.1007/s40273-016-0394-z","title":"Discretely Integrated Condition Event (DICE) Simulation for Pharmacoeconomics","year":2016,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":46,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Dice; Computer science; Event (particle physics); Discrete event simulation; Markov chain; Microsimulation; Markov model; Series (stratigraphy); Econometrics; Mathematical optimization; Statistics; Simulation; Mathematics; Machine learning; Engineering","score_opus":0.31195139351203566,"score_gpt":0.5117991670215949,"score_spread":0.19984777350955923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2301554896","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.47289607,0.0013009078,0.4414884,0.060804028,0.0054526413,0.004898843,0.0089429375,0.00046484533,0.0037513222],"genre_scores_gemma":[0.97373354,0.00043379204,0.003044976,0.018301472,0.0014171407,0.00073680433,0.00038709535,0.00015218001,0.0017930253],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9925951,0.0002249968,0.005199655,0.0011046035,0.000066020875,0.0008096185],"domain_scores_gemma":[0.9929249,0.0028016022,0.0031438235,0.0005619464,0.0001424845,0.0004252155],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.008312214,0.00047862448,0.0012283428,0.00047262872,0.00032696474,0.00015323548,0.0005210837,0.00022462901,0.0031092751],"category_scores_gemma":[0.0013745477,0.0005125859,0.0004271662,0.00012293638,0.00013653317,0.0017512742,0.0000789988,0.00018794641,0.004573611],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024017363,0.0010696383,0.027789287,0.0013748521,0.0023802274,0.000005407228,0.003013471,0.07799739,0.0038668078,0.4610158,0.38113168,0.037953723],"study_design_scores_gemma":[0.01073463,0.00015379168,0.0011314822,0.000090834656,0.00006379746,0.0000068710974,0.0002511075,0.23315023,0.001441988,0.034232777,0.7175476,0.0011948908],"about_ca_topic_score_codex":0.00012596173,"about_ca_topic_score_gemma":0.000037142192,"teacher_disagreement_score":0.50083745,"about_ca_system_score_codex":0.001937401,"about_ca_system_score_gemma":0.00023378417,"threshold_uncertainty_score":0.99973255},"labels":[],"label_agreement":null},{"id":"W2306623977","doi":"10.1007/s40273-016-0403-2","title":"Cancer Drugs Fund 2.0: A Missed Opportunity?","year":2016,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research; National Institute for Health and Care Research; University of Alberta","keywords":"Quality of Life Research; Health economics; Health administration; Public health; Cancer; Medicine; Pharmacoeconomics; Health care management; Business; Intensive care medicine; Nursing; Internal medicine","score_opus":0.09355009280973614,"score_gpt":0.31430926112923957,"score_spread":0.22075916831950343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2306623977","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7214185,0.0051669283,0.0030700068,0.026283626,0.0038654546,0.00053420523,0.0019649689,0.00023462014,0.2374617],"genre_scores_gemma":[0.9717775,0.0054626972,0.00020308582,0.009152956,0.0008827638,0.00010947544,0.000008638381,0.00008361798,0.012319268],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977643,0.000012894383,0.000913807,0.00063370814,0.000023842334,0.0006514553],"domain_scores_gemma":[0.9983469,0.00010599627,0.0005794396,0.00042684004,0.000040952942,0.00049986766],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0005161047,0.00030661045,0.0006076907,0.00022442947,0.00013478946,0.00009081833,0.00047352715,0.00013326919,0.011523596],"category_scores_gemma":[0.00007721348,0.00030081475,0.00022674067,0.00009548566,0.00013617551,0.0009332863,0.000096533025,0.00015193138,0.0039169667],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042469442,0.00035304498,0.09666517,0.000101482736,0.0007593622,0.000020019934,0.0012123529,0.00014588983,0.0034190244,0.44930446,0.21930695,0.22828756],"study_design_scores_gemma":[0.0022918286,0.00003680742,0.0027554198,0.000025031479,0.000016919346,0.0000040287987,0.000030553576,0.00035646668,0.0025857636,0.029614061,0.96161526,0.00066787336],"about_ca_topic_score_codex":0.0004259836,"about_ca_topic_score_gemma":0.00003027611,"teacher_disagreement_score":0.7423083,"about_ca_system_score_codex":0.00054728205,"about_ca_system_score_gemma":0.00016977516,"threshold_uncertainty_score":0.9999444},"labels":[],"label_agreement":null},{"id":"W2307171802","doi":"10.1007/s40273-016-0401-4","title":"Use of Intermediate Endpoints in the Economic Evaluation of New Treatments for Advanced Cancer and Methods Adopted When Suitable Overall Survival Data are Not Available","year":2016,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Hôpital Notre-Dame; Université de Montréal","funders":"Canadian Institutes of Health Research","keywords":"Economic evaluation; Medicine; Health economics; Proxy (statistics); Population; Quality-adjusted life year; Quality of life (healthcare); Time horizon; Clinical endpoint; Quality of Life Research; Cost effectiveness; Actuarial science; Clinical trial; Intensive care medicine; Public health; Statistics; Internal medicine; Environmental health; Risk analysis (engineering); Pathology","score_opus":0.7785772792293135,"score_gpt":0.5996900770819155,"score_spread":0.17888720214739806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2307171802","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004441397,0.9620854,0.0005168843,0.0010116278,0.0020075452,0.0055983234,0.02406503,0.000017325874,0.00025645827],"genre_scores_gemma":[0.00012197854,0.99068147,0.005540103,0.0007127095,0.00042199733,0.0008713332,0.00073634036,0.00011334917,0.0008007012],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9899629,0.0013901299,0.006670399,0.0012984703,0.00010982043,0.0005683021],"domain_scores_gemma":[0.98348194,0.0058507733,0.008882544,0.001502647,0.00010331378,0.00017875659],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.030782163,0.00057829113,0.004247967,0.00056172983,0.000080411024,0.00009972655,0.0012144545,0.00031081605,0.0010004613],"category_scores_gemma":[0.0021901443,0.00054784253,0.00033459996,0.00008396193,0.00010843861,0.0015036487,0.0003111795,0.00025813858,0.00018514802],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000293085,0.00028843444,0.0026161466,0.016144646,0.003088787,6.0404045e-7,0.0015613782,0.0007208205,0.0000043083255,0.004062771,0.06504221,0.9061768],"study_design_scores_gemma":[0.0039759153,0.00005681558,0.00022452691,0.0024993732,0.0007924078,0.0000023843002,0.00009518581,0.015008565,0.000013209083,0.0019706297,0.974755,0.0006059922],"about_ca_topic_score_codex":0.0023692264,"about_ca_topic_score_gemma":0.00069029623,"teacher_disagreement_score":0.9097128,"about_ca_system_score_codex":0.002240566,"about_ca_system_score_gemma":0.0017365385,"threshold_uncertainty_score":0.99991274},"labels":[],"label_agreement":null},{"id":"W2343725236","doi":"10.1007/s40273-016-0408-x","title":"Using Linear Equating to Map PROMIS® Global Health Items and the PROMIS-29 V2.0 Profile Measure to the Health Utilities Index Mark 3","year":2016,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":50,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Utilities Kingston (Canada)","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Cancer Institute; National Institutes of Health","keywords":"Equating; Health Utilities Index; Quality of life (healthcare); Health economics; Explained variation; Linear regression; Medicine; Psychology; Physical therapy; Statistics; Public health; Health related quality of life; Mathematics","score_opus":0.367823668569967,"score_gpt":0.48864437328638277,"score_spread":0.12082070471641576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2343725236","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.24908449,0.005672732,0.030303828,0.6997379,0.0026614633,0.008587702,0.0023359999,0.0001524319,0.00146346],"genre_scores_gemma":[0.8146542,0.00045431944,0.010118009,0.16916704,0.00277418,0.0010880479,0.000026506603,0.00014786042,0.0015698625],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9923379,0.0010440811,0.004325498,0.0010284982,0.00014997412,0.0011140726],"domain_scores_gemma":[0.9947022,0.0011798636,0.0024667587,0.0008159985,0.00010450399,0.0007306264],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.03140792,0.00043161304,0.0014424449,0.00019118964,0.00092292187,0.0002555956,0.000729099,0.000114832066,0.0002526562],"category_scores_gemma":[0.0017887347,0.00032556802,0.00017096369,0.00024635234,0.0001886432,0.0005255895,0.00030929982,0.0002897647,0.0013325734],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00282247,0.00052484113,0.12765792,0.0039214585,0.001380322,0.0000029832197,0.04402631,0.0061249468,0.00006491569,0.2476252,0.48185286,0.08399576],"study_design_scores_gemma":[0.012185205,0.00053830934,0.009021214,0.0009111386,0.00003933791,0.00005383223,0.0062818257,0.16965501,0.00005729576,0.01667823,0.7826361,0.0019424965],"about_ca_topic_score_codex":0.004012606,"about_ca_topic_score_gemma":0.00084156834,"teacher_disagreement_score":0.5655697,"about_ca_system_score_codex":0.0027292818,"about_ca_system_score_gemma":0.0011451653,"threshold_uncertainty_score":0.99991965},"labels":[],"label_agreement":null},{"id":"W2415515198","doi":"10.1007/s40273-016-0416-x","title":"Sustainable Financing of Innovative Therapies: A Review of Approaches","year":2016,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Seventh Framework Programme; Canadian Institutes of Health Research","keywords":"Externality; Health economics; Government (linguistics); Sustainability; Business; Process (computing); Finance; Health technology; Economics; Value (mathematics); Industrial organization; Health care; Public economics; Microeconomics; Economic growth","score_opus":0.5530567514504178,"score_gpt":0.5078534446458488,"score_spread":0.045203306804568966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2415515198","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000019415244,0.985176,0.00055148377,0.0018284855,0.00044792474,0.0026673067,0.0014958027,0.000031160685,0.0077823745],"genre_scores_gemma":[0.000028293809,0.99440503,0.00082373683,0.0021672668,0.00035278228,0.0005164909,0.00011918954,0.00013111925,0.0014560792],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9856154,0.00058208965,0.012137811,0.0009172345,0.000084743886,0.0006627289],"domain_scores_gemma":[0.9798985,0.0020774566,0.016602982,0.0010051397,0.00027138778,0.0001445404],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.020295825,0.00063659577,0.007732902,0.0008527918,0.00009107717,0.000027364851,0.0009536566,0.0003254761,0.0011924834],"category_scores_gemma":[0.0024533654,0.0006541545,0.00083004416,0.00062603306,0.00021418721,0.00060360617,0.00022853659,0.00037734536,0.0007250872],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008744227,0.00013588184,0.00005916048,0.6465781,0.0010115337,0.0000012712843,0.00065054744,0.0000026635093,1.13778796e-7,0.19496575,0.029842965,0.12674332],"study_design_scores_gemma":[0.00041747856,0.000041372863,0.0000028209765,0.05444931,0.00008346913,0.0000060144976,0.00021182631,0.000022426866,0.000003217885,0.0025353213,0.9416717,0.0005550342],"about_ca_topic_score_codex":0.00014980612,"about_ca_topic_score_gemma":0.000002509765,"teacher_disagreement_score":0.91182876,"about_ca_system_score_codex":0.0011845736,"about_ca_system_score_gemma":0.0013561837,"threshold_uncertainty_score":0.9997206},"labels":[],"label_agreement":null},{"id":"W2465326294","doi":"10.1007/s40273-016-0424-x","title":"Economic and Humanistic Burden of Osteoarthritis: A Systematic Review of Large Sample Studies","year":2016,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Osteoarthritis Treatment and Mechanisms","field":"Medicine","cited_by":200,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo; McMaster University","funders":"","keywords":"Medicine; Health economics; Comparability; Indirect costs; MEDLINE; Sample size determination; Sample (material); Public health; Statistics; Accounting; Economics","score_opus":0.04593320333790884,"score_gpt":0.38918566349071826,"score_spread":0.3432524601528094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2465326294","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000061836574,0.993719,0.0000034955992,0.00004465563,0.00032013317,0.003765502,0.0018725195,0.000025414392,0.0001874649],"genre_scores_gemma":[0.000059408118,0.9985421,0.00014529547,0.00010090585,0.00020563122,0.00043676907,0.00015619719,0.00007735559,0.00027637396],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99720675,0.0001375653,0.0018669717,0.00041776052,0.00008648506,0.0002844639],"domain_scores_gemma":[0.997206,0.00065638864,0.0014366905,0.00047911124,0.00008508404,0.00013674315],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005505329,0.0004851023,0.005967863,0.0001908904,0.00004208162,0.000008307557,0.00016082152,0.00012665296,0.00026936948],"category_scores_gemma":[0.00017645718,0.00036097647,0.0006330937,0.000039270046,0.00011200549,0.0000823546,0.00014622895,0.00013189887,0.00011133125],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001049032,0.000031149993,5.227479e-7,0.91548765,0.0009415352,0.000010612809,0.00006592509,8.8135215e-9,0.0000049114446,0.00090539124,0.00020230727,0.082339495],"study_design_scores_gemma":[0.0018170034,0.00047613395,1.0959881e-8,0.78755385,0.01045134,0.00014855449,0.000047314457,8.448311e-7,0.000049068305,0.00009193103,0.1991177,0.000246245],"about_ca_topic_score_codex":0.000004751453,"about_ca_topic_score_gemma":0.0000053766726,"teacher_disagreement_score":0.19891539,"about_ca_system_score_codex":0.00023531023,"about_ca_system_score_gemma":0.00026506712,"threshold_uncertainty_score":0.99988425},"labels":[],"label_agreement":null},{"id":"W2518788219","doi":"10.1007/s40273-016-0450-8","title":"Response to Letter to the Editor Regarding Discretely Integrated Condition Event Simulation for Pharmacoeconomics","year":2016,"lang":"en","type":"letter","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Pharmacoeconomics; Quality of Life Research; Health economics; Health administration; Event (particle physics); Medicine; Public health; Intensive care medicine; Nursing","score_opus":0.21760063962310017,"score_gpt":0.4726194633629623,"score_spread":0.2550188237398621,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2518788219","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003955613,0.00022562049,0.06830249,0.8834224,0.022708848,0.0066640805,0.014204253,0.00017715115,0.00033958277],"genre_scores_gemma":[0.0057034986,0.00005999314,0.001704131,0.88856465,0.093984336,0.0030666203,0.0011098476,0.00036324124,0.0054436917],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.988093,0.0011255078,0.0069553647,0.0020967617,0.00017387641,0.0015554941],"domain_scores_gemma":[0.9849821,0.008660379,0.004138608,0.0013976065,0.00028242273,0.0005389147],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.02292445,0.0010308829,0.0022226174,0.0011822436,0.00066445215,0.0005652754,0.0015596537,0.00089671894,0.0013953728],"category_scores_gemma":[0.0038934895,0.0010388043,0.0007921031,0.00023276561,0.00010470202,0.0010387623,0.0002741562,0.0013253371,0.012883815],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009974174,0.000022751783,0.000040786836,0.00020678344,0.00037014487,0.0000029008404,0.0006478474,0.016849838,0.000056862154,0.00039109477,0.979861,0.00055253954],"study_design_scores_gemma":[0.0029394662,0.00015604247,0.000024324152,0.00016565046,0.00007819561,0.000004246002,0.000080973616,0.022964355,0.000129548,0.001248521,0.9708952,0.0013134979],"about_ca_topic_score_codex":0.00013129458,"about_ca_topic_score_gemma":0.000034711138,"teacher_disagreement_score":0.07127549,"about_ca_system_score_codex":0.0047841817,"about_ca_system_score_gemma":0.00047685837,"threshold_uncertainty_score":0.9995175},"labels":[],"label_agreement":null},{"id":"W2537819449","doi":"10.1007/s40273-016-0457-1","title":"Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal","year":2016,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Health Technology Assessment Programme; Queen's University; Queen's University Belfast; National Institute for Health and Care Research","keywords":"Docetaxel; Cabazitaxel; Medicine; Oncology; Prostate cancer; Regimen; Quality of Life Research; Internal medicine; Health economics; Nice; Cost effectiveness; Chemotherapy; Cancer; Public health; Androgen deprivation therapy; Nursing","score_opus":0.09311260996567614,"score_gpt":0.45005130497973883,"score_spread":0.3569386950140627,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2537819449","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000461231,0.9854049,0.000060486243,0.0012868987,0.000113356975,0.011683198,0.0006951797,0.00013240505,0.00016230813],"genre_scores_gemma":[0.0003089255,0.9891905,0.0011133766,0.00016310127,0.00017763172,0.007882334,0.0002332345,0.00022275391,0.00070810865],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960596,0.0002474535,0.001260321,0.0012831299,0.00024521688,0.0009042545],"domain_scores_gemma":[0.9958963,0.00077907194,0.0015088536,0.0007878977,0.0006629698,0.0003649491],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00086343894,0.0008922152,0.003937089,0.0005732886,0.00012440281,0.000039146056,0.00048703916,0.0002136398,0.000084434745],"category_scores_gemma":[0.00028076879,0.0005681569,0.00058919436,0.00059288234,0.00043602064,0.0004932617,0.000115159615,0.0005660298,0.00001913567],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0051195794,0.0008414929,0.00006186509,0.10886237,0.007056395,0.0001379765,0.00050006947,0.0000013733918,0.00046667704,0.0003100526,0.0018504723,0.8747917],"study_design_scores_gemma":[0.013559192,0.010229016,0.000002063925,0.23623386,0.022937583,0.0004962636,0.00041162458,0.00006465381,0.0005216179,0.000082408806,0.714142,0.0013197217],"about_ca_topic_score_codex":0.00020042059,"about_ca_topic_score_gemma":0.000046931524,"teacher_disagreement_score":0.873472,"about_ca_system_score_codex":0.0019679791,"about_ca_system_score_gemma":0.002112589,"threshold_uncertainty_score":0.999677},"labels":[],"label_agreement":null},{"id":"W2557044136","doi":"10.1007/s40273-017-0492-6","title":"Evolocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal","year":2017,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"Health Technology Assessment Programme; National Institute for Health and Care Research","keywords":"Evolocumab; Ezetimibe; Medicine; Statin; Nice; Physical therapy; Placebo; Clinical trial; Cost effectiveness; Internal medicine; Alternative medicine; Cholesterol; Lipoprotein; Pathology","score_opus":0.11077338720664542,"score_gpt":0.4395810754571972,"score_spread":0.3288076882505518,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2557044136","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009353174,0.9934748,0.00010074562,0.0003606304,0.00035105832,0.004230981,0.00009638488,0.00006891723,0.0003811865],"genre_scores_gemma":[0.00023057057,0.9947652,0.002900775,0.0002783964,0.00079266663,0.000777791,0.00009892047,0.00012006921,0.000035562673],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971288,0.00021580952,0.0010890512,0.00096455135,0.00016625982,0.00043555454],"domain_scores_gemma":[0.99651784,0.00044581635,0.00120923,0.0013359565,0.00024585525,0.00024531787],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019491127,0.0005477416,0.004185362,0.00027597215,0.00017367382,0.0000432095,0.0004461271,0.0004563162,0.000009867138],"category_scores_gemma":[0.00090144057,0.00048553423,0.0008630765,0.00011900927,0.0002349233,0.00038238303,0.00021133511,0.000718395,0.000005412355],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000059145623,0.000103802995,0.000013948933,0.13211575,0.00059424393,0.0000072000034,0.000036260004,8.26709e-8,0.000046882098,0.00009109006,0.00014851804,0.8667831],"study_design_scores_gemma":[0.0018972723,0.0007700662,0.000016942975,0.0924432,0.008823151,0.00095883035,0.00008723844,0.000025099689,0.000050186438,0.00003660423,0.89436096,0.0005304652],"about_ca_topic_score_codex":0.000084687184,"about_ca_topic_score_gemma":0.000012969922,"teacher_disagreement_score":0.8942124,"about_ca_system_score_codex":0.0008370374,"about_ca_system_score_gemma":0.00079298625,"threshold_uncertainty_score":0.9997596},"labels":[],"label_agreement":null},{"id":"W2560119051","doi":"10.1007/s40273-016-0482-0","title":"Discounting the Recommendations of the Second Panel on Cost-Effectiveness in Health and Medicine","year":2016,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Health economics; Discounting; Panel data; CLARITY; Actuarial science; Health care; Health administration; Economics; Medicine; Public economics; Econometrics; Finance","score_opus":0.4921250129035416,"score_gpt":0.5115948805198597,"score_spread":0.01946986761631808,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560119051","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.64421606,0.0010960018,0.0005748317,0.34815994,0.0011260238,0.0015821203,0.0004106588,0.000015445725,0.0028189018],"genre_scores_gemma":[0.9767304,0.0006855622,0.000054601554,0.021589074,0.00021179071,0.00017091994,0.000005441052,0.000025777003,0.00052643876],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961085,0.00063491456,0.002525934,0.00038727568,0.000040683135,0.0003027215],"domain_scores_gemma":[0.99379116,0.003737395,0.0019222744,0.00041493218,0.000023265882,0.00011096968],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015011256,0.00016047533,0.0006657507,0.0001681704,0.00022699809,0.000021879974,0.00033505165,0.000049973183,0.0003935643],"category_scores_gemma":[0.0011785772,0.0001060198,0.00006458758,0.00012381203,0.0002105113,0.00029466196,0.00008454734,0.00017481076,0.000114854076],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015195577,0.0002472231,0.19299382,0.0013204303,0.00021297623,3.514117e-7,0.008733484,0.000375402,0.00025195538,0.7300778,0.04920646,0.01642815],"study_design_scores_gemma":[0.009109869,0.00026415955,0.17343822,0.0015434456,0.0000141892215,0.0000149043835,0.003919598,0.005805374,0.0006089157,0.06717604,0.73734856,0.00075670093],"about_ca_topic_score_codex":0.0005192629,"about_ca_topic_score_gemma":0.0003512051,"teacher_disagreement_score":0.6881421,"about_ca_system_score_codex":0.0005806831,"about_ca_system_score_gemma":0.00013451623,"threshold_uncertainty_score":0.5202632},"labels":[],"label_agreement":null},{"id":"W2598558594","doi":"10.1007/s40273-017-0498-0","title":"Authors’ Reply to Gandjour: “Can the EVIDEM Framework Tackle Issues Raised by Evaluating Treatments for Rare Diseases: Analysis of Issues and Policies, and Context-Specific Adaptation”","year":2017,"lang":"en","type":"letter","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; SNC-Lavalin (Canada)","funders":"","keywords":"Quality of Life Research; Health economics; Adaptation (eye); Context (archaeology); Health administration; Public health; Management science; Medicine; Engineering ethics; Psychology; Economics; Nursing; Engineering","score_opus":0.38170027764823494,"score_gpt":0.5104098940317277,"score_spread":0.1287096163834927,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598558594","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.035860967,0.05823377,0.0011690923,0.8820299,0.0008744598,0.0031017533,0.018589456,0.00004978395,0.00009083907],"genre_scores_gemma":[0.029369403,0.01790765,0.005507453,0.93010235,0.005151903,0.0017588469,0.0028949685,0.00029575135,0.0070116566],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99310917,0.0005068064,0.0042013875,0.0013703093,0.00014644738,0.000665865],"domain_scores_gemma":[0.9890948,0.0038709298,0.0052274754,0.001270755,0.00020855425,0.0003274641],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.006788178,0.0006271899,0.0028624267,0.0006318003,0.00083068345,0.00063892687,0.00076904637,0.00043649154,0.00034396988],"category_scores_gemma":[0.0030377365,0.00067442254,0.00044531593,0.00019484595,0.0002686189,0.00046703962,0.00016475377,0.0005521287,0.000055917415],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000073497715,0.000041709347,0.007888336,0.0003594068,0.0030855879,0.0000010999047,0.005809588,0.00025274183,0.000002182099,0.0016494363,0.9789812,0.0018552074],"study_design_scores_gemma":[0.0012919783,0.0001468527,0.0022493734,0.0001697892,0.0011069702,0.0000019510978,0.0011350383,0.017726988,0.000010015445,0.0051137726,0.97034836,0.0006988971],"about_ca_topic_score_codex":0.003367931,"about_ca_topic_score_gemma":0.000102104466,"teacher_disagreement_score":0.04807249,"about_ca_system_score_codex":0.0005537273,"about_ca_system_score_gemma":0.00021902386,"threshold_uncertainty_score":0.9995707},"labels":[],"label_agreement":null},{"id":"W2600944596","doi":"10.1007/s40273-017-0491-7","title":"An Investigation of the Overlap Between the ICECAP-A and Five Preference-Based Health-Related Quality of Life Instruments","year":2017,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; Providence Health Care; International Collaboration On Repair Discoveries; University of British Columbia; Vancouver Coastal Health Research Institute; Vancouver Coastal Health","funders":"","keywords":"Health economics; Quality of Life Research; Public health; Health administration; Preference; Quality-adjusted life year; Quality of life (healthcare); Quality (philosophy); Health related quality of life; Psychology; Environmental health; Medicine; MEDLINE; Political science; Nursing; Economics; Cost effectiveness; Risk analysis (engineering)","score_opus":0.5169471671780879,"score_gpt":0.4647352651113755,"score_spread":0.05221190206671239,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600944596","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.971373,0.00047344988,0.00007131659,0.025421418,0.00047996067,0.0008416811,0.0009008299,0.000015118585,0.00042320573],"genre_scores_gemma":[0.99423957,0.0001089792,0.000289949,0.005100297,0.00012138832,0.000036439196,0.000040454983,0.000022633523,0.000040305942],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.994198,0.000697626,0.004317622,0.0004290893,0.000082783314,0.00027485722],"domain_scores_gemma":[0.9887904,0.00068660773,0.009113268,0.0011076517,0.000067499386,0.00023455222],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01342727,0.00019054068,0.001022063,0.0001070747,0.0005835432,0.000098000346,0.000904222,0.000117763906,0.00007525133],"category_scores_gemma":[0.0009920812,0.00017739148,0.00012671802,0.00005984557,0.00048119915,0.0006901265,0.00012717868,0.00024060914,0.00003864054],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000026453155,0.000033242963,0.9841425,0.0003359149,0.00010921532,9.47042e-9,0.0016831309,0.0003563534,0.000024568888,0.012143603,0.00056329294,0.00058174616],"study_design_scores_gemma":[0.0017128538,0.00006280441,0.9731355,0.00006411943,0.000015136395,2.347919e-7,0.0003824168,0.011500331,0.00027861816,0.012153291,0.0004940937,0.00020063283],"about_ca_topic_score_codex":0.007364742,"about_ca_topic_score_gemma":0.0002191944,"teacher_disagreement_score":0.022866534,"about_ca_system_score_codex":0.00023933075,"about_ca_system_score_gemma":0.00050191634,"threshold_uncertainty_score":0.9992453},"labels":[],"label_agreement":null},{"id":"W2607056793","doi":"10.1007/s40273-017-0509-1","title":"Emerging Use of Early Health Technology Assessment in Medical Product Development: A Scoping Review of the Literature","year":2017,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":186,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto Public Health","funders":"","keywords":"Health technology; New product development; Health economics; Context (archaeology); Public health; Economic evaluation; Health administration; Health care; Business; Medicine; Risk analysis (engineering); Management science; Marketing; Engineering; Economics; Economic growth; Nursing","score_opus":0.5745355274741083,"score_gpt":0.5952101654926656,"score_spread":0.02067463801855729,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2607056793","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014912373,0.98114353,0.000037384612,0.013019253,0.0010721606,0.004038573,0.0003425157,0.0000211856,0.00017628665],"genre_scores_gemma":[0.000049693906,0.9941726,0.0017048444,0.0031909656,0.00018890771,0.00044841945,0.00007645815,0.000073571486,0.000094566705],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.98515785,0.0007683048,0.012411105,0.0009357091,0.00015959161,0.00056743296],"domain_scores_gemma":[0.9809818,0.0006977313,0.016582774,0.0014495362,0.000102269965,0.0001858667],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0231325,0.00049209746,0.006176973,0.0009720303,0.00019532,0.00007572693,0.0015834327,0.00035615615,0.00022072687],"category_scores_gemma":[0.0037951153,0.00048907194,0.0005006873,0.0004718303,0.00018269948,0.00053402723,0.00046549935,0.0011346814,0.00007967676],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000002656027,0.00012799677,0.0019093879,0.7044123,0.00027726442,0.0000019040073,0.00052823866,0.000005197952,1.724743e-8,0.005528408,0.0021546849,0.28505194],"study_design_scores_gemma":[0.00023084787,0.000011922338,0.00007433625,0.4450794,0.00002426626,0.000012072498,0.00001024533,0.000034738525,5.502266e-7,0.00008455641,0.5541676,0.00026945467],"about_ca_topic_score_codex":0.00018544264,"about_ca_topic_score_gemma":0.000115224786,"teacher_disagreement_score":0.5520129,"about_ca_system_score_codex":0.0012561326,"about_ca_system_score_gemma":0.0068512084,"threshold_uncertainty_score":0.9997561},"labels":[],"label_agreement":null},{"id":"W2613741907","doi":"10.1007/s40273-017-0510-8","title":"A Comparison of Four Software Programs for Implementing Decision Analytic Cost-Effectiveness Models","year":2017,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Risk and Safety Analysis","field":"Decision Sciences","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto; University of Alberta Hospital; University of Alberta","funders":"Faculty of Medicine and Dentistry, University of Alberta; Canadian Institutes of Health Research; Genome Canada","keywords":"Quality of Life Research; Health economics; Health administration; Public health; Cost effectiveness; Computer science; Software; Quality-adjusted life year; Management science; Risk analysis (engineering); Business; Medicine; Engineering; Nursing","score_opus":0.6970348946451114,"score_gpt":0.6133700622966806,"score_spread":0.0836648323484308,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2613741907","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009803987,0.8332342,0.1619903,0.000015186448,0.00057040184,0.0033250584,0.0004956595,0.000033316985,0.00023786929],"genre_scores_gemma":[0.002142071,0.9900898,0.0064546964,0.000010774201,0.00020370565,0.00069571205,0.00019255036,0.00007548274,0.00013525586],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99381536,0.00044854937,0.0032899957,0.001205059,0.00059320533,0.00064782856],"domain_scores_gemma":[0.98586893,0.007277336,0.0045896713,0.0014673676,0.0005674057,0.00022928824],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.008962103,0.0005945211,0.0053744055,0.00074861554,0.0005385873,0.00059486704,0.0028568744,0.0002655782,0.00009912683],"category_scores_gemma":[0.0012779908,0.00046601216,0.0029090426,0.00038734512,0.00012377735,0.000646382,0.00045556825,0.00034861665,0.000094357725],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000059590628,0.00009585724,0.00040322365,0.0016387681,0.00057229,0.0000012849395,0.000051292795,0.0023533965,1.0947624e-7,0.00008707603,0.00070094015,0.9940362],"study_design_scores_gemma":[0.00067573274,0.000048083395,0.0000067298806,0.0013737937,0.0022736497,0.000004404664,0.000047857033,0.07996222,0.0000059911013,0.013304775,0.90185124,0.00044549783],"about_ca_topic_score_codex":0.00003771584,"about_ca_topic_score_gemma":0.00008104343,"teacher_disagreement_score":0.99359065,"about_ca_system_score_codex":0.0002697773,"about_ca_system_score_gemma":0.0004905455,"threshold_uncertainty_score":0.99977916},"labels":[],"label_agreement":null},{"id":"W2616016052","doi":"10.2165/11590380-000000000-00000","title":"Cost Effectiveness of Budesonide/Formoterol Added to Tiotropium Bromide versus Placebo Added to Tiotropium Bromide in Patients with Chronic Obstructive Pulmonary Disease","year":2011,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"AstraZeneca; Pfizer","keywords":"Medicine; Tiotropium bromide; Budesonide; Formoterol; Budesonide/formoterol; COPD; Exacerbation; Placebo; Obstructive lung disease; Internal medicine; Indirect costs; Intensive care medicine; Corticosteroid; Lung","score_opus":0.029686809704364013,"score_gpt":0.307279062413236,"score_spread":0.277592252708872,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2616016052","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900789,0.00015751644,0.00017271817,0.00011018608,0.0006737163,0.006411247,0.00077256805,0.000082853534,0.0015402714],"genre_scores_gemma":[0.99742633,0.00003194996,0.00070775975,0.00019041172,0.00026070056,0.00078087987,0.0003165738,0.00016362597,0.00012177319],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961384,0.00030109292,0.0007817138,0.0011748242,0.0004825605,0.0011214043],"domain_scores_gemma":[0.9966298,0.00034446904,0.00025664602,0.00087839935,0.00036263574,0.0015280462],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00033534996,0.0006460975,0.0009891996,0.0006895854,0.00011037206,0.000032562028,0.000552062,0.0001308881,0.0008208617],"category_scores_gemma":[0.00016430396,0.00065618526,0.0002325458,0.00051848136,0.0002655503,0.0005094445,0.00040641366,0.0005514201,0.00030176414],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2840928,0.0025966107,0.68040127,0.0025074764,0.00096322125,0.00034144273,0.00068532996,0.0027178824,0.007840618,0.00026299793,0.00028107697,0.017309276],"study_design_scores_gemma":[0.023290414,0.0009515776,0.96143544,0.00039096287,0.00032562844,0.000006703142,0.00010070872,0.0013344369,0.010924187,0.000053076757,0.00055323524,0.00063361775],"about_ca_topic_score_codex":0.00057972124,"about_ca_topic_score_gemma":0.00014836856,"teacher_disagreement_score":0.2810342,"about_ca_system_score_codex":0.004353212,"about_ca_system_score_gemma":0.0012799869,"threshold_uncertainty_score":0.99958897},"labels":[],"label_agreement":null},{"id":"W270132110","doi":"10.1007/s40273-015-0285-8","title":"Systematic Literature Review of the Methods Used to Compare Newer Second-Generation Agents for the Management of Schizophrenia: A focus on Health Technology Assessment","year":2015,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Janssen Scientific Affairs","keywords":"Quetiapine; Olanzapine; Risperidone; Lurasidone; Medicine; Asenapine; Pharmacoeconomics; Population; Psychiatry; Systematic review; Antipsychotic; Randomized controlled trial; Schizophrenia (object-oriented programming); MEDLINE; Intensive care medicine; Internal medicine; Environmental health","score_opus":0.17674128122958377,"score_gpt":0.5194061597357834,"score_spread":0.34266487850619964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W270132110","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000013588063,0.9759214,0.00037359394,0.004756535,0.00050842145,0.017843263,0.00048483646,0.00001909203,0.00007926437],"genre_scores_gemma":[0.000047206377,0.97799104,0.017128507,0.0006239036,0.00013896661,0.0036237112,0.000188123,0.00005843994,0.00020012821],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9967499,0.000642999,0.0015216973,0.00045877905,0.00029986494,0.00032678762],"domain_scores_gemma":[0.996817,0.0003387459,0.0012198791,0.0011636165,0.00025458544,0.0002061699],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024078698,0.00044569143,0.0029892467,0.00030181702,0.00010292552,0.000028871147,0.00060568977,0.00009432007,0.000052800646],"category_scores_gemma":[0.000057545178,0.00022801777,0.00074518716,0.00055153295,0.000048240763,0.000034413762,0.00021840075,0.00045484107,0.000012427282],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001444393,0.0001526071,6.2161666e-7,0.6124287,0.0027155038,0.0000032859218,0.00002954583,0.000004364735,0.0000010055459,0.0025564393,0.008555537,0.37340793],"study_design_scores_gemma":[0.0033744108,0.00039831537,0.00000506543,0.5805243,0.005528534,0.000058133315,0.000045762245,0.0002510874,0.00007833109,0.00014347743,0.40936404,0.00022851476],"about_ca_topic_score_codex":0.0000036877718,"about_ca_topic_score_gemma":0.000022689917,"teacher_disagreement_score":0.4008085,"about_ca_system_score_codex":0.00087478454,"about_ca_system_score_gemma":0.0009892094,"threshold_uncertainty_score":0.9298295},"labels":[],"label_agreement":null},{"id":"W2731101119","doi":"10.1007/s40273-017-0534-0","title":"Validation of a DICE Simulation Against a Discrete Event Simulation Implemented Entirely in Code","year":2017,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Quality and Safety in Healthcare","field":"Health Professions","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Dice; Discrete event simulation; Code (set theory); Computer science; Event (particle physics); Quality of Life Research; Public health; Statistics; Medicine; Programming language; Simulation; Mathematics","score_opus":0.20129401367591784,"score_gpt":0.5753081631253333,"score_spread":0.37401414944941547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2731101119","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915751,0.000028628567,0.0030712213,0.002173591,0.0006940395,0.001133617,0.00031022468,0.000033298744,0.0009802856],"genre_scores_gemma":[0.9984573,0.00012254802,0.00009440349,0.0007172478,0.00019766888,0.000068789326,0.00023295626,0.000022018188,0.00008707884],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9975367,0.000492696,0.0012438383,0.00025881833,0.00012476368,0.000343191],"domain_scores_gemma":[0.99721754,0.0008663004,0.0012397491,0.00042980028,0.00014256607,0.00010406465],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016634762,0.00013783194,0.00031504472,0.00011196402,0.0007045134,0.000016631591,0.0002517456,0.00013250955,0.00023574743],"category_scores_gemma":[0.00036732852,0.0001529456,0.00007949877,0.00004477646,0.00004284454,0.00052143744,0.00013075594,0.00035317938,0.00006644052],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004977228,0.00008892638,0.23970601,0.00058824086,0.000042611293,0.0000013090475,0.0056837406,0.74182034,0.0010586459,0.000986911,0.00008322093,0.009442316],"study_design_scores_gemma":[0.0029055336,0.00003498988,0.07599353,0.00018400693,0.000027256852,5.0153098e-8,0.0008145481,0.9112597,0.0008562671,0.0009069425,0.0068272725,0.000189882],"about_ca_topic_score_codex":0.0009233663,"about_ca_topic_score_gemma":0.00058327086,"teacher_disagreement_score":0.16943938,"about_ca_system_score_codex":0.0003591002,"about_ca_system_score_gemma":0.00021497859,"threshold_uncertainty_score":0.62369406},"labels":[],"label_agreement":null},{"id":"W2751752943","doi":"10.1007/s40273-017-0558-5","title":"Modelling the Survival Outcomes of Immuno-Oncology Drugs in Economic Evaluations: A Systematic Approach to Data Analysis and Extrapolation","year":2017,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Bristol-Myers Squibb (Canada); Augmentium Pharma Consulting (Canada)","funders":"Bristol-Myers Squibb","keywords":"Medicine; Ipilimumab; Oncology; Survival analysis; Contouring; Clinical trial; Medical physics; Internal medicine; Statistics; Cancer; Mathematics; Computer science; Immunotherapy","score_opus":0.11388261087873913,"score_gpt":0.4255673181020439,"score_spread":0.31168470722330477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2751752943","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893189,0.00079775247,0.0059198295,0.0012963252,0.00022489886,0.0010464954,0.000071051174,0.0000075888524,0.0013171757],"genre_scores_gemma":[0.9976599,0.0006023838,0.0014015624,0.00013703924,0.000037265232,0.000058724505,0.00004953193,0.000010358814,0.00004320507],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99889773,0.00010235547,0.0005581879,0.00026035504,0.00005986294,0.00012150849],"domain_scores_gemma":[0.9984058,0.00023184218,0.00037370203,0.0009257817,0.00002278297,0.000040064748],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002196255,0.00010732149,0.0005700125,0.00019851257,0.00011707405,0.000052314423,0.00039241154,0.000041962794,0.000028025192],"category_scores_gemma":[0.000035276076,0.00008159072,0.00008896616,0.000053839638,0.000077129414,0.0002128723,0.000121557656,0.000075455006,0.0000035020173],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006590827,0.0011947386,0.513946,0.007312671,0.02929788,0.0000027532826,0.025375536,0.36364815,0.00994277,0.0019961179,0.00055608706,0.040136456],"study_design_scores_gemma":[0.001938097,0.000022697064,0.027248088,0.00005642651,0.0012974225,0.0000026272687,0.0006777485,0.9683971,0.00013060503,0.000052827556,0.00008352992,0.00009284941],"about_ca_topic_score_codex":0.0017278313,"about_ca_topic_score_gemma":0.00020285389,"teacher_disagreement_score":0.6047489,"about_ca_system_score_codex":0.00020125149,"about_ca_system_score_gemma":0.00013574502,"threshold_uncertainty_score":0.3327173},"labels":[],"label_agreement":null},{"id":"W2752145111","doi":"10.1007/s40273-017-0563-8","title":"Economic Considerations in the Use of Novel Targeted Therapies for Lung Cancer: Review of Current Literature","year":2017,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Lung cancer; Precision medicine; Erlotinib; Cancer; Population; Epidermal growth factor receptor; Intensive care medicine; Oncology; Internal medicine; Pathology; Environmental health","score_opus":0.23812144414758424,"score_gpt":0.5266995212851098,"score_spread":0.28857807713752553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2752145111","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000014344309,0.98879164,0.00002471773,0.0006540719,0.0006231191,0.0039006781,0.005930982,0.000005926459,0.000054514145],"genre_scores_gemma":[0.000021514452,0.9963095,0.00056250073,0.0005068187,0.00022182986,0.0013520259,0.0009303669,0.00003513189,0.00006027664],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99858624,0.00005358689,0.0009099305,0.00025568166,0.00004565591,0.00014891187],"domain_scores_gemma":[0.9978802,0.0004567447,0.0010633724,0.0004485749,0.0001077509,0.00004331267],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022460097,0.0002741115,0.0015653665,0.00013563814,0.00006939767,0.000043836204,0.00016407834,0.000078901714,0.0001022294],"category_scores_gemma":[0.000060945444,0.00018213106,0.00054712966,0.00004215995,0.00006641329,0.00016436746,0.000022348584,0.0002182816,9.656019e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000020267216,0.00033493352,0.000075207005,0.2440255,0.002085795,0.0000018861757,0.0006460496,0.000046866233,0.000002008763,0.0014917975,0.039436016,0.71183366],"study_design_scores_gemma":[0.0010844313,0.00002217737,0.0000054765997,0.07090438,0.004308555,0.000014527325,0.000003614808,0.00019745427,0.000003907662,0.000010828482,0.9233145,0.00013011853],"about_ca_topic_score_codex":0.00005831851,"about_ca_topic_score_gemma":0.000034181776,"teacher_disagreement_score":0.8838785,"about_ca_system_score_codex":0.00030284404,"about_ca_system_score_gemma":0.001440036,"threshold_uncertainty_score":0.74270886},"labels":[],"label_agreement":null},{"id":"W2761114208","doi":"10.1007/s40273-017-0577-2","title":"Disease-Modifying Therapies for Multiple Sclerosis: A Systematic Literature Review of Cost-Effectiveness Studies","year":2017,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Biogen","keywords":"Medicine; Health economics; Economic evaluation; Systematic review; Disease; Cost effectiveness; Population; Quality-adjusted life year; Pharmacoeconomics; MEDLINE; Population health; Health technology; Family medicine; Public health; Intensive care medicine; Environmental health; Health care; Internal medicine; Pathology; Risk analysis (engineering)","score_opus":0.5082972032652955,"score_gpt":0.5324333321966794,"score_spread":0.02413612893138395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761114208","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000006443246,0.97122705,0.000026220212,0.00014492498,0.0005858889,0.026286315,0.0016268668,0.000062672305,0.00003363562],"genre_scores_gemma":[0.000072776056,0.9777238,0.00023495835,0.00020357488,0.0004458829,0.020763498,0.00029842783,0.00015757643,0.0000995205],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9958712,0.0006793819,0.0017337225,0.00083579565,0.00030059752,0.00057932193],"domain_scores_gemma":[0.99140114,0.0042662467,0.0018813737,0.001264407,0.0008650468,0.00032181805],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0027350886,0.000892211,0.008312395,0.00034787765,0.00034562594,0.00010444099,0.0006810023,0.0001703541,0.000011867303],"category_scores_gemma":[0.005778357,0.00063089497,0.0021626116,0.00015760992,0.00030519516,0.00024655173,0.00036151195,0.0005248984,0.000022963623],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012555644,0.000108176486,0.000014451458,0.781821,0.0054211733,0.000007329812,0.00011992179,6.0841177e-7,0.000006017527,0.0000119173,0.0011146516,0.21124922],"study_design_scores_gemma":[0.001483142,0.000051257663,0.000019973337,0.70323277,0.0064582652,0.0000102608565,0.000030098525,0.000078510246,0.000007983904,0.0000054198517,0.28827763,0.00034471301],"about_ca_topic_score_codex":0.0000022613754,"about_ca_topic_score_gemma":0.0000014870577,"teacher_disagreement_score":0.28716296,"about_ca_system_score_codex":0.00063030573,"about_ca_system_score_gemma":0.0004903516,"threshold_uncertainty_score":0.99961424},"labels":[],"label_agreement":null},{"id":"W2767875195","doi":"10.1007/s40273-017-0583-4","title":"Oncology Modeling for Fun and Profit! Key Steps for Busy Analysts in Health Technology Assessment","year":2017,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Centre for Applied Research in Cancer Control; University of Toronto; Ottawa Public Health; Institute of Health Economics; University of Ottawa; Sunnybrook Health Science Centre; Cancer Care Ontario","funders":"","keywords":"Quality of Life Research; Health economics; Key (lock); Markov model; Profit (economics); Management science; Computer science; Health administration; Health technology; Risk analysis (engineering); Markov chain; Actuarial science; Public health; Medicine; Health care; Business; Economics; Nursing; Computer security","score_opus":0.5489813413919996,"score_gpt":0.5914322835205265,"score_spread":0.04245094212852685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767875195","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.69913477,0.0026183561,0.08065192,0.20885652,0.0014482746,0.004737772,0.0010115936,0.00007950451,0.0014613162],"genre_scores_gemma":[0.9482411,0.0010345135,0.040169973,0.00822365,0.00042066953,0.001569488,0.000064405016,0.000068315174,0.00020786418],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9944449,0.00010770482,0.0038462789,0.0008666761,0.000029985116,0.0007044416],"domain_scores_gemma":[0.99510807,0.0006356198,0.0033195193,0.0006330599,0.000076810866,0.00022691325],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.01565051,0.00026548578,0.0015391489,0.000637928,0.00063569436,0.00016844328,0.00053233106,0.00023268853,0.000035124478],"category_scores_gemma":[0.0009841016,0.00036162153,0.00013489115,0.000055057288,0.0001032732,0.0006144111,0.00013878127,0.000247796,0.000044797216],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028365772,0.0003724715,0.25595704,0.0030139268,0.0005309381,0.0000017484853,0.0021419057,0.01911888,0.000047523936,0.68132913,0.011713004,0.025489768],"study_design_scores_gemma":[0.004928206,0.0002378561,0.0025595725,0.000056474608,0.0000144905,0.0000052018377,0.0014475472,0.87747884,0.000017045852,0.042247698,0.07055899,0.00044805362],"about_ca_topic_score_codex":0.0007561229,"about_ca_topic_score_gemma":0.0008886115,"teacher_disagreement_score":0.85836,"about_ca_system_score_codex":0.0016259006,"about_ca_system_score_gemma":0.0005730822,"threshold_uncertainty_score":0.9998836},"labels":[],"label_agreement":null},{"id":"W2772072809","doi":"10.1007/s40273-017-0582-5","title":"Australian Utility Weights for the EORTC QLU-C10D, a Multi-Attribute Utility Instrument Derived from the Cancer-Specific Quality of Life Questionnaire, EORTC QLQ-C30","year":2017,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":132,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Centre for Applied Research in Cancer Control","funders":"National Health and Medical Research Council; Cancer Australia; Medical Research Council; Australian Government","keywords":"Quality of life (healthcare); Quality-adjusted life year; Life expectancy; Medicine; Health economics; Population; Psychology; Gerontology; Public health; Cost effectiveness; Environmental health; Nursing","score_opus":0.5925945040015864,"score_gpt":0.5019002339167253,"score_spread":0.09069427008486108,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2772072809","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87709504,0.006510282,0.009866132,0.08704919,0.0041794158,0.0032481155,0.011751825,0.00008083801,0.00021915631],"genre_scores_gemma":[0.98765707,0.0031345168,0.0015338253,0.0052975705,0.001171201,0.0007851528,0.00012042507,0.000063508785,0.00023672616],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9910623,0.000646226,0.0060431724,0.0012914333,0.00014753685,0.00080936344],"domain_scores_gemma":[0.9868769,0.0027778884,0.007000746,0.0026912342,0.0002274778,0.00042576896],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.017798303,0.0005254043,0.0017361551,0.0001022214,0.0018499441,0.00042104605,0.002304241,0.00026560476,0.0015402243],"category_scores_gemma":[0.0030094802,0.00048433433,0.0006020789,0.0000814557,0.00072836806,0.00094304915,0.0003384252,0.0004999684,0.0003694097],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002889725,0.0004615356,0.93479407,0.00041730888,0.0009831579,3.8829322e-7,0.002487837,0.00025488276,0.000048150563,0.017371424,0.037918385,0.004973892],"study_design_scores_gemma":[0.003763551,0.000030378127,0.83673644,0.000071251874,0.00006362337,6.544958e-7,0.0006347508,0.02750164,0.00037278354,0.0049759136,0.12525423,0.0005947543],"about_ca_topic_score_codex":0.023965353,"about_ca_topic_score_gemma":0.004219143,"teacher_disagreement_score":0.110562034,"about_ca_system_score_codex":0.000780744,"about_ca_system_score_gemma":0.00039863284,"threshold_uncertainty_score":0.9997608},"labels":[],"label_agreement":null},{"id":"W2779437291","doi":"10.1007/s40273-017-0603-4","title":"Towards a New Framework for Addressing Structural Uncertainty in Health Technology Assessment Guidelines","year":2017,"lang":"en","type":"editorial","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Health Technology Assessment international; Strong; Belgian Health Care Knowledge Centre; McGill University","keywords":"Health economics; Quality of Life Research; Public health; Health administration; Health informatics; Risk analysis (engineering); Business; Management science; Medicine; Economics; Nursing","score_opus":0.5059815237094502,"score_gpt":0.6015221664251202,"score_spread":0.09554064271567009,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2779437291","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00062143005,0.009988157,0.019823594,0.20708978,0.75230527,0.003214472,0.0060295295,0.00019745433,0.00073029776],"genre_scores_gemma":[0.0011575373,0.0044367923,0.16318753,0.019832507,0.8067883,0.00094813854,0.0017276992,0.00037551494,0.0015459373],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.986217,0.0002721246,0.010140262,0.001834808,0.00017604296,0.0013597475],"domain_scores_gemma":[0.9826674,0.0026959542,0.012383923,0.0015057625,0.00023229296,0.0005146887],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.020609781,0.00082794385,0.003898737,0.0012527524,0.0006308298,0.00054900016,0.0018664908,0.0022347593,0.00035223158],"category_scores_gemma":[0.019280927,0.0011312643,0.0004354387,0.00015901428,0.00017079766,0.0005783566,0.000312017,0.0024845586,0.00024890082],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000048356567,0.000025905021,0.0004039774,0.00097197236,0.00017496162,0.0000012350056,0.00026219318,0.001784315,2.3037468e-7,0.044278942,0.9459549,0.0060930103],"study_design_scores_gemma":[0.002163612,0.00008661467,0.000055818782,0.0006558484,0.000016381193,0.0000018767867,0.00020939374,0.02438817,0.0000013721403,0.14617588,0.82543033,0.00081472384],"about_ca_topic_score_codex":0.0063578086,"about_ca_topic_score_gemma":0.0012045989,"teacher_disagreement_score":0.18725727,"about_ca_system_score_codex":0.005482552,"about_ca_system_score_gemma":0.0072881416,"threshold_uncertainty_score":0.9998168},"labels":[],"label_agreement":null},{"id":"W2781023254","doi":"10.1007/s40273-017-0601-6","title":"A Systematic Review of the Cost-Effectiveness of Biologics for Ulcerative Colitis","year":2017,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Pharmacoeconomics; Checklist; MEDLINE; Cost effectiveness; Health economics; Outcomes research; Generalizability theory; Health care; Intensive care medicine; Ulcerative colitis; Quality-adjusted life year; Family medicine; Public health; Alternative medicine; Internal medicine; Disease; Risk analysis (engineering); Pathology","score_opus":0.06905995891591639,"score_gpt":0.4084833777747435,"score_spread":0.3394234188588271,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2781023254","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006096627,0.9867527,0.000048746526,0.0000037027517,0.00037156232,0.010210285,0.0023013176,0.0000032954074,0.00024743896],"genre_scores_gemma":[0.00010543064,0.99675053,0.00002484547,0.00009828232,0.00009662635,0.0024728633,0.00032829953,0.000040789477,0.00008233446],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9977216,0.0007986508,0.0009311273,0.00032379632,0.000048761794,0.00017604095],"domain_scores_gemma":[0.9965743,0.00020959009,0.002075294,0.0008750347,0.00020935298,0.00005646548],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013573798,0.000320584,0.0019338194,0.000029339337,0.00007437786,0.000011814029,0.0008403391,0.00019129388,0.000009039457],"category_scores_gemma":[0.0007207307,0.000219389,0.001166361,0.000023687697,0.00017360695,0.0000039839933,0.000211586,0.00009910169,0.000004522994],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000063560554,0.0000267904,0.000002353815,0.99371773,0.0007086854,8.677556e-7,0.0000022864856,0.0000014627303,0.000022054928,0.00018964909,0.0002942613,0.0049702697],"study_design_scores_gemma":[0.0005756552,0.000056071127,0.000019104351,0.6165657,0.004488615,0.000014766549,0.000002834034,0.00001053085,0.00092260964,0.00003562723,0.37692437,0.0003841122],"about_ca_topic_score_codex":0.0000014903641,"about_ca_topic_score_gemma":0.0000026175032,"teacher_disagreement_score":0.37715206,"about_ca_system_score_codex":0.000071227456,"about_ca_system_score_gemma":0.0006134169,"threshold_uncertainty_score":0.89464235},"labels":[],"label_agreement":null},{"id":"W2784872984","doi":"10.1007/s40273-018-0610-0","title":"The Relative Importance of Clinical, Economic, Patient Values and Feasibility Criteria in Cancer Drug Reimbursement in Canada: A Revealed Preferences Analysis of Recommendations of the Pan-Canadian Oncology Drug Review 2011–2017","year":2018,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dalhousie University","funders":"Canadian Institutes of Health Research","keywords":"Reimbursement; Medicine; Actuarial science; Consistency (knowledge bases); Transparency (behavior); Health economics; Logistic regression; Public health; Family medicine; Health care; Computer science; Business; Economics; Nursing","score_opus":0.4025310874392468,"score_gpt":0.5420175238655627,"score_spread":0.13948643642631586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2784872984","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93575734,0.012450363,0.000002577783,0.046164915,0.0009650887,0.0013789671,0.001818626,0.0000022456488,0.0014598549],"genre_scores_gemma":[0.9602677,0.03524552,0.00024454013,0.0038985137,0.00006158105,0.00015826084,0.00002109916,0.0000128204865,0.00008996225],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9903696,0.0011864194,0.0075026015,0.00055425335,0.000054677595,0.00033241275],"domain_scores_gemma":[0.9903907,0.0022817007,0.00633844,0.00070413767,0.00012902691,0.0001560003],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.017368259,0.00018797313,0.0018060775,0.0002878943,0.00013585658,0.000012822477,0.000523641,0.00006884123,0.00057338865],"category_scores_gemma":[0.0011285628,0.000174586,0.0001945134,0.00023459109,0.00036191993,0.0002798761,0.00011575359,0.00024562987,0.000011285844],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000039451483,0.000074542215,0.9452846,0.00026724685,0.0004462225,1.457949e-7,0.0018569062,0.000109720124,6.857977e-7,0.0016511162,0.048279535,0.0019898175],"study_design_scores_gemma":[0.0012254216,0.00007820426,0.9413419,0.00051303767,0.00025120072,5.045598e-7,0.0020115466,0.010434412,0.000041779153,0.006658307,0.0371,0.0003437303],"about_ca_topic_score_codex":0.9062493,"about_ca_topic_score_gemma":0.9948569,"teacher_disagreement_score":0.08860761,"about_ca_system_score_codex":0.002943859,"about_ca_system_score_gemma":0.003928756,"threshold_uncertainty_score":0.7698089},"labels":[],"label_agreement":null},{"id":"W2785073729","doi":"10.1007/s40273-018-0609-6","title":"Cost Effectiveness of Treatments for Chronic Constipation: A Systematic Review","year":2018,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Gastrointestinal motility and disorders","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Bone and Joint Health Institute; University of Calgary","funders":"","keywords":"Quality of Life Research; Health economics; Chronic constipation; Health administration; Medicine; Cost effectiveness; Public health; Constipation; Systematic review; Intensive care medicine; Pharmacoeconomics; MEDLINE; Risk analysis (engineering); Internal medicine; Nursing; Political science","score_opus":0.14093524339637134,"score_gpt":0.4596411349477078,"score_spread":0.31870589155133644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2785073729","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000068556906,0.9824163,0.00041798918,0.000014537631,0.00021579568,0.016343588,0.00029160915,0.000026464406,0.00026690232],"genre_scores_gemma":[0.000017761162,0.99597836,0.00023381383,0.00009935122,0.00010716552,0.0029080014,0.0005350153,0.000047867106,0.000072671086],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9980388,0.00024309754,0.0010671718,0.00036542746,0.00006700538,0.00021844612],"domain_scores_gemma":[0.99754566,0.00096001895,0.0008231222,0.00038874996,0.00015589553,0.00012654474],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00077075453,0.0003750711,0.0037420304,0.000101047786,0.000037443857,0.000008503297,0.00015436296,0.00009095457,0.000087119675],"category_scores_gemma":[0.0003665054,0.0003025422,0.0008822832,0.000094345945,0.00011645417,0.000050970735,0.000031504944,0.00012563444,0.000120299104],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000051640098,0.00012818097,0.000005634908,0.9807618,0.0010013072,0.0000017172476,0.0000030155957,3.5748073e-7,3.8105426e-7,0.000030170946,0.00032724816,0.017688494],"study_design_scores_gemma":[0.0017029449,0.0004316429,0.0000013583896,0.8854576,0.029980307,0.00018319242,0.000002016976,0.000054318287,0.000009160736,0.00001590229,0.08198695,0.00017463787],"about_ca_topic_score_codex":0.0000045786983,"about_ca_topic_score_gemma":0.0000011394628,"teacher_disagreement_score":0.09530428,"about_ca_system_score_codex":0.00060150423,"about_ca_system_score_gemma":0.00075196783,"threshold_uncertainty_score":0.99994266},"labels":[],"label_agreement":null},{"id":"W2786627764","doi":"10.1007/s40273-017-0605-2","title":"A Decision-Analytic Model to Assess the Cost-Effectiveness of Etelcalcetide vs. Cinacalcet","year":2018,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Parathyroid Disorders and Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"Amgen","keywords":"Cinacalcet; Calcimimetic; Medicine; Cost effectiveness; Quality-adjusted life year; Internal medicine; Parathyroid hormone; Secondary hyperparathyroidism; Risk analysis (engineering)","score_opus":0.11123208547633699,"score_gpt":0.4375608287289462,"score_spread":0.3263287432526092,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2786627764","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.977281,0.00024011794,0.015703186,0.00045751606,0.00020938805,0.0010813922,0.00005023874,0.0000226866,0.004954511],"genre_scores_gemma":[0.9963045,0.000101104364,0.0013446653,0.001820671,0.0000943938,0.00011769303,0.000010716926,0.000027451451,0.00017876724],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99894845,0.000061449144,0.0003085838,0.0003044241,0.00011694221,0.00026012474],"domain_scores_gemma":[0.9987875,0.00039073548,0.00009261002,0.0003946797,0.00013326785,0.0002011735],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005027912,0.0001780915,0.00042770716,0.000100445264,0.000087942026,0.00001929194,0.00020085907,0.000047913727,0.000062046165],"category_scores_gemma":[0.00008912762,0.00012619862,0.00015585046,0.00014788515,0.00010257905,0.00008029459,0.00009151941,0.00011214097,0.00030891635],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.052619465,0.007721701,0.3017157,0.00045460594,0.008111742,0.00016739272,0.0031859546,0.10065224,0.16033587,0.014566158,0.25073436,0.09973483],"study_design_scores_gemma":[0.023114871,0.0014698313,0.07014123,0.00013129978,0.0018092338,0.00008638723,0.00015380442,0.6527397,0.22069496,0.0059461384,0.022986107,0.00072644954],"about_ca_topic_score_codex":0.000037949005,"about_ca_topic_score_gemma":0.000013254301,"teacher_disagreement_score":0.5520874,"about_ca_system_score_codex":0.00014599231,"about_ca_system_score_gemma":0.00015714309,"threshold_uncertainty_score":0.514623},"labels":[],"label_agreement":null},{"id":"W2788315630","doi":"10.1007/s40273-018-0623-8","title":"Is EQ-5D-5L Better Than EQ-5D-3L? A Head-to-Head Comparison of Descriptive Systems and Value Sets from Seven Countries","year":2018,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":399,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"EuroQol Research Foundation","keywords":"Statistic; EQ-5D; Descriptive statistics; Valuation (finance); Statistics; Psychology; Medicine; Econometrics; Economics; Mathematics; Health related quality of life","score_opus":0.4166524124455467,"score_gpt":0.44531346182943976,"score_spread":0.028661049383893078,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2788315630","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9677382,0.0033906603,0.0023277062,0.016090704,0.0026654068,0.0013909305,0.0047271387,0.000081664446,0.001587589],"genre_scores_gemma":[0.9744326,0.00024301218,0.0028789968,0.020516416,0.001286606,0.00014776844,0.00009293976,0.00010326663,0.00029842995],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99257004,0.00037843222,0.004925867,0.0011960599,0.00013398501,0.0007956407],"domain_scores_gemma":[0.9946233,0.0010553916,0.002804193,0.0007957973,0.00018801844,0.00053329265],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.005679095,0.00052136515,0.0022634126,0.0005008738,0.00034900833,0.00027403186,0.0006076738,0.00028062792,0.00071180024],"category_scores_gemma":[0.00033891556,0.0006872717,0.00019805554,0.00017662128,0.0003224921,0.00086818944,0.0002313876,0.00033626636,0.0035505681],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045888845,0.00038948722,0.7404419,0.0010463515,0.0013802726,0.0000034196,0.062514596,0.001044905,0.00023388464,0.017263426,0.17425877,0.00096408906],"study_design_scores_gemma":[0.007673597,0.0009205606,0.09878147,0.0006815306,0.00025544563,0.000027480704,0.011209354,0.29948354,0.002756348,0.014542535,0.56066483,0.003003317],"about_ca_topic_score_codex":0.009931788,"about_ca_topic_score_gemma":0.0007408867,"teacher_disagreement_score":0.64166045,"about_ca_system_score_codex":0.0009197325,"about_ca_system_score_gemma":0.00023820714,"threshold_uncertainty_score":0.99955785},"labels":[],"label_agreement":null},{"id":"W2799437595","doi":"10.1007/s40273-018-0664-z","title":"Highly Priced Gene Therapies: A Wake-Up Call for Early Price Regulation","year":2018,"lang":"en","type":"letter","venue":"PharmacoEconomics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Impact","funders":"","keywords":"Health economics; Wake; Quality of Life Research; Public health; Health administration; Economics; Business; Actuarial science; Public economics; Medicine; Pathology; Engineering","score_opus":0.07024198141245815,"score_gpt":0.310089570329557,"score_spread":0.23984758891709884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2799437595","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04688865,0.004234328,0.008048334,0.8541748,0.016853422,0.0051520765,0.014903255,0.00052562583,0.049219523],"genre_scores_gemma":[0.018235842,0.0021862742,0.0026755154,0.925758,0.027230741,0.0008156336,0.0016760622,0.00057909027,0.020842828],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99485654,0.000047795114,0.0020659596,0.0016025488,0.00005802479,0.0013691072],"domain_scores_gemma":[0.99639696,0.0004032834,0.0017874568,0.00096321496,0.00013853077,0.00031057608],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.001006927,0.0008850403,0.0015055961,0.00062647666,0.0003009478,0.0004604663,0.0012178886,0.001104673,0.001762763],"category_scores_gemma":[0.000074618016,0.0011400245,0.0007478942,0.00018111856,0.00021250639,0.00057906297,0.0001979389,0.0012428818,0.004280308],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012756127,0.000052120657,0.0001808614,0.00021826576,0.00070792285,0.0000047140916,0.0004661174,0.000035949368,0.00014403532,0.007616008,0.9898655,0.00058094604],"study_design_scores_gemma":[0.0024146908,0.00011649314,0.00017448979,0.000016343578,0.00008710131,0.000008973571,0.0000028740444,0.009794153,0.0010081095,0.029682362,0.9554048,0.0012895806],"about_ca_topic_score_codex":0.00016478638,"about_ca_topic_score_gemma":0.0000064254928,"teacher_disagreement_score":0.07158323,"about_ca_system_score_codex":0.0008781714,"about_ca_system_score_gemma":0.00016857994,"threshold_uncertainty_score":0.99914974},"labels":[],"label_agreement":null},{"id":"W2800669514","doi":"10.1007/s40273-018-0669-7","title":"Economic Evaluation of Stiripentol for Dravet Syndrome: A Cost-Utility Analysis","year":2018,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Epilepsy research and treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Canadian Agency for Drugs and Technologies in Health; Hospital for Sick Children; University of Ottawa","funders":"Canadian Institutes of Health Research","keywords":"Dravet syndrome; Medicine; Clobazam; Cost–utility analysis; Cost effectiveness; Health economics; Pharmacoeconomics; Adjunctive treatment; Intensive care medicine; Pediatrics; Public health; Epilepsy; Psychiatry; Internal medicine; Risk analysis (engineering)","score_opus":0.09429722996436016,"score_gpt":0.4574857804400075,"score_spread":0.36318855047564735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2800669514","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932977,0.00012357224,0.00062811,0.00033970468,0.00016041557,0.0017828828,0.00033204036,0.00001759656,0.0033179736],"genre_scores_gemma":[0.9984819,0.000056465204,0.00057642325,0.00011654429,0.00012172355,0.00025858876,0.00022385865,0.000013758516,0.0001507105],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9988926,0.000060461196,0.0003665025,0.00030192395,0.00013050134,0.0002480225],"domain_scores_gemma":[0.9989607,0.00011505293,0.00014393938,0.00031328134,0.0002696797,0.00019735556],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012002131,0.00012015167,0.0004075811,0.00022495353,0.00005828386,0.000014934562,0.00009339629,0.000041730134,0.0029703488],"category_scores_gemma":[0.000059691705,0.000116467985,0.0002559597,0.0000997305,0.000117131414,0.000092080765,0.000029464285,0.000059962735,0.00015290576],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004870784,0.0016458511,0.81017447,0.00033767038,0.01990138,0.000011709539,0.00055711216,0.0012313039,0.0028462582,0.00076894014,0.011514826,0.14613973],"study_design_scores_gemma":[0.01182113,0.0009317421,0.21594732,0.000015253601,0.0093687745,0.000023675962,0.000075781165,0.7168951,0.037273508,0.00070842664,0.0067247734,0.00021451799],"about_ca_topic_score_codex":0.000109117376,"about_ca_topic_score_gemma":0.00017734835,"teacher_disagreement_score":0.7156638,"about_ca_system_score_codex":0.00042760416,"about_ca_system_score_gemma":0.0004023606,"threshold_uncertainty_score":0.9979411},"labels":[],"label_agreement":null},{"id":"W2883422525","doi":"10.1007/s40273-018-0697-3","title":"Probabilistic Sensitivity Analysis in Cost-Effectiveness Models: Determining Model Convergence in Cohort Models","year":2018,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":112,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Sensitivity (control systems); Probabilistic logic; Convergence (economics); Variance (accounting); Computer science; Mathematical optimization; Function (biology); Statistics; Econometrics; Mathematics","score_opus":0.4523610308962625,"score_gpt":0.47954391107213534,"score_spread":0.027182880175872837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2883422525","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86321783,0.00020013703,0.12949644,0.000741386,0.00043800703,0.001848026,0.00036499297,0.000062025254,0.0036311364],"genre_scores_gemma":[0.993845,0.00017801888,0.0021691066,0.0029214348,0.00016081291,0.000557208,0.000049854003,0.000058383936,0.00006020407],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9929993,0.0007424911,0.004023086,0.001335041,0.00008516661,0.0008148855],"domain_scores_gemma":[0.99613297,0.0013993807,0.0014094583,0.0006812107,0.000109391905,0.0002675719],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.023677029,0.000395855,0.0018962318,0.0012562028,0.00014279096,0.00009767848,0.00037243226,0.00020970366,0.00018919607],"category_scores_gemma":[0.00064423407,0.0005835293,0.00023393203,0.0007092968,0.0001959439,0.0017669107,0.00014480932,0.0003592482,0.0005571805],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006121646,0.00012603287,0.1506121,0.00012562817,0.00017464808,0.0000040858754,0.0010958757,0.827111,0.000010875662,0.020436954,0.00013066488,0.00011089439],"study_design_scores_gemma":[0.0012044536,0.00002385268,0.0185424,0.00004118362,0.000051897016,0.0000033068777,0.000115489376,0.92555016,0.000039623927,0.05379691,0.00008973858,0.00054098753],"about_ca_topic_score_codex":0.0023316527,"about_ca_topic_score_gemma":0.0038378742,"teacher_disagreement_score":0.1320697,"about_ca_system_score_codex":0.0022900794,"about_ca_system_score_gemma":0.00031454692,"threshold_uncertainty_score":0.9996616},"labels":[],"label_agreement":null},{"id":"W2890132602","doi":"10.1007/s40273-018-0711-9","title":"Trusting the Results of Model-Based Economic Analyses: Is there a Pragmatic Validation Solution?","year":2018,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Timeline; Transparency (behavior); Computer science; Risk analysis (engineering); Management science; Field (mathematics); Data aggregator; Health administration; Data science; Component (thermodynamics); Psychological intervention; Process management; Public health; Business; Medicine; Economics; Computer security","score_opus":0.44028548828523556,"score_gpt":0.5135493975386651,"score_spread":0.07326390925342957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890132602","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8296893,0.0012859736,0.069904715,0.064576335,0.0018110202,0.0019911733,0.0033974817,0.00015971909,0.02718426],"genre_scores_gemma":[0.98393786,0.000095317715,0.005290884,0.009325977,0.0007462998,0.00010154042,0.00008419843,0.00005820513,0.00035969433],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9933156,0.00032804336,0.0050909384,0.00070803246,0.00007267849,0.0004847331],"domain_scores_gemma":[0.99308795,0.0012187489,0.00452207,0.00089855766,0.0001119986,0.00016070246],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.013128546,0.00030116405,0.0009587505,0.00034116412,0.00040092703,0.00012267914,0.00066744455,0.0001400546,0.0009436253],"category_scores_gemma":[0.000890961,0.0003245369,0.0002776886,0.00015819563,0.00027025008,0.0006569616,0.00008558979,0.00020859634,0.0024845316],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008105508,0.0006805053,0.020294318,0.0015035247,0.001737239,0.0000012357049,0.019424327,0.48696712,0.0009649947,0.09655125,0.3688214,0.0022435219],"study_design_scores_gemma":[0.0019849243,0.00006530969,0.00045155734,0.00004426828,0.000049466926,0.0000018526516,0.00034810838,0.97015226,0.002387863,0.009948373,0.014211902,0.00035410395],"about_ca_topic_score_codex":0.00089208793,"about_ca_topic_score_gemma":0.00010903209,"teacher_disagreement_score":0.48318514,"about_ca_system_score_codex":0.00081591384,"about_ca_system_score_gemma":0.0004547192,"threshold_uncertainty_score":0.99996966},"labels":[],"label_agreement":null},{"id":"W2896731765","doi":"10.1007/s40273-018-0729-z","title":"Expanding the Scope of Costs and Benefits for Economic Evaluations in Health: Some Words of Caution","year":2018,"lang":"en","type":"letter","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Economics","funders":"","keywords":"Health economics; Quality of Life Research; Scope (computer science); Health administration; Public health; Public economics; Pharmacoeconomics; Cost–benefit analysis; Economics; Actuarial science; Medicine; Political science; Computer science; Nursing; Microeconomics","score_opus":0.3488546231059756,"score_gpt":0.49418185887871285,"score_spread":0.14532723577273726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2896731765","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1054092,0.025854023,0.0005384265,0.85205966,0.0032835796,0.0045439755,0.0076337242,0.000032384563,0.000645001],"genre_scores_gemma":[0.10270927,0.023369411,0.0033737991,0.8548324,0.010944925,0.0018885323,0.0015960673,0.0003920504,0.0008935087],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99096584,0.00042946456,0.007037644,0.0008507225,0.00007753709,0.0006387731],"domain_scores_gemma":[0.98920906,0.0027082174,0.0072278907,0.00065997464,0.000075649135,0.000119224496],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.018051464,0.00040708296,0.002060682,0.0008274797,0.00021317106,0.00006990687,0.0005698705,0.0004321962,0.0002923524],"category_scores_gemma":[0.00065102003,0.00049412716,0.0002525819,0.00009642673,0.00028096058,0.00058410084,0.00012304331,0.0005575304,0.00015596514],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000065184715,0.000066959394,0.0027219772,0.0029487256,0.00031177973,2.8187412e-7,0.0017799656,0.0019442,0.000007534971,0.020343293,0.96800673,0.0018033548],"study_design_scores_gemma":[0.0063183666,0.0004810883,0.002687059,0.001363882,0.00011141263,0.0000139114345,0.00063318445,0.040325217,0.0005148583,0.032126617,0.9138605,0.0015639096],"about_ca_topic_score_codex":0.00218295,"about_ca_topic_score_gemma":0.0005019283,"teacher_disagreement_score":0.05414625,"about_ca_system_score_codex":0.0022142536,"about_ca_system_score_gemma":0.0007410644,"threshold_uncertainty_score":0.99975103},"labels":[],"label_agreement":null},{"id":"W2899466366","doi":"10.1007/s40273-018-0732-4","title":"Cost Effectiveness of Midostaurin in the Treatment of Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in the United States","year":2018,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Novartis Pharmaceuticals Corporation","keywords":"Midostaurin; Medicine; Cytarabine; Daunorubicin; Quality-adjusted life year; Internal medicine; Myeloid leukemia; Placebo; Oncology; Cost effectiveness; Leukemia; Surgery; Pathology","score_opus":0.04306016700287379,"score_gpt":0.37204935814548384,"score_spread":0.32898919114261005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2899466366","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959766,0.00016515334,0.000028501936,0.0008482043,0.00009630046,0.002318615,0.00014147736,0.000015219435,0.00040991543],"genre_scores_gemma":[0.99464923,0.0037807173,0.00008583129,0.00069293496,0.000108745706,0.0002827323,0.0003362961,0.000034652505,0.000028882607],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977458,0.0007500434,0.0005726032,0.00031076634,0.00018967249,0.0004311215],"domain_scores_gemma":[0.9968871,0.0022163205,0.00018208838,0.00049689255,0.00013663863,0.00008096809],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014428643,0.00025308342,0.00056220905,0.00042954928,0.00005024437,0.000021028725,0.0004631783,0.00008666143,0.00008215502],"category_scores_gemma":[0.00006639265,0.000156975,0.00011805578,0.00074469874,0.0003946699,0.00009731946,0.000046522746,0.00029950647,0.000033648455],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.060693517,0.009932617,0.3075264,0.0020790782,0.005036152,0.002701375,0.16420235,0.022832068,0.31481642,0.0010667242,0.010559691,0.098553605],"study_design_scores_gemma":[0.05859732,0.004903118,0.16879259,0.0003022996,0.00066117145,0.00013670375,0.0080148075,0.06762555,0.6618998,0.00041758153,0.028097088,0.0005519345],"about_ca_topic_score_codex":0.005071077,"about_ca_topic_score_gemma":0.00031682584,"teacher_disagreement_score":0.34708342,"about_ca_system_score_codex":0.0018697778,"about_ca_system_score_gemma":0.00058285706,"threshold_uncertainty_score":0.7665985},"labels":[],"label_agreement":null},{"id":"W2902546796","doi":"10.1007/s40273-018-0751-1","title":"Measuring Public Preferences for Health Outcomes and Expenditures in a Context of Healthcare Resource Re-Allocation","year":2018,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Impact","funders":"Institut National de la Santé et de la Recherche Médicale","keywords":"Health economics; Health administration; Public health; Health care; Context (archaeology); Resource allocation; Quality of Life Research; Health services research; Business; Public economics; Medicine; Economics; Nursing; Economic growth; Geography; Management","score_opus":0.5460828892878852,"score_gpt":0.48836308252882693,"score_spread":0.057719806759058245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2902546796","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.809063,0.0053585046,0.0013840443,0.17971325,0.0007084722,0.0019531625,0.00064727425,0.000055342334,0.0011169385],"genre_scores_gemma":[0.9769959,0.00034197155,0.0014269112,0.020602133,0.00026733582,0.00022280151,0.000049572533,0.00003337141,0.000060039918],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9951197,0.00026209478,0.003506165,0.00058757537,0.00005280214,0.00047165217],"domain_scores_gemma":[0.99619204,0.0008559939,0.0023167005,0.0003307949,0.000071591145,0.0002328519],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.01038026,0.00020599763,0.0010986348,0.00047769057,0.00018670043,0.00007013229,0.00028723222,0.00010502999,0.00009003255],"category_scores_gemma":[0.00089009537,0.00026369854,0.00008815456,0.0000811927,0.00012976695,0.00053047074,0.000062465515,0.00014066343,0.00005964904],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026896287,0.00034179364,0.66228265,0.002890373,0.00028655934,2.5733428e-7,0.027966717,0.00008773129,0.000030223655,0.26127487,0.03043226,0.014137577],"study_design_scores_gemma":[0.014540032,0.0012842066,0.20449188,0.0005572736,0.000026700862,0.000010293721,0.029832413,0.029072974,0.0011259263,0.066694334,0.65022886,0.0021351015],"about_ca_topic_score_codex":0.0021057085,"about_ca_topic_score_gemma":0.0051724906,"teacher_disagreement_score":0.6197966,"about_ca_system_score_codex":0.0005471247,"about_ca_system_score_gemma":0.00026917824,"threshold_uncertainty_score":0.9999815},"labels":[],"label_agreement":null},{"id":"W2922512552","doi":"10.1007/s40273-019-00777-6","title":"Combining the Power of Artificial Intelligence with the Richness of Healthcare Claims Data: Opportunities and Challenges","year":2019,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Machine Learning in Healthcare","field":"Computer Science","cited_by":90,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Computer science; Health care; Data science; Identification (biology); Pipeline (software); Artificial intelligence; Big data; Health administration; Machine learning; Data mining","score_opus":0.16780540659326584,"score_gpt":0.3561746233826987,"score_spread":0.18836921678943283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2922512552","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8483423,0.0057155145,0.0066789454,0.13691911,0.0007884352,0.000668825,0.00004990971,0.000059665606,0.00077729445],"genre_scores_gemma":[0.9961306,0.0022946359,0.000795486,0.00070661434,0.000035468634,0.0000074184213,0.0000039185643,0.000011304598,0.000014543406],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9988489,0.00019219183,0.0003330352,0.00030893483,0.00012622663,0.00019072014],"domain_scores_gemma":[0.99798024,0.0005793264,0.0003425646,0.0009566275,0.000085140724,0.000056111574],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010654359,0.00012121927,0.00022696698,0.000050172697,0.00010602526,0.000044028653,0.0015342,0.00003243765,0.000016088448],"category_scores_gemma":[0.000012047749,0.00007439026,0.000020292457,0.00007957504,0.00018323793,0.00031790073,0.00061736477,0.00026904052,0.000003921127],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000089543944,0.00005968112,0.006118722,0.00069296313,0.000096158474,0.0000033150345,0.019153347,0.0023775396,0.00008971773,0.73981535,0.00012666502,0.23137696],"study_design_scores_gemma":[0.00063857035,0.0011534834,0.0069667595,0.0002777313,0.00006971352,0.00011409159,0.040238854,0.89423186,0.0040822932,0.010380831,0.040990863,0.0008549578],"about_ca_topic_score_codex":0.00016923624,"about_ca_topic_score_gemma":0.000068023306,"teacher_disagreement_score":0.8918543,"about_ca_system_score_codex":0.000015442107,"about_ca_system_score_gemma":0.00014745213,"threshold_uncertainty_score":0.30335468},"labels":[],"label_agreement":null},{"id":"W2949819367","doi":"10.1007/s40273-019-00814-4","title":"Cost Effectiveness of Advanced Pharmacy Services Provided in the Community and Primary Care Settings: A Systematic Review","year":2019,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Pharmaceutical Practices and Patient Outcomes","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Public Health","funders":"National Institute for Health and Care Excellence","keywords":"Medicine; Nice; Pharmacy; Checklist; Economic evaluation; MEDLINE; Guideline; Family medicine; Health economics; Systematic review; Health care; Public health; Nursing; Psychology; Political science","score_opus":0.17700224680052437,"score_gpt":0.483331069486977,"score_spread":0.3063288226864527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949819367","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010653975,0.97864056,4.7392865e-7,0.000091986934,0.0001970632,0.018972913,0.00016721767,0.000021391417,0.000842976],"genre_scores_gemma":[0.0010316209,0.9932282,0.000030356847,0.0040663504,0.000032516826,0.0010115772,0.0005333845,0.00005587987,0.000010130769],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99442714,0.0034436672,0.0013381224,0.00033218417,0.00017932104,0.0002795466],"domain_scores_gemma":[0.9925166,0.0053503066,0.0012829059,0.0006509364,0.00008561398,0.0001136864],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.003040993,0.00049750187,0.0041579227,0.00013325771,0.000077400655,0.000033182947,0.00054799684,0.00009182499,0.000015701034],"category_scores_gemma":[0.00013198418,0.00032009208,0.00042709467,0.00020747837,0.00005754596,0.00029194696,0.00022132759,0.0014108028,0.00003113579],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012569864,0.00013967272,0.00011320269,0.9481843,0.0003588484,0.000007563662,0.0004898182,9.198919e-7,0.0000038176795,0.0000062783565,0.000014046239,0.050555795],"study_design_scores_gemma":[0.002416865,0.00007946226,0.000013920158,0.7319344,0.012623721,0.0001257623,0.000400766,0.000054741187,0.000011925273,0.0000025939003,0.25203392,0.00030191318],"about_ca_topic_score_codex":0.000046802536,"about_ca_topic_score_gemma":0.0000031976845,"teacher_disagreement_score":0.25201988,"about_ca_system_score_codex":0.0003267866,"about_ca_system_score_gemma":0.00029384255,"threshold_uncertainty_score":0.99992514},"labels":[],"label_agreement":null},{"id":"W2950152695","doi":"10.1007/s40273-019-00816-2","title":"Decision Models for Assessing the Cost Effectiveness of Treatments for Pediatric Drug-Resistant Epilepsy: A Systematic Review of Economic Evaluations","year":2019,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Epilepsy research and treatment","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Hospital for Sick Children; University of Ottawa","funders":"","keywords":"Epilepsy; Medicine; Cannabis; Pharmacoeconomics; Cochrane Library; MEDLINE; Drug Resistant Epilepsy; Economic evaluation; Vagus nerve stimulation; Population; Health economics; Cost effectiveness; Epilepsy surgery; Dravet syndrome; Health care; Intensive care medicine; Psychiatry; Meta-analysis; Public health; Environmental health; Internal medicine","score_opus":0.1453148856653226,"score_gpt":0.5142805400626335,"score_spread":0.3689656543973109,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950152695","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015059898,0.95605624,0.0013474764,0.000020990643,0.00034240802,0.03994767,0.001972407,0.000011642741,0.00015057923],"genre_scores_gemma":[0.00046819384,0.9857724,0.00064882374,0.000028663479,0.00012481342,0.011905982,0.0008376929,0.00010242521,0.00011104824],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99633527,0.00058890734,0.0019820223,0.0005354965,0.0001967226,0.00036158782],"domain_scores_gemma":[0.9868606,0.010099361,0.0017742977,0.00081000524,0.00030415566,0.00015162428],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0037572784,0.00049281324,0.0047387383,0.00028930418,0.00010250415,0.00003225111,0.00036538517,0.000117278185,0.000027487817],"category_scores_gemma":[0.0003564953,0.00030731538,0.001806151,0.00012937891,0.00005045612,0.00016048359,0.000071498864,0.00016147966,0.00003352426],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017869519,0.00025854027,0.00002334372,0.9662971,0.0024094477,6.615553e-7,0.000009545954,0.0001014785,9.961183e-7,0.00024384512,0.0002786769,0.030197699],"study_design_scores_gemma":[0.0072311624,0.0004930035,0.000014993293,0.8710136,0.10483733,0.000023428134,0.000017808572,0.008628961,0.000050509654,0.0008359523,0.006409741,0.0004435558],"about_ca_topic_score_codex":0.000012655568,"about_ca_topic_score_gemma":0.0000017186795,"teacher_disagreement_score":0.10242788,"about_ca_system_score_codex":0.0013338326,"about_ca_system_score_gemma":0.00211555,"threshold_uncertainty_score":0.9999379},"labels":[],"label_agreement":null},{"id":"W2951182219","doi":"10.1007/s40273-019-00817-1","title":"Structural Design and Data Requirements for Simulation Modelling in HIV/AIDS: A Narrative Review","year":2019,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"HIV/AIDS Research and Interventions","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Simon Fraser University; St. Paul's Hospital","funders":"National Institute on Drug Abuse; Ministry of Health, British Columbia","keywords":"Context (archaeology); Computer science; Population health; Health economics; Population; Psychological intervention; Data quality; Risk analysis (engineering); Public health; Medicine; Environmental health; Business; Service (business); Marketing; Nursing; Geography","score_opus":0.4289183444733304,"score_gpt":0.5406009061041488,"score_spread":0.11168256163081841,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951182219","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000008576234,0.9590309,0.034256548,0.00008307908,0.000080594335,0.0058177896,0.0005752173,0.000014878412,0.00013236795],"genre_scores_gemma":[0.000013799146,0.98723954,0.007535528,0.0001383557,0.00015430363,0.0002432069,0.002721881,0.000055687666,0.0018976781],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9977399,0.00021194869,0.0009838769,0.00064223586,0.000101217796,0.00032083874],"domain_scores_gemma":[0.99842834,0.00043250865,0.0003538193,0.0005515682,0.00007934197,0.00015441413],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011066409,0.00031492938,0.0015419663,0.0002474252,0.00006121983,0.000046303063,0.0003426136,0.00010681097,0.00019404572],"category_scores_gemma":[0.0001796191,0.00027416638,0.00025183667,0.000112965216,0.00003679143,0.0004522775,0.00019214847,0.00037206267,0.000056066958],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008647316,0.000037185673,0.0000027614312,0.099939905,0.00042775212,0.000003074387,0.00010439655,0.0027599987,7.361918e-7,0.00004687132,0.016555225,0.88003564],"study_design_scores_gemma":[0.00070643536,0.00016209928,2.4675806e-8,0.02481235,0.000690769,0.0000070786223,0.00001287272,0.5118183,4.1770642e-7,0.000030921972,0.46161306,0.00014567569],"about_ca_topic_score_codex":0.0000069625817,"about_ca_topic_score_gemma":0.0000014359334,"teacher_disagreement_score":0.87988997,"about_ca_system_score_codex":0.00026390594,"about_ca_system_score_gemma":0.0003571405,"threshold_uncertainty_score":0.99997103},"labels":[],"label_agreement":null},{"id":"W2955784899","doi":"10.1007/s40273-019-00819-z","title":"Transparency in Decision Modelling: What, Why, Who and How?","year":2019,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":61,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of British Columbia","funders":"National Institute of General Medical Sciences; National Institutes of Health","keywords":"Transparency (behavior); Incentive; Stakeholder; Knowledge management; Business; Public relations; Computer science; Political science; Computer security; Economics","score_opus":0.6503032919285434,"score_gpt":0.5211485563238956,"score_spread":0.12915473560464785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2955784899","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00023934327,0.9840464,0.0055110436,0.0039792797,0.0022743412,0.0022736094,0.00067407294,0.00004994646,0.00095195806],"genre_scores_gemma":[0.000067941495,0.9925043,0.0014407234,0.004249416,0.0005179452,0.0002898883,0.00016348259,0.00018374987,0.0005825469],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9905925,0.00041662992,0.006420324,0.0016922229,0.000081585524,0.0007967803],"domain_scores_gemma":[0.9926014,0.0022168716,0.0038854878,0.00089732796,0.00003525724,0.0003636503],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.010833564,0.00080935255,0.0060458384,0.0011977232,0.00012175348,0.00066248066,0.00078552356,0.0006308322,0.0004049232],"category_scores_gemma":[0.00027152227,0.0010454685,0.0005656545,0.00025270533,0.00008415741,0.002314728,0.0001386231,0.00081540266,0.0022962075],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000050487226,0.00029599044,0.0006193952,0.07084515,0.00074392196,0.000013018881,0.00231869,0.0056243143,4.1712635e-8,0.04283199,0.058236916,0.8184201],"study_design_scores_gemma":[0.0009220586,0.000029183322,0.000004275042,0.005106902,0.000096281045,0.000014659019,0.00012523036,0.031719457,8.178627e-8,0.003586553,0.9574606,0.0009347295],"about_ca_topic_score_codex":0.00020241035,"about_ca_topic_score_gemma":0.00008133552,"teacher_disagreement_score":0.8992237,"about_ca_system_score_codex":0.0012491888,"about_ca_system_score_gemma":0.00040217754,"threshold_uncertainty_score":0.99919957},"labels":[],"label_agreement":null},{"id":"W2972254478","doi":"10.1007/s40273-019-00834-0","title":"Demand for Precision Medicine: A Discrete-Choice Experiment and External Validation Study","year":2019,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":42,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Centre for Applied Research in Cancer Control; University of British Columbia","funders":"National Institutes of Health","keywords":"Context (archaeology); Health care; Health economics; Price elasticity of demand; Test (biology); Health administration; Econometrics; Confidence interval; Medicine; Actuarial science; Economics; Statistics; Microeconomics; Mathematics","score_opus":0.039894023046103746,"score_gpt":0.3386219699148572,"score_spread":0.2987279468687535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2972254478","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9834872,0.002372181,0.00481015,0.00046376383,0.001330879,0.001425322,0.00008944425,0.000028887547,0.005992169],"genre_scores_gemma":[0.99682057,0.00041083113,0.00044028627,0.00052131014,0.00050707435,0.00014936524,0.000012689401,0.00004106763,0.0010968021],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983259,0.000013660959,0.00075526885,0.00058155524,0.000024109875,0.00029954786],"domain_scores_gemma":[0.9989222,0.00019522695,0.00043532668,0.00027286838,0.000027323984,0.00014703185],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007576383,0.000219467,0.000535906,0.00015504785,0.000100413454,0.00009649881,0.00021556293,0.00006750895,0.0008621078],"category_scores_gemma":[0.00007667123,0.00024251416,0.000079774676,0.000042835345,0.000047536214,0.00062929187,0.00008001515,0.00010529986,0.00029580994],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008506942,0.00053396483,0.89619464,0.00016938148,0.0003858639,0.0000018524094,0.0055573853,0.0015980712,0.0028344388,0.06366835,0.007713969,0.02049139],"study_design_scores_gemma":[0.040934887,0.004080322,0.33269775,0.0001690071,0.00020691814,0.000020316778,0.0020283808,0.053568233,0.010019828,0.09519113,0.45796892,0.003114325],"about_ca_topic_score_codex":0.0001974817,"about_ca_topic_score_gemma":0.000010768296,"teacher_disagreement_score":0.5634969,"about_ca_system_score_codex":0.00016762211,"about_ca_system_score_gemma":0.000019601464,"threshold_uncertainty_score":0.988944},"labels":[],"label_agreement":null},{"id":"W2975057760","doi":"10.1007/s40273-019-00841-1","title":"Cost-Effectiveness Analysis of Vedolizumab Compared with Other Biologics in Anti-TNF-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan","year":2019,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"TransCanada (Canada)","funders":"Takeda Pharmaceutical Company; Takeda Pharmaceuticals U.S.A.","keywords":"Vedolizumab; Medicine; Health economics; Adalimumab; Ulcerative colitis; Discontinuation; Golimumab; Infliximab; Tofacitinib; Quality-adjusted life year; Cost effectiveness; Internal medicine; Public health; Disease; Rheumatoid arthritis","score_opus":0.014921809709046201,"score_gpt":0.2817782373427612,"score_spread":0.266856427633715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2975057760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976902,0.000009242388,0.00010327573,0.0000070121423,0.000045735647,0.0013142376,0.0004692078,0.0000062814993,0.00035481236],"genre_scores_gemma":[0.99912626,0.000009135077,0.000112706606,0.00024538403,0.000014074685,0.000117421594,0.0003301267,0.000028470928,0.000016446498],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99873155,0.00017827,0.0002912654,0.00045684027,0.00006484553,0.0002772094],"domain_scores_gemma":[0.99932295,0.000031309024,0.00015629835,0.00027377266,0.00011991678,0.000095756885],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016998123,0.00022535239,0.00045332636,0.00022587029,0.000021547256,0.000018007015,0.00017463576,0.00008326953,0.00006816123],"category_scores_gemma":[0.000008972607,0.00020209371,0.00006543343,0.00024033805,0.00006427538,0.000016053058,0.00006493353,0.000093573115,0.000012945882],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0073411795,0.00018672796,0.7813549,0.000030316562,0.00044543212,0.0000042085535,0.00015792994,0.20821953,0.002039735,0.000028183507,0.0000074554114,0.0001844268],"study_design_scores_gemma":[0.0059620785,0.00019138485,0.9762158,0.000025445896,0.0001088331,5.014007e-7,0.00009810752,0.008005257,0.008944715,0.000005333283,0.00012884347,0.0003136971],"about_ca_topic_score_codex":0.00011930481,"about_ca_topic_score_gemma":0.0012717344,"teacher_disagreement_score":0.20021427,"about_ca_system_score_codex":0.00012396878,"about_ca_system_score_gemma":0.00012576317,"threshold_uncertainty_score":0.8241142},"labels":[],"label_agreement":null},{"id":"W2976981214","doi":"10.1007/s40273-019-00837-x","title":"A Need for Change! A Coding Framework for Improving Transparency in Decision Modeling","year":2019,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":70,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto","funders":"National Center for Advancing Translational Sciences; National Institute of Allergy and Infectious Diseases; National Cancer Institute; National Institutes of Health","keywords":"Computer science; Decision model; Transparency (behavior); Coding (social sciences); Decision analysis; Testbed; Data science; Decision support system; Management science; Data mining; Machine learning; Engineering","score_opus":0.4936290154930236,"score_gpt":0.49801941596912336,"score_spread":0.004390400476099732,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2976981214","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.47962302,0.001051982,0.50757545,0.0057837013,0.0017804428,0.0033933169,0.0005387592,0.000051428655,0.00020191271],"genre_scores_gemma":[0.91521686,0.000200133,0.07280415,0.009212251,0.00079962617,0.0015546712,0.000060461272,0.00009518473,0.000056674737],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9947155,0.000053077027,0.0036674086,0.0008387872,0.00004119825,0.0006840083],"domain_scores_gemma":[0.99590534,0.0022220314,0.0012381305,0.00040526513,0.000054185926,0.00017507264],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0091354055,0.00027623892,0.0011226287,0.0005016685,0.00014260046,0.000113472124,0.000396552,0.00022197436,0.0002187028],"category_scores_gemma":[0.0011237733,0.00039898243,0.00026192135,0.00012697099,0.000016199618,0.0009008318,0.00004083751,0.0002283619,0.00041123686],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001215807,0.00043997375,0.059750013,0.005345657,0.00024183997,9.1679766e-7,0.013439438,0.08066565,0.00030591112,0.8186989,0.002376918,0.017519005],"study_design_scores_gemma":[0.0029907327,0.00007066168,0.00024842145,0.00012226157,0.000010890839,0.0000010214671,0.0005846975,0.8942039,0.0000301664,0.0957612,0.0055339965,0.00044203197],"about_ca_topic_score_codex":0.000366197,"about_ca_topic_score_gemma":0.00008118687,"teacher_disagreement_score":0.81353825,"about_ca_system_score_codex":0.0007772576,"about_ca_system_score_gemma":0.00011139082,"threshold_uncertainty_score":0.9998462},"labels":[],"label_agreement":null},{"id":"W2977511836","doi":"10.1007/s40273-019-00830-4","title":"A Comparison of Different Analysis Methods for Reconstructed Survival Data to Inform Cost‑Effectiveness Analysis","year":2019,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario; Toronto General Hospital","funders":"","keywords":"Weibull distribution; Statistics; Goodness of fit; Parametric statistics; Mathematics; Survival analysis; Computer science","score_opus":0.6160843926293349,"score_gpt":0.6119821199724155,"score_spread":0.004102272656919426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2977511836","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7324159,0.00033385897,0.25586885,0.0018023506,0.001331678,0.0027539036,0.0044243215,0.000050553084,0.0010185298],"genre_scores_gemma":[0.95991045,0.000049581515,0.03642318,0.0014284027,0.00014272347,0.00030452124,0.0015303579,0.00005097188,0.00015983572],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99218,0.0006240603,0.0054070386,0.0011589262,0.00007436218,0.0005556267],"domain_scores_gemma":[0.9892367,0.0052150944,0.0033190998,0.0017224075,0.0001593015,0.0003473808],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.020801846,0.00036099515,0.0039637107,0.0018623236,0.00013725528,0.00010604123,0.0011511925,0.00016200943,0.0013806252],"category_scores_gemma":[0.0013991107,0.0004587484,0.0006557251,0.0014735535,0.00005698906,0.0006531619,0.0003334888,0.00019488715,0.0004274565],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024182827,0.00022727814,0.93622136,0.0005320291,0.012283961,5.1946937e-8,0.00083576236,0.027022367,0.0001436239,0.017289048,0.0010592967,0.0041434118],"study_design_scores_gemma":[0.0022336263,0.00011854427,0.15062971,0.000018806371,0.0019336534,4.090487e-7,0.0006451002,0.80253816,0.00070318807,0.0013998289,0.03903723,0.0007417179],"about_ca_topic_score_codex":0.0005220582,"about_ca_topic_score_gemma":0.00037117078,"teacher_disagreement_score":0.7855916,"about_ca_system_score_codex":0.000709265,"about_ca_system_score_gemma":0.0001308373,"threshold_uncertainty_score":0.99978644},"labels":[],"label_agreement":null},{"id":"W2978265398","doi":"10.1007/s40273-019-00843-z","title":"Bayesian Hierarchical Models for Meta-Analysis of Quality-of-Life Outcomes: An Application in Multimorbidity","year":2019,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Bayesian probability; Outcome (game theory); Random effects model; Bayesian hierarchical modeling; Quality of life (healthcare); Quality of Life Research; Meta-analysis; Econometrics; Hierarchical database model; Quality-adjusted life year; Quality (philosophy); Bayesian inference; Computer science; Statistics; Medicine; Data mining; Public health; Risk analysis (engineering); Mathematics; Cost effectiveness","score_opus":0.6129231057444139,"score_gpt":0.5373582919347197,"score_spread":0.07556481380969415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978265398","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8510269,0.0006430458,0.13539322,0.006182652,0.00027873545,0.0022106098,0.003405938,0.000032524815,0.0008263718],"genre_scores_gemma":[0.9836666,0.00005491322,0.0098501,0.005428829,0.000054196567,0.00055678724,0.00026058673,0.00004133322,0.000086653185],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99137753,0.00042823196,0.0069245533,0.0008128108,0.000083194725,0.00037365983],"domain_scores_gemma":[0.99246234,0.002304407,0.003985217,0.00091771747,0.00009299148,0.00023732065],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.017381337,0.0002698368,0.0040645692,0.0010078067,0.000046780857,0.000025447402,0.00053871464,0.00016986986,0.0007955776],"category_scores_gemma":[0.000628644,0.00033161524,0.0011917201,0.0003455332,0.00006930645,0.00078207644,0.000058326754,0.00018012842,0.00011454736],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017011388,0.00071606896,0.2595831,0.0008009986,0.02702601,5.270908e-8,0.001685438,0.345418,0.00007287447,0.36407498,0.0003258361,0.0001265432],"study_design_scores_gemma":[0.0018263055,0.00004636867,0.019121889,0.0000021195954,0.0023836324,8.648861e-8,0.00021724735,0.94951487,0.00004098559,0.025248459,0.0012134331,0.00038459458],"about_ca_topic_score_codex":0.002890885,"about_ca_topic_score_gemma":0.00074943586,"teacher_disagreement_score":0.6040969,"about_ca_system_score_codex":0.00029409866,"about_ca_system_score_gemma":0.00016173886,"threshold_uncertainty_score":0.9999136},"labels":[],"label_agreement":null},{"id":"W2981358885","doi":"10.1007/s40273-019-00850-0","title":"Improving Transparency in Decision Models: Current Issues and Potential Solutions","year":2019,"lang":"en","type":"editorial","venue":"PharmacoEconomics","topic":"Data Quality and Management","field":"Decision Sciences","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Quality of Life Research; Transparency (behavior); Health economics; Health administration; Public health; Current (fluid); Management science; Business; Risk analysis (engineering); Computer science; Economics; Medicine; Engineering; Nursing","score_opus":0.1391068268644732,"score_gpt":0.440017613013958,"score_spread":0.30091078614948474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981358885","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011068447,0.0075843027,0.03723712,0.0003691049,0.94986737,0.0006592025,0.002227494,0.00004265881,0.0009058846],"genre_scores_gemma":[0.022212263,0.06734134,0.0029937092,0.00024598048,0.90100586,0.0001747214,0.001689624,0.00016687045,0.0041695964],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9954954,0.0002234741,0.0015232624,0.0012693726,0.00097331475,0.0005152046],"domain_scores_gemma":[0.9966657,0.0016774284,0.00054317614,0.0007887671,0.00016055896,0.00016434744],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0051813587,0.00037772482,0.0007444421,0.0006314017,0.00015447402,0.0007878915,0.0014922667,0.00029711387,0.0002903921],"category_scores_gemma":[0.0007782674,0.00036347896,0.0001773489,0.00018337894,0.000090576345,0.0014688887,0.00082655513,0.00081478513,0.0004242166],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007251997,0.00007660401,0.0000046783944,0.000059862377,0.00001849862,0.000004423322,0.00017257432,0.0042264434,0.000006126107,0.00058515003,0.78831595,0.20645717],"study_design_scores_gemma":[0.0010475194,0.000023207154,0.0000069224443,0.000054420372,0.00005993215,7.05006e-7,0.0001087167,0.115807444,0.0000051163256,0.030292762,0.8522236,0.00036967825],"about_ca_topic_score_codex":0.0005160652,"about_ca_topic_score_gemma":0.00024884343,"teacher_disagreement_score":0.20608748,"about_ca_system_score_codex":0.00021315724,"about_ca_system_score_gemma":0.00029808548,"threshold_uncertainty_score":0.99988174},"labels":[],"label_agreement":null},{"id":"W2986774082","doi":"10.1007/s40273-019-00852-y","title":"Cost-Effectiveness of Tenofovir Alafenamide for Treatment of Chronic Hepatitis B in Canada","year":2019,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Hepatitis B Virus Studies","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Waterloo","funders":"Canadian Institutes of Health Research; Ontario Ministry of Research, Innovation and Science","keywords":"Medicine; Entecavir; Tenofovir alafenamide; Cost effectiveness; HBeAg; Chronic hepatitis; Hepatitis B virus; Internal medicine; Hepatitis B; Immunology; Lamivudine; Viral load; Virus; HBsAg","score_opus":0.03763253924656765,"score_gpt":0.33376211479872325,"score_spread":0.2961295755521556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2986774082","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957163,0.0007273023,0.000031867487,0.00009730322,0.00033878302,0.002239207,0.00030219633,0.0000055578885,0.0005414985],"genre_scores_gemma":[0.9972725,0.0021030994,0.00012061554,0.00006876024,0.000045452776,0.0002623655,0.00003445235,0.000022227723,0.00007056236],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991587,0.0000350661,0.0003560038,0.000184223,0.000054212538,0.00021183291],"domain_scores_gemma":[0.9992121,0.0003766256,0.00013290327,0.00016151604,0.00006041599,0.000056456975],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012793571,0.00013069247,0.00063047383,0.00007160331,0.000011429431,0.0000013426547,0.000054159143,0.000024605924,0.00009991312],"category_scores_gemma":[0.000017425524,0.00012645131,0.0000796063,0.000049427766,0.000029161372,0.00004525022,0.000018730278,0.00002898128,0.000007962271],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004066038,0.00017109294,0.9679225,0.00075132947,0.00023867929,0.000005506819,0.00010286444,0.0010771275,0.014171982,0.000088846435,0.00011698554,0.014946469],"study_design_scores_gemma":[0.012192311,0.0011579792,0.6050184,0.00021135504,0.00016745178,0.0000059035287,0.000034808403,0.01604111,0.35103264,0.000051490486,0.013871243,0.00021532777],"about_ca_topic_score_codex":0.88451093,"about_ca_topic_score_gemma":0.9252864,"teacher_disagreement_score":0.36290413,"about_ca_system_score_codex":0.0033612195,"about_ca_system_score_gemma":0.0017995447,"threshold_uncertainty_score":0.87894726},"labels":[],"label_agreement":null},{"id":"W2989903818","doi":"10.1007/s40273-019-00845-x","title":"Evaluating Partitioned Survival and Markov Decision-Analytic Modeling Approaches for Use in Cost-Effectiveness Analysis: Estimating and Comparing Survival Outcomes","year":2019,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bristol-Myers Squibb (Canada)","funders":"Bristol-Myers Squibb","keywords":"Markov model; Survival analysis; Everolimus; Medicine; Quality of Life Research; Markov chain; Quality-adjusted life year; Statistics; Time horizon; Cost effectiveness; Mathematics; Oncology; Public health; Mathematical optimization","score_opus":0.6806953585897056,"score_gpt":0.5257657187454701,"score_spread":0.15492963984423558,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2989903818","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8760888,0.00038360574,0.12026806,0.0005227612,0.00060583954,0.001810344,0.00014486423,0.00003393102,0.00014179958],"genre_scores_gemma":[0.9693223,0.000045693258,0.029624617,0.00039711528,0.00010063789,0.00035708293,0.0000770265,0.00004917406,0.000026299904],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99467635,0.00045907198,0.0032237777,0.0010342425,0.00008646352,0.00052009686],"domain_scores_gemma":[0.9917459,0.006371216,0.0012201611,0.0003950894,0.00006315053,0.0002045211],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.024911324,0.00032865105,0.002097806,0.0006903613,0.00021291494,0.00032806562,0.0001979216,0.00011785878,0.000059225953],"category_scores_gemma":[0.002005208,0.00042501237,0.00020543598,0.00023982876,0.000048564307,0.0011014794,0.00013759287,0.00021409917,0.00005620185],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000070496346,0.00003568869,0.57533574,0.00022152724,0.0003560374,1.4945851e-7,0.00022746979,0.41902536,0.0000015042156,0.004217053,0.000006314631,0.0005026926],"study_design_scores_gemma":[0.0029969055,0.000026902748,0.094033964,0.00005322812,0.00013946508,0.0000010102102,0.0005206826,0.8973861,0.0000017129719,0.004413908,0.000032491123,0.0003936571],"about_ca_topic_score_codex":0.00089105224,"about_ca_topic_score_gemma":0.0006253807,"teacher_disagreement_score":0.48130175,"about_ca_system_score_codex":0.0005149907,"about_ca_system_score_gemma":0.000078271805,"threshold_uncertainty_score":0.9998202},"labels":[],"label_agreement":null},{"id":"W2996129671","doi":"","title":"HEALTH STATE UTILITY VALUES FOR JUVENILE IDIOPATHIC ARTHRITIS: A SYSTEMATIC REVIEW","year":2019,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Quality of Life Research; Health economics; Public health; Arthritis; Juvenile; Health administration; Medicine; Environmental health; Nursing; Internal medicine; Biology","score_opus":0.07915591383738528,"score_gpt":0.4169901257717033,"score_spread":0.337834211934318,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2996129671","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000001663479,0.9805594,0.00011034919,0.0005977531,0.0005120553,0.01702084,0.0009612495,0.000115991024,0.00012066968],"genre_scores_gemma":[0.000008223116,0.9944463,0.00015786898,0.001685501,0.00016294446,0.0023764586,0.00042143784,0.0001581768,0.00058311084],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9947647,0.00063474866,0.0028045315,0.0007450763,0.00023774119,0.0008132024],"domain_scores_gemma":[0.9966642,0.00039308367,0.0013704014,0.0009008279,0.00015430796,0.0005171261],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0037145615,0.0006395444,0.00960342,0.0002097683,0.00015055969,0.0000892195,0.0003921378,0.00012884439,0.00016571033],"category_scores_gemma":[0.00036829652,0.0005353796,0.0015101773,0.00013460315,0.00007959621,0.00016702754,0.00010045957,0.00064586155,0.0008514748],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000016091322,0.000053878426,3.393422e-7,0.5935748,0.00043350612,0.00000495886,0.000028257717,4.9104276e-8,4.239187e-8,0.000020033212,0.0054560206,0.400412],"study_design_scores_gemma":[0.00077633094,0.00014471906,3.7540257e-8,0.49047422,0.0002727166,0.00019753478,0.000005028349,0.000046913603,6.209387e-7,0.00006296673,0.5077947,0.00022421412],"about_ca_topic_score_codex":0.000025906296,"about_ca_topic_score_gemma":0.000010299039,"teacher_disagreement_score":0.50233865,"about_ca_system_score_codex":0.0005237539,"about_ca_system_score_gemma":0.0026511508,"threshold_uncertainty_score":0.99992645},"labels":[],"label_agreement":null},{"id":"W2996593023","doi":"10.1007/s40273-019-00869-3","title":"One-Way Sensitivity Analysis for Probabilistic Cost-Effectiveness Analysis: Conditional Expected Incremental Net Benefit","year":2019,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Environmental Impact and Sustainability","field":"Environmental Science","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Economics; University of Alberta","funders":"Canadian Institutes of Health Research; University of Alberta; Genome Canada","keywords":"Probabilistic logic; Sensitivity (control systems); Decision analysis; Probabilistic analysis of algorithms; Value of information; Computer science; Value (mathematics); Cost–benefit analysis; Net present value; Conditional probability; Quality of Life Research; Econometrics; Statistics; Mathematics; Machine learning; Artificial intelligence; Production (economics); Economics; Medicine; Public health","score_opus":0.022066577806376657,"score_gpt":0.299888191216219,"score_spread":0.27782161340984235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2996593023","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99058044,0.000010502277,0.005659679,0.00007089761,0.00008856007,0.001971348,0.0006026857,0.000048073052,0.0009678174],"genre_scores_gemma":[0.99774927,0.000006312448,0.00041945037,0.00032437715,0.00004090829,0.0002818049,0.0009854978,0.000021949047,0.00017044226],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980527,0.00017580566,0.00038383616,0.00071822,0.00019593393,0.00047347049],"domain_scores_gemma":[0.9987871,0.00040770668,0.00018539302,0.00037883013,0.000016393862,0.0002245484],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00091256574,0.0002674249,0.00057656824,0.00016024352,0.00016473366,0.00006473139,0.00017723102,0.00008105757,0.006431175],"category_scores_gemma":[0.000032057815,0.00030666144,0.000500555,0.0005640079,0.00019251891,0.00048503175,0.00020197469,0.00013818784,0.00029700855],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020876389,0.00032603345,0.6537297,0.000024926298,0.0018492815,0.0000012945329,0.000096601325,0.33328292,0.009757718,0.00016831503,0.00003307953,0.00052138406],"study_design_scores_gemma":[0.0012407422,0.00006992507,0.8534501,0.000001528203,0.0023087834,0.0000012041194,0.00012359531,0.13448389,0.0065983003,0.0009015968,0.0004427674,0.00037755028],"about_ca_topic_score_codex":0.0005624509,"about_ca_topic_score_gemma":0.00048321378,"teacher_disagreement_score":0.19972041,"about_ca_system_score_codex":0.0017790283,"about_ca_system_score_gemma":0.000016815551,"threshold_uncertainty_score":0.99993855},"labels":[],"label_agreement":null},{"id":"W3004292749","doi":"10.2165/11594470-000000000-00000","title":"Measuring Quality of Life in Patients with Schizophrenia","year":2012,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":162,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Oakville-Trafalgar Memorial Hospital; Humber River Regional Hospital; University of Toronto","funders":"National Institutes of Health","keywords":"Schizophrenia (object-oriented programming); Quality of life (healthcare); Quality of Life Research; Construct (python library); Pharmacoeconomics; Scale (ratio); Health economics; Psychometrics; Quality (philosophy); Psychology; Health care; Foundation (evidence); Field (mathematics); Mental health; Quality-adjusted life year; Psychiatry; Public health; Medicine; Clinical psychology; Cost effectiveness; Psychotherapist; Computer science; Risk analysis (engineering); Intensive care medicine; Epistemology; Political science","score_opus":0.1591562692255742,"score_gpt":0.3903914705090308,"score_spread":0.2312352012834566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004292749","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.058361012,0.9396764,0.0000011765399,0.000017060736,0.00012351913,0.0013785589,0.00013470108,0.000020513713,0.00028706153],"genre_scores_gemma":[0.019599728,0.978977,0.00072697207,0.000030250236,0.0001936239,0.00012767002,0.0002442803,0.00007511476,0.000025322584],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978467,0.00016638306,0.0009668647,0.0003534865,0.00024278303,0.00042378495],"domain_scores_gemma":[0.99837947,0.00017184347,0.00049604534,0.00041451945,0.00007580959,0.0004623273],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00049232674,0.00038415266,0.0022332536,0.0003493187,0.000024142313,0.000012292322,0.00017802174,0.00013270945,0.00021284568],"category_scores_gemma":[0.00005831855,0.00028203957,0.00031946864,0.00016845347,0.000061955696,0.00011467874,0.00008633437,0.00049291574,0.00015299379],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00665974,0.0008573516,0.046253387,0.014761759,0.0010320375,0.0000041387907,0.00001569606,0.0000010274591,1.3455906e-7,0.00010364054,0.000032252534,0.93027884],"study_design_scores_gemma":[0.11013341,0.0011129607,0.1796656,0.020519417,0.008476787,0.000023408478,0.0000201916,0.000022548105,0.00005049723,0.00007668689,0.6772922,0.0026063023],"about_ca_topic_score_codex":0.00008340327,"about_ca_topic_score_gemma":0.00004923575,"teacher_disagreement_score":0.9276725,"about_ca_system_score_codex":0.0004531591,"about_ca_system_score_gemma":0.0010377967,"threshold_uncertainty_score":0.99996316},"labels":[],"label_agreement":null},{"id":"W3011675906","doi":"10.1007/s40273-020-00896-5","title":"A Budget Impact Model of the Addition of Telotristat Ethyl Treatment to the Standard of Care in Patients with Uncontrolled Carcinoid Syndrome","year":2020,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"Advanced Accelerator Applications; EMD Serono; Ipsen; Pfizer","keywords":"Carcinoid syndrome; Medicine; Discontinuation; Internal medicine","score_opus":0.01470325428347007,"score_gpt":0.31232168015496925,"score_spread":0.29761842587149917,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011675906","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99445814,0.000116802876,0.000012227903,0.0016140467,0.000022886088,0.0016375093,0.002062012,0.000005602009,0.00007074541],"genre_scores_gemma":[0.9994887,0.000048893766,0.00011792898,0.000219992,0.000012246775,0.000052796287,0.00002763774,0.000020233872,0.000011557961],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990285,0.00006487603,0.00034516046,0.00017258634,0.00020298618,0.00018591496],"domain_scores_gemma":[0.9992214,0.0000843215,0.00018876289,0.00023065426,0.00015119849,0.00012370222],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005290078,0.00013693528,0.00049733854,0.00006969662,0.000019877752,0.0000035799026,0.00016061217,0.0000056184454,0.00004181635],"category_scores_gemma":[0.000058057827,0.000071903734,0.0001198346,0.00015380148,0.00006730279,0.00006234695,0.00005505715,0.00012055441,0.0000013513644],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08115881,0.00086706126,0.50814104,0.0009245718,0.0008040621,0.00008839123,0.0060029128,0.38120192,0.013559038,0.000038461683,0.0014368815,0.0057768547],"study_design_scores_gemma":[0.1272137,0.052249365,0.17241809,0.0004401424,0.0010752917,0.000059711565,0.0027091873,0.050394602,0.59080493,0.00012335638,0.0018146212,0.0006969899],"about_ca_topic_score_codex":0.00012446816,"about_ca_topic_score_gemma":0.00011461938,"teacher_disagreement_score":0.5772459,"about_ca_system_score_codex":0.00029457035,"about_ca_system_score_gemma":0.00033131766,"threshold_uncertainty_score":0.29321492},"labels":[],"label_agreement":null},{"id":"W3022091895","doi":"10.1007/s40273-020-00912-8","title":"Economic Costs of Myasthenia Gravis: A Systematic Review","year":2020,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Myasthenia Gravis and Thymoma","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Children's Hospital of Eastern Ontario; Ottawa Hospital; University of Ottawa","funders":"Karolinska Institutet","keywords":"Quality of Life Research; Myasthenia gravis; Health economics; Health administration; Public health; Medicine; Immunology; Pathology","score_opus":0.03662681501559282,"score_gpt":0.379098939055621,"score_spread":0.34247212404002814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3022091895","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000005219438,0.992039,0.000006823057,0.00022119157,0.0004057787,0.0054521705,0.0004235033,0.00007037313,0.0013759221],"genre_scores_gemma":[0.000012237535,0.99715984,0.000118165946,0.0012261118,0.00034927783,0.00045605804,0.0002573788,0.00017967043,0.00024124909],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958429,0.00023349436,0.0027605682,0.0006629634,0.00013196506,0.00036811462],"domain_scores_gemma":[0.9964975,0.00022473958,0.0019376946,0.0008504182,0.000054408734,0.00043525052],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00056714256,0.0007638681,0.00906786,0.00021291856,0.00003578388,0.000027510452,0.0005562218,0.00020743726,0.000674155],"category_scores_gemma":[0.00007722492,0.0006223202,0.0018855113,0.00014104937,0.00007359708,0.000077492405,0.00015721962,0.00054987316,0.0023451748],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001505382,0.00004615704,8.1149085e-7,0.89070624,0.0012261104,0.000042298034,0.000015898258,1.2019134e-7,5.473774e-7,0.00059322076,0.003289937,0.10406359],"study_design_scores_gemma":[0.00037656646,0.00006296033,4.5323386e-8,0.42361477,0.012444132,0.0004306858,0.000003592051,0.00003626472,0.000002684851,0.0000102960175,0.56272143,0.00029657513],"about_ca_topic_score_codex":0.000015000495,"about_ca_topic_score_gemma":0.0000017184688,"teacher_disagreement_score":0.5594315,"about_ca_system_score_codex":0.0006873036,"about_ca_system_score_gemma":0.0008511206,"threshold_uncertainty_score":0.9996228},"labels":[],"label_agreement":null},{"id":"W3022637090","doi":"10.1007/s40273-020-00915-5","title":"Why it’s Time to Abandon the ICER","year":2020,"lang":"th","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":62,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Quality of Life Research; Health economics; Health administration; Public health; Medicine; Health care management; Nursing","score_opus":0.38459270800461726,"score_gpt":0.4602094669120927,"score_spread":0.07561675890747543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3022637090","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03950049,0.0032195442,0.0019798314,0.9252299,0.0026224942,0.0026972038,0.0022085386,0.00014917963,0.0223928],"genre_scores_gemma":[0.059942223,0.0010613976,0.00088004186,0.9261725,0.0054429616,0.00025025572,0.00009395742,0.00022198836,0.005934691],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98930377,0.0007796664,0.006853093,0.0016468528,0.00015276304,0.0012638844],"domain_scores_gemma":[0.99216944,0.0021250935,0.0031222778,0.0010696492,0.00011308571,0.0014004457],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.01314972,0.0007288065,0.00214229,0.00030117037,0.00062938686,0.0006330932,0.0017663917,0.00029525187,0.02825314],"category_scores_gemma":[0.0022738366,0.0008699628,0.000532333,0.00043616918,0.00016623392,0.0010102248,0.0005054036,0.0007862389,0.19939636],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014912551,0.0000995715,0.0009956624,0.00030025764,0.00039385312,0.0000027741328,0.0062506255,0.0035613764,0.000037796395,0.0034691363,0.9841425,0.00059733185],"study_design_scores_gemma":[0.001713335,0.00014585971,0.00037659708,0.00005135903,0.000073515825,0.0000063650723,0.00068994466,0.07714753,0.00007834042,0.00045813574,0.9183537,0.00090535433],"about_ca_topic_score_codex":0.00067618006,"about_ca_topic_score_gemma":0.00007230185,"teacher_disagreement_score":0.17114322,"about_ca_system_score_codex":0.0011417023,"about_ca_system_score_gemma":0.00048391454,"threshold_uncertainty_score":0.9993751},"labels":[],"label_agreement":null},{"id":"W3023257101","doi":"10.1007/s40273-020-00921-7","title":"Health State Utility Values in Juvenile Idiopathic Arthritis: What is the Evidence?","year":2020,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Autoimmune and Inflammatory Disorders Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; Alberta Children's Hospital; Alberta Bone and Joint Health Institute; University of Calgary","funders":"Canadian Institutes of Health Research; Arthritis Society; ZonMw; Genome Canada","keywords":"Medicine; Arthritis; Population; PsycINFO; CINAHL; EconLit; MEDLINE; Psychological intervention; Juvenile; Family medicine; Physical therapy; Psychiatry; Internal medicine; Environmental health","score_opus":0.10712298763180524,"score_gpt":0.4258787776795187,"score_spread":0.3187557900477135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3023257101","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008317489,0.9848368,0.0000071057016,0.0119174495,0.0004027571,0.002492823,0.000057479952,0.000057854035,0.00014455087],"genre_scores_gemma":[0.00017773977,0.99441534,0.000014478762,0.0045318515,0.00022391864,0.00025304392,0.000043393047,0.00008494684,0.00025527683],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99569666,0.0007027075,0.0019786253,0.00071959756,0.00025094266,0.0006514514],"domain_scores_gemma":[0.9979982,0.00028457798,0.0006730419,0.00069711765,0.000055428554,0.00029164893],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0028583442,0.00048564412,0.0033843494,0.00018669594,0.00016117282,0.00019971718,0.0005700903,0.00015738068,0.0005549977],"category_scores_gemma":[0.00013932442,0.00037108595,0.00064324716,0.0003046338,0.00016694018,0.0006351942,0.0002870856,0.0017765397,0.0009804795],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000047010668,0.000052750314,0.000037694845,0.013528145,0.00013794607,0.00005372822,0.0008611265,7.942863e-7,2.117152e-7,0.000004803102,0.008532217,0.9767436],"study_design_scores_gemma":[0.000637969,0.000102365506,0.00001693283,0.02864609,0.00011791056,0.00006420052,0.00022350681,0.00037983674,0.0000055813002,0.00010592175,0.9694328,0.00026690436],"about_ca_topic_score_codex":0.000121874305,"about_ca_topic_score_gemma":0.000030949686,"teacher_disagreement_score":0.97647667,"about_ca_system_score_codex":0.0006677627,"about_ca_system_score_gemma":0.0045306506,"threshold_uncertainty_score":0.9998741},"labels":[],"label_agreement":null},{"id":"W3023668533","doi":"10.1007/s40273-020-00914-6","title":"Calculating and Interpreting ICERs and Net Benefit","year":2020,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":138,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Cost effectiveness; Ranking (information retrieval); Computer science; Measure (data warehouse); Cost–benefit analysis; Incremental cost-effectiveness ratio; Scale (ratio); Cost-effectiveness analysis; Health economics; Health technology; Risk analysis (engineering); Health administration; Operations research; Data mining; Economics; Health care; Medicine; Machine learning; Mathematics","score_opus":0.30847562941787654,"score_gpt":0.4477828229898945,"score_spread":0.13930719357201798,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3023668533","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9257921,0.0029189703,0.0016139204,0.063408285,0.00034303003,0.00041068054,0.00018582297,0.000086769025,0.005240412],"genre_scores_gemma":[0.9327571,0.00038854883,0.0030057242,0.06327226,0.0004298146,0.000027035729,0.000015336522,0.000044826298,0.00005936573],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9967728,0.000069410155,0.002157202,0.00062831515,0.000027381646,0.0003448925],"domain_scores_gemma":[0.9978372,0.0005507473,0.0010334476,0.0001584597,0.000018472683,0.0004016738],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0031032448,0.0002068832,0.00069911487,0.0001072475,0.00018088656,0.00015711415,0.00015957604,0.00008432631,0.00033286258],"category_scores_gemma":[0.00073837413,0.00029739496,0.0000616201,0.000065118984,0.00007473669,0.0005610343,0.0001544322,0.00021017832,0.00040548263],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018058944,0.000089399095,0.59827924,0.0020167667,0.0006441862,0.00000848905,0.03585195,0.0052531757,0.0004682916,0.30255795,0.03960127,0.015048672],"study_design_scores_gemma":[0.0027873246,0.00012617215,0.011264315,0.00008257509,0.000035112742,0.000025024548,0.002723103,0.7941419,0.00012241195,0.01023542,0.17731708,0.0011395705],"about_ca_topic_score_codex":0.00027347569,"about_ca_topic_score_gemma":0.000017420345,"teacher_disagreement_score":0.7888887,"about_ca_system_score_codex":0.00016930375,"about_ca_system_score_gemma":0.00003251546,"threshold_uncertainty_score":0.99994785},"labels":[],"label_agreement":null},{"id":"W3025743578","doi":"10.1007/s40273-020-00923-5","title":"Economic Evaluation of Cannabinoid Oil for Dravet Syndrome: A Cost-Utility Analysis","year":2020,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Epilepsy research and treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Hospital for Sick Children; University of Ottawa","funders":"","keywords":"Dravet syndrome; Clobazam; Medicine; Cannabinoid; Adjunctive treatment; Psychiatry; Epilepsy; Internal medicine","score_opus":0.08761818601841995,"score_gpt":0.41109201558652475,"score_spread":0.3234738295681048,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3025743578","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99243426,0.00026801543,0.00017554824,0.0035714312,0.0000749613,0.0008027839,0.0005765959,0.0000226312,0.0020737832],"genre_scores_gemma":[0.99821115,0.00015515179,0.0003062539,0.0005088547,0.00008371097,0.0002822299,0.00033302288,0.000016322076,0.00010328188],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99886346,0.00006208369,0.0003805467,0.00032889412,0.00012929068,0.00023574784],"domain_scores_gemma":[0.9990746,0.00007667654,0.00013812064,0.00021263721,0.00015563254,0.00034237892],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006778645,0.00013023471,0.00047306716,0.000121577636,0.000040978153,0.000013581651,0.000096200405,0.000041185114,0.0014714005],"category_scores_gemma":[0.00008045818,0.00013056796,0.00030969302,0.00011417171,0.000050490537,0.00008240257,0.000032116113,0.00008861128,0.00007381595],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0073717483,0.001457482,0.63926893,0.0015310221,0.026785856,0.00004269562,0.0015685571,0.024841929,0.005943169,0.00057850446,0.023336532,0.26727358],"study_design_scores_gemma":[0.011069882,0.00052827736,0.052822776,0.000009151282,0.008513274,0.000012365046,0.00011041826,0.89642066,0.021158032,0.00013457931,0.009004552,0.0002160404],"about_ca_topic_score_codex":0.0001462861,"about_ca_topic_score_gemma":0.00008146913,"teacher_disagreement_score":0.8715787,"about_ca_system_score_codex":0.00038308185,"about_ca_system_score_gemma":0.0005630164,"threshold_uncertainty_score":0.9994414},"labels":[],"label_agreement":null},{"id":"W3036705592","doi":"10.1007/s40273-020-00935-1","title":"Surrogate Endpoints in Health Technology Assessment: An International Review of Methodological Guidelines","year":2020,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":72,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Horizon 2020 Framework Programme; European Commission; US-UK Fulbright Commission; Yale University","keywords":"Health technology; Surrogate endpoint; Medicine; Health care; Pharmacoeconomics; Health economics; Excellence; Documentation; Agency (philosophy); Economic evaluation; Public health; Intensive care medicine; Political science; Nursing","score_opus":0.8580959001230754,"score_gpt":0.6873668140175412,"score_spread":0.17072908610553417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3036705592","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000010171153,0.9345846,0.0008646839,0.05769942,0.0014882105,0.0019381108,0.0021127388,0.00008097849,0.0012210719],"genre_scores_gemma":[0.0000054063876,0.9510233,0.026501026,0.020734068,0.000548124,0.00036256568,0.00066357164,0.00009465223,0.000067295194],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.97861105,0.0020274322,0.01727087,0.0013899216,0.00010675174,0.0005939985],"domain_scores_gemma":[0.9847412,0.0014504214,0.012501635,0.0008234415,0.0001383638,0.000344911],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.039864883,0.00061352155,0.008158743,0.0012168768,0.00006928622,0.000048515125,0.0016050697,0.00042177338,0.0014249997],"category_scores_gemma":[0.006042071,0.00073730916,0.000633447,0.0005160672,0.00012151149,0.0006041414,0.00031972487,0.0009153476,0.0010007502],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000012510048,0.00032636884,0.000662645,0.21230409,0.0006837853,0.00001214538,0.00012906567,0.000049061167,2.2811975e-7,0.10635411,0.02456765,0.65489835],"study_design_scores_gemma":[0.00049034425,0.00007106633,0.000014822942,0.018985884,0.00004231439,0.000027001453,0.000061767096,0.0012528927,2.5973864e-7,0.0025685448,0.9759924,0.00049270823],"about_ca_topic_score_codex":0.00017423282,"about_ca_topic_score_gemma":0.000025796355,"teacher_disagreement_score":0.9514247,"about_ca_system_score_codex":0.0019456301,"about_ca_system_score_gemma":0.0013907535,"threshold_uncertainty_score":0.9997771},"labels":[],"label_agreement":null},{"id":"W3044208311","doi":"10.1007/s40273-020-00945-z","title":"Cost-Effectiveness of Cannabidiol Adjunct Therapy versus Usual Care for the Treatment of Seizures in Lennox-Gastaut Syndrome","year":2020,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Epilepsy research and treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Economics","funders":"Genentech","keywords":"Medicine; Health economics; Lennox–Gastaut syndrome; Quality-adjusted life year; Cost effectiveness; Health care; Epilepsy; Pediatrics; Public health; Psychiatry; Economics","score_opus":0.13521192117446132,"score_gpt":0.4168105716841582,"score_spread":0.2815986505096969,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3044208311","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98979753,0.0058500604,0.000040113893,0.0005507841,0.00015514316,0.003138151,0.00033008115,0.000010020419,0.0001281332],"genre_scores_gemma":[0.99502087,0.0040286584,0.00004942009,0.000079204154,0.00006870532,0.00064094504,0.00007362978,0.00002367075,0.000014910679],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999154,0.0000753761,0.00024457302,0.0002173399,0.000079652214,0.00022907543],"domain_scores_gemma":[0.9989829,0.00056145317,0.00007962507,0.00016541532,0.00007859972,0.00013202192],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012454031,0.00015830905,0.0004644621,0.000055995635,0.000032848868,0.000005249556,0.00009800409,0.00003665363,0.000056874673],"category_scores_gemma":[0.000021104388,0.00010652271,0.00018417611,0.00007950172,0.000073596806,0.00004144154,0.00001498611,0.00006828263,0.000004587846],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16818127,0.0055963686,0.38078985,0.0034959973,0.009528894,0.00047303506,0.020693347,0.009839874,0.034217216,0.0005028356,0.0008759835,0.36580533],"study_design_scores_gemma":[0.14765167,0.03181334,0.16312231,0.00015601807,0.0007297459,0.000040052724,0.0039293016,0.006770218,0.60493475,0.00003792453,0.04037941,0.00043525067],"about_ca_topic_score_codex":0.00043687728,"about_ca_topic_score_gemma":0.00009025238,"teacher_disagreement_score":0.5707176,"about_ca_system_score_codex":0.00032466027,"about_ca_system_score_gemma":0.0002538778,"threshold_uncertainty_score":0.434387},"labels":[],"label_agreement":null},{"id":"W3047292418","doi":"10.1007/s40273-020-00947-x","title":"Systematic Review and Meta-Analysis of Community- and Choice-Based Health State Utility Values for Lung Cancer","year":2020,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Cancer Institute; Erasmus Medisch Centrum","keywords":"Meta-analysis; Medicine; Lung cancer; Subgroup analysis; Study heterogeneity; Confidence interval; Psychological intervention; MEDLINE; Systematic review; Oncology; Internal medicine","score_opus":0.6761268977008804,"score_gpt":0.5850854871264585,"score_spread":0.09104141057442194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3047292418","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000009572827,0.95624125,0.0014798312,0.010409201,0.00013666511,0.008233308,0.023421196,0.000038507882,0.00003044715],"genre_scores_gemma":[0.000017042588,0.96809167,0.00078604976,0.027846381,0.00005415618,0.0024817106,0.00054158113,0.000093802395,0.000087616514],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9844135,0.0028462994,0.011348631,0.0008348865,0.000071381466,0.00048532523],"domain_scores_gemma":[0.97810465,0.0069335815,0.013413937,0.0009915566,0.00010800889,0.00044826014],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.028447295,0.000722818,0.023885123,0.00070717576,0.00032516546,0.000108481865,0.00062051154,0.00017035204,0.0003116329],"category_scores_gemma":[0.0016159561,0.0007633925,0.0022882987,0.00043778692,0.00014574509,0.0002926553,0.0001559368,0.0005564915,0.000017741713],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000002768842,0.00004609928,0.000029300028,0.89761096,0.09711621,6.493183e-8,0.00030898702,0.000032625263,2.0193005e-9,0.00033893035,0.0035757157,0.0009383241],"study_design_scores_gemma":[0.0006053369,0.00006389301,0.000009246148,0.0156232435,0.5871576,0.0000018837757,0.000066210385,0.018810851,1.0762153e-7,0.00027881813,0.37645414,0.0009286705],"about_ca_topic_score_codex":0.0017973054,"about_ca_topic_score_gemma":0.00029009665,"teacher_disagreement_score":0.88198775,"about_ca_system_score_codex":0.00077043707,"about_ca_system_score_gemma":0.0007037556,"threshold_uncertainty_score":0.9994817},"labels":[],"label_agreement":null},{"id":"W3079151182","doi":"10.1007/s40273-020-00950-2","title":"Correction to: Calculating and Interpreting ICERs and Net Benefit","year":2020,"lang":"en","type":"erratum","venue":"PharmacoEconomics","topic":"demographic modeling and climate adaptation","field":"Decision Sciences","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Quality of Life Research; Health economics; Health administration; Public health; Computer science; Information retrieval; Medicine; Pathology","score_opus":0.0703299118165864,"score_gpt":0.3858785051849443,"score_spread":0.31554859336835794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3079151182","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3914087,0.006165288,0.029147372,0.016254172,0.3568448,0.0018928467,0.0004966073,0.00063843635,0.19715174],"genre_scores_gemma":[0.86983776,0.0056356275,0.0043235146,0.019649599,0.005390825,0.00008514503,0.00043248956,0.0002579627,0.09438706],"study_design_codex":"not_applicable","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9978214,0.00006683969,0.0007610725,0.0008441606,0.00026067175,0.00024589215],"domain_scores_gemma":[0.9982408,0.00071547163,0.00044091194,0.00020028441,0.000111993795,0.00029050658],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011109895,0.00026698282,0.00045325593,0.00030336608,0.00020365337,0.0006418027,0.00028366342,0.0001559679,0.00010557466],"category_scores_gemma":[0.0008057289,0.00026607525,0.000092390794,0.00021911217,0.000047701258,0.0002545581,0.00027049895,0.00063744263,0.00007575616],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003923367,0.0000044935155,0.00072161545,0.000019504947,0.000035882655,0.0000018956916,0.0012398937,0.0035231875,0.00005784878,0.000058361424,0.82595795,0.16834013],"study_design_scores_gemma":[0.00015961198,0.00003531264,0.00022202649,0.000073394716,0.000046732785,0.000009845966,0.00065585074,0.6856772,0.000010200863,0.0009195553,0.31194028,0.00025001992],"about_ca_topic_score_codex":0.00016826372,"about_ca_topic_score_gemma":0.00012848296,"teacher_disagreement_score":0.68215394,"about_ca_system_score_codex":0.00005880615,"about_ca_system_score_gemma":0.000056998524,"threshold_uncertainty_score":0.99997914},"labels":[],"label_agreement":null},{"id":"W3084165494","doi":"10.1007/s40273-020-00957-9","title":"The SF-6Dv2: How Does the New Classification System Impact the Distribution of Responses Compared with the Original SF-6D?","year":2020,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; Vancouver Coastal Health","funders":"","keywords":"Quality of Life Research; Health economics; Public health; Health administration; Statistics; Medicine; Mathematics; Nursing","score_opus":0.30514779123155,"score_gpt":0.42792486373214983,"score_spread":0.12277707250059983,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3084165494","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4786311,0.0014768249,0.004085725,0.5119911,0.0006460157,0.0014732663,0.0011155898,0.0000674302,0.00051293825],"genre_scores_gemma":[0.99233603,0.00029009153,0.000069421665,0.0057697734,0.000937401,0.00014217426,0.0000724332,0.00004034384,0.00034232892],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959657,0.00086321466,0.0020586275,0.0005076333,0.00012967175,0.0004751069],"domain_scores_gemma":[0.9921244,0.0036190748,0.0030558368,0.0008731474,0.00010659274,0.00022096014],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009439431,0.0003094907,0.000710874,0.00004942239,0.0010468756,0.00045535096,0.0012206582,0.00008254818,0.000086154396],"category_scores_gemma":[0.0007104321,0.00015067866,0.00023970555,0.00026400122,0.00038502304,0.00043968702,0.00009150475,0.00040844447,0.00037969652],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019629097,0.00009640418,0.038302444,0.00039212854,0.0012325014,0.0000014589922,0.008662769,0.008565841,0.0001616898,0.338618,0.6006761,0.0013277526],"study_design_scores_gemma":[0.0018775092,0.00015832142,0.0316188,0.000051854495,0.00011558284,0.000026255631,0.015862219,0.16078298,0.00027326355,0.0008676397,0.7878718,0.00049380545],"about_ca_topic_score_codex":0.00074193,"about_ca_topic_score_gemma":0.00018941944,"teacher_disagreement_score":0.5137049,"about_ca_system_score_codex":0.00079090026,"about_ca_system_score_gemma":0.0005956731,"threshold_uncertainty_score":0.8051827},"labels":[],"label_agreement":null},{"id":"W3086476996","doi":"10.1007/s40273-020-00959-7","title":"On Pandemic Preparedness: How Well is the Modeling Community Prepared for COVID-19?","year":2020,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"COVID-19 epidemiological studies","field":"Mathematics","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Social distance; Public health; Pandemic; Preparedness; Socioeconomic status; Context (archaeology); Economic impact analysis; Social inequality; Social determinants of health; Psychological intervention; Epidemiology; Economic growth; Environmental health; Health economics; Development economics; Medicine; Inequality; Political science; Population; Geography; Coronavirus disease 2019 (COVID-19); Economics; Infectious disease (medical specialty); Nursing; Disease","score_opus":0.5614062400663362,"score_gpt":0.49535503699358047,"score_spread":0.06605120307275575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3086476996","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.80376923,0.00023532902,0.09925852,0.0916238,0.0003169433,0.002582053,0.0004887424,0.0006515685,0.0010738362],"genre_scores_gemma":[0.8904891,0.00026455135,0.0013609946,0.10711802,0.00024958295,0.00036857845,0.000018451155,0.000044778906,0.000085965476],"study_design_codex":"not_applicable","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99804646,0.000456997,0.0005267542,0.00045524194,0.000096119016,0.00041841436],"domain_scores_gemma":[0.98644185,0.012343965,0.000303333,0.0005363843,0.000061390405,0.00031304747],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0018459116,0.00031883747,0.0005830311,0.000025950007,0.000787035,0.000069263755,0.00085879106,0.00010510803,0.0002123206],"category_scores_gemma":[0.0085242335,0.00023396926,0.00029857212,0.0000780904,0.000120406614,0.00011430842,0.00043099964,0.00053057977,0.000050540384],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018768,0.00040255097,0.0020454389,0.0013907334,0.00089100754,0.0000026181278,0.035767503,0.091688745,0.0005016591,0.013434206,0.8506749,0.001323839],"study_design_scores_gemma":[0.0015942393,0.00014569826,0.0000043141104,0.0000123974005,0.0001703451,0.000001611147,0.0018037052,0.6883019,0.00021608967,0.18465926,0.122723505,0.0003669056],"about_ca_topic_score_codex":0.00012404639,"about_ca_topic_score_gemma":0.000058743793,"teacher_disagreement_score":0.7279514,"about_ca_system_score_codex":0.0004606923,"about_ca_system_score_gemma":0.00012279133,"threshold_uncertainty_score":0.9998274},"labels":[],"label_agreement":null},{"id":"W3087414342","doi":"10.1007/s40273-020-00962-y","title":"Cost Effectiveness of Teplizumab for Prevention of Type 1 Diabetes Among Different Target Patient Groups","year":2020,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Diabetes and associated disorders","field":"Biochemistry, Genetics and Molecular Biology","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Human leukocyte antigen; Reimbursement; Medicine; Allele; Cost effectiveness; Health economics; Immunology; Public health; Health care; Genetics; Biology; Antigen; Economics; Risk analysis (engineering)","score_opus":0.015570843668834246,"score_gpt":0.27407521792443945,"score_spread":0.2585043742556052,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087414342","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998284,0.0003574997,0.0004819428,0.00002416025,0.00012822887,0.00050359167,0.00013709506,0.0000049205396,0.000078587414],"genre_scores_gemma":[0.99926746,0.00009724924,0.00009653931,0.000085812346,0.000041119012,0.000053146796,0.0003363368,0.000017955228,0.0000044044114],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9994024,0.00004631534,0.00020711416,0.00017868055,0.000029660754,0.00013582209],"domain_scores_gemma":[0.9995985,0.00003324233,0.00017897174,0.00007722646,0.0000581136,0.000053914035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007730708,0.00009709162,0.0002047533,0.000014243611,0.000017730265,0.000005082931,0.00009300995,0.000053541524,0.000014915301],"category_scores_gemma":[0.000039872288,0.00010216765,0.00012496965,0.000028620247,0.00003414015,0.0000047806134,0.00005307029,0.000031490228,8.9827387e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00053630635,0.00030396951,0.090267375,0.00047675922,0.0004478946,5.9689455e-8,0.000070934715,0.0023155382,0.89361286,0.0000717667,0.0008085037,0.01108806],"study_design_scores_gemma":[0.0014645399,0.000698872,0.007106117,0.000019172601,0.000056373094,1.864431e-8,0.000043826003,0.0029793663,0.9857883,0.00016517223,0.0015485818,0.00012965575],"about_ca_topic_score_codex":0.0000018896611,"about_ca_topic_score_gemma":7.96091e-7,"teacher_disagreement_score":0.09217547,"about_ca_system_score_codex":0.000012922323,"about_ca_system_score_gemma":0.000018781206,"threshold_uncertainty_score":0.4166276},"labels":[],"label_agreement":null},{"id":"W3095966269","doi":"10.1007/s40273-020-00974-8","title":"Evaluating New Zealanders’ Values for Drug Coverage Decision Making: Trade-Offs between Treatments for Rare and Common Conditions","year":2020,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Advancing Health Outcomes; University of British Columbia","funders":"","keywords":"Payment; Cash; Equity (law); Public health; Health economics; Actuarial science; Ranking (information retrieval); Quality of life (healthcare); Medicine; Business; Quality (philosophy); Public economics; Finance; Economics; Nursing","score_opus":0.4880991223190696,"score_gpt":0.5308752155511116,"score_spread":0.04277609323204201,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095966269","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88264334,0.001997731,0.042746186,0.05968233,0.00079075416,0.004354146,0.0070982217,0.00014069714,0.0005466129],"genre_scores_gemma":[0.9562387,0.00025920803,0.017024426,0.023448423,0.0015423532,0.0004131819,0.00066147477,0.00011099255,0.00030124714],"study_design_codex":"not_applicable","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99538934,0.00013954239,0.0030242526,0.00086970825,0.0000635114,0.0005136474],"domain_scores_gemma":[0.9931022,0.0044230195,0.0016908349,0.0002836753,0.000033668184,0.00046661365],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0039523323,0.00034628742,0.0012715528,0.00017689721,0.00049186026,0.00020352207,0.00030748348,0.00013360573,0.00030072],"category_scores_gemma":[0.0010779446,0.00046511885,0.0002619982,0.000085476306,0.000053403222,0.00066543446,0.000068142705,0.00015900662,0.00022124664],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00084400765,0.00026878557,0.16902445,0.0014898472,0.0019697323,0.000002014278,0.016693495,0.005997634,0.00007723841,0.030351182,0.7350399,0.03824172],"study_design_scores_gemma":[0.028049259,0.0010372746,0.036795523,0.00027648217,0.00063401327,0.000012357439,0.0017629863,0.38927042,0.00030886734,0.31618762,0.2234833,0.0021818941],"about_ca_topic_score_codex":0.00009055678,"about_ca_topic_score_gemma":0.000023557364,"teacher_disagreement_score":0.51155657,"about_ca_system_score_codex":0.0004854187,"about_ca_system_score_gemma":0.00019506583,"threshold_uncertainty_score":0.99978006},"labels":[],"label_agreement":null},{"id":"W3108709596","doi":"10.1007/s40273-020-00983-7","title":"Probabilistic One-Way Sensitivity Analysis with Multiple Comparators: The Conditional Net Benefit Frontier","year":2020,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Economics; University of Alberta","funders":"Medical Research Council","keywords":"Probabilistic logic; Sensitivity (control systems); Econometrics; Conditional probability; Economic model; Probabilistic analysis of algorithms; Efficient frontier; Computer science; Economics; Mathematics; Statistics; Artificial intelligence; Microeconomics","score_opus":0.2836535530466422,"score_gpt":0.4000692221858455,"score_spread":0.11641566913920331,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3108709596","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87440056,0.00081748376,0.031674333,0.08550576,0.00040479683,0.0015529981,0.0037145235,0.00015499,0.0017745724],"genre_scores_gemma":[0.9582844,0.00005166619,0.0018190589,0.038443886,0.00073298556,0.0001446867,0.00038148378,0.00004742769,0.000094448464],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9955414,0.00030122433,0.0026659702,0.00088352914,0.00010190803,0.0005059897],"domain_scores_gemma":[0.9956375,0.0015349799,0.0018125966,0.0005119842,0.000097922646,0.0004050304],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0050556418,0.00033157077,0.0013676116,0.00020376906,0.00036635684,0.00020116464,0.00036307363,0.00010078,0.0012724542],"category_scores_gemma":[0.00059670187,0.00034693765,0.00027730776,0.00039975505,0.00020179637,0.0006020271,0.00008949897,0.00034346554,0.002338441],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033801567,0.00041537412,0.43383968,0.00033678507,0.005085433,0.0000073083897,0.0041090488,0.385054,0.0000326326,0.09700251,0.07358769,0.00019151573],"study_design_scores_gemma":[0.0023796808,0.00009308464,0.08797009,0.000013314294,0.00037684772,0.0000066335174,0.0005769436,0.8159772,0.00006286864,0.005201873,0.086523294,0.00081813306],"about_ca_topic_score_codex":0.00057478197,"about_ca_topic_score_gemma":0.00055651227,"teacher_disagreement_score":0.43092322,"about_ca_system_score_codex":0.0004647764,"about_ca_system_score_gemma":0.00013164575,"threshold_uncertainty_score":0.99989825},"labels":[],"label_agreement":null},{"id":"W3123759598","doi":"10.1007/s40273-020-00990-8","title":"NICE’s Discounting Review: Clear Thinking on Rational Revision Meets Obstacle of Industrial Interests","year":2021,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Economics; University of Alberta","funders":"","keywords":"Nice; Quality of Life Research; Discounting; Health economics; Obstacle; Health administration; Economics; Positive economics; Public health; Public economics; Political science; Medicine; Law; Computer science; Nursing; Finance","score_opus":0.6158531719708071,"score_gpt":0.5486504033419459,"score_spread":0.06720276862886121,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3123759598","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010716442,0.9860837,0.00007650658,0.0054084533,0.0028358211,0.0020197802,0.0011752279,0.000050673047,0.0022426918],"genre_scores_gemma":[0.000053928936,0.98747534,0.0006385723,0.008603366,0.001875676,0.0001334118,0.0008022804,0.00015683184,0.00026060923],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9855192,0.0010715331,0.011299074,0.0013372521,0.00018543647,0.00058754516],"domain_scores_gemma":[0.98461956,0.0027643174,0.011217943,0.001022149,0.00012129727,0.000254744],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.019207023,0.00071658415,0.006262298,0.0005789939,0.00024008048,0.00018936099,0.0010219471,0.0004992918,0.0021296667],"category_scores_gemma":[0.004340601,0.0008713787,0.0011829595,0.00032007185,0.00008961332,0.00070161954,0.00033127677,0.0010759566,0.0023029817],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004029875,0.00042334627,0.00018382803,0.09665402,0.0014604361,0.000010327626,0.000594965,0.00016892041,2.163712e-7,0.10882806,0.4256071,0.3660285],"study_design_scores_gemma":[0.00056572165,0.000050369723,0.0000015160716,0.051135406,0.00020417225,0.000015596333,0.00005067313,0.0002606078,0.0000012840943,0.00041846596,0.9466331,0.00066305965],"about_ca_topic_score_codex":0.00009798459,"about_ca_topic_score_gemma":0.0000128240745,"teacher_disagreement_score":0.521026,"about_ca_system_score_codex":0.0015578839,"about_ca_system_score_gemma":0.0009024446,"threshold_uncertainty_score":0.9993737},"labels":[],"label_agreement":null},{"id":"W3124464435","doi":"10.1007/s40273-020-00995-3","title":"Early-Phase Clinical Trials and Reimbursement Submissions to the Pan-Canadian Oncology Drug Review","year":2021,"lang":"en","type":"letter","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia, Okanagan Campus; University of British Columbia; Canadian Centre for Applied Research in Cancer Control; Simon Fraser University","funders":"Canadian Institutes of Health Research; Michael Smith Health Research BC","keywords":"Reimbursement; Quality of Life Research; Health economics; Medicine; Clinical trial; Public health; Health administration; Drug approval; Family medicine; Clinical Oncology; Oncology; Alternative medicine; Drug; Drug development; Internal medicine; Pharmacology; Health care; Nursing; Political science; Cancer; Pathology","score_opus":0.7247299571339836,"score_gpt":0.6212900794390437,"score_spread":0.1034398776949399,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3124464435","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0018799019,0.0687925,0.0001186275,0.91192126,0.005789,0.0039943717,0.0035259968,0.00004335912,0.0039349673],"genre_scores_gemma":[0.00034237653,0.07276804,0.000651034,0.9099525,0.010041857,0.00080655364,0.0006867245,0.0001327079,0.004618182],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.97684515,0.00594296,0.01413232,0.0017862573,0.0001231435,0.0011701982],"domain_scores_gemma":[0.9818091,0.00891601,0.0063379277,0.0015652073,0.00014862006,0.0012231786],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaresearch","insufficient_payload"],"category_scores_codex":[0.10338887,0.0006722907,0.00540402,0.00054817327,0.00051483617,0.0003179203,0.0011235472,0.00082433876,0.004811318],"category_scores_gemma":[0.012865887,0.00070521276,0.00083824806,0.00021750905,0.00015896864,0.00029747965,0.00029299248,0.0026304526,0.006973039],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000012353979,0.00006716863,0.00031967217,0.00084586616,0.00045962725,0.000035545705,0.00032998263,0.0000049170326,2.0820131e-7,0.0008488874,0.9899408,0.0071349377],"study_design_scores_gemma":[0.0015346856,0.00009302374,0.00016360512,0.00063130615,0.00022469806,0.00002252606,0.000104199185,0.00030870823,0.000001257634,0.000707593,0.99548286,0.0007255579],"about_ca_topic_score_codex":0.016515052,"about_ca_topic_score_gemma":0.0061936215,"teacher_disagreement_score":0.090522975,"about_ca_system_score_codex":0.0021368028,"about_ca_system_score_gemma":0.0024977634,"threshold_uncertainty_score":0.9996705},"labels":[],"label_agreement":null},{"id":"W3128103964","doi":"10.1007/s40273-020-00988-2","title":"Modifying NICE’s Approach to Equity Weighting","year":2021,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Economics; University of Alberta","funders":"","keywords":"Nice; Equity (law); Excellence; Population; Health economics; Health technology; Population health; Actuarial science; Health care; Weighting; Economics; Medicine; Public economics; Risk analysis (engineering); Computer science; Political science; Economic growth; Law","score_opus":0.5740007790783229,"score_gpt":0.5192792688717156,"score_spread":0.054721510206607316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3128103964","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4540982,0.0051525016,0.08527492,0.056088947,0.0042535597,0.0015624401,0.00084477203,0.00039827876,0.39232638],"genre_scores_gemma":[0.85716265,0.000339432,0.048477087,0.08849735,0.0019501565,0.0002946244,0.00014948154,0.00014474035,0.0029844537],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9938245,0.0002422913,0.003874294,0.00114954,0.00008354131,0.00082584796],"domain_scores_gemma":[0.99671024,0.00055691565,0.0013314786,0.0007445388,0.00009515824,0.00056167174],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.010819739,0.0003208459,0.0011654198,0.0003015459,0.00034506313,0.00028778255,0.0005766279,0.00014981383,0.001001853],"category_scores_gemma":[0.0013992257,0.00048321724,0.0002386055,0.0002728571,0.000042048665,0.0007612113,0.00045926563,0.00034089008,0.0073912796],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000065473854,0.000866827,0.024701769,0.0013332488,0.0006084851,0.000012632518,0.0070986217,0.017671831,0.00078868825,0.7418448,0.19947529,0.0055323453],"study_design_scores_gemma":[0.0032295894,0.000050935778,0.0034431212,0.00008752639,0.000045641085,0.000075328986,0.0024479898,0.19781464,0.0016802085,0.03566419,0.7533986,0.0020622401],"about_ca_topic_score_codex":0.0002398484,"about_ca_topic_score_gemma":0.00002857847,"teacher_disagreement_score":0.7061806,"about_ca_system_score_codex":0.0011634197,"about_ca_system_score_gemma":0.0003033669,"threshold_uncertainty_score":0.99991137},"labels":[],"label_agreement":null},{"id":"W3135068797","doi":"10.1007/s40273-021-01007-8","title":"The Continued Need for Transparent Evidence on the Cost Effectiveness of Drugs for Rare Diseases","year":2021,"lang":"en","type":"letter","venue":"PharmacoEconomics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Quality of Life Research; Health economics; Health administration; Public health; Pharmacoeconomics; Medicine; Intensive care medicine; Nursing","score_opus":0.16470911239705432,"score_gpt":0.3657572656773199,"score_spread":0.2010481532802656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135068797","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0098531395,0.020099068,0.0027390402,0.9080444,0.0064672083,0.010254539,0.039989274,0.000066689885,0.0024866336],"genre_scores_gemma":[0.22462004,0.01356928,0.000094823066,0.7420322,0.006893497,0.0092712045,0.0016142578,0.000420503,0.0014841864],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99683625,0.00015956322,0.0013394741,0.0008477237,0.00004548066,0.0007715396],"domain_scores_gemma":[0.98317647,0.014715461,0.0010735414,0.00077411695,0.00012397909,0.0001364178],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017973104,0.0005356057,0.0012844125,0.0001350044,0.00041320518,0.00028865546,0.001231831,0.00031485068,0.00017197529],"category_scores_gemma":[0.00053448544,0.00044671635,0.0010871025,0.00010176615,0.00026858872,0.00016893054,0.000094494724,0.0007677406,0.000066996545],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011518406,0.000111022295,0.00026598736,0.0016039275,0.0011272378,0.0000028170057,0.00015857191,0.000501186,0.00005799548,0.06546263,0.92696804,0.0025887713],"study_design_scores_gemma":[0.0020139797,0.00008858404,0.00010310802,0.00020378122,0.00017780958,0.0000011697018,0.000027586695,0.006248415,0.0024761274,0.01695476,0.9711578,0.00054691476],"about_ca_topic_score_codex":0.000039247065,"about_ca_topic_score_gemma":0.0000053718177,"teacher_disagreement_score":0.2147669,"about_ca_system_score_codex":0.0003866493,"about_ca_system_score_gemma":0.0001894502,"threshold_uncertainty_score":0.9997985},"labels":[],"label_agreement":null},{"id":"W3143019137","doi":"10.1007/s40273-021-01022-9","title":"Cost-Effectiveness Analysis of Afatinib, Erlotinib, and Gefitinib as First-Line Treatments for EGFR Mutation-Positive Non-Small-Cell Lung Cancer in Ontario, Canada","year":2021,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Waterloo","funders":"","keywords":"Afatinib; Erlotinib; Gefitinib; Medicine; Lung cancer; Cost effectiveness; Internal medicine; Oncology; Epidermal growth factor receptor; Cancer registry; Cancer; Risk analysis (engineering)","score_opus":0.025514685803821453,"score_gpt":0.36743199878691274,"score_spread":0.3419173129830913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3143019137","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99450743,0.00066953525,0.00024441793,0.00035809964,0.00021405703,0.0017422829,0.0012196032,0.0000069654106,0.001037606],"genre_scores_gemma":[0.9958306,0.00032733957,0.00044288815,0.00046761628,0.000035297584,0.00094114,0.0010080027,0.000025863183,0.0009212574],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989262,0.000030323734,0.00037120123,0.00037734953,0.000069948146,0.00022493348],"domain_scores_gemma":[0.9989504,0.00040285138,0.00018012094,0.00013441854,0.00019013387,0.00014206198],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008545346,0.0001961259,0.00056129246,0.00015022545,0.00007878015,0.000016577742,0.00004148291,0.000046569035,0.0004195982],"category_scores_gemma":[0.00001523661,0.00020177667,0.00012303439,0.00022675945,0.00002324823,0.00007826841,0.000022642434,0.00009362863,6.0162614e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009875201,0.0009461915,0.926221,0.00041467274,0.013412386,0.00017167728,0.0038845702,0.04401021,0.0014092554,0.000059593447,0.00022866295,0.00825422],"study_design_scores_gemma":[0.025166927,0.00028103383,0.82908046,0.00022098796,0.023113437,0.000018089848,0.0007068783,0.042917844,0.076682925,0.00003194599,0.0013658947,0.00041355556],"about_ca_topic_score_codex":0.8534752,"about_ca_topic_score_gemma":0.9741099,"teacher_disagreement_score":0.12063469,"about_ca_system_score_codex":0.0020320376,"about_ca_system_score_gemma":0.002681793,"threshold_uncertainty_score":0.8228214},"labels":[],"label_agreement":null},{"id":"W3147761275","doi":"","title":"A cost comparison of oral tegafur plus uracil/folinic acid and parenteral fluorouracil for colorectal cancer in Canada.","year":2003,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Folinic acid; Fluorouracil; Quality of Life Research; Medicine; Tegafur; Colorectal cancer; Uracil; Internal medicine; Cancer; Health administration; Gastroenterology; Public health; Chemistry; Nursing; Biochemistry","score_opus":0.06443878898341866,"score_gpt":0.3865505635148839,"score_spread":0.3221117745314653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3147761275","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99408984,0.003409417,0.000011484565,0.0003832685,0.00033456154,0.00082367286,0.00035082825,0.000007397308,0.0005895427],"genre_scores_gemma":[0.9984119,0.00066406094,0.0002132019,0.00026956605,0.00003301288,0.00030950145,0.000019046178,0.000015685355,0.000064036794],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990418,0.000021428546,0.00038466242,0.0002262183,0.00006170367,0.00026419453],"domain_scores_gemma":[0.99955803,0.00008377079,0.00012784958,0.00006412715,0.000053314718,0.00011291758],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008901268,0.00016481768,0.0005863511,0.00004871085,0.000050242223,0.000008246628,0.000043787033,0.000029198003,0.00012594678],"category_scores_gemma":[0.000026389964,0.00015226123,0.000055663488,0.000053435422,0.00004362539,0.000057896024,0.000023382872,0.000104715604,7.6850097e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032382624,0.00020966945,0.9383091,0.00016925429,0.0004953097,0.000011834087,0.0016044326,0.00061219867,0.001328,0.00008426652,0.0037143682,0.050223347],"study_design_scores_gemma":[0.083603874,0.0028734524,0.43958277,0.00032764522,0.0018669822,0.00011545329,0.0111508565,0.10446149,0.19492657,0.00018797762,0.15919137,0.0017115466],"about_ca_topic_score_codex":0.2012974,"about_ca_topic_score_gemma":0.80153894,"teacher_disagreement_score":0.60024154,"about_ca_system_score_codex":0.0013440935,"about_ca_system_score_gemma":0.0012490917,"threshold_uncertainty_score":0.80402124},"labels":[],"label_agreement":null},{"id":"W3157441924","doi":"10.1007/s40273-021-01018-5","title":"Health Economists on Involving Patients in Modeling: Potential Benefits, Harms, and Variables of Interest","year":2021,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia","funders":"Canadian Institutes of Health Research; Michael Smith Health Research BC","keywords":"Health economics; Health administration; Process (computing); Qualitative research; Actuarial science; Management science; Public health; Psychology; Medicine; Computer science; Economics; Nursing; Sociology; Social science","score_opus":0.389916815006682,"score_gpt":0.4312852943937915,"score_spread":0.04136847938710947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3157441924","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9810751,0.004354785,0.0004476765,0.011335352,0.0008999206,0.00042868243,0.0006889109,0.00002489307,0.0007446593],"genre_scores_gemma":[0.9842017,0.003677927,0.0013031717,0.010341599,0.00018960238,0.00003399372,0.0001427096,0.000049795755,0.000059498816],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9943966,0.00022123946,0.004102837,0.00077231956,0.000036926478,0.00047007293],"domain_scores_gemma":[0.9972294,0.00034896407,0.0016950815,0.00038988827,0.00007195727,0.0002646891],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004729913,0.00026049546,0.0012389015,0.00039562318,0.00011402614,0.0000893037,0.00024457488,0.00012102913,0.00027133888],"category_scores_gemma":[0.000569826,0.00038591938,0.00010883719,0.00010812032,0.000047961305,0.00053284736,0.00014605653,0.0002620281,0.0001718502],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002479914,0.0016954979,0.3191803,0.0022650904,0.00041030944,0.000006086336,0.003991022,0.17160301,0.00004875052,0.48272985,0.012679778,0.0051423027],"study_design_scores_gemma":[0.009976465,0.00028378185,0.04599983,0.00060340273,0.000023182216,0.0000139763,0.0013356837,0.8950241,0.0003518172,0.03426602,0.010680308,0.0014414113],"about_ca_topic_score_codex":0.0014016837,"about_ca_topic_score_gemma":0.0007329622,"teacher_disagreement_score":0.7234211,"about_ca_system_score_codex":0.00075045286,"about_ca_system_score_gemma":0.00030004047,"threshold_uncertainty_score":0.9998593},"labels":[],"label_agreement":null},{"id":"W3160261501","doi":"10.1007/s40273-021-01028-3","title":"Cost Effectiveness of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Pre-/Perimenopausal, HR+ and HER2− Advanced Breast Cancer: A Canadian Healthcare Perspective","year":2021,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Breast cancer; Quality-adjusted life year; Tamoxifen; Discontinuation; Aromatase inhibitor; Cost effectiveness; Internal medicine; Oncology; Cost-effectiveness analysis; Health economics; Gynecology; Hazard ratio; Cancer; Public health; Confidence interval","score_opus":0.02113951258208011,"score_gpt":0.3660010550140271,"score_spread":0.34486154243194694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3160261501","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.985506,0.007833676,0.000023978118,0.0028661254,0.00031647008,0.0011343686,0.002183878,0.00003245006,0.00010303243],"genre_scores_gemma":[0.99719346,0.00087345234,0.00041493238,0.00089893566,0.00015305857,0.00028471352,0.00009669834,0.00006115026,0.00002360473],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9983183,0.00014848389,0.0003828201,0.0005741424,0.00009467251,0.00048158504],"domain_scores_gemma":[0.99872655,0.00012848261,0.0001482064,0.00027068894,0.00022771822,0.0004983356],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020621004,0.0002823113,0.0006922943,0.00019607255,0.00007347887,0.000020470514,0.000091407834,0.00008893911,0.000099506746],"category_scores_gemma":[0.00002214965,0.00032274233,0.000060407183,0.00022217054,0.00017033328,0.00028290454,0.00006644679,0.0003329926,0.000005116569],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03937608,0.0013268515,0.2498177,0.0058398275,0.001793074,0.0015357491,0.01951557,0.008115441,0.5279966,0.0021092235,0.000185286,0.14238858],"study_design_scores_gemma":[0.06347408,0.000914296,0.48986787,0.0036610137,0.0004499546,0.0031246904,0.011343097,0.0036004605,0.41292453,0.0009161267,0.007833419,0.0018904618],"about_ca_topic_score_codex":0.07516361,"about_ca_topic_score_gemma":0.08030609,"teacher_disagreement_score":0.24005017,"about_ca_system_score_codex":0.0027301337,"about_ca_system_score_gemma":0.002630457,"threshold_uncertainty_score":0.99992245},"labels":[],"label_agreement":null},{"id":"W3160294153","doi":"10.1007/s40273-021-01031-8","title":"What are the Economic Costs to Society Attributable to Alcohol Use? A Systematic Review and Modelling Study","year":2021,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Substance Abuse Treatment and Outcomes","field":"Medicine","cited_by":160,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; Institute for Work & Health; Centre for Addiction and Mental Health","funders":"Technische Universität Dresden","keywords":"Health economics; Quality of Life Research; Health administration; Public health; Environmental health; Public economics; Systematic review; Pharmacoeconomics; Economics; MEDLINE; Medicine; Business; Political science; Intensive care medicine; Nursing","score_opus":0.16284389797184504,"score_gpt":0.41539621465990023,"score_spread":0.2525523166880552,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3160294153","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013530236,0.98373336,0.000020691534,0.0006294076,0.0005564244,0.013588056,0.000054981014,0.00005133069,0.000012717325],"genre_scores_gemma":[0.00008604225,0.98926747,0.00014637344,0.0071173306,0.0001891092,0.0019165205,0.00008356696,0.00011592743,0.0010776506],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9971956,0.00020660677,0.0012364556,0.0008070272,0.000112017166,0.00044230107],"domain_scores_gemma":[0.9974899,0.00066237914,0.0005158259,0.0008982538,0.00007530267,0.00035831574],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008259922,0.00068668945,0.0053737527,0.00008995061,0.00017271689,0.000400393,0.0003101348,0.00011027309,0.0000899003],"category_scores_gemma":[0.000043140353,0.00046100633,0.0008429236,0.0001852657,0.000020485519,0.0003957267,0.00021561753,0.00034826325,0.0004670271],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000292413,0.00030559633,0.00065815187,0.93322355,0.012441932,0.000104609666,0.0023636944,0.0005885701,1.2831383e-7,0.000030730498,0.02243438,0.027819421],"study_design_scores_gemma":[0.0016729225,0.00009037746,0.000002406523,0.5922507,0.058518425,0.00018441092,0.0031555828,0.00059601705,0.0000020383145,0.0000011467076,0.3425762,0.0009497366],"about_ca_topic_score_codex":0.000021197658,"about_ca_topic_score_gemma":0.000042620002,"teacher_disagreement_score":0.3409728,"about_ca_system_score_codex":0.0018059976,"about_ca_system_score_gemma":0.00031958855,"threshold_uncertainty_score":0.9997842},"labels":[],"label_agreement":null},{"id":"W3164984637","doi":"10.1007/s40273-021-01042-5","title":"Cluster Analysis of Care Pathways in Adults with Major Depressive Disorder with Acute Suicidal Ideation or Behavior in the USA","year":2021,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Treatment of Major Depression","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Janssen Scientific Affairs","keywords":"Suicidal ideation; Major depressive disorder; Psychiatry; Cluster (spacecraft); Medicine; Clinical psychology; Psychology; Poison control; Suicide prevention; Emergency medicine; Mood","score_opus":0.015612625681551164,"score_gpt":0.30762794213114486,"score_spread":0.2920153164495937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3164984637","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982066,0.000286201,0.000043923355,0.0003408331,0.000028398787,0.00071340846,0.000116582225,0.000010094443,0.00025393345],"genre_scores_gemma":[0.998136,0.0001531741,0.00059859286,0.0003799827,0.000023523502,0.00023636121,0.00038642023,0.000023037335,0.000062937106],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99893093,0.00007310723,0.00031491366,0.00033796387,0.00015111134,0.00019197386],"domain_scores_gemma":[0.99926114,0.000118358876,0.00016098825,0.00031619245,0.000088870634,0.000054456843],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000072639814,0.00017942705,0.00042384685,0.00021477319,0.000031778723,0.000017596005,0.000108494605,0.000057008212,0.0001995772],"category_scores_gemma":[0.000010166455,0.000104414474,0.000082345075,0.00044956664,0.000041899955,0.00015629771,0.00004053837,0.0001718781,0.000004094649],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004745997,0.00048238548,0.98417753,0.00007348504,0.0006571628,0.000604517,0.0027633912,0.0023241045,0.0010544874,0.000011980154,0.000020780246,0.0030841946],"study_design_scores_gemma":[0.013194899,0.00036936995,0.9657458,0.000106296626,0.00473528,0.000068150846,0.0018932427,0.0020941927,0.011579784,0.0000014455118,0.00005153594,0.00016000807],"about_ca_topic_score_codex":0.0006500669,"about_ca_topic_score_gemma":0.03243363,"teacher_disagreement_score":0.031783562,"about_ca_system_score_codex":0.00013526333,"about_ca_system_score_gemma":0.00015874975,"threshold_uncertainty_score":0.9852219},"labels":[],"label_agreement":null},{"id":"W3170157997","doi":"10.1007/s40273-021-01027-4","title":"Cost Effectiveness of Ribociclib in Combination with Fulvestrant for the Treatment of Postmenopausal Women with HR+/HER2− Advanced Breast Cancer Who Have Received No or Only One Prior Line of Endocrine Therapy: A Canadian Healthcare Perspective","year":2021,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Novartis Pharmaceuticals Corporation","keywords":"Fulvestrant; Medicine; Hazard ratio; Oncology; Metastatic breast cancer; Discontinuation; Internal medicine; Breast cancer; Cancer; Progression-free survival; Quality-adjusted life year; Letrozole; Cost effectiveness; Gynecology; Estrogen receptor; Tamoxifen; Confidence interval; Overall survival","score_opus":0.033363795315044825,"score_gpt":0.35892055458306005,"score_spread":0.3255567592680152,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170157997","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893654,0.0022655602,0.000110901885,0.0030640094,0.000071515155,0.0034858768,0.0015902617,0.00001075433,0.000035704874],"genre_scores_gemma":[0.99349123,0.004223267,0.00077426597,0.0002332107,0.00006308567,0.0010041755,0.000059715803,0.00006248644,0.00008857745],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986291,0.000105291656,0.00039660715,0.00036977686,0.00012008043,0.0003791368],"domain_scores_gemma":[0.9978786,0.00038443774,0.00035000304,0.0002688288,0.00094448257,0.00017364272],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015619643,0.00026826275,0.0008425147,0.00012998687,0.000055638604,0.000005965351,0.00009709642,0.000041888597,0.00010160802],"category_scores_gemma":[0.000012379984,0.00018082936,0.000052938045,0.00020328122,0.00018792959,0.0001282585,0.000008192493,0.00012313087,2.6180072e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.36811277,0.005543308,0.054458577,0.002018291,0.005427297,0.000090230234,0.023612281,0.008519922,0.098980255,0.0005212603,0.0000030464864,0.43271276],"study_design_scores_gemma":[0.11635025,0.02564809,0.40633932,0.001770123,0.00051747565,0.00027522736,0.012583782,0.001593115,0.43226743,0.00019240518,0.0018410587,0.00062173547],"about_ca_topic_score_codex":0.03844422,"about_ca_topic_score_gemma":0.10078149,"teacher_disagreement_score":0.43209103,"about_ca_system_score_codex":0.0027735252,"about_ca_system_score_gemma":0.0027068595,"threshold_uncertainty_score":0.96795887},"labels":[],"label_agreement":null},{"id":"W3171952049","doi":"10.1007/s40273-021-01037-2","title":"A Net Benefit Approach for the Optimal Allocation of a COVID-19 Vaccine","year":2021,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Vaccine Coverage and Hesitancy","field":"Social Sciences","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; Institute of Health Economics","funders":"Government of Alberta","keywords":"Context (archaeology); Population; Public health; Medicine; Population health; Psychological intervention; Environmental health; Geography","score_opus":0.0491800786459314,"score_gpt":0.3596159511467342,"score_spread":0.31043587250080285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171952049","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.61270237,0.009004398,0.26371422,0.08934352,0.0014043765,0.002623956,0.0002534816,0.00016084743,0.020792807],"genre_scores_gemma":[0.98608243,0.0020531167,0.0048730243,0.0044899425,0.0007352419,0.00011144617,0.00005455112,0.000015987776,0.0015842362],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993413,0.00003968154,0.00020932916,0.00017408367,0.00005741686,0.00017819933],"domain_scores_gemma":[0.9992165,0.00032773765,0.00011268934,0.00014286215,0.00009631785,0.000103895814],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00054765545,0.00007047777,0.00013771995,0.000024510511,0.00030597067,0.00004548555,0.00022777608,0.000039290888,0.00043043718],"category_scores_gemma":[0.00014676063,0.00006459591,0.00009508927,0.00009652228,0.000010326428,0.00014930461,0.000037981627,0.000058498605,0.000005586152],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009736609,0.00097233336,0.022661325,0.0005633161,0.0010041166,0.000008339992,0.05068902,0.22238559,0.0067232368,0.41449174,0.22102779,0.058499534],"study_design_scores_gemma":[0.003136192,0.00004559791,0.0012247795,0.0000045389065,0.0002461762,0.000005600235,0.006413195,0.06834954,0.0056528053,0.003173792,0.9114269,0.00032090844],"about_ca_topic_score_codex":0.00032538953,"about_ca_topic_score_gemma":0.00033395388,"teacher_disagreement_score":0.6903991,"about_ca_system_score_codex":0.00010723186,"about_ca_system_score_gemma":0.000464289,"threshold_uncertainty_score":0.47129855},"labels":[],"label_agreement":null},{"id":"W3173737570","doi":"10.1007/s40273-021-01059-w","title":"Utility Values Associated with Atypical Hemolytic Uremic Syndrome-Related Attributes: A Discrete Choice Experiment in Five Countries","year":2021,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Complement system in diseases","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Alexion Pharmaceuticals","keywords":"Medicine; Life expectancy; Kidney disease; Population; Dialysis; Public health; Demography; Internal medicine; Environmental health; Pathology","score_opus":0.021425084205299646,"score_gpt":0.2988199142499436,"score_spread":0.27739483004464394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3173737570","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99284303,0.0046457592,0.000017817276,0.0005388238,0.00055722176,0.0005065894,0.0005212012,0.00011380831,0.0002557423],"genre_scores_gemma":[0.9976147,0.00007545419,0.0000128850215,0.00035859982,0.000015137123,0.000084047606,0.00089124485,0.00002847237,0.00091945246],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978236,0.00040171147,0.0006338531,0.0005624359,0.00004674051,0.0005316465],"domain_scores_gemma":[0.9986462,0.0006363552,0.00022448752,0.0003390914,0.000092346396,0.00006149651],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00028412143,0.00029407107,0.0005682044,0.00008158226,0.00015031426,0.000041222433,0.00026532565,0.0001527291,0.0037539927],"category_scores_gemma":[0.00016525129,0.0002910003,0.000116864125,0.00015109415,0.0002229802,0.000174892,0.00017884947,0.00031689773,0.0003201052],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017589517,0.0017428629,0.9315652,0.00020327963,0.004002451,0.00042804182,0.002579207,0.00085538713,0.03016866,0.0009820912,0.025475565,0.00023827034],"study_design_scores_gemma":[0.03282313,0.00053149223,0.6973975,0.0011525052,0.0010526367,0.00077489926,0.0034441813,0.0035376644,0.22447522,0.00085628114,0.031489994,0.002464493],"about_ca_topic_score_codex":0.00010718642,"about_ca_topic_score_gemma":0.00018806741,"teacher_disagreement_score":0.23416774,"about_ca_system_score_codex":0.0004006367,"about_ca_system_score_gemma":0.0002820083,"threshold_uncertainty_score":0.9999542},"labels":[],"label_agreement":null},{"id":"W3174028996","doi":"10.1007/s40273-021-01051-4","title":"Economic Evidence on Potentially Curative Gene Therapy Products: A Systematic Literature Review","year":2021,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Providence Health Care; Centre for Advancing Health Outcomes; University of British Columbia","funders":"","keywords":"Medicine; Cost effectiveness; MEDLINE; EconLit; CINAHL; Health economics; Systematic review; Economic evaluation; Quality-adjusted life year; Cost–benefit analysis; Intensive care medicine; Public health; Actuarial science; Psychological intervention; Psychiatry; Pathology; Risk analysis (engineering)","score_opus":0.12902176028496853,"score_gpt":0.45309648081650333,"score_spread":0.3240747205315348,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3174028996","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000069727926,0.9853682,0.0000063509688,0.0013902615,0.0011496713,0.011108598,0.00019614273,0.00008805634,0.00068577414],"genre_scores_gemma":[3.0277272e-7,0.9853094,0.0002985924,0.0034094795,0.0016642831,0.001652842,0.0005966763,0.00026179178,0.0068066036],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.99424314,0.0011929626,0.0020296925,0.0015486124,0.000328501,0.0006570893],"domain_scores_gemma":[0.9955175,0.00079343835,0.0011285042,0.0018412861,0.00034866872,0.00037062177],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0018764258,0.0010925235,0.0062209903,0.00041712067,0.0001059071,0.00028532688,0.0007880754,0.00033852825,0.003912354],"category_scores_gemma":[0.00036104213,0.0008522398,0.0016315355,0.00046773517,0.00009404145,0.00031720186,0.00017720221,0.0016153348,0.0014498311],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000077236706,0.00011397519,1.5376015e-7,0.58568656,0.0017841272,0.00024882672,0.00005371598,0.0000013125556,0.00009606267,0.00003120484,0.010421184,0.40148562],"study_design_scores_gemma":[0.00040990434,0.00012936948,3.3734967e-8,0.44783658,0.0013690557,0.0008045211,0.0000025589088,0.000007781888,0.00022429528,0.0000015160308,0.54883504,0.00037930926],"about_ca_topic_score_codex":0.0000045990128,"about_ca_topic_score_gemma":0.0000011302848,"teacher_disagreement_score":0.5384139,"about_ca_system_score_codex":0.0017568831,"about_ca_system_score_gemma":0.002725005,"threshold_uncertainty_score":0.9993928},"labels":[],"label_agreement":null},{"id":"W3177437141","doi":"10.1007/s40273-021-01039-0","title":"Towards Transparency in the Selection of Published Health Utility Inputs in Cost-Utility Analyses: The Health Utility Application Tool (HAT)","year":2021,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre; St. Joseph’s Healthcare Hamilton; Toronto Public Health; Hamilton Health Sciences; Toronto General Hospital; University Health Network; University of Ottawa; Canadian Centre for Applied Research in Cancer Control; Sunnybrook Health Science Centre; McMaster University; Impact","funders":"","keywords":"Health economics; Transparency (behavior); Population health; Health services research; Population; Public health; Health administration; Medicine; Context (archaeology); Reimbursement; Actuarial science; Health care; Computer science; Economics; Environmental health; Nursing","score_opus":0.40149455450833305,"score_gpt":0.5137128038663795,"score_spread":0.11221824935804647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3177437141","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.75452816,0.0057838396,0.022489645,0.20763999,0.0007824391,0.004647605,0.0012458785,0.00007115964,0.002811299],"genre_scores_gemma":[0.9721655,0.0009403733,0.00054720533,0.025462454,0.00016020537,0.0004675891,0.00021073224,0.000026249481,0.000019661202],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9881112,0.0025215498,0.0072894273,0.0011566727,0.00015904958,0.00076212484],"domain_scores_gemma":[0.9945079,0.000883594,0.003138602,0.001145768,0.00013759038,0.00018653828],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.04667364,0.00032381006,0.0015654381,0.00034705814,0.00029410076,0.00014717237,0.00078888243,0.00016070584,0.00073272246],"category_scores_gemma":[0.0013070286,0.00032883347,0.00025867525,0.0010137592,0.0001477571,0.0009020019,0.00007674354,0.0007164052,0.00008304298],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002766636,0.002477172,0.894941,0.0020666507,0.00021316495,0.0000012159072,0.01679274,0.0024867929,0.000027301568,0.022712244,0.022765877,0.035239194],"study_design_scores_gemma":[0.002252433,0.000089331224,0.7429413,0.000052743748,0.000013195028,0.0000083682335,0.0020799024,0.18540588,0.00021205927,0.010728412,0.055779472,0.00043688912],"about_ca_topic_score_codex":0.011819626,"about_ca_topic_score_gemma":0.010501406,"teacher_disagreement_score":0.21763739,"about_ca_system_score_codex":0.0015447764,"about_ca_system_score_gemma":0.0020012509,"threshold_uncertainty_score":0.9999164},"labels":[],"label_agreement":null},{"id":"W3180826043","doi":"10.1007/s40273-021-01050-5","title":"Implementing Outcomes-Based Managed Entry Agreements for Rare Disease Treatments: Nusinersen and Tisagenlecleucel","year":2021,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Neurogenetic and Muscular Disorders Research","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Horizon 2020; Università Bocconi; Australian Government","keywords":"Population; Population health; Reimbursement; Medicine; Health economics; European union; Health care; Business; Public health; Economic growth; Environmental health; Nursing; Economics","score_opus":0.03657067670491413,"score_gpt":0.37479128884331225,"score_spread":0.3382206121383981,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3180826043","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913775,0.001288576,0.0010178104,0.0031550815,0.00012332425,0.0011968238,0.0001916007,0.000037123235,0.0016122045],"genre_scores_gemma":[0.9853287,0.0007963371,0.0020540603,0.0059473338,0.000096005206,0.00021119302,0.00055584306,0.00006273634,0.004947805],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988144,0.00003958444,0.00023367324,0.00038590984,0.00010370887,0.0004227239],"domain_scores_gemma":[0.9992736,0.000064051485,0.00005628516,0.00023682897,0.0000584976,0.00031071116],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013504644,0.00016647107,0.0002447417,0.00007150171,0.00014824193,0.000045423076,0.000060638642,0.00002388824,0.00047669522],"category_scores_gemma":[0.000041477047,0.00016666121,0.00020077753,0.000055075707,0.000032091255,0.000054906563,0.00009766391,0.00007467711,0.00001974154],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014304708,0.0017204513,0.7616444,0.0015251447,0.0034045454,0.0008241271,0.0001950406,0.000117148484,0.027802952,0.00031393315,0.012778858,0.1882429],"study_design_scores_gemma":[0.096629485,0.00041432932,0.32327238,0.00015421418,0.0054318644,0.00005989167,0.0011833566,0.042239368,0.06603817,0.00061929465,0.46256158,0.0013960599],"about_ca_topic_score_codex":0.0000076765755,"about_ca_topic_score_gemma":0.000006192784,"teacher_disagreement_score":0.44978273,"about_ca_system_score_codex":0.000070533235,"about_ca_system_score_gemma":0.00018205366,"threshold_uncertainty_score":0.6796247},"labels":[],"label_agreement":null},{"id":"W3182482494","doi":"10.1007/s40273-021-01044-3","title":"Lack of Cost-Effectiveness of Preoperative Erythropoiesis-Stimulating Agents and/or Iron Therapy in Anaemic, Elective Surgery Patients: A Systematic Review and Updated Analysis","year":2021,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Iron Metabolism and Disorders","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Blood Services; Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Health economics; Quality of Life Research; Intravenous iron; Erythropoiesis; Health administration; Abdominal surgery; Intensive care medicine; Iron therapy; Hematinic; General surgery; Anemia; Surgery; Public health; Internal medicine; Iron deficiency; Nursing","score_opus":0.09232097224802718,"score_gpt":0.41998019079104987,"score_spread":0.3276592185430227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3182482494","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03502309,0.9588921,0.000011385202,0.000007891337,0.000057113113,0.005739065,0.00022959197,0.000008191517,0.00003154329],"genre_scores_gemma":[0.007083176,0.99147964,0.00003885731,0.00019257204,0.0000112657135,0.0003696545,0.00075999985,0.000047164143,0.000017653103],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99609095,0.0013499019,0.0016847204,0.0005266354,0.000117956886,0.00022985866],"domain_scores_gemma":[0.9969637,0.0011951032,0.0012025798,0.0003103007,0.00022794708,0.00010038848],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011793436,0.00046180355,0.0075171106,0.0005625825,0.00003172659,0.000014225883,0.000093132636,0.00014538066,0.00013056457],"category_scores_gemma":[0.0003910149,0.00035038215,0.0005089426,0.0009207384,0.000109033834,0.00013475261,0.000073021176,0.00024229489,0.0000012826448],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015852152,0.0003452561,0.008881505,0.964422,0.0029893238,0.0000057668935,0.00018318497,0.00002047277,0.0000016593999,0.000008600272,0.00006705654,0.02291668],"study_design_scores_gemma":[0.010287161,0.00056598405,0.00858252,0.80204135,0.17042021,0.00003498694,0.00047510545,0.00082298287,0.00013992572,0.000008343279,0.004666788,0.001954662],"about_ca_topic_score_codex":0.00007996436,"about_ca_topic_score_gemma":0.000011121473,"teacher_disagreement_score":0.1674309,"about_ca_system_score_codex":0.0001563638,"about_ca_system_score_gemma":0.00032445692,"threshold_uncertainty_score":0.9998948},"labels":[],"label_agreement":null},{"id":"W3188660209","doi":"10.1007/s40273-021-01068-9","title":"Cost Effectiveness of Triplet Selinexor-Bortezomib-Dexamethasone (XVd) in Previously Treated Multiple Myeloma (MM) Based on Results from the Phase III BOSTON Trial","year":2021,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Notre-Dame","funders":"Karyopharm Therapeutics","keywords":"Medicine; Bortezomib; Multiple myeloma; Dexamethasone; Internal medicine; Oncology; Pomalidomide; Progression-free survival; Chemotherapy","score_opus":0.08245124933852116,"score_gpt":0.3953296840196429,"score_spread":0.31287843468112175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3188660209","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915673,0.0003514643,0.00012610774,0.00071879,0.00033339727,0.004433547,0.0019004075,0.000054213007,0.0005147599],"genre_scores_gemma":[0.99487686,0.00034061534,0.0003872311,0.0004410406,0.00031070746,0.00041678993,0.0030483482,0.000063661784,0.00011476781],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9962172,0.0010775645,0.0010171506,0.00080693915,0.0003058228,0.0005753124],"domain_scores_gemma":[0.9924096,0.00592417,0.00032996753,0.00080675574,0.0001874407,0.0003420647],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001608948,0.00040091752,0.0010514626,0.00019248092,0.000099116514,0.000042344047,0.00024698468,0.00015515383,0.000291371],"category_scores_gemma":[0.0017421355,0.0003124073,0.00031760585,0.00037743498,0.000123561,0.000116030846,0.000076796125,0.00051598717,0.00005569553],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.85496753,0.0073966794,0.020161487,0.00015219524,0.0009463904,0.00074097636,0.00042391132,0.0018543209,0.046679463,0.000008047439,0.0010590958,0.065609924],"study_design_scores_gemma":[0.5924601,0.0013332866,0.014232071,0.00028693248,0.0002898108,0.0000082299875,0.00009371576,0.091205575,0.297426,0.0000104996825,0.002398255,0.00025552878],"about_ca_topic_score_codex":0.0015885428,"about_ca_topic_score_gemma":0.00029004784,"teacher_disagreement_score":0.2625074,"about_ca_system_score_codex":0.00052791194,"about_ca_system_score_gemma":0.0006536098,"threshold_uncertainty_score":0.9999328},"labels":[],"label_agreement":null},{"id":"W3195253306","doi":"10.1007/s40273-021-01074-x","title":"Conceptualising ‘Benefits Beyond Health’ in the Context of the Quality-Adjusted Life-Year: A Critical Interpretive Synthesis","year":2021,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Coastal Health Research Institute; University of British Columbia; Vancouver Coastal Health; Simon Fraser University","funders":"","keywords":"Context (archaeology); Health care; Conceptual framework; Health economics; Sociology; Quality of life (healthcare); Psychology; Public relations; Medicine; Economics; Nursing; Political science; Social science; Economic growth","score_opus":0.4710139165391754,"score_gpt":0.5318463444281387,"score_spread":0.060832427888963314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3195253306","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00019023835,0.9544887,0.000088652174,0.033381943,0.0019566673,0.0021622665,0.00585939,0.000028338849,0.0018438346],"genre_scores_gemma":[0.0074829,0.9504194,0.00025076006,0.04032501,0.0006013751,0.0006664574,0.000068197165,0.00013058727,0.000055272703],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9804283,0.0055424166,0.011817366,0.0012084494,0.00015813328,0.0008453375],"domain_scores_gemma":[0.96017927,0.030032499,0.0077995895,0.0015192961,0.00014384185,0.00032552204],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.027401963,0.0007061326,0.006566123,0.00046407824,0.00030366197,0.00021354586,0.0018066118,0.00045099045,0.000907675],"category_scores_gemma":[0.028120996,0.0006400307,0.0012951309,0.00054060685,0.00049386563,0.00042042026,0.0003560647,0.0012154945,0.0005050507],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000033720167,0.000533619,0.00048047552,0.027444266,0.0010298721,0.000002682426,0.018082786,0.000059639904,1.4061087e-7,0.80277336,0.048870526,0.10068891],"study_design_scores_gemma":[0.00043642495,0.00003543129,0.000078302364,0.013222994,0.00018539431,0.00002292863,0.0105507765,0.00029781405,0.0000017065294,0.0008305907,0.9734876,0.00085004105],"about_ca_topic_score_codex":0.001327278,"about_ca_topic_score_gemma":0.00035133553,"teacher_disagreement_score":0.92461705,"about_ca_system_score_codex":0.0018418984,"about_ca_system_score_gemma":0.002045232,"threshold_uncertainty_score":0.9996051},"labels":[],"label_agreement":null},{"id":"W3203366108","doi":"10.1007/s40273-021-01089-4","title":"Modeling Challenges in Cost-Effectiveness Analysis of First-Line Immuno-Oncology Therapies in Non-small Cell Lung Cancer: A Systematic Literature Review","year":2021,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Pfizer","keywords":"Medicine; Lung cancer; Quality of Life Research; Health economics; Oncology; Intensive care medicine; Pharmacoeconomics; Clinical Oncology; Internal medicine; Cancer; Public health; Medical physics; Pathology","score_opus":0.08006326009607585,"score_gpt":0.42086895525250584,"score_spread":0.34080569515643,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203366108","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00068227923,0.9914831,0.000012501046,0.0002476586,0.00028612718,0.006994583,0.00018751211,0.000011809353,0.000094465555],"genre_scores_gemma":[0.001385565,0.98903394,0.000042270793,0.00014406002,0.00008684238,0.008834539,0.00039061252,0.00007167103,0.0000105110585],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99638504,0.0006376037,0.0017920461,0.00074138417,0.00010137666,0.00034252994],"domain_scores_gemma":[0.99755895,0.00082057755,0.00077264034,0.000596621,0.00015300307,0.00009818047],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012058073,0.0006136306,0.0086942,0.00085253624,0.000024070272,0.000021461397,0.00024226125,0.00030256732,0.000067342524],"category_scores_gemma":[0.000028036171,0.000488934,0.0012514251,0.0009498289,0.000020066087,0.000070992755,0.00009505183,0.00051600934,0.0000020698235],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002996949,0.0005855544,0.00036722736,0.863348,0.007910781,0.00014007902,0.0006175261,0.004315871,3.5767056e-7,0.00000657398,0.000009727252,0.12266833],"study_design_scores_gemma":[0.0022561625,0.000078928875,0.000012055315,0.8949981,0.049924906,0.00002326484,0.0000621772,0.025726197,0.0000064797878,0.0000010018608,0.026513977,0.00039674804],"about_ca_topic_score_codex":0.00023090061,"about_ca_topic_score_gemma":0.0013468036,"teacher_disagreement_score":0.12227158,"about_ca_system_score_codex":0.0032317701,"about_ca_system_score_gemma":0.0006109618,"threshold_uncertainty_score":0.9997562},"labels":[],"label_agreement":null},{"id":"W3203852858","doi":"10.1007/s40273-021-01087-6","title":"Empirical Estimates of the Marginal Cost of Health Produced by a Healthcare System: Methodological Considerations from Country-Level Estimates","year":2021,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Global Health Care Issues","field":"Health Professions","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Health economics; Health administration; Quality of Life Research; Health care; Public health; Health services research; Public economics; Economics; Actuarial science; Environmental health; Econometrics; Medicine; Economic growth; Nursing","score_opus":0.5755898216990788,"score_gpt":0.6149285070464087,"score_spread":0.03933868534732987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203852858","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00022216978,0.9650891,0.00028231752,0.004675545,0.0031872797,0.0061407303,0.020172808,0.00012321703,0.00010684201],"genre_scores_gemma":[0.0007932593,0.9809222,0.01219945,0.0027960653,0.00041410216,0.0009893341,0.0017138751,0.00013566342,0.000036012538],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9849971,0.0074879485,0.0049377517,0.0010990482,0.00038816352,0.001089998],"domain_scores_gemma":[0.979375,0.013477439,0.004897809,0.0011190268,0.0006820423,0.00044867993],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0041581444,0.0008149743,0.0062134927,0.0001400421,0.0009256665,0.0000271086,0.000754958,0.00078524626,0.0004903092],"category_scores_gemma":[0.002360029,0.00060656114,0.00059075095,0.00039971675,0.00032905728,0.00011000375,0.00057534786,0.001990942,0.00010312213],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011777204,0.0006316334,0.0057910257,0.34290484,0.0018260801,0.000022903198,0.0023728237,0.000059390946,0.000030079915,0.0077776765,0.54875326,0.089712515],"study_design_scores_gemma":[0.0010105488,0.000101951526,0.0001998929,0.040945474,0.0013122098,0.000047428155,0.0010614629,0.00036676848,0.00009301225,0.00033755362,0.9538555,0.00066819455],"about_ca_topic_score_codex":0.004799268,"about_ca_topic_score_gemma":0.00022731414,"teacher_disagreement_score":0.40510225,"about_ca_system_score_codex":0.0022177226,"about_ca_system_score_gemma":0.010244792,"threshold_uncertainty_score":0.99963856},"labels":[],"label_agreement":null},{"id":"W3206304124","doi":"10.1007/s40273-021-01095-6","title":"Systematic Literature Review to Assess Economic Evaluations in Spinal Muscular Atrophy (SMA)","year":2021,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Neurogenetic and Muscular Disorders Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"F. Hoffmann-La Roche; Roche","keywords":"Medicine; SMA*; Neuromuscular disease; Systematic review; Economic evaluation; MEDLINE; Physical medicine and rehabilitation; Cochrane Library; Reimbursement; Cost effectiveness; EconLit; Quality of life (healthcare); Spinal muscular atrophy; Physical therapy; Health care; Intensive care medicine; Disease; Randomized controlled trial; Surgery; Pathology; Risk analysis (engineering); Nursing","score_opus":0.10929610605984029,"score_gpt":0.49663223390911965,"score_spread":0.38733612784927934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3206304124","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000044422133,0.9908655,0.00003896386,0.0004049844,0.00046604982,0.0075478824,0.00008640214,0.000027949367,0.00051781896],"genre_scores_gemma":[0.0000040260447,0.9947842,0.00034823467,0.0016135746,0.00030918518,0.0020294634,0.00042085873,0.0001350122,0.00035545308],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.99588454,0.0007754976,0.0016220316,0.0009426513,0.0002521125,0.00052318745],"domain_scores_gemma":[0.99792135,0.00014731869,0.00035065072,0.0010084435,0.00013508058,0.00043718008],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012938891,0.0006057089,0.004084552,0.000613711,0.000059147387,0.00012796404,0.00046318816,0.0002219555,0.0005026324],"category_scores_gemma":[0.00023582115,0.0005549617,0.0014186233,0.0005153974,0.000032823966,0.00008850722,0.00022727951,0.0008834612,0.0010101974],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000007846077,0.000095324656,0.0000023165246,0.81084704,0.0006047563,0.00024840757,0.000018279754,0.00001463456,0.0000028527568,0.0000866796,0.0022414117,0.18583047],"study_design_scores_gemma":[0.0004435561,0.000059404898,0.000001850926,0.43644515,0.0027592918,0.0003957656,0.000007146417,0.00007037054,0.0000025226823,0.0000027789017,0.55949426,0.0003179104],"about_ca_topic_score_codex":0.000004892893,"about_ca_topic_score_gemma":0.000006538413,"teacher_disagreement_score":0.5572528,"about_ca_system_score_codex":0.0008287992,"about_ca_system_score_gemma":0.0017819435,"threshold_uncertainty_score":0.99976766},"labels":[],"label_agreement":null},{"id":"W3206420890","doi":"10.1007/s40273-021-01093-8","title":"The Utility of a Rapid Review Evaluation Process to a National HTA Agency","year":2021,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trinity College","funders":"","keywords":"Medicine; Pharmacoeconomics; Reimbursement; Health technology; Orphan drug; Economic evaluation; Health economics; Intensive care medicine; Public health; Health care; Nursing; Bioinformatics; Pathology","score_opus":0.7108393322923651,"score_gpt":0.6075579680623567,"score_spread":0.10328136423000833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3206420890","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000015846239,0.9747756,0.00012571155,0.006901919,0.001426033,0.0051248996,0.0017303654,0.000032237538,0.009867349],"genre_scores_gemma":[0.000056868383,0.98764133,0.0002720631,0.008311518,0.00061364705,0.0022926203,0.00046317113,0.000089477435,0.0002592796],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9856206,0.0015820054,0.01069433,0.0012220889,0.000303372,0.00057757675],"domain_scores_gemma":[0.9874866,0.0026592393,0.007812534,0.0010296889,0.0006982178,0.00031371138],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":["metaresearch","insufficient_payload"],"category_scores_codex":[0.05753957,0.00057173986,0.0045333877,0.00037941747,0.0003174325,0.00012356792,0.0011760992,0.00025425828,0.004269929],"category_scores_gemma":[0.010498043,0.00059794635,0.0009623918,0.0005806136,0.00010073806,0.00039689094,0.00019003024,0.0004832762,0.0022832255],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00000749445,0.0001645768,0.000024241639,0.08056411,0.00079921255,5.9649113e-7,0.00037463612,0.000028367602,3.1691386e-8,0.009134232,0.29984668,0.6090558],"study_design_scores_gemma":[0.00027868198,0.000022184528,0.000011732897,0.009017731,0.00029315724,0.000011120023,0.00003911531,0.0020865237,4.726875e-7,0.0024042756,0.98532456,0.0005104143],"about_ca_topic_score_codex":0.000054076732,"about_ca_topic_score_gemma":0.000023200051,"teacher_disagreement_score":0.6854779,"about_ca_system_score_codex":0.0013538781,"about_ca_system_score_gemma":0.0035651647,"threshold_uncertainty_score":0.9996472},"labels":[],"label_agreement":null},{"id":"W334668128","doi":"10.1007/s40273-015-0278-7","title":"Does it Matter Whether Canada’s Separate Health Technology Assessment Process for Cancer Drugs has an Economic Rationale?","year":2015,"lang":"en","type":"letter","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; Canadian Agency for Drugs and Technologies in Health; Cancer Care Ontario; Saskatchewan Cancer Agency; Canadian Centre for Applied Research in Cancer Control; St. Michael's Hospital","funders":"","keywords":"Health economics; Pharmacoeconomics; Health technology; Health care; Economic evaluation; Population health; Medicine; Gerontology; Library science; Political science; Law; Computer science; Intensive care medicine","score_opus":0.32836396874757645,"score_gpt":0.5090665514113875,"score_spread":0.180702582663811,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W334668128","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005723051,0.0014442925,0.00045290106,0.9620295,0.006878776,0.003833736,0.017604783,0.000121237405,0.0019116922],"genre_scores_gemma":[0.004134155,0.00042541733,0.0012253311,0.9691475,0.008802161,0.0041258163,0.0028874066,0.00037280552,0.008879381],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98899347,0.00040329192,0.0067816055,0.0021384214,0.00016691444,0.0015163152],"domain_scores_gemma":[0.9902057,0.000640117,0.007201634,0.0011699967,0.00026060527,0.00052197056],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.009109499,0.0009659821,0.0030522137,0.0008123658,0.00059693377,0.00042042395,0.0013624285,0.00089629233,0.0043769227],"category_scores_gemma":[0.000117775155,0.001068693,0.00027438608,0.000111590685,0.0002126388,0.0010879716,0.0001240402,0.0014570367,0.0014298942],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000024752835,0.000050468683,0.0031355126,0.001126913,0.00049899175,0.0000018710641,0.00091605465,0.0047467,4.5077272e-7,0.0013743028,0.9880193,0.000104675084],"study_design_scores_gemma":[0.0016384887,0.00006820665,0.00006840229,0.00008232059,0.000044668897,0.000006584975,0.00092769065,0.015418335,0.000010907565,0.00950686,0.9709501,0.0012773833],"about_ca_topic_score_codex":0.16360538,"about_ca_topic_score_gemma":0.30496144,"teacher_disagreement_score":0.14135608,"about_ca_system_score_codex":0.013574557,"about_ca_system_score_gemma":0.01924661,"threshold_uncertainty_score":0.9993476},"labels":[],"label_agreement":null},{"id":"W4200248641","doi":"10.1007/s40273-021-01115-5","title":"Systematic Literature Review to Identify Utility Values in Patients with Spinal Muscular Atrophy (SMA) and Their Caregivers","year":2021,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Neurogenetic and Muscular Disorders Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"F. Hoffmann-La Roche","keywords":"Spinal muscular atrophy; SMA*; Health economics; Quality of Life Research; Medicine; Public health; Physical medicine and rehabilitation; Physical therapy; Gerontology; Pathology; Disease; Computer science","score_opus":0.030892511151640295,"score_gpt":0.3814285843364808,"score_spread":0.3505360731848405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200248641","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00302834,0.99095106,0.000012059137,0.00008312785,0.00012986816,0.005624634,0.00008560037,0.00001595299,0.00006937792],"genre_scores_gemma":[0.00021323387,0.9985186,0.00006511418,0.00048464985,0.000056473335,0.0002950425,0.00023759616,0.00007308239,0.000056228808],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99740505,0.00046469574,0.0007578813,0.00078393344,0.00021966992,0.00036877344],"domain_scores_gemma":[0.99855816,0.00005405848,0.00022612732,0.00064964575,0.00018174772,0.00033022984],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004913062,0.00052209286,0.0029253266,0.00027744783,0.000051211384,0.000084777435,0.00024536517,0.00013523667,0.000057410765],"category_scores_gemma":[0.00009478321,0.00036566905,0.0005262185,0.00041828767,0.000062529485,0.00007498967,0.00019819514,0.00059517013,0.000026809465],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000033629138,0.00011327249,0.00012340843,0.85051113,0.0006343825,0.0000989167,0.00010610476,3.0485816e-7,4.1765918e-7,0.0000031010757,0.00045002298,0.1479253],"study_design_scores_gemma":[0.0015215664,0.00024254671,0.00025522235,0.73471314,0.002616086,0.000098472,0.00006702531,0.000009883658,0.000002485609,0.0000022020529,0.2600029,0.00046849527],"about_ca_topic_score_codex":0.000005175018,"about_ca_topic_score_gemma":0.0000018023228,"teacher_disagreement_score":0.25955287,"about_ca_system_score_codex":0.000178648,"about_ca_system_score_gemma":0.00031666667,"threshold_uncertainty_score":0.99987954},"labels":[],"label_agreement":null},{"id":"W4200579141","doi":"10.1007/s40273-021-01106-6","title":"Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom","year":2021,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Charles-Le Moyne; Hôpital Notre-Dame; Centre intégré de santé et de services sociaux de Chaudière-Appalaches","funders":"Sanofi Genzyme; EMD Serono; Monash University; Novartis Pharma; Alexion Pharmaceuticals; Teva Pharmaceutical Industries; Mylan; Biogen; MedDay Pharmaceuticals; Celgene; Sanofi","keywords":"Fingolimod; Natalizumab; Medicine; Multiple sclerosis; Health economics; Relapsing remitting; Cost effectiveness; Quality of Life Research; Public health; Pharmacoeconomics; Disease; Intensive care medicine; Physical therapy; Immunology; Internal medicine; Pathology","score_opus":0.11934353170114638,"score_gpt":0.3735801482993999,"score_spread":0.25423661659825353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200579141","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970742,0.00035682617,0.000041573076,0.0002519584,0.00003140032,0.0021656693,0.000058470527,0.00000966577,0.0000102641525],"genre_scores_gemma":[0.9991381,0.00017562104,0.00016323464,0.00012673851,0.000008989567,0.00033513486,0.000028660814,0.000022870945,6.6163136e-7],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996995,0.0017135497,0.00034888674,0.00043984377,0.00017302137,0.00032971514],"domain_scores_gemma":[0.9943333,0.0051055285,0.000101289974,0.00020057517,0.00014254017,0.00011671603],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020772177,0.00022116242,0.00060698227,0.00047818257,0.00009129757,0.00004291809,0.00010240622,0.000041068957,0.00000239265],"category_scores_gemma":[0.00094912807,0.0001777109,0.000031323314,0.00061852025,0.00017705416,0.0001753977,0.00017874835,0.0003332572,5.745998e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028732484,0.00040026673,0.9441116,0.0005008257,0.00010194883,0.000020662996,0.005756407,0.0034085272,0.014134037,0.00001924375,0.0000018017033,0.0028122293],"study_design_scores_gemma":[0.018397793,0.00017609342,0.96609825,0.0018479796,0.000026592334,0.0000016608958,0.00100555,0.0070773014,0.0051525156,0.000012705414,0.00003168635,0.0001718972],"about_ca_topic_score_codex":0.0007255175,"about_ca_topic_score_gemma":0.00031618626,"teacher_disagreement_score":0.02198666,"about_ca_system_score_codex":0.00035242882,"about_ca_system_score_gemma":0.00011804905,"threshold_uncertainty_score":0.724684},"labels":[],"label_agreement":null},{"id":"W4205508841","doi":"10.1007/s40273-021-01124-4","title":"Public Preferences for a COVID-19 Vaccination Program in Quebec: A Discrete Choice Experiment","year":2022,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Vaccine Coverage and Hesitancy","field":"Social Sciences","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institut Universitaire en Santé Mentale de Québec; Université de Montréal; Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal; Université de Sherbrooke","funders":"Fonds de Recherche du Québec - Santé","keywords":"Coronavirus disease 2019 (COVID-19); Health economics; Quality of Life Research; Public health; 2019-20 coronavirus outbreak; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Health administration; Vaccination; Medicine; Public economics; Virology; Economics; Nursing; Outbreak; Infectious disease (medical specialty)","score_opus":0.10267109511763596,"score_gpt":0.41702008499681426,"score_spread":0.3143489898791783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205508841","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.945686,0.00093755877,0.0005381506,0.037709292,0.0009427556,0.0036142399,0.00008769125,0.00024778405,0.010236562],"genre_scores_gemma":[0.99276453,0.00014454203,0.00027370168,0.0018609794,0.00027188918,0.0031485243,0.000048710528,0.000013331685,0.001473807],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99878234,0.00019134725,0.00026264568,0.00029337915,0.000117382515,0.00035290714],"domain_scores_gemma":[0.99931526,0.00023086497,0.00013473393,0.00010207042,0.000029907489,0.0001871533],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00075001793,0.00010251204,0.00014990145,0.00013605577,0.00068644376,0.00019611996,0.00036450665,0.000029075602,0.0021688514],"category_scores_gemma":[0.00017122179,0.00012059477,0.000073854586,0.00017423948,0.000008792482,0.0005715234,0.00009749404,0.00012101946,0.0000074117715],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005822472,0.002230752,0.21186784,0.00023663524,0.00020394038,0.000012905983,0.118175454,0.0031903412,0.000536054,0.10621483,0.117123686,0.43962532],"study_design_scores_gemma":[0.0015941715,0.00008904432,0.0023404798,0.0000012289867,0.000011743302,2.91385e-7,0.00491247,0.0016700751,0.00010909225,0.0030304983,0.986026,0.00021493914],"about_ca_topic_score_codex":0.016649447,"about_ca_topic_score_gemma":0.07545741,"teacher_disagreement_score":0.86890227,"about_ca_system_score_codex":0.0012664302,"about_ca_system_score_gemma":0.0007971987,"threshold_uncertainty_score":0.9987433},"labels":[],"label_agreement":null},{"id":"W4206321249","doi":"10.1007/s40273-021-01112-8","title":"Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations","year":2022,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":94,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Institute of Health Economics; University of Ottawa","funders":"National Institute for Health and Care Research; National Institute for Health Research Health Protection Research Unit","keywords":"Economic evaluation; Checklist; Public health; Context (archaeology); Health care; Health economics; Rebuttal; Public relations; Health policy; Stakeholder; Health administration; Population health; Medicine; Political science; Psychology; Nursing; Law","score_opus":0.3605172056295309,"score_gpt":0.5650338421019704,"score_spread":0.2045166364724395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206321249","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6072018,0.020406958,0.018790357,0.24144228,0.01929467,0.022396859,0.06373534,0.0009633976,0.0057683066],"genre_scores_gemma":[0.8894013,0.0019321782,0.011024652,0.06814651,0.0023321577,0.010700876,0.0137049295,0.0006582729,0.0020991205],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.95635366,0.0022462436,0.036167882,0.0027209655,0.0004991942,0.0020120526],"domain_scores_gemma":[0.9255365,0.0009218505,0.0709913,0.0014266381,0.0003628033,0.00076088036],"candidate_categories":["metaresearch","metaepi_narrow","sts","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.21080244,0.0007597879,0.003210096,0.0010716291,0.0028560967,0.00036638166,0.0009217275,0.0001519452,0.010909048],"category_scores_gemma":[0.0067761615,0.001199115,0.00063803885,0.00031344141,0.00014419245,0.0013820486,0.00041399265,0.0007803001,0.00056869444],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0002612986,0.00025540794,0.0080496445,0.0005698853,0.00084213057,0.0000026854964,0.004341612,0.18947957,0.00006058158,0.016035737,0.7759537,0.004147717],"study_design_scores_gemma":[0.005441707,0.00040750965,0.0010429127,0.000060091792,0.00007000257,0.000058581045,0.003467182,0.45730424,0.000120281846,0.007213678,0.52355736,0.0012564427],"about_ca_topic_score_codex":0.003175463,"about_ca_topic_score_gemma":0.0010089113,"teacher_disagreement_score":0.28219947,"about_ca_system_score_codex":0.035807535,"about_ca_system_score_gemma":0.011752119,"threshold_uncertainty_score":0.99904585},"labels":[],"label_agreement":null},{"id":"W4211031897","doi":"10.1007/s40273-022-01134-w","title":"Correction to: Public Preferences for a COVID-19 Vaccination Program in Quebec: A Discrete Choice Experiment","year":2022,"lang":"en","type":"erratum","venue":"PharmacoEconomics","topic":"Vaccine Coverage and Hesitancy","field":"Social Sciences","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institut universitaire en santé mentale de Montréal; Institut Universitaire en Santé Mentale de Québec; Université de Montréal; Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal; Université de Sherbrooke","funders":"","keywords":"Health economics; Coronavirus disease 2019 (COVID-19); Quality of Life Research; Public health; 2019-20 coronavirus outbreak; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Health administration; Medicine; Virology; Outbreak; Nursing; Infectious disease (medical specialty)","score_opus":0.059554445466792325,"score_gpt":0.41142534208965603,"score_spread":0.3518708966228637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4211031897","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.027243493,0.009313221,0.0027273179,0.111252554,0.47627175,0.036948968,0.0011562769,0.0020714495,0.33301497],"genre_scores_gemma":[0.103152536,0.006035438,0.0006559373,0.010217173,0.013508347,0.026908737,0.0032630633,0.00022065664,0.8360381],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976147,0.00029478245,0.0005389812,0.00071083626,0.00023138446,0.0006093583],"domain_scores_gemma":[0.99845564,0.00044201233,0.00038156676,0.00021602261,0.00008858028,0.00041618792],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00092417264,0.000302411,0.00043003814,0.00043911516,0.0007278309,0.0005448599,0.00066678226,0.00019395929,0.00385273],"category_scores_gemma":[0.00090774,0.00036435213,0.00018654669,0.0003523326,0.00001096032,0.00069023186,0.00015269389,0.0005754469,0.000025564856],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006571344,0.00016705801,0.0010448277,0.00008339423,0.00004263082,0.0000014579035,0.0077583543,0.00012064903,0.0000036607703,0.00048178135,0.94717735,0.043053094],"study_design_scores_gemma":[0.0007540204,0.00013662844,0.0006042308,0.000017576149,0.000036273977,3.1857255e-7,0.0024438463,0.0010918084,0.000013068721,0.00031598116,0.99416065,0.00042559195],"about_ca_topic_score_codex":0.05957175,"about_ca_topic_score_gemma":0.43195507,"teacher_disagreement_score":0.50302315,"about_ca_system_score_codex":0.004201966,"about_ca_system_score_gemma":0.0032203675,"threshold_uncertainty_score":0.99988085},"labels":[],"label_agreement":null},{"id":"W4233811006","doi":"10.2165/11633650-000000000-00000","title":"The Authors’ Reply","year":2012,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Oakville-Trafalgar Memorial Hospital; Humber River Regional Hospital; University of Toronto","funders":"","keywords":"Quality of Life Research; Health economics; Health administration; Public health; Medicine; Nursing","score_opus":0.043183239044388894,"score_gpt":0.37449832528882926,"score_spread":0.3313150862444404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4233811006","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96978545,0.0025760515,0.000016265218,0.01646654,0.0007458442,0.00031897216,0.0000065866834,0.000059549988,0.010024731],"genre_scores_gemma":[0.993932,0.0006416081,0.00065243215,0.0015355486,0.00075957243,0.000043840373,0.000007507723,0.000015000086,0.002412466],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993491,0.000023796138,0.00012540938,0.000092805625,0.00006474923,0.00034410178],"domain_scores_gemma":[0.999292,0.00010954838,0.000030004128,0.00021144134,0.000018993047,0.00033801535],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00035857738,0.00007336411,0.00009075006,0.000024284329,0.00014447876,0.000025176223,0.00006940523,0.000016524706,0.00026169737],"category_scores_gemma":[0.000040423784,0.0000459899,0.00006901943,0.000033477943,0.000043270826,0.00008623733,0.00003625233,0.00013689509,0.0009927092],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01090282,0.0008290448,0.20998913,0.000045818564,0.0012140266,0.00004811702,0.00059405976,0.0000063913526,0.003537169,0.038436353,0.27653772,0.45785934],"study_design_scores_gemma":[0.0033646352,0.00008351151,0.048352476,0.000004854733,0.00010356688,0.00012140334,0.000067573914,0.00056384853,0.022042558,0.00062130194,0.92455894,0.00011532569],"about_ca_topic_score_codex":0.000014361041,"about_ca_topic_score_gemma":0.0000032878115,"teacher_disagreement_score":0.6480212,"about_ca_system_score_codex":0.00010834993,"about_ca_system_score_gemma":0.000078627374,"threshold_uncertainty_score":0.9997851},"labels":[],"label_agreement":null},{"id":"W4247657589","doi":"10.2165/00019053-200523080-00010","title":"The authors’ reply","year":2005,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Case Reports on Hematomas","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Quality of Life Research; Health economics; Health administration; Public health; Medicine; Nursing","score_opus":0.023422205533933683,"score_gpt":0.35319992582309323,"score_spread":0.3297777202891595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4247657589","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.914217,0.0011287649,0.000042911928,0.04186552,0.00068935123,0.0003649334,0.000004512571,0.00017794808,0.041509047],"genre_scores_gemma":[0.978351,0.0005622034,0.00090717245,0.008391516,0.0012657148,0.000029574328,0.000005518677,0.000035951827,0.010451361],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991789,0.000012386726,0.00033252905,0.00018551188,0.00007182093,0.0002188785],"domain_scores_gemma":[0.99923176,0.00009395853,0.00010650319,0.00035826213,0.00003602097,0.0001734738],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041968256,0.00009770587,0.00015223015,0.000032872296,0.00011972929,0.00003539132,0.000071766175,0.00002755529,0.00040609358],"category_scores_gemma":[0.000056225737,0.00007280628,0.000105674415,0.000039299266,0.000051972507,0.00008386739,0.00003871159,0.00017268094,0.0006299329],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043433864,0.00035923504,0.009596304,0.00006711413,0.0004407483,0.00040261733,0.00047304347,0.00013628356,0.013341545,0.0062983814,0.58967984,0.37877056],"study_design_scores_gemma":[0.00058388145,0.000014434854,0.00062814896,0.0000051940096,0.0000571375,0.001174318,0.000024717767,0.003845154,0.022456719,0.00008744148,0.9710396,0.00008324017],"about_ca_topic_score_codex":0.000010689736,"about_ca_topic_score_gemma":0.000007696957,"teacher_disagreement_score":0.38135976,"about_ca_system_score_codex":0.00015299133,"about_ca_system_score_gemma":0.00010671754,"threshold_uncertainty_score":0.80967236},"labels":[],"label_agreement":null},{"id":"W4280518447","doi":"10.1007/s40273-022-01142-w","title":"Evaluating the Individual Healthcare Costs and Burden of Disease Associated with RSV Across Age Groups","year":2022,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Respiratory viral infections research","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Health; University of Calgary; University of British Columbia; Public Health Ontario; BC Children's Hospital; University of Toronto; Institute of Health Economics; University of Alberta","funders":"Canadian Immunization Research Network","keywords":"Medicine; Incidence (geometry); Disease burden; Comorbidity; Vaccination; Health care; Public health; Pediatrics; Health economics; Disease; Demography; Internal medicine; Immunology","score_opus":0.16119341745767313,"score_gpt":0.4793994207351008,"score_spread":0.31820600327742765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280518447","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961264,0.00047923188,0.0000026732146,0.0021096456,0.00007990119,0.0007125604,0.0003329286,0.000027136546,0.00012949438],"genre_scores_gemma":[0.9979827,0.000040395422,0.000019469699,0.0014450504,0.00009845427,0.00016849943,0.00007705946,0.000026209198,0.00014216996],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986387,0.0003205324,0.00026035807,0.00022532682,0.000286431,0.00026864512],"domain_scores_gemma":[0.9991303,0.00023326767,0.00015379391,0.00021072726,0.00008141912,0.0001904637],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014505737,0.00010620559,0.00020619281,0.000064009546,0.00046763886,0.00004109428,0.00014771566,0.000019735673,0.00018125854],"category_scores_gemma":[0.00015075652,0.00008391979,0.000043993936,0.00017889164,0.00015977913,0.0000884559,0.00028423493,0.00046195637,0.0000037634939],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0073745665,0.0009223365,0.7975661,0.00057059864,0.0019954997,0.00026456238,0.012949759,0.017873868,0.017877292,0.00086113135,0.0039167367,0.13782753],"study_design_scores_gemma":[0.031119931,0.010844501,0.81789774,0.00024927114,0.0013020048,0.00015779433,0.0122177275,0.1028863,0.005194447,0.00056653545,0.016360192,0.0012035607],"about_ca_topic_score_codex":0.00019223616,"about_ca_topic_score_gemma":0.000036444017,"teacher_disagreement_score":0.13662398,"about_ca_system_score_codex":0.0003682954,"about_ca_system_score_gemma":0.00027452142,"threshold_uncertainty_score":0.35967475},"labels":[],"label_agreement":null},{"id":"W4285726954","doi":"10.1007/s40273-022-01169-z","title":"The Cost Effectiveness of Axicabtagene Ciloleucel Versus Best Supportive Care in the Treatment of Adult Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL) After Two or More Lines of Systemic Therapy in Canada","year":2022,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Gilead Sciences (Canada); McMaster University","funders":"Gilead Sciences","keywords":"Medicine; Aggressive lymphoma; Cost effectiveness; Quality of life (healthcare); Quality-adjusted life year; Health care; Health economics; Public health; Lymphoma; Health administration; Quality of Life Research; Rituximab; Cost-effectiveness analysis; Intensive care medicine; Oncology; Internal medicine; Risk analysis (engineering); Nursing","score_opus":0.021292195897557455,"score_gpt":0.32236795008721936,"score_spread":0.3010757541896619,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285726954","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949869,0.0013531058,3.936269e-7,0.000039498907,0.00021887559,0.0025745735,0.0007131441,0.0000031108018,0.00011039978],"genre_scores_gemma":[0.99633557,0.0024558841,0.0000044204344,0.00007585262,0.000029445306,0.00084950804,0.00010477584,0.000039707174,0.00010482833],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99808925,0.0004843541,0.0005381157,0.00026743658,0.00031232904,0.0003085329],"domain_scores_gemma":[0.9979218,0.001074707,0.00030637207,0.00041027815,0.00022169796,0.0000651299],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036715946,0.00021474321,0.0005444223,0.000117238604,0.000058779726,0.000005132151,0.00025827895,0.000029786439,0.0002477952],"category_scores_gemma":[0.000018350038,0.00011749979,0.00008814367,0.00024700744,0.000087928514,0.00004251345,0.000044801654,0.00015264342,6.080516e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42984402,0.0073697525,0.47330862,0.0008528711,0.0007740229,0.00026759948,0.015890699,0.0010709045,0.012544731,0.0000037826505,0.00006254686,0.05801045],"study_design_scores_gemma":[0.439332,0.03055054,0.14430559,0.0006181967,0.0004837074,0.00003367684,0.097282834,0.0016317806,0.27601275,0.0000018808836,0.008989558,0.0007574905],"about_ca_topic_score_codex":0.11385025,"about_ca_topic_score_gemma":0.24620423,"teacher_disagreement_score":0.32900304,"about_ca_system_score_codex":0.002386184,"about_ca_system_score_gemma":0.0022766814,"threshold_uncertainty_score":0.8920507},"labels":[],"label_agreement":null},{"id":"W4285727040","doi":"10.1007/s40273-022-01151-9","title":"China Health Related Outcomes Measures (CHROME): Development of a New Generic Preference-Based Measure for the Chinese Population","year":2022,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; McMaster University Medical Centre; Impact","funders":"National Natural Science Foundation of China","keywords":"Health economics; China; Quality of Life Research; Health administration; Measure (data warehouse); Preference; Population health; Public health; Population; Environmental health; Medicine; Geography; Statistics; Computer science; Data mining; Nursing; Mathematics","score_opus":0.5756447524729171,"score_gpt":0.49666025212832327,"score_spread":0.07898450034459387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285727040","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00065664505,0.9807618,0.0040516127,0.0049882624,0.0022787873,0.0055103526,0.0014701628,0.00009525163,0.00018710345],"genre_scores_gemma":[0.0014561252,0.9842895,0.0060756295,0.002660029,0.00048664724,0.0022854828,0.0018577323,0.0002766113,0.00061224453],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9863553,0.00070456293,0.010976392,0.0010868118,0.00018599635,0.00069091725],"domain_scores_gemma":[0.984883,0.0019236514,0.011845783,0.0009619619,0.000047580077,0.00033799192],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.019938163,0.00079589867,0.005273789,0.00071798894,0.0007398211,0.00010044991,0.0011806255,0.0002827734,0.001156176],"category_scores_gemma":[0.0015462374,0.0007404702,0.0010752901,0.0004571645,0.00005324694,0.00029404782,0.00014939925,0.0006072873,0.00020281997],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000059432605,0.00033527284,0.0036667762,0.025439363,0.0028586958,3.8581663e-7,0.0033152923,0.004087752,7.7725176e-8,0.0037424457,0.01932159,0.9371729],"study_design_scores_gemma":[0.0013590639,0.000053088883,0.0034070069,0.00052501954,0.00016158617,0.0000045290176,0.00004991688,0.0025507694,1.7666859e-7,0.0009837399,0.9901776,0.00072755234],"about_ca_topic_score_codex":0.0017716527,"about_ca_topic_score_gemma":0.00032647318,"teacher_disagreement_score":0.97085595,"about_ca_system_score_codex":0.0032586923,"about_ca_system_score_gemma":0.0037514274,"threshold_uncertainty_score":0.99975693},"labels":[],"label_agreement":null},{"id":"W4287092191","doi":"10.1007/s40273-022-01175-1","title":"Collaborating with Patient Partners to Model Clinical Care Pathways in Major Depressive Disorder: The Benefits of Mixing Evidence and Lived Experience","year":2022,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Mental Health and Patient Involvement","field":"Health Professions","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre for Advancing Health Outcomes; Vancouver Coastal Health Research Institute; University of British Columbia; Arthritis Research Centre of Canada; Vancouver Coastal Health","funders":"Genome British Columbia; Michael Smith Health Research BC; Genome Canada","keywords":"General partnership; Health care; Best practice; Process (computing); Medicine; Psychology; Process management; Knowledge management; Nursing; Business; Computer science; Political science","score_opus":0.3285797779699407,"score_gpt":0.49089423232397783,"score_spread":0.16231445435403713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4287092191","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950868,0.0018348022,0.000040618423,0.00031944553,0.0003162426,0.0020655727,0.00016202395,0.000012042972,0.00016244387],"genre_scores_gemma":[0.9928335,0.00037388556,0.00061715266,0.0044510993,0.000033724944,0.0016414595,0.000021831738,0.00001673174,0.000010622006],"study_design_codex":"observational","study_design_gemma":"qualitative","domain_scores_codex":[0.9978092,0.00048866635,0.00084216945,0.00033608056,0.00015430176,0.00036958768],"domain_scores_gemma":[0.9983455,0.00075127004,0.0004260766,0.0002040521,0.00008339736,0.00018968427],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00061388954,0.00013228005,0.00024903688,0.00005369808,0.0008595753,0.0000065791883,0.00020855265,0.000031072366,0.00005097528],"category_scores_gemma":[0.00004169767,0.00010589889,0.000023828376,0.00014174372,0.00005052354,0.00011565369,0.00042318777,0.00040258863,0.0000032737867],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00074520655,0.00010652923,0.7262782,0.00037297216,0.00001112038,0.0000016367225,0.17016733,0.09310128,0.00007950385,0.00018913586,0.00014253384,0.0088045625],"study_design_scores_gemma":[0.009260781,0.0028202385,0.021929676,0.002020729,0.00008558953,0.0000022051274,0.7275593,0.22902566,0.0018015293,0.0001242589,0.0044799345,0.0008900917],"about_ca_topic_score_codex":0.00042810212,"about_ca_topic_score_gemma":0.00075663824,"teacher_disagreement_score":0.7043485,"about_ca_system_score_codex":0.0002517599,"about_ca_system_score_gemma":0.0003989291,"threshold_uncertainty_score":0.6611245},"labels":[],"label_agreement":null},{"id":"W4288176181","doi":"10.1007/s40273-022-01176-0","title":"Tools for the Economic Evaluation of Precision Medicine: A Scoping Review of Frameworks for Valuing Heterogeneity-Informed Decisions","year":2022,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; Vancouver Coastal Health; Canadian Centre for Applied Research in Cancer Control; Vancouver Coastal Health Research Institute; University of British Columbia","funders":"Canadian Institutes of Health Research; Canadian Cancer Society","keywords":"EconLit; Precision medicine; Psychological intervention; Health care; Health economics; Cost–benefit analysis; MEDLINE; Computer science; Management science; Actuarial science; Risk analysis (engineering); Medicine; Business; Economics","score_opus":0.7536605107723361,"score_gpt":0.6234118746189133,"score_spread":0.13024863615342275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4288176181","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000035105248,0.96098554,0.009451349,0.0016940992,0.0032250825,0.020299174,0.0038411214,0.000025599886,0.00044293454],"genre_scores_gemma":[0.000018281042,0.98214877,0.0028039773,0.0031160857,0.0008827977,0.009970307,0.0008849507,0.00014966681,0.000025181622],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9822314,0.00087489496,0.014952778,0.0010893873,0.00024827092,0.0006032886],"domain_scores_gemma":[0.92190933,0.05995158,0.016257754,0.0014153223,0.00027776253,0.00018824234],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.07468908,0.000647599,0.0063954997,0.0006815935,0.00042950208,0.000079002966,0.0015422293,0.00047607612,0.0025672347],"category_scores_gemma":[0.036223616,0.00064086705,0.001767017,0.00023633908,0.00016760563,0.0007261453,0.00027192457,0.0006022374,0.00009302712],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000045863733,0.0000611616,0.0000077679815,0.2699084,0.0011041715,4.8217853e-8,0.00033971094,0.0027805762,9.2998356e-8,0.0070904684,0.022679131,0.69598264],"study_design_scores_gemma":[0.0013967211,0.00012565599,0.0000016840413,0.13137677,0.0014760839,0.0000062085996,0.00013145419,0.020084282,0.0000020617242,0.00258435,0.84228736,0.0005273857],"about_ca_topic_score_codex":0.00008359256,"about_ca_topic_score_gemma":0.000047995003,"teacher_disagreement_score":0.8196082,"about_ca_system_score_codex":0.003402625,"about_ca_system_score_gemma":0.003689997,"threshold_uncertainty_score":0.9996043},"labels":[],"label_agreement":null},{"id":"W4288748903","doi":"10.1007/s40273-022-01179-x","title":"Developing an Online Infrastructure to Enhance Model Accessibility and Validation: The Peer Models Network","year":2022,"lang":"en","type":"letter","venue":"PharmacoEconomics","topic":"Healthcare Systems and Technology","field":"Business, Management and Accounting","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; Centre for Advancing Health Outcomes; University of British Columbia; St. Paul's Hospital; University of British Columbia Hospital","funders":"","keywords":"Quality of Life Research; Health economics; Health administration; Public health; Health informatics; Peer review; Computer science; Business; Process management; Medicine; Nursing; Political science","score_opus":0.07771509447881658,"score_gpt":0.35066329016791425,"score_spread":0.2729481956890977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4288748903","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.17349017,0.0001481841,0.0077681714,0.81466275,0.0017023302,0.0010001296,0.00015397953,0.00022861725,0.00084565463],"genre_scores_gemma":[0.06024961,0.00006579083,0.0027644625,0.9214339,0.013778964,0.00018012646,0.001050169,0.00009744559,0.00037951756],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979198,0.000043189233,0.00059361215,0.0007394549,0.00019778586,0.0005061546],"domain_scores_gemma":[0.9987467,0.00005290565,0.0004412604,0.0005506204,0.00018651878,0.000022001701],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00080845726,0.0003595393,0.0004392096,0.00016059118,0.0005110037,0.000411862,0.0008798872,0.0003358403,0.00023339948],"category_scores_gemma":[0.00002876731,0.00031371706,0.00006190741,0.00020453373,0.00004676947,0.0010422819,0.00089391036,0.0015654939,0.000020088472],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000022879269,0.000009469912,0.00026235936,0.00039452538,0.000055444147,0.000009428832,0.000097537755,0.094071,0.0000036843064,0.005132134,0.87456566,0.02537586],"study_design_scores_gemma":[0.00008655861,0.0000037617574,0.0000468009,0.000013956941,0.000031936375,0.0000035473352,0.000033817938,0.20794864,0.0000037021318,0.03282875,0.7586801,0.00031840024],"about_ca_topic_score_codex":0.00058756967,"about_ca_topic_score_gemma":0.0001584966,"teacher_disagreement_score":0.11588555,"about_ca_system_score_codex":0.00025641182,"about_ca_system_score_gemma":0.00018653554,"threshold_uncertainty_score":0.9999315},"labels":[],"label_agreement":null},{"id":"W4294992035","doi":"10.1007/s40273-022-01180-4","title":"Engaging Patients and Caregivers in an Early Health Economic Evaluation: Discerning Treatment Value Based on Lived Experience","year":2022,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Centre for Applied Research in Cancer Control; Ottawa Public Health; University of Toronto; Sunnybrook Health Science Centre; University of Ottawa; Ottawa Hospital","funders":"Ontario Institute for Cancer Research","keywords":"Economic evaluation; Medicine; Quality of life (healthcare); Health economics; Qualitative research; Health care; Public health; Nursing; Political science","score_opus":0.37430102742359167,"score_gpt":0.4838093124781059,"score_spread":0.10950828505451421,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294992035","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890372,0.00047904294,0.00008178901,0.0063416837,0.0010162737,0.0014791149,0.00051613257,0.00004817042,0.0010005559],"genre_scores_gemma":[0.9897102,0.00009449996,0.00037472192,0.00853654,0.00015571297,0.0008294312,0.00018890512,0.0000567394,0.00005322161],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9947339,0.0011135481,0.0024455094,0.0010425828,0.00011068993,0.0005537593],"domain_scores_gemma":[0.9970318,0.0005451887,0.001612183,0.00045151453,0.000023124436,0.0003361714],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.008030297,0.00031532088,0.00085586775,0.0005590482,0.0006951696,0.00013667614,0.00032821918,0.000049418057,0.0011083797],"category_scores_gemma":[0.0001423561,0.00045716937,0.0001002479,0.00009465619,0.000064168045,0.00070715573,0.00009554506,0.00027797924,0.00018015485],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017500177,0.000548273,0.6694895,0.000069323025,0.000058059082,0.0000017847145,0.03873202,0.2800507,0.0000029972036,0.004556435,0.0009295981,0.0053862915],"study_design_scores_gemma":[0.007914181,0.00096655264,0.09035787,0.000025495385,0.000012900071,0.0000014458597,0.00819261,0.87932265,0.00001539906,0.00064266735,0.011826165,0.0007220761],"about_ca_topic_score_codex":0.003901627,"about_ca_topic_score_gemma":0.00023690703,"teacher_disagreement_score":0.59927195,"about_ca_system_score_codex":0.008336136,"about_ca_system_score_gemma":0.00049078715,"threshold_uncertainty_score":0.99980474},"labels":[],"label_agreement":null},{"id":"W4308954619","doi":"10.1007/s40273-022-01198-8","title":"Patient Preferences in Targeted Pharmacotherapy for Cancers: A Systematic Review of Discrete Choice Experiments","year":2022,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Economic and Environmental Valuation","field":"Economics, Econometrics and Finance","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Macquarie University","keywords":"Quality of Life Research; Health economics; Pharmacotherapy; Pharmacoeconomics; Health administration; Medicine; Public health; Intensive care medicine; Oncology; Internal medicine; Nursing","score_opus":0.21727704471184267,"score_gpt":0.37035633105890164,"score_spread":0.15307928634705897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308954619","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013630277,0.99011326,0.00003522136,0.000017178296,0.0008156462,0.0056753806,0.002249155,0.000016637186,0.0009412029],"genre_scores_gemma":[0.00013220702,0.9912668,0.0001535972,0.00058497244,0.00007308662,0.006966041,0.0006141689,0.00009983034,0.00010929904],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.99548155,0.00013077763,0.0032240297,0.00074905367,0.000046710345,0.0003678663],"domain_scores_gemma":[0.9958616,0.00032404278,0.0032872185,0.00042570118,0.000007931596,0.000093511815],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010049631,0.0004972416,0.0036324468,0.00033187386,0.00006905258,0.000027921811,0.0005407113,0.00011046213,0.0043738848],"category_scores_gemma":[0.00007127728,0.0005523123,0.00073405716,0.00015878958,0.000044980567,0.0002788534,0.00012084609,0.00025905814,0.00010479462],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000012589037,0.0001382063,0.00008633615,0.9691185,0.00070157705,5.4238166e-7,0.00028356398,0.00008765609,6.660794e-7,0.000448463,0.0009807657,0.028141186],"study_design_scores_gemma":[0.0009417575,0.000108707114,0.00000217933,0.08541129,0.00049332227,0.0000024336837,0.000060766306,0.00058800384,0.000018820678,0.0002601507,0.91136646,0.00074612803],"about_ca_topic_score_codex":0.00019655176,"about_ca_topic_score_gemma":0.0000073532697,"teacher_disagreement_score":0.91038567,"about_ca_system_score_codex":0.00192185,"about_ca_system_score_gemma":0.00013062204,"threshold_uncertainty_score":0.99969286},"labels":[],"label_agreement":null},{"id":"W4310595031","doi":"10.1007/s40273-022-01225-8","title":"Best Practices: A Collection of Systematic Critical Reviews of Modeling Approaches in Specific Disease Areas","year":2022,"lang":"en","type":"editorial","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Quality of Life Research; Health economics; Public health; Health administration; Systematic review; Disease; MEDLINE; Management science; Medicine; Political science; Economics; Pathology","score_opus":0.6882038685906825,"score_gpt":0.5168785522757147,"score_spread":0.17132531631496783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310595031","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0067185126,0.16398013,0.0037480718,0.0056166006,0.79433185,0.011034257,0.008107123,0.000078105215,0.006385323],"genre_scores_gemma":[0.09331979,0.18866605,0.00972787,0.002429929,0.6842302,0.013624982,0.003852884,0.0011222789,0.0030260056],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.983662,0.001612033,0.012811197,0.0011707996,0.0002337426,0.00051019556],"domain_scores_gemma":[0.9757267,0.00727678,0.015455209,0.0010769806,0.00015484776,0.00030948748],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.031373903,0.00051730307,0.0045306925,0.0011216607,0.00015254875,0.00008705725,0.00085460424,0.00039137903,0.0011725358],"category_scores_gemma":[0.029191064,0.0007173445,0.00053177366,0.0003634146,0.00011830318,0.0007689794,0.00019899332,0.0010100503,0.00031160875],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035097802,0.001239891,0.0010876253,0.21590605,0.00032363617,0.0000049091013,0.002191774,0.017961266,0.0000016910224,0.012221739,0.7486797,0.000030745665],"study_design_scores_gemma":[0.0023723703,0.00016861732,0.000013381862,0.0074906796,0.00036160013,0.000004094123,0.0024556827,0.38774443,0.0000035574014,0.0051881927,0.5928022,0.0013951795],"about_ca_topic_score_codex":0.0012792861,"about_ca_topic_score_gemma":0.000109390625,"teacher_disagreement_score":0.36978316,"about_ca_system_score_codex":0.0022676648,"about_ca_system_score_gemma":0.0009841303,"threshold_uncertainty_score":0.99974054},"labels":[],"label_agreement":null},{"id":"W4311329766","doi":"10.1007/s40273-022-01197-9","title":"Caregiver Burden of Spinal Muscular Atrophy: A Systematic Review","year":2022,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Neurogenetic and Muscular Disorders Research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital; Children's Hospital of Eastern Ontario; McGill University","funders":"","keywords":"Caregiver burden; SMA*; Medicine; Spinal muscular atrophy; Quality of life (healthcare); Anxiety; Caregiver stress; Disease burden; Gerontology; Disease; Psychiatry; Physical therapy; Nursing; Pathology","score_opus":0.07882230820770512,"score_gpt":0.41957258342108233,"score_spread":0.3407502752133772,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311329766","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000100678935,0.99265414,0.0000074747554,0.000072411436,0.00019787857,0.005892956,0.00006709669,0.000025776164,0.0010722026],"genre_scores_gemma":[0.0000068228633,0.9977378,0.000042214706,0.00035390456,0.00014694134,0.0009477371,0.00015343464,0.00011950202,0.00049159664],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970696,0.000410955,0.0012558615,0.0005433053,0.00036516617,0.0003551062],"domain_scores_gemma":[0.9980717,0.00009851852,0.00065061817,0.0008871394,0.00006475057,0.00022732235],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00057711866,0.0004483539,0.0043576565,0.00026570534,0.000060924714,0.000012018806,0.0005342041,0.00009793131,0.0023128977],"category_scores_gemma":[0.000103883736,0.00038311526,0.0019606582,0.00025428587,0.00008041128,0.00003206143,0.00029461563,0.00064601604,0.00019537956],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000011514482,0.000045509332,1.19133446e-7,0.89298236,0.0012149871,0.00008713563,0.000021858841,0.0000012757404,0.0000012509931,0.000017448072,0.0007832333,0.1048333],"study_design_scores_gemma":[0.00040562547,0.00012671448,2.5081407e-8,0.21311222,0.014128201,0.00029093173,0.000025739204,0.000017987975,0.00000149325,0.0000019181348,0.7716697,0.00021944537],"about_ca_topic_score_codex":0.000036368918,"about_ca_topic_score_gemma":2.5098294e-7,"teacher_disagreement_score":0.7708865,"about_ca_system_score_codex":0.00028480423,"about_ca_system_score_gemma":0.0008651878,"threshold_uncertainty_score":0.9998621},"labels":[],"label_agreement":null},{"id":"W4317474345","doi":"10.1007/s40273-022-01232-9","title":"Whether and How Disutilities of Adverse Events were Used in the Economic Evaluation of Drug Therapy for Cancer Treatment","year":2023,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Government of Jiangsu Province","keywords":"Quality of Life Research; Health economics; Medicine; Adverse effect; Public health; Cancer therapy; Drug; Cancer; Health administration; Cancer drugs; Intensive care medicine; Pharmacotherapy; Pharmacoeconomics; Pharmacology; Internal medicine; Nursing","score_opus":0.6428468017640477,"score_gpt":0.5620661032464104,"score_spread":0.08078069851763736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317474345","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.059203483,0.92433304,0.0000109351695,0.0026684608,0.00095458253,0.006439803,0.0062381784,0.000017609558,0.00013390451],"genre_scores_gemma":[0.0063727885,0.98860496,0.00006979501,0.0002752709,0.00033863256,0.003665765,0.00020901875,0.00010551114,0.00035824854],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9939423,0.00093240506,0.0039347983,0.0007204733,0.00008806508,0.0003819116],"domain_scores_gemma":[0.99148756,0.002812808,0.0049829064,0.00057831575,0.000056471174,0.0000819582],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.018944573,0.00047929186,0.0033387113,0.00054881134,0.000084023835,0.000021312164,0.00048493812,0.00020265624,0.00023227629],"category_scores_gemma":[0.00023230145,0.0004505155,0.0006070535,0.00010045443,0.000109769164,0.00034008382,0.000046160556,0.00016014793,0.000080575504],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043676564,0.0014949692,0.03819375,0.11006061,0.011202044,0.0000012883818,0.050470803,0.0081652235,0.000001791288,0.050250217,0.02751382,0.7022087],"study_design_scores_gemma":[0.0047351066,0.00011487969,0.0005346836,0.0016743349,0.0005136779,0.0000019506028,0.0024117336,0.011222108,0.0000050819417,0.0051018344,0.9729997,0.0006849465],"about_ca_topic_score_codex":0.0015367746,"about_ca_topic_score_gemma":0.0011095725,"teacher_disagreement_score":0.94548583,"about_ca_system_score_codex":0.0022549296,"about_ca_system_score_gemma":0.0010555668,"threshold_uncertainty_score":0.99979466},"labels":[],"label_agreement":null},{"id":"W4317613981","doi":"10.1007/s40273-022-01238-3","title":"Population-Based Screening Using Low-Dose Chest Computed Tomography: A Systematic Review of Health Economic Evaluations","year":2023,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"University of Twente; ZonMw","keywords":"Medicine; Lung cancer screening; Context (archaeology); Cost effectiveness; Population; Quality-adjusted life year; Lung cancer; Cost-effectiveness analysis; Health care; Intensive care medicine; Internal medicine; Environmental health","score_opus":0.14688918361923978,"score_gpt":0.4771261555207007,"score_spread":0.33023697190146095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317613981","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000040073235,0.99135256,0.00014866327,0.0002609602,0.00043256173,0.007169259,0.0004867861,0.00009377932,0.000015342048],"genre_scores_gemma":[0.00012263095,0.994626,0.001172442,0.0008846564,0.00017390806,0.0007326916,0.0021425826,0.0001347548,0.000010366395],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99587065,0.00038982678,0.0027068038,0.00054443977,0.00016235399,0.00032593278],"domain_scores_gemma":[0.99598324,0.0005390382,0.0025551566,0.0006271096,0.00008346308,0.0002120085],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014063274,0.000511518,0.005231222,0.00051550654,0.00011444166,0.0000291657,0.00020208574,0.00010665089,0.000117355135],"category_scores_gemma":[0.000050457835,0.00045859165,0.0012650815,0.00031603334,0.00002869974,0.000072210874,0.000051193158,0.00022302597,0.00007317975],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000040870664,0.00010681575,0.00014664677,0.96954787,0.0016227477,0.00000298532,0.000008691111,0.00068715547,1.995787e-8,0.000018431578,0.0002782828,0.027576258],"study_design_scores_gemma":[0.001063967,0.000051439332,0.00005868508,0.96396965,0.013849945,0.000019926627,0.000004016261,0.015313103,9.478307e-7,0.0000039729057,0.005339628,0.0003247165],"about_ca_topic_score_codex":0.00048977934,"about_ca_topic_score_gemma":0.000022923328,"teacher_disagreement_score":0.027251543,"about_ca_system_score_codex":0.0022763184,"about_ca_system_score_gemma":0.0020584988,"threshold_uncertainty_score":0.99978656},"labels":[],"label_agreement":null},{"id":"W4318345202","doi":"10.1007/s40273-022-01236-5","title":"Cost Effectiveness of Implementing a Universal Birth Hepatitis B Vaccination Program in Ontario","year":2023,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Hepatitis B Virus Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Waterloo","funders":"Ontario Ministry of Research and Innovation; Canadian Institutes of Health Research","keywords":"Medicine; Vaccination; Hepatitis B; Public health; Health economics; Cost effectiveness; Cost-effectiveness analysis; Environmental health; Hepatitis B vaccine; Demography; Pediatrics; Immunology; Hepatitis B virus; Risk analysis (engineering)","score_opus":0.05315135069654738,"score_gpt":0.37040243647340376,"score_spread":0.3172510857768564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318345202","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99518394,0.000019471365,0.000028339924,0.000080608035,0.00015744845,0.001202067,0.000028282302,0.00010173043,0.0031981093],"genre_scores_gemma":[0.99898773,0.00026136366,0.0002403101,0.000043588174,0.000029020792,0.00015669223,0.00007985489,0.000020742666,0.00018071517],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991037,0.00006057461,0.0002876046,0.00019656798,0.000068608366,0.00028290972],"domain_scores_gemma":[0.99953455,0.00015330302,0.00009960423,0.00009696312,0.000061222454,0.00005436691],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053479936,0.00010963423,0.00030080188,0.0002577351,0.000043443237,0.0000090223775,0.000058703812,0.000030825257,0.0002520574],"category_scores_gemma":[0.000034564022,0.00012584621,0.00006001983,0.00022374821,0.000018817147,0.00012844155,0.00009336372,0.00014299173,0.000053323503],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014305662,0.00010383875,0.9670176,0.0002156392,0.000096538424,0.000028918406,0.0007196103,0.000102681406,0.0014067912,0.00016280147,0.00022268074,0.029779878],"study_design_scores_gemma":[0.002999218,0.00012583258,0.96937007,0.000066454864,0.000042955475,0.0000025464885,0.00006318753,0.0052291127,0.008570728,0.000060190883,0.013362501,0.000107195454],"about_ca_topic_score_codex":0.10331867,"about_ca_topic_score_gemma":0.34791067,"teacher_disagreement_score":0.244592,"about_ca_system_score_codex":0.0007995098,"about_ca_system_score_gemma":0.00019094288,"threshold_uncertainty_score":0.9026524},"labels":[],"label_agreement":null},{"id":"W4318832711","doi":"10.1007/s40273-023-01244-z","title":"Filgotinib for Treating Moderately to Severely Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal","year":2023,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Health Technology Assessment Programme; National Institute for Health and Care Research","keywords":"Nice; Medicine; Excellence; Health technology; Critical appraisal; Population; Systematic review; Health care; Family medicine; Health economics; Population health; MEDLINE; Public health; Alternative medicine; Nursing; Pathology; Political science; Environmental health","score_opus":0.5971191702844785,"score_gpt":0.5753690734773254,"score_spread":0.02175009680715312,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318832711","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00019919062,0.9716482,0.0021170455,0.006414665,0.001089296,0.009119337,0.008284153,0.00023434685,0.0008937214],"genre_scores_gemma":[0.000108816675,0.9833779,0.0061142743,0.0035273691,0.0007742573,0.0050906134,0.0003492587,0.00029994332,0.00035759262],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.98777544,0.0008661244,0.008161384,0.0021316803,0.000106627864,0.00095875177],"domain_scores_gemma":[0.98214775,0.0077393292,0.0081889285,0.0010333011,0.00044382853,0.00044687444],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.011322726,0.00092496764,0.007137796,0.0012981991,0.00030606033,0.00012966801,0.0012099529,0.0005617814,0.00023199679],"category_scores_gemma":[0.011603661,0.0012017167,0.00086281926,0.0008685432,0.0001675361,0.0012207282,0.0002720408,0.00064869993,0.0012642156],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001363523,0.0014710776,0.000021149523,0.31011635,0.005882687,0.000011968904,0.009572309,0.00062983454,0.0000023139378,0.30914506,0.071089566,0.29069415],"study_design_scores_gemma":[0.0011561016,0.0008872444,0.00002650561,0.051435538,0.0007842002,0.00004148552,0.0022925222,0.0030836896,0.000013204809,0.007964887,0.93042016,0.0018944901],"about_ca_topic_score_codex":0.0005791086,"about_ca_topic_score_gemma":0.00035728616,"teacher_disagreement_score":0.8593306,"about_ca_system_score_codex":0.0035390945,"about_ca_system_score_gemma":0.0009948359,"threshold_uncertainty_score":0.9995134},"labels":[],"label_agreement":null},{"id":"W4318922016","doi":"10.1007/s40273-022-01235-6","title":"Identifying Attributes for a Value Assessment Framework in China: A Qualitative Study","year":2023,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; McMaster University Medical Centre; Impact","funders":"","keywords":"Quality of Life Research; Health economics; Health administration; Public health; China; Value (mathematics); Qualitative research; Medicine; Statistics; Geography; Mathematics; Sociology; Nursing; Social science","score_opus":0.5276679003206807,"score_gpt":0.60088825065496,"score_spread":0.07322035033427932,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318922016","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9458735,0.00045585298,0.023498662,0.022637295,0.0020020313,0.003443956,0.0010861456,0.00021917371,0.00078336924],"genre_scores_gemma":[0.9832814,0.00018040306,0.009326785,0.004156462,0.000558323,0.0018798042,0.00014644615,0.00009801764,0.00037236078],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9928081,0.0006725668,0.0046075415,0.0010150345,0.00008757638,0.00080919365],"domain_scores_gemma":[0.9934314,0.003985322,0.0018061094,0.00051352294,0.000048610593,0.00021507184],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.033346146,0.00033500555,0.0013899748,0.00089095795,0.00029623896,0.00021027718,0.0005203714,0.0001502166,0.00028563075],"category_scores_gemma":[0.002176664,0.00047776103,0.0002331438,0.00053779193,0.00005463835,0.0007789568,0.00016068925,0.00040606645,0.0019033636],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012202451,0.0012020894,0.14437486,0.0009776797,0.0007516629,0.0000106062635,0.20842995,0.0100873895,0.000028251186,0.585781,0.04781769,0.00041683644],"study_design_scores_gemma":[0.0069337306,0.0003866028,0.105378635,0.0001941269,0.000055015902,0.000003560039,0.13376382,0.17112224,0.00004225459,0.5593547,0.021090474,0.0016748138],"about_ca_topic_score_codex":0.0007671801,"about_ca_topic_score_gemma":0.00013022264,"teacher_disagreement_score":0.16103485,"about_ca_system_score_codex":0.0013808387,"about_ca_system_score_gemma":0.00020544603,"threshold_uncertainty_score":0.9997674},"labels":[],"label_agreement":null},{"id":"W4323920777","doi":"10.1007/s40273-022-01234-7","title":"Capturing the Impact of Constraints on the Cost-Effectiveness of Cell and Gene Therapies: A Systematic Review","year":2023,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Innovate UK; National Institute for Health and Care Research","keywords":"Medicine; Health care; MEDLINE; Health economics; Systematic review; Payment; Economic evaluation; Cost effectiveness; Actuarial science; Public health; Risk analysis (engineering); Business; Nursing; Economics; Pathology; Finance; Biology","score_opus":0.531812539584388,"score_gpt":0.5290833640695236,"score_spread":0.0027291755148644015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323920777","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007019306,0.98510486,0.000047551883,0.00046268158,0.00032118591,0.010459294,0.0022444755,0.000024939407,0.00063306064],"genre_scores_gemma":[0.0026415635,0.9945755,0.000021714855,0.00086469017,0.00010706657,0.0015884035,0.00004705173,0.00010620703,0.000047797057],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9897007,0.00244478,0.0067665093,0.0006120948,0.000079582125,0.00039633503],"domain_scores_gemma":[0.9755288,0.014429445,0.008819964,0.0010265436,0.000069615744,0.00012564078],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.034644306,0.00056207774,0.0064185066,0.00030143614,0.0001442293,0.000059271184,0.00087149075,0.00018256297,0.0002351792],"category_scores_gemma":[0.0017520944,0.00037784738,0.001082906,0.00024611695,0.00031470833,0.0001357424,0.00013351384,0.00045349877,0.00055506954],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000007531894,0.000059030688,0.00001659672,0.9908612,0.0015850012,6.500429e-7,0.00038656927,0.000055129378,6.624031e-7,0.0049556675,0.0010750917,0.0009968795],"study_design_scores_gemma":[0.0019961759,0.0002952913,0.00010113599,0.9493625,0.003050582,0.00008535495,0.0007932542,0.0017485957,0.00003402129,0.0036004104,0.036914546,0.0020181446],"about_ca_topic_score_codex":0.00027759824,"about_ca_topic_score_gemma":0.000003803579,"teacher_disagreement_score":0.041498702,"about_ca_system_score_codex":0.00075285265,"about_ca_system_score_gemma":0.00045418827,"threshold_uncertainty_score":0.9998673},"labels":[],"label_agreement":null},{"id":"W4362704228","doi":"10.1007/s40273-023-01262-x","title":"Developing a Framework of Cost Elements of Socioeconomic Burden of Rare Disease: A Scoping Review","year":2023,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Genomics and Rare Diseases","field":"Biochemistry, Genetics and Molecular Biology","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Alberta Health Services; SickKids Foundation; University of Toronto; Ontario Genomics; Children's Hospital of Eastern Ontario; Genome Canada; Alberta Bone and Joint Health Institute; McGill University; University of Ottawa; Institute for Clinical Evaluative Sciences; University of Calgary; Alberta Children's Hospital","funders":"Canadian Institutes of Health Research","keywords":"EconLit; PsycINFO; Health economics; Socioeconomic status; Medicine; Health care; Systematic review; MEDLINE; Health administration; Rare disease; Comparability; Public health; Family medicine; Disease; Nursing; Environmental health; Population; Political science; Economic growth; Economics; Pathology","score_opus":0.06618045749901443,"score_gpt":0.42112342945115405,"score_spread":0.35494297195213964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362704228","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00090066326,0.9950694,0.00014730512,0.000030482697,0.00027917273,0.0018281298,0.0017085881,0.00000770978,0.000028545108],"genre_scores_gemma":[0.00015462533,0.997282,0.00077262876,0.00012398152,0.00022788146,0.00020691099,0.0011008385,0.00009804163,0.00003306849],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973085,0.00009691773,0.001748529,0.00049504224,0.00007352927,0.0002775046],"domain_scores_gemma":[0.99727696,0.00009575688,0.0018460163,0.0005316178,0.00010467074,0.00014497801],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003443405,0.00039070236,0.0018289933,0.00012851911,0.000034718196,0.000008929966,0.00061799545,0.00018845471,0.000104085884],"category_scores_gemma":[0.00011609591,0.00040802907,0.0008522868,0.00009074127,0.00010432859,0.0000052454457,0.00041379486,0.00013846411,0.000027347807],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000058461606,0.00008021979,0.000079895086,0.7164438,0.0020862902,0.0000072374,0.000026193988,0.00006411854,0.00012635464,0.000348055,0.0012135517,0.27946582],"study_design_scores_gemma":[0.00068003265,0.00006921647,0.0000076411225,0.4607175,0.0032153132,0.0000087454055,0.000035455065,0.000027490469,0.0010935166,0.0002825707,0.5327554,0.0011071586],"about_ca_topic_score_codex":0.000011621047,"about_ca_topic_score_gemma":0.0000026871112,"teacher_disagreement_score":0.5315418,"about_ca_system_score_codex":0.000073735755,"about_ca_system_score_gemma":0.0017583799,"threshold_uncertainty_score":0.99983716},"labels":[],"label_agreement":null},{"id":"W4367187286","doi":"10.1007/s40273-023-01274-7","title":"Patient and Public Involvement in Health Economics Modelling Raises the Need for Normative Guidance","year":2023,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Mental Health and Patient Involvement","field":"Health Professions","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of British Columbia Hospital","funders":"Michael Smith Health Research BC","keywords":"Normative; Health economics; Public health; Health administration; Perspective (graphical); Interpretation (philosophy); Quality of Life Research; Public relations; Value (mathematics); Health policy; Public finance; Medicine; Positive economics; Public economics; Engineering ethics; Sociology; Political science; Economics; Nursing; Computer science; Law","score_opus":0.31200491538175945,"score_gpt":0.4432809946576637,"score_spread":0.13127607927590423,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4367187286","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97996324,0.0007933849,0.000955667,0.011659324,0.0014210824,0.004244902,0.00033180905,0.000074774434,0.000555796],"genre_scores_gemma":[0.9507977,0.0083103,0.0009100376,0.036533024,0.0002448653,0.002546072,0.0004362412,0.00004922089,0.00017256697],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9972108,0.0002962337,0.0012231653,0.00032339283,0.00006537048,0.0008810429],"domain_scores_gemma":[0.9981074,0.0008084144,0.00053400756,0.00021002306,0.000054670585,0.00028548273],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019133594,0.0001927454,0.00031152696,0.00018483681,0.0009375343,0.00002271402,0.00017302856,0.00005968708,0.00005858911],"category_scores_gemma":[0.000016466503,0.00016488801,0.000051363164,0.00014568136,0.00004940416,0.00024028549,0.0001819161,0.00030403506,0.00012127427],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017625173,0.0009039567,0.29174152,0.016918175,0.0003409203,0.000002914497,0.1785081,0.19971557,0.00006698303,0.066933535,0.13202727,0.11107854],"study_design_scores_gemma":[0.003406144,0.00024209303,0.00042722275,0.000261449,0.0000075598523,2.8956916e-7,0.022660982,0.64753383,0.00008322359,0.005076226,0.32000145,0.0002994989],"about_ca_topic_score_codex":0.00080684316,"about_ca_topic_score_gemma":0.00072476827,"teacher_disagreement_score":0.44781828,"about_ca_system_score_codex":0.0006800507,"about_ca_system_score_gemma":0.00046916865,"threshold_uncertainty_score":0.7210851},"labels":[],"label_agreement":null},{"id":"W4372295364","doi":"10.1007/s40273-023-01271-w","title":"Cost-Effectiveness of Thrombopoietin Mimetics in Patients with Thrombocytopenia: A Systematic Review","year":2023,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Platelet Disorders and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital; University of Alberta; Alberta Environment and Protected Areas","funders":"","keywords":"Health economics; Quality of Life Research; Thrombopoietin; Medicine; Pharmacoeconomics; Public health; Intensive care medicine; Quality-adjusted life year; Romiplostim; Cost effectiveness; Pathology","score_opus":0.08885232747354482,"score_gpt":0.4068468718428829,"score_spread":0.31799454436933805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4372295364","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001010819,0.98268205,0.000002201837,0.0000085208185,0.0001257436,0.015678082,0.00025451652,0.000036142454,0.00020194153],"genre_scores_gemma":[0.00014039883,0.99759936,0.000048529324,0.00008717567,0.0000119040205,0.0012063595,0.00073092274,0.00013394275,0.00004139006],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99737865,0.0003473065,0.0012993602,0.00047613116,0.00017441106,0.00032413582],"domain_scores_gemma":[0.997917,0.0005264389,0.00084596634,0.0005016503,0.00008988201,0.00011909326],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006880737,0.00055101415,0.008020167,0.00025241118,0.000022976763,0.000012054824,0.00023174459,0.000159904,0.00005016827],"category_scores_gemma":[0.00008093399,0.00038561417,0.00044766508,0.00040227585,0.000058366753,0.00007434914,0.00008605145,0.00034406132,0.00026126852],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006351501,0.00049326103,0.00024180245,0.9916311,0.0018009888,0.000073374205,0.000011632747,0.0000010581966,4.456242e-8,0.000009663832,0.00009035822,0.0055832206],"study_design_scores_gemma":[0.0044304645,0.00024636355,0.00014847779,0.9706779,0.016677277,0.00003409501,0.0000049845894,0.000006476603,0.000003569567,0.000010852251,0.0073634987,0.00039605208],"about_ca_topic_score_codex":0.00001919094,"about_ca_topic_score_gemma":0.000005300418,"teacher_disagreement_score":0.020953191,"about_ca_system_score_codex":0.00044917126,"about_ca_system_score_gemma":0.00033324142,"threshold_uncertainty_score":0.9998596},"labels":[],"label_agreement":null},{"id":"W4379197252","doi":"10.1007/s40273-023-01279-2","title":"A Systematic Review of the Cost-Effectiveness Analyses of Anaplastic Lymphoma Kinase (ALK) Inhibitors in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)","year":2023,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Waterloo; Women's College Hospital; University of Toronto","funders":"","keywords":"Ceritinib; Crizotinib; Medicine; Anaplastic lymphoma kinase; Alectinib; ALK inhibitor; Lung cancer; Internal medicine; Systematic review; Oncology; Cochrane Library; Population; non-small cell lung cancer (NSCLC); Intensive care medicine; MEDLINE; Meta-analysis; Environmental health","score_opus":0.045303811579656184,"score_gpt":0.41740954539548386,"score_spread":0.3721057338158277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379197252","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0037411617,0.9784313,0.000037219124,0.0000080379505,0.00032067415,0.016701665,0.0006844092,0.000015580743,0.000059964575],"genre_scores_gemma":[0.0025231862,0.99270624,0.000074093514,0.00010173545,0.000022630065,0.0042155194,0.00016816604,0.00010819852,0.00008021411],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99715775,0.00032690456,0.0016024323,0.00043301552,0.000206396,0.00027347807],"domain_scores_gemma":[0.9965877,0.00077943655,0.0017972583,0.00048813978,0.00022826015,0.000119220014],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003292267,0.00051279744,0.003796913,0.00029853414,0.000038419654,0.000010078283,0.0002614527,0.00006517595,0.00003369823],"category_scores_gemma":[0.00011852409,0.00027718418,0.0005172304,0.0008250058,0.00007033652,0.000086003914,0.00007709838,0.0001602999,0.000006572924],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022858233,0.00042263538,0.00035263557,0.9708501,0.0030134942,0.000015757709,0.000054176755,0.00034547283,0.0000013737867,0.000001106564,0.00003896276,0.024675692],"study_design_scores_gemma":[0.0064886217,0.00025584418,0.00020274984,0.9444293,0.04703252,0.0000046410532,0.00002916581,0.00021321097,0.000114908325,5.3500656e-7,0.0009271713,0.0003013239],"about_ca_topic_score_codex":0.0001932679,"about_ca_topic_score_gemma":0.000101814694,"teacher_disagreement_score":0.044019025,"about_ca_system_score_codex":0.0012207446,"about_ca_system_score_gemma":0.0023897258,"threshold_uncertainty_score":0.99996805},"labels":[],"label_agreement":null},{"id":"W4382631068","doi":"10.1007/s40273-023-01295-2","title":"Systematic Literature Review to Identify Cost and Resource Use Data in Patients with Early-Stage Non-small Cell Lung Cancer (NSCLC)","year":2023,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Lung cancer; Stage (stratigraphy); Health care; Checklist; Indirect costs; Health economics; Disease; Family medicine; Public health; Oncology; Internal medicine; Pathology; Business; Psychology; Political science","score_opus":0.059147768534668646,"score_gpt":0.3996942043017581,"score_spread":0.3405464357670895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382631068","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0018012343,0.9818046,0.0000015606158,0.00011104716,0.00024855277,0.012899208,0.0030455396,0.00003634801,0.00005187712],"genre_scores_gemma":[0.000020492793,0.9929324,0.00006643302,0.0012877386,0.00014669269,0.0023870983,0.002071596,0.00017524125,0.0009123332],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9971315,0.00014942695,0.001091069,0.0010399338,0.00017506818,0.00041295035],"domain_scores_gemma":[0.99734735,0.0003126992,0.00060735346,0.001293058,0.000075040814,0.0003644793],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004979041,0.0006259964,0.0028778957,0.0002819265,0.000047924463,0.00021834573,0.00044163893,0.00014605101,0.0000353945],"category_scores_gemma":[0.000042870797,0.00045284847,0.00016640453,0.0004056823,0.000019607087,0.00024588473,0.0004183061,0.0004889423,0.00008027622],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000043302432,0.00015607031,0.010040794,0.96459717,0.00094283454,0.000119827935,0.00012999449,0.0000027591354,1.8886007e-8,9.1802764e-7,0.012622873,0.011343449],"study_design_scores_gemma":[0.0016138515,0.000049701484,0.0009499206,0.6602372,0.0066937506,0.000004855508,0.0000033378813,0.000025158306,3.646711e-7,3.8977916e-8,0.3300764,0.00034545234],"about_ca_topic_score_codex":0.00017456354,"about_ca_topic_score_gemma":0.00012303206,"teacher_disagreement_score":0.31745353,"about_ca_system_score_codex":0.0009759317,"about_ca_system_score_gemma":0.0003211873,"threshold_uncertainty_score":0.99979234},"labels":[],"label_agreement":null},{"id":"W4382795765","doi":"10.1007/s40273-023-01293-4","title":"Cost-Effectiveness of Emerging Treatments for Atopic Dermatitis: A Systematic Review","year":2023,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; EconLit; Health economics; Dupilumab; Cost effectiveness; Atopic dermatitis; Systematic review; MEDLINE; Health care; Economic evaluation; Health technology; Health administration; Cochrane Library; Family medicine; Public health; Randomized controlled trial; Nursing; Surgery; Dermatology; Political science","score_opus":0.1403825494111308,"score_gpt":0.466394680152419,"score_spread":0.3260121307412882,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382795765","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000007402432,0.98487747,0.000039487073,0.000039756327,0.00037065728,0.014041784,0.0004112242,0.00007367471,0.00013855143],"genre_scores_gemma":[0.000011363554,0.99051934,0.000036764548,0.00040949835,0.000052250853,0.0079986,0.00065801013,0.00008463086,0.00022953043],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99779826,0.0003313132,0.0012291376,0.00032306393,0.000067341745,0.00025085622],"domain_scores_gemma":[0.9970397,0.0016245752,0.0007510107,0.00038439434,0.000067737,0.00013263506],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00046281764,0.00038331444,0.004701851,0.00018239413,0.00005089491,0.000007869644,0.00019179558,0.00013833336,0.000042989097],"category_scores_gemma":[0.0002922107,0.00031394092,0.0010954805,0.00013430747,0.00004202207,0.00006310674,0.000048617076,0.0001341424,0.00020730721],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000076925935,0.00008254605,0.00001200545,0.9745873,0.0033899308,0.00003335763,0.000008752751,2.9787932e-7,4.6327788e-8,0.00004190927,0.0039319135,0.017904202],"study_design_scores_gemma":[0.0010110572,0.000019169294,0.000003884954,0.7840754,0.04193028,0.00023747262,0.0000057541156,0.00003260382,0.0000085218,0.000042645206,0.17241684,0.00021639555],"about_ca_topic_score_codex":0.0000024659937,"about_ca_topic_score_gemma":3.8479033e-7,"teacher_disagreement_score":0.19051196,"about_ca_system_score_codex":0.00023754724,"about_ca_system_score_gemma":0.0003159468,"threshold_uncertainty_score":0.9999313},"labels":[],"label_agreement":null},{"id":"W4384626521","doi":"10.1007/s40273-023-01296-1","title":"Economic and Humanistic Burden of Osteoarthritis: An Updated Systematic Review of Large Sample Studies","year":2023,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Osteoarthritis Treatment and Mechanisms","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Impact; McMaster University Medical Centre","funders":"","keywords":"Medicine; WOMAC; Health economics; Indirect costs; MEDLINE; Systematic review; Osteoarthritis; Sample size determination; Sample (material); Quality of life (healthcare); Quality of Life Research; Public health; Alternative medicine; Accounting; Statistics; Pathology","score_opus":0.0733953867695345,"score_gpt":0.4112069541592986,"score_spread":0.3378115673897641,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384626521","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003524111,0.99261904,0.0000011903178,0.000023657141,0.00038589476,0.0041511827,0.0023309144,0.00006856448,0.00006716367],"genre_scores_gemma":[0.000059667796,0.9970279,0.0001378174,0.00009188403,0.00018062606,0.00037939727,0.0017653902,0.000122007594,0.00023535317],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9968793,0.00018894204,0.0020336555,0.0004931072,0.00009656674,0.0003084221],"domain_scores_gemma":[0.9974944,0.00034242563,0.0013396739,0.00055439194,0.0000955461,0.00017356155],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00071543315,0.0005124285,0.005958303,0.00025824746,0.000055741133,0.0000141399305,0.0001963209,0.00014524735,0.00020504103],"category_scores_gemma":[0.00010688168,0.00045313346,0.0004911525,0.0000875334,0.00009514521,0.00011789488,0.00015372898,0.00018736978,0.0001250794],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000012147478,0.00005018452,6.6844e-7,0.9752332,0.0012062195,0.000021630327,0.00011581167,1.2509284e-7,0.0000041404487,0.0006472963,0.00034049913,0.022368064],"study_design_scores_gemma":[0.0023292156,0.0010308699,5.030694e-8,0.87330705,0.02214417,0.00015500945,0.00024450378,0.000016231977,0.000047826827,0.00012345168,0.10016852,0.00043312192],"about_ca_topic_score_codex":0.000018769211,"about_ca_topic_score_gemma":0.000027037668,"teacher_disagreement_score":0.101926185,"about_ca_system_score_codex":0.00019965056,"about_ca_system_score_gemma":0.00026265855,"threshold_uncertainty_score":0.99979204},"labels":[],"label_agreement":null},{"id":"W4384627184","doi":"10.1007/s40273-023-01294-3","title":"Cost-Effectiveness of Hydroxyurea for Sickle Cell Anemia in a Low-Income African Setting: A Model-Based Evaluation of Two Dosing Regimens","year":2023,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Hemoglobinopathies and Related Disorders","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"Haukeland Universitetssjukehus; Norges Forskningsråd; Universitetet i Bergen","keywords":"Medicine; Cost effectiveness; Dosing; Regimen; Economic evaluation; Disease burden; Quality-adjusted life year; Health economics; Pediatrics; Sickle cell anemia; Anemia; Public health; Disease; Internal medicine","score_opus":0.0418944135521632,"score_gpt":0.3783064997852639,"score_spread":0.3364120862331007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384627184","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951196,0.00014922691,0.0011176113,0.00020011367,0.0001295177,0.0020745117,0.00006124204,0.000036894508,0.0011113147],"genre_scores_gemma":[0.999104,0.000048508427,0.00040963353,0.00007809649,0.000025193274,0.00018682147,0.000095225594,0.000034946355,0.000017575183],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.998814,0.00011628509,0.0004316214,0.00024428772,0.0001360008,0.00025782234],"domain_scores_gemma":[0.9990299,0.0003288491,0.00022911563,0.00018368069,0.00014652488,0.000081962324],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020561158,0.00014174146,0.00038868503,0.0002779657,0.00003175226,0.000004929807,0.00008111136,0.00007992172,0.000016389735],"category_scores_gemma":[0.000066202716,0.000146754,0.00012705123,0.00027213508,0.000059216996,0.00006013797,0.000024854673,0.00014204631,0.0000052366286],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00088194193,0.00023986209,0.0029588668,0.0014734436,0.000043727785,0.0000024073015,0.00056106027,0.894406,0.09625207,0.00004142355,0.00007831377,0.003060877],"study_design_scores_gemma":[0.012085381,0.000082519284,0.00040058384,0.00024076636,0.00023089608,9.631252e-7,0.00016530164,0.81117535,0.17504495,0.00042680232,0.000035249217,0.00011121646],"about_ca_topic_score_codex":0.00005603943,"about_ca_topic_score_gemma":0.000005340198,"teacher_disagreement_score":0.083230644,"about_ca_system_score_codex":0.0002873074,"about_ca_system_score_gemma":0.00045740017,"threshold_uncertainty_score":0.5984454},"labels":[],"label_agreement":null},{"id":"W4385968941","doi":"10.1007/s40273-023-01308-0","title":"Are We Capturing the Socioeconomic Burden of Rare Genetic Disease? A Scoping Review of Economic Evaluations and Cost-of-Illness Studies","year":2023,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Genomics and Rare Diseases","field":"Biochemistry, Genetics and Molecular Biology","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital; Alberta Bone and Joint Health Institute; University of Calgary","funders":"Canadian Institutes of Health Research","keywords":"Socioeconomic status; Health economics; Psychological intervention; Indirect costs; Economic cost; Medicine; Government (linguistics); Health care; Disease burden; Economic evaluation; Health administration; Public health; Economic impact analysis; Cost–benefit analysis; Environmental health; Business; Economic growth; Economics; Psychiatry; Population; Nursing; Political science; Pathology","score_opus":0.10651673489686381,"score_gpt":0.44336325701213886,"score_spread":0.33684652211527505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385968941","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005564158,0.99050766,0.0000045115594,0.00013746206,0.00034744287,0.0020114481,0.0014068623,0.000005909545,0.000014541233],"genre_scores_gemma":[0.001555123,0.99737424,0.000025145984,0.00007314584,0.00027792132,0.00038201627,0.00019270432,0.00007331835,0.000046409088],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99783176,0.00016440333,0.0012567798,0.00047874398,0.00005409824,0.0002142107],"domain_scores_gemma":[0.99714047,0.00018395811,0.0019481269,0.0005195675,0.000099592326,0.00010831552],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00041178847,0.0003677605,0.001558268,0.000097510456,0.000087903376,0.000013955719,0.00045450559,0.00010153358,0.000034574365],"category_scores_gemma":[0.00008726971,0.0003078041,0.00059313234,0.00003721971,0.0002672015,0.0000065198046,0.00043123067,0.00010554267,0.000011236475],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000042594274,0.000052705866,0.000087905,0.7684186,0.0038690188,0.0000060843504,0.00027027042,0.0031917216,0.000057692287,0.000057033616,0.0026953751,0.221251],"study_design_scores_gemma":[0.0018553291,0.00011353143,0.00008070268,0.57328355,0.0150116505,0.00005444543,0.0016933345,0.00068575976,0.00062901556,0.0004399334,0.40387252,0.0022802427],"about_ca_topic_score_codex":0.000015068683,"about_ca_topic_score_gemma":0.00001792357,"teacher_disagreement_score":0.40117714,"about_ca_system_score_codex":0.000076536664,"about_ca_system_score_gemma":0.0008355984,"threshold_uncertainty_score":0.9999374},"labels":[],"label_agreement":null},{"id":"W4385997350","doi":"10.1007/s40273-023-01309-z","title":"Cost-Effectiveness Analysis of Pharmacogenomics (PGx)-Based Warfarin, Apixaban, and Rivaroxaban Versus Standard Warfarin for the Management of Atrial Fibrillation in Ontario, Canada","year":2023,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Pharmacogenetics and Drug Metabolism","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute for Clinical Evaluative Sciences; Western University","funders":"Canadian Institutes of Health Research","keywords":"Warfarin; Apixaban; Rivaroxaban; Medicine; Pharmacogenomics; Atrial fibrillation; Quality-adjusted life year; Cost-effectiveness analysis; Cost effectiveness; Internal medicine; Pharmacology; Risk analysis (engineering)","score_opus":0.17157161540634408,"score_gpt":0.43830788094396717,"score_spread":0.2667362655376231,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385997350","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914289,0.0012083136,0.00043958635,0.0002523905,0.0027608636,0.0021839899,0.0014963022,0.000030177007,0.00019948989],"genre_scores_gemma":[0.9960589,0.0028634244,0.0002444674,0.00020149775,0.0001389645,0.00013702198,0.00025236516,0.000042920004,0.000060457343],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99753374,0.00029173814,0.0009054809,0.00050900073,0.00019790589,0.000562112],"domain_scores_gemma":[0.9966993,0.0022018177,0.000466401,0.00027928833,0.0001561826,0.00019703452],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0020206345,0.00035264544,0.000811502,0.00047233427,0.00018737788,0.00002062935,0.00041176178,0.00014196134,0.000321843],"category_scores_gemma":[0.000024779463,0.0003481302,0.00036519804,0.0007632216,0.00017399757,0.00008997719,0.00019365808,0.00039104398,0.0000025052982],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014018234,0.00005530305,0.058192752,0.0002820615,0.008386974,0.0000127307385,0.0004122642,0.8674371,0.0048461594,0.0006739456,0.00043533265,0.045247134],"study_design_scores_gemma":[0.027516833,0.00014361944,0.06332721,0.000021374071,0.011237171,0.0000012267525,0.00020475879,0.61254424,0.07954708,0.00016527875,0.20465222,0.0006389999],"about_ca_topic_score_codex":0.1270072,"about_ca_topic_score_gemma":0.30664796,"teacher_disagreement_score":0.2548929,"about_ca_system_score_codex":0.00067119236,"about_ca_system_score_gemma":0.0007646346,"threshold_uncertainty_score":0.99989706},"labels":[],"label_agreement":null},{"id":"W4387033463","doi":"10.1007/s40273-023-01318-y","title":"Economic Evaluations Comparing Deep Brain Stimulation to Best Medical Therapy for Movement Disorders: A Meta-Analysis","year":2023,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Neurological disorders and treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Impact; University of Toronto; McMaster University","funders":"","keywords":"Deep brain stimulation; Medicine; Meta-analysis; Movement disorders; Economic evaluation; Quality-adjusted life year; Population; Systematic review; MEDLINE; Physical medicine and rehabilitation; Cost effectiveness; Physical therapy; Disease; Parkinson's disease; Internal medicine; Pathology","score_opus":0.3161301884010959,"score_gpt":0.514219521678214,"score_spread":0.19808933327711814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387033463","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00040533216,0.98486966,0.0021811926,0.0046472917,0.00029305278,0.0067646536,0.00042935784,0.000113638336,0.00029583529],"genre_scores_gemma":[0.00027943717,0.9873476,0.00029373434,0.0065383213,0.00018271174,0.0035105345,0.0013407603,0.000106128304,0.00040077016],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973385,0.0001424979,0.0011052726,0.000834943,0.00019416556,0.00038464012],"domain_scores_gemma":[0.9978163,0.0009731724,0.00036890665,0.00042013358,0.00003229072,0.0003891885],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00065256446,0.0005266677,0.003648605,0.00052423606,0.00012922239,0.000060545386,0.00027511077,0.00019297103,0.002063912],"category_scores_gemma":[0.00008891506,0.00040823326,0.0033605094,0.00027905786,0.00003123301,0.0000647734,0.000103953294,0.00023465537,0.0007030413],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001246285,0.0007567777,0.00015368903,0.0012093092,0.26969707,0.0000056020567,0.000053615986,0.009463954,1.8544634e-7,0.00021512488,0.0030860791,0.7152339],"study_design_scores_gemma":[0.0031083704,0.00045936703,0.00003744083,0.00008029219,0.43008924,8.7210424e-7,0.0000119617525,0.053986076,7.8677795e-7,0.0018550381,0.5098426,0.000527979],"about_ca_topic_score_codex":0.0000755286,"about_ca_topic_score_gemma":0.0005427413,"teacher_disagreement_score":0.71470594,"about_ca_system_score_codex":0.00030076542,"about_ca_system_score_gemma":0.00026506782,"threshold_uncertainty_score":0.999837},"labels":[],"label_agreement":null},{"id":"W4388541047","doi":"10.1007/s40273-023-01331-1","title":"A Systematic Review of Methods Used by Pediatric Cost-Utility Analyses to Include Family Spillover Effects","year":2023,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mental Health Research Canada; Institute for Clinical Evaluative Sciences; University of Toronto; SickKids Foundation; Public Health Ontario; Hospital for Sick Children","funders":"Hospital for Sick Children; Canada Excellence Research Chairs, Government of Canada","keywords":"Spillover effect; CINAHL; Medicine; Meta-analysis; MEDLINE; Systematic review; Actuarial science; Psychological intervention; Business; Economics; Psychiatry; Political science","score_opus":0.6886712454235581,"score_gpt":0.6439042946604315,"score_spread":0.044766950763126534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388541047","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000032714768,0.9759978,0.0032092084,0.0006116066,0.0017828417,0.013295738,0.004219453,0.00015990986,0.00069073366],"genre_scores_gemma":[0.0000041576013,0.98268825,0.002598865,0.009785284,0.0004964659,0.0032897599,0.0004256821,0.00027836286,0.00043319378],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.97423184,0.0039022511,0.018927375,0.0017880205,0.00017571685,0.00097478065],"domain_scores_gemma":[0.9714943,0.011522866,0.014202043,0.0019093581,0.00014291202,0.0007284879],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.047672242,0.0011535294,0.016583659,0.0014890648,0.00016597632,0.00012341587,0.0017115326,0.0005171598,0.00033195416],"category_scores_gemma":[0.013298242,0.0013128031,0.002029896,0.0013465404,0.00007581972,0.00045845963,0.00050419435,0.0006942676,0.008983273],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000003224662,0.00009343487,0.000021803313,0.9259581,0.0011103838,0.0000012022176,0.000103857754,0.000006567425,4.3894718e-7,0.00038226202,0.070315145,0.0020035522],"study_design_scores_gemma":[0.0006482603,0.000072843606,0.000009501666,0.2647118,0.004077269,0.0000070535402,0.00004778337,0.0006031685,0.0000035506257,0.00031152868,0.727899,0.0016082055],"about_ca_topic_score_codex":0.00040257003,"about_ca_topic_score_gemma":0.000008263292,"teacher_disagreement_score":0.66124636,"about_ca_system_score_codex":0.0019250124,"about_ca_system_score_gemma":0.00078421645,"threshold_uncertainty_score":0.9989322},"labels":[],"label_agreement":null},{"id":"W4388902252","doi":"10.1007/s40273-023-01334-y","title":"Surrogacy and the Valuation of ATMPs: Taking Our Place in the Evidence Generation/Assessment Continuum","year":2023,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Geomechanica (Canada)","funders":"Bristol-Myers Squibb","keywords":"Health technology; Relevance (law); Risk analysis (engineering); Health economics; Surrogate endpoint; Psychological intervention; Valuation (finance); Medicine; Actuarial science; Health care; Business; Economics; Public health; Political science; Nursing","score_opus":0.6501982156129451,"score_gpt":0.543712539937482,"score_spread":0.10648567567546308,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388902252","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89212155,0.0019222914,0.00070875185,0.1021544,0.00083003705,0.0012280723,0.00007570194,0.000031572996,0.00092762994],"genre_scores_gemma":[0.99058,0.0014361229,0.00041195523,0.0066184676,0.00046084696,0.00027646773,0.000026279853,0.000021498823,0.00016836387],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.995461,0.0009142952,0.0027924634,0.0004294853,0.000092686445,0.00031010268],"domain_scores_gemma":[0.9943306,0.0029123637,0.0022360138,0.0004116124,0.000054680117,0.000054737942],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.04280813,0.00016803827,0.00065476564,0.0002458134,0.00021711588,0.00015005823,0.00041477467,0.00006564647,0.00006553231],"category_scores_gemma":[0.0021887408,0.00015104191,0.00009987694,0.00026137225,0.00009393848,0.0006588496,0.000087489876,0.0002157363,0.0002802494],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019907021,0.00019283583,0.288966,0.00076230813,0.00034105056,0.0000037663299,0.039100043,0.024902377,0.00032877162,0.5166751,0.12598117,0.0025474671],"study_design_scores_gemma":[0.0069746147,0.00006915893,0.16446745,0.00015596078,0.000056823817,0.000012507207,0.011323208,0.7740963,0.000114029994,0.022683803,0.019455226,0.00059089076],"about_ca_topic_score_codex":0.0007499624,"about_ca_topic_score_gemma":0.00051400904,"teacher_disagreement_score":0.74919397,"about_ca_system_score_codex":0.00028685405,"about_ca_system_score_gemma":0.00016201794,"threshold_uncertainty_score":0.98563045},"labels":[],"label_agreement":null},{"id":"W4389272687","doi":"10.1007/s40273-023-01321-3","title":"Recommendations for Emerging Good Practice and Future Research in Relation to Family and Caregiver Health Spillovers in Health Economic Evaluations: A Report of the SHEER Task Force","year":2023,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; Irish Research Council; University of Galway; National Institute for Health and Care Research; Health Service Executive; Harvard T.H. Chan School of Public Health; Tufts Medical Center","keywords":"Health economics; Quality of Life Research; Psychological intervention; Task force; Task (project management); Public health; Health administration; Public economics; Relation (database); Health care; Psychology; Medicine; Business; Economics; Political science; Economic growth; Nursing; Management; Computer science; Psychiatry; Public administration","score_opus":0.41454006501719176,"score_gpt":0.5650736797024618,"score_spread":0.15053361468527005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389272687","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.31557482,0.0029723926,0.00047310736,0.67416096,0.0013159417,0.0038392243,0.0006602124,0.000029963676,0.0009733926],"genre_scores_gemma":[0.9185399,0.02158228,0.010151473,0.045082435,0.0011750014,0.001793863,0.00039076485,0.00017399425,0.0011103352],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9940306,0.00076362555,0.0038116171,0.00074619777,0.00008603437,0.0005619175],"domain_scores_gemma":[0.9952153,0.0020662951,0.002004063,0.00042968054,0.000083008046,0.00020165964],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.043495294,0.0001735823,0.0007240552,0.0010370754,0.00033319998,0.00006765418,0.00021704752,0.00009593106,0.000025254067],"category_scores_gemma":[0.0013102018,0.00021845184,0.00006821738,0.0005128582,0.000065825225,0.00079033803,0.00014227697,0.00032487736,0.0000678263],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003998742,0.00038073142,0.13030833,0.003458375,0.00031578972,0.000004596572,0.110373,0.051544596,0.000045219436,0.35268685,0.31934598,0.031136645],"study_design_scores_gemma":[0.003126872,0.00016491149,0.07657434,0.00025988644,0.000008835027,0.000020935351,0.025062645,0.07316429,0.0000053938425,0.014605918,0.8065914,0.00041455837],"about_ca_topic_score_codex":0.0048258165,"about_ca_topic_score_gemma":0.0014223161,"teacher_disagreement_score":0.6290785,"about_ca_system_score_codex":0.0021886334,"about_ca_system_score_gemma":0.00082706206,"threshold_uncertainty_score":0.9849229},"labels":[],"label_agreement":null},{"id":"W4389477446","doi":"10.1007/s40273-023-01325-z","title":"A Framework for the Fair Pricing of Medicines","year":2023,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research","keywords":"Economic surplus; Health economics; Incentive; Public economics; Health care; Willingness to pay; Marginal cost; Economics; Public health; Population; Fair value; Health administration; Population health; Actuarial science; Business; Welfare; Microeconomics; Medicine; Finance; Economic growth","score_opus":0.4724225739610756,"score_gpt":0.5252047214042598,"score_spread":0.05278214744318416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389477446","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.37948668,0.007608651,0.21780653,0.37379393,0.009252232,0.004915991,0.0017173825,0.0004975599,0.0049210642],"genre_scores_gemma":[0.94789875,0.0019304677,0.011044058,0.03494594,0.0023872564,0.00074397365,0.000065661225,0.00012011282,0.00086380925],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99606645,0.000073910334,0.0029770979,0.00041005327,0.00004785123,0.0004246375],"domain_scores_gemma":[0.9911921,0.006350494,0.0018178226,0.00046851722,0.000055471126,0.000115581664],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.012262344,0.00017584194,0.0007936799,0.00028642878,0.00022530311,0.00003922841,0.00049099873,0.000103821425,0.00034512542],"category_scores_gemma":[0.0030616957,0.0001804194,0.00020461703,0.00026620488,0.00010431987,0.00025551306,0.000077767145,0.00017060642,0.0011841658],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000059193655,0.00006135471,0.016663896,0.00080821855,0.0003893982,5.2149926e-7,0.0044946843,0.005484818,0.00005011132,0.75095737,0.2190876,0.0019428344],"study_design_scores_gemma":[0.0020454118,0.00010116359,0.0088720415,0.00012783479,0.000059676982,0.000004482781,0.0036982626,0.21984872,0.000381236,0.29324135,0.47102723,0.00059257424],"about_ca_topic_score_codex":0.0001529785,"about_ca_topic_score_gemma":0.000016455435,"teacher_disagreement_score":0.56841207,"about_ca_system_score_codex":0.00019226866,"about_ca_system_score_gemma":0.00010148373,"threshold_uncertainty_score":0.99959356},"labels":[],"label_agreement":null},{"id":"W4390267034","doi":"10.1007/s40273-023-01345-9","title":"An Exploratory Analysis of the Cost-Effectiveness of a Multi-cancer Early Detection Blood Test Compared with Standard of Care Screening in Ontario, Canada","year":2023,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Waterloo","funders":"","keywords":"Medicine; Cost effectiveness; Cost-effectiveness analysis; Health care; Health administration; Quality-adjusted life year; Cancer screening; Breast cancer screening; Breast cancer; Public health; Cancer; Internal medicine; Mammography","score_opus":0.07472670987217402,"score_gpt":0.3515686772154051,"score_spread":0.2768419673432311,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390267034","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99890035,0.00012190938,0.00016093146,0.000010024801,0.000055153032,0.0004564283,0.0002610939,0.000010532795,0.000023579987],"genre_scores_gemma":[0.99973553,0.000018280258,0.00010450415,0.000034305667,0.000010055717,0.00005815307,0.00002307761,0.000012048914,0.00000401085],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99908173,0.000070908136,0.00032470396,0.00019075588,0.0001762676,0.00015564605],"domain_scores_gemma":[0.99912757,0.00012122732,0.00024561878,0.00020744254,0.00023019781,0.0000679667],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029066845,0.000111082445,0.0005320291,0.00019006705,0.00003364804,0.0000045989414,0.00013019577,0.000029863037,0.000029752126],"category_scores_gemma":[0.000017856053,0.000092976225,0.000083498824,0.0006938348,0.000058873124,0.00011563269,0.000029845503,0.00015795366,8.478302e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001480643,0.00003503799,0.8772667,0.000109068416,0.00054911536,0.0000055834175,0.0017070145,0.09809763,0.019957038,7.985942e-7,0.0000039794513,0.000787371],"study_design_scores_gemma":[0.0027785653,0.00022861705,0.78826094,0.00021505544,0.0010894712,8.008386e-7,0.0024185588,0.009857226,0.19503163,4.2928127e-7,0.000036706642,0.000081988255],"about_ca_topic_score_codex":0.88459134,"about_ca_topic_score_gemma":0.99331754,"teacher_disagreement_score":0.17507458,"about_ca_system_score_codex":0.0005708215,"about_ca_system_score_gemma":0.0010140836,"threshold_uncertainty_score":0.37914604},"labels":[],"label_agreement":null},{"id":"W4390973218","doi":"10.1007/s40273-023-01348-6","title":"Making Decision Models Fit for Purpose: The Importance of Ensuring Stakeholder Involvement","year":2024,"lang":"en","type":"editorial","venue":"PharmacoEconomics","topic":"Complex Systems and Decision Making","field":"Decision Sciences","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stornoway Diamond (Canada); University of British Columbia; Vancouver Coastal Health","funders":"","keywords":"Quality of Life Research; Health economics; Health administration; Stakeholder; Public health; Business; Stakeholder engagement; Health services research; Process management; Management science; Environmental resource management; Medicine; Economics; Public relations; Political science; Nursing","score_opus":0.4173727128217211,"score_gpt":0.4740352929066522,"score_spread":0.05666258008493108,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390973218","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0038048178,0.01238581,0.031632245,0.0001833208,0.9456271,0.0018323028,0.002012547,0.0000753477,0.0024465066],"genre_scores_gemma":[0.1251099,0.0005628293,0.00556394,0.0005358576,0.8587662,0.00059611804,0.00006530998,0.00035200614,0.008447852],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99203926,0.00014603046,0.0034774079,0.0015495621,0.002191201,0.0005965336],"domain_scores_gemma":[0.97796243,0.017240733,0.0019846982,0.0016955758,0.0009799204,0.00013664582],"candidate_categories":["metaepi_narrow","scholarly_communication"],"consensus_categories":[],"category_scores_codex":[0.009260746,0.0005921588,0.0013174486,0.00060408254,0.0003217153,0.0012262986,0.0030175198,0.0004016503,0.00037889846],"category_scores_gemma":[0.0021323264,0.00040180515,0.00083480723,0.00043141577,0.00010978467,0.00049916684,0.001176297,0.0007937437,0.00014504569],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016098616,0.000028154125,0.000027604678,0.00010905425,0.00011335223,0.000006323368,0.00034960316,0.014198928,0.000029643626,0.003840112,0.9583097,0.022826537],"study_design_scores_gemma":[0.00054114824,0.000030758492,0.0000030740764,0.00024774243,0.000084199695,0.0000021811895,0.00021858947,0.09120883,0.000046037843,0.14578995,0.761492,0.0003354806],"about_ca_topic_score_codex":0.00002647614,"about_ca_topic_score_gemma":0.00018448752,"teacher_disagreement_score":0.1968177,"about_ca_system_score_codex":0.00027058067,"about_ca_system_score_gemma":0.00049089984,"threshold_uncertainty_score":0.99984336},"labels":[],"label_agreement":null},{"id":"W4391786302","doi":"10.1007/s40273-024-01357-z","title":"Exploring the Use of Pictorial Approaches in the Development of Paediatric Patient-Reported Outcome Instruments: A Systematic Review","year":2024,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Pediatric Pain Management Techniques","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University","funders":"EuroQol Research Foundation; Flinders University; University of Technology Sydney; Australian Government","keywords":"Patient-reported outcome; Context (archaeology); Inclusion (mineral); Likert scale; Quality of life (healthcare); Systematic review; Medicine; Quality of Life Research; MEDLINE; Psychology; Medical education; Family medicine; Nursing; Public health; Developmental psychology; Social psychology","score_opus":0.4874934670233488,"score_gpt":0.3950674980723151,"score_spread":0.09242596895103367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391786302","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008031192,0.98905736,0.000028363776,0.000059501057,0.0007063573,0.009142263,0.00002387483,0.000058947284,0.00012023589],"genre_scores_gemma":[0.0005315469,0.9945373,0.00097531267,0.00020141299,0.00021199322,0.003395276,0.000069221336,0.000060419654,0.000017549144],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.99421877,0.0005229187,0.0042395876,0.00039585074,0.00035930157,0.00026355928],"domain_scores_gemma":[0.9963615,0.0006173854,0.0020996325,0.00082636636,0.000043228298,0.000051922365],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0029746215,0.0004727759,0.003027074,0.00053864275,0.000032446496,0.00003264306,0.0005975288,0.00008354847,0.0000070334704],"category_scores_gemma":[0.00050785736,0.00025510148,0.0006446875,0.00074156694,0.000046889345,0.00019420811,0.000310065,0.00057142426,0.000016065795],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000062133745,0.00010906766,0.000103693535,0.8833383,0.00088386505,0.000008992918,0.0003895734,4.4164744e-7,6.770318e-8,0.000029276976,0.00074934924,0.11438116],"study_design_scores_gemma":[0.00057527673,0.00006889094,0.000023576526,0.38738072,0.044901013,0.00004978063,0.0001857119,0.00007614784,0.000004542406,0.000015578347,0.5661195,0.0005992699],"about_ca_topic_score_codex":0.000008954076,"about_ca_topic_score_gemma":0.0000016426648,"teacher_disagreement_score":0.56537014,"about_ca_system_score_codex":0.00041540817,"about_ca_system_score_gemma":0.00037551066,"threshold_uncertainty_score":0.9999901},"labels":[],"label_agreement":null},{"id":"W4392739550","doi":"10.1007/s40273-024-01369-9","title":"Reply to Comment on “A Framework for Fair Pricing of Medicines”","year":2024,"lang":"en","type":"letter","venue":"PharmacoEconomics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Quality of Life Research; Health economics; Health administration; Public health; Business; Actuarial science; Economics; Medicine; Nursing","score_opus":0.08685281343077769,"score_gpt":0.36353599715388063,"score_spread":0.27668318372310297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392739550","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002356549,0.0012262606,0.003935648,0.9676817,0.0054554595,0.0013910014,0.004678685,0.00008536698,0.015310205],"genre_scores_gemma":[0.0016268154,0.0005044477,0.0034438511,0.98512614,0.0074531804,0.00033930255,0.00022882706,0.0002471453,0.0010302695],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959355,0.00002075817,0.00198441,0.001191889,0.000048959144,0.00081848167],"domain_scores_gemma":[0.99704367,0.00094163214,0.00088081346,0.00081420207,0.00004607522,0.00027359146],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00091832946,0.00061905844,0.0015584382,0.00082881976,0.00008545317,0.00012555037,0.0008963132,0.0005407555,0.00093017734],"category_scores_gemma":[0.00020150347,0.0007417631,0.00060906826,0.00015478149,0.000085049694,0.00010663896,0.0002318502,0.001700598,0.0024753017],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006531991,0.000045863704,0.000023561533,0.0006185335,0.000407268,0.0000087354,0.0002953188,0.0001961975,0.000004087111,0.13133317,0.8662455,0.00075646443],"study_design_scores_gemma":[0.0005164495,0.00016466068,0.0000024534838,0.00015813629,0.00008379154,0.000002796269,0.000007990874,0.0028010819,0.00045208607,0.19281185,0.8024205,0.00057817507],"about_ca_topic_score_codex":0.00013254482,"about_ca_topic_score_gemma":0.0000011919493,"teacher_disagreement_score":0.06382495,"about_ca_system_score_codex":0.00055629096,"about_ca_system_score_gemma":0.00008968459,"threshold_uncertainty_score":0.99998313},"labels":[],"label_agreement":null},{"id":"W4394063337","doi":"10.1007/s40273-024-01372-0","title":"Value of Information for Clinical Trial Design: The Importance of Considering All Relevant Comparators","year":2024,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences; SickKids Foundation; Public Health Ontario; Hospital for Sick Children","funders":"Natural Sciences and Engineering Research Council of Canada; Canada Research Chairs","keywords":"Value of information; Context (archaeology); Computer science; Risk analysis (engineering); Management science; Research design; Decision analysis; Health economics; Data science; Medicine; Public health; Artificial intelligence; Engineering; Mathematics; Statistics","score_opus":0.6583874461216297,"score_gpt":0.5621874695543043,"score_spread":0.09619997656732537,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394063337","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86089754,0.0068283514,0.09482694,0.022873422,0.006994786,0.0048722904,0.0012529822,0.000100815436,0.001352901],"genre_scores_gemma":[0.96979296,0.001504402,0.016060265,0.011224438,0.0008972269,0.000339647,0.000068627836,0.000051644485,0.000060813716],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9918181,0.00026210665,0.0072613256,0.0003250156,0.000053243977,0.00028024518],"domain_scores_gemma":[0.99112666,0.005416955,0.0028865954,0.00039291193,0.00006890902,0.00010799028],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02474231,0.0001770766,0.0010316359,0.00021163079,0.00007491182,0.00007742624,0.00034960292,0.00011653568,0.00013428075],"category_scores_gemma":[0.0018768153,0.00018497875,0.00033044248,0.00010000167,0.00014573944,0.0007917048,0.000053889413,0.00020143023,0.0002528237],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004331262,0.00022309506,0.011889109,0.0022999977,0.0012406515,6.7901993e-7,0.003989952,0.013128152,0.00002656525,0.73492426,0.2263776,0.0015686504],"study_design_scores_gemma":[0.0152733615,0.0004538053,0.0006940618,0.00010711796,0.00009626768,0.000005861886,0.0006113275,0.4431573,0.00045105876,0.040719878,0.49796867,0.00046129563],"about_ca_topic_score_codex":0.00006210511,"about_ca_topic_score_gemma":0.000007427188,"teacher_disagreement_score":0.6942044,"about_ca_system_score_codex":0.00022092256,"about_ca_system_score_gemma":0.000355184,"threshold_uncertainty_score":0.8575241},"labels":[],"label_agreement":null},{"id":"W4394751671","doi":"10.1007/s40273-024-01374-y","title":"Barriers and Facilitators of Using R for Decision Analytic Modeling in Health Technology Assessment: Focus Group Results","year":2024,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; University of Toronto; Institute for Clinical Evaluative Sciences; SickKids Foundation; Hospital for Sick Children","funders":"","keywords":"Focus group; Facilitator; Health technology; Knowledge management; Incentive; Standardization; Process management; Public relations; Business; Medicine; Health care; Computer science; Psychology; Political science; Marketing","score_opus":0.33840827808757995,"score_gpt":0.5143683553736645,"score_spread":0.1759600772860846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394751671","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8212138,0.010112589,0.15098447,0.013819772,0.0008093285,0.0011296751,0.0016786827,0.00006812162,0.00018357653],"genre_scores_gemma":[0.97574353,0.00085838133,0.022316065,0.00084413966,0.00009088707,0.00006902702,0.000020093206,0.0000410024,0.00001690083],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9939947,0.00010495369,0.004670019,0.00074905605,0.000040965777,0.0004402733],"domain_scores_gemma":[0.99731296,0.0011902023,0.00096103863,0.00029407535,0.000032018525,0.00020968178],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.014613537,0.00020469385,0.0010239907,0.0013239515,0.00012387712,0.00007302593,0.0002091066,0.00014158995,0.00004691859],"category_scores_gemma":[0.0012209325,0.00027903458,0.000117282376,0.00026931288,0.00007446194,0.00052394933,0.000069861424,0.00022491513,0.000022064061],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041846497,0.00014563138,0.046562076,0.0056239692,0.00060658285,0.0000050617728,0.00477881,0.2523366,0.00013386116,0.658776,0.004756938,0.02585601],"study_design_scores_gemma":[0.0011557343,0.00006387952,0.0001004663,0.0002181408,0.0000081598755,0.0000038741914,0.00096204673,0.9392655,0.000008739233,0.051775444,0.0062185326,0.00021946616],"about_ca_topic_score_codex":0.0009199695,"about_ca_topic_score_gemma":0.00016514382,"teacher_disagreement_score":0.6869289,"about_ca_system_score_codex":0.0012016048,"about_ca_system_score_gemma":0.0003868714,"threshold_uncertainty_score":0.9999662},"labels":[],"label_agreement":null},{"id":"W4396769645","doi":"10.1007/s40273-024-01383-x","title":"Meeting the Challenges of Preference-Weighted Health-Related Quality-of-Life Measurement in Children","year":2024,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences; SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"EuroQol Research Foundation; Flinders University; University of Technology Sydney; Australian Government","keywords":"Quality of Life Research; Health economics; Health administration; Public health; Quality of life (healthcare); Preference; Quality-adjusted life year; Health related quality of life; Medicine; Environmental health; Statistics; Nursing; Cost effectiveness; Mathematics; Risk analysis (engineering); Internal medicine","score_opus":0.574580267070628,"score_gpt":0.46145077725317746,"score_spread":0.11312948981745058,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396769645","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8281687,0.11276532,0.00017985677,0.05131607,0.0009466514,0.0013037227,0.00034603683,0.000073738374,0.004899889],"genre_scores_gemma":[0.99204355,0.0053306003,0.00031106977,0.0019521656,0.00016991337,0.00009910985,0.000017502265,0.0000461613,0.000029927935],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.98994994,0.0008287921,0.007991795,0.00063540746,0.00013804938,0.00045600516],"domain_scores_gemma":[0.9951539,0.0010933012,0.0030129664,0.0004972203,0.000072383664,0.00017023906],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.038875002,0.00025385656,0.0014664201,0.00047552356,0.00009495232,0.000044666536,0.00051602704,0.00012532313,0.00027077275],"category_scores_gemma":[0.0011054953,0.00026934114,0.00021666793,0.00024334909,0.000114069575,0.00036000315,0.00009038934,0.00035999613,0.00031836363],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008062387,0.00044191405,0.09718374,0.0032878201,0.0012214648,3.9361865e-7,0.014247986,0.0022004587,0.00006120455,0.8690092,0.0074542426,0.0048109815],"study_design_scores_gemma":[0.0119639,0.000555237,0.57759124,0.0034788253,0.00011882216,0.000025839789,0.008790228,0.12893471,0.0009873463,0.22087754,0.043302756,0.0033735118],"about_ca_topic_score_codex":0.0036327392,"about_ca_topic_score_gemma":0.0004079824,"teacher_disagreement_score":0.6481316,"about_ca_system_score_codex":0.0007544928,"about_ca_system_score_gemma":0.0005626159,"threshold_uncertainty_score":0.99997586},"labels":[],"label_agreement":null},{"id":"W4399232927","doi":"10.1007/s40273-024-01397-5","title":"A Systematic Review of Methods and Practice for Integrating Maternal, Fetal, and Child Health Outcomes, and Family Spillover Effects into Cost-Utility Analyses","year":2024,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mental Health Research Canada; Institute for Clinical Evaluative Sciences; University of Toronto; SickKids Foundation; Public Health Ontario; Hospital for Sick Children","funders":"Sickkids Research Institute; Canada Excellence Research Chairs, Government of Canada","keywords":"Health economics; Quality of Life Research; Spillover effect; Public health; Health administration; Medicine; Systematic review; Environmental health; Public economics; Actuarial science; MEDLINE; Economics; Nursing; Political science","score_opus":0.513144724203133,"score_gpt":0.6380443423790316,"score_spread":0.12489961817589867,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399232927","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000032927022,0.98132247,0.0034345828,0.003947882,0.0007375165,0.009094437,0.0010906418,0.00004346822,0.0002960712],"genre_scores_gemma":[0.000017396755,0.96102357,0.024402773,0.012928969,0.00013144774,0.0012353695,0.00008996798,0.000115513634,0.000055003526],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.986222,0.002355089,0.009619917,0.0012646654,0.00006761649,0.00047066252],"domain_scores_gemma":[0.97887224,0.010857914,0.009144816,0.00064853503,0.00009259901,0.00038392463],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.042252716,0.000780691,0.009948528,0.0005629102,0.00021400048,0.00025669704,0.00033465945,0.00024528426,0.00001766935],"category_scores_gemma":[0.012746864,0.00073923834,0.0005882216,0.00019032833,0.00015476228,0.0006335559,0.0002692418,0.0005179256,0.000056334644],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000006668434,0.000038315222,0.000028045562,0.9696848,0.0014902708,5.6531906e-7,0.0002240411,2.3412807e-7,7.664459e-8,0.0032213232,0.0021294984,0.023176204],"study_design_scores_gemma":[0.0007526335,0.00013650658,0.00002346318,0.48614907,0.0041239806,0.00013060363,0.00023806372,0.0027316837,6.2115083e-7,0.0010592447,0.5037812,0.00087295],"about_ca_topic_score_codex":0.0007548679,"about_ca_topic_score_gemma":0.000018833998,"teacher_disagreement_score":0.5016517,"about_ca_system_score_codex":0.00066333835,"about_ca_system_score_gemma":0.00035352563,"threshold_uncertainty_score":0.9995059},"labels":[],"label_agreement":null},{"id":"W4401010505","doi":"10.1007/s40273-024-01413-8","title":"Systematic Review of Economic Evaluations of Systemic Treatments for Advanced and Metastatic Gastric Cancer","year":2024,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trinity College","funders":"Enterprise Ireland","keywords":"Quality of Life Research; Health economics; Medicine; Cancer; Pharmacoeconomics; Intensive care medicine; Health administration; Public health; Internal medicine; Pathology","score_opus":0.07880618533681719,"score_gpt":0.46942738858019645,"score_spread":0.39062120324337923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401010505","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000033987944,0.9890061,0.0000381881,0.00005637551,0.00051936356,0.009308725,0.0009223534,0.000019371995,0.000095559786],"genre_scores_gemma":[0.000030894626,0.9951649,0.00032020532,0.00008898554,0.000070000795,0.0031500617,0.0001828356,0.00006952023,0.0009226373],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99738246,0.00007444434,0.0018799411,0.0003794731,0.000091387556,0.00019228394],"domain_scores_gemma":[0.99779046,0.00029575487,0.0014192461,0.00033678347,0.00006785156,0.00008990148],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00050732156,0.00040006122,0.004402589,0.00038738726,0.000019843648,0.0000118100015,0.00014950728,0.00004593796,0.000091762544],"category_scores_gemma":[0.000053124575,0.00030428002,0.00081124,0.0001444854,0.00003648523,0.0000716209,0.000060388455,0.00010271972,0.000023433251],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000010505473,0.000023435006,0.0000025930315,0.92154306,0.005185118,0.0000011559333,0.000017006667,0.0000062179265,0.0000010259166,0.00009730514,0.0008341518,0.07227845],"study_design_scores_gemma":[0.0012109071,0.000100698846,3.7102356e-7,0.8109772,0.17282791,0.00006961977,0.000026900383,0.00033570206,0.0000038008384,0.000018540992,0.014238766,0.00018958063],"about_ca_topic_score_codex":0.00001549957,"about_ca_topic_score_gemma":0.0000022480438,"teacher_disagreement_score":0.1676428,"about_ca_system_score_codex":0.00068199896,"about_ca_system_score_gemma":0.0006019706,"threshold_uncertainty_score":0.99994093},"labels":[],"label_agreement":null},{"id":"W4401391220","doi":"10.1007/s40273-024-01401-y","title":"Improving Transparency of Decision Models Through the Application of Decision Analytic Models with Omitted Objects Displayed (DAMWOOD)","year":2024,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Advanced Causal Inference Techniques","field":"Mathematics","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Institute of Health Economics; University of Alberta","funders":"Medical Research Council","keywords":"Transparency (behavior); Computer science; Decision model; Decision analysis; Management science; Scrutiny; Data science; Economics; Machine learning; Computer security; Mathematical economics; Political science","score_opus":0.09701390709738864,"score_gpt":0.40910001256669143,"score_spread":0.3120861054693028,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401391220","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.19221865,0.00034851828,0.805654,0.00004090627,0.000060867933,0.00065609656,0.0000600533,0.00014893526,0.0008119913],"genre_scores_gemma":[0.87469476,0.00038537045,0.12467389,0.0000377439,0.000032516396,0.000094324954,0.000010234048,0.000057810474,0.000013372751],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9982152,0.000036519352,0.00086681003,0.00042553782,0.00021388516,0.00024202785],"domain_scores_gemma":[0.9974892,0.001353076,0.00037266006,0.00059755467,0.00013226544,0.00005522763],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004272108,0.00026595203,0.00046766002,0.00012977829,0.0000627225,0.000036941317,0.0004653271,0.00009477947,0.000018875488],"category_scores_gemma":[0.000041396263,0.00018607407,0.00014088931,0.0003012112,0.0001162986,0.00093971967,0.00007544979,0.00025305225,0.000003778157],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008873481,0.0003961102,0.000035845736,0.0009909313,0.00038535486,0.0000097852,0.0049504465,0.27291575,0.045543715,0.53199106,0.00040553187,0.14148813],"study_design_scores_gemma":[0.00028213076,0.000047677157,0.0000012894603,0.00011874767,0.00012941669,0.000005609581,0.000077826684,0.49999815,0.03621787,0.46298322,0.000020662503,0.00011739103],"about_ca_topic_score_codex":0.00010404159,"about_ca_topic_score_gemma":0.00006920535,"teacher_disagreement_score":0.6824761,"about_ca_system_score_codex":0.00013225924,"about_ca_system_score_gemma":0.000121507306,"threshold_uncertainty_score":0.75878805},"labels":[],"label_agreement":null},{"id":"W4403011711","doi":"10.1007/s40273-024-01434-3","title":"Incorporating Complexity and System Dynamics into Economic Modelling for Mental Health Policy and Planning","year":2024,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital","funders":"University of Sydney","keywords":"Quality of Life Research; Health economics; Health administration; Public health; Mental health; System dynamics; Dynamics (music); Health policy; Public economics; Management science; Economics; Psychology; Computer science; Medicine; Psychiatry; Nursing","score_opus":0.3731745996694658,"score_gpt":0.49937677884003134,"score_spread":0.12620217917056553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403011711","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5698197,0.02837077,0.25460106,0.12843628,0.004782321,0.0038408614,0.0062933024,0.0006475452,0.0032082025],"genre_scores_gemma":[0.96545416,0.0005970315,0.026064007,0.005557622,0.0016181294,0.00017041879,0.0002947142,0.00011881765,0.00012511734],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99532074,0.00012239994,0.003095081,0.00090169493,0.000033932974,0.00052615686],"domain_scores_gemma":[0.99743664,0.00073997607,0.0011863547,0.00024321761,0.000020637295,0.00037315895],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.008074467,0.00032656378,0.0010646327,0.0005491358,0.0005908492,0.00044727983,0.00019547535,0.00011438395,0.000016556522],"category_scores_gemma":[0.00011395773,0.00046011273,0.00011058723,0.00007917863,0.00014633118,0.0008532646,0.00013314684,0.00021950589,0.0001361675],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029928591,0.0000154472,0.0021799747,0.0027175562,0.00015793927,7.1949984e-7,0.0038403606,0.012240448,0.0000023508956,0.9730979,0.004305532,0.0014118372],"study_design_scores_gemma":[0.00073530007,0.000048603495,0.000052046977,0.00018105053,0.00000848603,0.000026912146,0.0019542212,0.9380702,0.0000040106183,0.036717877,0.021820886,0.00038041678],"about_ca_topic_score_codex":0.0034555898,"about_ca_topic_score_gemma":0.00023937636,"teacher_disagreement_score":0.93638,"about_ca_system_score_codex":0.0039239293,"about_ca_system_score_gemma":0.00045092864,"threshold_uncertainty_score":0.9998998},"labels":[],"label_agreement":null},{"id":"W4404997121","doi":"10.1007/s40273-024-01456-x","title":"Cost-Effectiveness of Capivasertib as a Second-Line Therapy for Advanced Breast Cancer","year":2024,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Fulvestrant; Medicine; Cost effectiveness; Anastrozole; Breast cancer; Quality of Life Research; Oncology; Health economics; Internal medicine; Cancer; Gynecology; Tamoxifen; Public health; Nursing; Risk analysis (engineering)","score_opus":0.04592795873233327,"score_gpt":0.4144842457790218,"score_spread":0.3685562870466885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404997121","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9768801,0.014069572,0.0022193524,0.0013676438,0.0011768946,0.0025088424,0.0013146094,0.00016497548,0.0002980263],"genre_scores_gemma":[0.9937248,0.0019897022,0.00061617355,0.0012279712,0.00048323005,0.0013197851,0.00006494873,0.00011025709,0.00046308912],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987959,0.000034963927,0.00034183223,0.00043110037,0.00007735636,0.000318818],"domain_scores_gemma":[0.9990498,0.00032750014,0.00009776441,0.00022999194,0.00014557216,0.00014937123],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00026194338,0.00025630902,0.00050790433,0.00012972648,0.000042340915,0.000019386067,0.00012500111,0.00006343321,0.0014543959],"category_scores_gemma":[0.00000845968,0.0002360281,0.00022228036,0.00012534641,0.000093854454,0.00027352353,0.000024441275,0.0001753927,0.000029030967],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014661795,0.00019076992,0.00062612206,0.0016019436,0.000968779,0.000012867786,0.0003317553,0.0015295298,0.49987873,0.0007557258,0.00017005675,0.47927192],"study_design_scores_gemma":[0.011506229,0.00039742806,0.0024172824,0.0005323794,0.0001877629,0.00020396958,0.00010213925,0.0039067925,0.83413523,0.0016501812,0.14457925,0.00038135616],"about_ca_topic_score_codex":0.00004342953,"about_ca_topic_score_gemma":0.00000956667,"teacher_disagreement_score":0.47889057,"about_ca_system_score_codex":0.00037709597,"about_ca_system_score_gemma":0.0004270561,"threshold_uncertainty_score":0.99945843},"labels":[],"label_agreement":null},{"id":"W4406274851","doi":"10.1007/s40273-024-01465-w","title":"Projections of Public Spending on Pharmaceuticals: A Review of Methods","year":2025,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Institut National d'assurance Maladie-Invalidité; Uppsala Universitet; Universidad Carlos III de Madrid","keywords":"Quality of Life Research; Health economics; Public health; Health administration; Public finance; Business; Medicine; Public economics; Economics; Nursing","score_opus":0.4462416303200376,"score_gpt":0.5513911100974495,"score_spread":0.10514947977741185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406274851","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000014781275,0.89392984,0.00059329043,0.00044896113,0.0011525794,0.0015126844,0.0021108403,0.000039429953,0.1002109],"genre_scores_gemma":[0.000011720791,0.99495214,0.0017568233,0.0020052795,0.00025303403,0.00028873913,0.00010464446,0.00009677021,0.000530854],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9936994,0.0003304511,0.0043178094,0.0009515957,0.00003782879,0.0006629583],"domain_scores_gemma":[0.9942344,0.0014705305,0.0031927023,0.0007252365,0.000060831142,0.00031633084],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003994062,0.0007121903,0.0052604694,0.0014802159,0.00008476899,0.000049348175,0.0011702375,0.0003263252,0.0029940058],"category_scores_gemma":[0.0007761569,0.0008001796,0.0018665667,0.0008251894,0.00020287365,0.0002344193,0.00035190914,0.00088708196,0.00062473473],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000072066746,0.00027800127,0.0000138046125,0.18278424,0.0009660872,7.889914e-7,0.000012252918,0.0000027971257,9.1487146e-7,0.19274357,0.0063245413,0.61686575],"study_design_scores_gemma":[0.0004307724,0.000039789757,6.5867033e-7,0.022059659,0.00058867206,0.000006716486,0.0000025710958,0.0003368305,0.00006152588,0.0023444197,0.973558,0.00057039526],"about_ca_topic_score_codex":0.000023615998,"about_ca_topic_score_gemma":8.4465256e-7,"teacher_disagreement_score":0.9672334,"about_ca_system_score_codex":0.00051360164,"about_ca_system_score_gemma":0.00044422643,"threshold_uncertainty_score":0.9994449},"labels":[],"label_agreement":null},{"id":"W4408622151","doi":"10.1007/s40273-025-01479-y","title":"What are the Revealed and Stated Population Preferences for Environmental Sustainability in Healthcare? A Scoping Review","year":2025,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Climate Change and Health Impacts","field":"Environmental Science","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Université Catholique de Louvain","keywords":"Health economics; Sustainability; Health care; Quality of Life Research; Health administration; Population health; Public health; Population; Health services research; Public economics; Business; Environmental health; Environmental planning; Medicine; Economics; Nursing; Geography; Economic growth","score_opus":0.11562820263609733,"score_gpt":0.45322801381734346,"score_spread":0.33759981118124616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408622151","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005450068,0.9872355,0.0000012039295,0.0036399527,0.0002392763,0.008109314,0.00019629819,0.000013266772,0.000020173376],"genre_scores_gemma":[0.00014128744,0.995968,0.000018167464,0.0023926394,0.00004510941,0.0010465031,0.00029464066,0.000019787758,0.00007385105],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99784756,0.00029035856,0.0008545844,0.0005183776,0.00007599093,0.00041313632],"domain_scores_gemma":[0.9984879,0.00054237404,0.00057479035,0.0002591635,0.0000043936243,0.00013140481],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011112508,0.00029887172,0.0010895726,0.00005605057,0.00016692792,0.00007695273,0.00022920134,0.000111614325,0.00019510204],"category_scores_gemma":[0.00009845071,0.00022939758,0.00012069834,0.00012179239,0.00007423973,0.00040210123,0.00022510318,0.0002585391,0.000012396528],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008505388,0.000021576363,0.0020583617,0.17873712,0.000006264601,5.795887e-7,0.000052230793,0.0000036154047,1.8689999e-8,0.0000018173894,0.00061787857,0.81849205],"study_design_scores_gemma":[0.0010756274,0.000106222236,0.0049463566,0.55733645,0.0007882048,0.000016307618,0.00047175228,0.00021165806,6.6158884e-7,0.0017271575,0.4322139,0.0011057043],"about_ca_topic_score_codex":0.00028909027,"about_ca_topic_score_gemma":0.0010186383,"teacher_disagreement_score":0.8173863,"about_ca_system_score_codex":0.0014163023,"about_ca_system_score_gemma":0.00011326383,"threshold_uncertainty_score":0.9354562},"labels":[],"label_agreement":null},{"id":"W4409000501","doi":"10.1007/s40273-025-01485-0","title":"Defining Biological and Clinical Plausibility: The DICSA Framework for Protocolized Assessment in Survival Extrapolations Across Therapeutic Areas","year":2025,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Observational study; Operationalization; Set (abstract data type); A priori and a posteriori; Medicine; Computer science","score_opus":0.6791320076222206,"score_gpt":0.657551346819709,"score_spread":0.021580660802511642,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409000501","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00047534934,0.95253474,0.014635539,0.00471507,0.0020325119,0.021670626,0.0033008305,0.00005718975,0.0005781447],"genre_scores_gemma":[0.00031231035,0.97396666,0.0070715365,0.0038152635,0.0006324396,0.0137593215,0.0002683449,0.00007965073,0.000094464114],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.98694354,0.0016459527,0.009098012,0.001454032,0.000060845894,0.0007976001],"domain_scores_gemma":[0.96790326,0.026765488,0.004203064,0.00085755653,0.00005414623,0.00021648286],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.037151236,0.00062104536,0.004550143,0.0002852473,0.00047476514,0.0003091553,0.00079376675,0.00081423804,0.00020764994],"category_scores_gemma":[0.004335223,0.0005801108,0.0008363852,0.0002727339,0.00029875833,0.00025783226,0.00028513404,0.0013908609,0.00015117257],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009368489,0.0004612339,0.042685334,0.014604275,0.0011982588,0.0000016996673,0.000728854,0.000030240406,9.94078e-9,0.6523763,0.0008795557,0.28694054],"study_design_scores_gemma":[0.0016129842,0.000079216086,0.0025344018,0.0019972252,0.00014168707,0.00000513984,0.00032562483,0.0020059762,2.5252993e-8,0.08045377,0.9101457,0.0006982286],"about_ca_topic_score_codex":0.000095413125,"about_ca_topic_score_gemma":0.00015843177,"teacher_disagreement_score":0.9092662,"about_ca_system_score_codex":0.0010337871,"about_ca_system_score_gemma":0.0011382257,"threshold_uncertainty_score":0.999665},"labels":[],"label_agreement":null},{"id":"W4409086257","doi":"10.1007/s40273-025-01484-1","title":"A Hemophilia Joint Health Score-Based Model for the Economic Evaluation of Hemophilia A Prophylaxis Interventions","year":2025,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Hemophilia Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Impact; McMaster University; University of Waterloo","funders":"","keywords":"Medicine; Psychological intervention; Face validity; Health economics; Time horizon; Economic evaluation; Physical therapy; Public health; Economics; Psychometrics; Clinical psychology; Finance; Psychiatry","score_opus":0.18348839057683064,"score_gpt":0.4544855835411183,"score_spread":0.27099719296428765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409086257","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9347207,0.00264162,0.016615922,0.03580239,0.0007068352,0.008004,0.0003264196,0.00006473582,0.0011173788],"genre_scores_gemma":[0.9952485,0.00026298274,0.0011690427,0.0009419661,0.00010853018,0.00076039415,0.00008622102,0.000025738773,0.0013966503],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99837273,0.00008764577,0.00071461505,0.00034909605,0.00015843511,0.00031745384],"domain_scores_gemma":[0.9988054,0.0001820331,0.00022197033,0.0004331257,0.00023156994,0.00012590102],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021101448,0.00018489406,0.00044889923,0.00028211827,0.00019256341,0.000022911516,0.00016901793,0.0000648108,0.00018715572],"category_scores_gemma":[0.00009695571,0.00014009465,0.00052419875,0.000108820335,0.00013572842,0.00007576444,0.00005870701,0.00018634483,0.000023987224],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043857135,0.00297812,0.011167101,0.008998931,0.0037160923,0.000002827388,0.0010698399,0.4667823,0.009418796,0.014558332,0.039448664,0.43747327],"study_design_scores_gemma":[0.0058676773,0.00029943828,0.0008508191,0.00020708612,0.00043178108,0.0000019052836,0.000037608435,0.9795409,0.010261516,0.0017229608,0.00067991146,0.000098423596],"about_ca_topic_score_codex":0.000072703595,"about_ca_topic_score_gemma":0.00010103658,"teacher_disagreement_score":0.51275855,"about_ca_system_score_codex":0.001327988,"about_ca_system_score_gemma":0.0030866256,"threshold_uncertainty_score":0.5712894},"labels":[],"label_agreement":null},{"id":"W4409503028","doi":"10.1007/s40273-025-01489-w","title":"Correction: What are the Revealed and Stated Population Preferences for Environmental Sustainability in Healthcare? A Scoping Review","year":2025,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Healthcare and Environmental Waste Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Health economics; Sustainability; Population health; Quality of Life Research; Health care; Health administration; Public health; Public economics; Population; Health services research; Business; Medicine; Environmental health; Economics; Nursing; Economic growth","score_opus":0.060093842245396815,"score_gpt":0.4226044510783155,"score_spread":0.3625106088329187,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409503028","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015422559,0.9825722,0.000007007432,0.0053088656,0.00058957416,0.011266391,0.00005430509,0.000016995058,0.00003041713],"genre_scores_gemma":[0.00028382792,0.99430245,0.000022168393,0.0028525034,0.000088709065,0.0014140112,0.0005422612,0.000025148242,0.0004689379],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9978714,0.00028199732,0.00095602893,0.0005218269,0.00008212159,0.0002866324],"domain_scores_gemma":[0.99878716,0.0003653199,0.0004342994,0.00029263934,0.0000105020135,0.000110071094],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00081641675,0.00030631706,0.0013783969,0.00011452505,0.00011936435,0.00004600924,0.00010511495,0.00011291276,0.00002679013],"category_scores_gemma":[0.00006771381,0.00023863824,0.00018285195,0.000107339045,0.000049425238,0.00018027444,0.00012293406,0.0003506385,0.000004040662],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000020459185,0.000032777654,0.00081836374,0.27528143,0.000038056976,0.0000016957516,0.000016644928,0.0000019591157,5.084982e-9,0.0000019116617,0.0005592996,0.7232274],"study_design_scores_gemma":[0.00085505476,0.00012722788,0.0013815194,0.550778,0.001296744,0.000027518226,0.0005975137,0.00016765128,3.4951609e-7,0.00009362791,0.44428763,0.00038717143],"about_ca_topic_score_codex":0.00014888613,"about_ca_topic_score_gemma":0.00014345263,"teacher_disagreement_score":0.72284025,"about_ca_system_score_codex":0.0014983903,"about_ca_system_score_gemma":0.0002537686,"threshold_uncertainty_score":0.9731385},"labels":[],"label_agreement":null},{"id":"W4409722550","doi":"10.1007/s40273-025-01488-x","title":"Cost-Effectiveness of Adjuvant Alectinib Versus Chemotherapy for Patients with Resectable, ALK-positive Non-small Cell Lung Cancer in Canada","year":2025,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; Roche (Canada)","funders":"F. Hoffmann-La Roche","keywords":"Alectinib; Medicine; Lung cancer; Quality of Life Research; Oncology; Chemotherapy; Health economics; Adjuvant chemotherapy; Internal medicine; Pharmacoeconomics; Cisplatin; Intensive care medicine; Public health; Cancer; Crizotinib; Pathology","score_opus":0.013683453788698027,"score_gpt":0.3488611628773168,"score_spread":0.33517770908861877,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409722550","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920625,0.0003758615,0.0002530657,0.00015699577,0.000544234,0.0031085133,0.0005149217,0.0000059645977,0.00297793],"genre_scores_gemma":[0.99810106,0.00019611773,0.00021192161,0.00032468393,0.000026619045,0.00081231917,0.000115033006,0.000022909442,0.00018936401],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99929446,0.000021281017,0.00019438507,0.00023159086,0.000047623635,0.0002106606],"domain_scores_gemma":[0.99928933,0.00030065232,0.00009638818,0.00010784531,0.00014341896,0.00006234956],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000673582,0.00013808598,0.00031465775,0.000082833685,0.00004021021,0.000005776393,0.000060215327,0.000026310212,0.00003795725],"category_scores_gemma":[0.00000570616,0.00012427523,0.0000390927,0.00012271389,0.000017045802,0.0000531025,0.000012152451,0.00008213956,2.309604e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019214313,0.0006070229,0.9544552,0.0010357784,0.0014188059,0.0000055527253,0.00051849626,0.0052958075,0.0011031799,0.000024930352,0.0016228894,0.014698016],"study_design_scores_gemma":[0.13069686,0.00074919104,0.65098625,0.00082662015,0.0014721969,4.9278094e-7,0.00032190955,0.010450912,0.19995932,0.000014085319,0.0041127726,0.00040941604],"about_ca_topic_score_codex":0.32951698,"about_ca_topic_score_gemma":0.3314595,"teacher_disagreement_score":0.30346897,"about_ca_system_score_codex":0.0023646774,"about_ca_system_score_gemma":0.0029091602,"threshold_uncertainty_score":0.68073964},"labels":[],"label_agreement":null},{"id":"W4410254351","doi":"10.1007/s40273-025-01483-2","title":"The Use of EQ-5D in the Middle East and North Africa Region: A Systematic Literature Review","year":2025,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Health Technology Assessment international; King Hussein Cancer Center","keywords":"Quality of Life Research; Middle East; Health economics; Public health; Health administration; Systematic review; Geography; Environmental health; Medicine; MEDLINE; Political science; Nursing; Archaeology","score_opus":0.7772787200599502,"score_gpt":0.45473236566846653,"score_spread":0.3225463543914837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410254351","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00001653859,0.9871226,0.000028346636,0.005338895,0.0006447131,0.0054379124,0.0007882309,0.000019025907,0.0006037627],"genre_scores_gemma":[0.000012229094,0.9908444,0.000118622804,0.0064947694,0.00022504345,0.001364147,0.00009655349,0.00005112841,0.0007930908],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9877509,0.001979322,0.008876372,0.00079313334,0.00008604953,0.0005142139],"domain_scores_gemma":[0.9839545,0.0077886973,0.0066797608,0.0013663156,0.000080743645,0.0001299808],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0138268145,0.0005804351,0.0050963373,0.00038995568,0.00025604776,0.00036805312,0.001179345,0.00025027824,0.00002100569],"category_scores_gemma":[0.0034195704,0.00043838916,0.0006394271,0.0006812895,0.00014224915,0.0004871699,0.00018636494,0.0007258997,0.00019040663],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000047843473,0.00005206566,0.000047411362,0.92062587,0.00028310277,0.000005316131,0.0020950465,0.0000082344795,7.1038786e-10,0.011513287,0.05951506,0.005849839],"study_design_scores_gemma":[0.00019381217,0.000012968144,0.0000042998095,0.20716564,0.0002548907,0.00004942829,0.00015229257,0.00023484083,2.0840845e-9,0.00020995348,0.7914176,0.00030424565],"about_ca_topic_score_codex":0.00004092499,"about_ca_topic_score_gemma":0.00010079487,"teacher_disagreement_score":0.73190254,"about_ca_system_score_codex":0.0004737106,"about_ca_system_score_gemma":0.00039277,"threshold_uncertainty_score":0.99980676},"labels":[],"label_agreement":null},{"id":"W4411500165","doi":"10.1007/s40273-025-01512-0","title":"Innovation Headroom for a Highly Accurate PD-L1 Companion Diagnostic in Non-small Cell Lung Cancer","year":2025,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Providence Health Care; University of British Columbia Hospital; Polytechnique Montréal; University of British Columbia","funders":"NanoMedicines Innovation Network","keywords":"Medicine; Lung cancer; Oncology","score_opus":0.02262593603436821,"score_gpt":0.3470991397382342,"score_spread":0.324473203703866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411500165","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900065,0.0016202566,0.001537634,0.0032012148,0.0012016492,0.0013786991,0.00007250546,0.000033924447,0.00094758195],"genre_scores_gemma":[0.99025404,0.0014919688,0.0002661146,0.006537761,0.0001908573,0.0004330446,0.000097254815,0.000022756643,0.0007062078],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998985,0.00001568695,0.00046427542,0.0002587161,0.000033478096,0.00024285485],"domain_scores_gemma":[0.9993555,0.00025685783,0.00013741446,0.00013889656,0.00007641791,0.000034919813],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002514055,0.00015498402,0.000278655,0.00028477612,0.000053804426,0.000029427227,0.000100104575,0.00006801815,0.00009329142],"category_scores_gemma":[0.000025270841,0.00016325653,0.000073646974,0.0003394121,0.00002534795,0.000102057325,0.000025442823,0.00014353369,0.0000057635093],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010809096,0.0009286337,0.37462717,0.0030729314,0.0007825734,0.000016355418,0.0011317731,0.0026125708,0.4239407,0.00076584244,0.10990711,0.07140525],"study_design_scores_gemma":[0.04546555,0.0002497835,0.30614,0.0010521695,0.0005885444,0.000006408911,0.00022969989,0.14610144,0.3540509,0.00026804092,0.14499126,0.0008561693],"about_ca_topic_score_codex":0.0004301352,"about_ca_topic_score_gemma":0.00014358881,"teacher_disagreement_score":0.14348887,"about_ca_system_score_codex":0.0005093652,"about_ca_system_score_gemma":0.0002998165,"threshold_uncertainty_score":0.6657408},"labels":[],"label_agreement":null},{"id":"W4413291804","doi":"10.1007/s40273-025-01532-w","title":"Developing a Comprehensive Framework for Cost-Effectiveness Evaluation in Metastatic Castration-Sensitive Prostate Cancer: Insights from a Systematic Review","year":2025,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Pharmaceuticals Bayer","keywords":"Health economics; Economic evaluation; Systematic review; Health administration; Cost effectiveness; Prostate cancer; Health care; Health technology; Flexibility (engineering); Agency (philosophy); Cost–benefit analysis; Medicine; Management science; Risk analysis (engineering); MEDLINE; Public health; Cancer; Economics; Sociology","score_opus":0.21509109056000753,"score_gpt":0.5196098635613617,"score_spread":0.3045187730013542,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413291804","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000088623856,0.94405925,0.00070154504,0.00020681118,0.0004559124,0.053496096,0.00093486527,0.000029304145,0.000027562828],"genre_scores_gemma":[0.000051728395,0.95278984,0.0013354133,0.00056052767,0.00010179191,0.04245886,0.0025953872,0.00006407138,0.000042360793],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99615645,0.0011159682,0.0013348899,0.00076777954,0.00024414234,0.0003807507],"domain_scores_gemma":[0.994148,0.0040057227,0.00073115004,0.00035105378,0.0006343362,0.000129729],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007177073,0.00060086715,0.0044991076,0.00041275483,0.000101606805,0.000059930717,0.00016747457,0.0001611713,0.000026517519],"category_scores_gemma":[0.00042799904,0.0004761359,0.00047558174,0.00048267623,0.000054472635,0.00014777368,0.00006753129,0.0005193103,0.000025381967],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016887662,0.000062585335,0.0000029651494,0.8763438,0.0021412226,0.000025409852,0.0001667838,0.000021121828,0.0000015437594,0.00025403575,0.000049568538,0.12076212],"study_design_scores_gemma":[0.0029948493,0.000059825416,0.0000062779873,0.95716316,0.018864207,0.000014708681,0.00008333821,0.0008910304,0.00007307377,0.0009295008,0.018469099,0.00045095637],"about_ca_topic_score_codex":0.00012398748,"about_ca_topic_score_gemma":0.00005474653,"teacher_disagreement_score":0.120311156,"about_ca_system_score_codex":0.004001376,"about_ca_system_score_gemma":0.0055379327,"threshold_uncertainty_score":0.9998221},"labels":[],"label_agreement":null},{"id":"W4413301583","doi":"10.1007/s40273-025-01530-y","title":"Eliciting and Anchoring Health State Preferences Using Discrete Choice Experiments Among Adults, Adolescents, and Children","year":2025,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; McMaster University Medical Centre; Impact","funders":"EuroQol Research Foundation","keywords":"Health economics; Quality of Life Research; Anchoring; Public health; Health administration; Psychology; Discrete choice; Medicine; Economics; Social psychology; Econometrics; Nursing","score_opus":0.19532427329104582,"score_gpt":0.4631339987364767,"score_spread":0.2678097254454309,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413301583","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9861689,0.0076372116,0.0018192835,0.0019915614,0.0005078875,0.00095995003,0.00026840525,0.0000638009,0.0005829554],"genre_scores_gemma":[0.9894425,0.0021277585,0.0018946035,0.00608518,0.00027832325,0.000053896994,0.000022758959,0.000038122285,0.000056852637],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99569315,0.00019203918,0.0026524852,0.00083945115,0.000053776246,0.0005690741],"domain_scores_gemma":[0.99753904,0.00023611663,0.0016088965,0.00028130502,0.000035967485,0.00029868708],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004295636,0.00030029353,0.0009270961,0.0003414649,0.00043341526,0.00023306474,0.0002291376,0.00007784252,0.000033038494],"category_scores_gemma":[0.00031968733,0.00040987914,0.00006159861,0.00011173208,0.000121068326,0.000882067,0.00019667405,0.00024705418,0.000029824694],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002386983,0.000040399333,0.9898061,0.00053355686,0.00013703434,1.3403157e-7,0.0016211927,0.0003268561,0.000013009104,0.0012059709,0.0010804002,0.0052114334],"study_design_scores_gemma":[0.0065898965,0.00010622182,0.86979103,0.0019996583,0.000042465534,0.000008131469,0.0021236197,0.101498395,0.000310731,0.006849457,0.0091648735,0.0015155176],"about_ca_topic_score_codex":0.005609299,"about_ca_topic_score_gemma":0.0002756697,"teacher_disagreement_score":0.12001511,"about_ca_system_score_codex":0.00065160706,"about_ca_system_score_gemma":0.00015235734,"threshold_uncertainty_score":0.9998353},"labels":[],"label_agreement":null},{"id":"W4416459789","doi":"10.1007/s40273-025-01561-5","title":"The ‘Values in Modelling’ Framework for Patient and Public Involvement in Health Economics Modelling: Development and Application in the LEAP Model Project","year":2025,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Vancouver Coastal Health Research Institute; Stornoway Diamond (Canada); Vancouver Coastal Health","funders":"Canadian Institutes of Health Research; Michael Smith Health Research BC","keywords":"Health economics; Public health; Deliberation; Process (computing); Quality of Life Research; Health administration; Health informatics; Outcome (game theory); Cost–benefit analysis","score_opus":0.38643299910462664,"score_gpt":0.4564710037805315,"score_spread":0.07003800467590487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416459789","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6645256,0.006036204,0.2808856,0.04425443,0.00020402914,0.003772022,0.000076304525,0.00001758236,0.00022821262],"genre_scores_gemma":[0.93481296,0.008833959,0.035946805,0.017431043,0.00006842737,0.0027855628,0.000043380696,0.00003834585,0.000039499406],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99462306,0.00022807352,0.003805696,0.00072275137,0.00003881948,0.00058158557],"domain_scores_gemma":[0.9969376,0.001437146,0.0011376095,0.0003758984,0.000027761605,0.00008399267],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.01468138,0.00024899322,0.0006826918,0.00053356605,0.00033544708,0.00022490825,0.00036237654,0.00012698528,0.0000011401578],"category_scores_gemma":[0.00018035149,0.00025529746,0.000049856655,0.00018850857,0.000084441104,0.00038319136,0.00010392825,0.00032739254,0.0000071759046],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000041979052,0.000127366,0.008306428,0.00029827992,0.000026145444,5.7279586e-8,0.010510138,0.53800654,9.186316e-8,0.43817383,0.00039134244,0.004117814],"study_design_scores_gemma":[0.0007564789,0.000018736644,0.00012957616,0.000048624395,0.0000017431983,3.3988735e-7,0.0031314613,0.78735393,0.0000028147886,0.1813781,0.02699569,0.00018249931],"about_ca_topic_score_codex":0.0013176132,"about_ca_topic_score_gemma":0.0021453674,"teacher_disagreement_score":0.27028736,"about_ca_system_score_codex":0.0013282477,"about_ca_system_score_gemma":0.0006632296,"threshold_uncertainty_score":0.9999899},"labels":[],"label_agreement":null},{"id":"W4417329433","doi":"10.1007/s40273-025-01579-9","title":"Economic Consequences of Increasing the NICE Cost-Effectiveness Threshold","year":2025,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Quality of Life Research; Nice; Health economics; Public health; Health administration; Public finance","score_opus":0.31248029096377505,"score_gpt":0.4946353380343216,"score_spread":0.18215504707054653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417329433","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93873805,0.0036459188,0.0017103943,0.022944978,0.0024124312,0.0018324826,0.00052442856,0.000074254414,0.028117044],"genre_scores_gemma":[0.9880827,0.0005451597,0.0003823441,0.010183749,0.00023572275,0.00028541882,0.000021989961,0.000033368022,0.00022952503],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.994521,0.0006005934,0.0037057803,0.0006573335,0.000043496653,0.0004717519],"domain_scores_gemma":[0.9928605,0.004144727,0.0021205686,0.00069105363,0.0000572934,0.00012588743],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.020544907,0.00028947566,0.0011921999,0.00035972812,0.00031089902,0.00012033191,0.00081159757,0.00013828876,0.0005318772],"category_scores_gemma":[0.0009163123,0.00032090629,0.00024348835,0.00016657887,0.00044199944,0.0005860081,0.00015817738,0.00028552694,0.0009323548],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020529063,0.00011382099,0.22042522,0.00060061907,0.0005442298,9.3382613e-7,0.0005943001,0.008175071,0.00046259977,0.753305,0.01489991,0.00067296595],"study_design_scores_gemma":[0.010325327,0.00018544952,0.14316103,0.0007569969,0.00026502996,0.0000625943,0.0033532726,0.08153059,0.019100526,0.3201351,0.41856816,0.0025559417],"about_ca_topic_score_codex":0.0021408142,"about_ca_topic_score_gemma":0.00014305524,"teacher_disagreement_score":0.43316996,"about_ca_system_score_codex":0.0011026887,"about_ca_system_score_gemma":0.00053143775,"threshold_uncertainty_score":0.9999243},"labels":[],"label_agreement":null},{"id":"W576972216","doi":"10.1007/s40273-015-0297-4","title":"The Silence in Hoch et al.’s Commentary about the Rationale for and Objective(s) of Canada’s Separate HTA Process for Cancer Drugs: The Importance of Transparency and Accountability when Allocating Taxpayers’ Dollars","year":2015,"lang":"en","type":"letter","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University","funders":"","keywords":"Accountability; Transparency (behavior); Ambiguity; Medicine; Law and economics; Public relations; Positive economics; Sociology; Political science; Law; Economics; Computer science","score_opus":0.24557794106517278,"score_gpt":0.4589232006110723,"score_spread":0.2133452595458995,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W576972216","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1838021,0.010906908,0.00016040834,0.7942266,0.0005138649,0.0035948143,0.0066654477,0.0000051797824,0.00012467847],"genre_scores_gemma":[0.13513336,0.003195129,0.00024967172,0.85760707,0.00048110806,0.002944408,0.00020614201,0.000067049,0.000116072995],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9952987,0.00029599897,0.003236644,0.00062821445,0.00010820301,0.00043222887],"domain_scores_gemma":[0.9904891,0.005162174,0.0035986626,0.00045821263,0.00022443762,0.00006737328],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.015277441,0.00030857793,0.0010008096,0.00007128072,0.00034726723,0.000072093644,0.00063479587,0.00013852913,0.000023650284],"category_scores_gemma":[0.0006079345,0.00025495692,0.00009733457,0.000066508306,0.00029560487,0.00034608078,0.000057110236,0.0004877203,4.7881895e-7],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000156802,0.000025236375,0.016252218,0.0014120665,0.00025231548,1.1375917e-7,0.016042866,0.0014785536,0.0000025450568,0.00082283345,0.9633993,0.00015517454],"study_design_scores_gemma":[0.0023448654,0.000073311225,0.0018774124,0.00019070767,0.00007592209,0.0000023997895,0.0097159315,0.024060797,0.0000659684,0.014423276,0.946586,0.00058338785],"about_ca_topic_score_codex":0.078769445,"about_ca_topic_score_gemma":0.25074205,"teacher_disagreement_score":0.1719726,"about_ca_system_score_codex":0.00086523726,"about_ca_system_score_gemma":0.0020985552,"threshold_uncertainty_score":0.9999903},"labels":[],"label_agreement":null},{"id":"W659344829","doi":"10.1007/s40273-015-0293-8","title":"Disinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review","year":2015,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":94,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Cancer Institute NSW; National Health and Medical Research Council; HCF Research Foundation","keywords":"Disinvestment; Reimbursement; Value-Based Purchasing; Public economics; Health economics; Purchasing; Business; Stakeholder; Formulary; Grey literature; Pharmaceutical policy; Health care; Health policy; Economics; Economic growth; Medicine; Marketing; Political science","score_opus":0.7054976458037195,"score_gpt":0.6065338041121112,"score_spread":0.09896384169160832,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W659344829","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000021880895,0.9790873,0.002846079,0.0068843635,0.0020098719,0.0039702696,0.003259548,0.00009978191,0.0018209167],"genre_scores_gemma":[0.0000102199865,0.96552324,0.0053078393,0.025259335,0.0012093608,0.0012721744,0.0011549192,0.0001623651,0.000100560406],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9911096,0.0005719883,0.0062620784,0.0013269441,0.000104275656,0.0006251154],"domain_scores_gemma":[0.9931441,0.001182296,0.004187086,0.00068619545,0.00011926572,0.00068103604],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.01822887,0.0007152884,0.004179605,0.0004731048,0.000190704,0.00044330893,0.00084593025,0.0002838035,0.00036727154],"category_scores_gemma":[0.00076754816,0.0008651713,0.0005292383,0.000117703705,0.00015390707,0.0014355573,0.00012666312,0.00040957422,0.0005737644],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000047896123,0.0004828654,0.000051513263,0.17920089,0.0014458031,0.0000041643457,0.0003897689,0.0002892597,2.1057225e-7,0.30361906,0.07642797,0.43804058],"study_design_scores_gemma":[0.0010256766,0.00006031065,0.0000012468212,0.005101128,0.00037760948,0.000015935933,0.00007283583,0.011736595,1.9652202e-7,0.00842057,0.97238964,0.000798278],"about_ca_topic_score_codex":0.000058852616,"about_ca_topic_score_gemma":0.0000040557156,"teacher_disagreement_score":0.89596164,"about_ca_system_score_codex":0.0016543652,"about_ca_system_score_gemma":0.0013709266,"threshold_uncertainty_score":0.9993799},"labels":[],"label_agreement":null},{"id":"W874651150","doi":"","title":"Up the garden PATH of 'cost savings' in Ontario Canada: When costing less means costing more.","year":2007,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Activity-based costing; Health economics; Quality of Life Research; Health administration; Public health; Pharmacoeconomics; Operations management; Business; Economics; Public economics; Actuarial science; Agricultural economics; Medicine; Accounting; Nursing; Microeconomics","score_opus":0.20817539888370737,"score_gpt":0.44016017304388405,"score_spread":0.23198477416017668,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W874651150","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887895,0.000047166992,0.0007118078,0.00512984,0.00072541804,0.0006887226,0.000023721901,0.000015336143,0.0038685005],"genre_scores_gemma":[0.99111784,0.000027295107,0.0012469066,0.0069263014,0.00023180756,0.000010477032,0.000057694782,0.0000286727,0.00035298284],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99784607,0.000050540264,0.0013502317,0.00021866872,0.00018564495,0.00034886354],"domain_scores_gemma":[0.9968233,0.002111982,0.0005557724,0.00022885817,0.0001387206,0.00014138223],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026440965,0.0001517188,0.00032814374,0.00006504896,0.000071874034,0.000017168113,0.00017997278,0.000046117515,0.0003727451],"category_scores_gemma":[0.0012756408,0.00013720966,0.000062854546,0.00006671737,0.000052169296,0.00014259777,0.00009324874,0.00057278574,0.0000056361678],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009572117,0.00014559802,0.8602841,0.000084901,0.00019236856,0.00007081118,0.0063149403,0.0018180847,0.0034393761,0.000065260174,0.022310602,0.10431678],"study_design_scores_gemma":[0.020823812,0.00020079051,0.6048559,0.00043694986,0.0010434523,0.00021579236,0.054700095,0.026675863,0.017777631,0.00016106678,0.27209473,0.0010139046],"about_ca_topic_score_codex":0.92082644,"about_ca_topic_score_gemma":0.99020016,"teacher_disagreement_score":0.25542814,"about_ca_system_score_codex":0.0016151796,"about_ca_system_score_gemma":0.0015755835,"threshold_uncertainty_score":0.5595248},"labels":[],"label_agreement":null}]}